Number O
of O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
lymphocytes O
and O
their O
sensitivity O
to O
hormone O
action O
. O

The O
study O
demonstrated O
a O
decreased O
level O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
GR B_PROTEIN[GENE]/B_DISEASE
) O
in O
peripheral O
blood O
lymphocytes O
from O
hypercholesterolemic O
subjects O
, O
and O
an O
elevated O
level O
in O
patients O
with O
acute O
myocardial O
infarction O
. O

In O
the O
lymphocytes O
with O
a O
high O
GR B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
number O
, O
dexamethasone O
inhibited O
[ O
3H O
] O
-thymidine O
and O
[ O
3H O
] O
-acetate O
incorporation O
into O
DNA O
and O
cholesterol O
, O
respectively O
, O
in O
the O
same O
manner O
as O
in O
the O
control O
cells O
. O

On O
the O
other O
hand O
, O
a O
decreased O
GR B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
number O
resulted O
in O
a O
less O
efficient O
dexamethasone O
inhibition O
of O
the O
incorporation O
of O
labeled O
compounds O
. O

These O
data O
showed O
that O
the O
sensitivity O
of O
lymphocytes O
to O
glucocorticoids O
changed O
only O
with O
a O
decrease O
of O
GR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
level O
. O

[ O
1 B_DISEASE_ADJECTIVE[DISEASE]
, I_DISEASE_ADJECTIVE[DISEASE]
25-Dihydroxyvitamin I_DISEASE_ADJECTIVE[DISEASE]
D3 I_DISEASE_ADJECTIVE[DISEASE]
receptors I_DISEASE_ADJECTIVE[DISEASE]
in O
lymphocytes O
and O
T- O
and O
B-lymphocyte O
count O
in O
patients O
with O
glomerulonephritis O
] O
. O

content B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
hormonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
D3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
1.25 B_MEASURE/B_LOCATION
( O
OH B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
constituted O
27.3 B_MEASURE/B_ENT
fmole/mg I_MEASURE/I_ENT
of O
protein B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
in O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
peripheric B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
children B_PERSON/B_BIO
with O
glomerulonephritis B_DISEASE
. O

In O
the O
patients B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
concentration I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
of O
total B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ionized B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
Ca2+ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
decreased O
down O
to O
2.04 B_MEASURE
mmole/L I_MEASURE
and O
1.09 B_MEASURE/B_LOCATION
mmole/L I_MEASURE/I_LOCATION
, O
respectively O
, O
while O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
parathormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
PTH B_PROTEIN[GENE]/B_LOCATION
) O
by O
36 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
and O
a O
distinct B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
25 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
OH O
) O
D B_PROTEIN[GENE]
concentration I_PROTEIN[GENE]
( O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
1.25 B_MEASURE
ng/ml I_MEASURE
) O
was O
found O
in O
blood B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O
content B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cAMP B_GENE
was O
also O
decreased O
in O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
33 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
% I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

At O
the O
same B_TIME[MEASURE]/B_LOCATION
time I_TIME[MEASURE]/I_LOCATION
, O
total B_MEASURE/B_ENT
content I_MEASURE/I_ENT
of O
T B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphocytes B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
decreased O
1.5-fold B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
peripheric B_PERSON/B_DISEASE
blood I_PERSON/I_DISEASE
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
I-hydroxyvitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
D3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
1-1.5 B_MEASURE
mg O
daily O
, O
within O
4 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
) O
led O
to O
normalization B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
total B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
ionized B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
Ca2+ B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
of O
25 B_MEASURE/B_LOCATION
( O
OH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
but O
did O
not O
affect O
the O
PTH B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
content I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

concentration O
of O
the O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
1.25 O
( O
OH O
) O
2D3 O
was O
elevated O
up O
to O
39.7 O
fmole/mg O
after O
I O
week O
of O
the O
treatment O
, O
whereas O
it O
was O
decreased O
to O
the O
initial O
level O
24.8 O
fmole/mg O
within O
4 O
weeks O
; O
simultaneous O
alteration O
in O
the O
Camp O
content O
was O
observed O
in O
lymphocytes O
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
1- B_MEASURE
( O
OH O
) O
D3 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
normalized O
also O
the O
T B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
lymphocytes O
content B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
peripheric B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

The O
data O
obtained O
suggest O
that O
under O
conditions O
of O
glomerulonephritis O
only O
high O
content O
of O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
1.25 O
( O
OH O
) O
2D3 O
in O
lymphocytes O
enabled O
to O
perform O
the O
cell O
response O
to O
the O
hormone O
effect O
. O

Tumor B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
serum O
beta-2-microglobulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
women B_PERSON/B_BIO
with O
breast B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
. O

To O
investigate O
whether O
the O
tumor O
expression O
of O
beta-2-microglobulin B_GENE
( O
beta B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
could O
serve O
as O
a O
marker O
of O
tumor O
biologic O
behavior O
, O
the O
authors O
studied O
specimens O
of O
breast O
carcinomas O
from O
60 O
consecutive O
female O
patients O
. O

presence O
of O
beta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
analyzed O
by O
immunohistochemistry O
. O

No O
significant O
correlations O
were O
found O
between O
tumor B_GENE
beta I_GENE
2-M I_GENE
expression O
and O
several O
histologic O
attributes O
such O
as O
type O
, O
histologic O
and O
nuclear O
grades O
, O
mitotic O
index O
, O
necrosis O
, O
vascular O
invasion O
, O
and O
lymphocytic O
infiltration O
. O

Likewise O
, O
beta B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
associated O
with O
markers O
of O
disease O
extension O
such O
as O
TNM O
, O
( O
UICC O
, O
classification O
of O
malignant O
tumors O
) O
staging O
and O
axillary O
lymph O
node O
involvement O
or O
with O
estrogen O
, O
progesterone O
, O
and O
glucocorticoid O
receptor O
levels O
. O

However O
, O
there O
was O
a O
significantly O
positive O
association O
between O
tumor B_GENE
beta I_GENE
2-M I_GENE
expression O
and O
the O
degree O
of O
lymphocytic O
infiltration O
in O
the O
tumor O
tissue O
. O

Beta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum O
levels O
were O
determined O
by O
an O
enzyme-linked O
immunosorbent O
assay O
in O
samples O
from O
22 O
of O
the O
above O
women O
. O

Although O
some O
of O
the O
highest O
values O
had O
been O
obtained O
in O
women O
with O
larger O
( O
T4 O
) O
primary O
tumors O
, O
the O
authors O
failed O
to O
detect O
any O
statistical O
relationship O
between O
beta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
in O
the O
tumor O
with O
serum O
levels O
or O
between O
serum B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2-M I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
above O
histologic O
, O
laboratory O
, O
and O
clinical O
factors O
. O

[ O
Preliminary O
observation O
of O
level O
free-form B_GENE
E I_GENE
receptor I_GENE
levels O
in O
serum O
of O
normal O
childbearing-aged O
and O
pregnant O
women O
] O
. O

In O
137 O
cases O
of O
childbearing-aged O
and O
pregnant O
women O
, O
free B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
( O
sE B_LOCATION/B_ORGANIZATION
) O
in O
serum O
were O
measured O
by O
ELISA O
. O

The O
level O
of O
sE B_GENE/B_DISEASE
was O
significantly O
decreased O
during O
the O
first O
trimester O
, O
slightly O
higher O
in O
the O
second O
trimester O
, O
and O
recovered O
to O
normal O
in O
the O
third O
trimester O
. O

The O
level B_MEASURE
remained O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
29 B_PERSON
PIH I_PERSON
women I_PERSON
but O
appeared O
higher O
in O
overdue B_PERSON
pregnancies I_PERSON
as O
compared O
with O
the O
normal B_MEASURE/B_PERSON
3rd B_MEASURE/I_PERSON
trimester B_MEASURE/I_PERSON
range B_MEASURE/I_PERSON
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O
that O
there O
is O
a O
relationship B_PERSON/B_MEASURE
between O
a O
change B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
T B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pregnancy B_DISEASE
. O

Kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B-specific I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O
role O
in O
the O
regulation O
of O
human B_GENE
interleukin-2 I_GENE
gene I_GENE
expression O
. O

Transcriptional O
activation O
of O
the O
human B_GENE
interleukin-2 I_GENE
( I_GENE
IL-2 I_GENE
) I_GENE
gene I_GENE
, O
like O
induction O
of O
the O
IL-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-2R I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
type O
1 O
human O
immunodeficiency O
virus O
( O
HIV-1 O
) O
, O
is O
shown O
to O
be O
modulated O
by O
a O
kappa B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B-like B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancer B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

mutation O
of O
a O
kappa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
core B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sequence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
identified O
in O
the O
IL-2 B_GENE
promoter I_GENE
( O
-206 O
to O
-195 O
) O
partially O
inhibits O
both O
mitogen- O
and O
HTLV-I O
Tax-mediated O
activation O
of O
this O
transcription B_GENE/B_LOCATION
unit I_GENE/I_LOCATION
and O
blocks O
the O
specific O
binding O
of O
two O
inducible B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cellular B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factors B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

These O
kappa B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B-specific B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
80 O
to O
90 O
and O
50 O
to O
55 O
kilodaltons O
) O
similarly O
interact O
with O
the O
functional O
kappa B_GENE/B_LOCATION
B I_GENE/I_LOCATION
enhancer I_GENE/I_LOCATION
present O
in O
the O
IL-2R B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
alpha B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

These O
data O
suggest O
that O
these O
kappa B_GENE/B_LOCATION
B-specific I_GENE/I_LOCATION
proteins I_GENE/I_LOCATION
have O
a O
role O
in O
the O
coordinate O
regulation O
of O
this O
growth O
factor-growth O
factor O
receptor O
gene O
system O
that O
controls O
T O
cell O
proliferation O
. O

Novel O
region O
within O
the O
V B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
responsible O
for O
tissue O
and O
stage-specific O
expression O
of O
immunoglobulin B_GENE
genes I_GENE
in O
human O
lymphoid O
neoplasms O
. O

Immunoglobulin B_PERSON/B_GENE
gene-specific I_PERSON/I_GENE
transacting I_PERSON/I_GENE
factors I_PERSON/I_GENE
have O
been O
shown O
to O
play O
a O
role O
in O
lymphoid O
tissue-specific O
expression O
of O
immunoglobulin B_GENE
genes I_GENE
. O

The O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
factors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
B-cell B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
differentiation I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O
stage-specific B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
these O
genes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
, O
however O
, O
not O
fully O
understood O
. O

We O
have O
used O
a O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
human B_DISEASE
lymphoid I_DISEASE
neoplasia I_DISEASE
to O
address O
this O
question B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Different O
fragments O
of O
unrearranged B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
human B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variable B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O
immunoglobulin B_GENE
kappa I_GENE
gene I_GENE
( O
V B_GENE
kappa I_GENE
) O
were O
used O
for O
cell-free O
in O
vitro O
transcription O
and O
DNA O
mobility O
shift O
assays O
. O

Previously O
described O
enhancement O
of O
in O
vitro O
transcription O
that O
was O
only O
seen O
with O
nuclear O
extracts O
derived O
from O
B-cell O
neoplasms O
corresponding O
to O
the O
late O
stages O
of O
B-cell O
differentiation O
was O
shown O
to O
be O
dependent O
on O
the O
actions O
of O
these O
factor O
( O
s O
) O
on O
the O
DNA O
region O
within O
the O
V B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
region O
is O
located O
within O
the O
920 O
BP O
fragment O
located O
210 O
BP O
upstream O
from O
the O
coding O
region O
and O
this O
fragment O
represents O
a O
possible O
novel O
DNA O
region O
, O
which O
plays O
a O
role O
in O
the O
stage- O
and O
tissue-specific O
expression O
of O
immunoglobulin B_GENE
genes I_GENE
. O

[ O
determination O
of O
the O
sensitivity O
to O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
vitro O
] O
. O

A O
modified O
method O
for O
the O
determination O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
human O
lymphocytes O
is O
suggested O
. O

The O
principal O
distinction O
of O
the O
method O
is O
standardization O
by O
the O
lymphocyte O
count O
in O
a O
sample O
( O
1 O
mln O
) O
and O
the O
labeled O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
concentration O
. O

The O
modification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saves O
time B_TIME[MEASURE]/B_LOCATION
and O
money B_ORGANIZATION/B_MEASURE
, O
limits O
the O
range B_MEASURE
of O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
variations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
, O
and O
makes O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
lesser B_MEASURE/B_LOCATION
volume B_MEASURE/I_LOCATION
of O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

examinations O
of O
70 O
children O
aged O
4 O
to O
15 O
suffering O
from O
the O
nephrotic O
form O
of O
glomerulonephritis O
have O
made O
it O
possible O
to O
distinguish O
two O
groups O
of O
patients O
: O
with O
relatively O
high O
values O
of O
specific O
binding O
X O
= O
6820.1 O
+/- O
530.0 O
( O
n O
= O
30 O
, O
p O
= O
0.95 O
, O
t O
= O
2.04 O
) O
, O
this O
corresponding O
to O
a O
clinical O
form O
of O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-sensitive O
glomerulonephritis O
, O
and O
with O
relatively O
low O
values O
of O
specific O
binding O
X O
= O
1815.2 O
+/- O
302.8 O
( O
n O
= O
40 O
, O
p O
= O
0.95 O
, O
t O
= O
1.96 O
) O
, O
that O
corresponds O
to O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-resistant O
glomerulonephritis O
. O

Dynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
not O
shown O
any O
statistically O
significant B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
binding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
values I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

These O
results O
permit O
regarding O
the O
specific O
binding O
value O
as O
a O
prognostic O
criterion O
in O
the O
assessment O
of O
corticosteroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O
; O
this O
allows O
a O
wide O
employment O
of O
the O
described O
method O
in O
practical O
nephrology O
. O

Octamer-binding B_GENE
proteins I_GENE
from O
B O
or O
HeLa O
cells O
stimulate O
transcription O
of O
the O
immunoglobulin B_GENE
heavy-chain I_GENE
promoter I_GENE
in O
vitro O
. O

The O
B-cell O
-type O
specificity O
of O
the O
immunoglobulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Ig B_PROTEIN[GENE]/B_LOCATION
) O
heavy-chain O
and O
light-chain O
promoters O
is O
mediated O
by O
an O
octanucleotide B_GENE
( I_GENE
OCTA I_GENE
) I_GENE
element I_GENE
, O
ATGCAAAT O
, O
that O
is O
also O
a O
functional O
component O
of O
other O
RNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
such O
as O
snRNA O
and O
histone O
H2B O
promoters O
. O

Two O
nuclear B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
bind O
specifically O
and O
with O
high O
affinity O
to O
the O
OCTA B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
element B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
have O
been O
identified O
. O

NF-A1 B_GENE
is O
present O
in O
a O
variety O
of O
cell O
types O
, O
whereas O
the O
presence O
of O
NF-A2 B_GENE
is O
essentially O
confined O
to O
B O
cells O
, O
leading O
to O
the O
hypothesis O
that O
NF-A2 B_GENE
activates O
cell-type-specific O
transcription O
of O
the O
Ig B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
and O
NF-A1 B_GENE/B_LOCATION
mediates O
the O
other O
responses O
of O
the O
OCTA B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
element B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Extracts O
of O
the O
B-cell O
line O
, O
BJA-B O
, O
contain O
high O
levels O
of O
NF-A2 B_GENE
and O
specifically O
transcribe O
Ig B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast O
, O
extracts O
from O
HeLa O
cells O
transcribed O
the O
Ig B_GENE
promoter I_GENE
poorly O
. O

surprisingly O
, O
addition O
of O
either O
affinity-enriched O
NF-A2 O
or O
NF-A1 O
to O
either O
a O
HeLa O
extract O
or O
a O
partially O
purified O
reaction O
system O
specifically O
stimulates O
the O
Ig B_GENE
promoter I_GENE
. O

This O
suggests O
that O
the O
constitutive O
OCTA-binding B_GENE
factor I_GENE
NF-A1 I_GENE
can O
activate O
transcription O
of O
the O
Ig B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
and O
that O
B-cell O
-specific O
transcription O
of O
this O
promoter O
, O
at O
least O
in O
vitro O
, O
is O
partially O
due O
to O
a O
quantitative O
difference O
in O
the O
amount O
of O
OCTA-binding B_GENE
protein I_GENE
. O

Because O
NF-A1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
stimulate O
Ig B_GENE/B_DISEASE
transcription O
, O
the O
inability O
of O
this O
factor O
to O
activate O
in O
vivo O
the O
Ig B_GENE
promoter I_GENE
to O
the O
same O
degree O
as O
the O
snRNA B_GENE/B_MEASURE
promoters I_GENE/I_MEASURE
probably O
reflects O
a O
difference O
in O
the O
context O
of O
the O
OCTA B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
element B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
these O
two O
types O
of O
promoters B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

identification O
of O
a O
putative O
regulator O
of O
early B_DISEASE
T I_DISEASE
cell I_DISEASE
activation I_DISEASE
genes I_DISEASE
. O

molecules O
involved O
in O
the O
antigen O
receptor-dependent O
regulation O
of O
early B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
T B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cell B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O
investigated O
with O
the O
use O
of O
functional O
sequences O
of O
the O
T B_GENE/B_LOCATION
cell I_GENE/I_LOCATION
activation-specific I_GENE/I_LOCATION
enhancer I_GENE/I_LOCATION
of O
interleukin-2 B_GENE
( O
IL-2 B_GENE
) O
. O

One O
of O
these O
sequences O
forms O
a O
protein O
complex O
, O
NFAT-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
specifically O
with O
nuclear O
extracts O
of O
activated O
T O
cells O
. O

This O
complex O
appeared O
10 O
to O
25 O
minutes O
before O
the O
activation O
of O
the O
IL-2 B_GENE
gene I_GENE
. O

Studies O
with O
inhibitors O
of O
protein O
synthesis O
indicated O
that O
the O
time O
of O
synthesis O
of O
the O
activator O
of O
the O
IL-2 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
in O
Jurkat O
T O
cells O
corresponds O
to O
the O
time O
of O
appearance O
of O
NFAT-1 B_GENE
. O

NFAT-1 B_GENE
, O
or O
a O
very O
similar O
protein O
, O
bound O
functional O
sequences O
of O
the O
long B_GENE
terminal I_GENE
repeat I_GENE
( O
LTR B_GENE/B_DISEASE
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
; O
the O
LTR B_GENE/B_DISEASE
of O
this O
virus O
is O
known O
to O
be O
stimulated O
during O
early O
T O
cell O
activation O
. O

The O
binding B_GENE
site I_GENE
for O
this O
complex O
activated O
a O
linked O
promoter O
after O
transfection O
into O
antigen O
receptor-activated O
T O
cells O
but O
not O
other O
cell O
types O
. O

These O
characteristics O
suggest O
that O
NFAT-1 B_GENE
transmits O
signals O
initiated O
at O
the O
T B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
cell B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
antigen B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

characterization O
of O
thyroid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
human O
IM-9 O
lymphocytes O
. O

Although O
putatively O
identified O
more O
than O
10 O
years O
ago O
, O
thyroid B_GENE/B_BIO
hormone I_GENE/I_BIO
receptors I_GENE/I_BIO
in O
human O
tissues O
remain O
poorly O
characterized O
. O

As O
a O
first O
step O
towards O
understanding O
the O
mechanism O
of O
thyroid O
hormone O
action O
in O
man O
we O
have O
characterized O
T3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
nuclei O
of O
the O
human O
lymphoblastoid O
line O
, O
IM-9 O
cells O
. O

In O
whole O
cell O
experiments O
at O
37 O
degrees O
C O
, O
nuclear O
binding O
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
125I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
T3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
saturable O
( O
Kd O
34 O
+/- O
6 O
pmol/l O
) O
and O
of O
finite O
capacity O
( O
approximately O
equal O
to O
350 O
sites/cell O
) O
. O

The O
binding B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
sites B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
were O
extracted O
from O
a O
nuclear O
pellet O
by O
treatment O
with O
0.4 O
mol/l O
KCl O
and O
sonication O
. O

separation O
of O
bound O
from O
free O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
125I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
extracts O
was O
achieved O
using O
the O
calcium O
phosphate O
matrix O
, O
hydroxyapatite O
at O
a O
concentration O
of O
0.3 O
ml O
of O
a O
150 O
g/l O
slurry O
. O

Rectilinear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
Scatchard I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
plots I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
obtained O
only O
when O
the O
hydroxyapatite B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
washed O
with O
a O
buffer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
0.5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Triton I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X-100 O
. O

Under O
these O
conditions O
T3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
nuclear O
extracts O
were O
present O
at O
a O
concentration O
of O
22.4 O
+/- O
8.6 O
fmol/mg O
protein O
and O
showed O
an O
affinity O
of O
( O
Kd O
, O
room O
temperature O
) O
140 O
+/- O
10 O
pmol/l O
. O

The O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
used O
to O
determine O
the O
hierarchy B_MEASURE
of O
affinities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
a O
range B_LOCATION/B_MEASURE
of O
natural B_EDU[ORGANIZATION]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
synthetic B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analogues I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Calling O
T3 B_MEASURE/B_PERSON
100 I_MEASURE/I_PERSON
, O
the O
order B_MEASURE/B_DISEASE
of O
potencies B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
observed O
was O
: O
Triac B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
500 B_MEASURE
; O
3 B_NUMBER[MEASURE]
, O
5-diiodo-3'-isopropylthyronine B_TIME[MEASURE]
, O
89 B_MEASURE
; O
T4 B_PROTEIN[GENE]
, O
32 B_MEASURE
; O
3 B_NUMBER[MEASURE]
, O
5-dimethyl-3'isopropylthyronine B_TIME[MEASURE]
2 I_TIME[MEASURE]
; O
3 B_NUMBER[MEASURE]
, O
5-T2 B_MEASURE
, O
0.7 B_MEASURE
, O
rT3 B_MEASURE/B_PROTEIN[GENE]
, O
0.4 B_MEASURE
; O
3'5'-T2 B_PROTEIN[GENE]/B_MEASURE
, O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
0.01 B_MEASURE/B_LOCATION
. O

These O
results O
suggest O
that O
the O
T3 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sites I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
present O
in O
human O
IM-9 O
lymphocyte O
nuclei O
and O
extracts O
thereof O
are O
thyroid B_DISEASE_ADJECTIVE[DISEASE]
hormone I_DISEASE_ADJECTIVE[DISEASE]
receptors I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
cells O
may O
be O
a O
useful O
tool O
to O
increase O
our O
understanding O
of O
human B_DISEASE
T3 I_DISEASE
receptors I_DISEASE
. O

definition O
of O
T-cell B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
specific I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA-binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
interact O
with O
a O
3'-silencer B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
CD4+ B_GENE
T-cell I_GENE
gene I_GENE
Rpt-1 I_GENE
. O

Analysis O
of O
the O
region O
3 O
' O
to O
the O
CD4+ B_GENE/B_LOCATION
T-cell I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
Rpt-1 I_GENE/I_LOCATION
( O
encoding O
regulatory O
protein O
T-lymphocyte B_PROTEIN[GENE]/B_MEASURE
1 I_PROTEIN[GENE]/I_MEASURE
) O
led O
to O
the O
definition O
of O
a O
silencer B_GENE
element I_GENE
that O
inhibits O
heterologous B_GENE
gene I_GENE
expression O
in O
certain O
CD4+ O
T-cell O
lines O
but O
not O
in O
B-cell O
or O
non-lymphoid O
cell O
lines O
. O

functional O
silencer B_GENE
activity O
in O
vivo O
was O
associated O
with O
the O
presence O
of O
a O
specific O
silencer-DNA-protein B_GENE
complex I_GENE
in O
electrophoretic O
mobility O
shift O
assays O
with O
T-cell O
extracts O
. O

Formation O
of O
this O
complex O
was O
selectively O
inhibited O
by O
the O
region O
in O
HIV-1 B_BIO/B_GENE
containing O
a O
silencer B_GENE
element I_GENE
. O

We O
discuss O
the O
possibility O
that O
DNA-binding B_DISEASE/B_GENE
factors B_DISEASE/I_GENE
may O
coregulate O
HIV-1 O
and O
Rpt-1 O
gene O
expression O
through O
a O
common O
transcriptional B_GENE/B_LOCATION
silencer B_GENE/I_LOCATION
element B_GENE/I_LOCATION
. O

Congenital O
immunodeficiencies O
associated O
with O
absence O
of O
HLA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O
lymphocytes O
result O
from O
distinct O
mutations O
in O
trans-acting B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

coordinate O
regulation O
of O
HLA B_GENE/B_BIO
class I_GENE/I_BIO
II I_GENE/I_BIO
gene I_GENE/I_BIO
expression O
during O
development O
and O
coinduction O
of O
class B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
soluble B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggests O
that O
common O
trans-acting B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
s O
) O
control O
expression O
of O
these O
genes O
. O

In O
B-lymphoblastoid O
cell O
lines O
derived O
from O
two O
independent O
class O
II-deficient O
bare O
lymphocyte O
syndrome O
patients O
, O
we O
observed O
a O
drastic O
decrease O
in O
transcription O
rates O
of O
the O
class B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

When O
these O
cell O
lines O
are O
fused O
, O
class B_GENE/B_PERSON
II I_GENE/I_PERSON
genes I_GENE/I_PERSON
are O
reexpressed O
, O
indicating O
that O
immunodeficiencies O
in O
bare O
lymphocyte O
syndrome O
patients O
are O
the O
result O
of O
two O
distinct O
mutations O
. O

Further O
studies O
show O
that O
genes O
governing O
the O
expression O
of O
class B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fall O
into O
at O
least O
three O
complementation O
groups O
; O
two O
of O
these O
were O
previously O
unidentified O
in O
mutant O
cell O
lines O
generated O
in O
vitro O
. O

In O
addition O
, O
we O
report O
the O
identification O
of O
two O
discrete O
complexes O
, O
NFX1.1 B_GENE
and O
NFX1.2 B_GENE
, O
that O
bind O
to O
the O
DRA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consensus I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Though O
the O
mutation O
in O
at O
least O
one O
mutant O
line O
generated O
in O
vitro O
( O
RJ2.2.5 O
) O
affects O
products O
functioning O
via O
interaction O
with O
the O
X B_GENE
box I_GENE
, O
clear O
alterations O
in O
either O
NFX1.1 B_GENE/B_DISEASE
or O
NFX1.2 B_GENE
are O
not O
found O
in O
any O
of O
the O
mutant O
cell O
lines O
. O

In O
vivo O
responsiveness O
to O
glucocorticoid O
correlated O
with O
glucocorticoid B_GENE
receptor I_GENE
content O
in O
peripheral O
blood O
leukocytes O
in O
normal O
humans O
. O

dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loading I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0.1 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dexamethasone/kg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
iv B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
performed O
in O
18 B_MEASURE/B_PERSON
normal I_MEASURE/I_PERSON
males I_MEASURE/I_PERSON
to O
evaluate O
the O
individual B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responsiveness I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
glucocorticoid O
. O

There O
were O
inter-individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
peripheral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
polymorphonuclear B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leukocyte B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
count B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
decrease O
in O
peripheral B_DISEASE/B_GENE
blood B_DISEASE/I_GENE
lymphocyte B_DISEASE/I_GENE
count B_DISEASE/I_GENE
, O
and O
increase O
in O
plasma B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
free B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
fatty B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acids B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
after O
dexamethasone B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
there O
was O
a O
significant B_MEASURE/B_PERSON
correlation I_MEASURE/I_PERSON
between O
the O
maximum B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
increase B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
polymorphonuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
leukocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O
the O
maximum B_MEASURE
decrease I_MEASURE
in O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O
r B_GENE/B_OTHER
= O
0.7514 B_MEASURE
, O
p B_MEASURE
less I_MEASURE
than O
0.0003 B_NUMBER[MEASURE]/B_LOCATION
) O
. O

simultaneous O
measurements O
of O
glucocorticoid B_GENE
receptor I_GENE
content O
by O
whole-cell O
assay O
revealed O
that O
glucocorticoid B_GENE
receptor I_GENE
content O
in O
polymorphonuclear O
leukocytes O
linearly O
correlated O
with O
that O
in O
the O
corresponding O
lymphocytes O
( O
r O
= O
0.9482 O
, O
p O
less O
than O
0.0001 O
) O
. O

There O
were O
also O
significant O
correlations O
between O
the O
maximum O
increase O
in O
polymorphonuclear O
leukocytes O
and O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O
in O
polymorphonuclear O
leukocytes O
( O
r O
= O
0.7239 O
, O
p O
less O
than O
0.0007 O
) O
, O
and O
between O
the O
maximum O
decrease O
in O
lymphocytes O
and O
glucocorticoid B_GENE
receptor I_GENE
content O
in O
lymphocytes O
( O
r O
= O
0.7703 O
, O
p O
less O
than O
0.0002 O
) O
. O

These O
results O
suggest O
that O
individual O
differences O
are O
preserved O
both O
in O
glucocorticoid O
responsiveness O
and O
in O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O
in O
peripheral O
blood O
leukocytes O
in O
normal O
humans O
. O

Estradiol O
receptors O
in O
the O
cytosol O
of O
peripheral O
blood O
mononuclear O
cells O
in O
hepatitis O
B O
virus O
carriers O
treated O
with O
interferon-alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
cytosol O
of O
peripheral O
blood O
mononuclear O
cells O
and O
the O
effects O
of O
interferon-alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
IFN-alpha B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
on O
estradiol B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
studied O
in O
asymptomatic O
hepatitis O
B O
virus O
( O
HBV O
) O
carriers O
, O
patients O
with O
chronic O
hepatitis O
B O
and O
normal O
controls O
. O

The O
level O
of O
estradiol B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
cytosol O
of O
mononuclear O
cells O
was O
significantly O
lower O
in O
asymptomatic O
HBV O
carriers O
and O
patients O
with O
chronic O
hepatitis O
B O
, O
compared O
to O
normal O
controls O
. O

This O
low O
level O
of O
cytosol O
estradiol B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients O
with O
chronic O
hepatitis O
B O
was O
increased O
by O
the O
administration O
of O
IFN-alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

In O
addition O
, O
when O
peripheral O
blood O
mononuclear O
cells O
from O
patients O
with O
chronic O
hepatitis O
B O
were O
incubated O
with O
IFN-alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
vitro O
, O
the O
level O
of O
cytosol O
estradiol B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
increased O
by O
increasing O
the O
concentration O
of O
IFN-alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

We O
previously O
reported O
that O
the O
response O
of O
mononuclear O
cells O
to O
estrogen O
is O
impaired O
in O
HBV O
carriers O
, O
and O
our O
present O
results O
suggested O
that O
this O
may O
be O
due O
to O
the O
low O
level O
of O
estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
cytosol O
of O
mononuclear O
cells O
. O

Association O
of O
increased O
lytic O
effector O
cell O
function O
with O
high O
estrogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O
in O
tumor-bearing O
patients O
with O
breast O
cancer O
. O

Tumor-bearing O
patients B_PERSON/B_SPECIES[BIO]
with O
breast B_DISEASE
cancer I_DISEASE
were O
assayed O
for O
their O
natural B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
killer B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
NK B_PROTEIN[GENE]/B_LOCATION
) O
cell B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
for O
the O
function B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
activated O
cytotoxic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T-cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
assessed O
by O
lectin-dependent B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cellular B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytotoxicity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LDCC B_DISEASE/B_LOCATION
) O
. O

Tumor-bearing O
patients B_PERSON
with O
breast B_DISEASE
cancer I_DISEASE
had O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
NK B_DISEASE
activity I_DISEASE
and O
in O
LDCC B_DISEASE/B_GENE
, O
as O
compared O
with O
healthy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
individuals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Although O
the O
enhanced O
NK O
cell O
activity O
and O
LDCC O
were O
closely O
associated O
with O
high O
levels O
( O
greater O
than O
31 O
fmol/mg O
) O
of O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
ER B_PROTEIN[GENE]/B_LOCATION
) O
content O
in O
the O
primary O
tumor O
, O
no O
other O
clinical O
or O
histologic O
correlation O
between O
the O
increase O
in O
either O
parameter O
of O
cytotoxic O
effector O
cell O
function O
could O
be O
found O
. O

Thus O
, O
ER B_GENE
levels O
greater O
than O
31 O
fmol/mg O
might O
be O
associated O
with O
increased O
cytotoxic O
effector O
cell O
function O
in O
tumor-bearing O
patients O
with O
breast O
cancer O
. O

Properties O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
Epstein-Barr O
virus-transformed O
lymphocytes O
from O
patients O
with O
familial O
cortisol O
resistance O
. O

In O
a O
previous O
report O
of O
two O
patients O
with O
familial O
glucocorticoid O
resistance O
due O
to O
reduced O
numbers O
of O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GR B_LOCATION/B_PROTEIN[GENE]
) O
, O
we O
have O
shown O
decreased O
numbers O
of O
GR B_PROTEIN[GENE]/B_DISEASE
in O
peripheral O
mononuclear O
cells O
and O
cultured O
fibroblasts O
but O
normal O
affinity O
of O
GR B_PROTEIN[GENE]/B_DISEASE
in O
both O
patients O
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
these O
patients B_PERSON/B_BIO
, O
one B_PERSON
patient I_PERSON
's I_PERSON
son I_PERSON
and O
daughter B_PERSON
, O
and O
normal B_PERSON/B_BIO
subjects I_PERSON/I_BIO
were O
transformed O
with O
Epstein-Barr B_DISEASE/B_GENE
virus B_DISEASE/I_GENE
. O

reduced O
numbers O
and O
normal O
affinity O
of O
GR B_LOCATION/B_ORGANIZATION
were O
found O
in O
the O
Epstein-Barr O
virus-transformed O
lymphocytes O
from O
both O
patients O
while O
the O
son O
and O
daughter O
had O
normal O
numbers O
and O
affinity O
of O
GR B_PROTEIN[GENE]/B_DISEASE
. O

The O
thermal O
stability O
of O
GR B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O
thermal O
activation O
of O
cytosolic B_PROTEIN[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_PROTEIN[GENE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
patients O
were O
found O
to O
be O
normal O
. O

Although O
the O
percentages O
of O
nuclear O
bound O
GR B_PROTEIN[GENE]/B_DISEASE
were O
similar O
in O
both O
patients O
and O
normal O
controls O
, O
the O
absolute O
amounts O
of O
nuclear O
bound O
GR B_PROTEIN[GENE]/B_DISEASE
of O
the O
patients O
were O
about O
one-half O
that O
of O
normal O
controls O
. O

These O
abnormal O
properties O
of O
GR B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
( O
reduced O
numbers O
of O
GR B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
) O
were O
preserved O
in O
the O
transformed O
cells O
from O
the O
patients O
. O

Octamer O
transcription O
factors O
1 O
and O
2 O
each O
bind O
to O
two O
different O
functional B_LOCATION/B_BIO
elements I_LOCATION/I_BIO
in O
the O
immunoglobulin B_GENE
heavy-chain I_GENE
promoter I_GENE
. O

Immunoglobulin B_PERSON/B_GENE
heavy-chain I_PERSON/I_GENE
genes I_PERSON/I_GENE
contain O
two O
conserved B_GENE/B_LOCATION
sequence B_GENE/I_LOCATION
elements B_GENE/I_LOCATION
5 O
' O
to O
the O
site O
of O
transcription O
initiation O
: O
the O
octamer O
ATGCAAAT O
and O
the O
heptamer O
CTCATGA O
. O

Both O
of O
these O
elements O
are O
required O
for O
normal B_GENE
cell-specific I_GENE
promoter I_GENE
function O
. O

The O
present O
study O
demonstrates O
that O
both O
the O
ubiquitous B_GENE/B_LOCATION
and I_GENE/I_LOCATION
lymphoid-cell-specific I_GENE/I_LOCATION
octamer I_GENE/I_LOCATION
transcription I_GENE/I_LOCATION
factors I_GENE/I_LOCATION
( O
OTF-1 B_GENE
and O
OTF-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
) O
interact O
specifically O
with O
each O
of O
the O
two O
conserved B_GENE/B_LOCATION
sequence I_GENE/I_LOCATION
elements I_GENE/I_LOCATION
, O
forming O
either O
homo- B_LOCATION/B_PERSON
or I_LOCATION/I_PERSON
heterodimeric I_LOCATION/I_PERSON
complexes I_LOCATION/I_PERSON
. O

This O
was O
surprising B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
since O
the O
heptamer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
octamer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
motifs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
bear O
no O
obvious B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
similarity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
each O
other B_TIME[MEASURE]/B_DISEASE
. O

binding O
of O
either O
factor O
to O
the O
octamer B_LOCATION/B_BIO
element B_LOCATION/I_BIO
occurred O
independently O
. O

However O
, O
OTF B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
interaction O
with O
the O
heptamer B_GENE/B_LOCATION
sequence I_GENE/I_LOCATION
appeared O
to O
require O
the O
presence O
of O
an O
intact O
octamer O
motif O
and O
occurred O
with O
a O
spacing O
of O
either O
2 B_LOCATION/B_PERSON
or I_LOCATION/I_PERSON
14 I_LOCATION/I_PERSON
base I_LOCATION/I_PERSON
pairs I_LOCATION/I_PERSON
between O
the O
two O
elements O
, O
suggesting O
coordinate O
binding O
resulting O
from O
protein-protein O
interactions O
. O

The O
degeneracy O
in O
sequences O
recognized O
by O
the O
OTFs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
may O
be O
important O
in O
widening O
the O
range O
over O
which O
gene O
expression O
can O
be O
modulated O
and O
in O
establishing O
cell O
type O
specificity O
. O

identification O
of O
a O
novel O
lymphoid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
specific I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
octamer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
OTF-2B B_GENE/B_LOCATION
) O
by O
proteolytic O
clipping O
bandshift O
assay O
( O
PCBA O
) O
. O

The O
octamer O
sequence O
ATGCAAAT O
is O
found O
in O
the O
promoters O
of O
immunoglobulin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ig I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heavy I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
in O
the O
heavy B_GENE
chain I_GENE
enhancer I_GENE
and O
is O
a O
major O
determinant O
of O
the O
cell O
type O
specific O
expression O
of O
Ig B_GENE
genes I_GENE
in O
B O
cells O
. O

An O
apparent O
paradox O
is O
that O
the O
same O
sequence O
serves O
as O
an O
upstream B_GENE/B_TIME[MEASURE]
promoter I_GENE/I_TIME[MEASURE]
or I_GENE/I_TIME[MEASURE]
enhancer I_GENE/I_TIME[MEASURE]
element I_GENE/I_TIME[MEASURE]
in O
a O
variety O
of O
housekeeping B_GENE/B_LOCATION
genes I_GENE/I_LOCATION
such O
as O
the O
histone B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
H2B I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
and I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
U I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
snRNA I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
genes I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
differential O
usage O
of O
this O
regulatory O
sequence O
motif O
is O
thought O
to O
be O
mediated O
by O
different O
species O
of O
octamer B_GENE
binding I_GENE
proteins I_GENE
. O

One O
species O
of O
100 O
kd O
, O
designated O
OTF-1 B_GENE
, O
is O
present O
in O
all O
cell O
types O
and O
may O
exert O
its O
activating O
function O
only O
when O
it O
can O
interact O
with O
additional O
adjacent O
transcription B_BIO/B_GENE
factors I_BIO/I_GENE
. O

The O
lymphoid B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
specific I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
octamer I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
60 O
kd O
( O
OTF-2A B_GENE
) O
specifically O
stimulates O
Ig B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
consist O
essentially O
of O
a O
TATA-box B_GENE/B_MEASURE
and O
an O
octamer B_GENE/B_LOCATION
sequence I_GENE/I_LOCATION
upstream O
of O
it O
. O

Here O
we O
present O
evidence O
for O
yet O
another O
B B_GENE/B_MEASURE
cell I_GENE/I_MEASURE
specific I_GENE/I_MEASURE
octamer I_GENE/I_MEASURE
binding I_GENE/I_MEASURE
protein I_GENE/I_MEASURE
of O
75 O
kd O
( O
OTF-2B B_GENE
) O
. O

From O
several O
findings O
, O
including O
the O
absence O
of O
OTF-2B B_GENE
( O
but O
not O
OTF-2A B_GENE
) O
from O
a O
lymphocyte O
line O
that O
can O
not O
respond O
to O
the O
IgH B_GENE
enhancer I_GENE
, O
we O
propose O
a O
role O
of O
the O
novel B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
octamer I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
long O
range O
activation O
by O
the O
IgH B_GENE/B_MEASURE
enhancer I_GENE/I_MEASURE
. O

We O
have O
used O
the O
proteolytic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
clipping I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
bandshift I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
PCBA B_DISEASE/B_GENE
) O
technique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
distinguish O
the O
three B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
different B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
forms B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
found O
in O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

This O
analysis O
indicates O
that O
the O
75 O
kd-species O
OTF-2B B_GENE/B_MEASURE
is O
closely O
related O
to O
the O
60 B_MEASURE/B_GENE
kd I_MEASURE/I_GENE
species I_MEASURE/I_GENE
OTF-2A I_MEASURE/I_GENE
. O

Inhibition O
of O
interleukin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O
proliferation O
of O
cloned O
murine O
T O
cells O
by O
glucocorticoids O
. O

possible O
involvement O
of O
an O
inhibitory B_PERSON/B_ORGANIZATION
protein I_PERSON/I_ORGANIZATION
. O

The O
ability O
of O
glucocorticoids O
to O
inhibit O
interleukin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
IL B_GENE
2 I_GENE
) O
-induced O
T O
cell O
proliferation O
in O
two O
cytotoxic O
T O
cell O
( O
CTL O
) O
clones O
has O
been O
studied O
. O

A O
complete O
inhibition O
of O
DNA O
synthesis O
by O
dexamethasone O
( O
Dx O
) O
could O
be O
observed O
when O
IL O
2-depleted O
cultures O
of O
CTL O
were O
either O
incubated O
for O
6 O
h O
with O
the O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prior O
to O
the O
addition O
of O
IL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O
treated O
simultaneously O
with O
Dx O
and O
a O
low O
concentration O
of O
IL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

No O
significant O
reduction O
in O
the O
number O
and O
affinity O
of O
IL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
seen O
after O
6 O
h O
incubation O
with O
Dx O
. O

The O
order O
of O
potency O
observed O
with O
the O
different O
steroids O
indicated O
that O
this O
inhibitory O
effect O
was O
mediated O
through O
binding O
to O
a O
specific O
glucocorticoid B_PROTEIN[GENE]
receptor I_PROTEIN[GENE]
. O

The O
action O
of O
these O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possibly O
involves O
the O
synthesis O
of O
an O
inhibitory B_GENE
protein I_GENE
( O
s O
) O
, O
since O
the O
presence O
of O
cycloheximide O
during O
the O
incubation O
with O
Dx O
prevented O
the O
inhibition O
of O
DNA O
synthesis O
. O

Furthermore O
, O
supernatant O
from O
Dx-treated O
CTL O
contained O
a O
nondialyzable O
factor O
which O
inhibited O
DNA O
synthesis O
and O
cell O
growth O
of O
CTL O
clones O
induced O
by O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

blocking O
of O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O
and O
IL B_GENE
2 I_GENE
receptor I_GENE
formation O
have O
been O
proposed O
as O
one O
of O
the O
major O
mechanisms O
of O
glucocorticoid-induced O
immunosuppression O
. O

Our O
results O
indicate O
that O
these O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O
also O
affect O
T O
cell O
proliferation O
by O
inhibiting O
IL B_GENE
2 I_GENE
activity O
. O

identification O
and O
purification O
of O
a O
human B_GENE/B_MEASURE
immunoglobulin-enhancer-binding I_GENE/I_MEASURE
protein I_GENE/I_MEASURE
( O
NF-kappa B_GENE/B_DISEASE
B I_GENE/I_DISEASE
) O
that O
activates O
transcription O
from O
a O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
vitro O
. O

The O
enhancer-binding B_GENE/B_MEASURE
factor I_GENE/I_MEASURE
NF-kappa I_GENE/I_MEASURE
B I_GENE/I_MEASURE
, O
which O
is O
found O
only O
in O
cells O
that O
transcribe O
immunoglobulin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
light I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
has O
been O
purified O
from O
nuclear O
extracts O
of O
Namalwa O
cells O
( O
human O
Burkitt O
lymphoma O
cells O
) O
by O
sequence-specific O
DNA O
affinity O
chromatography O
. O

The O
purified O
NF-kappa B_GENE
B I_GENE
has O
been O
identified O
as O
a O
51-kDa B_GENE
polypeptide I_GENE
by O
UV-crosslinking O
analysis O
. O

`` O
Footprint O
'' O
and O
methylation-interference O
analyses O
have O
shown O
that O
purified O
NF-kappa B_GENE/B_LOCATION
B I_GENE/I_LOCATION
has O
a O
binding O
activity O
specific O
for O
the O
kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
light I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
purified O
factor O
activated O
in O
vitro O
transcription O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
binding O
to O
an O
upstream B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B-binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Lymphocyte O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O
in O
depression O
: O
normal O
values O
following O
recovery O
. O

The O
number O
of O
glucocorticoid B_GENE
receptor I_GENE
sites O
in O
lymphocytes O
and O
plasma O
cortisol O
concentrations O
were O
measured O
in O
20 O
patients O
who O
had O
recovered O
from O
major O
depressive O
disorder O
and O
20 O
healthy O
control O
subjects O
. O

The O
number O
of O
glucocorticoid B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O
in O
lymphocytes O
from O
the O
recovered O
depressed O
group O
was O
not O
significantly O
different O
from O
that O
of O
the O
control O
group O
. O

Although O
the O
mean B_MEASURE
plasma I_MEASURE
cortisol I_MEASURE
concentration I_MEASURE
in O
recovered O
depressives B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
was O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
in O
control B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
difference B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
just O
reached O
significance B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
study O
shows O
that O
the O
reduction O
in O
glucocorticoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
numbers O
which O
occurs O
during O
acute O
depressive O
illness O
does O
not O
persist O
on O
recovery O
and O
is O
, O
therefore O
, O
state-dependent O
. O

identification O
and O
purification O
of O
a O
human B_PROTEIN[GENE]/B_MEASURE
lymphoid-specific I_PROTEIN[GENE]/I_MEASURE
octamer-binding I_PROTEIN[GENE]/I_MEASURE
protein I_PROTEIN[GENE]/I_MEASURE
( O
OTF-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
that O
activates O
transcription O
of O
an O
immunoglobulin B_GENE
promoter I_GENE
in O
vitro O
. O

The O
octamer O
sequence O
5'-ATGCAAAT O
, O
in O
either O
orientation O
, O
serves O
as O
an O
upstream B_GENE/B_PERSON
element I_GENE/I_PERSON
in O
a O
variety O
of O
promoters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
also O
occurs O
as O
a O
modular B_GENE/B_PERSON
enhancer I_GENE/I_PERSON
element I_GENE/I_PERSON
. O

It O
is O
of O
particular O
interest O
in O
immunoglobulin B_SPECIES[BIO]/B_GENE
genes I_SPECIES[BIO]/I_GENE
since O
it O
is O
found O
in O
the O
upstream B_LOCATION/B_GENE
regions I_LOCATION/I_GENE
of O
all O
heavy B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
light I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
the O
heavy B_GENE/B_LOCATION
chain I_GENE/I_LOCATION
enhancer I_GENE/I_LOCATION
, O
both O
of O
which O
are O
known O
to O
be O
necessary O
for O
cell-specific O
expression O
. O

We O
report O
here O
the O
chromatographic O
separation O
of O
ubiquitous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
cell-specific I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
octamer-binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
proteins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

The O
B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
purified O
to O
homogeneity O
using O
affinity O
chromatography O
and O
consists O
of O
three O
peptides O
of O
62 O
, O
61 O
, O
and O
58.5 O
+/- O
1.5 O
kd O
. O

Each O
of O
the O
polypeptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
renatured O
after O
SDS-PAGE B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
shown O
to O
bind O
to O
the O
octamer B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
specific O
DNA O
binding O
activity O
of O
the O
pure O
B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
cell-specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O
indistinguishable O
from O
that O
of O
the O
affinity-purified B_GENE/B_BIO
ubiquitous I_GENE/I_BIO
factor I_GENE/I_BIO
. O

This O
B B_GENE
cell-specific I_GENE
octamer-binding I_GENE
factor I_GENE
, O
in O
pure O
form O
, O
activated O
transcription O
from O
a O
kappa B_GENE
light I_GENE
chain I_GENE
promoter I_GENE
in O
vitro O
, O
thus O
demonstrating O
that O
it O
is O
indeed O
a O
B B_GENE/B_PERSON
cell-specific I_GENE/I_PERSON
transcription I_GENE/I_PERSON
factor I_GENE/I_PERSON
for O
this O
gene O
. O

In O
addition O
to O
the O
ubiquitous B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
B I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cell-specific I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
octamer-binding I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
we O
identified O
several O
additional O
proteins O
, O
one O
of O
which O
is O
B O
cell O
-specific O
, O
that O
interact O
with O
the O
kappa B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
. O

decreased O
deoxyribonucleic O
acid O
binding O
of O
glucocorticoid-receptor B_GENE
complex I_GENE
in O
cultured O
skin O
fibroblasts O
from O
a O
patient O
with O
the O
glucocorticoid O
resistance O
syndrome O
. O

A O
patient B_PERSON
with O
the O
syndrome B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
glucocorticoid B_DISEASE
resistance I_DISEASE
was O
studied O
. O

A O
27-yr-old B_PERSON
woman I_PERSON
initially O
was O
diagnosed O
as O
having O
Cushing B_DISEASE
's I_DISEASE
disease I_DISEASE
, O
based O
on O
the O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
high B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
plasma B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
ACTH B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
serum O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
increased O
urinary B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cortisol B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretion B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
resistance B_DISEASE_ADJECTIVE[DISEASE]
to O
adrenal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppression I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
bilateral B_DISEASE_ADJECTIVE[DISEASE]
adrenal I_DISEASE_ADJECTIVE[DISEASE]
hyperplasia I_DISEASE_ADJECTIVE[DISEASE]
by O
computed B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tomography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
scintigraphy B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
adrenal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
glands I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
she O
had O
no O
signs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
symptoms B_DISEASE
of O
Cushing B_DISEASE
's I_DISEASE
syndrome I_DISEASE
. O

During O
a O
5-yr B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
follow-up B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
no O
clinical B_DISEASE
abnormalities I_DISEASE
developed O
, O
although O
hypercortisolism B_DISEASE
persisted O
. O

End-organ B_DISEASE_ADJECTIVE[DISEASE]
resistance I_DISEASE_ADJECTIVE[DISEASE]
to O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
suspected O
. O

To O
explain O
the O
end-organ O
resistance O
to O
cortisol O
, O
the O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
GR B_PROTEIN[GENE]/B_DISEASE
) O
in O
peripheral O
mononuclear O
leukocytes O
and O
cultured O
skin O
fibroblasts O
from O
a O
forearm O
skin O
biopsy O
were O
characterized O
and O
compared O
with O
the O
results O
of O
similar O
studies O
in O
normal O
subjects O
. O

The O
patient O
's O
GR B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O
whole O
cell O
assays O
had O
an O
increased O
dissociation O
constant O
( O
Kd O
) O
. O

In O
the O
cytosol B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cultured B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
skin I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
fibroblasts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O
the O
patient B_PERSON/B_BIO
, O
there O
was O
also O
decreased O
binding B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
thermal B_MEASURE/B_LOCATION
stability I_MEASURE/I_LOCATION
and O
the O
sedimentation B_MEASURE
coefficient I_MEASURE
in O
a O
sucrose B_MEASURE
density I_MEASURE
gradient I_MEASURE
of O
the O
receptors B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
cytosol B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
cultured B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
skin I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibroblasts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
the O
patient B_PERSON/B_DISEASE
and O
normal B_PERSON/B_BIO
subjects I_PERSON/I_BIO
were O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

GR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complex I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
analyzed O
by O
DEAE-cellulose B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
was O
decreased O
in O
the O
patient B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

DNA B_BIO/B_GENE
binding O
of O
the O
GR B_GENE
complex I_GENE
after O
temperature-induced O
activation O
was O
lower O
in O
the O
patient O
than O
in O
normal O
subjects O
. O

Nuclear O
translocation O
of O
GR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
patient O
was O
also O
slightly O
decreased O
. O

These O
results O
suggest O
that O
the O
patient O
's O
glucocorticoid O
resistance O
was O
due O
to O
a O
decrease O
in O
the O
affinity O
of O
the O
receptor O
for O
glucocorticoids O
and O
a O
decrease O
in O
the O
binding O
of O
the O
GR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complex I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
DNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Granulocyte-macrophage B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
colony-stimulating I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
factor I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

sensitive B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
receptor-mediated B_DISEASE_ADJECTIVE[DISEASE]
regulation I_DISEASE_ADJECTIVE[DISEASE]
by O
1 B_MEASURE
, O
25-dihydroxyvitamin B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D3 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
normal B_BIO/B_DISEASE
human I_BIO/I_DISEASE
peripheral I_BIO/I_DISEASE
blood I_BIO/I_DISEASE
lymphocytes I_BIO/I_DISEASE
. O

We O
show O
that O
1 O
, O
25-dihydroxyvitamin O
D3 O
( O
1 O
, O
25 O
[ O
OH O
] O
2D3 O
) O
, O
the O
most O
hormonally O
active O
metabolite O
of O
vitamin O
D3 O
, O
modulates O
sensitively O
and O
specifically O
both O
the O
protein O
and O
messenger B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
accumulation O
of O
the O
multilineage B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
granulocyte-macrophage I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

The O
regulation O
of O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O
is O
seen O
in O
both O
normal O
human O
mitogen-activated O
T O
lymphocytes O
and O
T O
lymphocytes O
from O
a O
line O
( O
S-LB1 O
) O
transformed O
with O
human O
T O
cell O
lymphotropic O
virus O
1 O
( O
HTLV-1 O
) O
. O

In O
contrast O
, O
cells O
from O
a O
HTLV-1 O
transformed O
T O
lymphocyte O
line O
( O
Ab-VDR O
) O
established O
from O
a O
patient O
with O
vitamin O
D-resistant O
rickets O
type O
II O
with O
undetectable O
1 B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
25 I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OH I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2D3 I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cellular I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
resistant O
to O
the O
action O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
. O

Inhibition O
of O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
can O
occur O
independently O
of O
interleukin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation O
and O
is O
probably O
mediated O
through O
cellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
25 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
OH I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2D3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
conclude O
that O
1 B_MEASURE
, O
25 B_MEASURE
( O
OH O
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
may O
be O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
physiology B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hematopoiesis B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

altered O
interaction O
between O
triiodothyronine O
and O
its O
nuclear B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
absence O
of O
cortisol O
: O
a O
proposed O
mechanism O
for O
increased O
thyrotropin O
secretion O
in O
corticosteroid O
deficiency O
states O
. O

Thyroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
occasionally O
appear O
less O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
when O
administered O
alone O
to O
patients B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
panhypopituitarism B_DISEASE
, O
and O
manifestations B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggestive I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hypothyroidism B_DISEASE
have O
been O
reported O
in O
patients B_PERSON
suffering O
from O
untreated B_DISEASE
Addison I_DISEASE
's I_DISEASE
disease I_DISEASE
. O

In O
the O
latter B_PERSON/B_DISEASE
condition I_PERSON/I_DISEASE
, O
thyrotropin B_DISEASE
secretion I_DISEASE
is O
increased O
: O
this O
occurs O
already O
after O
as O
little B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
2 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
of O
temporary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
withdrawal I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
substitution B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
corticosteroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
while O
circulating O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
thyroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
remain O
within O
normal B_MEASURE/B_PERSON
limits B_MEASURE/I_PERSON
. O

Therefore O
, O
a O
possible O
role O
of O
cortisol O
in O
interaction O
between O
triiodothyronine O
and O
its O
nuclear B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
examined O
at O
the O
level O
of O
circulating O
lymphocytes O
obtained O
from O
patients O
with O
primary O
or O
secondary O
adrenocortical O
failure O
. O

The O
affinity B_GENE/B_MEASURE
of O
these O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
to O
be O
decreased O
, O
by O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
on O
average B_MEASURE/B_SOCIAL_CIRCUMSTANCES
, O
in O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
change B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
promptly O
corrected O
upon O
resumption B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
. O

The O
number B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
binding O
sites B_LOCATION/B_ENT
was O
not O
significantly O
modified O
. O

The O
influence O
of O
cortisol O
on O
thyroid B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discussed O
here O
might O
account O
for O
the O
clinical O
observations O
mentioned O
above O
. O

Inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
natural I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
killer I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NK B_LOCATION/B_PERSON
) O
cell B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
natural B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
killer B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
NK B_PROTEIN[GENE]/B_LOCATION
) O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peripheral I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mononuclear I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PBM B_LOCATION
) O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
studied O
in O
vitro B_MEASURE/B_LOCATION
using O
a O
direct B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
4-h B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
51Cr-release B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
assay B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
K B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
562 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
line B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O
a O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

preincubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O
20 B_MEASURE
h O
of O
PBM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
drawn O
from O
healthy B_PERSON/B_BIO
donors I_PERSON/I_BIO
with O
1 B_MEASURE/B_LOCATION
X I_MEASURE/I_LOCATION
10 I_MEASURE/I_LOCATION
( O
-8 O
) O
to O
1 B_MEASURE/B_LOCATION
X I_MEASURE/I_LOCATION
10 I_MEASURE/I_LOCATION
( O
-5 O
) O
M B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cortisol I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
resulted O
in O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
NK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
magnitude B_MEASURE
of O
the O
suppression B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
directly O
related O
to O
the O
steroid B_MEASURE
concentration I_MEASURE
and O
inversely O
related O
to O
the O
number B_MEASURE/B_LOCATION
of O
effector B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
able B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
minimize O
the O
enhancement B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
NK B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cytotoxicity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
obtainable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
the O
presence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
immune B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interferon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
IFN-gamma B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

A O
significantly O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suppression B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
achieved O
after O
sequential B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
PBM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
to O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
equimolar B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
PGE2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
. O

The O
concomitant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
incubation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
isobutyl-methylxanthine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
failed O
to O
enhance O
the O
cortisol-induced B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppression B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
PgE2-dependent B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O
increased O
after O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
PBM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
methyl-xanthines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
inhibitory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
partially O
or O
totally O
prevented O
by O
the O
concomitant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incubation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
equimolar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
11-deoxycortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
RU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
486 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
not O
of O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Treatment O
of O
NK O
effectors O
with O
a O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
anti-human I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
corticosteroid-binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
globulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CBG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
produced O
an O
enhancement O
of O
the O
spontaneous O
NK O
activity O
and O
a O
partial O
suppression O
of O
cortisol-mediated O
effects O
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
play O
a O
role B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
in O
the O
regulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
NK B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cell-mediated B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
cytotoxicity B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

Since O
the O
effect O
of O
cortisol O
was O
additive O
to O
that O
of O
PgE2 O
and O
was O
not O
changed O
by O
phosphodiesterase B_ENZYME[GENE]
inhibitors O
, O
it O
is O
conceivable O
that O
the O
hormone O
acts O
at O
a O
level O
different O
from O
the O
adenylate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cyclase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
phosphodiesterase B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O
. O

Data O
obtained O
with O
the O
use O
of O
antiglucocorticoids O
and O
the O
anti-CBG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O
compatible O
with O
a O
role O
both O
of O
high-affinity O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
of O
CBG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
mediating O
cortisol O
action O
on O
the O
human O
NK O
cell O
activity O
. O

interaction O
of O
cell-type-specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
immunoglobulin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
VH I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

All O
human B_GENE/B_LOCATION
and I_GENE/I_LOCATION
murine I_GENE/I_LOCATION
immunoglobulin I_GENE/I_LOCATION
heavy I_GENE/I_LOCATION
chain I_GENE/I_LOCATION
variable I_GENE/I_LOCATION
region I_GENE/I_LOCATION
( I_GENE/I_LOCATION
VH I_GENE/I_LOCATION
) I_GENE/I_LOCATION
genes I_GENE/I_LOCATION
contain O
the O
sequence O
ATGCAAAT O
approximately O
70 O
nucleotides O
5 O
' O
from O
the O
site O
of O
transcription O
initiation O
. O

This O
octanucleotide O
, O
in O
reverse O
orientation O
, O
is O
also O
found O
in O
all O
light B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
variable I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
VL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
in O
the O
immunoglobulin B_GENE/B_BIO
heavy I_GENE/I_BIO
chain I_GENE/I_BIO
transcriptional I_GENE/I_BIO
enhancer I_GENE/I_BIO
. O

Transfection O
studies O
have O
established O
that O
this O
octamer O
is O
involved O
in O
the O
lymphoid-specific O
transcription O
of O
immunoglobulin B_GENE
genes I_GENE
. O

Octamer-containing B_PERSON/B_LOCATION
fragments I_PERSON/I_LOCATION
have O
been O
reported O
to O
bind O
a O
factor O
present O
in O
nuclear O
extracts O
of O
human O
cell O
lines O
; O
however O
, O
identical O
binding O
activity O
was O
detected O
in O
both O
B O
lymphoid O
and O
non-lymphoid O
cells O
. O

Here O
we O
establish O
that O
nuclear O
extracts O
from O
distinct O
cell O
types O
differ O
in O
their O
ability O
to O
interact O
with O
octamer-containing B_GENE
fragments I_GENE
. O

We O
have O
also O
detected O
a O
DNA-protein O
interaction O
that O
may O
be O
involved O
in O
the O
cell-type O
specificity O
of O
immunoglobulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
, O
and O
we O
have O
determined O
that O
a O
sequence O
upstream O
of O
the O
octamer O
participates O
in O
an O
interaction O
with O
a O
nuclear B_GENE/B_BIO
protein I_GENE/I_BIO
( O
s O
) O
. O

Preferential O
transcription O
of O
HTLV-I B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
cell-free O
extracts O
of O
human O
T O
cells O
producing O
HTLV-I B_DISEASE/B_GENE
viral B_DISEASE/I_GENE
proteins B_DISEASE/I_GENE
. O

The O
promoters B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
adenovirus B_GENE/B_DISEASE
2 I_GENE/I_DISEASE
major I_GENE/I_DISEASE
late I_GENE/I_DISEASE
gene I_GENE/I_DISEASE
, O
the O
mouse B_GENE
beta-globin I_GENE
gene I_GENE
, O
the O
mouse B_GENE
immunoglobulin I_GENE
VH I_GENE
gene I_GENE
and O
the O
LTR B_GENE/B_BIO
of O
the O
human O
T-lymphotropic O
retrovirus O
type O
I O
were O
tested O
for O
their O
transcription O
activities O
in O
cell-free O
extracts O
of O
four O
cell O
lines O
; O
HeLa O
, O
CESS O
( O
Epstein-Barr O
virus-transformed O
human O
B O
cell O
line O
) O
, O
MT-1 O
( O
HTLV-I-infected O
human O
T O
cell O
line O
without O
viral O
protein O
synthesis O
) O
, O
and O
MT-2 O
( O
HTLV-I-infected O
human O
T O
cell O
line O
producing O
viral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

LTR B_GENE/B_DISEASE
was O
preferentially O
transcribed O
in O
the O
extracts O
of O
MT-2 O
although O
the O
other O
three O
genes O
were O
transcribed O
with O
relatively O
constant O
efficiencies O
in O
different O
extracts O
. O

The O
results O
agree O
well O
with O
the O
previous O
in O
vivo O
studies O
on O
the O
promoter O
activity O
of O
HTLV-I B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Mixing O
of O
HeLa B_VIRUS[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
MT-2 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
extracts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
the O
presence B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
LTR-specific B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulating I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
MT-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
extracts B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

A O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
binds O
to O
a O
conserved O
sequence O
motif O
in O
transcriptional B_GENE/B_MEASURE
control I_GENE/I_MEASURE
elements I_GENE/I_MEASURE
of O
immunoglobulin B_GENE/B_SPECIES[BIO]
genes B_GENE/I_SPECIES[BIO]
. O

Trans-acting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
mediate O
B-cell O
specific O
transcription O
of O
immunoglobulin B_GENE
genes I_GENE
have O
been O
postulated O
based O
on O
an O
analysis O
of O
the O
expression O
of O
exogenously O
introduced O
immunoglobulin B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recombinants I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
lymphoid O
and O
non-lymphoid O
cells O
. O

Two O
B-cell-specific O
, O
cis-acting B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcriptional B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
regulatory B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
elements B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
have O
been O
identified O
. O

One O
element O
is O
located O
in O
the O
intron O
between O
the O
variable O
( O
V O
) O
and O
constant O
( O
C O
) O
regions O
of O
both O
heavy B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light-chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
acts O
as O
a O
transcriptional O
enhancer O
. O

The O
second O
element B_GENE/B_LOCATION
is O
found O
upstream O
of O
both O
heavy B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light-chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
element O
directs O
lymphoid-specific O
transcription O
even O
in O
the O
presence O
of O
viral B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
enhancers B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

We O
have O
sought O
nuclear O
factors O
that O
might O
bind O
specifically O
to O
these O
two O
regulatory B_GENE/B_LOCATION
elements I_GENE/I_LOCATION
by O
application O
of O
a O
modified O
gel O
electrophoresis O
DNA O
binding O
assay O
. O

We O
report O
here O
the O
identification O
of O
a O
human B_PROTEIN[GENE]/B_MEASURE
B-cell I_PROTEIN[GENE]/I_MEASURE
nuclear I_PROTEIN[GENE]/I_MEASURE
factor I_PROTEIN[GENE]/I_MEASURE
( O
IgNF-A B_GENE
) O
that O
binds O
to O
DNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
upstream B_LOCATION/B_BIO
regions I_LOCATION/I_BIO
of O
both O
the O
mouse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
heavy I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light-chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
also O
to O
the O
mouse B_GENE/B_BIO
heavy-chain I_GENE/I_BIO
gene I_GENE/I_BIO
enhancer I_GENE/I_BIO
. O

This O
sequence-specific O
binding O
is O
probably O
mediated O
by O
a O
highly O
conserved O
sequence O
motif O
, O
ATTTGCAT O
, O
present O
in O
all O
three O
transcriptional B_GENE/B_LOCATION
elements I_GENE/I_LOCATION
. O

Interestingly O
, O
a O
factor O
showing O
similar O
binding O
specificity O
to O
IgNF-A B_GENE
is O
also O
present O
in O
human O
HeLa O
cells O
. O

The O
new B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
world I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
primates O
as O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
glucocorticoid B_DISEASE
resistance I_DISEASE
. O

Many B_PERSON
New I_PERSON
World I_PERSON
primate I_PERSON
species I_PERSON
have O
greatly O
increased O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
cortisol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
concentrations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O
decreased O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cortisol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding O
globulin B_MEASURE/B_LOCATION
capacity I_MEASURE/I_LOCATION
and O
affinity B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
marked B_DISEASE
resistance I_DISEASE
of O
the O
hypothalamic-pituitary-adrenal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
axis B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
to O
suppression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
no O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
glucocorticoid B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excess I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
primates B_PERSON/B_BIO
also O
have O
high B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
circulating O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
mineralocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
androgen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
glucocorticoid O
target O
tissues O
that O
have O
been O
examined O
( O
circulating O
mononuclear O
lymphocytes O
and O
cultured O
skin O
fibroblasts O
) O
have O
normal O
concentrations O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
decreased O
affinity O
for O
dexamethasone O
. O

transformation O
of O
B-lymphocytes O
with O
the O
Epstein-Barr O
virus O
leads O
to O
glucocorticoid B_GENE/B_DISEASE
receptor I_GENE/I_DISEASE
induction O
that O
is O
less O
than O
that O
observed O
with O
cells O
from O
Old O
World O
primates O
. O

The O
receptor B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
cells B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
a O
low B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
low B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affinity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
leads O
to O
an O
increased O
loss B_MEASURE
of O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bound O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
thermal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Meroreceptor B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generation I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
molecular B_MEASURE/B_LOCATION
weight I_MEASURE/I_LOCATION
of O
the O
receptor B_GENE
, O
determined O
by O
SDS-PAGE B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
is O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
that O
of O
Old B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
World B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
primates B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
approximately O
92 B_MEASURE
, O
000 B_MEASURE
) O
and O
the O
activation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
per O
se B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
examined O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
heating O
cytosol B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
performing O
phosphocellulose B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
appears O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
that O
of O
human B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
ratios O
of O
nuclear O
to O
cytosolic B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
hormone-receptor-complexes I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
of O
cytosolic O
activated O
to O
unactivated B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complexes B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O
intact O
cells O
are O
similar O
to O
Old O
World O
primates O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
mixing O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O
not O
support O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
a O
binding B_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_DISEASE_ADJECTIVE[DISEASE]
( O
s O
) O
or O
a O
deficient B_ENZYME[GENE]/B_MEASURE
cytosolic I_ENZYME[GENE]/I_MEASURE
positive I_ENZYME[GENE]/I_MEASURE
modifier I_ENZYME[GENE]/I_MEASURE
( O
s B_DISEASE/B_PROTEIN[GENE]
) O
of O
binding B_GENE/B_DISEASE
underlies O
the O
findings B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
primates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

The O
New B_PERSON/B_SPECIES[BIO]
World I_PERSON/I_SPECIES[BIO]
primates O
, O
unlike O
men B_PERSON/B_BIO
with O
the O
syndrome B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
primary B_DISEASE
cortisol I_DISEASE
resistance I_DISEASE
, O
have O
compensated O
for O
their O
condition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
intra-adrenal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
mineralocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adaptations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Thus O
, O
unlike O
Old O
World O
primates O
, O
cortisol O
in O
New O
World O
primates O
has O
only O
weak O
sodium-retaining O
potency O
because O
the O
aldosterone B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
a O
low O
affinity O
for O
cortisol O
. O

The O
common B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
element I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
would O
explain O
the O
apparent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resistance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
six B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steroid B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormones B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
New B_SPECIES[BIO]/B_PERSON
World I_SPECIES[BIO]/I_PERSON
primates I_SPECIES[BIO]/I_PERSON
. O

Acetylation O
and O
modulation O
of O
erythroid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Kruppel-like I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
EKLF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
activity O
by O
interaction O
with O
histone B_GENE
acetyltransferases I_GENE
. O

Erythroid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Kruppel-like I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
EKLF B_LOCATION/B_DISEASE
) O
is O
a O
red B_GENE
cell-specific I_GENE
transcriptional I_GENE
activator I_GENE
that O
is O
crucial O
for O
consolidating O
the O
switch O
to O
high O
levels O
of O
adult O
beta-globin O
expression O
during O
erythroid O
ontogeny O
. O

EKLF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
required O
for O
integrity O
of O
the O
chromatin O
structure O
at O
the O
beta-like B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
globin B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
locus B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
it O
interacts O
with O
a O
positive-acting B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
vivo O
. O

We O
find O
that O
EKLF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
an O
acetylated B_GENE
transcription I_GENE
factor I_GENE
, O
and O
that O
it O
interacts O
in O
vivo O
with O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
p300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
P/CAF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
its O
interactions O
with O
these O
histone B_GENE/B_LOCATION
acetyltransferases I_GENE/I_LOCATION
are O
not O
equivalent O
, O
as O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
p300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
P/CAF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
utilize O
EKLF B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans-activation O
region O
. O

The O
functional O
effects O
of O
these O
interactions O
are O
that O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
p300 B_GENE/B_LOCATION
, O
but O
not O
P/CAF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
enhance O
EKLF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
's O
transcriptional O
activation O
of O
the O
beta-globin B_GENE
promoter I_GENE
in O
erythroid O
cells O
. O

These O
results O
establish O
EKLF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
tissue-specific B_GENE/B_MEASURE
transcription I_GENE/I_MEASURE
factor I_GENE/I_MEASURE
that O
undergoes O
post-translational O
acetylation O
and O
suggest O
a O
mechanism O
by O
which O
EKLF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
able O
to O
alter O
chromatin O
structure O
and O
induce O
beta-globin O
expression O
within O
the O
beta-like B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
globin I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
cluster I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O

recognition O
of O
herpes B_DISEASE
simplex I_DISEASE
virus I_DISEASE
type I_DISEASE
2 I_DISEASE
tegument I_DISEASE
proteins I_DISEASE
by O
CD4 O
T O
cells O
infiltrating O
human O
genital O
herpes O
lesions O
. O

The O
local B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cellular B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
herpes B_DISEASE/B_VIRUS[BIO]
simplex B_DISEASE/I_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
( O
HSV B_VIRUS[BIO]/B_DISEASE
) O
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
recurrent B_DISEASE
HSV I_DISEASE
infection I_DISEASE
. O

The O
antiviral B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
functions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
infiltrating O
CD4-bearing B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
may O
include O
cytotoxicity B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
viral B_DISEASE_ADJECTIVE[DISEASE]
growth I_DISEASE_ADJECTIVE[DISEASE]
, O
lymphokine B_DISEASE_ADJECTIVE[DISEASE]
secretion I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
support B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
humoral B_GENE
and O
CD8 B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
responses B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
antigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
recognized O
by O
many B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
HSV-specific B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CD4 B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
localizing O
to O
genital B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
HSV-2 I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lesions I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
are O
unknown B_DISEASE_ADJECTIVE[DISEASE]
. O

T O
cells O
recognizing O
antigens O
encoded O
within O
map O
units O
0.67 O
to O
0.73 O
of O
HSV B_GENE/B_VIRUS[BIO]
DNA I_GENE/I_VIRUS[BIO]
are O
frequently O
recovered O
from O
herpetic O
lesions O
. O

expression O
cloning O
with O
this O
region O
of O
DNA O
now O
shows O
that O
tegument B_GENE/B_VIRUS[BIO]
protein B_GENE/I_VIRUS[BIO]
VP22 B_GENE/I_VIRUS[BIO]
and O
the O
viral B_GENE
dUTPase I_GENE
, O
encoded O
by O
genes B_GENE/B_PERSON
UL49 I_GENE/I_PERSON
and I_GENE/I_PERSON
UL50 I_GENE/I_PERSON
, O
respectively O
, O
are O
T-cell B_DISEASE_ADJECTIVE[DISEASE]
antigens I_DISEASE_ADJECTIVE[DISEASE]
. O

separate O
epitopes B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O
VP22 B_GENE/B_BIO
were O
defined O
for O
T-cell O
clones O
from O
each O
of O
three O
patients O
. O

Reactivity O
with O
the O
tegument B_PROTEIN[GENE]
protein I_PROTEIN[GENE]
encoded O
by O
UL21 B_GENE
was O
identified O
for O
an O
additional O
patient O
. O

Three O
new O
epitopes O
were O
identified O
in O
VP16 B_GENE/B_SPECIES[BIO]
, O
a O
tegument B_PROTEIN[GENE]/B_LOCATION
protein I_PROTEIN[GENE]/I_LOCATION
associated O
with O
VP22 B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Some O
tegument-specific B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CD4 I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
T-cell I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
clones I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exhibited O
cytotoxic B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O
HSV-infected B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
results O
suggest O
that O
herpes B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simplex I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tegument I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
processed O
for O
antigen O
presentation O
in O
vivo O
and O
are O
possible O
candidate O
compounds O
for O
herpes O
simplex O
vaccines O
. O

Fibrinogen B_GENE
activates O
NF-kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
mononuclear O
phagocytes O
. O

adhesion B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
extracellular B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
matrices B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
known O
to O
modulate O
leukocyte B_DISEASE
activation I_DISEASE
, O
although O
the O
mechanisms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
not O
fully O
understood O
. O

Mononuclear O
phagocytes O
are O
exposed O
to O
fibrinous O
provisional O
matrix O
throughout O
migration O
into O
inflammatory O
foci O
, O
so O
this O
study O
was O
undertaken O
to O
determine O
whether O
fibrinogen O
triggers O
activation O
of O
NF-kappa B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
B I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
factors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

U937 O
cells O
differentiated O
with O
PMA O
in O
nonadherent O
culture O
were O
shown O
to O
express O
two O
fibrinogen-binding B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
integrins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
predominately O
CD11b/CD18 B_GENE
, O
and O
to O
a O
lesser O
extent O
, O
CD11c/CD18 B_GENE
. O

cells O
stimulated O
with O
fibrinogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
10-100 O
microg/ml O
) O
/Mn2+ O
( O
50 O
microM O
) O
for O
2 O
h O
were O
examined O
by O
electrophoretic O
mobility O
shift O
assay O
. O

NF-kappa B_GENE
B I_GENE
activation O
, O
minimal O
in O
unstimulated O
cells O
, O
was O
substantially O
up-regulated O
by O
fibrinogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

Fibrinogen B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
caused O
activation O
of O
AP-1 B_GENE
, O
but O
not O
SP1 B_GENE
or O
cAMP B_GENE
response I_GENE
element-binding I_GENE
protein I_GENE
( I_GENE
CREB I_GENE
) I_GENE
factors I_GENE
. O

blocking O
mAbs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O
CD18 B_GENE
and O
CD11b B_GENE
abrogated O
fibrinogen B_GENE
-induced O
NF-kappa B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
B I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
activation O
. O

To O
determine O
the O
effects O
on O
transcriptional O
regulation O
, O
U937 O
cells O
were O
transfected O
with O
a O
plasmid O
containing O
the O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
bearing O
two O
NF-kappa B_GENE/B_LOCATION
B I_GENE/I_LOCATION
sites I_GENE/I_LOCATION
) O
coupled O
to O
a O
chloramphenicol B_GENE
acetyltransferase I_GENE
( I_GENE
CAT I_GENE
) I_GENE
reporter I_GENE
. O

cells O
were O
subsequently O
stimulated O
with O
1 O
) O
PMA O
for O
24 O
h O
, O
inducing O
Cat O
activity O
by O
2.6-fold O
, O
2 O
) O
fibrinogen B_GENE
/Mn2+ O
for O
2 O
h O
, O
inducing O
Cat O
activity O
by O
3.2-fold O
, O
or O
3 O
) O
costimulation O
with O
fibrinogen B_GENE
and O
PMA O
, O
inducing O
5.7-fold O
the O
Cat O
activity O
induced O
by O
PMA O
alone O
. O

We O
conclude O
that O
contact O
with O
fibrinogen-derived B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
may O
contribute O
to O
mononuclear O
phagocyte O
activation O
by O
signaling O
through O
CD11b/CD18 B_GENE
, O
resulting O
in O
selective O
activation O
of O
transcriptional B_GENE
regulatory I_GENE
factors I_GENE
, O
including O
NF-kappa B_GENE
B I_GENE
. O

Peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lines I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
derived O
from O
patients B_PERSON/B_DISEASE
with O
lupus B_DISEASE/B_LOCATION
express I_DISEASE/I_LOCATION
estrogen I_DISEASE/I_LOCATION
receptor I_DISEASE/I_LOCATION
transcripts I_DISEASE/I_LOCATION
similar I_DISEASE/I_LOCATION
to O
those O
of O
normal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

objective O
: O
To O
identify O
and O
characterize O
estrogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ER I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expressed O
in O
immune O
cells O
of O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
and O
healthy O
donors O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O
prepared O
from O
patients B_PERSON/B_BIO
with O
SLE B_DISEASE/B_LOCATION
( O
n B_OTHER/B_MEASURE
= O
6 B_MEASURE
) O
and O
healthy B_DISEASE
donors I_DISEASE
( O
n B_OTHER/B_MEASURE
= O
8 B_MEASURE
) O
. O

T B_PERSON/B_LOCATION
cells I_PERSON/I_LOCATION
were O
separated O
into O
CD4 B_GENE
and O
CD8 B_GENE
. O

Some O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O
stimulated O
with O
estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
PMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
ionomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Epstein-Barr B_PERSON/B_DISEASE
virus-transformed O
B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lines B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
n B_MEASURE/B_LOCATION
= O
7 B_MEASURE
) O
and O
B B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hybridomas I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
n B_MEASURE/B_LOCATION
= O
2 B_MEASURE
) O
established O
from O
patients B_PERSON
with O
SLE B_DISEASE/B_LOCATION
and O
a O
healthy B_DISEASE/B_PERSON
individual I_DISEASE/I_PERSON
were O
used O
as O
a O
B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
source I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
cells O
were O
examined O
for O
ER B_GENE
mRNA I_GENE
by O
reverse O
transcription O
nested O
polymerase O
chain O
reaction O
. O

Amplified O
cDNA B_GENE/B_LOCATION
were O
sequenced O
by O
standard O
methods O
. O

Results O
: O
In O
all O
cells O
tested O
, O
ER B_GENE
mRNA I_GENE
was O
expressed O
without O
prior O
in O
vitro O
stimulation O
. O

partial O
sequences O
from O
exons B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
1-8 I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
were O
nearly O
identical O
to O
the O
published O
sequence O
of O
the O
human B_GENE/B_BIO
ER I_GENE/I_BIO
mRNA I_GENE/I_BIO
. O

There O
were O
no O
notable O
differences O
in O
the O
ER B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transcripts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O
patients O
and O
healthy O
controls O
. O

variant O
receptor O
transcripts O
lacking O
exon B_GENE
5 I_GENE
or O
exon B_MEASURE/B_LOCATION
7 I_MEASURE/I_LOCATION
, O
which O
encodes O
the O
hormone B_GENE
binding I_GENE
domain I_GENE
, O
were O
identified O
in O
the O
majority O
of O
the O
cells O
. O

precise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
deletion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O
the O
exons B_GENE
suggests O
that O
they O
are O
alternatively O
spliced O
transcripts B_LOCATION/B_GENE
. O

Whether O
the O
detected O
transcripts O
are O
translated O
into O
functional B_GENE
receptor I_GENE
proteins I_GENE
remains O
to O
be O
determined O
. O

In O
vitro O
stimulation O
did O
not O
affect O
ER B_GENE
mRNA I_GENE
expression O
. O

The O
presence B_MEASURE/B_DISEASE
of O
variants B_DISEASE
did O
not O
correlate O
with O
disease B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
medication B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

conclusion O
: O
Monocytes O
, O
T O
cells O
, O
and O
B O
cells O
in O
patients O
express O
transcripts O
of O
the O
normal O
wild B_GENE
type I_GENE
ER I_GENE
and O
the O
hormone B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
binding B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
domain B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variants B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
vivo O
. O

DNA O
damaging O
agents O
induce O
expression O
of O
Fas B_GENE
ligand I_GENE
and O
subsequent O
apoptosis O
in O
T O
lymphocytes O
via O
the O
activation O
of O
NF-kappa B_GENE
B I_GENE
and O
AP-1 B_GENE
. O

Apoptosis O
induced O
by O
DNA O
damage O
and O
other O
stresses O
can O
proceed O
via O
expression O
of O
Fas B_GENE
ligand I_GENE
( O
FasL B_GENE/B_LOCATION
) O
and O
ligation O
of O
its O
receptor O
, O
Fas O
( O
CD95 O
) O
. O

We O
report O
that O
activation O
of O
the O
two O
transcription B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AP-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
crucially O
involved O
in O
FasL B_GENE
expression O
induced O
by O
etoposide O
, O
teniposide O
, O
and O
UV O
irradiation O
. O

A O
nondegradable B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mutant B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
I B_GENE
kappa I_GENE
B I_GENE
blocked O
both O
FasL B_GENE
expression O
and O
apoptosis O
induced O
by O
DNA O
damage O
but O
not O
Fas O
ligation O
. O

These O
stimuli B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
induced O
the O
stress-activated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
SAPK/JNK B_GENE/B_LOCATION
) O
, O
which O
was O
required O
for O
the O
maximal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
apoptosis B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

A O
1.2 O
kb O
FasL B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
responded O
to O
DNA O
damage O
, O
as O
well O
as O
coexpression O
with O
p65 B_GENE
Rel I_GENE
or O
Fos/Jun B_GENE
. O

mutations O
in O
the O
relevant O
NF-kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AP-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
eliminated O
these O
responses O
. O

Thus O
, O
activation O
of O
NF-kappa B_GENE
B I_GENE
and O
AP-1 B_GENE
contributes O
to O
stress-induced O
apoptosis O
via O
the O
expression O
of O
FasL B_GENE
. O

A O
small O
, O
nonpeptidyl O
mimic O
of O
granulocyte-colony-stimulating B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
see O
commetns O
] O
. O

A O
nonpeptidyl O
small O
molecule O
SB O
247464 O
, O
capable O
of O
activating O
granulocyte-colony-stimulating B_GENE
factor I_GENE
( O
G-CSF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
signal O
transduction O
pathways O
, O
was O
identified O
in O
a O
high-throughput O
assay O
in O
cultured O
cells O
. O

Like O
G-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
SB O
247464 O
induced O
tyrosine O
phosphorylation O
of O
multiple B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
stimulated O
primary O
murine O
bone O
marrow O
cells O
to O
form O
granulocytic O
colonies O
in O
vitro O
. O

It O
also O
elevated O
peripheral B_DISEASE/B_GENE
blood I_DISEASE/I_GENE
neutrophil I_DISEASE/I_GENE
counts I_DISEASE/I_GENE
in O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
extracellular O
domain O
of O
the O
murine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G-CSF B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
required O
for O
the O
activity O
of O
SB O
247464 O
, O
suggesting O
that O
the O
compound O
acts O
by O
oligomerizing B_MEASURE/B_GENE
receptor I_MEASURE/I_GENE
chains I_MEASURE/I_GENE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
a O
small B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
molecule I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
can O
activate O
a O
receptor B_ENZYME[GENE]/B_LOCATION
that O
normally O
binds O
a O
relatively O
large B_DISEASE_ADJECTIVE[DISEASE]
protein I_DISEASE_ADJECTIVE[DISEASE]
ligand I_DISEASE_ADJECTIVE[DISEASE]
. O

minimal O
residual O
disease O
in O
acute O
myelogenous O
leukemia O
with O
PML/RAR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O
AML1/ETO B_GENE/B_DISEASE
mRNA I_GENE/I_DISEASE
and O
phenotypic O
analysis O
of O
possible O
T O
and O
natural O
killer O
cells O
in O
bone O
marrow O
. O

Here O
we O
studied O
minimal O
residual O
disease O
( O
MRD O
) O
of O
patients O
with O
acute O
myeloid O
leukemia O
( O
AML O
) O
who O
have O
PML/RAR B_DISEASE/B_GENE
alpha I_DISEASE/I_GENE
or O
AML1/ETO B_DISEASE/B_GENE
as O
well O
as O
the O
phenotypic O
analysis O
of O
lymphocyte O
subsets O
involved O
in O
antitumor O
immunity O
. O

Eight B_TIME[MEASURE]/B_PERSON
patients B_TIME[MEASURE]/I_PERSON
in O
long-term B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
Lt B_PERSON/B_LOCATION
; O
3 B_NUMBER[MEASURE]/B_LOCATION
to O
15 B_TIME[MEASURE]
years I_TIME[MEASURE]
) O
and O
15 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
in O
short-term B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
ST B_PROTEIN[GENE]/B_DISEASE
; O
up O
to O
3 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
) O
remission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
were O
studied O
. O

Using O
the O
reverse O
transcription-polymerase O
chain O
reaction O
( O
RT O
) O
assay O
, O
the O
limit O
of O
detection O
was O
10 O
( O
-5 O
) O
to O
10 O
( O
-6 O
) O
for O
PML/RAR B_GENE
alpha I_GENE
transcript I_GENE
and O
10 O
( O
-4 O
) O
to O
10 O
( O
-5 O
) O
for O
the O
AML1/ETO B_GENE/B_MEASURE
transcript I_GENE/I_MEASURE
. O

simultaneously O
, O
T B_LOCATION/B_GENE
lymphocyte I_LOCATION/I_GENE
subsets I_LOCATION/I_GENE
and O
NK B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
peripheral B_BODY_PART_OR_ORGAN_COMPONENT
blood I_BODY_PART_OR_ORGAN_COMPONENT
( O
PB B_LOCATION
) O
and O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
marrow I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
BM B_LOCATION
) O
were O
investigated O
by O
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytometric I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Four B_NUMBER[MEASURE]
of O
the O
eight B_PERSON
patients I_PERSON
in O
LT B_DISEASE/B_PROTEIN[GENE]
and O
7 B_NUMBER[MEASURE]
of O
the O
15 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
in O
ST B_MEASURE/B_DISEASE
remission I_MEASURE/I_DISEASE
were O
MRD-positive B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

Although O
all O
MRD-positive B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
in O
LT B_DISEASE/B_LOCATION
remission B_DISEASE/I_LOCATION
are O
still O
until O
now O
event-free B_DISEASE_ADJECTIVE[DISEASE]
, O
3 B_NUMBER[MEASURE]
of O
the O
7 B_NUMBER[MEASURE]
MRD-positive I_NUMBER[MEASURE]
( O
MRD+ B_PROTEIN[GENE]/B_LOCATION
) O
patients B_PERSON/B_LOCATION
in O
ST B_MEASURE/B_DISEASE
remission I_MEASURE/I_DISEASE
soon O
relapsed O
. O

The O
total O
populations O
of O
CD4 B_GENE
+ O
, O
CD8 B_GENE
+ O
and O
CD56 B_GENE
+ O
[ O
possible O
T-cell O
and O
natural O
killer O
( O
T/NK O
) O
populations O
] O
in O
the O
BM O
of O
ST O
patients O
and O
MRD+/LT O
patients O
were O
significantly O
( O
p O
< O
.01 O
) O
low O
. O

The O
CD8+ B_PERSON/B_GENE
CD28+ I_PERSON/I_GENE
population I_PERSON/I_GENE
showed O
the O
same B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
tendency B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
p B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
.01-.02 O
) O
. O

The O
T/NK B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
subsets O
in O
the O
BM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
MRD-negative B_DISEASE
( O
MRD- B_LOCATION
) O
LT B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
MRD-/LT B_LOCATION/B_DISEASE
) O
patients B_PERSON/B_BIO
showed O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numbers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
as O
normal B_PERSON/B_ORGANIZATION
volunteers I_PERSON/I_ORGANIZATION
. O

basically O
, O
the O
total B_MEASURE/B_PERSON
percentage I_MEASURE/I_PERSON
of O
the O
CD4+ B_GENE
, O
CD8+ B_GENE
and O
CD56+ B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
populations I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
BM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
was O
increased O
and O
in O
the O
following B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
order I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
: O
MRD-/LT B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
, O
normal B_PERSON/B_PROTEIN[GENE]
volunteers B_PERSON/I_PROTEIN[GENE]
, O
MRD+/LT B_DISEASE/B_PROTEIN[GENE]
patients B_DISEASE/I_PROTEIN[GENE]
and O
MRD+ B_PROTEIN[GENE]/B_LOCATION
or O
-/ST B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
patients I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

The O
percentages B_MEASURE/B_LOCATION
of O
the O
T/NK-cell B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subsets I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
PB B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
not O
significantly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
these O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
, O
the O
difference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
possible B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T/NK-cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phenotype I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
BM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
may O
strongly O
influence O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
molecular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
remission I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
still O
remain O
to O
be O
confirmed O
by O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
functional B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anti-tumor I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
immunity I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
T/NK B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
cells I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
of O
AML B_DISEASE/B_PERSON
in O
remission B_DISEASE/B_BIO
. O

Mycobacterium O
tuberculosis O
mannose-capped O
lipoarabinomannan O
can O
induce O
NF-kappaB B_GENE
-dependent O
activation O
of O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
long I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeat I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
T O
cells O
. O

Tuberculosis B_DISEASE/B_LOCATION
has O
emerged O
as O
an O
epidemic B_DISEASE/B_LOCATION
, O
extended O
by O
the O
large B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
individuals B_PERSON/B_BIO
infected O
with O
human B_DISEASE
immunodeficiency I_DISEASE
virus I_DISEASE
type I_DISEASE
1 I_DISEASE
( O
HIV-1 B_DISEASE
) O
. O

The O
major B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
goal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
determine O
whether O
the O
mycobacterial B_DISEASE_ADJECTIVE[DISEASE]
cell I_DISEASE_ADJECTIVE[DISEASE]
wall I_DISEASE_ADJECTIVE[DISEASE]
component I_DISEASE_ADJECTIVE[DISEASE]
mannose-capped O
lipoarabinomannan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ManLAM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
of O
Mycobacterium B_DISEASE
tuberculosis I_DISEASE
( O
M B_OTHER/B_PROTEIN[GENE]
. O
tuberculosis B_DISEASE/B_PROTEIN[GENE]
) O
could O
activate O
transcription B_GENE
of O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
with O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
an O
in O
vitro B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
experiments O
are O
of O
prime O
importance O
considering O
that O
CD4 B_GENE
-expressing O
T O
lymphocytes O
represent O
the O
major O
virus O
reservoir O
in O
the O
peripheral O
blood O
of O
infected O
individuals O
. O

Using O
the O
1G5 O
cell O
line O
harbouring O
the O
luciferase O
reporter O
gene O
under O
the O
control O
of O
the O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
was O
first O
found O
that O
culture O
protein O
filtrates O
( O
CFP O
) O
from O
M. O
tuberculosis O
or O
purified O
ManLAM O
could O
activate O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR-dependent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
unlike O
similarly O
prepared O
CFP O
extracts O
devoid O
of O
ManLAM O
. O

The O
implication O
of O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
s I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
protein B_GENE
kinase I_GENE
A I_GENE
and/or O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
highlighted O
by O
the O
abrogation O
of O
the O
ManLAM-mediated O
activation O
of O
HIV-1 O
LTR-driven O
gene O
expression O
using O
herbimycin O
A O
and O
H7 O
. O

It O
was O
also O
determined O
, O
using O
electrophoresis O
mobility O
shift O
assays O
, O
that O
M. O
tuberculosis O
ManLAM O
led O
to O
the O
nuclear O
translocation O
of O
the O
transcription B_ENZYME[GENE]/B_BIO
factor I_ENZYME[GENE]/I_BIO
NF-kappaB I_ENZYME[GENE]/I_BIO
. O

M. O
tuberculosis O
ManLAM O
resulted O
in O
clear O
induction O
of O
the O
luciferase B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
placed O
under O
the O
control O
of O
the O
wild-type B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
but B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
not B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
the B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
kappaB-mutated B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
HIV-1 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
LTR B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Finally O
, O
the O
ManLAM-mediated O
activation O
of O
HIV-1 O
LTR O
transcription O
was O
found O
to O
be O
independent O
of O
the O
autocrine O
or O
paracrine O
action O
of O
endogenous B_GENE
TNF-alpha I_GENE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
M B_OTHER/B_PROTEIN[GENE]
. O
tuberculosis B_DISEASE/B_BACTERIUM[BIO]
can O
upregulate O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O
could O
thus O
have O
the O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
influence O
the O
pathogenesis B_DISEASE_ADJECTIVE[DISEASE]
of O
HIV-1 B_DISEASE
infection I_DISEASE
. O

Human B_PERSON
immunodeficiency I_PERSON
virus I_PERSON
type I_PERSON
1 I_PERSON
long I_PERSON
terminal I_PERSON
repeat I_PERSON
quasispecies O
differ O
in O
basal O
transcription O
and O
nuclear O
factor O
recruitment O
in O
human O
glial O
cells O
and O
lymphocytes O
. O

The O
generation B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
genomic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
diversity I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O
the O
course B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O
the O
potential B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
affect O
all O
aspects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
HIV-1 O
replication B_TIME[MEASURE]/B_DISEASE
, O
including O
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
the O
proviral B_GENE
genome I_GENE
. O

To O
gain O
a O
better O
understanding O
of O
the O
impact O
of O
long B_GENE
terminal I_GENE
repeat I_GENE
( O
LTR B_PROTEIN[GENE]/B_DISEASE
) O
sequence O
diversity O
on O
LTR-directed B_GENE
gene I_GENE
expression O
in O
cells O
of O
the O
central O
nervous O
system O
( O
CNS O
) O
and O
immune O
system O
, O
we O
amplified O
and O
cloned O
LTRs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O
proviral O
DNA O
in O
HIV-1-infected O
peripheral O
blood O
. O

sequence O
analysis O
of O
nineteen O
LTRs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cloned O
from O
2 O
adult O
and O
3 O
pediatric O
patients O
revealed O
an O
average O
of O
33 O
nucleotide O
changes O
( O
with O
respect O
to O
the O
sequence O
of O
the O
LAI B_LOCATION/B_GENE
LTR I_LOCATION/I_GENE
) O
within O
the O
455-bp B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
U3 I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Transient O
expression O
analyses O
in O
cells O
of O
neuroglial O
and O
lymphocytic O
origin O
demonstrated O
that O
some O
of O
these O
LTRs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
had O
activities O
which O
varied O
significantly O
from O
the O
LAI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
LTR I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
U-373 O
MG O
cells O
( O
an O
astrocytoma O
cell O
line O
) O
as O
well O
as O
in O
Jurkat O
cells O
( O
a O
CD4-positive O
lymphocyte O
cell O
line O
) O
. O

While O
LTRs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O
demonstrated O
the O
highest O
activities O
in O
U-373 O
MG O
cells O
also O
yielded O
high O
activities O
in O
Jurkat O
cells O
, O
the O
LTRs B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
were O
generally O
more O
active O
in O
Jurkat O
cells O
when O
compared O
to O
the O
LAI B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LTR I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

differences O
in O
LTR B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
also O
resulted O
in O
differences O
in O
transcription O
factor O
recruitment O
to O
cis-acting B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sites B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
within O
the O
U3 B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
of O
the O
LTR B_GENE/B_DISEASE
, O
as O
demonstrated O
by O
electrophoretic O
mobility O
shift O
assays O
. O

In O
particular O
, O
naturally O
occurring O
sequence O
variation O
impacted O
transcription B_GENE/B_LOCATION
factor I_GENE/I_LOCATION
binding O
to O
an O
activating B_GENE
transcription I_GENE
factor I_GENE
/ O
cAMP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ATF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
CREB B_LOCATION/B_ORGANIZATION
) O
binding O
site O
( O
located O
between O
the O
LEF-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
distal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappaB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
that O
we O
identified O
in O
previous O
studies O
of O
the O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
findings O
suggest O
that O
LTR B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sequence B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
changes O
can O
significantly O
affect O
basal O
LTR O
function O
and O
transcription O
factor O
recruitment O
, O
which O
may O
, O
in O
turn O
, O
alter O
the O
course O
of O
viral O
replication O
in O
cells O
of O
CNS O
and O
immune O
system O
origin O
. O

HMG B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
box I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcription I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
lymphocyte O
differentiation O
. O

The O
identification O
of O
the O
mammalian B_GENE/B_BIO
sex-determining I_GENE/I_BIO
gene I_GENE/I_BIO
Sry I_GENE/I_BIO
has O
led O
to O
the O
discovery O
of O
a O
large O
family O
of O
related O
( O
' O
HMG B_GENE/B_PERSON
box I_GENE/I_PERSON
' O
) O
transcription B_GENE/B_BIO
factors I_GENE/I_BIO
that O
control O
developmental O
events O
in O
yeast O
, O
C. O
elegans O
, O
Drosophila O
and O
vertebrates O
. O

In O
lymphocyte O
differentiation O
, O
several O
HMG B_GENE
box I_GENE
proteins I_GENE
play O
a O
decisive O
role O
. O

Sox-4 B_GENE
is O
important O
for O
very O
early O
B-cell O
differentiation O
, O
while O
TCF-1 B_LOCATION/B_ORGANIZATION
/ O
LEF-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
play O
a O
crucial O
role O
in O
early O
thymocyte O
development O
. O

TCF/LEF B_PERSON
proteins I_PERSON
have O
recently O
been O
found O
to O
constitute O
a O
downstream O
component O
of O
the O
Wingless/Wnt O
signal O
transduction O
pathway O
. O

In O
flies B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
this O
pathway B_LOCATION
controls O
segment B_MEASURE/B_ORGANISM_FUNCTION
polarity I_MEASURE/I_ORGANISM_FUNCTION
; O
in O
Xenopus B_SPECIES[BIO]
it O
controls O
the O
definition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
body B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
axis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Deregulation B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
pathway B_GENE/B_DISEASE
occurs O
in O
several B_DISEASE
human I_DISEASE
tumors I_DISEASE
. O

These O
insights O
in O
the O
molecular O
events O
that O
are O
involved O
in O
TCF/LEF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
function O
in O
these O
organisms O
may O
eventually O
lead O
to O
the O
understanding O
of O
the O
function O
of O
these O
HMG B_GENE
box I_GENE
proteins I_GENE
in O
lymphoid O
development O
. O

Transcriptional O
regulation O
by O
C/EBP B_DISEASE_ADJECTIVE[DISEASE]
alpha I_DISEASE_ADJECTIVE[DISEASE]
and I_DISEASE_ADJECTIVE[DISEASE]
-beta I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
expression O
of O
the O
gene O
for O
the O
MRP14 B_GENE
myeloid I_GENE
calcium I_GENE
binding I_GENE
protein I_GENE
. O

Transcriptional O
regulation O
of O
the O
gene O
for O
the O
myeloid B_GENE
calcium I_GENE
binding I_GENE
protein I_GENE
, O
MRP14 B_GENE
, O
was O
investigated O
in O
human O
monocytic O
leukemia O
cell O
lines O
. O

The O
MRP14 B_GENE/B_MEASURE
gene I_GENE/I_MEASURE
was O
not O
expressed O
in O
monoblastic O
ML-1 O
cells O
, O
promonocytic O
U-937 O
cells O
, O
or O
promyelocytic O
HL-60 O
cells O
. O

On O
the O
other B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
hand I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
gene B_GENE/B_MEASURE
was O
expressed O
in O
monocytic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
THP-1 O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
in O
the O
HL-60 O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
treated O
with O
1 B_MEASURE
, O
25-dihydroxyvitamin B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D3 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
VD3 B_PROTEIN[GENE]/B_MEASURE
) O
. O

The O
level O
of O
MRP14 B_GENE
in O
VD3-treated O
HL-60 O
cells O
was O
two-fold O
higher O
than O
that O
in O
THP-1 O
cells O
. O

Among O
several O
known O
transcription B_GENE/B_MEASURE
factor I_GENE/I_MEASURE
binding I_GENE/I_MEASURE
motifs I_GENE/I_MEASURE
, O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
s I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
VD3-treated O
HL-60 O
cells O
and O
THP-1 O
cells O
bound O
to O
the O
CCAAT/enhancer B_GENE/B_LOCATION
binding I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
( I_GENE/I_LOCATION
C/EBP I_GENE/I_LOCATION
) I_GENE/I_LOCATION
-binding I_GENE/I_LOCATION
motif I_GENE/I_LOCATION
that O
was O
located O
in O
the O
upstream B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
region I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
MRP14 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
( O
-81 O
) O
, O
as O
evidenced O
by O
the O
competitive O
gel O
mobility-shift O
assay O
. O

An O
antibody O
for O
C/EBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
super-shifted O
the O
nucleoprotein B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
THP-1 O
cells O
but O
not O
in O
the O
VD3-treated O
HL-60 O
cells O
, O
whereas O
an O
antibody O
for O
C/EBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocked O
the O
formation O
of O
the O
complex O
with O
the O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
factor I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
HL-60 O
cells O
but O
not O
with O
that O
of O
THP-1 O
cells O
. O

An O
anti-C/EBP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
delta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
had O
no O
effect O
on O
the O
complex O
in O
either O
cell O
. O

Thus O
, O
it O
was O
concluded O
that O
C/EBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
able O
to O
bind O
to O
the O
C/EBP B_GENE
motif I_GENE
, O
and O
that O
C/EBP B_GENE/B_MEASURE
alpha I_GENE/I_MEASURE
bound O
to O
the O
motif O
in O
THP-1 O
cells O
and O
C/EBP B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O
to O
that O
in O
the O
VD3-treated O
HL-60 O
cells O
. O

Furthermore O
, O
to O
examine O
the O
transcriptional O
activity O
of O
the O
C/EBP B_GENE
motif I_GENE
, O
we O
transfected O
several O
constructed O
luciferase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reporter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNAs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
into O
HL-60 O
cells O
and O
THP-1 O
cells O
. O

The O
luciferase O
activity O
of O
the O
C/EBP B_GENE
motif I_GENE
in O
HL-60 O
cells O
was O
increased O
by O
VD3 O
treatment O
. O

The O
C/EBP B_GENE/B_LOCATION
motif I_GENE/I_LOCATION
in O
the O
MRP14 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
was O
confirmed O
to O
function O
as O
a O
regulatory O
region O
in O
VD3-treated O
HL-60 O
cells O
and O
THP-1 O
cells O
by O
the O
assay O
. O

Since O
C/EBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
detected O
in O
VD3-untreated O
HL-60 O
cells O
by O
immunoblotting O
, O
VD3 O
activated O
C/EBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
bind O
to O
the O
motif O
, O
probably O
through O
post-translational O
modification O
. O

patients B_PERSON/B_BIO
with O
high-risk B_DISEASE/B_LOCATION
myelodysplastic I_DISEASE/I_LOCATION
syndrome I_DISEASE/I_LOCATION
can O
have O
polyclonal B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
clonal B_DISEASE
haemopoiesis I_DISEASE
in O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
haematological I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
remission I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

The O
clonality O
of O
mature O
peripheral O
blood-derived O
myeloid O
and O
lymphoid O
cells O
and O
bone O
marrow O
haemopoietic O
progenitors O
from O
18 O
females O
with O
myelodysplasia O
( O
MDS O
) O
( O
five O
refractory O
anaemia O
, O
RA O
; O
one O
RA O
with O
ringed O
sideroblasts O
, O
RARS O
; O
three O
chronic O
myelomonocytic O
leukaemia O
, O
CMML O
; O
four O
RA O
with O
excess O
of O
blasts O
, O
RAEB O
; O
five O
RAEB O
in O
transformation O
, O
RAEB-t O
) O
was O
studied O
by O
X-chromosome B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inactivation O
analysis O
. O

Using O
the O
human B_GENE
androgen-receptor I_GENE
( O
HUMARA B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
we O
analysed O
the O
clonal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
patterns B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
highly O
purified B_TIME[MEASURE]/B_GENE
immature I_TIME[MEASURE]/I_GENE
CD34+ I_TIME[MEASURE]/I_GENE
38- I_TIME[MEASURE]/I_GENE
and O
committed O
CD34+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
38+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
marrow-derived I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
progenitors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
CD16+ B_GENE/B_TIME[MEASURE]
14- I_GENE/I_TIME[MEASURE]
granulocytes I_GENE/I_TIME[MEASURE]
, O
CD14+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
CD3+ B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
CD19+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
B I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O
peripheral B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
high-risk B_DISEASE/B_MEASURE
patients I_DISEASE/I_MEASURE
( O
RAEB B_DISEASE
, O
RAEB-t B_DISEASE/B_LOCATION
) O
, O
clonality B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
performed O
before O
and O
after O
intensive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
remission-induction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

All O
patients B_PERSON/B_BIO
, O
except O
one B_NUMBER[MEASURE]/B_PERSON
with O
RA B_DISEASE/B_LOCATION
, O
had O
predominance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
a O
single B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
clone B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
their O
granulocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

The O
same B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
clonal B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pattern B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O
found O
in O
CD34+ B_BIO/B_DISEASE
progenitor I_BIO/I_DISEASE
cells I_BIO/I_DISEASE
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
CD3+ B_PERSON/B_GENE
T I_PERSON/I_GENE
lymphocytes I_PERSON/I_GENE
were O
polyclonal B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
oligoclonal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
14/18 B_PERSON/B_MEASURE
patients B_PERSON/I_MEASURE
. O

X-chromosome B_GENE/B_DISEASE
inactivation O
patterns O
of O
CD19+ O
B O
cells O
were O
highly O
concordant O
with O
CD3+ O
T O
cells O
except O
for O
two O
patients O
( O
one O
RA O
, O
one O
CMML O
) O
with O
monoclonal O
B O
and O
polyclonal O
T O
lymphocytes O
, O
therefore O
suggesting O
a O
clonal O
mutation O
in O
a O
progenitor O
common O
to O
the O
myeloid O
and O
B-lymphoid O
lineages O
or O
the O
coexistence O
of O
MDS O
and O
a O
B-cell O
disorder O
in O
these O
particular O
patients O
. O

After O
high-dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
non-myeloablative I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
polyclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
haemopoiesis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
reinstalled O
in O
the O
mature B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
myeloid I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
immature B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
and O
committed B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
marrow I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
progenitors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
three B_NUMBER[MEASURE]/B_PERSON
of O
four B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
achieving O
complete B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
haematological I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
remission I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Therefore O
we O
conclude O
that O
most O
haematological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remissions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
MDS B_DISEASE/B_PERSON
are O
associated O
with O
restoration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
polyclonal B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
haemopoiesis B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

prominent B_PERSON
sex I_PERSON
steroid O
metabolism B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
in O
human B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

steroid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
metabolism I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
investigated O
in O
cultured O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
B-lymphoblastoid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
B-LCL B_DISEASE
) O
, O
and O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Gene B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
examined O
by O
reverse-transcription B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polymerase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
amplification I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
RT-PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

appropriate O
sized O
transcripts B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
detected O
in O
both O
cultured O
and O
fresh O
peripheral O
lymphocytes O
for O
CYP11A B_GENE/B_LOCATION
, O
CYP17 B_GENE
, O
HSD11L B_GENE/B_DISEASE
( O
11beta-hydroxysteroid B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
HSD17B1 B_GENE/B_DISEASE
( O
17beta-hydroxysteroid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
and O
SRD5A1 B_GENE/B_DISEASE
( O
5alpha-reductase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

B-LCL O
, O
but O
not O
T O
and O
B O
cells O
, O
expressed O
CYP11B B_GENE
. O

There O
was O
minimal O
expression O
of O
HSD3B1 B_GENE/B_LOCATION
and O
HSD3B2 B_GENE/B_DISEASE
( O
3beta-hydroxysteroid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
in O
B-LCL O
and O
T O
cells O
. O

Transcripts O
for O
CYP19 B_GENE/B_DISEASE
and O
HSD11K B_GENE
were O
not O
detected O
. O

corresponding O
enzymatic O
activity O
was O
detectable O
only O
for O
17-hydroxysteroid B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
5alpha-reductase B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
respectively O
producing O
testosterone O
and O
5alpha-dihydrotestosterone O
. O

steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
identities I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
confirmed O
by O
gas B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography/mass I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
spectrometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
GC/MS B_MEASURE/B_DISEASE
) O
. O

One B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
metabolite I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
thought O
to O
be O
deoxycorticosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
identified O
by O
GC/MS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
6alpha-hydroxypregnanolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

It O
was O
concluded O
that O
sex B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolism B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
androgen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
occurs O
in O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O
and O
may O
modulate O
immune B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Human O
white O
blood O
cells O
and O
hair O
follicles O
are O
good O
sources O
of O
mRNA B_GENE
for O
the O
pterin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carbinolamine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydratase/dimerization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cofactor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
HNF1 B_GENE
for O
mutation O
detection O
. O

Pterin B_PROTEIN[GENE]/B_TIME[MEASURE]
carbinolamine I_PROTEIN[GENE]/I_TIME[MEASURE]
dehydratase/dimerization I_PROTEIN[GENE]/I_TIME[MEASURE]
cofactor I_PROTEIN[GENE]/I_TIME[MEASURE]
of O
HNF1 B_GENE/B_DISEASE
( O
PCD/DCoH B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
is O
a O
protein O
that O
has O
a O
dual O
function O
. O

It O
is O
a O
pterin B_ENZYME[GENE]
4alpha-carbinolamine I_ENZYME[GENE]
dehydratase I_ENZYME[GENE]
that O
is O
involved O
in O
the O
regeneration O
of O
the O
cofactor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetrahydrobiopterin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
the O
phenylalanine O
hydroxylase- O
catalyzed O
hydroxylation O
of O
phenylalanine O
. O

In O
addition O
, O
it O
is O
the O
dimerization O
cofactor O
of O
HNF1 B_GENE
that O
is O
able O
to O
activate O
the O
transcriptional O
activity O
of O
HNF1 B_GENE
. O

Deficiencies O
in O
the O
gene O
for O
this O
dual B_GENE
functional I_GENE
protein I_GENE
result O
in O
hyperphenylalaninemia O
. O

Here O
we O
report O
for O
the O
first O
time O
that O
the O
PCD/DCoH B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
present O
in O
human O
white O
blood O
cells O
and O
hair O
follicles O
. O

Taking O
advantage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
, O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
convenient B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
screening B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
mutations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
occurring O
in O
the O
coding B_LOCATION/B_PERSON
region I_LOCATION/I_PERSON
of O
this O
gene B_GENE/B_LOCATION
has O
been O
described O
. O

Copyright B_LOCATION/B_PERSON
1998 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

Biochemical O
characterization O
of O
the O
NF-Y B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
transcription I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
factor I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
complex I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
during O
B O
lymphocyte O
development O
. O

The O
transcription B_GENE
factor I_GENE
, O
NF-Y B_GENE
, O
plays O
a O
critical O
role O
in O
tissue-specific O
major B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O
. O

In O
this O
report O
the O
biochemical O
properties O
of O
the O
heterotrimeric B_GENE
NF-Y I_GENE
complex I_GENE
have O
been O
characterized O
during O
stage-specific O
B-cell O
development O
, O
and O
in O
several O
class O
II- O
mutant O
B-cell O
lines O
, O
which O
represent O
distinct O
bare O
lymphocyte O
syndrome O
class O
II O
genetic O
complementation O
groups O
. O

The O
NF-Y B_GENE
complex I_GENE
derived O
from O
class O
II+ O
mature O
B-cells O
bound O
with O
high O
affinity O
to O
anion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
exchangers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
eluted O
as O
an O
intact O
trimeric B_LOCATION
complex I_LOCATION
, O
whereas O
, O
NF-Y B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derived O
from O
class O
II- O
plasma O
B-cells O
, O
and O
from O
bare O
lymphocyte O
syndrome O
group O
II O
cell O
lines O
, O
RJ2.2.5 O
and O
RM3 O
, O
dissociated O
into O
discrete O
NF-YA B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
NF-YB B_PROTEIN[GENE]
: I_PROTEIN[GENE]
C I_PROTEIN[GENE]
subunit I_PROTEIN[GENE]
fractions I_PROTEIN[GENE]
. O

Recombination O
of O
the O
MPC11 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B-cell B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derived B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NF-Y B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
low O
molecular O
mass O
protein O
fraction O
, O
NF-Y-associated B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
YAFs B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
derived O
from O
mature O
A20 O
B-cell O
nuclei O
, O
conferred O
high O
affinity O
anion O
exchange O
binding O
to O
NF-Y B_GENE
as O
an O
intact B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trimeric I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
complex I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Recombination O
of O
the O
native B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NF-YA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
the O
transcriptional B_GENE/B_PERSON
cofactor I_GENE/I_PERSON
, O
PC4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
likewise O
conferred O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
affinity I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
NF-Y I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
binding O
to O
anion B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exchangers I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
stabilized O
NF-Y B_GENE/B_PERSON
interaction O
with O
CCAAT-box B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
vitro O
. O

interaction O
between O
PC4 B_GENE
and O
NF-Y B_GENE
was O
mapped O
to O
the O
C-terminal B_LOCATION/B_BIO
region I_LOCATION/I_BIO
of O
PC4 B_GENE
, O
and O
the O
subunit B_LOCATION/B_MEASURE
interaction I_LOCATION/I_MEASURE
subdomain I_LOCATION/I_MEASURE
of O
the O
highly B_PROTEIN[GENE]
conserved I_PROTEIN[GENE]
DNA I_PROTEIN[GENE]
binding-subunit I_PROTEIN[GENE]
interaction I_PROTEIN[GENE]
domain I_PROTEIN[GENE]
( O
DBD B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
of O
NF-YA B_GENE
. O

These O
results O
suggest O
that O
in O
class O
II+ O
mature O
B-cells O
NF-Y B_GENE
is O
associated O
with O
the O
protein O
cofactor O
, O
PC4 B_GENE
, O
which O
may O
play O
an O
important O
role O
in O
NF-Y-mediated O
transcriptional O
control O
of O
class B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

arrest B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocyte B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
terminal B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
differentiation B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
CD40 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
mechanism B_DISEASE_ADJECTIVE[DISEASE]
for O
lack B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
antibody-secreting O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
germinal B_BIO/B_DISEASE
centers I_BIO/I_DISEASE
. O

Despite O
extensive O
research O
, O
the O
role O
of O
CD40 B_GENE
signaling O
in O
B O
cell O
terminal O
differentiation O
remains O
controversial O
. O

Here O
we O
show O
that O
CD40 B_GENE/B_LOCATION
engagement O
arrests O
B O
cell O
differentiation O
prior O
to O
plasma O
cell O
formation O
. O

This O
arrest O
is O
manifested O
at O
a O
molecular O
level O
as O
a O
reduction O
in O
mRNA O
levels O
of O
secretory O
immunoglobulin O
gene O
products O
such O
as O
Mu O
( O
s O
) O
and O
J O
chain O
as O
well O
as O
the O
loss O
of O
the O
transcriptional B_GENE
regulator I_GENE
BLIMP-1 I_GENE
. O

Furthermore O
, O
the O
inhibition O
of O
B O
cell O
differentiation O
by O
CD40 B_GENE
engagement O
could O
not O
be O
overcome O
by O
either O
mitogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
but O
could O
be O
reversed O
by O
antibodies O
that O
interfere O
with O
the O
CD40 B_GENE
/ O
gp39 B_GENE/B_LOCATION
interaction O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
secretory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunoglobulin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
not O
produced O
by O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
that O
are O
actively O
engaged O
by O
gp39-expressing O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

A O
positively O
charged O
alpha-lipoic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analogue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
increased O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uptake B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
more O
potent B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
immunomodulatory I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

alpha-Lipoic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
LA B_LOCATION/B_ORGANIZATION
) O
is O
taken O
up O
by O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O
reduced O
to O
its O
potent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
dithiol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
form I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
dihydrolipoate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DHLA B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
, O
much B_MEASURE/B_LOCATION
of O
which O
is O
rapidly O
effluxed O
out O
from O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

To O
improve O
retention B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
the O
LA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
molecule I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
modified O
to O
confer O
a O
positive B_MEASURE/B_LOCATION
charge I_MEASURE/I_LOCATION
at O
physiological B_LOCATION/B_PROTEIN[GENE]
pH B_LOCATION/I_PROTEIN[GENE]
. O

N B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
N-dimethyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
N'-2-amidoethyl-lipoate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
synthesized O
. O

The O
protonated B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecule I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
referred O
to O
as O
LA-Plus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
uptake B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
LA-Plus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Wurzburg I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
compared O
to O
that O
of O
LA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Several-fold O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
amounts B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
DHLA-Plus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
the O
corresponding B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O
form B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
LA-Plus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
were O
detected O
in O
LA-Plus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
treated O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
compared O
to O
the O
amount B_MEASURE/B_LOCATION
of O
DHLA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
found O
in O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
treated O
with O
LA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

At O
100 O
microM O
, O
LA O
did O
not O
but O
LA-Plus O
inhibited O
H2O2 O
induced O
NF-kappaB B_GENE
activation O
and O
NF-kappaB B_GENE
directed O
IL-2 B_GENE
receptor I_GENE
expression O
. O

Both O
LA O
and O
LA-Plus O
synergised O
with O
selenium O
in O
inhibiting O
H2O2 O
induced O
NF-kappaB B_GENE
activation O
. O

At O
150 O
microM O
LA-Plus O
, O
but O
not O
LA O
, O
inhibited O
TNFalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O
NF-kappaB B_GENE
activation O
. O

At O
5 B_GENE
microM I_GENE
LA-Plus I_GENE
, O
but O
not O
LA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
protected O
against O
both O
spontaneous B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
etoposide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O
apoptosis B_DISEASE
in O
rat B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
thymocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

LA-Plus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
thus O
an O
improved B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
form I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
of O
LA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
increased O
therapeutic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
potential I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Copyright B_LOCATION/B_PERSON
1998 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

carrier B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identification I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
X-linked B_LOCATION
immunodeficiency I_LOCATION
diseases I_LOCATION
. O

objective O
: O
Carrier O
identification O
in O
X-linked O
immunodeficiency O
disorders O
can O
be O
based O
on O
the O
demonstration O
of O
non-random O
X O
inactivation O
( O
NRXI O
) O
in O
affected O
blood O
cell O
lineages O
when O
growth O
is O
impaired O
in O
cells O
expressing O
the O
abnormal B_GENE
gene I_GENE
. O

We O
examined O
the O
utility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
seeking O
evidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
NRXI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
test O
the O
carrier B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
status I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
women B_PERSON
in O
families B_PERSON/B_SOCIAL_CIRCUMSTANCES
affected O
by O
X-linked B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
severe I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
combined O
immunodeficiency B_DISEASE
( O
XSCID B_LOCATION/B_DISEASE
) O
and O
X-linked B_DISEASE/B_MEASURE
hypogammaglobulinaemia I_DISEASE/I_MEASURE
( O
XLH B_DISEASE/B_LOCATION
) O
, O
to O
identify O
as O
carriers B_PERSON
the O
mothers B_PERSON/B_DISEASE
of O
boys B_PERSON
with O
SCID B_DISEASE
or O
hypogammaglobulinaemia B_DISEASE
whose O
phenotype B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggested O
X-linkage B_DISEASE/B_GENE
and O
to O
infer O
X-linkage B_PERSON/B_GENE
in O
boys B_PERSON
with O
SCID B_DISEASE
or O
hypogammaglobulinaemia B_PERSON
whose O
disease B_DISEASE/B_GENE
was O
not O
clearly O
X-linked O
on O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
either O
of O
family B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
or O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
immunological B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

methodology O
: O
A O
polymerase O
chain O
reaction-based O
method O
was O
used O
to O
amplify O
a O
polymorphic O
CAG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
repeat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
first B_GENE/B_LOCATION
exon I_GENE/I_LOCATION
of O
the O
androgen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
after O
selective O
digestion O
of O
the O
active B_GENE
X I_GENE
chromosome I_GENE
with O
a O
methylation-sensitive B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
HpaII B_TIME[MEASURE]/B_BACTERIUM[BIO]
to O
distinguish O
between O
the O
paternal B_GENE/B_PERSON
and I_GENE/I_PERSON
maternal I_GENE/I_PERSON
alleles I_GENE/I_PERSON
and O
to O
identify O
their O
methylation O
status O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
heterozygosity B_DISEASE/B_LOCATION
was O
found O
in O
24 B_NUMBER[MEASURE]
of O
31 B_NUMBER[MEASURE]/B_PERSON
female I_NUMBER[MEASURE]/I_PERSON
subjects I_NUMBER[MEASURE]/I_PERSON
( O
77 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
. O

As O
anticipated O
, O
NRXI O
could O
be O
demonstrated O
in O
all O
lymphoid O
cells O
studied O
from O
obligate O
carriers O
of O
XSCID O
and O
an O
obligate O
carrier O
of O
XLH O
but O
not O
on O
a O
carrier O
of O
X-linked O
immunodeficiency O
with O
hyper-IgM B_DISEASE
. O

The O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
NRXI B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
mother B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O
a O
boy B_PERSON
with O
a O
SCID B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
variant B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
showed O
her O
to O
be O
a O
carrier B_PERSON/B_MEASURE
of O
XSCID B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
establishes O
that O
her O
son B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
has O
XSCID O
, O
not O
otherwise O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
This O
PCR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
provides O
a O
rapid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
carrier B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
X-linked B_DISEASE/B_GENE
immunodeficiencies B_DISEASE/I_GENE
, O
and O
has O
allowed O
us O
to O
expand O
the O
phenotype B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
XSCID B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Leukocyte-endothelial B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
interaction B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O
augmented O
by O
high B_DISEASE
glucose I_DISEASE
concentrations I_DISEASE
and O
hyperglycemia B_DISEASE
in O
a O
NF-kB-dependent B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
fashion I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

We O
addressed O
the O
role O
of O
hyperglycemia O
in O
leukocyte-endothelium O
interaction O
under O
flow O
conditions O
by O
exposing O
human O
umbilical O
vein O
endothelial O
cells O
for O
24 O
h O
to O
normal O
( O
5 O
mm O
) O
, O
high O
concentration O
of O
glucose O
( O
30 O
mm O
) O
, O
advanced O
glycosylation O
end O
product-albumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
100 O
microg/ml O
) O
, O
or O
hyperglycemic O
( O
174-316 O
mg/dl O
) O
sera O
from O
patients O
with O
diabetes O
and O
abnormal O
hemoglobin O
A1c O
( O
8.1+/-1.4 O
% O
) O
. O

At O
the O
end B_LOCATION/B_TIME[MEASURE]
of O
incubation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
endothelial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
cells I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
were O
perfused O
with O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leukocyte I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suspension I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
plate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
flow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
chamber B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
under O
laminar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
flow I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
1.5 B_LOCATION/B_PROTEIN[GENE]
dyn/cm2 I_LOCATION/I_PROTEIN[GENE]
) O
. O

rolling B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
adherent B_TIME[MEASURE]/B_PERSON
cells I_TIME[MEASURE]/I_PERSON
were O
evaluated O
by O
digital B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
image I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O
that O
30 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
glucose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
significantly O
( O
P B_MEASURE
< I_MEASURE
0.01 I_MEASURE
) O
increased O
the O
number B_MEASURE/B_PERSON
of O
adherent B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leukocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
endothelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
respect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
control O
( O
5 B_MEASURE/B_LOCATION
mm I_MEASURE/I_LOCATION
glucose I_MEASURE/I_LOCATION
; O
151+/-19 B_MEASURE/B_LOCATION
versus I_MEASURE/I_LOCATION
33+/-8 I_MEASURE/I_LOCATION
cells/mm2 I_MEASURE/I_LOCATION
) O
. O

A O
similar O
response O
was O
induced O
by O
endothelial O
stimulation O
with O
IL-1beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
here O
used O
as O
positive O
control O
( O
195+/-20 O
cells/mm2 O
) O
. O

The O
number B_MEASURE/B_LOCATION
of O
rolling B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
on O
endothelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
surface I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
not O
affected O
by O
high B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Stable B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adhesion B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
leukocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
glucose-treated O
as O
well O
as O
to O
IL-1beta-stimulated B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
endothelial B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
preceded O
by O
short B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
leukocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
with O
the O
endothelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
surface I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

The O
distance B_MEASURE/B_LOCATION
travelled O
by O
leukocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
before O
arrest B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
30 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
on O
IL-1beta-treated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
endothelial I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
was O
significantly O
( O
P B_TIME[MEASURE]/B_LOCATION
< I_TIME[MEASURE]/I_LOCATION
0.01 I_TIME[MEASURE]/I_LOCATION
) O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
observed O
for O
leukocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
adhering O
on O
control B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
endothelium I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
30 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
: O
76.7+/-3.5 B_MEASURE
; O
IL1beta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
69.7+/-4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
21.5+/-5 B_MEASURE
microm I_MEASURE
) O
. O

functional O
blocking O
of O
E-selectin B_GENE
, O
intercellular B_GENE
cell I_GENE
adhesion I_GENE
molecule-1 I_GENE
, O
and O
vascular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecule-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O
endothelial O
cells O
with O
the O
corresponding O
mouse B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mAb I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
significantly O
inhibited O
glucose-induced O
increase O
in O
leukocyte O
adhesion O
( O
67+/-16 O
, O
83+/-12 O
, O
62+/-8 O
versus O
144+/-21 O
cells/ O
mm2 O
) O
. O

Confocal O
fluorescence O
microscopy O
studies O
showed O
that O
30 O
mm O
glucose O
induced O
an O
increase O
in O
endothelial O
surface O
expression O
of O
E-selectin B_GENE
, O
intercellular B_GENE
cell I_GENE
adhesion I_GENE
molecule-1 I_GENE
, O
and O
vascular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecule-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Electrophoretic O
mobility O
shift O
assay O
of O
nuclear O
extracts O
of O
human O
umbilical O
vein O
endothelial O
cells O
( O
HUVEC O
) O
exposed O
for O
1 O
h O
to O
30 O
mm O
glucose O
revealed O
an O
intense O
NF-kB B_GENE
activation O
. O

Treatment O
of O
HUVEC O
exposed O
to O
high O
glucose O
with O
the O
NF-kB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pyrrolidinedithiocarbamate O
( O
100 O
microM O
) O
and O
tosyl-phe-chloromethylketone O
( O
25 O
microM O
) O
significantly O
reduced O
( O
P O
< O
0.05 O
) O
leukocyte O
adhesion O
in O
respect O
to O
HUVEC O
treated O
with O
glucose O
alone O
. O

A O
significant O
( O
P O
< O
0.01 O
) O
inhibitory O
effect O
on O
glucose-induced O
leukocyte O
adhesion O
was O
observed O
after O
blocking O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
with O
staurosporine O
( O
5 O
nm O
) O
. O

When O
HUVEC O
were O
treated O
with O
specific O
antisense O
oligodesoxynucleotides O
against O
PKCalpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PKCepsilon I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
before O
the O
addition O
of O
30 O
mm O
glucose O
, O
a O
significant O
( O
P O
< O
0.05 O
) O
reduction O
in O
the O
adhesion O
was O
also O
seen O
. O

Advanced O
glycosylation O
end O
product-albumin B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
significantly O
increased O
the O
number O
of O
adhering O
leukocytes O
in O
respect O
to O
native B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
albumin I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
used O
as O
control O
( O
110+/-16 O
versus O
66+/-7 O
, O
P O
< O
0.01 O
) O
. O

Sera O
from O
diabetic O
patients O
significantly O
( O
P O
< O
0.01 O
) O
enhanced O
leukocyte O
adhesion O
as O
compared O
with O
controls O
, O
despite O
normal O
levels O
of O
IL-1beta B_GENE
and O
TNFalpha B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
sera O
. O

These O
data O
indicate O
that O
high O
glucose O
concentration O
and O
hyperglycemia O
promote O
leukocyte O
adhesion O
to O
the O
endothelium O
through O
upregulation O
of O
cell O
surface O
expression O
of O
adhesive O
proteins O
, O
possibly O
depending O
on O
NF-kB B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O
. O

Ikaros B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O
hemopoietic O
lineage O
determination O
and O
homeostasis O
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
the O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O
control O
hemopoietic B_DISEASE/B_ORGANISM_FUNCTION
differentiation B_DISEASE/I_ORGANISM_FUNCTION
have O
focused O
on O
signaling O
cascades B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O
nuclear B_LOCATION/B_ORGANIZATION
effectors I_LOCATION/I_ORGANIZATION
that O
drive O
this O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developmental B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
regulated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fashion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Here O
we O
review O
the O
role O
of O
Ikaros B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
founding O
member O
of O
a O
unique O
family O
of O
zinc B_GENE/B_BIO
finger I_GENE/I_BIO
transcription I_GENE/I_BIO
factors I_GENE/I_BIO
in O
this O
developmental O
process O
. O

Studies O
on O
an O
Ikaros B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
null O
mutation O
have O
revealed O
an O
essential O
role O
for O
this O
factor O
in O
lymphoid O
cell O
fate O
determination O
and O
at O
subsequent O
branch O
points O
of O
the O
T O
cell O
differentiation O
pathway O
. O

differences O
in O
the O
phenotypes O
of O
a O
null O
and O
a O
dominant B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
negative I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DN I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Ikaros I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
provide O
insight O
into O
a O
regulatory O
network O
through O
which O
Ikaros B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exert O
their O
effects O
in O
development O
. O

In O
addition O
a O
comparative O
analysis O
of O
the O
hemopoietic O
stem O
cell O
and O
precursor O
compartment O
resulting O
from O
the O
two O
Ikaros B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O
a O
profound O
yet O
not O
absolute O
requirement O
for O
Ikaros B_DISEASE/B_GENE
. O

induction O
of O
early B_DISEASE/B_VIRUS[BIO]
B B_DISEASE/I_VIRUS[BIO]
cell B_DISEASE/I_VIRUS[BIO]
factor B_DISEASE/I_VIRUS[BIO]
( O
EBF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
multiple B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lineage I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
the O
basic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
helix-loop-helix I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transcription I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
E12 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
transcription B_GENE
factors I_GENE
encoded O
by O
the O
E2A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
early B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
B I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
cell I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
EBF B_PROTEIN[GENE]/B_LOCATION
) O
genes O
are O
required O
for O
the O
proper O
development O
of O
B O
lymphocytes O
. O

However O
, O
the O
absence B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
B B_DISEASE/B_GENE
lineage I_DISEASE/I_GENE
cells I_DISEASE/I_GENE
in O
E2A- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
EBF-deficient B_DISEASE/B_LOCATION
mice I_DISEASE/I_LOCATION
has O
made O
it O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
determine O
the O
function B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
or O
relationship B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
these O
proteins B_LOCATION/B_GENE
. O

We O
report O
the O
identification O
of O
a O
novel O
model O
system O
in O
which O
the O
role O
of O
E2A B_LOCATION/B_GENE
and O
EBF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
regulation O
of O
multiple O
B O
lineage O
traits O
can O
be O
studied O
. O

We O
found O
that O
the O
conversion O
of O
70Z/3 O
pre-B O
lymphocytes O
to O
cells O
with O
a O
macrophage-like O
phenotype O
is O
associated O
with O
the O
loss O
of O
E2A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
EBF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Moreover O
, O
we O
show O
that O
ectopic O
expression O
of O
the O
E2A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein O
E12 B_GENE/B_MEASURE
in O
this O
macrophage O
line O
results O
in O
the O
induction O
of O
many B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lineage I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
EBF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
IL7Ralpha B_GENE
, O
lambda5 B_GENE
, O
and O
Rag-1 O
, O
and O
the O
ability O
to O
induce O
kappa B_GENE/B_DISEASE
light I_GENE/I_DISEASE
chain I_GENE/I_DISEASE
in O
response O
to O
mitogen O
. O

activation O
of O
EBF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
one O
of O
the O
critical O
functions O
of O
E12 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
regulating O
the O
B O
lineage O
phenotype O
since O
expression O
of O
EBF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
leads O
to O
the O
activation O
of O
a O
subset O
of O
E12 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-inducible O
traits O
. O

Our O
data O
demonstrate O
that O
, O
in O
the O
context O
of O
this O
macrophage O
line O
, O
E12 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
expression O
of O
EBF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
together O
these O
transcription B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coordinately O
regulate O
numerous O
B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lineage-associated I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
genes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Activation-induced O
down-regulation O
of O
retinoid B_GENE
receptor I_GENE
RXRalpha I_GENE
expression O
in O
human O
T O
lymphocytes O
. O

role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
cell B_ORGANIZATION/B_PERSON
cycle I_ORGANIZATION/I_PERSON
regulation I_ORGANIZATION/I_PERSON
. O

A O
5.4-kilobase B_GENE
mRNA I_GENE
, O
the O
expression O
of O
which O
is O
down-regulated O
after O
treatment O
of O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
with O
various O
T O
cell-activating O
agents O
, O
was O
isolated O
using O
an O
mRNA O
differential O
display O
method O
. O

Nucleotide O
sequence O
analysis O
identified O
the O
5 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
end I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
this O
RNA B_GENE/B_BIO
as O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
retinoid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RXRalpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Here O
, O
we O
report O
the O
nucleotide O
sequence O
of O
3.6 B_DISEASE/B_GENE
kilobases B_DISEASE/I_GENE
of O
this O
RNA O
, O
which O
represents O
the O
3 B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
RXRalpha B_GENE
mRNA I_GENE
, O
the O
sequence O
of O
which O
has O
not O
been O
previously O
described O
. O

activated O
PBMCs O
also O
expressed O
lower O
levels O
of O
RXRalpha B_GENE/B_LOCATION
protein O
, O
and O
a O
DNA O
binding O
assay O
showed O
that O
the O
activation-induced O
loss O
of O
RXRalpha B_GENE
mRNA I_GENE
and O
protein O
expression O
correlated O
with O
the O
loss O
of O
DNA O
binding O
activity O
of O
this O
protein O
. O

We O
present O
evidence O
that O
the O
transition O
from O
G0/G1 O
to O
S O
phase O
of O
the O
cell O
cycle O
results O
in O
the O
down-regulation O
of O
RXRalpha B_GENE
expression O
and O
that O
cell O
cycle O
inhibitors O
, O
which O
block O
the O
cells O
in O
G1 O
phase O
, O
prevent O
this O
down-regulation O
. O

The O
decrease O
in O
the O
levels O
of O
RXRalpha B_GENE
mRNA I_GENE
was O
found O
to O
be O
regulated O
at O
the O
post-transcriptional O
level O
and O
involved O
new O
protein O
synthesis O
. O

These O
observations O
indicate O
that O
the O
levels O
of O
RXRalpha B_GENE/B_LOCATION
expression O
in O
T O
lymphocytes O
are O
coupled O
to O
cell O
cycle O
progression O
, O
and O
there O
is O
tight O
regulatory O
control O
of O
RXRalpha B_GENE/B_BIO
expression O
during O
the O
transition O
from O
G0/G1 O
to O
S O
phase O
of O
the O
cell O
cycle O
. O

Epidemiology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pathogenesis B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
AIDS-related B_DISEASE
lymphomas I_DISEASE
. O

Among O
patients B_PERSON/B_BIO
with O
congenital B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O
acquired O
immunodeficiencies B_DISEASE
, O
non-Hodgkin B_DISEASE
's I_DISEASE
lymphoma I_DISEASE
( O
NHLs B_DISEASE
) O
are O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
tumors I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
the O
immune B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
setting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
human B_DISEASE
immunodeficiency I_DISEASE
virus I_DISEASE
( O
HIV B_DISEASE/B_VIRUS[BIO]
) O
infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
as O
many B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
10 B_NUMBER[MEASURE]
% I_NUMBER[MEASURE]
to O
20 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
people B_PERSON
ultimately O
developed O
NHLs B_DISEASE
. O

These O
tumors B_DISEASE/B_PERSON
are O
clinically O
aggressive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
frequently O
involve O
extranodal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sites B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
and O
often O
exhibit O
unique B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
distinguish O
them O
from O
NHL B_DISEASE/B_ORGANIZATION
arising O
in O
individuals B_PERSON/B_ORGANIZATION
with O
other B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
forms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
immunosuppression B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Important O
in O
the O
development O
of O
HIV-associated O
NHL O
are O
cytokines B_DISEASE
and O
other O
factors O
that O
induce O
B-cell O
proliferation O
and O
increase O
the O
likelihood O
of O
mutations O
of O
c-myc B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
bcl-6 B_GENE
, O
and O
other O
tumor-suppressor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
carcinogenic O
potential O
. O

specific O
forms O
of O
HIV-associated O
NHL O
are O
linked O
to O
expression O
of O
Epstein-Barr B_DISEASE/B_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
( B_DISEASE/I_VIRUS[BIO]
EBV B_DISEASE/I_VIRUS[BIO]
) B_DISEASE/I_VIRUS[BIO]
-latent B_DISEASE/I_VIRUS[BIO]
proteins B_DISEASE/I_VIRUS[BIO]
; O
the O
newly O
described O
DNA O
virus O
, O
Karposi O
's O
sarcoma-associated O
herpesvirus/human O
herpesvirus-8 O
( O
KSHV/HHV-8 O
) O
; O
and O
perhaps O
HIV O
. O

elucidation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
contribute O
to O
the O
high B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
incidence I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
NHL B_DISEASE
among O
patients B_PERSON/B_BIO
infected O
with O
HIV B_DISEASE/B_VIRUS[BIO]
provides O
insights B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
important B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
elements I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
lymphomagenesis B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Matrix B_GENE/B_PERSON
metalloproteinase I_GENE/I_PERSON
expression O
in O
human O
breast O
cancer O
: O
an O
immunohistochemical O
study O
including O
correlation O
with O
cathepsin B_GENE
D I_GENE
, O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
collagen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
laminin B_GENE
, O
fibronectin B_GENE
, O
EGFR B_GENE
, O
c-erbB-2 B_GENE/B_LOCATION
oncoprotein I_GENE/I_LOCATION
, O
p53 B_GENE
, O
steroid O
receptors O
status O
and O
proliferative O
indices O
. O

Matrix B_GENE/B_PERSON
metalloproteinase I_GENE/I_PERSON
s O
( O
MMPs B_GENE/B_BACTERIUM[BIO]
) O
are O
a O
group O
of O
enzymes O
thought O
to O
be O
responsible O
for O
both O
normal O
connective O
tissue O
matrix O
remodelling O
and O
accelerated O
breakdown O
associated O
with O
tumour O
development O
. O

The O
current O
study O
aimed O
to O
investigate O
the O
immunohistochemical O
expression O
of O
matrix B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
metalloproteinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
3 I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MMP-3 B_GENE/B_LOCATION
, O
stromelysin-1 B_GENE/B_MEASURE
) O
in O
correlation O
with O
the O
expression O
of O
Basement B_GENE
Membrane I_GENE
( I_GENE
BM I_GENE
) I_GENE
antigen I_GENE
( O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
collagen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
laminin B_GENE
) O
, O
fibronectin B_GENE
, O
cathepsin B_GENE
D I_GENE
, O
p53 B_GENE
, O
c-erbB-2 B_GENE
, O
proliferative O
activity O
( O
Ki-67 B_GENE/B_LOCATION
, O
PCNA B_GENE/B_MEASURE
) O
, O
steroid O
receptor O
content O
as O
well O
as O
to O
the O
other O
conventional O
clinicopathological O
parameters O
in O
breast O
cancer O
. O

This O
study O
was O
performed O
on O
a O
series O
of O
frozen O
and O
paraffin O
sections O
from O
84 O
breast O
cancer O
specimens O
by O
immunohistochemistry O
using O
the O
monoclonal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibody I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MMP-3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Ab-1 B_GENE/B_MEASURE
) O
. O

Stromelysin-1 B_GENE/B_DISEASE
( O
ST1 B_GENE/B_DISEASE
) O
was O
observed O
in O
about O
10 O
% O
of O
epithelial O
cells O
in O
the O
control O
groups O
( O
cases O
of O
fibrocystic O
and O
benign O
proliferative O
breast O
disease O
) O
, O
while O
expression O
( O
> O
10 O
% O
of O
expression O
) O
was O
detected O
in O
89.7 O
% O
of O
tumours O
. O

The O
expression O
of O
ST1 B_GENE
in O
carcinoma O
cells O
was O
strongly O
associated O
with O
its O
presence O
in O
the O
stroma O
( O
p O
< O
0.001 O
) O
. O

A O
significantly O
positive O
correlation O
was O
found O
between O
ST1 B_GENE
expression O
, O
and O
p53 B_GENE/B_PERSON
tumour O
suppressor O
gene O
product O
( O
p O
= O
0.004 O
) O
, O
and O
a O
relationship O
with O
c-erbB-2 B_GENE
protein O
and O
progesterone O
receptor O
status O
was O
also O
indicated O
. O

These O
findings O
suggest O
that O
ST1 B_GENE
expression O
in O
breast O
cancer O
tissue O
is O
irrespective O
of O
the O
expression O
of O
the O
extracellular O
matrix O
component O
, O
the O
proteolytic B_ENZYME[GENE]/B_MEASURE
enzyme B_ENZYME[GENE]/I_MEASURE
cathepsin B_ENZYME[GENE]/I_MEASURE
D B_ENZYME[GENE]/I_MEASURE
and O
the O
growth O
fraction O
of O
the O
tumour O
, O
and O
that O
it O
could O
be O
a O
potential O
new O
prognostic O
marker O
in O
breast O
cancer O
. O

Use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
transfected B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
liver I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
cells I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
to O
evaluate O
potential B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
alcohol-induced B_DISEASE_ADJECTIVE[DISEASE]
liver I_DISEASE_ADJECTIVE[DISEASE]
injury I_DISEASE_ADJECTIVE[DISEASE]
[ O
see O
comments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] O
. O

There O
is O
increased O
activity O
of O
the O
proinflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
alcoholic O
liver O
disease O
( O
ALD O
) O
. O

Hepatic B_DISEASE
neutrophil I_DISEASE
infiltration I_DISEASE
is O
a O
principal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injurious B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manifestation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ALD B_DISEASE
. O

TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O
induce O
cellular O
oxidative O
injury O
directly O
, O
and O
indirectly O
by O
inducing O
neutrophil O
chemotactic O
factor O
( O
IL-8 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
production O
by O
hepatocytes O
. O

IL-8 B_DISEASE/B_GENE
activates O
and O
chemotactically O
attracts O
neutrophils O
to O
the O
liver O
where O
they O
release O
oxidizing O
substances O
. O

patients O
with O
ALD O
also O
have O
decreased O
protective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
cellular O
oxidative O
injury O
. O

Manganous B_ENZYME[GENE]
superoxide I_ENZYME[GENE]
dismutase I_ENZYME[GENE]
( O
MnSOD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
is O
an O
antioxidant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
protective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
. O

The O
objectives O
of O
these O
studies O
were O
to O
investigate O
mechanisms O
for O
induction O
of O
an O
injurious B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
IL-8 B_GENE/B_LOCATION
) O
and O
a O
protective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
( O
MnSOD B_GENE/B_LOCATION
) O
in O
the O
HepG2 O
human O
hepatoma O
cell O
line O
. O

In O
the O
first O
set O
of O
experiments O
, O
IL-8 B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
gene I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
reporter I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
constructs I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
were O
used O
to O
transiently O
transfect O
a O
derivative O
( O
MVh2E1-9 O
) O
of O
the O
HepG2 O
cell O
line O
which O
expresses O
P-4502E1 B_GENE/B_DISEASE
and O
metabolizes O
ethanol O
. O

Inactivation O
of O
the O
NF-kappaB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3'NF-IL-6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
decreased O
IL-8 B_GENE/B_PERSON
gene I_GENE/I_PERSON
transcriptional O
activation O
in O
response O
to O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
while O
inactivation O
of O
the O
5'NF-IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
increased O
IL-8 B_GENE/B_BIO
gene I_GENE/I_BIO
transcriptional O
activity O
in O
response O
to O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

This O
system O
may O
be O
useful O
to O
assess O
the O
effects O
of O
ethanol O
on O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O
hepatocyte O
IL-8 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O
. O

In O
the O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
set I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
HepG2 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
cultured O
in O
25 B_MEASURE
to O
100 B_MEASURE
mmol I_MEASURE
concentrations I_MEASURE
of O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Both O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ethanol O
increased O
HepG2 O
cell O
MnSOD B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
in O
short-term O
( O
72 O
hr O
) O
cultures O
with O
ethanol O
. O

However O
, O
after O
long-term O
( O
10 O
weeks O
) O
culture O
with O
ethanol O
, O
there O
was O
no O
induction O
of O
MnSOD B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
ethanol O
and O
there O
was O
a O
diminished O
induction O
of O
MnSOD B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
response O
to O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Further O
studies O
are O
needed O
to O
assess O
the O
effect O
of O
this O
diminished O
induction O
of O
MnSOD B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
chronic O
ethanol O
culture O
on O
HepG2 O
cell O
susceptibility O
to O
TNF O
cytotoxicity O
. O

We O
conclude O
that O
transfected O
liver O
cell O
lines O
can O
be O
used O
to O
evaluate O
mechanisms O
for O
increased O
injurious B_DISEASE/B_GENE
factors I_DISEASE/I_GENE
and O
decreased O
protective B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
alcoholic O
liver O
injury O
. O

tissue O
factor O
transcription O
driven O
by O
Egr-1 B_GENE
is O
a O
critical O
mechanism O
of O
murine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pulmonary I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibrin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
deposition O
in O
hypoxia O
. O

Local B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hypoxemia I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
stasis B_DISEASE
trigger I_DISEASE
thrombosis I_DISEASE
. O

We O
have O
demonstrated O
previously O
that O
in O
a O
murine O
model O
of O
normobaric O
hypoxia O
pulmonary O
fibrin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
deposition O
is O
a O
result O
of O
expression O
of O
tissue B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
especially O
in O
oxygen-deprived B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mononuclear I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
phagocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MPs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

We O
now O
show O
that O
transcription B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
early-growth-response I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
product I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Egr-1 B_GENE/B_DISEASE
) O
is O
rapidly O
activated O
in O
hypoxia O
, O
both O
in O
vitro O
and O
in O
vivo O
, O
and O
is O
responsible O
for O
transcription O
and O
expression O
of O
tissue B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
hypoxic O
lung O
. O

MPs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
HeLa O
cells O
subjected O
to O
hypoxia O
( O
pO2 O
approximately O
13 O
torr O
) O
had O
increased O
levels O
of O
tissue B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
approximately O
18-fold O
) O
and O
an O
increased O
rate O
of O
transcription O
( O
approximately O
15-fold O
) O
, O
based O
on O
nuclear O
run-on O
analysis O
. O

Gel-shift O
analysis O
of O
nuclear O
extracts O
from O
hypoxic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MPs B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
HeLa O
cells O
demonstrated O
increased O
DNA-binding O
activity O
at O
the O
serum B_LOCATION
response I_LOCATION
region I_LOCATION
( O
SRR O
; O
-111/+14 O
BP O
) O
of O
the O
tissue B_GENE
factor I_GENE
promoter I_GENE
at O
Egr-1 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
motifs I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Using O
32P-labeled O
Egr O
consensus O
oligonucleotide O
, O
we O
observed O
induction O
of O
DNA-binding O
activity O
in O
nuclear O
extracts O
from O
hypoxic O
lung O
and O
HeLa O
cells O
because O
of O
activation O
of O
Egr-1 B_GENE
, O
by O
means O
of O
supershift O
analysis O
. O

Transient O
transfection O
of O
HeLa O
cells O
with O
chimeric B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plasmids I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
containing O
wild-type B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SRR I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
tissue B_GENE/B_BIO
factor I_GENE/I_BIO
promoter I_GENE/I_BIO
showed O
that O
intact B_GENE/B_MEASURE
Sp1 I_GENE/I_MEASURE
sites I_GENE/I_MEASURE
are O
necessary O
for O
basal O
promoter O
activity O
, O
whereas O
the O
integrity O
of O
Egr-1 B_GENE/B_MEASURE
sites I_GENE/I_MEASURE
was O
required O
for O
hypoxia-enhanced O
expression O
. O

A O
central O
role O
for O
Egr-1 B_GENE
in O
hypoxia-mediated O
tissue O
factor O
expression O
was O
confirmed O
by O
experiments O
with O
homozygous O
Egr-1 B_GENE/B_DISEASE
null O
mice O
; O
wild-type O
mice O
subjected O
to O
oxygen B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
deprivation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
expressed I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tissue I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factor I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
showed O
fibrin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
deposition O
, O
but O
hypoxic O
homozygous O
Egr-1 B_GENE/B_DISEASE
null O
mice O
displayed O
neither O
tissue B_DISEASE/B_GENE
factor B_DISEASE/I_GENE
nor O
fibrin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

These O
data O
delineate O
a O
novel O
biology O
for O
hypoxia-induced O
fibrin B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deposition O
, O
in O
which O
oxygen O
deprivation-induced O
activation O
of O
Egr-1 B_GENE
, O
resulting O
in O
expression O
of O
tissue B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
has O
an O
unexpected O
and O
central O
role O
. O

Kinetics O
of O
cytokine O
and O
NFAT O
gene O
expression O
in O
human O
interleukin-2-dependent O
T O
lymphoblasts O
stimulated O
via O
T-cell B_GENE
receptor I_GENE
. O

T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
respond O
to O
mitogenic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
antigenic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
proliferation B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
by O
turning O
on O
cytokine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

Here O
we O
have O
analysed O
the O
kinetics O
and O
nature O
of O
cytokine O
production O
in O
human O
peripheral O
blood-derived O
T O
lymphoblasts O
stimulated O
with O
anti-CD3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
Lens B_GENE/B_SPECIES[BIO]
culinaris I_GENE/I_SPECIES[BIO]
lectin I_GENE/I_SPECIES[BIO]
( O
LCL B_DISEASE/B_PROTEIN[GENE]
) O
. O

T O
cells O
were O
purified O
from O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
and O
primarily O
activated O
with O
anti-CD3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
cultured O
in O
the O
presence O
of O
interleukin-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IL-2 B_GENE
) O
. O

Anti-CD3-restimulated O
T O
cells O
( O
mainly O
CD8+ O
) O
produced O
IL-2 B_GENE
, O
interferon-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
IFN-gamma B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
tumour B_GENE
necrosis I_GENE
factor-alpha I_GENE
( O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
low O
levels O
of O
IL-4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-10 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
proteins O
. O

No O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
was O
observed O
. O

In O
LCL-stimulated B_PERSON/B_BIO
cells I_PERSON/I_BIO
the O
cytokine B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
production I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pattern I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
very O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Steady-state O
mRNA O
levels O
of O
IL-2 B_GENE
, O
IL-10 B_GENE
and O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
peaked O
at O
3 O
hr O
after O
anti-CD3 O
stimulation O
and O
declined O
rapidly O
thereafter O
. O

The O
kinetics O
of O
TNF-alpha B_GENE
mRNA I_GENE
expression O
was O
faster O
, O
being O
at O
its O
peak O
level O
1 O
hr O
after O
stimulation O
. O

Anti-CD3-stimulated O
IL-2 B_GENE
gene I_GENE
expression O
was O
down-regulated O
by O
protein O
synthesis O
inhibitor O
, O
whereas O
IL-10 B_GENE/B_PERSON
, I_GENE/I_PERSON
IFN-gamma I_GENE/I_PERSON
and I_GENE/I_PERSON
TNF-alpha I_GENE/I_PERSON
genes I_GENE/I_PERSON
were O
readily O
induced O
independent O
of O
ongoing O
protein O
synthesis O
. O

T-cell B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation O
also O
induced O
a O
very O
rapid O
expression O
of O
c-jun B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-fos I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NFATc1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NFATc I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
gene O
products O
of O
which O
are O
involved O
in O
cytokine O
gene O
expression O
. O

In O
conclusion O
, O
the O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesized O
by O
IL-2-dependent O
T O
cells O
were O
predominantly O
IL-2 B_GENE
, O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

An O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
to O
study O
local B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
oxidation I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
of O
LDL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
its O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
arterial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wall I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Oxidized B_LOCATION/B_ORGANIZATION
LDL I_LOCATION/I_ORGANIZATION
( O
oxLDL B_GENE
) O
is O
present B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
atherosclerotic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lesions I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
is O
believed O
to O
play O
a O
key B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
atherogenesis B_DISEASE
. O

mainly O
on O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
culture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
oxLDL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O
been O
shown O
to O
produce O
many B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
biological I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
influence O
the O
atherosclerotic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
process B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

To O
study O
LDL B_DISEASE/B_GENE
oxidation I_DISEASE/I_GENE
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
we O
have O
established O
a O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
which O
Sprague-Dawley B_SPECIES[BIO]/B_PERSON
rats I_SPECIES[BIO]/I_PERSON
are O
given O
a O
single B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
unmodified B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LDL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
> B_MEASURE/B_OTHER
or O
= O
4 B_MEASURE
mg/kg O
body B_MEASURE
weight I_MEASURE
) O
. O

Within O
6 O
hours O
, O
an O
accumulation O
of O
apolipoprotein O
B O
and O
epitopes B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
present O
on O
oxLDL O
are O
detected O
in O
the O
arterial O
endothelium O
and O
media O
. O

The O
presence O
of O
oxLDL O
is O
associated O
with O
activation O
of O
the O
transcription B_GENE/B_LOCATION
factor I_GENE/I_LOCATION
nuclear I_GENE/I_LOCATION
factor-kappaB I_GENE/I_LOCATION
in O
the O
endothelium O
as O
well O
as O
endothelial O
expression O
of O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
. O

Injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
LDL B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
enriched O
with O
the O
antioxidant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probucol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O
in O
arterial B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
accumulation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
apolipoprotein B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
the O
expression B_GENE/B_MEASURE
of O
oxLDL-specific B_GENE
epitopes I_GENE
was O
reduced O
at O
24 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
. O

Thus O
, O
this O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
has O
the O
potential B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
analyze O
the O
mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behind O
and O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
LDL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Molecular O
mechanisms O
of O
promoter O
regulation O
of O
the O
gp34 B_GENE
gene I_GENE
that O
is O
trans-activated O
by O
an O
oncoprotein B_GENE/B_DISEASE
Tax I_GENE/I_DISEASE
of O
human O
T O
cell O
leukemia O
virus O
type O
I O
. O

We O
investigated O
the O
molecular O
mechanism O
of O
transcriptional O
activation O
of O
the O
gp34 B_GENE
gene I_GENE
by O
the O
Tax B_GENE
oncoprotein I_GENE
of O
human O
T O
cell O
leukemia O
virus O
type O
I O
( O
HTLV-I O
) O
. O

gp34 B_GENE
is O
a O
type B_GENE
II I_GENE
transmembrane I_GENE
molecule I_GENE
belonging O
to O
the O
tumor O
necrosis O
factor O
family O
and O
is O
constitutively O
expressed O
on O
HTLV-I-producing O
cells O
but O
not O
normal O
resting O
T O
cells O
. O

The O
transcriptional O
regulatory O
region O
of O
the O
gp34 B_GENE
gene I_GENE
was O
activated O
by O
HTLV-I O
Tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
human O
T O
cell O
line O
Jurkat O
, O
in O
which O
endogenous O
gp34 B_GENE
is O
induced O
by O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

sequence O
analysis O
demonstrated O
that O
two O
NF-kappaB-like B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
1 O
and O
2 O
) O
were O
present O
in O
the O
regulatory B_LOCATION/B_BIO
region B_LOCATION/I_BIO
. O

Both O
NF-kappaB-like B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elements B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
able O
to O
bind O
to O
NF-kappaB B_GENE/B_DISEASE
or O
its O
related O
factor O
( O
s O
) O
in O
a O
Tax B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O
manner O
. O

Chloramphenicol B_GENE
acetyltransferase I_GENE
assays O
indicated O
that O
NF-kappaB-like B_GENE
element I_GENE
1 I_GENE
was O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
-responsive O
, O
although O
the O
activity O
was O
lower O
than O
that O
the O
native B_GENE/B_MEASURE
promoter I_GENE/I_MEASURE
. O

NF-kappaB B_GENE/B_LOCATION
-like O
element O
2 O
elevated O
promoter O
activity O
when O
combined O
with O
NF-kappaB-like B_GENE
element I_GENE
1 I_GENE
, O
indicating O
cooperative O
function O
of O
the O
elements O
for O
maximum O
promoter O
function O
. O

Unlike O
typical O
NF-kappaB B_GENE/B_BIO
elements I_GENE/I_BIO
, O
the O
NF-kappaB-like B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
gp34 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
not O
activated O
by O
treatment O
of O
Jurkat O
cells O
with O
phorbol O
ester O
despite O
induction O
of O
the O
NF-kappaB B_GENE
-like O
binding O
activity O
. O

Chloramphenicol B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acetyltransferase B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter O
assays O
using O
the O
region O
upstream O
of O
the O
NF-kappaB-like B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
identified O
an O
upstream O
region O
that O
reduced O
transcription O
from O
cognate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
noncognate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
core B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
promoters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
a O
Tax-independent O
manner O
. O

Our O
results O
imply O
complex O
regulation O
of O
expression O
of O
the O
gp34 B_GENE
gene I_GENE
and O
suggest O
implication O
of O
gp34 B_GENE
in O
proliferation O
of O
HTLV-I O
infected O
T O
cells O
. O

beta-Amyloid B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
fibrils I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
activate O
parallel O
mitogen-activated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways O
in O
microglia O
and O
THP1 O
monocytes O
. O

The O
senile O
plaques O
of O
Alzheimer O
's O
disease O
are O
foci O
of O
local O
inflammatory O
responses O
, O
as O
evidenced O
by O
the O
presence O
of O
acute B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phase B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
proteins B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
oxidative O
damage O
. O

Fibrillar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
forms I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
beta-amyloid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
Abeta B_PROTEIN[GENE]/B_DISEASE
) O
, O
which O
are O
the O
primary O
constituents O
of O
senile O
plaques O
, O
have O
been O
shown O
to O
activate O
tyrosine O
kinase-dependent O
signal O
transduction O
cascades O
, O
resulting O
in O
inflammatory O
responses O
in O
microglia O
. O

However O
, O
the O
downstream O
signaling O
pathways O
mediating O
Abeta B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O
inflammatory O
events O
are O
not O
well O
characterized O
. O

We O
report O
that O
exposure O
of O
primary O
rat O
microglia O
and O
human O
THP1 O
monocytes O
to O
fibrillar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Abeta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
results O
in O
the O
tyrosine B_GENE
kinase I_GENE
-dependent O
activation O
of O
two O
parallel O
signal O
transduction O
cascades O
involving O
members O
of O
the O
mitogen-activated B_GENE/B_PERSON
protein I_GENE/I_PERSON
kinase I_GENE/I_PERSON
( I_GENE/I_PERSON
MAPK I_GENE/I_PERSON
) I_GENE/I_PERSON
superfamily I_GENE/I_PERSON
. O

Abeta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O
the O
rapid O
, O
transient O
activation O
of O
extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ERK1 B_GENE
) O
and O
ERK2 B_GENE
in O
microglia O
and O
ERK2 B_GENE
in O
THP1 O
monocytes O
. O

A O
second O
superfamily B_GENE/B_PERSON
member I_GENE/I_PERSON
, O
p38 B_GENE
MAPK I_GENE
, O
was O
also O
activated O
with O
similar O
kinetics O
. O

Scavenger B_GENE
receptor I_GENE
and O
receptor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
for I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
advanced I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
end I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
products I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
RAGE B_GENE/B_DISEASE
) O
ligands O
failed O
to O
activate O
ERK B_GENE
and O
p38 B_GENE
MAPK I_GENE
in O
the O
absence O
of O
significant O
increases O
in O
protein O
tyrosine O
phosphorylation O
, O
demonstrating O
that O
scavenger B_GENE
receptors I_GENE
and O
RAGE B_GENE
are O
not O
linked O
to O
these O
pathways O
. O

importantly O
, O
the O
stress-activated B_GENE/B_BIO
protein I_GENE/I_BIO
kinases I_GENE/I_BIO
( O
SAPKs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
were O
not O
significantly O
activated O
in O
response O
to O
Abeta B_DISEASE/B_GENE
. O

downstream O
effectors O
of O
the O
MAPK O
signal O
transduction O
cascades O
include O
MAPKAP B_ENZYME[GENE]/B_BIO
kinases I_ENZYME[GENE]/I_BIO
, O
such O
as O
RSK1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
RSK2 B_GENE
, O
as O
well O
as O
transcription B_GENE
factors I_GENE
. O

exposure O
of O
microglia O
and O
THP1 O
monocytes O
to O
Abeta B_GENE
resulted O
in O
the O
activation O
of O
RSK1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
RSK2 B_GENE
and O
phosphorylation O
of O
cAMP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element-binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
at O
Ser133 O
, O
providing O
a O
mechanism O
for O
Abeta B_GENE/B_DISEASE
-induced O
changes O
in O
gene O
expression O
. O

Regulation O
of O
cellular B_GENE/B_DISEASE
retinoic I_GENE/I_DISEASE
acid I_GENE/I_DISEASE
binding I_GENE/I_DISEASE
protein I_GENE/I_DISEASE
( O
CRABP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
during O
human O
monocyte O
differentiation O
in O
vitro O
. O

Cellular B_GENE/B_PERSON
retinoic I_GENE/I_PERSON
acid I_GENE/I_PERSON
binding I_GENE/I_PERSON
proteins I_GENE/I_PERSON
( O
CRABP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
are O
low B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecular I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
weight I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
whose O
precise O
function O
remains O
unknown O
. O

They O
bind O
retinoids B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
may O
thereby O
modulate O
the O
intracellular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steady-state I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
retinoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Whereas O
CRABP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
ubiquitously O
expressed O
, O
CRABP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
mainly O
detected O
in O
various O
cell O
types O
of O
the O
skin O
. O

By O
representative O
difference O
analysis O
we O
found O
that O
CRABP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
also O
strongly O
expressed O
in O
human O
monocyte-derived O
macrophages O
( O
MAC O
) O
but O
not O
in O
freshly O
isolated O
monocytes O
( O
Mo O
) O
. O

The O
CRABP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
gradually O
upregulated O
during O
differentiation O
from O
Mo O
to O
MAC O
in O
the O
presence O
of O
2 O
% O
serum O
. O

Adherence O
, O
which O
is O
important O
for O
Mo O
differentiation O
, O
induced O
CRABP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
, O
but O
the O
addition O
of O
10 O
( O
-7 O
) O
M O
retinoic O
acid O
inhibited O
the O
upregulation O
of O
CRABP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
expression O
during O
MO/MAC O
differentiation O
. O

As O
Mo O
can O
differentiate O
along O
the O
classical O
pathway O
not O
only O
to O
MAC O
but O
also O
to O
dendritic O
cells O
we O
analyzed O
the O
expression O
of O
CRABP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
MO-derived O
dendritic O
cells O
cultured O
with O
10 O
% O
FCS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
IL-4 B_GENE/B_LOCATION
, O
and O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
contrast O
to O
MAC O
, O
MO-derived O
dendritic O
cells O
showed O
an O
extremely O
low O
expression O
of O
CRABP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

From O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
conclude O
( O
1 B_SEQUENCE[MEASURE]
) O
that O
the O
availability B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
the O
metabolism B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
retinoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
may O
be O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
MAC B_DISEASE/B_PROTEIN[GENE]
compared O
to O
MO B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O
dendritic B_LOCATION/B_PERSON
cells I_LOCATION/I_PERSON
and O
( O
2 B_SEQUENCE[MEASURE]
) O
that O
this O
may O
influence O
differentiation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
activation B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
those O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O

Transcription B_GENE
factor I_GENE
B-cell-specific I_GENE
activator I_GENE
protein I_GENE
( O
BSAP B_LOCATION/B_ORGANIZATION
) O
is O
differentially O
expressed O
in O
B O
cells O
and O
in O
subsets O
of O
B-cell O
lymphomas O
. O

The O
paired B_GENE
box I_GENE
containing I_GENE
gene I_GENE
PAX-5 I_GENE
encodes O
the O
transcription B_GENE/B_DISEASE
factor I_GENE/I_DISEASE
BSAP I_GENE/I_DISEASE
( O
B-cell-specific B_PROTEIN[GENE]/B_DISEASE
activator I_PROTEIN[GENE]/I_DISEASE
protein I_PROTEIN[GENE]/I_DISEASE
) O
, O
which O
plays O
a O
key O
role O
in O
B-lymphocyte O
development O
. O

Despite O
its O
known O
involvement O
in O
a O
rare O
subtype O
of O
non-Hodgkin O
's O
lymphoma O
( O
NHL O
) O
, O
a O
detailed O
examination O
of O
BSAP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
in O
NHL O
has O
not O
been O
previously O
reported O
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
analyzed O
normal B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
malignant B_DISEASE/B_PERSON
lymphoid I_DISEASE/I_PERSON
tissues I_DISEASE/I_PERSON
and O
cell B_DISEASE
lines I_DISEASE
, O
including O
102 B_MEASURE/B_PERSON
cases B_MEASURE/I_PERSON
of O
B-cell B_DISEASE
NHL I_DISEASE
, O
23 B_MEASURE
cases I_MEASURE
of O
T- O
and O
null-cell B_DISEASE
NHL I_DISEASE
, O
and O
18 B_NUMBER[MEASURE]/B_PERSON
cases I_NUMBER[MEASURE]/I_PERSON
of O
Hodgkin B_DISEASE
's I_DISEASE
disease I_DISEASE
. O

Normal O
lymphoid O
tissues O
showed O
strong O
nuclear O
BSAP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
in O
mantle O
zone O
B O
cells O
, O
less O
intense O
reactivity O
in O
follicular O
center O
B O
cells O
, O
and O
no O
expression O
in O
cells O
of O
the O
T-cell-rich O
zones O
. O

Monocytoid B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O
weak B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
expression I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
whereas O
plasma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
extrafollicular B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
large I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
transformed O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Of O
the O
102 O
B-cell O
NHLs O
, O
83 O
( O
81 O
% O
) O
demonstrated O
BSAP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
. O

All O
of O
the O
13 B_MEASURE
( O
100 B_MEASURE
% I_MEASURE
) O
B-cell B_DISEASE_ADJECTIVE[DISEASE]
chronic I_DISEASE_ADJECTIVE[DISEASE]
lymphocytic I_DISEASE_ADJECTIVE[DISEASE]
leukemias I_DISEASE_ADJECTIVE[DISEASE]
( O
B-CLLs B_DISEASE/B_LOCATION
) O
, O
21 B_MEASURE
of O
( O
100 B_MEASURE
% I_MEASURE
) O
mantle B_DISEASE
cells I_DISEASE
( O
MCLs B_DISEASE/B_PROTEIN[GENE]
) O
, O
and O
20 B_NUMBER[MEASURE]
of O
21 B_NUMBER[MEASURE]
( O
95 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
follicular B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphomas B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
FLs B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
were O
positive B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Moderate B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
staining I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intensities I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
found O
in O
most B_DISEASE/B_PROTEIN[GENE]
B-CLL B_DISEASE/I_PROTEIN[GENE]
and O
FL B_LOCATION/B_ORGANIZATION
cases I_LOCATION/I_ORGANIZATION
, O
whereas O
most B_NUMBER[MEASURE]/B_PERSON
MCLs B_NUMBER[MEASURE]/I_PERSON
showed O
strong B_DISEASE_ADJECTIVE[DISEASE]
reactions I_DISEASE_ADJECTIVE[DISEASE]
, O
paralleling O
the O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactivity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nonmalignant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mantle I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Eight O
of O
12 O
( O
67 O
% O
) O
marginal O
zone O
lymphoma O
cases O
showed O
negative O
or O
low O
BSAP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
, O
and O
17 O
of O
24 O
( O
71 O
% O
) O
large O
B-cell O
lymphomas O
displayed O
moderate O
to O
strong O
expression O
. O

None O
of O
the O
23 O
T- O
and O
null-cell O
lymphomas O
reacted O
with O
the O
BSAP B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
antisera O
, O
whereas O
in O
Hodgkin O
's O
disease O
, O
2 O
of O
4 O
( O
50 O
% O
) O
nodular O
lymphocytic O
predominance O
and O
5 O
of O
14 O
( O
36 O
% O
) O
classical O
cases O
showed O
weak O
nuclear O
or O
nucleolar O
BSAP B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions O
in O
a O
fraction O
of O
the O
tumor O
cells O
. O

Western O
blot O
analysis O
showed O
a O
52-kD O
BSAP B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
band O
in O
B-cell O
lines O
, O
but O
not O
in O
non-B-cell O
or O
plasma O
cell O
lines O
. O

We O
conclude O
that O
BSAP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
is O
largely O
restricted O
to O
lymphomas O
of O
B-cell O
lineage O
and O
that O
BSAP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
varies O
in O
B-cell O
subsets O
and O
subtypes O
of O
B-cell O
NHL O
. O

The O
high O
levels O
of O
BSAP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
especially O
those O
found O
in O
large-cell O
lymphomas O
and O
in O
some O
follicular O
lymphomas O
, O
may O
be O
a O
consequence O
of O
deregulated O
gene O
expression O
and O
suggest O
a O
possible O
involvement O
of O
PAX-5 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
certain O
B-cell O
malignancies O
. O

This O
is O
a O
US B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
government I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
work I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

There O
are O
no O
restrictions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
its O
use B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

Mitogen O
and O
growth O
factor-induced O
activation O
of O
a O
STAT-like B_GENE/B_LOCATION
molecule I_GENE/I_LOCATION
in O
channel O
catfish O
lymphoid O
cells O
. O

This O
article O
describes O
the O
identification O
of O
a O
putative B_GENE
STAT I_GENE
molecule I_GENE
in O
the O
channel O
catfish O
( O
Ictalurus O
punctatus O
) O
, O
the O
first O
report O
of O
such O
a O
molecule O
in O
a O
'lower O
' O
vertebrate O
. O

A O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
human B_GENE
STAT6 I_GENE
recognizes O
an O
approximately O
100 B_PROTEIN[GENE]/B_LOCATION
kDa I_PROTEIN[GENE]/I_LOCATION
molecule I_PROTEIN[GENE]/I_LOCATION
that O
becomes O
activated O
and O
translocates O
to O
the O
nucleus O
upon O
both O
growth O
factor O
and O
mitogen O
stimulation O
of O
catfish O
leukocytes O
. O

This O
presumed O
catfish B_LOCATION
STAT I_LOCATION
binds O
the O
mammalian B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon-gamma I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
known O
motif O
of O
mammalian O
STAT O
binding O
, O
as O
shown O
by O
electromobility O
shift O
assays O
. O

Purification O
of O
the O
proteins O
present O
in O
these O
DNA B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
confirms O
that O
the O
catfish O
reactive O
molecule O
binds O
to O
the O
interferon-gamma B_GENE
activation I_GENE
site I_GENE
sequence I_GENE
. O

These O
results O
suggest O
that O
STAT B_GENE/B_BIO
molecules I_GENE/I_BIO
have O
been O
highly O
conserved O
in O
vertebrate O
evolution O
. O

isolation O
and O
analysis O
of O
a O
T O
cell O
clone O
variant O
exhibiting O
constitutively O
phosphorylated B_GENE
Ser133 I_GENE
cAMP I_GENE
response I_GENE
element-binding I_GENE
protein I_GENE
. O

In O
driving O
T O
cell O
proliferation O
, O
IL-2 B_GENE
stimulates O
a O
new O
program O
of O
gene O
expression O
that O
includes O
proliferating B_GENE/B_DISEASE
cell I_GENE/I_DISEASE
nuclear I_GENE/I_DISEASE
antigen I_GENE/I_DISEASE
( O
PCNA B_GENE
) O
, O
a O
requisite O
processivity O
factor O
for O
DNA B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
polymerase B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
delta B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

PCNA B_GENE
transcription O
is O
regulated O
in O
part O
through O
tandem O
CRE B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
promoter B_GENE
and I_GENE
CRE I_GENE
binding I_GENE
proteins I_GENE
; O
IL-2 B_GENE
stimulates O
CREB O
phosphorylation O
in O
the O
resting O
cloned O
T O
lymphocyte O
, O
L2 O
. O

After O
culturing O
L2 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
for O
greater B_MEASURE
than O
91 B_NUMBER[MEASURE]/B_ENT
days I_NUMBER[MEASURE]/I_ENT
, O
we O
consistently O
isolate O
a O
stable B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variant B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O
exhibits O
constitutive B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
CREB I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
phosphorylation I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

L2 O
and O
L2 O
variant O
cells O
were O
tested O
for O
IL-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
responsiveness O
and O
rapamycin O
sensitivity O
with O
respect O
to O
specific O
kinase O
activity O
, O
PCNA O
expression O
and O
proliferation O
. O

In O
L2 O
cells O
, O
IL-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulated O
and O
rapamycin O
inhibited O
the O
following O
: O
cAMP-independent O
CREB B_GENE/B_LOCATION
kinase I_GENE/I_LOCATION
activity O
, O
PCNA O
expression O
and O
proliferation O
. O

In O
L2 O
variant O
cells O
, O
CREB B_GENE
kinase I_GENE
activity O
was O
constitutively O
high O
; O
IL-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulated O
and O
rapamycin O
blocked O
PCNA O
expression O
and O
proliferation O
. O

These O
results O
indicate O
that O
IL-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
a O
rapamycin-sensitive O
, O
cAMP-independent O
CREB B_GENE/B_DISEASE
kinase I_GENE/I_DISEASE
activity O
in O
L2 O
cells O
. O

However O
, O
phosphorylation O
of O
CREB B_GENE
alone O
is O
not O
sufficient O
to O
drive O
PCNA B_GENE
expression O
and O
L2 O
cell O
proliferation O
in O
the O
absence O
of O
IL-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Serotonin O
derivative O
, O
N- O
( O
p-coumaroyl O
) O
serotonin O
, O
inhibits O
the O
production O
of O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
IL-1alpha B_GENE
, O
IL-1beta B_GENE
, O
and O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
by O
endotoxin-stimulated O
human O
blood O
monocytes O
. O

We O
have O
reported O
that O
N- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p-coumaroyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CS B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
its O
derivatives B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
antioxidative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
safflower B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
seeds I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O

As O
reactive O
oxygen O
species O
( O
ROS O
) O
are O
implicated O
in O
the O
signaling O
of O
lipopolysaccharide O
( O
LPS O
) O
, O
we O
examined O
whether O
CS O
has O
a O
suppressive O
effect O
on O
inflammatory B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokine B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generation O
from O
human O
monocyte O
s O
in O
vitro O
. O

CS O
at O
50-200 O
microM O
reduced O
tumor B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
necrosis B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factor B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
TNF B_GENE/B_LOCATION
) O
, O
interleukin-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
IL-1 B_GENE
) O
, O
and O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activities O
in O
the O
culture O
supernatants O
from O
LPS-stimulated O
human O
blood O
monocytes O
without O
cytotoxicity O
. O

ELISA O
assay O
revealed O
that O
the O
production O
of O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
IL-1alpha B_GENE
, O
IL-1beta B_GENE
, O
and O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O
inhibited O
by O
CS O
. O

Northern O
blot O
analysis O
showed O
that O
LPS-induced O
expression O
of O
these O
cytokine B_GENE
mRNA I_GENE
in O
monocytes O
was O
suppressed O
by O
CS O
. O

NF-kappaB B_GENE/B_PERSON
activation I_GENE/I_PERSON
was O
also O
inhibited O
by O
CS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

These O
findings O
indicate O
that O
CS O
has O
a O
suppressive O
effect O
on O
proinflammatory O
cytokine O
production O
from O
monocytes O
, O
and O
this O
effect O
is O
based O
in O
part O
on O
the O
suppression O
of O
cytokine B_GENE
mRNA I_GENE
expression O
through O
inhibition O
of O
NF-kappaB B_GENE
activation O
. O

elevated O
expression O
of O
differentiation B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitory I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nm23 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
monoblastic O
crisis O
of O
a O
patient O
with O
chronic O
myelogenous O
leukemia O
. O

Differentiation B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitory I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nm23 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
found O
to O
be O
expressed O
in O
high O
quantities O
in O
acute O
myelogenous O
leukemia O
( O
AML O
) O
, O
especially O
in O
acute O
monocytic O
leukemia O
( O
AML-M5 O
) O
and O
is O
suggested O
as O
a O
new O
prognostic O
factor O
in O
AML-M5 O
. O

We O
report O
an O
example O
of O
elevated O
expression O
of O
nm23 B_GENE
mRNA I_GENE
in O
a O
patient O
with O
chronic O
myelogenous O
leukemia O
( O
CML O
) O
who O
developed O
monoblastic O
crisis O
. O

relative O
levels O
of O
nm23-H1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-H2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
extracted O
from O
the O
patient O
's O
peripheral O
blood O
mononuclear O
cells O
and O
bone O
marrow O
mononuclear O
cells O
were O
measured O
by O
quantitative O
reverse O
transcriptase O
polymerase O
chain O
reaction O
. O

The O
level O
of O
nm23-H1 B_GENE
mRNA I_GENE
in O
CML O
cells O
at O
the O
chronic O
phase O
was O
as O
high O
as O
that O
in O
bone O
marrow O
cells O
from O
healthy O
volunteers O
. O

The O
mRNA O
level O
of O
nm23-H2 B_GENE
was O
slightly O
below O
the O
normal O
level O
. O

At O
blastic O
crisis O
, O
however O
, O
expression O
of O
both O
nm23-H1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-H2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
elevated O
to O
about O
three O
to O
nine O
times O
of O
that O
at O
the O
chronic O
phase O
. O

Proliferated O
blastic O
cells O
were O
positive O
for O
non-specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
esterase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
the O
serum O
lysozyme O
level O
was O
elevated O
and O
diagnosed O
as O
monoblastic O
crisis O
. O

The O
patient B_PERSON/B_ORGANIZATION
received O
combined O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
but O
response B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
was O
partial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

These O
findings O
are O
compatible O
with O
our O
previous O
report O
that O
nm23 B_GENE
gene I_GENE
is O
overexpressed O
in O
monocytic O
leukemia O
. O

increased O
transcription O
decreases O
the O
spontaneous O
mutation O
rate O
at O
the O
thymidine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
human O
cells O
. O

Transcription B_GENE
increases I_MEASURE
DNA I_MEASURE
repair I_MEASURE
efficiency I_MEASURE
and O
modulates O
the O
distribution B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
certain B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
types B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
DNA B_DISEASE/B_GENE
damage I_DISEASE/I_GENE
. O

Furthermore O
, O
increased O
transcription B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulates O
spontaneous B_MEASURE
mutation I_MEASURE
rate I_MEASURE
in O
yeast B_BIO/B_DISEASE
. O

We O
explored O
whether O
transcription B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
affects O
spontaneous B_MEASURE
mutation I_MEASURE
rate I_MEASURE
in O
human B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
first O
developed O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
thymidine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
TK B_PROTEIN[GENE]/B_DISEASE
) O
inducible B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
human I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lines I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O
the O
Gal4-Estrogen B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
system I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
our O
TK6i-G3 O
and O
G9 O
tk O
heterozygous O
cell O
lines O
, O
the O
active O
tk B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
allele I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
linked O
to O
an O
inducible O
promoter B_GENE/B_LOCATION
element I_GENE/I_LOCATION
. O

Tk B_DISEASE/B_ORGANISM_FUNCTION
mRNA I_DISEASE/I_ORGANISM_FUNCTION
is O
induced O
following O
treatment O
with O
estrogen O
. O

Spontaneous B_GENE
mutation I_GENE
rate I_GENE
was O
significantly O
decreased O
in O
human B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cell I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
lines I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
after O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
in O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
report B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
yeast B_SPECIES[BIO]
. O

Thus O
, O
humans B_PERSON/B_BIO
may O
have O
evolved O
different B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
or O
additional B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
to O
deal O
with O
transcription B_GENE/B_DISEASE
related O
spontaneous B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutagenesis B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Copyright B_LOCATION/B_ORGANIZATION
1998 I_LOCATION/I_ORGANIZATION
Elsevier I_LOCATION/I_ORGANIZATION
Science I_LOCATION/I_ORGANIZATION
B.V I_LOCATION/I_ORGANIZATION
. O

All O
rights B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reserved O
. O

mutation O
of O
BCL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
normal O
B O
cells O
by O
the O
process O
of O
somatic O
hypermutation O
of O
Ig B_GENE
genes I_GENE
. O

Immunoglobulin B_PERSON/B_GENE
( I_PERSON/I_GENE
Ig I_PERSON/I_GENE
) I_PERSON/I_GENE
genes I_PERSON/I_GENE
are O
hypermutated O
in O
B O
lymphocytes O
that O
are O
the O
precursors O
to O
memory O
B O
cells O
. O

The O
mutations O
are O
linked O
to O
transcription O
initiation O
, O
but O
non-Ig B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
promoters I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
permissible O
for O
the O
mutation O
process O
; O
thus O
, O
other O
genes O
expressed O
in O
mutating O
B O
cells O
may O
also O
be O
subject O
to O
somatic O
hypermutation O
. O

significant O
mutations O
were O
not O
observed O
in O
c-MYC B_DISEASE/B_GENE
, I_DISEASE/I_GENE
S14 I_DISEASE/I_GENE
, I_DISEASE/I_GENE
or I_DISEASE/I_GENE
alpha-fetoprotein I_DISEASE/I_GENE
( I_DISEASE/I_GENE
AFP I_DISEASE/I_GENE
) I_DISEASE/I_GENE
genes I_DISEASE/I_GENE
, O
but O
BCL-6 B_GENE
was O
highly O
mutated O
in O
a O
large O
proportion O
of O
memory O
B O
cells O
of O
normal O
individuals O
. O

The O
mutation O
pattern O
was O
similar O
to O
that O
of O
Ig B_GENE/B_BIO
genes I_GENE/I_BIO
. O

CD28-mediated B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activation I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
CD45RA+ B_GENE
and O
CD45RO+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
: O
enhanced O
levels B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
reactive B_GENE/B_BACTERIUM[BIO]
oxygen I_GENE/I_BACTERIUM[BIO]
intermediates I_GENE/I_BACTERIUM[BIO]
and O
c-Rel B_DISEASE/B_GENE
nuclear I_DISEASE/I_GENE
translocation I_DISEASE/I_GENE
in O
CD45RA+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

We O
have O
analyzed O
the O
effect O
of O
complete O
T O
cell O
activation O
( O
anti-CD3 O
plus O
anti-CD28 O
) O
on O
the O
activation O
of O
NF-kappaB B_GENE
in O
CD45RA+ O
( O
naive O
) O
and O
CD45RO+ O
( O
memory/effector O
) O
T O
cells O
. O

Long O
exposure O
( O
24 O
h O
) O
induced O
stronger O
NF-kappaB B_GENE
DNA O
binding O
in O
CD45RA+ O
cells O
than O
in O
CD45RO+ O
cells O
. O

Analysis O
of O
the O
nuclear B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
c-Rel B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
that O
after O
anti-CD3+anti-CD28 O
stimulation O
the O
level O
of O
c-Rel B_GENE
was O
higher O
in O
CD45RA+ O
cells O
. O

Analysis O
of O
the O
cytoplasmic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
inhibitor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
IkappaBalpha I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
indicated O
that O
anti-CD3+anti-CD28 O
stimulation O
induced O
a O
long-lasting O
degradation O
in O
CD45RA+ O
cells O
but O
in O
CD45RO+ O
cells O
the O
degradation O
process O
was O
more O
rapid O
. O

Because O
the O
CD28 B_GENE
costimulus O
is O
known O
to O
induce O
the O
production O
of O
reactive O
oxygen O
intermediates O
( O
ROIs O
) O
, O
the O
intracellular O
ROI O
levels O
in O
CD45RA+ O
and O
CD45RO+ O
cells O
were O
compared O
by O
flow O
cytometry O
. O

ROIs B_MEASURE/B_GENE
were O
produced O
in O
both O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
types I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
but O
more O
strongly O
in O
CD45RA+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
further O
emphasize O
the O
differences B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O
CD45RA+ B_GENE
and O
CD45RO+ B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
ROI-dependent B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O
pathways B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Non-Hodgkin B_DISEASE
's I_DISEASE
lymphoma I_DISEASE
involving O
bilateral B_DISEASE/B_PERSON
breasts B_DISEASE/I_PERSON
[ B_DISEASE/I_PERSON
see O
comments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

We O
describe O
here O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
diffuse B_DISEASE/B_GENE
large I_DISEASE/I_GENE
cell I_DISEASE/I_GENE
type I_DISEASE/I_GENE
non-Hodgkin I_DISEASE/I_GENE
's I_DISEASE/I_GENE
lymphoma I_DISEASE/I_GENE
affecting O
the O
bilateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
breasts I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
contralateral B_DISEASE
tumor I_DISEASE
in O
one B_PERSON
case I_PERSON
appeared O
17 B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
after O
the O
first B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
mastectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
whereas O
the O
bilateral B_DISEASE_ADJECTIVE[DISEASE]
tumors I_DISEASE_ADJECTIVE[DISEASE]
occurred O
concurrently O
in O
the O
other B_PERSON
patient I_PERSON
who O
was O
pregnant B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
showed O
widespread B_DISEASE
dissemination I_DISEASE
at O
initial B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
presentation I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Lymphoma O
cells O
from O
both O
cases O
showed O
the O
mature O
B-cell O
immunophenotype O
and O
had O
rearrangements O
of O
the O
BCL6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Both O
patients B_PERSON
developed O
progressive B_DISEASE
disease I_DISEASE
despite O
chemo-radiotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
died O
of O
leukemic B_DISEASE
manifestations I_DISEASE
. O

There O
were O
no O
apparent B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathological I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
lymphomas B_DISEASE
of O
mucosa-associated B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
lymphoid I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
tissue I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
origin I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

Biochemical O
characterization O
of O
MIP-1 B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
alpha B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
nuclear B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

A O
family O
of O
hematopoietic B_GENE/B_NUMBER[MEASURE]
specific I_GENE/I_NUMBER[MEASURE]
transcription I_GENE/I_NUMBER[MEASURE]
factors I_GENE/I_NUMBER[MEASURE]
, O
MIP-1 B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
nuclear I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
( I_GENE/I_LOCATION
MNP I_GENE/I_LOCATION
) I_GENE/I_LOCATION
family I_GENE/I_LOCATION
, O
has O
recently O
been O
identified O
. O

They O
are O
intimately O
involved O
in O
regulating O
the O
transcription O
of O
the O
huMIP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
monocytes O
, O
T-cells O
, O
and O
transformed O
B-cells O
. O

One O
member O
of O
the O
family O
( O
MNP-1 B_GENE/B_DISEASE
) O
is O
essential O
for O
promoter O
activity O
in O
monocytes O
and O
B-cells O
, O
while O
another O
( O
MNP-2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
required O
for O
full O
promotor O
activity O
in O
T-cells O
. O

A O
third O
member O
of O
the O
family O
( O
MNP-3 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
expressed O
in O
PMA O
induced O
HL60 O
cells O
and O
probably O
has O
a O
role O
in O
monocyte O
differentiation O
. O

In O
this O
communication O
we O
demonstrate O
by O
two O
techniques O
that O
MNP-1 B_GENE
and O
MNP-2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
distinct O
but O
related O
factors O
, O
and O
we O
present O
further O
evidence O
to O
show O
that O
MNP-1 B_GENE/B_PERSON
acts O
as O
a O
heterodimer B_GENE
. O

Bcl-3 B_GENE
expression O
and O
nuclear O
translocation O
are O
induced O
by O
granulocyte-macrophage B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
erythropoietin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
proliferating O
human O
erythroid O
precursors O
. O

Bcl-3 B_GENE
is O
a O
proto-oncogene B_GENE/B_BIO
involved O
in O
the O
chromosomal O
translocation O
t B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
14 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
; I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
19 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
found O
in O
some O
patients O
with O
chronic O
lymphocytic O
leukemia O
. O

It O
shares O
structural O
similarities O
with O
and O
is O
a O
member O
of O
the O
IkappaB B_GENE/B_PERSON
family I_GENE/I_PERSON
of O
proteins O
. O

In O
this O
report O
, O
involvement O
of O
Bcl-3 B_GENE
in O
hematopoietic O
growth O
factor-stimulated O
erythroid O
proliferation O
and O
differentiation O
was O
examined O
. O

In O
TF-1 O
cells O
, O
an O
erythroleukemia O
cell O
line O
, O
granulocyte-macrophage B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
GM-CSF B_GENE/B_LOCATION
) O
and O
erythropoietin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Epo B_GENE/B_LOCATION
) O
greatly O
enhanced O
Bcl-3 B_GENE
expression O
at O
both O
the O
protein O
and O
mRNA O
levels O
in O
association O
with O
stimulation O
of O
proliferation O
. O

Bcl-3 B_GENE
protein O
was O
also O
highly O
expressed O
in O
early O
burst-forming O
unit-erythroid O
( O
BFU-E O
) O
-derived O
erythroid O
precursors O
( O
day O
7 O
) O
and O
decreased O
during O
maturation O
( O
days O
10 O
and O
14 O
) O
, O
suggesting O
that O
Bcl-3 B_GENE
is O
involved O
in O
normal O
erythroid O
proliferation O
. O

In O
these O
hematopoietic O
cells O
, O
Bcl-3 B_GENE
was O
hyperphosphorylated O
. O

GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
Epo B_GENE
modulated O
the O
subcellular O
localization O
of O
Bcl-3 B_GENE
. O

Upon O
stimulation O
of O
TF-1 O
cells O
with O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
Epo B_GENE
, O
the O
nuclear O
translocation O
of O
Bcl-3 B_GENE
was O
dramatically O
enhanced O
. O

Overexpression O
of O
Bcl-3 B_GENE
in O
TF-1 O
cells O
by O
transient O
transfection O
along O
with O
the O
NF-kappaB B_GENE
factors I_GENE
p50 I_GENE
or I_GENE
p52 I_GENE
resulted O
in O
significant O
induction O
of O
an O
human B_GENE
immunodeficiency I_GENE
virus-type I_GENE
1 I_GENE
( I_GENE
HIV-1 I_GENE
) I_GENE
kappaB-TATA-luceriferase I_GENE
reporter I_GENE
plasmid I_GENE
, O
demonstrating O
that O
Bcl-3 B_GENE
has O
a O
positive O
role O
in O
transactivation O
of O
kappaB-containing B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
erythroid O
cells O
. O

stimulation O
with O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
enhanced O
c-myb B_GENE
mRNA I_GENE
expression O
in O
these O
cells O
. O

Bcl-3 B_GENE
in O
nuclear O
extracts O
of O
TF-1 O
cells O
bound O
to O
a O
kappaB B_GENE/B_LOCATION
enhancer B_GENE/I_LOCATION
in O
the O
c-myb B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
promoter B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
together O
with O
NF-kappaB2/p52 B_GENE
and O
this O
binding O
activity O
was O
enhanced O
by O
GM-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stimulation O
. O

Furthermore O
, O
cotransfection O
of O
Bcl-3 B_GENE
with O
p52 B_GENE
or O
p50 B_GENE
in O
TF-1 O
cells O
resulted O
in O
significant O
activation O
of O
a O
c-myb B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappaB-TATA-luceriferase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
findings O
suggest O
that O
Bcl-3 B_GENE
may O
participate O
in O
the O
transcriptional O
regulation O
of O
certain O
kappaB-containing B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
involved O
in O
hematopoiesis O
, O
including O
c-myb B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Copyright B_LOCATION/B_PERSON
1998 I_LOCATION/I_PERSON
by O
The O
American B_ORGANIZATION/B_LOCATION
Society I_ORGANIZATION/I_LOCATION
of O
Hematology B_PERSON
. O

5-Lipoxygenase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
compartmentalization O
in O
granulocytic O
cells O
is O
modulated O
by O
an O
internal B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bipartite I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclear I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localizing I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
factor I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
kappa I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
B I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
complex I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
formation O
. O

A O
region O
of O
basic O
amino O
acids O
spanning O
residues B_NUMBER[MEASURE]/B_GENE
639-656 I_NUMBER[MEASURE]/I_GENE
in O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
5-lipoxygenase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resembles O
a O
consensus B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bipartite B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nuclear B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localizing B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
synthetic O
peptide O
consisting O
of O
the O
Kaposi B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
fibroblast I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
growth I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
signal I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
fused O
to O
the O
5-lipoxygenase639-656 B_GENE
bipartite I_GENE
nuclear I_GENE
localizing I_GENE
sequence I_GENE
has O
a O
prominent O
inhibitory O
effect O
on O
5-lipoxygenase B_GENE
catalysis O
in O
granulocytic O
HL-60 O
cells O
activated O
by O
calcium O
ionophor O
A23187 O
. O

Recombinant O
5-lipoxygenase B_GENE
was O
not O
affected O
by O
the O
peptide O
. O

The O
peptide O
also O
inhibited O
redistribution O
of O
5-lipoxygenase B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
cytosol O
to O
the O
nuclear O
membrane O
of O
HL-60 O
cells O
stimulated O
by O
A23187 O
. O

5-Lipoxygenase B_GENE
protein I_GENE
was O
detected O
in O
nuclear B_GENE/B_NUMBER[MEASURE]
factor B_GENE/I_NUMBER[MEASURE]
kappaB B_GENE/I_NUMBER[MEASURE]
( B_GENE/I_NUMBER[MEASURE]
NF-kappaB B_GENE/I_NUMBER[MEASURE]
) B_GENE/I_NUMBER[MEASURE]
p65 B_GENE/I_NUMBER[MEASURE]
subunit B_GENE/I_NUMBER[MEASURE]
immunoprecipitate O
fractions O
prepared O
from O
HL-60 O
cell O
lysates O
. O

The O
amount O
of O
5-lipoxygenase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coimmunoprecipitated O
by O
NF-kappaB O
antiserum O
was O
increased O
following O
A23187 O
stimulation O
. O

In O
cells O
treated O
with O
agents O
that O
block O
5-lipoxygenase B_GENE
translocation O
to O
the O
nucleus O
, O
5-lipoxygenase B_GENE
protein O
appearing O
in O
the O
NF-kappaB B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
immunoprecipitate O
was O
diminished O
. O

Our O
results O
implicate O
an O
internal B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
bipartite I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
localizing I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
a O
regulatory O
domain O
that O
modulates O
5-lipoxygenase B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
redistribution O
and O
catalysis O
in O
granulocytic O
cells O
. O

Additionally O
, O
our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
molecular B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determinants B_LOCATION/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
govern O
5-lipoxygenase B_GENE
and O
NF-kappaB B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
redistribution B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
the O
nucleus B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
may O
be O
coordinately O
controlled O
in O
granulocytic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Copyright B_LOCATION/B_PERSON
1998 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

Inhibition O
of O
CD28/CD3-mediated O
costimulation O
of O
naive O
and O
memory O
human O
T O
lymphocytes O
by O
intracellular O
incorporation O
of O
polyclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
specific O
for O
the O
activator B_GENE
protein-1 I_GENE
transcriptional I_GENE
complex I_GENE
. O

A O
number O
of O
indirect O
methods O
have O
been O
utilized O
in O
demonstrating O
activator B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein-1 B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O
factor O
function O
in O
IL-2 O
promoter O
activity O
. O

However O
, O
there O
has O
been O
no O
direct O
demonstration O
that O
activator B_GENE
protein-1 I_GENE
is O
involved O
in O
CD28-dependent O
costimulation O
of O
IL-2 B_GENE
gene I_GENE
transcription O
in O
freshly O
isolated O
naive O
and O
memory O
human O
T O
lymphocytes O
. O

To O
address O
this O
issue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
scrape B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
loading I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
applied O
to O
purified B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blood I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
T I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Since O
scrape B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loading B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
relies O
on O
adherent B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
human I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
( O
PB-T B_PROTEIN[GENE]/B_MEASURE
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
immobilized O
on O
the O
nonspecific B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
cell B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
attachment B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
factor B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
poly-L-lysine B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
. O

cells O
scraped O
off O
poly-L-lysine O
in O
the O
presence O
of O
Ig B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
FITC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
efficiently O
incorporated O
Ig O
, O
with O
relatively O
uniform O
fluorescence O
. O

T O
cells O
retained O
their O
physical O
parameters O
as O
measured O
by O
forward O
and O
side O
light O
scatter O
, O
and O
functional O
activity O
as O
measured O
by O
costimulation O
of O
proliferation O
and O
IL-2 B_GENE
production O
after O
being O
scraped O
off O
this O
substrate O
. O

CD28/CD3-costimulated O
T O
cells O
produced O
intracellular O
IL-2 B_GENE
from O
all O
subsets O
measured O
( O
CD4+ O
, O
CD4- O
, O
CD45RO+ O
, O
and O
CD45RO- O
) O
. O

IL-2 B_GENE
production O
and O
intracellular O
accumulation O
in O
nonscraped O
PB-T O
cells O
activated O
with O
CD28/CD3 O
coligation O
were O
skewed O
favoring O
CD45RO+ O
and O
CD4+ O
subsets O
, O
as O
was O
IL-2 B_GENE
production O
in O
scraped O
PB-T O
cells O
. O

The O
intracellular O
incorporation O
of O
ABS O
specific O
for O
c-Fos B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Jun I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
members I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
scrape O
loading O
inhibited O
the O
production O
and O
intracellular O
accumulation O
of O
IL-2 B_GENE
within O
6 O
h O
of O
costimulation O
with O
PMA/ionomycin O
, O
or O
costimulation O
by O
CD28 O
and O
CD3 O
ligation O
. O

Scrape O
loading O
thus O
provides O
an O
efficient O
mechanism O
for O
intracellular O
incorporation O
of O
macromolecules O
, O
and O
the O
first O
direct O
evidence O
that O
c-Fos B_GENE
and O
c-Jun B_GENE
are O
involved O
in O
transcription O
of O
the O
IL-2 B_GENE
gene I_GENE
within O
its O
correct O
chromosomal O
context O
, O
in O
resting O
human O
T O
lymphocyte O
subpopulations O
. O

differential O
expression O
of O
Nur77 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
human O
T-lymphotropic O
virus O
type O
1-infected O
cells O
: O
transactivation O
of O
the O
TR3/nur77 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
Tax B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
analyzed O
the O
differential O
expression O
and O
regulation O
of O
three O
members O
of O
the O
Nur77 B_GENE/B_BIO
transcription I_GENE/I_BIO
factor I_GENE/I_BIO
family I_GENE/I_BIO
by O
the O
human O
T-lymphotropic O
virus O
type O
1 O
( O
HTLV-1 O
) O
Tax B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
have O
demonstrated O
that O
in O
both O
HTLV-1-infected O
cells O
and O
Tax-expressing O
JPX-9 O
cells O
, O
TR3/nur77 B_GENE
is O
highly O
expressed O
, O
whereas O
neither O
NOR-1 O
nor O
Not O
expression O
is O
detectable O
. O

Transient O
transfection O
analysis O
further O
confirmed O
the O
Tax B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transactivation O
of O
the O
TR3/nur77 B_GENE/B_LOCATION
promoter O
but O
not O
the O
NOR-1 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoter I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
different O
cell O
types O
. O

Furthermore O
, O
expression O
of O
a O
luciferase B_GENE
reporter I_GENE
gene I_GENE
driven O
by O
the O
NGFI-B B_GENE
( I_GENE
rat I_GENE
homolog I_GENE
of I_GENE
TR3/Nur77 I_GENE
) I_GENE
response I_GENE
element I_GENE
( O
NBRE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
provided O
evidence O
that O
Tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-mediated O
transactivation O
resulted O
in O
the O
induction O
of O
a O
functional O
protein O
. O

Cotransfection O
assays O
with O
the O
TR3/nur77 B_GENE
promoter I_GENE
sequence I_GENE
or O
the O
NBRE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O
motif O
together O
with O
a O
series O
of O
Tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants O
have O
shown O
that O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O
TR3/nur77 B_GENE
expression O
is O
mediated O
by O
CREB/ATF-related B_GENE
transcription I_GENE
factors I_GENE
. O

negative O
regulation O
of O
the O
heat O
shock O
transcriptional O
response O
by O
HSBP1 B_GENE
. O

In O
response O
to O
stress O
, O
heat B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
shock I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
HSF1 B_GENE
) O
acquires O
rapid O
DNA O
binding O
and O
transient O
transcriptional O
activity O
while O
undergoing O
conformational O
transition O
from O
an O
inert O
non-DNA-binding B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monomer B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
active O
functional O
trimers O
. O

Attenuation O
of O
the O
inducible O
transcriptional O
response O
occurs O
during O
heat O
shock O
or O
upon O
recovery O
at O
non-stress O
conditions O
and O
involves O
dissociation O
of O
the O
HSF1 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trimer B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
loss O
of O
activity O
. O

We O
have O
used O
the O
hydrophobic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
repeats I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
the O
HSF1 B_GENE/B_DISEASE
trimerization O
domain O
in O
the O
yeast O
two-hybrid O
protein O
interaction O
assay O
to O
identify O
heat B_GENE
shock I_GENE
factor I_GENE
binding I_GENE
protein I_GENE
1 I_GENE
( O
HSBP1 B_GENE
) O
, O
a O
novel O
, O
conserved O
, O
76-amino-acid B_PROTEIN[GENE]/B_PERSON
protein I_PROTEIN[GENE]/I_PERSON
that O
contains O
two O
extended O
arrays O
of O
hydrophobic B_PROTEIN[GENE]/B_LOCATION
repeats I_PROTEIN[GENE]/I_LOCATION
that O
interact O
with O
the O
HSF1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
heptad I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeats I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

HSBP1 B_GENE/B_DISEASE
is O
nuclear-localized O
and O
interacts O
in O
vivo O
with O
the O
active O
trimeric O
state O
of O
HSF1 B_GENE
that O
appears O
during O
heat O
shock O
. O

During O
attenuation O
of O
HSF1 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
inert O
monomer O
, O
HSBP1 B_GENE
associates O
with O
Hsp70 O
. O

HSBP1 B_GENE/B_DISEASE
negatively O
affects O
HSF1 B_GENE/B_BIO
DNA-binding O
activity O
, O
and O
overexpression O
of O
HSBP1 B_GENE
in O
mammalian O
cells O
represses O
the O
transactivation O
activity O
of O
HSF1 B_GENE
. O

To O
establish O
a O
biological O
role O
for O
HSBP1 B_GENE
, O
the O
homologous O
Caenorhabditis B_GENE/B_LOCATION
elegans I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
was O
overexpressed O
in O
body O
wall O
muscle O
cells O
and O
was O
shown O
to O
block O
activation O
of O
the O
heat O
shock O
response O
from O
a O
heat B_GENE/B_DISEASE
shock I_GENE/I_DISEASE
promoter-reporter I_GENE/I_DISEASE
construct I_GENE/I_DISEASE
. O

Alteration O
in O
the O
level O
of O
HSBP1 B_GENE
expression O
in O
C. O
elegans O
has O
severe O
effects O
on O
survival O
of O
the O
animals O
after O
thermal O
and O
chemical O
stress O
, O
consistent O
with O
a O
role O
for O
HSBP1 B_GENE
as O
a O
negative O
regulator O
of O
the O
heat O
shock O
response O
. O

Long-range B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transcriptional I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
regulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
cytokine B_GENE
gene I_GENE
expression I_GENE
. O

Most O
studies O
on O
the O
control O
of O
cytokine O
gene O
expression O
have O
involved O
the O
functional O
analysis O
of O
proximal B_GENE
promoters I_GENE
. O

Recent O
work O
has O
identified O
distal B_LOCATION/B_BIO
elements I_LOCATION/I_BIO
that O
mediate O
long-range O
cytokine O
gene O
regulation O
and O
has O
implicated O
chromatin O
reorganization O
in O
regulation O
of O
cytokine B_GENE
gene I_GENE
loci I_GENE
. O

These O
studies O
have O
begun O
to O
elucidate O
the O
basis O
for O
cell-specificity O
and O
high-level O
expression O
of O
cytokine B_GENE/B_DISEASE
genes I_GENE/I_DISEASE
. O

A O
signaling O
complex O
of O
Ca2+-calmodulin-dependent B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ O
see O
comments O
] O
. O

stimulation O
of O
T O
lymphocytes O
results O
in O
a O
rapid O
increase O
in O
intracellular O
calcium O
concentration O
( O
[ O
Ca2+ O
] O
i O
) O
that O
parallels O
the O
activation O
of O
Ca2+-calmodulin-dependent B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
CaMKIV B_GENE
) O
, O
a O
nuclear B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
can O
phosphorylate O
and O
activate O
the O
cyclic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adenosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
monophosphate I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cAMP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element-binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
CREB B_GENE/B_DISEASE
) O
. O

However O
, O
inactivation O
of O
CaMKIV B_GENE
occurs O
despite O
the O
sustained O
increase O
in O
[ O
Ca2+ O
] O
i O
that O
is O
required O
for O
T O
cell O
activation O
. O

A O
stable O
and O
stoichiometric O
complex O
of O
CaMKIV B_GENE
with O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serine-threonine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PP2A B_GENE
) O
was O
identified O
in O
which O
PP2A B_GENE
dephosphorylates O
CaMKIV B_GENE
and O
functions O
as O
a O
negative O
regulator O
of O
CaMKIV B_GENE
signaling O
. O

In O
Jurkat O
T O
cells O
, O
inhibition O
of O
PP2A B_GENE
activity O
by O
small O
t O
antigen O
enhanced O
activation O
of O
CREB B_GENE
-mediated O
transcription O
by O
CaMKIV B_GENE
. O

These O
findings O
reveal O
an O
intracellular O
signaling O
mechanism O
whereby O
a O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serine-threonine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
CaMKIV B_GENE/B_LOCATION
) O
is O
regulated O
by O
a O
tightly O
associated O
protein B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
serine-threonine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PP2A B_GENE/B_LOCATION
) O
. O

Hypoxia O
down-regulates O
MCP-1 B_GENE
expression O
: O
implications O
for O
macrophage O
distribution O
in O
tumors O
. O

Monocyte B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chemoattractant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MCP-1 B_GENE
) O
is O
likely O
to O
contribute O
to O
the O
macrophage O
infiltrate O
in O
human O
ovarian O
carcinomas O
. O

Although O
MCP-1 B_GENE
is O
predominantly O
expressed O
by O
the O
tumor O
parenchyma O
, O
macrophages O
accumulate O
at O
highest O
density O
in O
necrotic O
regions O
, O
which O
are O
associated O
with O
low O
oxygen O
tensions O
. O

Tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
can O
stimulate O
MCP-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O
and O
is O
also O
present O
within O
ovarian O
carcinomas O
. O

We O
have O
investigated O
the O
effect O
of O
hypoxia O
both O
on O
MCP-1 B_GENE
expression O
in O
ovarian O
cancer O
cell O
lines O
and O
monocyte O
migration O
. O

Hypoxia O
down-regulated O
TNF-alpha-induced B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MCP-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
protein O
production O
by O
ovarian O
cancer O
cells O
. O

The O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
mimicked O
by O
cobalt B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
desferrioxamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
a O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
oxygen-sensing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
mechanism I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Unlike O
antioxidants B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
hypoxia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O
not O
inhibit O
nuclear B_GENE
factor I_GENE
KB I_GENE
mobilization I_GENE
. O

Monocyte O
migration O
in O
response O
to O
MCP-1 B_GENE
was O
also O
diminished O
under O
hypoxic O
conditions O
. O

Down-regulation O
of O
MCP-1 B_GENE
expression O
and O
the O
inhibition O
of O
monocyte O
migration O
are O
independent O
effects O
of O
hypoxia O
that O
may O
contribute O
to O
the O
distribution O
of O
macrophages O
within O
ovarian O
tumors O
. O

activation O
of O
nuclear B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
factor I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
kappa I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
B I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
inflammatory O
bowel O
disease O
[ O
see O
comments O
] O
. O

Background O
: O
expression O
of O
pro-inflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
increased O
in O
the O
intestinal O
lamina O
propria O
of O
patients O
with O
inflammatory O
bowel O
disease O
( O
IBD O
) O
. O

Nuclear B_GENE/B_MEASURE
factor I_GENE/I_MEASURE
kappa I_GENE/I_MEASURE
B I_GENE/I_MEASURE
( O
NF B_GENE
kappa I_GENE
B I_GENE
) O
controls O
transcription O
of O
inflammation B_GENE/B_DISEASE
genes I_GENE/I_DISEASE
. O

On O
activation O
, O
NF B_GENE
kappa I_GENE
B I_GENE
is O
rapidly O
released O
from O
its O
cytoplasmic B_ENZYME[GENE]/B_PERSON
inhibitor I_ENZYME[GENE]/I_PERSON
( O
I B_GENE/B_DISEASE
kappa I_GENE/I_DISEASE
B I_GENE/I_DISEASE
) O
, O
transmigrates O
into O
the O
nucleus O
, O
and O
binds O
to O
DNA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elements I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
gene O
promoter O
regions O
. O

aims O
: O
To O
investigate O
whether O
increased O
activation O
of O
NF B_GENE
kappa I_GENE
B I_GENE
is O
important O
in O
IBD O
and O
may O
be O
down-regulated O
by O
anti-inflammatory O
treatment O
. O

methods O
: O
activation O
of O
NF B_GENE
kappa I_GENE
B I_GENE
was O
determined O
by O
western O
blot O
assessment O
and O
electrophoretic O
mobility O
shift O
assay O
in O
nuclear O
extracts O
of O
colonic O
biopsy O
samples O
as O
well O
as O
lamina O
propria O
mononuclear O
cells O
. O

Results O
: O
Nuclear O
levels O
of O
NF B_GENE
kappa I_GENE
B I_GENE
p65 I_GENE
are O
increased O
in O
lamina O
propria O
biopsy O
specimens O
from O
patients O
with O
Crohn O
's O
disease O
in O
comparison O
with O
patients O
with O
ulcerative O
colitis O
and O
controls O
. O

increased O
activation O
of O
NF B_GENE
kappa I_GENE
B I_GENE
was O
detected O
in O
lamina O
propria O
mononuclear O
cells O
from O
patients O
with O
active O
IBD O
. O

Corticosteroids O
strongly O
inhibit O
intestinal O
NF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kappa B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O
in O
IBD O
in O
vivo O
and O
in O
vitro O
by O
stabilising O
the O
cytosolic B_GENE
inhibitor I_GENE
I I_GENE
kappa I_GENE
B I_GENE
alpha O
against O
activation O
induced O
degradation O
. O

conclusions O
: O
In O
both O
IBDs O
, O
but O
particularly O
Crohn O
's O
disease O
, O
increased O
activation O
of O
NF B_GENE
kappa I_GENE
B I_GENE
may O
be O
involved O
in O
the O
regulation O
of O
the O
inflammatory O
response O
. O

Inhibition O
of O
NF B_GENE
kappa I_GENE
B I_GENE
activation O
may O
represent O
a O
mechanism O
by O
which O
steroids O
exert O
an O
anti-inflammatory O
effect O
in O
IBD O
. O

insufficient O
glycemic O
control O
increases O
nuclear B_GENE
factor-kappa I_GENE
B I_GENE
binding O
activity O
in O
peripheral O
blood O
mononuclear O
cells O
isolated O
from O
patients O
with O
type O
1 O
diabetes O
. O

objective O
: O
The O
redox-sensitive B_GENE
transcription I_GENE
factor I_GENE
nuclear I_GENE
factor-kappa I_GENE
B I_GENE
( O
NF-kappa B_GENE
B I_GENE
) O
is O
believed O
to O
contribute O
to O
late O
diabetic O
complications O
. O

It O
is O
unknown O
whether O
NF-kappa B_GENE/B_DISEASE
B B_GENE/I_DISEASE
is O
influenced O
by O
glycemic O
control O
. O

Research O
Design O
AND O
methods O
: O
To O
determine O
whether O
NF-kappa B_GENE
B I_GENE
is O
activated O
in O
patients O
with O
insufficient O
glycemic O
control O
( O
HbA1c O
> O
10 O
% O
) O
, O
we O
developed O
a O
tissue O
culture-independent O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
-based O
semiquantitative O
detection O
system O
that O
allowed O
us O
to O
determine O
NF-kappa B_GENE
B I_GENE
activation O
in O
ex O
vivo-isolated O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
. O

We O
included O
43 B_PERSON
patients I_PERSON
with O
type B_DISEASE/B_LOCATION
1 I_DISEASE/I_LOCATION
diabetes I_DISEASE/I_LOCATION
in O
this O
cross-sectional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

10 B_NUMBER[MEASURE]/B_PERSON
of O
those O
received O
the O
antioxidant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
thioctic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
600 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mg/day B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
p.o B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O
) O
for O
2 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Results O
: O
Monocytes O
of O
patients O
with O
HbA1c O
levels O
> O
10 O
% O
demonstrated O
significantly O
higher O
NF-kappa B_GENE
B I_GENE
binding O
activity O
in O
an O
EMSA O
and O
a O
stronger O
NF-kappa B_GENE
B I_GENE
staining O
in O
immunohistochemistry O
than O
monocytes O
of O
patients O
with O
HbA1c O
levels O
of O
6-8 O
% O
. O

The O
increase O
in O
NF-kappa B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O
correlated O
with O
an O
increase O
in O
plasmatic O
markers O
of O
lipid O
peroxidation O
. O

Treatment O
with O
the O
antioxidant O
thioctic O
acid O
decreased O
NF-kappa B_GENE
B I_GENE
binding O
activity O
. O

conclusions O
: O
Hyperglycemia O
induces O
activation O
of O
the O
transcription O
factor O
NF-kappa B_GENE
B I_GENE
in O
ex O
vivo-isolated O
PBMCs O
of O
patients O
with O
type O
1 O
diabetes O
. O

NF-kappa B_GENE
B I_GENE
activation O
is O
at O
least O
partially O
dependent O
on O
oxidative O
stress O
, O
since O
the O
antioxidant O
thioctic O
acid O
significantly O
lowered O
the O
extent O
of O
NF-kappa B_GENE
B I_GENE
binding O
activity O
. O

Synergistic O
activation O
of O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ERK1/2 B_GENE/B_LOCATION
) O
by O
erythropoietin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
stem B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
essential O
for O
expanded O
erythropoiesis O
. O

Stem B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
SCF B_GENE/B_LOCATION
) O
and O
erythropoietin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
EPO B_LOCATION/B_ORGANIZATION
) O
work O
synergistically O
to O
support O
erythropoiesis O
, O
but O
the O
mechanism O
for O
this O
synergism O
is O
unknown O
. O

By O
using O
purified O
human O
erythroid O
colony-forming O
cells O
( O
ECFC O
) O
, O
we O
have O
found O
that O
SCF B_GENE/B_BIO
and O
EPO B_LOCATION/B_ORGANIZATION
synergistically O
activate O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MAPK B_GENE
, O
ERK1/2 B_GENE
) O
, O
which O
correlates O
with O
the O
cell O
growth O
and O
thus O
may O
be O
responsible O
for O
the O
synergistic O
effects O
. O

Treatment O
of O
the O
cells O
with O
PD98059 O
and O
wortmannin O
, O
inhibitors O
of O
MEK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
PI-3 B_GENE
kinase I_GENE
, O
respectively O
, O
inhibited O
the O
synergistic O
activation O
of O
MAPK B_GENE
and O
also O
the O
cell O
growth O
, O
further O
supporting O
this O
conclusion O
. O

Wortmannin O
only O
inhibits O
MAPK B_GENE
activation O
induced O
by O
EPO B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
not O
that O
by O
SCF B_GENE/B_BIO
, O
suggesting O
that O
SCF B_GENE/B_BIO
and O
EPO B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
activate O
MAPK B_GENE
through O
different O
pathways O
, O
which O
would O
facilitate O
synergy O
. O

Furthermore O
, O
EPO B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
SCF B_GENE/B_BIO
, O
led O
to O
activation O
of O
STAT5 B_GENE
, O
whereas O
SCF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
wortmannin O
had O
no O
effect O
on O
the O
EPO B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O
STAT5 B_GENE
activation O
, O
suggesting O
that O
STAT5 B_GENE
is O
not O
involved O
in O
the O
synergistic O
action O
of O
SCF B_GENE/B_LOCATION
and O
EPO B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Together O
, O
the O
data O
suggest O
that O
synergistic O
activation O
of O
MAPK B_GENE
by O
SCF B_GENE/B_BIO
and O
EPO B_GENE/B_LOCATION
is O
essential O
for O
expanded O
erythropoiesis O
. O

Copyright B_LOCATION/B_PERSON
1998 I_LOCATION/I_PERSON
by O
The O
American B_ORGANIZATION/B_LOCATION
Society I_ORGANIZATION/I_LOCATION
of O
Hematology B_PERSON
. O

The O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
phenotypic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
primary B_DISEASE/B_LOCATION
central I_DISEASE/I_LOCATION
nervous I_DISEASE/I_LOCATION
system I_DISEASE/I_LOCATION
lymphoma I_DISEASE/I_LOCATION
identifies O
distinct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
categories B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
disease B_DISEASE
and O
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
histogenetic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivation I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
germinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
center-related O
B B_DISEASE
cells I_DISEASE
. O

Primary B_DISEASE
central I_DISEASE
nervous I_DISEASE
system I_DISEASE
lymphoma I_DISEASE
( O
PCNSL B_DISEASE
) O
is O
a O
major B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cause I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
morbidity B_DISEASE
and O
mortality B_DISEASE
among O
human B_DISEASE
immunodeficiency I_DISEASE
virus I_DISEASE
( O
HIV B_DISEASE/B_VIRUS[BIO]
) O
-infected O
individuals B_PERSON/B_BIO
. O

The O
precise B_DISEASE
histogenetic I_DISEASE
derivation I_DISEASE
and O
the O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathogenesis B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PCNSL B_DISEASE
is O
poorly O
understood O
. O

In O
an O
attempt B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
clarify O
the O
histogenesis B_DISEASE_ADJECTIVE[DISEASE]
and O
pathogenesis B_DISEASE
of O
these O
lymphomas B_DISEASE/B_PERSON
, O
49 B_NUMBER[MEASURE]/B_BIO
PCNSL I_NUMBER[MEASURE]/I_BIO
( O
26 B_MEASURE
acquired O
immunodeficiency B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
[ O
AIDS B_DISEASE
] I_DISEASE
-related O
and O
23 B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
AIDS-unrelated I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
) O
were O
analyzed O
for O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
biologic B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
markers B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
which O
are O
known O
to O
bear O
histogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
pathogenetic B_DISEASE_ADJECTIVE[DISEASE]
significance I_DISEASE_ADJECTIVE[DISEASE]
for O
mature B_DISEASE/B_PERSON
B-cell I_DISEASE/I_PERSON
neoplasms I_DISEASE/I_PERSON
. O

PCNSL O
associated O
frequently O
( O
50.0 O
% O
) O
with O
mutations O
of O
BCL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
noncoding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
are O
regarded O
as O
a O
marker O
of O
B-cell O
transition O
through O
the O
germinal O
center O
( O
GC O
) O
. O

expression O
of O
BCL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
is O
restricted O
to O
GC O
B O
cells O
throughout O
physiologic O
B-cell O
maturation O
, O
was O
detected O
in O
100 O
% O
AIDS-unrelated O
PCNSL O
and O
in O
56.2 O
% O
AIDS-related O
cases O
. O

notably O
, O
among O
AIDS-related O
PCNSL O
, O
expression O
of O
BCL-6 B_GENE
was O
mutually O
exclusive O
with O
expression O
of O
Epstein-Barr B_GENE
virus I_GENE
( I_GENE
EBV I_GENE
) I_GENE
-encoded I_GENE
latent I_GENE
membrane I_GENE
protein I_GENE
( I_GENE
LMP I_GENE
) I_GENE
-1 I_GENE
and O
, O
with O
few O
exceptions O
, O
also O
of O
BCL-2 B_GENE
. O

All O
but O
one B_NUMBER[MEASURE]/B_PERSON
PCNSL I_NUMBER[MEASURE]/I_PERSON
expressed O
hMSH2 B_GENE
, O
which O
among O
mature O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
selectively O
stains O
GC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
data O
suggest O
that O
PCNSL O
may O
be O
frequently O
related O
to O
GC O
B O
cells O
and O
may O
be O
segregated O
into O
two O
major O
biologic O
categories O
based O
on O
the O
expression O
pattern O
of O
BCL-6 B_GENE
, O
LMP-1 B_GENE/B_DISEASE
, O
and O
BCL-2 B_GENE
. O

BCL-6 B_GENE/B_DISEASE
( O
+ O
) O
/ O
LMP-1 B_GENE
( O
- O
) O
/ O
BCL-2 B_GENE
( O
- O
) O
PCNSL O
occur O
both O
in O
the O
presence O
and O
in O
the O
absence O
of O
HIV O
infection O
and O
consistently O
display O
a O
large O
noncleaved O
cell O
morphology O
. O

Conversely O
, O
BCL-6 B_GENE
( O
- O
) O
/ O
LMP-1 B_GENE
( O
+ O
) O
/ O
BCL-2 B_GENE
( O
+ O
) O
PCNSL O
are O
restricted O
to O
HIV-infected O
hosts O
and O
are O
represented O
by O
lymphomas O
with O
immunoblastic O
features O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
relevant B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
pathogenesis B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
histogenesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
PCNSL B_DISEASE
and O
may O
be O
helpful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
to O
segregate O
distinct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
biologic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
prognostic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
categories I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
lymphomas B_DISEASE/B_PERSON
. O

Copyright B_LOCATION/B_PERSON
1998 I_LOCATION/I_PERSON
by O
The O
American B_ORGANIZATION/B_LOCATION
Society I_ORGANIZATION/I_LOCATION
of O
Hematology B_PERSON
. O

antioxidant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
phorbol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ester-induced O
adhesion B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
Jurkat I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
T-cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
to O
endothelial B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Regulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
adhesion B_GENE/B_ORGANISM_FUNCTION
molecule B_GENE/I_ORGANISM_FUNCTION
expression B_GENE/I_ORGANISM_FUNCTION
and O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
reactive B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygen B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
redox B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sensitive B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
have O
been O
reported O
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O
clinically O
safe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antioxidants I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
regulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
adhesion B_GENE
molecule I_GENE
expression I_GENE
in O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
endothelial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
ECV B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
, O
and O
adherence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Jurkat I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O
ECV B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
investigated O
. O

The O
thiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antioxidant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
alpha-lipoate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
at O
clinically O
relevant B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
doses B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
down-regulated O
phorbol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12-myristate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
13-acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
-induced O
adhesion B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
molecule B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
expression B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
cell-cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
adhesion B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

Inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
PMA-induced B_GENE/B_LOCATION
ICAM-1 I_GENE/I_LOCATION
and O
VCAM-1 O
expression B_GENE
as O
well O
as O
PMA-induced B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adhesion I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Jurkat B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
T-cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
to O
ECV B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
alpha-lipoate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
dose B_DISEASE_ADJECTIVE[DISEASE]
dependent I_DISEASE_ADJECTIVE[DISEASE]
( O
50-250 B_MEASURE
microM I_MEASURE
) O
. O

The O
effect O
was O
significant O
for O
ICAM-1 B_GENE
( O
p O
< O
.01 O
) O
and O
VCAM-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
p O
< O
.01 O
) O
expression O
in O
cells O
pretreated O
with O
100 O
microM O
alpha-lipoate O
compared O
to O
PMA-activated O
untreated O
cells O
. O

Inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
PMA-induced B_DISEASE_ADJECTIVE[DISEASE]
adhesion I_DISEASE_ADJECTIVE[DISEASE]
molecule I_DISEASE_ADJECTIVE[DISEASE]
expression I_DISEASE_ADJECTIVE[DISEASE]
and O
cell-cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
adhesion B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
was O
more O
pronounced O
when O
a O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
antioxidants B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
alpha-lipoate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
alpha-tocopherol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
were O
used O
compared O
to O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
either O
of O
these O
antioxidant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
. O

The O
regulation O
of O
adhesion O
molecule O
expression O
and O
function O
by O
low O
concentration O
of O
antioxidants O
investigated O
does O
not O
appear O
to O
be O
NF-kappaB B_GENE
regulated O
or O
transcription O
dependent O
because O
no O
change O
in O
the O
mRNA O
response O
was O
observed O
. O

Protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PKC B_GENE
) O
has O
been O
suggested O
to O
regulate O
PMA-induced O
adhesion O
molecule O
expression O
by O
post-transcriptional O
stabilization O
of O
adhesion B_GENE
molecule I_GENE
mRNA I_GENE
. O

Alpha-lipoate O
pretreatment O
did O
not O
influence O
the O
response O
of O
PKC B_GENE
activity O
to O
PMA O
. O

Oxidants B_PERSON/B_GENE
are O
known O
to O
be O
involved O
in O
the O
regulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cell B_DISEASE
adhesion I_DISEASE
processes I_DISEASE
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
ECV B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
PMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
generation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
intracellular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oxidants B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Alpha-lipoate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
100 B_MEASURE
or O
250 B_MEASURE
microM I_MEASURE
) O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
decreased O
PMA-induced B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
generation I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
intracellular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxidants I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
inhibitory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
low B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
concentration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
alpha-lipaote B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alone O
or O
in O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O
alpha-tocopherol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
agonist-induced B_DISEASE/B_GENE
adhesion I_DISEASE/I_GENE
processes I_DISEASE/I_GENE
observed O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O
be O
of O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapeutic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
value I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

binding O
of O
human O
immunodeficiency O
virus O
type O
1 O
to O
CD4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CXCR4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
differentially O
regulates O
expression O
of O
inflammatory B_GENE
genes I_GENE
and O
activates O
the O
MEK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ERK O
signaling O
pathway O
. O

We O
have O
previously O
shown O
that O
binding O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
virions O
to O
CD4 B_GENE
receptors I_GENE
stimulates O
association O
of O
Lck B_GENE/B_BACTERIUM[BIO]
with O
Raf-1 B_GENE
and O
results O
in O
the O
activation O
of O
Raf-1 B_GENE
kinase O
in O
a O
Ras-independent O
manner O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
HIV-1 B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
envelope B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
glycoproteins B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
both O
T-cell-tropic O
and O
macrophagetropic O
strains O
rapidly O
activate O
the O
ERK/mitogen-activated O
protein O
( O
Map O
) O
kinase O
pathway O
and O
the O
binding O
of O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
AP-1 B_GENE
, O
NF-kappaB B_GENE
, O
and O
C/EBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
stimulate O
expression O
of O
cytokine B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemokine I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
activation O
of O
this O
signaling O
pathway O
requires O
functional O
CD4 B_GENE
receptors I_GENE
and O
is O
independent O
of O
binding O
to O
CXCR4 B_GENE
. O

binding O
of O
the O
natural O
ligand O
stromal B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell-derived I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
SDF-1 B_GENE
) O
to O
CXCR4 B_GENE
, O
which O
inhibits O
entry O
of O
T-cell-tropic O
HIV-1 O
, O
activates O
also O
the O
ERK/ O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathway O
. O

However O
, O
SDF-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
did O
not O
affect O
the O
CD4-mediated O
expression O
of O
cytokine B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemokine I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results O
provide O
firm O
molecular O
evidence O
that O
binding O
of O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
envelope I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glycoproteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
CD4 B_GENE
receptor I_GENE
initiates O
a O
signaling O
pathway O
( O
s O
) O
independent O
of O
the O
binding O
to O
the O
chemokine B_GENE
receptor I_GENE
that O
leads O
to O
the O
aberrant O
expression O
of O
inflammatory B_GENE
genes I_GENE
and O
may O
contribute O
significantly O
to O
HIV-1 O
replication O
as O
well O
as O
to O
deregulation O
of O
the O
immune O
system O
. O

Antigen O
receptor O
signaling O
induces O
Map O
kinase-mediated O
phosphorylation O
and O
degradation O
of O
the O
BCL-6 B_GENE
transcription I_GENE
factor I_GENE
. O

The O
bcl-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proto-oncogene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encodes O
a O
POZ/zinc B_GENE/B_MEASURE
finger I_GENE/I_MEASURE
transcriptional I_GENE/I_MEASURE
repressor I_GENE/I_MEASURE
expressed O
in O
germinal O
center O
( O
GC O
) O
B O
and O
T O
cells O
and O
required O
for O
GC O
formation O
and O
antibody O
affinity O
maturation O
. O

Deregulation O
of O
bcl-6 B_GENE
expression O
by O
chromosomal O
rearrangements O
and O
point O
mutations O
of O
the O
bcl-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
implicated O
in O
the O
pathogenesis O
of O
B-cell O
lymphoma O
. O

The O
signals O
regulating O
bcl-6 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
are O
not O
known O
. O

Here O
we O
show O
that O
antigen O
receptor O
activation O
leads O
to O
BCL-6 B_GENE
phosphorylation O
by O
mitogen-activated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MAPK B_GENE
) O
. O

Phosphorylation O
, O
in O
turn O
, O
targets O
BCL-6 B_GENE
for O
rapid O
degradation O
by O
the O
ubiquitin B_GENE
/ O
proteasome B_GENE
pathway O
. O

These O
findings O
indicate O
that O
BCL-6 B_GENE
expression O
is O
directly O
controlled O
by O
the O
antigen O
receptor O
via O
MAPK B_GENE
activation O
. O

This O
signaling O
pathway O
may O
be O
crucial O
for O
the O
control O
of O
B-cell O
differentiation O
and O
antibody O
response O
and O
has O
implications O
for O
the O
regulation O
of O
other O
POZ/zinc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finger B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcription B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
other O
tissues O
. O

Glucocorticoid B_PERSON/B_GENE
receptors I_PERSON/I_GENE
are O
differentially O
expressed O
in O
the O
cells O
and O
tissues O
of O
the O
immune O
system O
. O

Cytosolic B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GR B_LOCATION/B_ORGANIZATION
) O
binding O
studies O
on O
immune O
tissues O
demonstrate O
that O
the O
thymus O
exhibits O
three O
to O
four O
times O
higher O
levels O
of O
GR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
than O
the O
spleen O
. O

High O
levels O
of O
GR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
consistent O
with O
the O
exquisite O
sensitivity O
of O
the O
thymus O
to O
glucocorticoid O
exposure O
. O

Nevertheless O
, O
whole O
cell O
binding O
studies O
reveal O
similar O
levels O
of O
GR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
immature O
thymic O
T O
lymphocytes O
and O
more O
mature O
, O
splenic O
T O
lymphocytes O
. O

Moreover O
, O
whole O
cell O
binding O
techniques O
indicate O
that O
neutrophils O
( O
which O
represent O
roughly O
30 O
% O
of O
splenic O
leukocytes O
) O
exhibit O
higher O
GR B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O
both O
T O
and O
B O
lymphocytes O
, O
further O
contradicting O
results O
from O
cytosolic O
binding O
studies O
. O

To O
address O
these O
inconsistencies O
, O
GR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
assessed O
in O
immune O
cells O
and O
tissues O
using O
cytosolic O
radioligand O
binding O
. O

Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
immunocytochemistry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

consistent O
with O
previous O
cytosolic O
receptor O
binding O
studies O
on O
immune O
tissue O
homogenates O
, O
thymic O
T O
cells O
were O
found O
to O
have O
higher O
levels O
of O
GR B_GENE/B_DISEASE
than O
T O
cells O
isolated O
from O
the O
spleen O
. O

In O
addition O
, O
neutrophils O
were O
found O
to O
have O
fewer O
GR B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
than O
lymphocytes O
and O
monocytes O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
indicate O
a O
meaningful B_MEASURE/B_PERSON
relationship I_MEASURE/I_PERSON
between O
receptor B_DISEASE/B_GENE
expression I_DISEASE/I_GENE
and O
known O
sensitivity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

functional O
replacement O
of O
the O
mouse B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
E2A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
a O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
HEB I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
mammalian B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
E2A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HEB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E2-2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encode O
a O
unique O
class O
of O
basic B_GENE
helix-loop-helix I_GENE
( I_GENE
bHLH I_GENE
) I_GENE
transcription I_GENE
factors I_GENE
that O
are O
evolutionarily O
conserved O
and O
essential O
for O
embryonic O
and O
postnatal O
development O
. O

While O
the O
structural O
and O
functional O
similarities O
among O
the O
gene B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
products B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O
well O
demonstrated O
, O
it O
is O
not O
clear O
why O
deletion O
of O
E2A B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
HEB B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
E2-2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
leads O
to O
a O
complete O
arrest O
in O
B-lymphocyte O
development O
. O

To O
understand O
the O
molecular O
basis O
of O
the O
functional O
specificity O
between O
E2A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
HEB B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
E2-2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mammalian O
development O
, O
we O
generated O
and O
tested O
a O
panel O
of O
E2A B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
knockin O
mutations O
including O
subtle O
mutations O
in O
the O
E12 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E47 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exons I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
substitution O
of O
both O
E12 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E47 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exons I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
a O
human B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HEB I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
find O
that O
the O
alternatively O
spliced O
E12 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E47 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
E2A B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
gene I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
play O
similar O
and O
additive O
roles O
in O
supporting O
B O
lymphopoiesis O
. O

Further O
, O
we O
find O
that O
HEB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
driven O
by O
the O
endogenous B_GENE/B_LOCATION
E2A I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
can O
functionally O
replace O
E2A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
supporting O
B-cell O
commitment O
and O
differentiation O
toward O
completion O
. O

Finally O
, O
the O
postnatal O
lethality O
associated O
with O
E2A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
disruption O
is O
fully O
rescued O
by O
the O
addition O
of O
HEB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

This O
study O
suggests O
that O
the O
functional O
divergence O
among O
E12 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
E47 B_GENE
, O
and O
HEB B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
different O
cell O
types O
is O
partially O
defined O
by O
the O
context O
of O
gene O
expression O
. O

Biased O
dependency O
of O
CD80 B_GENE
versus O
CD86 B_GENE
in O
the O
induction O
of O
transcription B_GENE
factors I_GENE
regulating O
the O
human B_GENE/B_DISEASE
IL-2 I_GENE/I_DISEASE
promoter I_GENE/I_DISEASE
. O

In O
addition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
signals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O
by O
ligation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
TCR B_GENE
, O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
need O
additional B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O
co-stimulatory B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
activated O
. O

One O
such O
co-stimulatory O
signal O
is O
delivered O
when O
CD28 B_GENE
on O
T O
cells O
binds O
to O
CD80 B_GENE
or O
CD86 B_GENE
on O
antigen-presenting O
cells O
( O
APC O
) O
. O

In O
the O
present O
study O
, O
we O
analyzed O
the O
ability O
of O
CD80 B_GENE
and O
CD86 B_GENE
to O
co-stimulate O
human O
T O
cells O
activated O
by O
superantigen O
. O

Using O
the O
Raji O
B O
cell O
lymphoma O
, O
which O
express O
similar O
levels O
of O
CD80 B_GENE
and O
CD86 B_GENE
, O
it O
was O
found O
that O
T O
cell O
proliferation O
was O
mainly O
co-stimulated O
by O
CD80 B_GENE
. O

To O
further O
characterize O
the O
consequences O
of O
this O
biased O
co-stimulatory O
dependency O
, O
we O
employed O
a O
well-defined O
system O
of O
transfected O
Cho O
cells O
expressing O
human B_GENE
MHC I_GENE
class I_GENE
II I_GENE
together O
with O
CD80 B_GENE
, O
CD86 B_GENE
or O
CD80 B_GENE
and O
CD86 B_GENE
. O

proliferation O
of O
freshly O
prepared O
CD4+ O
T O
cells O
required O
the O
presence O
of O
either O
CD80 B_GENE
or O
CD86 B_GENE
. O

However O
, O
IL-2 B_GENE
production O
reached O
only O
suboptimal O
levels O
in O
the O
presence O
of O
CD86 B_GENE
but O
optimal O
levels O
with O
CD80 B_GENE
. O

To O
analyze O
IL-2 B_GENE
transcriptional O
activity O
in O
CD80 B_GENE
and O
CD86 B_GENE
co-stimulated O
T O
cells O
we O
used O
Jurkat O
T O
cells O
transfected O
with O
luciferase B_GENE
reporter I_GENE
gene I_GENE
constructs I_GENE
. O

CD80 B_GENE
induced O
higher O
levels O
of O
IL-2 B_GENE/B_DISEASE
promoter I_GENE/I_DISEASE
-enhancer O
activity O
compared O
to O
CD86 B_GENE
. O

Furthermore O
, O
the O
activity O
of O
transcription B_GENE
factors I_GENE
regulating O
the O
IL-2 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
promoter-enhancer B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
including O
activation B_GENE
protein-1 I_GENE
, O
CD28 B_GENE
response I_GENE
element I_GENE
and O
nuclear B_GENE
factor I_GENE
kappaB I_GENE
were O
4-8 O
times O
higher O
after O
CD80 B_GENE
compared O
to O
CD86 B_GENE
ligation O
. O

Our O
results O
suggest O
that O
the O
eventual O
appearance O
of O
CD80 B_GENE
on O
recently O
activated O
CD86+ O
APC O
is O
important O
for O
the O
superinduction O
of O
IL-2 B_GENE
production O
and O
to O
support O
vigorous O
T O
cell O
proliferation O
. O

Duplication O
of O
the O
DR3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
on O
human B_GENE/B_MEASURE
chromosome B_GENE/I_MEASURE
1p36 B_GENE/I_MEASURE
and O
its O
deletion O
in O
human O
neuroblastoma O
. O

The O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DR3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
whose O
product O
is O
also O
known O
as O
Wsl-1/APO-3/TRAMP/LARD B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
encodes O
a O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-related I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
is O
expressed O
primarily O
on O
the O
surface O
of O
thymocytes O
and O
lymphocytes O
. O

DR3 B_GENE
is O
capable O
of O
inducing O
both O
NF-kappa B_GENE
B I_GENE
activation O
and O
apoptosis O
when O
overexpressed O
in O
mammalian O
cells O
, O
although O
its O
ligand O
has O
not O
yet O
been O
identified O
. O

We O
report O
here O
that O
the O
DR3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
tandemly O
duplicated O
on O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chromosome I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
band I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1p36.2-p36.3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
that O
these O
genes O
are O
hemizygously O
deleted O
and/or O
translocated O
to O
another O
chromosome O
in O
neuroblastoma O
( O
NB O
) O
cell O
lines O
with O
amplified O
MYCN O
. O

Duplication O
of O
at O
least O
a O
portion O
of O
the O
DR3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
the O
extracellular B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
transmembrane B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
regions B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
but O
not O
the O
cytoplasmic B_GENE
domain I_GENE
, O
was O
demonstrated O
by O
both O
fluorescence O
in O
situ O
hybridization O
and O
genomic O
Southern O
blotting O
. O

In O
most O
NB O
cell O
lines O
, O
both O
the O
DR3 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
the B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DR3L B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O
simultaneously O
deleted O
and/or O
translocated O
to O
another O
chromosome B_GENE/B_LOCATION
. O

Finally O
, O
DR3/ B_GENE
Wsl-1 I_GENE
protein I_GENE
expression O
is O
quite O
variable O
among O
these O
NB O
cell O
lines O
, O
with O
very O
low O
or O
undetectable O
levels O
in O
7 O
of O
17 O
NB O
cell O
lines O
. O

Differential B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
protection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
normal B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
malignant B_DISEASE
human I_DISEASE
myeloid I_DISEASE
progenitors I_DISEASE
( O
CFU-GM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
from O
Ara-C B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
toxicity I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
using O
cycloheximide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Cycloheximide O
, O
a O
reversible O
protein O
synthesis O
inhibitor O
, O
is O
thought O
to O
block O
DNA O
replication O
in O
normal O
cells O
by O
preventing O
synthesis O
of O
a O
labile B_GENE
protein I_GENE
. O

In O
animal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
systems I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
cycloheximide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protects O
normal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
from O
cytotoxic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
S-phase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
cytosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arabinoside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Ara-C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
. O

Malignant B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cells I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
appear O
not O
to O
be O
susceptible B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
cycloheximide-induced B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arrest B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
, O
subsequently O
, O
may O
not O
be O
protected O
from O
Ara-C B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cytotoxicity I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cycloheximide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
granulocyte/macrophage B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
progenitors B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
CFU-GM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
) O
after O
in O
vitro B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
Ara-C I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
was O
examined O
using O
normal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
human I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
bone I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
marrow I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O
malignant B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
progenitors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
patients B_PERSON/B_BIO
with O
chronic B_DISEASE
myelogenous I_DISEASE
leukemia I_DISEASE
( O
CML B_LOCATION/B_ORGANIZATION
) O
, O
and O
clonogenic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
human B_DISEASE/B_BIO
acute I_DISEASE/I_BIO
nonlymphocytic I_DISEASE/I_BIO
leukemia I_DISEASE/I_BIO
cell I_DISEASE/I_BIO
lines I_DISEASE/I_BIO
HL-60 O
and O
KG-1 B_GENE/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
. O

mononuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
or O
clonogenic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
incubated O
for O
one B_TIME[MEASURE]/B_ENT
hour I_TIME[MEASURE]/I_ENT
with O
cycloheximide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
followed O
by O
the O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
for O
three B_NUMBER[MEASURE]
or O
17 B_NUMBER[MEASURE]/B_ENT
hours I_NUMBER[MEASURE]/I_ENT
, O
of O
Ara-C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
before O
being O
plated O
in O
a O
methylcellulose B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
culture I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

CFU-GM B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
survival I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O
significantly O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
if O
normal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O
treated O
with O
cycloheximide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
before O
Ara-C B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Similar B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
cycloheximide I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
pretreatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
CML B_DISEASE_ADJECTIVE[DISEASE]
progenitors I_DISEASE_ADJECTIVE[DISEASE]
and O
clonogenic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
HL-60 B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
KG-1 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O
to O
protect O
CFU-GM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
from O
Ara-C-induced B_DISEASE_ADJECTIVE[DISEASE]
cytotoxicity I_DISEASE_ADJECTIVE[DISEASE]
. O

Primary O
cortisol O
resistance O
accompanied O
by O
a O
reduction O
in O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
two O
members O
of O
the O
same O
family O
. O

This O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
describes O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
a O
man B_PERSON/B_BIO
suspected O
of O
having O
primary B_DISEASE/B_LOCATION
cortisol I_DISEASE/I_LOCATION
resistance I_DISEASE/I_LOCATION
. O

This O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
based O
on O
his O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
plasma I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cortisol I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
levels I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
high B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
24-h B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urinary B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
17-hydroxycorticosteroid B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excretion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
plus O
the O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
he O
had O
no O
manifestations B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Cushing B_DISEASE
's I_DISEASE
syndrome I_DISEASE
. O

Among O
family B_PERSON
members I_PERSON
tested O
, O
his O
mother B_PERSON
also O
had O
hypercortisolemia B_DISEASE/B_PERSON
. O

Both O
mother B_PERSON
and O
son B_PERSON
had O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
unbound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
but O
their O
plasma B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ACTH I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
concentrations I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
within O
the O
normal B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
range B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Both O
were O
partially O
resistant B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
dexamethasone O
adrenal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suppression I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
both O
had O
mild B_DISEASE
hypertension I_DISEASE
without O
hypokalemia B_DISEASE
. O

To O
study O
this O
apparent O
end-organ O
resistance O
to O
cortisol O
, O
we O
examined O
the O
glucocorticoid B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
peripheral O
mononuclear O
cells O
. O

Using O
whole O
cell O
assays O
, O
glucocorticoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
patients O
were O
found O
to O
have O
reduced O
total O
binding O
capacity O
. O

We O
conclude O
that O
these O
two O
patients O
, O
members O
of O
the O
same O
family O
, O
have O
primary O
cortisol O
resistance O
accompanied O
by O
a O
reduced O
number O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

[ O
Glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
response O
to O
polychemotherapy O
in O
acute O
lymphatic O
leukemia O
] O
. O

Glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GR B_LOCATION/B_ORGANIZATION
) O
levels O
were O
quantified O
in O
leukemic O
blasts O
from O
peripheral O
blood O
of O
86 O
patients O
with O
acute O
lymphoblastic O
leukemia O
. O

The O
subsequent B_MEASURE
achievement I_MEASURE
of O
complete B_DISEASE_ADJECTIVE[DISEASE]
remission I_DISEASE_ADJECTIVE[DISEASE]
after O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O
correlated O
with O
high B_DISEASE
receptor I_DISEASE
levels I_DISEASE
. O

Forty-seven B_MEASURE
of O
50 B_PERSON
patients I_PERSON
with O
leukemic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
containing O
more B_MEASURE/B_PERSON
than O
6 B_MEASURE
, O
000 B_MEASURE
receptor I_MEASURE
sites I_MEASURE
and O
22 B_NUMBER[MEASURE]
of O
36 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
with O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
containing O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
6 B_MEASURE
, O
000 B_MEASURE
receptor I_MEASURE
sites I_MEASURE
achieved O
remission B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
study O
of O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
leukemic O
cells O
may O
predict O
response O
to O
combination O
chemotherapy O
in O
patients O
with O
acute O
lymphoblastic O
leukemia O
. O

specific B_MEASURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
uptake I_MEASURE/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
1 B_MEASURE
, O
25-dihydroxycholecalciferol B_TIME[MEASURE]
by O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
chronic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
myeloid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukemia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
have O
examined O
mononuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
patients B_PERSON/B_BIO
with O
chronic B_DISEASE
myeloid I_DISEASE
leukemia I_DISEASE
[ I_DISEASE
CML I_DISEASE
] O
for O
binding O
of O
and O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
1 B_NUMBER[MEASURE]
, O
25-dihydroxycholecalciferol B_MEASURE
[ I_MEASURE
1 I_MEASURE
, O
25- B_MEASURE
( O
OH B_LOCATION/B_MEASURE
) O
2D3 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Whole B_PERSON
cells I_PERSON
specifically O
took O
up O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
-1 O
, O
25- B_MEASURE
( O
OH B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
with O
high B_MEASURE/B_LOCATION
affinity I_MEASURE/I_LOCATION
( O
Kd B_MEASURE/B_LOCATION
3.6 I_MEASURE/I_LOCATION
X I_MEASURE/I_LOCATION
10 I_MEASURE/I_LOCATION
( O
-11 O
) O
M B_MEASURE
) O
and O
low B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

subcellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fractionation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
labeled O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O
that O
binding O
was O
restricted O
to O
cytosols B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
nuclei B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

sucrose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gradient I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
centrifugation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
preincubated O
with O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
-1 O
, O
25- B_MEASURE
( O
OH O
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
revealed O
a O
single B_MEASURE/B_BIO
3.6S B_MEASURE/I_BIO
peak B_MEASURE/I_BIO
which O
was O
totally O
displaced O
with O
100-fold B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excess I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nonradioactive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
we O
were O
unable B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
demonstrate O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
1 B_MEASURE
, O
25- B_MEASURE
( O
OH O
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
by O
postlabeling O
standard B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytosol I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
preparations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
cytosols B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
prepared O
from O
a O
mixture B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
CML B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
and O
1 B_NUMBER[MEASURE]
, O
25- B_MEASURE
( O
OH B_MEASURE/B_PROTEIN[GENE]
) O
2D3 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor-positive I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
T47D I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
human B_DISEASE/B_LOCATION
breast I_DISEASE/I_LOCATION
cancer I_DISEASE/I_LOCATION
) O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
had O
less B_MEASURE
than O
10 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
the O
binding B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
measured O
in O
T47D B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytosol I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
alone O
. O

However O
, O
the O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
binding O
in O
T47D B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytosols I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
not O
reduced O
if O
the O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
occupied O
with O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
-1 O
, O
25- B_MEASURE
( O
OH O
) O
2D3 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PROTEIN[GENE]
to O
the O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
CML B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytosols I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Thus O
, O
CML B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
appear O
to O
contain O
both O
the O
receptor B_GENE
for O
1 B_MEASURE
, O
25- B_MEASURE
( O
OH B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
an O
unknown B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
substance B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
which O
prevents O
its O
detection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
following O
the O
preparation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cytosol B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

Cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
patients B_PERSON/B_BIO
with O
CML B_DISEASE/B_LOCATION
in O
the O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
phase B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
specifically O
bound O
more B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
, O
25- B_MEASURE
( O
OH O
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
[ O
18.0 B_MEASURE
+/- O
3.2 B_MEASURE
( O
S.E B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O
) O
fmol/10 B_MEASURE/B_LOCATION
( O
7 B_MEASURE/B_LOCATION
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
] I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
than O
did O
those O
in O
acute B_DISEASE/B_PERSON
myeloid I_DISEASE/I_PERSON
transformation I_DISEASE/I_PERSON
[ I_DISEASE/I_PERSON
7.2 I_DISEASE/I_PERSON
+/- I_DISEASE/I_PERSON
1.5 I_DISEASE/I_PERSON
] I_DISEASE/I_PERSON
or O
than O
did O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
patients B_PERSON/B_LOCATION
with O
acute B_DISEASE
myeloid I_DISEASE
leukemia I_DISEASE
[ I_DISEASE
2.6 I_DISEASE
+/- I_DISEASE
0.8 I_DISEASE
] I_DISEASE
. O

Only O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
from O
the O
first B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_BIO
responded O
to O
the O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
1 B_MEASURE
, O
25- B_MEASURE
( O
OH O
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
by O
differentiating O
along O
the O
monocyte-macrophage B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
conclude O
that O
the O
differentiation-induction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
1 B_MEASURE
, O
25- B_MEASURE
( O
OH B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
is O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
depend O
on O
adequate B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
receptor B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
that O
intact B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
rather O
than O
cytosol B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
preparations B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
should O
be O
studied O
before O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
a O
particular B_DISEASE/B_MEASURE
tissue I_DISEASE/I_MEASURE
are O
designated O
as O
receptor B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
negative B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cell B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cycle I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
position I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
dexamethasone B_MEASURE/B_DISEASE
binding B_MEASURE/I_DISEASE
by O
mouse B_SPECIES[BIO]/B_DISEASE
and O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoid I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
cell I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
lines I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
: O
correlation B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
dexamethasone B_MEASURE
binding I_MEASURE
during O
S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dexamethasone B_DISEASE_ADJECTIVE[DISEASE]
sensitivity I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
determined O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cell B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
position B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
amount B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
was O
specifically O
bound O
by O
mouse B_SPECIES[BIO]/B_DISEASE
and O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoid I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
cell I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
lines I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Cell B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
lines I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O
were O
either O
sensitive B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
or O
resistant B_DISEASE_ADJECTIVE[DISEASE]
to O
growth B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
inhibition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
by O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
compared O
. O

Exponentially O
growing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
separated O
by O
centrifugal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
elutriation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
into O
fractions B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
that O
corresponded O
to O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
positions B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
the O
cell B_TIME[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cycle B_TIME[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
cell B_MEASURE
cycle I_MEASURE
phase I_MEASURE
distribution I_MEASURE
of O
each O
fraction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
estimated O
by O
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
autoradiography B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
amount B_MEASURE/B_LOCATION
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bound O
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
each O
fraction B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
measured O
by O
a O
whole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O
assay B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
dexamethasone-sensitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lines B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
two B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
mouse I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
and O
one B_PERSON/B_BIO
human B_PERSON/I_BIO
) O
, O
we O
found O
that O
the O
amount B_MEASURE/B_LOCATION
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bound O
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
increased O
2-4-fold B_DISEASE_ADJECTIVE[DISEASE]
between O
G1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
and O
S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
and O
then O
decreased O
during O
G2/M B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
were O
the O
same O
when O
the O
amount O
of O
dexamethasone O
bound O
per O
milligram O
of O
cell B_PROTEIN[GENE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
protein B_PROTEIN[GENE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
was O
measured O
. O

binding B_TIME[MEASURE]/B_LOCATION
affinity I_TIME[MEASURE]/I_LOCATION
was O
the O
same B_MEASURE/B_LOCATION
during O
G1 B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
but O
the O
proportion B_MEASURE
of O
bound O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
translocated O
to O
the O
nucleus B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
was O
greater B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
during O
S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

In O
contrast B_MEASURE
, O
we O
found O
that O
the O
amount B_MEASURE/B_LOCATION
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bound O
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
by O
three B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
dexamethasone-resistant I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lines I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
two B_SPECIES[BIO]/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
mouse B_SPECIES[BIO]/I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
and O
one B_BIO/B_PERSON
human I_BIO/I_PERSON
) O
did O
not O
increase O
during O
S B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
phase I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

Our O
results O
indicate O
that O
cell O
cycle O
changes O
in O
dexamethasone O
binding O
are O
not O
simply O
related O
to O
changes O
in O
cell B_GENE/B_MEASURE
protein B_GENE/I_MEASURE
or O
cell O
volume O
during O
the O
cell O
cycle O
. O

An O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
dexamethasone B_MEASURE/B_DISEASE
binding I_MEASURE/I_DISEASE
during O
S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
may O
be O
required O
for O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
inhibit O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
growth B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
and O
a O
failure B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
dexamethasone B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
increase O
during O
S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
might O
represent O
a O
new B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mechanism I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
dexamethasone B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resistance I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
lymphoid B_DISEASE/B_BIO
cells I_DISEASE/I_BIO
. O

presence O
and O
steroid O
inducibility O
of O
glutamine B_GENE/B_LOCATION
synthetase I_GENE/I_LOCATION
in O
human O
leukemic O
cells O
. O

Glutamine B_GENE
synthetase I_GENE
( O
EC O
6.3.1.2 O
; O
GS O
) O
is O
present O
in O
lymphoblasts O
from O
patients O
with O
acute O
lymphoblastic O
leukemia O
( O
All O
) O
as O
well O
as O
in O
normal O
peripheral O
blood O
lymphocytes O
. O

In O
16 O
out O
of O
20 O
All O
patients O
studied O
exposure O
of O
the O
cells O
to O
physiological O
concentrations O
of O
dexamethasone O
in O
vitro O
increased O
enzyme B_GENE
activity O
above O
the O
control O
levels O
. O

The O
increase O
was O
specific O
for O
glucocorticoid B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
receptor I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
ligands O
. O

A O
direct O
correlation O
was O
found O
between O
the O
magnitude O
of O
glucocorticoid-mediated O
increase O
of O
GS O
activity O
and O
the O
cellular O
levels O
of O
specific O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assayed O
in O
the O
same O
cell O
specimen O
. O

Moreover O
, O
the O
basal O
levels O
of O
the O
enzyme B_GENE
measured O
in O
cells O
prior O
to O
exposure O
to O
dexamethasone O
correlated O
negatively O
with O
receptor O
density O
. O

It O
is O
suggested O
that O
the O
presence O
of O
steroid-inducible B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GS I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
All O
cells O
may O
prove O
to O
be O
a O
marker O
for O
functional B_DISEASE/B_GENE
receptor I_DISEASE/I_GENE
sites I_DISEASE/I_GENE
. O

binding O
of O
progestins O
to O
the O
glucocorticoid B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
receptor I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O

correlation B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
their O
glucocorticoid-like B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
functions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
mononuclear I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
leukocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

A O
number O
of O
physiological O
and O
synthetic O
progestins O
were O
tested O
for O
their O
ability O
to O
compete O
with O
[ O
3H O
] O
dexamethasone O
for O
the O
binding O
to O
the O
glucocorticoid B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
of O
human O
mononuclear O
leukocytes O
and O
their O
ability O
to O
elicit O
glucocorticoid-like O
effects O
on O
the O
same O
cells O
. O

As O
compared O
to O
the O
reference B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
compound I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
dexamethasone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
relative B_TIME[MEASURE]/B_LOCATION
receptor I_TIME[MEASURE]/I_LOCATION
binding I_TIME[MEASURE]/I_LOCATION
affinity I_TIME[MEASURE]/I_LOCATION
defined O
as O
100 B_MEASURE
% I_MEASURE
) O
, O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthetic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
progestins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
a O
pregnane-type B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
megestrol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
medroxyprogesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
were O
found O
to O
display O
a O
considerable B_MEASURE
binding I_MEASURE
affinity I_MEASURE
towards O
the O
receptor B_GENE
( O
46 B_MEASURE
and O
42 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
respectively O
) O
. O

The O
relative B_MEASURE/B_DISEASE
binding I_MEASURE/I_DISEASE
affinity I_MEASURE/I_DISEASE
of O
the O
naturally O
occurring O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
to O
the O
receptor B_GENE
was O
clearly O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
. O

The O
effective O
binding O
of O
medroxyprogesterone O
acetate O
to O
the O
glucocorticoid B_GENE
receptor I_GENE
was O
confirmed O
by O
direct O
binding O
studies O
utilizing O
a O
tritiated O
derivative O
of O
this O
steroid O
. O

No O
evidence O
for O
the O
existence O
of O
a O
specific O
progesterone B_PROTEIN[GENE]
receptor I_PROTEIN[GENE]
in O
human O
mononuclear O
leukocytes O
was O
obtained O
as O
judged O
by O
the O
results O
of O
competition O
experiments O
where O
a O
progesterone O
receptor-specific O
ligand O
[ O
3H O
] O
org O
2058 O
was O
used O
. O

Medroxyprogesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
megestrol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
induced O
glucocorticoid-like B_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
lymphocyte B_BODY_PART_OR_ORGAN_COMPONENT
functions I_BODY_PART_OR_ORGAN_COMPONENT
. O

These O
included O
inhibition O
of O
the O
proliferative O
responses O
to O
the O
T-cell B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mitogens I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concanavalin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
phytohaemagglutinin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
an O
enhanced O
accumulation O
of O
immunoglobulin O
secreting O
cells O
in O
pokeweed O
mitogen-stimulated O
cultures O
. O

The O
progestin B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
appears O
to O
be O
mediated O
through O
a O
radiosensitive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
suppressor B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
) O
subpopulation B_MEASURE
of O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast O
, O
the O
synthetic O
progestins O
related O
structurally O
to O
19-nortestosterone O
, O
norethisterone O
and O
d-norgestrel O
, O
were O
virtually O
devoid O
of O
binding O
affinity O
towards O
the O
glucocorticoid B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
nor O
did O
they O
measurably O
influence O
the O
in O
vitro O
lymphocyte O
functions O
. O

These O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrate O
that O
certain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
progestins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
common B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
probably O
possess O
inherent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
glucocorticoid I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
suggest O
that O
side B_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
attributable I_DISEASE_ADJECTIVE[DISEASE]
to O
this O
character B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
e.g B_DISEASE/B_PROTEIN[GENE]
. O
suppression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
pituitary-adrenal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
axis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O
might O
be O
expected O
when O
these O
compounds B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
used O
in O
pharmacological B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Metabolic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
ultrastructural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
in O
vitro B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lysis I_ORGANIZATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chronic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukemia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Human O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
cells O
like O
prothymocytes O
and O
immunoactivated O
T-lymphocytes O
are O
readily O
lysed O
in O
vitro O
by O
pharmacological O
concentrations O
of O
glucocorticoids O
such O
as O
cortisol O
, O
whereas O
peripheral O
blood O
lymphocytes O
and O
thymocytes O
are O
unaffected O
by O
the O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
metabolic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
ultrastructural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
cortisol-induced B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
killing B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
process B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O
CLL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
are O
recorded O
. O

In O
vitro B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
lysis I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
found O
to O
be O
temperature B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dependent I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
was O
detected O
only O
after O
6 B_NUMBER[MEASURE]/B_LOCATION
to O
8 B_MEASURE
hr I_MEASURE
incubation I_MEASURE
with O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
means B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
trypan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blue I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exclusion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
30 O
min O
of O
incubation O
with O
cortisol O
at O
either O
37 O
degrees O
or O
4 O
degrees O
followed O
by O
the O
removal O
of O
the O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
still O
sufficient O
to O
induce O
the O
lytic O
process O
. O

Ultrastructural O
studies O
demonstrated O
sequential O
changes O
in O
the O
cytoplasm O
, O
including O
swelling O
of O
mitochondria O
and O
cytoplasmic O
decompartmentalization O
, O
followed O
by O
loss O
of O
surface O
microvilli O
with O
the O
appearance O
of O
`` O
holes O
'' O
in O
the O
cell O
membrane O
, O
and O
subsequent O
condensation O
of O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
chromatin I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
large O
holes O
in O
the O
membrane O
appearing O
after O
6 O
hr O
of O
incubation O
with O
the O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
the O
cause O
for O
the O
penetration O
of O
the O
viable O
stain O
into O
the O
dead O
cells O
, O
as O
seen O
by O
light O
microscopy O
. O

Addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
metabolic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O
actinomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
puromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
and O
cycloheximide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
following O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O
in O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lysis B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

An O
excess B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
an O
antagonist B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
such I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
as O
cortexolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
found O
to O
inhibit O
the O
cortisol-induced B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cytolysis B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
the O
CLL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

It O
is O
suggested O
that O
the O
glucocorticoid-induced O
lysis O
of O
human O
CLL O
cells O
is O
similar O
to O
the O
phenomenon O
observed O
in O
rat O
or O
murine O
lymphocytes O
and O
is O
mediated O
by O
interaction O
of O
the O
steroid O
molecule O
with O
the O
cytoplasmic B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
resulting O
complex O
appears O
to O
activate O
specific O
gene B_GENE
( O
s O
) O
the O
products O
of O
which O
eventually O
cause O
cytolysis O
. O

Glucocorticoid B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
lymphoid O
tumors O
. O

There O
is O
a O
range O
of O
levels O
of O
glucocorticoid B_GENE
receptor I_GENE
numbers O
seen O
in O
the O
various O
subclasses O
of O
acute O
lymphatic O
leukemia O
( O
All O
) O
. O

This O
variability B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
not O
be O
explained O
by O
the O
known O
correlation B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
active B_DISEASE/B_ORGANISM_FUNCTION
cell I_DISEASE/I_ORGANISM_FUNCTION
proliferation I_DISEASE/I_ORGANISM_FUNCTION
and O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
number B_MEASURE
of O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
since O
the O
tumors B_DISEASE/B_PERSON
with O
the O
highest B_MEASURE/B_DISEASE
growth I_MEASURE/I_DISEASE
fraction I_MEASURE/I_DISEASE
( O
i.e O
. O
, O
Burkitt B_DISEASE
's I_DISEASE
lymphoma I_DISEASE
and O
T-cell B_DISEASE/B_GENE
leukemia I_DISEASE/I_GENE
) O
tend O
to O
have O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
average B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
receptor B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
numbers B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
do O
tumors B_DISEASE/B_PERSON
with O
lower B_DISEASE/B_MEASURE
growth I_DISEASE/I_MEASURE
fractions I_DISEASE/I_MEASURE
such I_DISEASE/I_MEASURE
as O
common B_LOCATION/B_MEASURE
All O
. O

All O
clinical O
specimens O
from O
patients O
with O
lymphatic O
leukemia O
have O
some O
measurable O
level O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
; O
therefore O
, O
the O
resistance O
seen O
in O
vivo O
can O
not O
be O
explained O
by O
the O
lack O
of O
receptors O
. O

However O
, O
there O
has O
been O
a O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
our O
hands B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
receptor B_MEASURE/B_DISEASE
level B_MEASURE/I_DISEASE
and O
prognosis B_MEASURE/B_DISEASE
. O

On O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
it O
is O
proposed O
that O
perhaps O
the O
high B_DISEASE/B_PERSON
receptor I_DISEASE/I_PERSON
cell I_DISEASE/I_PERSON
lines I_DISEASE/I_PERSON
( O
i.e B_PROTEIN[GENE]/B_LOCATION
. O
, O
common B_LOCATION/B_MEASURE
All O
of O
childhood B_PERSON/B_DISEASE
) O
have O
relative B_MEASURE
stability I_MEASURE
of O
their O
genetic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
material I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
making O
glucocorticoid-resistant B_DISEASE
mutations I_DISEASE
less O
likely B_DISEASE_ADJECTIVE[DISEASE]
to O
occur O
in O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
these O
cells B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
than O
in O
low-receptor B_DISEASE/B_PERSON
cell I_DISEASE/I_PERSON
lines I_DISEASE/I_PERSON
( O
i.e O
. O
, O
T-cell B_DISEASE/B_PERSON
leukemia I_DISEASE/I_PERSON
) O
. O

This O
greater B_DISEASE_ADJECTIVE[DISEASE]
genetic I_DISEASE_ADJECTIVE[DISEASE]
variability I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
low-receptor B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
lines I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
could O
account O
for O
the O
earlier B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
emergence B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
clinical B_DISEASE
glucocorticoid I_DISEASE
resistance I_DISEASE
in O
these O
patients B_PERSON/B_BIO
. O

[ O
tumor O
histology O
and O
steroid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
receptors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
breast O
carcinoma O
] O
. O

In O
specimens O
of O
115 O
patients O
with O
breast O
cancer O
4 O
tumorparameters O
( O
tumorsize O
, O
tumorboder O
, O
nucleargrade O
, O
lymphocytic O
stromal O
reaction O
) O
3 O
features O
of O
regional O
lymphnodes O
( O
sinushistiocytosis O
, O
T-cellreaction O
, O
lymphnode O
metastases O
) O
and O
estrogen B_DISEASE
and I_DISEASE
progesteron I_DISEASE
receptors I_DISEASE
were O
determined O
. O

A O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sinushistiocytosis B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
T-cellreaction B_DISEASE
could O
be O
verified O
mainly O
in O
metastases B_DISEASE/B_BIO
in O
free B_DISEASE/B_BIO
lymphnodes I_DISEASE/I_BIO
. O

The O
steroid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O
does O
not O
correlate O
with O
histological O
parameters O
. O

Aldosterone-receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deficiency O
in O
pseudohypoaldosteronism O
. O

Pseudohypoaldosteronism B_DISEASE
, O
a O
syndrome B_DISEASE
characterized O
by O
salt B_DISEASE
wasting I_DISEASE
and O
failure B_DISEASE_ADJECTIVE[DISEASE]
to O
thrive O
, O
usually O
presents O
in O
infancy B_TIME[MEASURE]/B_PERSON
as O
high B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
urinary I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
despite O
hyponatremia B_DISEASE
, O
hyperkalemia B_DISEASE
, O
hyperreninemia B_DISEASE
, O
and O
elevated O
aldosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

We O
have O
investigated O
this O
syndrome O
for O
the O
possibility O
of O
abnormal B_DISEASE_ADJECTIVE[DISEASE]
Type I_DISEASE_ADJECTIVE[DISEASE]
I I_DISEASE_ADJECTIVE[DISEASE]
or O
`` B_MEASURE/B_PROTEIN[GENE]
mineralocorticoid-like I_MEASURE/I_PROTEIN[GENE]
'' I_MEASURE/I_PROTEIN[GENE]
receptors I_MEASURE/I_PROTEIN[GENE]
, O
which O
have O
intrinsic O
steroid O
specificity O
indistinguishable O
from O
that O
of O
renal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mineralocorticoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
are O
found O
in O
many O
tissues O
and O
cells O
, O
including O
mononuclear O
leukocytes O
. O

We O
have O
studied O
three B_PERSON
patients I_PERSON
with O
pseudohypoaldosteronism B_DISEASE/B_LOCATION
: O
the O
28-year-old B_PERSON
index I_PERSON
case I_PERSON
in O
Melbourne B_LOCATION
( O
Patient B_LOCATION/B_MEASURE
1 I_LOCATION/I_MEASURE
) O
and O
two B_PERSON/B_NUMBER[MEASURE]
siblings B_PERSON/I_NUMBER[MEASURE]
in O
Munich B_LOCATION/B_NUMBER[MEASURE]
, O
eight B_NUMBER[MEASURE]/B_LOCATION
and O
two B_NUMBER[MEASURE]
years I_NUMBER[MEASURE]
of O
age B_TIME[MEASURE]
( O
patients B_NUMBER[MEASURE]
2 I_NUMBER[MEASURE]
and O
3 B_NUMBER[MEASURE]
) O
; O
clinically O
, O
patient B_PERSON
3 I_PERSON
had O
a O
less O
severe B_DISEASE/B_PERSON
case I_DISEASE/I_PERSON
than O
his O
sister B_PERSON
. O

Percoll-separated B_MEASURE/B_GENE
control I_MEASURE/I_GENE
monocytes I_MEASURE/I_GENE
bound O
[ O
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
aldosterone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
affinity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
Kd B_PROTEIN[GENE]/B_MEASURE
approximately O
3 B_MEASURE/B_COLOR
nm I_MEASURE/I_COLOR
) O
and O
limited B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
capacity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
150 B_MEASURE/B_LOCATION
to O
600 B_MEASURE/B_ENT
sites I_MEASURE/I_ENT
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
) O
. O

On O
repeated O
examination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
no O
[ B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O
aldosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
found O
in O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O
patients B_NUMBER[MEASURE]/B_PERSON
1 I_NUMBER[MEASURE]/I_PERSON
and O
2 B_NUMBER[MEASURE]
; O
in O
patient B_PERSON/B_MEASURE
3 B_PERSON/I_MEASURE
, O
the O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
62 B_MEASURE
sites I_MEASURE
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
, O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
2 B_MEASURE/B_LOCATION
S.D I_MEASURE/I_LOCATION
. O
below O
those O
of O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Levels B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
parents B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
Munich B_PERSON/B_ORGANIZATION
patients I_PERSON/I_ORGANIZATION
( O
first B_PERSON/B_MEASURE
cousins B_PERSON/I_MEASURE
) O
were O
normal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

It O
appears O
that O
pseudohypoaldosteronism O
is O
caused O
by O
a O
Type O
I O
receptor O
defect O
, O
that O
the O
defect O
may O
be O
complete O
or O
partial O
, O
that O
transmission O
may O
be O
autosomal O
recessive O
, O
and O
that O
the O
study O
of O
patients O
with O
pseudohypoaldosteronism O
may O
indicate O
physiologic O
roles O
for O
Type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
nonepithelial O
tissues O
. O

Glucocorticoid O
inhibition O
of O
urokinase-like B_DISEASE/B_GENE
plasminogen B_DISEASE/I_GENE
activators B_DISEASE/I_GENE
in O
cultured O
human O
lymphoblasts O
. O

Two B_MEASURE/B_LOCATION
human I_MEASURE/I_LOCATION
lymphoblast I_MEASURE/I_LOCATION
cell I_MEASURE/I_LOCATION
lines I_MEASURE/I_LOCATION
, O
LICR-LON-HMy2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
( O
HMy2 B_GENE
cells I_GENE
) O
and O
GM4672A B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
are O
moderately O
growth B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibited O
by O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
1 B_MEASURE
, O
4-pregnadien-9-fluoro-16 B_TIME[MEASURE]
alpha-methyl-11 O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
17 B_MEASURE/B_PERSON
alpha I_MEASURE/I_PERSON
, O
21-triol-3 B_MEASURE
, O
20-dione B_MEASURE
) O
( O
Dex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Both O
cell O
types O
secrete O
a O
urokinase B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
UK I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
-like I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
plasminogen I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activator I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PA B_LOCATION/B_ORGANIZATION
) O
. O

Treatment O
of O
both O
HMy2 O
and O
GM4672A O
cells O
with O
Dex O
for O
1-4 O
days O
inhibits O
extracellular O
PA B_GENE/B_DISEASE
activity O
in O
a O
concentration-dependent O
manner O
, O
being O
half-maximal O
at O
approximately O
1 O
X O
10 O
( O
-9 O
) O
M O
. O

Inhibition O
of O
PA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
both O
cell O
types O
is O
specific O
for O
active O
glucocorticoids O
, O
and O
this O
specificity O
parallels O
the O
ability O
of O
various O
steroids O
to O
bind O
to O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

HMy2 O
cell O
PA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
is O
fully O
suppressible O
by O
Dex O
, O
whereas O
up O
to O
one O
third O
of O
the O
activator O
expressed O
by O
GM4672A O
cells O
is O
resistant O
to O
glucocorticoid O
inhibition O
. O

Mixing O
experiments O
using O
a O
UK O
standard O
and O
conditioned O
media O
from O
Dex-treated O
cells O
suggest O
an O
absence O
of O
glucocorticoid-inducible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
UK B_GENE
or O
plasmin B_LOCATION
in O
both O
cell O
types O
. O

However O
, O
conditioned O
media B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
from O
Dex-treated B_DISEASE/B_BIO
GM4672A I_DISEASE/I_BIO
cells I_DISEASE/I_BIO
inhibits O
a O
portion B_MEASURE
of O
the O
homologous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellular I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
activator I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
conditioned O
media B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
from O
control B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
GM4672A I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

Thus O
, O
low O
levels O
of O
glucocorticoid-inducible B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O
contribute O
to O
, O
but O
can O
not O
fully O
account O
for O
, O
Dex O
inhibition O
of O
GM4672A B_GENE
PA I_GENE
activity O
. O

Glucocorticoid-inducible B_GENE/B_TIME[MEASURE]
inhibitors I_GENE/I_TIME[MEASURE]
in O
HMy2 O
cells O
are O
either O
totally O
absent O
or O
are O
present O
at O
undetectable O
levels O
. O

Thus O
, O
regulation O
of O
UK-like B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PAs I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
HMy2 O
and O
GM4672A O
cells O
differs O
with O
respect O
to O
the O
extent O
to O
which O
glucocorticoids O
inhibit O
constitutively B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expressed I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
, O
as O
well O
as O
the O
possible O
contribution O
of O
glucocorticoid-inducible B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
regulatory O
process O
in O
GM4672A O
cells O
. O

Characterization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
aldosterone B_GENE
binding I_GENE
sites I_GENE
in O
circulating O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
mononuclear I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
leukocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

aldosterone B_GENE/B_PERSON
binding I_GENE
sites B_LOCATION/B_ENT
in O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
mononuclear I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
leukocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O
characterized O
after O
separation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
blood B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
a O
Percoll B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gradient I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

After O
washing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
resuspension B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
RPMI-1640 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
incubated O
at O
37 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
for O
1 B_MEASURE
h O
with O
different B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
concentrations I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
aldosterone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
plus O
a O
100-fold B_MEASURE
concentration I_MEASURE
of O
RU-26988 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
11 B_MEASURE/B_PERSON
alpha I_MEASURE/I_PERSON
, O
17 B_NUMBER[MEASURE]
alpha-dihydroxy-17 I_NUMBER[MEASURE]
beta-propynylandrost-1 I_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
, O
6-trien-3-one B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
with O
or O
without O
an O
excess B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
unlabeled B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aldosterone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

aldosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
binds I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
single B_MEASURE/B_LOCATION
class B_MEASURE/I_LOCATION
of O
receptors B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
an O
affinity B_MEASURE
of O
2.7 B_MEASURE
+/- I_MEASURE
0.5 I_MEASURE
nm I_MEASURE
( O
means B_MEASURE/B_LOCATION
+/- O
SD B_MEASURE/B_DISEASE
, O
n O
= O
14 B_MEASURE
) O
and O
a O
capacity B_MEASURE/B_LOCATION
of O
290 B_MEASURE
+/- O
108 B_MEASURE
sites/cell I_MEASURE
( O
n B_MEASURE/B_LOCATION
= O
14 B_MEASURE
) O
. O

The O
specificity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
show O
a O
hierarchy B_PERSON/B_MEASURE
of O
affinity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
desoxycorticosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
= O
corticosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
= O
aldosterone B_MEASURE
greater I_MEASURE
than O
hydrocortisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
greater I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results O
indicate O
that O
mononuclear O
leukocytes O
could O
be O
useful O
for O
studying O
the O
physiological O
significance O
of O
these O
mineralocorticoid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
their O
regulation O
in O
humans O
. O

Mineralocorticoid B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
circulating O
mononuclear O
leukocytes O
of O
patients O
with O
primary O
hyperaldosteronism O
. O

Mineralocorticoid B_GENE/B_PERSON
and I_GENE/I_PERSON
glucocorticoid I_GENE/I_PERSON
receptors I_GENE/I_PERSON
were O
measured O
in O
circulating O
mononuclear O
leukocytes O
in O
5 O
patients O
affected O
by O
Conn O
's O
syndrome O
( O
3 O
cases O
of O
bilateral O
adrenal O
hyperplasia O
and O
2 O
cases O
of O
adenoma O
plus O
unilateral O
hyperplasia O
) O
. O

The O
number B_MEASURE
of O
the O
binding B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
sites I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
resulted O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O
189 B_MEASURE
+/- O
114 B_MEASURE
, O
mean B_MEASURE
+/- O
SD B_MEASURE/B_DISEASE
) O
, O
as O
compared O
with O
the O
normal B_MEASURE/B_PERSON
controls I_MEASURE/I_PERSON
( O
298 B_MEASURE/B_PROTEIN[GENE]
+/- I_MEASURE/I_PROTEIN[GENE]
105 I_MEASURE/I_PROTEIN[GENE]
) O
. O

The O
affinity B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
aldosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
the O
receptor B_GENE
was O
found O
to O
be O
not O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
that O
of O
healthy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
control I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
subjects I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
capacity O
and O
the O
affinity O
of O
dexamethasone O
for O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ranged O
in O
the O
normal O
values O
. O

These O
data O
suggest O
a O
possible O
down-regulation O
of O
mineralocorticoid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
humans O
. O

Short-term B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
long-term B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
lymphoid B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
lymphoid B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O
some O
remarks B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
the O
significance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
carcinogenesis B_DISEASE/B_ORGANISM_FUNCTION
. O

estrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O
long O
been O
thought O
to O
play O
a O
role B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
regulating O
the O
immune B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
difference B_MEASURE
in O
some O
types B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
immune B_DISEASE
responses I_DISEASE
between O
males B_PERSON
and O
females B_PERSON/B_BIO
is O
well-known B_DISEASE_ADJECTIVE[DISEASE]
, O
as O
is O
the O
pronounced B_DISEASE_ADJECTIVE[DISEASE]
thymic I_DISEASE_ADJECTIVE[DISEASE]
involution I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
estrogens I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Estrogens O
stimulate O
some O
aspects O
of O
macrophage O
activity O
and O
, O
depending O
on O
dose O
and O
mitogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
inhibit O
or O
stimulate O
lymphocyte O
proliferative O
response O
in O
vitro O
. O

Another O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
the O
estrogen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
delayed B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
type I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
hypersensitivity I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
response I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
broad B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
review I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
given O
of O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
estrogen I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
lymphoid B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
immune B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Most B_NUMBER[MEASURE]/B_PERSON
of O
the O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
published O
so O
far O
are O
phenomenological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
the O
recent O
description O
of O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
thymus O
and O
in O
some O
lymphocyte O
subpopulations O
, O
as O
well O
as O
a O
deeper O
understanding O
of O
regulating O
factors O
in O
the O
immune O
system O
, O
open O
the O
possibility O
of O
a O
more O
detailed O
understanding O
of O
the O
estrogen O
mechanism O
of O
interference O
. O

estrogen B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
adults B_PERSON/B_BIO
are O
reversible B_DISEASE_ADJECTIVE[DISEASE]
. O

After O
treating O
neonatal B_PERSON/B_DISEASE
mice I_PERSON/I_DISEASE
with O
the O
synthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
estrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diethylstilbestrol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DES B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
disturbances B_DISEASE_ADJECTIVE[DISEASE]
are O
induced O
in O
lymphocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
populations I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
lymphocyte B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
are O
permanent B_DISEASE_ADJECTIVE[DISEASE]
and O
irreversible B_DISEASE_ADJECTIVE[DISEASE]
. O

Lymphocytes O
from O
adult O
, O
neonatally O
DES-treated O
female O
mice O
have O
a O
reduced O
mitogen O
response O
to O
ConA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
T B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mitogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
the O
delayed O
type O
hypersensitivity O
response O
is O
depressed O
. O

A O
detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O
a O
decreased O
T B_DISEASE/B_MEASURE
helper I_DISEASE/I_MEASURE
cell I_DISEASE/I_MEASURE
population I_DISEASE/I_MEASURE
. O

The O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Natural B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
killer I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O
permanently O
reduced O
and O
this O
functional B_DISEASE_ADJECTIVE[DISEASE]
impairment I_DISEASE_ADJECTIVE[DISEASE]
is O
related O
to O
a O
decreased O
number B_MEASURE
of O
these O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
in O
turn B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determined O
at O
the O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
marrow I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
level I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O

The O
same B_PERSON/B_ENT
animals I_PERSON/I_ENT
have O
an O
increased O
sensitivity B_DISEASE/B_MEASURE
to O
chemical B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carcinogens B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
methylcholanthrene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
) O
and O
they O
spontaneously O
develop O
epithelial B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
uterine B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cervix I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
which O
morphologically O
are O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
adenocarcinoma B_DISEASE
. O

The O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
estrogen-associated B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
malignancy I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
estrogen B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
lymphocyte B_PERSON/B_DISEASE
functions I_PERSON/I_DISEASE
deserves O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
affecting O
the O
hormonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
normal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
leukaemic B_DISEASE/B_PERSON
peripheral I_DISEASE/I_PERSON
leucocytes I_DISEASE/I_PERSON
. O

The O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigated O
the O
behaviour B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
uptake I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
leukaemic B_DISEASE
cells I_DISEASE
( O
CML B_DISEASE/B_LOCATION
, O
CLL B_DISEASE/B_LOCATION
, O
AML B_DISEASE
, O
All O
) O
, O
in O
basal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conditions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
after O
incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
modify O
the O
cellular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cAMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
PGE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
PGF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
leukaemic B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
cells I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O
an O
alteration B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
incorporation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

This O
alteration O
was O
scarcely O
modified O
by O
incubation O
with O
theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
which O
increases O
cellular O
concentration O
of O
Camp O
. O

On O
the O
other B_PERSON/B_MEASURE
hand I_PERSON/I_MEASURE
, O
it O
was O
moderately O
counteracted O
by O
thioproline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
was O
evidently O
inhibited O
by O
flurbiprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
also O
reduced O
cellular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
prostaglandins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
particularly O
PGE2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
with O
the O
exception B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
PGF2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
which O
showed O
a O
poor B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
in O
the O
behavior B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
hormonal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uptake I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CML B_DISEASE
, O
in O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
that O
of O
AML B_DISEASE/B_LOCATION
, O
CLL B_DISEASE
and O
All O
peripheral B_LOCATION
leucocytes I_LOCATION
. O

Human B_DISEASE
breast I_DISEASE
cancer I_DISEASE
and O
impaired B_DISEASE
NK I_DISEASE
cell I_DISEASE
function I_DISEASE
. O

Recent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
advances I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
tumor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunology I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
led O
to O
the O
discovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
a O
new B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphoid B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
unique B_DISEASE
antitumor I_DISEASE
activity I_DISEASE
. O

Natural B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
killer I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O
NK B_PROTEIN[GENE]/B_LOCATION
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
form O
an O
antitumor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
surveillance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
appear O
to O
be O
vital B_DISEASE_ADJECTIVE[DISEASE]
in O
preventing O
tumor B_DISEASE
growth I_DISEASE
and O
metastasis B_DISEASE/B_ORGANISM_FUNCTION
in O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

We O
studied O
NK B_DISEASE_ADJECTIVE[DISEASE]
activity I_DISEASE_ADJECTIVE[DISEASE]
in O
patients B_PERSON/B_BIO
with O
benign B_DISEASE_ADJECTIVE[DISEASE]
and O
malignant B_DISEASE
breast I_DISEASE
disease I_DISEASE
, O
using O
a O
chromium-51 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
release I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
microtiter I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cytotoxicity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
K562 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
as O
targets B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Compared O
with O
benign B_PERSON/B_BIO
controls I_PERSON/I_BIO
, O
patients B_PERSON/B_BIO
with O
malignancies B_DISEASE
had O
significantly O
depressed O
NK B_DISEASE_ADJECTIVE[DISEASE]
-mediated I_DISEASE_ADJECTIVE[DISEASE]
lysis I_DISEASE_ADJECTIVE[DISEASE]
( O
P B_MEASURE
less I_MEASURE
than O
0.01 B_MEASURE
) O
. O

Furthermore O
, O
lysis B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
those O
with O
advanced B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
disease I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
stages B_TIME[MEASURE]/B_PROTEIN[GENE]
II I_TIME[MEASURE]/I_PROTEIN[GENE]
, O
III B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
, O
and O
IV B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
) O
was O
significantly O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
in O
those O
with O
limited B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
disease I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
stage B_LOCATION
I I_LOCATION
) O
( O
P B_MEASURE
less I_MEASURE
than O
0.01 B_MEASURE
) O
. O

NK B_DISEASE_ADJECTIVE[DISEASE]
activity I_DISEASE_ADJECTIVE[DISEASE]
was O
not O
correlated O
to O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
progesterone O
receptor B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
states I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

Positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
correlation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
a O
depressed B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
natural B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
killer B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activity B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
with O
the O
extent B_DISEASE/B_MEASURE
of O
tumor B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
spread I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
supports O
the O
concept B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
an O
NK B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
immune B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
surveillance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
breast B_DISEASE
cancer I_DISEASE
and O
emphasizes O
its O
importance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
malignancy B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

immunosuppressive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
progesterone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O
pregnancy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
depends O
on O
the O
progesterone B_MEASURE/B_LOCATION
binding I_MEASURE/I_LOCATION
capacity I_MEASURE/I_LOCATION
of O
the O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

cytotoxic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
progesterone B_MEASURE/B_LOCATION
binding I_MEASURE/I_LOCATION
capacity I_MEASURE/I_LOCATION
of O
the O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
together O
with O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
progesterone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
concentrations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
were O
determined O
in O
women B_PERSON/B_ORGANIZATION
with O
normal B_DISEASE/B_ORGANISM_FUNCTION
pregnancy I_DISEASE/I_ORGANISM_FUNCTION
or O
with O
a O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
threatened B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
abortion I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
or O
threatened O
premature B_ORGANISM_FUNCTION/B_DISEASE
labour I_ORGANISM_FUNCTION/I_DISEASE
. O

The O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
women B_PERSON
with O
threatened B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
abortion I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
or O
threatened O
premature B_ORGANISM_FUNCTION/B_DISEASE
labour I_ORGANISM_FUNCTION/I_DISEASE
showed O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
cytotoxic B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
activity B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0.001 B_MEASURE
) O
and O
significantly O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
progesterone I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
binding I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
capacity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0.001 B_MEASURE
) O
than O
did O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O
from O
the O
healthy B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
pregnant B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
women B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
. O

significant B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inverse I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
between O
progesterone B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cytotoxic B_MEASURE
activity I_MEASURE
of O
the O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
P B_MEASURE
less I_MEASURE
than O
0.001 B_MEASURE
) O
, O
but O
the O
progesterone B_MEASURE/B_LOCATION
concentration I_MEASURE/I_LOCATION
of O
the O
pregnancy B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O
to O
have O
no O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
two I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicate O
that O
intact B_MEASURE/B_DISEASE
progesterone B_MEASURE/I_DISEASE
binding B_MEASURE/I_DISEASE
capacity B_MEASURE/I_DISEASE
of O
the O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
an O
essential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
factor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
for O
the O
manifestation B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
blocking O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
exerted O
by O
pregnancy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
serum I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
lymphocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
cytotoxicity B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_ORGANISM_FUNCTION
in O
vitro B_SPECIES[BIO]/B_LOCATION
. O

serum O
sex O
steroid O
and O
peptide O
hormone O
concentrations O
, O
and O
endometrial O
estrogen O
and O
progestin O
receptor O
levels O
during O
administration O
of O
human B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leukocyte I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interferon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Five O
normally O
cycling O
healthy O
women O
were O
given O
daily O
subcutaneous O
injections O
of O
human B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leukocyte I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interferon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
3 O
X O
10 O
( O
6 O
) O
units/day O
) O
from O
the O
3rd O
through O
23rd O
day O
of O
the O
menstrual O
cycle O
, O
and O
serum O
steroid O
and O
peptide O
hormone O
concentrations O
monitored O
at O
3-day O
intervals O
during O
the O
treatment O
and O
the O
preceding O
control O
cycle O
. O

concentrations O
of O
cytosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nuclear I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
estrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
ERC B_LOCATION/B_ORGANIZATION
and O
ERN B_LOCATION/B_ORGANIZATION
, O
respectively O
) O
and O
progestin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PRC B_LOCATION
and O
PRN B_LOCATION/B_ORGANIZATION
) O
were O
also O
measured O
from O
endometrial O
biopsies O
taken O
on O
the O
24th O
day O
of O
the O
control O
and O
treatment O
cycle O
. O

In O
addition B_MEASURE/B_LOCATION
, O
an O
extensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monitoring I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chemical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
hematological B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
blood B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
performed O
. O

serum O
estradiol O
and O
progesterone O
concentrations O
were O
significantly O
decreased O
during O
the O
treatment O
cycle O
, O
suggesting O
that O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interacts O
in O
vivo O
with O
the O
function O
of O
both O
FSH O
and O
LH O
. O

No O
significant O
changes O
were O
observed O
in O
the O
serum O
peptide O
hormone O
concentrations O
measured O
( O
FSH O
, O
LH O
, O
prolactin O
, O
insulin O
, O
growth O
hormone O
and O
TSH O
) O
; O
neither O
were O
the O
levels O
of O
endometrial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ERC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ERN I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
PRC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
PRN I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
affected O
by O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O
. O

As O
expected O
, O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
resulted O
in O
decreased O
leukocyte O
counts O
. O

Moreover O
, O
an O
increasing O
tendency O
in O
the O
activities O
of O
serum B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
alkaline I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
gamma-glutamyltransferase B_GENE
during O
the O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
shows O
that O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
may O
slightly O
interfere O
with O
the O
liver O
function O
. O

These O
results O
suggest O
that O
one O
of O
the O
mechanisms O
by O
which O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O
may O
affect O
the O
growth O
of O
hormone-dependent O
neoplasms O
could O
be O
the O
interaction O
with O
production O
and/or O
function O
of O
circulating O
hormonal O
compounds O
. O

[ O
Glucocorticoid B_GENE
receptor I_GENE
level O
in O
the O
blood O
leukocytes O
in O
different O
acute O
diseases O
] O
. O

Content O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
cytosol O
of O
blood O
leukocytes O
, O
concentration O
of O
cortisol O
and O
amount O
of O
leukocytes O
in O
blood O
were O
studied O
in O
20 O
patients O
with O
acute O
impairments O
within O
the O
second O
day O
of O
the O
disease O
. O

content B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
cytosol B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
blood B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
leukocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O
studied O
using O
3H-triamcinolone B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

distinct O
increase O
in O
amount O
of O
the O
leukocyte B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
in O
patients O
with O
poisoning O
by O
dichlorethane O
and O
hypnotic O
drugs O
under O
conditions O
of O
acute O
myocardial O
infarction O
. O

In O
acute O
pancreatitis O
content O
of O
the O
leukocyte B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
receptors B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
not O
altered O
as O
compared O
with O
controls O
. O

concentration B_MEASURE/B_ENT
of O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cortisol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
increased O
in O
blood B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
all O
the O
patients B_PERSON/B_BIO
, O
except O
of O
the O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
acetate B_DISEASE/B_PERSON
intoxication I_DISEASE/I_PERSON
. O

Reverse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
observed O
between O
concentration B_MEASURE/B_LOCATION
of O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
blood B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
content B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
leukocytes B_BODY_PART_OR_ORGAN_COMPONENT
. O

But O
in O
the O
patients O
with O
acute O
pancreatitis O
the O
decrease O
in O
content O
of O
leukocyte B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
not O
observed O
although O
there O
was O
an O
increase O
in O
cortisol O
concentration O
in O
blood O
. O

The O
role O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
immunological O
processes O
under O
conditions O
of O
purulent O
complications O
and O
possibility O
to O
regulate O
the O
metabolism O
in O
leukocytes O
. O

therapeutic O
concentrations O
of O
glucocorticoids O
suppress O
the O
antimicrobial O
activity O
of O
human O
macrophages O
without O
impairing O
their O
responsiveness O
to O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

By O
exposing O
human B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
blood-derived O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
alveolar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
to O
dexamethasone O
, O
we O
showed O
in O
these O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
that O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
markedly O
suppress O
the O
antimicrobial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
but O
not O
macrophage O
activation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
by O
lymphokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

As O
little B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
2.5 B_MEASURE
X I_MEASURE
10 I_MEASURE
( O
-8 O
) O
mol/liter B_MEASURE/B_LOCATION
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prevented O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
from O
inhibiting O
germination B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_BIO
of O
Aspergillus B_BIO
spores I_BIO
or O
from O
eliminating O
ingested B_BIO/B_DISEASE
bacteria I_BIO/I_DISEASE
such I_BIO/I_DISEASE
as O
Listeria B_BACTERIUM[BIO]
, O
Nocardia B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O
or O
Salmonella B_BACTERIUM[BIO]
. O

damage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
macrophage B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
inhibited O
by O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
appeared O
to O
be O
receptor-mediated O
. O

In O
accordance B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
observations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
required O
24-36 B_MEASURE
h O
to O
suppress O
antimicrobial B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

While O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interfered O
with O
base-line B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
comparable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
patients B_PERSON/B_BIO
had O
no O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
macrophage B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Proliferating O
lymphocytes O
and O
gamma-interferon B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thus O
increased O
the O
antimicrobial O
activity O
of O
phagocytes O
exposed O
to O
glucocorticoids O
over O
that O
of O
control O
cells O
. O

Macrophage O
activation O
and O
correction O
of O
the O
dexamethasone O
effect O
by O
gamma-interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
however O
, O
was O
dependent O
on O
the O
pathogen O
. O

The O
lymphokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enhanced O
the O
antimicrobial O
activity O
of O
dexamethasone-treated O
macrophages O
against O
Listeria O
and O
Salmonella O
but O
not O
against O
Aspergillus O
or O
Nocardia O
. O

Dexamethasone-induced B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
antimicrobial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
vitro B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parallels O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
glucocorticoids O
render B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
laboratory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
susceptible I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
listeriosis B_DISEASE/B_BACTERIUM[BIO]
and O
aspergillosis B_DISEASE
by O
damaging B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resident B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
macrophages B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

suppression O
of O
macrophage O
antimicrobial O
activity O
should O
thus O
be O
considered O
when O
treating O
patients O
with O
glucocorticoids O
; O
its O
prevention O
by O
gamma-interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O
be O
beneficial O
for O
some O
but O
not O
all O
pathogens O
. O

Interleukin B_GENE
2 I_GENE
receptor I_GENE
( O
Tac B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
expression O
in O
HTLV-I-associated O
adult O
T-cell O
leukemia O
. O

Interleukin-2 B_GENE
( O
IL-2 B_GENE
) O
is O
a O
lymphokine B_GENE
synthesized O
by O
some O
T-cells O
following O
activation O
. O

resting O
T-cells O
do O
not O
express O
IL-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
receptors O
are O
rapidly O
expressed O
on O
T-cells O
following O
interaction O
of O
antigens O
, O
mitogens O
, O
or O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O
the O
antigen-specific B_GENE
T-cell I_GENE
receptor I_GENE
complex I_GENE
. O

Using O
anti-Tac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
recognizes O
the O
IL-2 B_GENE
receptor I_GENE
, O
the O
receptor O
has O
been O
purified O
and O
shown O
to O
be O
a O
Mr O
33 O
, O
000 O
peptide O
that O
is O
posttranslationally O
glycosylated O
to O
a O
Mr O
55 O
, O
000 O
mature O
form O
. O

Normal O
resting O
T-cells O
and O
most O
leukemic O
T-cell O
populations O
do O
not O
express O
IL-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O
however O
, O
the O
leukemic O
cells O
of O
the O
11 O
patients O
examined O
who O
had O
human O
T-cell O
lymphotropic O
virus-associated O
adult O
T-cell O
leukemia O
expressed O
the O
Tac B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
human O
T-cell O
lymphotropic O
virus-I O
infected O
cells O
, O
the O
Mr O
42 O
, O
000 O
long O
open B_GENE
reading I_GENE
frame I_GENE
protein I_GENE
encoded O
in O
part O
by O
the O
pX B_GENE
region I_GENE
of O
this O
virus O
may O
act O
as O
a O
transacting B_GENE
transcriptional I_GENE
activator I_GENE
that O
induces O
IL-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription O
, O
thus O
providing O
an O
explanation O
for O
the O
constant O
association O
of O
IL-2 B_GENE
receptor I_GENE
expression O
with O
adult O
T-cell O
lymphotropic O
virus-I O
infection O
of O
lymphoid O
cells O
. O

The O
constant O
expression O
of O
large O
numbers O
of O
IL-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
may O
be O
aberrant O
may O
play O
a O
role O
in O
the O
uncontrolled O
growth O
of O
adult O
T-cell O
leukemia O
cells O
. O

Two O
patients O
with O
Tac-positive O
adult O
T-cell O
leukemia O
have O
been O
treated O
with O
the O
anti-Tac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

One O
of O
the O
patients O
had O
6- O
and O
3-mo O
remissions O
of O
his O
leukemia O
following O
two O
courses O
of O
therapy O
with O
this O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
directed O
toward O
this O
growth B_PROTEIN[GENE]/B_DISEASE
factor I_PROTEIN[GENE]/I_DISEASE
receptor I_PROTEIN[GENE]/I_DISEASE
. O

Lymphocyte O
glucocorticoid B_GENE
receptor I_GENE
binding O
in O
depressed O
patients O
with O
hypercortisolemia O
. O

Despite O
elevated O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
serum B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
urinary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
patients B_PERSON
with O
depressive B_DISEASE/B_LOCATION
illness I_DISEASE/I_LOCATION
manifest O
none B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stigmata I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
glucocorticoid B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excess I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
hypercortisolemia O
in O
the O
absence O
of O
clinical O
effects O
suggests O
a O
state O
of O
hormone O
resistance O
and O
could O
be O
mediated O
by O
alterations O
in O
the O
glucocorticoid B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
receptor I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
. O

Earlier O
studies O
have O
shown O
that O
small O
doses O
of O
glucocorticoids O
cause O
a O
decrease O
in O
glucocorticoid B_GENE
receptor I_GENE
binding O
in O
normal O
human O
lymphocytes O
. O

White B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
depressed B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
significant B_DISEASE/B_LOCATION
hypercortisolemia I_DISEASE/I_LOCATION
would O
be O
expected O
to O
show O
a O
similar B_MEASURE
change I_MEASURE
in O
receptor B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
if O
peripheral B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tissues I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
adequately O
exposed O
to O
and O
sensitive B_DISEASE
to O
the O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O
compared O
the O
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dexamethasone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
normal B_PERSON/B_MEASURE
subjects I_PERSON/I_MEASURE
and O
depressed B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
hypercortisolemia B_DISEASE/B_LOCATION
. O

lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
normal B_PERSON/B_BIO
subjects I_PERSON/I_BIO
had O
a O
mean B_MEASURE
receptor I_MEASURE
concentration I_MEASURE
of O
10.2 B_NUMBER[MEASURE]
+/- I_NUMBER[MEASURE]
0.66 I_NUMBER[MEASURE]
fm/10 I_NUMBER[MEASURE]
( O
6 B_MEASURE/B_LOCATION
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
S.E.M B_MEASURE/B_PERSON
. O
) O
and O
a O
dissociation B_MEASURE
constant I_MEASURE
of O
4.8 B_MEASURE
+/- I_MEASURE
0.47 I_MEASURE
nm I_MEASURE
. O

lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
from O
depressed B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
abnormal B_MEASURE
0800 I_MEASURE
h O
serum B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cortisol I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
had O
a O
mean B_MEASURE/B_PERSON
receptor I_MEASURE/I_PERSON
concentration I_MEASURE/I_PERSON
of O
8.8 B_MEASURE
+/- I_MEASURE
0.75 I_MEASURE
fm/10 I_MEASURE
( O
6 B_NUMBER[MEASURE]
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
which O
was O
not O
significantly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
that O
in O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
from O
normal B_PERSON/B_MEASURE
subjects I_PERSON/I_MEASURE
or O
from O
depressed B_PERSON/B_BIO
subjects I_PERSON/I_BIO
with O
normal B_DISEASE
post-dexamethasone I_DISEASE
cortisol I_DISEASE
levels I_DISEASE
( O
9.4 B_MEASURE
+/- I_MEASURE
0.95 I_MEASURE
fm/10 I_MEASURE
( O
6 B_NUMBER[MEASURE]
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
) O
. O

lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
depressed B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
elevated B_DISEASE/B_LOCATION
urinary I_DISEASE/I_LOCATION
free I_DISEASE/I_LOCATION
cortisol I_DISEASE/I_LOCATION
excretion I_DISEASE/I_LOCATION
( O
UFC B_ORGANIZATION/B_LOCATION
) O
also O
had O
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concentration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
binding B_MEASURE
affinity I_MEASURE
for O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
lack O
of O
a O
change O
in O
lymphocyte O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
concentration O
in O
the O
presence O
of O
cortisol O
excess O
suggests O
the O
possibility O
that O
hypercortisolemia O
in O
depressive O
illness O
represents O
a O
state O
of O
peripheral O
glucocorticoid O
resistance O
. O

Structure O
and O
regulation O
of O
the O
glucocorticoid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hormone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
glucocorticoid B_GENE/B_LOCATION
receptor I_GENE/I_LOCATION
is O
an O
intracellular B_PROTEIN[GENE]/B_BIO
protein I_PROTEIN[GENE]/I_BIO
which O
possesses O
three O
distinct O
domains O
, O
one O
that O
binds O
agonist O
and O
antagonist O
steroids O
, O
one O
that O
binds O
DNA O
, O
and O
one O
that O
binds O
anti-receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
is O
required O
for O
glucocorticoid O
modulation O
of O
gene O
expression O
. O

In O
intact B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
receptor B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
, O
affinity B_GENE/B_MEASURE
and O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
can O
change O
in O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
factors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
bind O
to O
the O
receptor B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
or O
that O
act B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indirectly O
through O
ill-defined B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
may O
include O
resumption B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
arrest B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
cycling B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
variations B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
intracellular B_MEASURE/B_DISEASE
calcium I_MEASURE/I_DISEASE
ion I_MEASURE/I_DISEASE
concentrations I_MEASURE/I_DISEASE
. O

Some O
of O
these O
factors O
appear O
to O
exert O
their O
effect O
by O
controlling O
critical O
receptor O
properties O
such O
as O
ATP-dependent O
phosphorylation O
, O
integrity O
of O
thiol B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
exposure O
of O
key B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amino I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
residues I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
agonists I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
promote O
the O
'transformation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O
of O
the O
receptor B_GENE
into O
the O
DNA-binding B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
state B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
which O
is O
competent B_DISEASE_ADJECTIVE[DISEASE]
for O
modulating O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Glucocorticoid O
antagonists O
are O
steroids O
that O
interact O
with O
the O
receptor O
but O
either O
fail O
to O
produce O
a O
stable B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
complex B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
or O
produce O
a O
stable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
but I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inefficient I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
complex I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
substituent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O
confer O
agonist B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
antagonist B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
identified O
, O
the O
molecular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
determinants I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
this O
difference B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
receptor B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
remain O
unknown B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

Most B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
receptor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
accommodated O
by O
postulating O
the O
existence B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
an O
intracellular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
involves O
five B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
states I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
the O
receptor B_GENE
. O

The O
active B_GENE
free I_GENE
receptor I_GENE
is O
phosphorylated O
, O
reduced O
, O
and O
presumably O
oligomeric B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
( O
state B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Following O
binding B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
an O
agonist B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
state B_LOCATION/B_MEASURE
B I_LOCATION/I_MEASURE
) O
, O
it O
can O
become O
transformed O
by O
dissociation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
into O
its O
subunits B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
dephosphorylation B_ENZYME[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
state B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
transformed B_GENE
receptor I_GENE
then O
interacts O
with O
chromatin B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
state O
D O
) O
. O

Dissociation O
of O
the O
steroid O
and O
oxidation O
of O
receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thiol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
s O
) O
lead O
to O
the O
inactive O
receptor O
form O
( O
state O
E O
) O
. O

Reduction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
rephosphorylation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
the O
receptor B_GENE
enable O
it O
to O
bind O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
again O
so O
that O
the O
cycle B_TIME[MEASURE]/B_LOCATION
is O
closed O
. O

Thermodynamics O
of O
steroid O
binding O
to O
the O
human B_GENE
glucocorticoid I_GENE
receptor I_GENE
. O

The O
thermodynamics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O
their O
receptor B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
studied O
in O
cytosol B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoblastoid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
rate B_MEASURE
and O
affinity B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constants B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
0 B_MEASURE
degree I_MEASURE
and O
25 B_MEASURE
degrees I_MEASURE
C I_MEASURE
were O
calculated O
by O
curve-fitting O
from O
time-course B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
equilibrium B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
kinetics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
with O
a O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reversible I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
bimolecular I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Arrhenius B_PERSON/B_LOCATION
and O
VA B_DISEASE/B_MEASURE
n't O
Hoff B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
plots I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
curvilinear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
both O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

At O
equilibrium B_MEASURE/B_LOCATION
, O
the O
solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
the O
equation B_MEASURE/B_PROTEIN[GENE]
delta B_MEASURE/I_PROTEIN[GENE]
G B_MEASURE/I_PROTEIN[GENE]
= O
delta B_MEASURE/B_PROTEIN[GENE]
H I_MEASURE/I_PROTEIN[GENE]
- O
T B_MEASURE/B_GENE
X I_MEASURE/I_GENE
delta I_MEASURE/I_GENE
S I_MEASURE/I_GENE
( O
eqn B_MEASURE/B_LOCATION
. O
1 B_MEASURE/B_LOCATION
) O
was O
( O
in O
kJ B_MEASURE
X I_MEASURE
mol-1 I_MEASURE
) O
-47 O
= O
36 B_MEASURE
- O
83 B_MEASURE
( O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
-42 O
= O
-9 O
- O
33 B_MEASURE
( O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
at O
0 B_MEASURE/B_LOCATION
degree I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
. O

Enthalpy B_MEASURE/B_LOCATION
and O
entropy B_MEASURE
changes I_MEASURE
decreased O
quasi-linearly O
with O
temperature B_MEASURE
such I_MEASURE
that O
, O
at O
25 B_MEASURE
degrees I_MEASURE
C I_MEASURE
, O
the O
respective B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
-50 B_MEASURE
= O
-75 O
+ B_MEASURE
25 I_MEASURE
and O
-43 B_MEASURE
= O
-48 O
+ O
5 B_MEASURE
. O

Thus O
, O
for O
both O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
entropy-driven B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
at O
low B_MEASURE
temperature I_MEASURE
and O
became O
entirely O
enthalpy-driven B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
at O
20 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
. O

Thermodynamic B_MEASURE/B_LOCATION
values B_MEASURE/I_LOCATION
for O
the O
transition B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
state I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
calculated O
from O
the O
rate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constants I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
the O
forward B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reaction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
eqn O
. O
( O
1 B_MEASURE
) O
gave O
45 B_MEASURE
= O
84 B_MEASURE
- O
39 B_MEASURE
( O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
46 B_MEASURE
= O
60 B_MEASURE
- O
14 B_MEASURE
( O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
at O
0 B_MEASURE/B_LOCATION
degree I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
, O
and O
44 B_MEASURE
= O
24 B_MEASURE
+ I_MEASURE
20 I_MEASURE
( O
dexamethasone O
) O
and O
46 B_MEASURE
= O
28 B_MEASURE
+ I_MEASURE
18 I_MEASURE
( O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
at O
25 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fit O
quite O
well O
with O
a O
two-step B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ross I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
& O
Subramanian B_PERSON
( O
1981 B_MEASURE
) O
Biochemistry B_MEASURE
20 I_MEASURE
, O
3096-3102 B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
proposed O
for O
ligand-protein B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
involves O
a O
partial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
immobilization I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
reacting O
species B_BIO/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
governed O
by O
hydrophobic B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
forces I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
followed O
by O
stabilization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
complex B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
short-range B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

On O
the O
basis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
this O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
an O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
transition-state B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
thermodynamics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
led O
to O
the O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
no O
more B_MEASURE
than O
half B_MEASURE/B_LOCATION
of O
the O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
area I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
engaged O
in O
the O
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
process I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Cell O
cycle-related O
changes O
in O
number O
of O
T-lymphocyte B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O
glucocorticoids O
and O
insulin O
. O

Enriched O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T-lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
stimulated O
with O
PHA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
examined O
for O
variations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
receptor B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numbers B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
the O
early B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
phases I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cycle I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

cells O
in O
G0 O
, O
G1a O
and O
G1b O
phases O
, O
where O
the O
G1a O
- O
G1b O
transition O
is O
an O
Interleukin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent O
event O
, O
were O
quantitated O
by O
flow O
cytometry O
. O

Few O
but O
significant O
numbers O
of O
glucocorticoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2700/cell O
) O
and O
no O
insulin B_GENE
receptors I_GENE
( O
-1/cell O
) O
were O
found O
in O
the O
resting O
( O
G0 O
) O
phase O
. O

As O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
entered O
the O
G1a B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
the O
specific B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increased O
and O
of O
insulin B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
took O
place B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Although O
the O
specific B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
binding I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
further O
increased O
as O
T-cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
entered O
the O
G1b B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
as O
measured O
at O
44 B_MEASURE
h O
of O
incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
and O
using O
hydroxyurea-treated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
the O
major B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
changes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
specific B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
binding I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
took O
place B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
during O
the O
period B_TIME[MEASURE]
16 I_TIME[MEASURE]
- O
20 B_MEASURE
h I_MEASURE
after O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
. O

Based O
on O
these O
findings O
, O
it O
is O
concluded O
that O
both O
receptor O
types O
( O
cell B_PROTEIN[GENE]/B_LOCATION
membrane I_PROTEIN[GENE]/I_LOCATION
and I_PROTEIN[GENE]/I_LOCATION
cytoplasmic I_PROTEIN[GENE]/I_LOCATION
receptors I_PROTEIN[GENE]/I_LOCATION
) O
are O
being O
formed O
and O
increased O
at O
G1 O
phase O
prior O
to O
cell O
proliferation O
, O
indicating O
the O
importance O
of O
G1 O
phase O
in O
immunoregulation O
. O

Glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
cortico-sensitivity O
in O
a O
human O
clonal O
monocytic O
cell O
line O
, O
CM-SM O
. O

CM-SM B_DISEASE/B_PROTEIN[GENE]
is O
a O
clonal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
line I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
of O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
precursor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
mononuclear I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
phagocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
inducible I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
to O
macrophage O
differentiation B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
tumor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phorbol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ester I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
12-O-tetradecanoyl-phorbol-13-acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
TPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
. O

untreated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
CM-SM I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
contain O
single B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
high-affinity B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
( O
KD B_DISEASE/B_PROTEIN[GENE]
= O
4.0 B_MEASURE/B_LOCATION
X I_MEASURE/I_LOCATION
10 I_MEASURE/I_LOCATION
( O
-9 O
) O
M B_OTHER/B_MEASURE
) O
glucocorticoid-specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
approximately O
60 B_MEASURE
, O
000 B_MEASURE
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
) O
, O
as O
measured O
by O
a O
whole B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
at O
37 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
, O
using O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triamcinolone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
CM-SM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
to O
dexamethasone O
( O
DEX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
produced O
a O
progressive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
dose- B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
time-related B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
CM-SM B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cell B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
growth B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
saturation B_MEASURE
density I_MEASURE
, O
morphology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
properties B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
with O
half-maximal B_MEASURE/B_LOCATION
effects I_MEASURE/I_LOCATION
at O
about O
10 B_MEASURE
( O
-9 O
) O
M B_MEASURE/B_OTHER
for O
DEX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

TA-receptor B_GENE
sites I_GENE
rapidly O
decreased O
( O
about O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
after O
DEX B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
without O
any O
apparent B_DISEASE_ADJECTIVE[DISEASE]
change I_DISEASE_ADJECTIVE[DISEASE]
in O
steroid B_MEASURE/B_LOCATION
specificity I_MEASURE/I_LOCATION
and O
affinity B_GENE/B_MEASURE
. O

After O
5 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
culture B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
with O
a O
saturating B_MEASURE
concentration I_MEASURE
( O
3.6 B_MEASURE/B_LOCATION
X I_MEASURE/I_LOCATION
10 I_MEASURE/I_LOCATION
( O
-8 O
) O
M B_MEASURE
) O
of O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
reached O
a O
saturation B_MEASURE/B_LOCATION
density I_MEASURE/I_LOCATION
of O
about O
9.0 B_NUMBER[MEASURE]
X I_NUMBER[MEASURE]
10 I_NUMBER[MEASURE]
( O
6 B_MEASURE
) O
viable B_MEASURE/B_LOCATION
cells/ml I_MEASURE/I_LOCATION
( O
about O
4.0 B_NUMBER[MEASURE]
X I_NUMBER[MEASURE]
10 I_NUMBER[MEASURE]
( O
6 B_MEASURE
) O
viable B_MEASURE/B_LOCATION
cells/ml I_MEASURE/I_LOCATION
in O
the O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
while O
the O
modal B_MEASURE/B_LOCATION
volume I_MEASURE/I_LOCATION
of O
the O
resulting O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
approximately O
60 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
, O
as O
compared O
to O
the O
volume B_MEASURE
of O
untreated B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

DEX-treated B_PERSON/B_BIO
cells I_PERSON/I_BIO
appeared O
less O
differentiated B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
than O
controls B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
assessed O
by O
combined O
morphologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
antigenic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
cytoenzymatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analyses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Dex O
almost O
completely O
inhibited O
TPA O
activation O
of O
the O
following O
macrophage O
functions O
: O
adherency O
to O
the O
culture O
plate O
, O
expression O
of O
lysosomal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzymes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
Fc B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
C3 B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
receptors B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
and O
stimulation O
of O
phagocytosis O
. O

After O
removal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
DEX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O
within O
a O
few B_TIME[MEASURE]/B_LOCATION
passages I_TIME[MEASURE]/I_LOCATION
, O
returned O
to O
a O
state B_MEASURE
apparently O
identical B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
untreated B_PERSON/B_MEASURE
controls I_PERSON/I_MEASURE
and O
could O
be O
induced O
to O
macrophage O
differentiation B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
TPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Acute B_DISEASE
lymphoblastic I_DISEASE
leukemia I_DISEASE
in O
children B_PERSON/B_LOCATION
: O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
controversies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perspective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Disease-free B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
survival I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
DFS B_DISEASE
) O
in O
childhood B_PERSON/B_MEASURE
All O
is O
60 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
and O
survival B_MEASURE/B_DISEASE
in O
good B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
average B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
poor B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
prognostic I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
groups I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
defined O
by O
initial B_MEASURE/B_PERSON
WBC B_MEASURE/I_PERSON
and O
age B_GENE
is O
90 B_MEASURE
, O
60 B_MEASURE
, O
and O
45 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
respectively O
. O

Additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
immunological I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
morphological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
cytokinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
cytogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
have O
been O
identified O
, O
illustrating O
the O
heterogeneity B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
All O
and O
its O
derivation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
from O
malignant B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
clones B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O
various B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
stages I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
differentiation B_ORGANISM_FUNCTION/B_DISEASE
and O
with O
varying O
rates B_MEASURE/B_LOCATION
of O
proliferation B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Of O
biologic B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
importance I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
these O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
may O
refine O
further B_LOCATION
the O
characteristic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
features I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
clinically-determined B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognostic I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Multivariate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
large B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
prospective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
homogeneous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
will O
be O
required O
to O
determine O
the O
independent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
importance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
strategies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
in O
All O
include O
( O
1 B_SEQUENCE[MEASURE]/B_PERSON
) O
tailoring O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
its O
intensity B_MEASURE/B_PERSON
to O
prognostic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
groups I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
; O
( O
2 O
) O
multiple-drug O
combinations B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
induction B_PERSON
; O
( O
3 B_NUMBER[MEASURE]/B_LOCATION
) O
early B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
use I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
intrathecal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
IT O
) O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
; O
( O
4 B_NUMBER[MEASURE]
) O
CNS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
prophylaxis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
IT O
MTX O
alone O
in O
good B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
prognosis I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
patients I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
combined B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cranial I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
radiation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
CXRT B_LOCATION
) O
, O
1800 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
rads I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
plus O
IT O
MTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
average B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
poor B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
prognosis I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
patients I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
show O
a O
CNS B_MEASURE
relapse I_MEASURE
rate I_MEASURE
of O
5 B_MEASURE/B_DISEASE
% B_MEASURE/I_DISEASE
in O
all O
prognostic B_PERSON/B_LOCATION
groups I_PERSON/I_LOCATION
. O

Late B_DISEASE_ADJECTIVE[DISEASE]
neuropsychological I_DISEASE_ADJECTIVE[DISEASE]
defects I_DISEASE_ADJECTIVE[DISEASE]
caused O
by O
cranial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
XRT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PROTEIN[GENE]
and O
IT O
MTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
prompted O
programs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
designed O
to O
reduce O
the O
potential B_MEASURE
late I_MEASURE
toxicity I_MEASURE
of O
CNS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
prophylaxis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

More O
pronounced O
in O
younger B_PERSON/B_ENT
children I_PERSON/I_ENT
, O
these O
abnormalities B_DISEASE_ADJECTIVE[DISEASE]
include O
decreased O
IQ B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
visual-motor B_DISEASE
incoordination I_DISEASE
, O
poor B_DISEASE_ADJECTIVE[DISEASE]
performance I_DISEASE_ADJECTIVE[DISEASE]
in O
mathematics B_EDU[ORGANIZATION]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
memory B_DISEASE
dysfunction I_DISEASE
. O

Until O
1980 B_TIME[MEASURE]
, O
more O
intensive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
consolidation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
and O
maintenance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
had O
failed O
to O
prolong O
DFS B_DISEASE
in O
children B_PERSON/B_BIO
with O
a O
poor B_DISEASE
prognosis I_DISEASE
. O

In O
West B_LOCATION/B_MEASURE
Germany I_LOCATION/I_MEASURE
( O
Berlin-Frankfurt-Muenster B_MEASURE/B_LOCATION
protocol I_MEASURE/I_LOCATION
) O
a O
70 B_MEASURE/B_LOCATION
to O
75 B_MEASURE
% I_MEASURE
DFS I_MEASURE
is O
seen O
in O
all O
patients B_PERSON
regardless O
of O
initial B_MEASURE/B_DISEASE
WBC B_MEASURE/I_DISEASE
, O
suggesting O
that O
effective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
will O
override O
prognostic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Ultra-high-dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
MTX I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
without O
cranial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
radiation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
is O
also O
showing O
promise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
poor B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognosis I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
issues I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
include O
the O
optimal B_MEASURE
duration I_MEASURE
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
the O
role B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
testicular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biopsies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
prophylactic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
testicular I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
radiation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggest O
that O
prognostic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
lose O
their O
significance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
2 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
of O
continuous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
complete I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
remission I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
that O
2 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
years B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
maintenance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
adequate B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Bilateral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
open-wedge I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
testicular I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
biopsies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
identified O
occult B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
testicular I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
8 B_NUMBER[MEASURE]/B_LOCATION
to O
10 B_MEASURE
% I_MEASURE
of O
males B_PERSON
. O

A O
unified B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
children B_PERSON
with O
leukemia/lymphoma B_DISEASE/B_GENE
, O
a O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
a O
particularly O
poor B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
prognosis I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
utilizing O
NHL-type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
may O
be O
more O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
conventional B_LOCATION/B_RELIGION[SOCIAL_CIRCUMSTANCES]
All O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

( O
abstract B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRUNCATED I_MEASURE
AT O
400 B_LOCATION/B_PERSON
Words I_LOCATION/I_PERSON
) O
. O

Glucocorticoid B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
vitro O
sensitivity O
to O
steroid O
hormones O
in O
human O
lymphoproliferative O
diseases O
and O
myeloid O
leukemia O
. O

The O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GR B_PROTEIN[GENE]/B_DISEASE
) O
quantitation O
by O
a O
whole-cell O
assay O
and/or O
cytosol O
technique O
and O
the O
in O
vitro O
sensitivity O
to O
steroids O
have O
been O
assessed O
in O
peripheral O
blood O
cells O
from O
normal O
donors O
and O
patients O
with O
chronic O
lymphatic O
leukemia O
( O
CLL O
) O
, O
acute O
lymphoblastic O
leukemia O
( O
All O
) O
, O
lymphosarcoma O
cell O
leukemia O
( O
LSCL O
) O
, O
acute O
nonlymphatic O
leukemia O
( O
ANLL O
) O
, O
and O
chronic O
myeloid O
leukemia O
( O
CML O
) O
. O

Within O
the O
lymphoproliferative O
diseases O
, O
All O
cells O
exhibited O
the O
highest O
GR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O
( O
regardless O
of O
the O
method O
used O
) O
and O
the O
highest O
in O
vitro O
inhibition O
of O
spontaneous O
[ O
3H O
] O
thymidine O
( O
[ O
3H O
] O
TdR O
) O
uptake O
by O
glucocorticoids O
. O

A O
significant O
relationship O
between O
GR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O
( O
whole-cell O
assay O
) O
and O
in O
vitro O
sensitivity O
to O
dexamethasone O
was O
also O
found O
. O

On O
the O
contrary B_PERSON/B_MEASURE
, O
CLL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
presented O
the O
highest B_MEASURE/B_PERSON
sensitivity B_MEASURE/I_PERSON
to O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
PHA-stimulated B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
cell I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
cultures I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

Cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
from O
the O
only B_NUMBER[MEASURE]
two I_NUMBER[MEASURE]
All O
patients B_PERSON
who O
did O
not O
undergo O
a O
remission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
after O
glucocorticoid-inclusive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
had O
both O
the O
lowest B_MEASURE
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sensitivity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
the O
lowest B_MEASURE
GR I_MEASURE
concentration I_MEASURE
with O
whole-cell B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

concerning O
myeloid O
leukemia O
, O
ANLL O
patients O
had O
GR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentrations O
slightly O
higher O
than O
those O
found O
in O
the O
All O
group O
but O
exhibited O
the O
lowest O
degree O
of O
inhibition O
of O
spontaneous O
[ O
3H O
] O
TdR O
uptake O
by O
dexamethasone O
( O
stimulatory O
effects O
occurred O
in O
some O
cases O
) O
. O

CML B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
exhibited O
an O
inhibition B_MEASURE/B_DISEASE
degree B_MEASURE/I_DISEASE
by O
in O
vitro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
of O
ANLL B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
but O
not O
different B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
from O
that O
of O
lymphoproliferative B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
diseases B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

No O
clear B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationship I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
GR B_DISEASE_ADJECTIVE[DISEASE]
pattern I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cell I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
sensitivity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
clinicohematologic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
in O
myeloid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
leukemia-bearing O
patients B_PERSON/B_BIO
. O

Glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
vitro O
corticosensitivity O
of O
peanut-positive O
and O
peanut-negative O
human O
thymocyte O
subpopulations O
. O

In O
6 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thymus I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glands I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
immature B_MEASURE/B_GENE
subset I_MEASURE/I_GENE
of O
thymocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
was O
separated O
from O
the O
more O
mature B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
one B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O
by O
differential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peanut I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lectin I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agglutination I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
2 O
cell O
subpopulations O
were O
analyzed O
for O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O
by O
using O
a O
whole O
cell O
assay O
, O
with O
( O
3H O
) O
-triamcinolone O
acetonide O
as O
tracer O
. O

The O
unagglutinated B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
thymocytes I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O
peanut B_DISEASE_ADJECTIVE[DISEASE]
negative I_DISEASE_ADJECTIVE[DISEASE]
) O
contained O
about O
2 B_MEASURE/B_ORGANIZATION
times I_MEASURE/I_ORGANIZATION
more I_MEASURE/I_ORGANIZATION
receptor I_MEASURE/I_ORGANIZATION
sites I_MEASURE/I_ORGANIZATION
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
than O
agglutinated O
( O
peanut B_DISEASE_ADJECTIVE[DISEASE]
positive I_DISEASE_ADJECTIVE[DISEASE]
) O
ones B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
7650 B_PROTEIN[GENE]/B_LOCATION
+/- I_PROTEIN[GENE]/I_LOCATION
1550 I_PROTEIN[GENE]/I_LOCATION
S.D I_PROTEIN[GENE]/I_LOCATION
. O
verus B_MEASURE/B_PERSON
3195 I_MEASURE/I_PERSON
+/- O
896 B_MEASURE
S.D I_MEASURE
. O
) O
. O

The O
affinity B_GENE/B_MEASURE
for O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subsets B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
as O
was O
the O
stereospecificity B_MEASURE
for O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
time-course B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
steroid-receptor B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
association B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
cytoplasmic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
to O
nuclear B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
translocation B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Despite O
the O
greater O
number O
of O
glucocorticoid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
receptor I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
sites O
, O
the O
peanut-negative O
thymocyte O
subpopulation O
did O
not O
differ O
from O
the O
peanut-positive O
one O
in O
its O
sensitivity O
to O
the O
inhibitory O
effects O
of O
triamcinolone O
acetonide O
, O
as O
determined O
by O
measurements O
of O
the O
incorporation O
of O
radiolabeled O
precursors O
of O
protein O
and O
DNA O
. O

Moreover O
, O
the O
peanut-negative B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subset B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appeared O
more O
resistant B_DISEASE_ADJECTIVE[DISEASE]
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
steroid-induced B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lysis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
as O
compared O
to O
the O
peanut-positive B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
one I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
, O
our O
data O
suggest O
that O
glucocorticoid O
receptor O
density O
and O
corticosensitivity O
are O
not O
directly O
correlated O
and O
that O
the O
number O
of O
glucocorticoid B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O
may O
be O
dependent O
on O
the O
degree O
of O
immunologic O
maturation O
. O

Defective O
binding O
and O
function O
of O
1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
25-dihydroxyvitamin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
D3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
peripheral O
mononuclear O
cells O
of O
patients O
with O
end-organ O
resistance O
to O
1 O
, O
25-dihydroxyvitamin O
D O
. O

Lectin-induced B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
DNA B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
synthesis B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mononuclear I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
17 B_PERSON/B_MEASURE
normal I_PERSON/I_MEASURE
donors I_PERSON/I_MEASURE
was O
inhibited O
( O
40-60 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O
by O
1 B_NUMBER[MEASURE]
, O
25-dihydroxyvitamin B_MEASURE
D3 I_MEASURE
( O
1 B_MEASURE/B_LOCATION
, O
25 B_MEASURE
[ I_MEASURE
OH I_MEASURE
] I_MEASURE
2D3 I_MEASURE
) O
at O
physiological B_MEASURE/B_LOCATION
concentrations B_MEASURE/I_LOCATION
( O
10 B_MEASURE
( O
-10 B_MEASURE
) O
-10 B_MEASURE/B_LOCATION
( O
-9 B_MEASURE
) O
M B_MEASURE/B_LOCATION
) O
. O

The O
lymphocytes O
acquire O
specific O
receptors O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
upon O
activation O
by O
the O
lectins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

This O
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
precedes O
the O
inhibitory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
1 B_TIME[MEASURE]
, O
25 B_MEASURE
( O
OH B_LOCATION/B_PROTEIN[GENE]
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

We O
studied O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
six B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
from O
four B_LOCATION/B_ENT
different I_LOCATION/I_ENT
kindreds I_LOCATION/I_ENT
with O
the O
syndrome B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hereditary B_DISEASE
end-organ I_DISEASE
resistance I_DISEASE
to O
1 B_MEASURE
, O
25 B_MEASURE
( O
OH O
) O
2D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
the O
so-called B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
vitamin B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
D-dependent B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
rickets B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
type B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
II B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
) O
. O

In O
five B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
three B_MEASURE/B_ENT
kindreds I_MEASURE/I_ENT
) O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
mononuclear I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
did O
not O
acquire O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
1 B_MEASURE
, O
25 B_MEASURE
( O
OH O
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
upon O
phytohemagglutinin-induced B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
activation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Moreover O
, O
in O
contrast O
to O
normal O
lymphocytes O
, O
the O
mitogenic O
stimulation O
of O
these O
patients O
' O
lymphocytes O
by O
phytohemagglutinin B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
concanavalin O
A O
was O
not O
inhibited O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
. O

activated O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
of O
the O
sixth B_PERSON/B_BIO
patient B_PERSON/I_BIO
from O
a O
fourth B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
kindred I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
exhibited I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
normal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
binding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] O
1 B_MEASURE
, O
25 B_MEASURE
( O
OH O
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
but O
the O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O
to O
inhibit O
the O
mitogenic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
vitamin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effector I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
previously O
observed O
in O
fibroblasts B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cultured O
from O
skin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
biopsies I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
of O
the O
same B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_BIO
. O

The O
conclusions O
from O
these O
findings O
are O
: O
( O
a O
) O
the O
inhibition O
of O
mitogenic O
stimulation O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
is O
mediated O
by O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
functional I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
the O
hormone O
; O
and O
( O
b O
) O
the O
receptors O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
in O
mononuclear O
cells O
are O
probably O
controlled O
genetically O
by O
the O
same O
mechanisms O
as O
the O
effector O
system O
in O
well-characterized O
target O
organs O
of O
the O
hormone O
, O
such O
as O
intestine O
and O
kidney O
. O

Glucocorticoid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
receptors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
mononuclear O
leukocytes O
from O
myasthenia O
gravis O
patients O
. O

The O
present O
study O
was O
performed O
to O
analyse O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
GR B_LOCATION/B_ORGANIZATION
) O
binding O
in O
peripheral O
blood O
mononuclear O
leukocytes O
( O
MNL O
) O
from O
39 O
myasthenia O
gravis O
( O
MG O
) O
patients O
( O
unoperated O
patients O
( O
n O
= O
13 O
) O
, O
thymectomized O
patients O
( O
n O
= O
14 O
) O
and O
patients O
receiving O
glucocorticoids O
: O
thymectomized O
( O
n O
= O
11 O
) O
and O
unoperated O
( O
n O
= O
6 O
] O
. O

A O
whole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
with O
3 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
H B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
used O
. O

GR B_PERSON
mean O
values O
were O
significantly O
higher O
in O
the O
MNL O
of O
MG O
patients O
( O
thymectomized O
or O
not O
) O
not O
receiving O
glucocorticoid O
than O
in O
the O
MNL O
of O
healthy O
donors O
. O

affinity B_GENE/B_TIME[MEASURE]
was O
within O
the O
normal B_MEASURE/B_LOCATION
range B_MEASURE/I_LOCATION
. O

Sex B_PERSON/B_MEASURE
, O
age B_TIME[MEASURE]/B_PERSON
or O
clinical B_MEASURE/B_LOCATION
forms I_MEASURE/I_LOCATION
of O
illness B_DISEASE
did O
not O
influence O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
patients O
receiving O
prednisone O
( O
PD O
) O
the O
GR B_GENE/B_DISEASE
values O
were O
significantly O
lower O
than O
in O
MG O
patients O
without O
PD O
therapy O
, O
independent O
of O
PD O
dose O
or O
time O
of O
administration O
. O

No O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
receptor B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O
normal B_PERSON/B_LOCATION
subjects B_PERSON/I_LOCATION
and O
MG B_PERSON/B_BIO
patients I_PERSON/I_BIO
receiving O
Pd B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
found O
. O

immunological B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
interference I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
high B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
corticosteroids I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

High-dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
corticosteroids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
HDC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
will O
influence O
cellular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O
well O
as O
humoral B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
participants B_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
immune B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
lymphoid B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
will O
decrease O
in O
size B_MEASURE
and O
weight B_MEASURE/B_LOCATION
after O
prolonged B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
HDC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Lymphocyte B_PERSON
functions I_PERSON
will O
be O
impaired O
. O

reduced O
synthesis B_MEASURE/B_GENE
of O
B- O
as O
well O
as O
T-lymphocytes B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
be O
seen O
. O

The O
inhibitory O
effect O
on O
B-cell O
function O
can O
be O
observed O
both O
as O
decreased O
serum O
levels O
of O
immunoglobulins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
as O
impaired O
binding O
of O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
complement O
to O
the O
cellular O
surface O
. O

reduced O
T-cell O
function O
indicated O
by O
impaired O
stimulation O
by O
PHA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
porkweed B_DISEASE/B_GENE
as O
well O
as O
by O
impaired O
lymphokinin O
effects O
on O
leukocyte O
migration O
inhibition O
has O
been O
reported O
. O

reduced O
lymphocyte B_MEASURE/B_DISEASE
adherence B_MEASURE/I_DISEASE
to O
antigen B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
suppressed B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lymphocyte B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reaction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
have O
also O
been O
observed O
. O

humoral B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factors I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
involved O
in O
chemotaxis B_DISEASE
, O
opsonisation B_DISEASE_ADJECTIVE[DISEASE]
, O
phagocytosis B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
vascular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
permeability B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leading O
to O
leakage B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
fluid B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
factors B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involved O
in O
lysis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
antigens B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
are O
impaired O
. O

This O
can O
be O
explained O
partly O
by O
the O
observed O
reduced O
complement B_DISEASE_ADJECTIVE[DISEASE]
activation I_DISEASE_ADJECTIVE[DISEASE]
via O
the O
alternative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
well O
as O
the O
classical B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pathway B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
HDC B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processes I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
increased O
vascular B_DISEASE_ADJECTIVE[DISEASE]
permeability I_DISEASE_ADJECTIVE[DISEASE]
and O
accumulation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
leukocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
impairing O
factors B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
could O
be O
influenced O
beneficially O
by O
HDC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

This O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
can O
be O
seen O
in O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O
septic B_DISEASE
shock I_DISEASE
or O
rejection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
transplant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

However O
, O
if O
sepsis B_DISEASE
or O
rejection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
not O
rapidly O
reversed O
, O
complications B_DISEASE_ADJECTIVE[DISEASE]
such I_DISEASE_ADJECTIVE[DISEASE]
as O
multisystem B_DISEASE
organ I_DISEASE
failure I_DISEASE
and O
bacteremia B_DISEASE
are O
prone B_DISEASE_ADJECTIVE[DISEASE]
to O
appear O
. O

identification O
of O
human B_GENE/B_LOCATION
leukemic I_GENE/I_LOCATION
glucocorticoid I_GENE/I_LOCATION
receptors I_GENE/I_LOCATION
using O
affinity O
labeling O
and O
anti-human B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Antisera O
raised O
against O
human B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
lymphoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
glucocorticoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
used O
in O
combination O
with O
the O
glucocorticoid O
receptor O
affinity O
label O
[ O
3H O
] O
dexamethasone O
21-mesylate O
[ O
( O
3H O
] O
DM O
) O
to O
identify O
the O
glucocorticoid B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
human O
B-lymphoblastoid O
cell O
line O
IM-9 O
and O
the O
human O
T-cell O
leukemic O
cell O
line O
CEM-C7 O
. O

Antisera O
were O
obtained O
following O
immunization O
of O
New O
Zealand O
White O
rabbits O
with O
[ B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3H I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
triamcinolone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acetonide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3H I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-glucocorticoid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
partially O
purified O
by O
two-stage O
DNA-cellulose O
chromatography O
. O

The O
presence O
of O
anti-human B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
verified O
by O
: O
( O
a O
) O
adsorption O
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
TA-receptor-antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
complexes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
Protein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
( O
b O
) O
a O
shift O
to O
higher O
apparent O
molecular O
weight O
in O
the O
elution O
position O
from O
Sephacryl O
S300 O
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
TA-receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complexes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
incubated O
with O
immune O
serum O
; O
and O
( O
c O
) O
the O
ability O
of O
immune O
serum O
to O
displace O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
TA-receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
complexes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
on O
sucrose O
gradients O
. O

These O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
recognized O
rat O
liver O
and O
murine B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
S49 I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
glucocorticoid I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
receptors I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
. O

Sodium B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dodecyl I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulfate-polyacrylamide I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gel I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
electrophoresis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
[ B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DM-labeled I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IM-9 I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytosol I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identified O
a O
major B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
competable B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
band B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
with O
a O
molecular B_MEASURE/B_PERSON
weight I_MEASURE/I_PERSON
of O
approximately O
90 B_MEASURE
, O
000 B_MEASURE
, O
three B_NUMBER[MEASURE]/B_PERSON
minor I_NUMBER[MEASURE]/I_PERSON
competable I_NUMBER[MEASURE]/I_PERSON
components I_NUMBER[MEASURE]/I_PERSON
with O
molecular B_MEASURE/B_LOCATION
weights I_MEASURE/I_LOCATION
of O
approximately O
78 B_MEASURE
, O
000 B_MEASURE
, O
approximately O
51 B_MEASURE
, O
000 B_MEASURE
, O
and O
approximately O
38 B_MEASURE
, O
500 B_MEASURE
, O
and O
at O
least O
21 B_NUMBER[MEASURE]/B_LOCATION
other I_NUMBER[MEASURE]/I_LOCATION
noncompetable I_NUMBER[MEASURE]/I_LOCATION
components I_NUMBER[MEASURE]/I_LOCATION
. O

Following O
immunoprecipitation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
[ O
3H B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
] B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
DM-labeled B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
cytosol B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
with O
immune B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
serum I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
only O
the O
Mr B_MEASURE/B_PERSON
90 I_MEASURE/I_PERSON
, O
000 B_MEASURE
and O
78 B_MEASURE
, O
000 B_MEASURE
components I_MEASURE
were O
seen O
. O

Sodium B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dodecyl I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulfate-polyacrylamide I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gel I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
electrophoresis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
DM-labeled B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
CEM-C7 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
cytosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
revealed O
a O
larger B_MEASURE/B_LOCATION
number B_MEASURE/I_LOCATION
of O
[ O
3H B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DM-labeled I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
components I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
after O
immunoprecipitation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
DM-labeled B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CEM-C7 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cytosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
a O
predominant B_DISEASE/B_PROTEIN[GENE]
competable B_DISEASE/I_PROTEIN[GENE]
component B_DISEASE/I_PROTEIN[GENE]
with O
a O
molecular B_MEASURE/B_PERSON
weight I_MEASURE/I_PERSON
of O
90 B_MEASURE
, O
000 B_MEASURE
was O
easily O
identified O
. O

This O
component B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
markedly O
diminished O
when O
cytosols B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
from O
the O
glucocorticoid B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
receptor-deficient I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
line I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
ICR-27 I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
were O
used O
. O

Thus O
, O
the O
combination O
of O
affinity O
labeling O
and O
anti-human B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
capable O
of O
providing O
direct O
physical O
identification O
of O
human B_GENE
lymphoid I_GENE
glucocorticoid I_GENE
receptors I_GENE
. O

Effect O
of O
thymosin O
on O
glucocorticoid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
and O
glucocorticoid O
sensitivity O
of O
human O
thymocytes O
. O

Incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O
thymosin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fraction B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
( O
TMS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
F5 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O
300 B_MEASURE/B_LOCATION
micrograms/ml I_MEASURE/I_LOCATION
) O
a O
partially O
purified O
thymic B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
reduced O
the O
steroid B_MEASURE/B_DISEASE
binding I_MEASURE/I_DISEASE
activity I_MEASURE/I_DISEASE
of O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
infant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
thymocytes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
9.6 B_MEASURE
+/- O
2.1 B_MEASURE
fmole/ml I_MEASURE
to O
5.0 B_MEASURE
+/- I_MEASURE
2.0 I_MEASURE
fmole/ml I_MEASURE
. O

The O
glucocorticoid B_PROTEIN[GENE]/B_MEASURE
receptor I_PROTEIN[GENE]/I_MEASURE
activity O
in O
normal O
infant O
thymocytes O
was O
found O
to O
be O
2 O
, O
146 O
+/- O
726 O
( O
s.d. O
) O
sites O
per O
cell O
with O
dissociation O
constant O
of O
1.4 O
+/- O
0.6 O
X O
10 O
( O
-8 O
) O
M O
. O

TMS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
F5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O
increased O
the O
resistance B_DISEASE_ADJECTIVE[DISEASE]
of O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
thymocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
cytolytic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effect I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
2.5 B_MEASURE/B_LOCATION
X B_MEASURE/I_LOCATION
10 B_MEASURE/I_LOCATION
( O
-8 O
) O
M B_OTHER/B_MEASURE
) O
to O
168.6 B_MEASURE/B_LOCATION
+/- O
30.2 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0.01 B_MEASURE
) O
. O

In O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
medullary B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
and O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O
more O
resistant B_DISEASE_ADJECTIVE[DISEASE]
to O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O
immature B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
thymic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O
that O
thymosin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O
induce O
changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
consistent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O
differentiation B_PROTEIN[GENE]/B_DISEASE
in O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
thymocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
a O
physiological B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
thymosin B_GENE
in O
intrathymic B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
T B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
cell B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
maturation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
man B_SPECIES[BIO]
. O

Incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
a O
human B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
malignant B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
thymus B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
derived O
T B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
line B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
MOLT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
3 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
with O
TMS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
F5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O
resulted O
in O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
number B_MEASURE/B_DISEASE
of O
steroid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
binding I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
sites I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
to O
44.2 B_MEASURE/B_LOCATION
+/- O
15.3 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0.05 B_MEASURE
) O
, O
but O
TMS B_LOCATION/B_PERSON
F5 I_LOCATION/I_PERSON
did O
not O
significantly O
reduce O
the O
glucocorticoid B_MEASURE
sensitivity I_MEASURE
of O
MOLT B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Specific B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
high-affinity B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
1 O
, O
25-dihydroxyvitamin O
D3 O
in O
human O
peripheral O
blood O
mononuclear O
cells O
: O
presence O
in O
monocytes O
and O
induction O
in O
T O
lymphocytes O
following O
activation O
. O

Human B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
peripheral I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
have O
high B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
1 B_MEASURE
, O
25- B_MEASURE
( O
OH B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
Kd B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0.14 I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nM I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sedimentation B_MEASURE/B_LOCATION
coefficient I_MEASURE/I_LOCATION
3.7S I_MEASURE/I_LOCATION
) O
. O

resting O
human O
peripheral O
blood O
T O
lymphocytes O
, O
however O
, O
do O
not O
have O
a O
demonstrable O
1 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
25- I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
OH I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2D3 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

After O
activation O
with O
phytohemagglutinin B_BIO/B_GENE
the O
T O
cells O
exhibit O
the O
receptor O
within O
24 O
h O
, O
and O
this O
expression O
is O
blocked O
by O
cycloheximide O
. O

The O
receptor B_GENE
in O
activated O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
has O
a O
sedimentation B_MEASURE/B_LOCATION
coefficient I_MEASURE/I_LOCATION
of O
3.7S B_MEASURE
and O
a O
high B_LOCATION/B_MEASURE
affinity B_LOCATION/I_MEASURE
( O
Kd B_LOCATION/B_MEASURE
0.10 I_LOCATION/I_MEASURE
nm I_LOCATION/I_MEASURE
) O
for O
the O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chronic B_DISEASE
glucocorticoid I_DISEASE
excess I_DISEASE
in O
man B_PERSON/B_BIO
on O
insulin B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
circulating O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
: O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
between O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
exogenous B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
hypercorticism B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
measured O
[ O
125I B_MEASURE/B_DISEASE
] B_MEASURE/I_DISEASE
insulin B_MEASURE/I_DISEASE
binding B_MEASURE/I_DISEASE
to O
circulating O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
or O
erythrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
16 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
with O
chronic B_DISEASE/B_LOCATION
glucocorticoid I_DISEASE/I_LOCATION
excess I_DISEASE/I_LOCATION
, O
9 B_NUMBER[MEASURE]
chronically O
treated O
with O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
7 B_NUMBER[MEASURE]
with O
adrenocortical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hyperfunction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

With O
monocytes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
[ O
125I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
insulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
iincreased O
in O
all O
patients B_PERSON/B_BIO
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
binding O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicated O
that O
increased O
binding B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients B_PERSON/B_BIO
treated O
with O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
due O
to O
an O
ncrease B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
receptor B_MEASURE/B_BIO
concentration B_MEASURE/I_BIO
, O
whereas O
in O
patients B_PERSON/B_BIO
with O
adrenocortical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hyperfunction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
was O
due O
to O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
receptor B_MEASURE
affinity I_MEASURE
. O

With O
erythrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
patients B_PERSON/B_BIO
with O
adrenocortical B_DISEASE
hyperfunction I_DISEASE
there O
was O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
receptor B_MEASURE
affinity I_MEASURE
and O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
receptor B_MEASURE
concentration I_MEASURE
, O
so O
that O
the O
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
125I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
insulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
disparity O
of O
results O
between O
endogenous O
and O
exogenous O
hypercorticism O
, O
between O
the O
two O
cell O
types O
, O
and O
between O
the O
present O
studies O
and O
previous O
studies O
suggest O
that O
the O
effects O
of O
glucocorticoid O
excess O
on O
the O
insulin B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
receptor I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
are O
extremely O
complex O
and O
wide-ranging O
and O
that O
in O
this O
condition O
, O
extrapolations O
in O
humans O
from O
data O
with O
circulating O
cells O
to O
liver O
and O
muscle O
may O
not O
be O
appropriate O
. O

reduced O
level O
of O
cellular B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients O
with O
anorexia O
nervosa O
. O

specific O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
measured O
in O
circulating O
mononuclear O
leukocytes O
from O
12 O
patients O
with O
anorexia O
nervosa O
and O
21 O
healthy O
control O
subjects O
. O

cells O
from O
patients O
were O
found O
to O
contain O
a O
significantly O
( O
p O
less O
than O
0.01 O
) O
lower O
level O
of O
glucocorticoid B_GENE
receptor I_GENE
( O
3830 O
+/- O
210 O
sites/cell O
, O
mean O
+/- O
SE O
) O
than O
those O
from O
controls O
( O
4930 O
+/- O
250 O
sites/cell O
) O
. O

A O
partial O
glucocorticoid B_GENE
receptor I_GENE
defect O
may O
well O
explain O
the O
abnormal O
cortisol O
metabolism O
and O
glucocorticoid O
resistance O
commonly O
found O
in O
patients O
with O
anorexia O
nervosa O
. O

Regulation O
of O
the O
glucocorticoid B_GENE
receptor I_GENE
in O
human O
lymphocytes O
. O

The O
presence O
of O
a O
glucocorticoid B_GENE
receptor I_GENE
in O
human O
lymphocytes O
is O
well O
established O
, O
but O
factors O
affecting O
its O
regulation O
have O
not O
been O
described O
. O

Using O
a O
competitive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
binding I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
whole I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cell I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
we O
have O
examined O
the O
binding B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-dexamethasone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O
24 B_MEASURE
and O
37 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
in O
untreated B_PERSON/B_BIO
normal I_PERSON/I_BIO
subjects I_PERSON/I_BIO
and O
in O
healthy B_PERSON/B_BIO
subjects I_PERSON/I_BIO
taking O
various B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
preparations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

At O
24 B_MEASURE
degrees I_MEASURE
C I_MEASURE
normal I_MEASURE
human I_MEASURE
lymphocytes I_MEASURE
had O
6000 B_NUMBER[MEASURE]
binding O
sites/cell B_LOCATION
and O
a O
dissociation B_MEASURE
constant I_MEASURE
of O
4 B_MEASURE
x O
10 B_MEASURE
( O
-9 B_MEASURE
) O
M B_MEASURE
. O

The O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_MEASURE/B_LOCATION
mg I_MEASURE/I_LOCATION
of O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
37.5 B_MEASURE/B_LOCATION
mg I_MEASURE/I_LOCATION
of O
cortisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
resulted O
in O
a O
30 B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
binding O
sites B_MEASURE
after O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
week I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
no O
change B_MEASURE
in O
binding O
affinity B_TIME[MEASURE]/B_GENE
. O

No O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
number B_MEASURE/B_LOCATION
of O
binding O
sites B_LOCATION/B_ENT
was O
noted O
before O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
diminished B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
persisted O
for O
1 B_TIME[MEASURE]
week I_TIME[MEASURE]
after O
discontinuation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
hospitalized O
patients B_PERSON/B_BIO
taking O
40-60 B_MEASURE
mg I_MEASURE
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O
demonstrated O
the O
same B_MEASURE
change I_MEASURE
in O
number B_MEASURE/B_LOCATION
of O
binding O
sites B_LOCATION/B_ENT
that O
was O
seen O
in O
normal B_PERSON/B_BIO
subjects I_PERSON/I_BIO
taking O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

When O
binding O
assays B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
carried O
out O
at O
physiologic B_MEASURE/B_LOCATION
temperature B_MEASURE/I_LOCATION
there O
was O
the O
same B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
number B_MEASURE
of O
binding O
sites B_LOCATION/B_ENT
after O
dexamethasone B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
, O
and O
in O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
there O
was O
a O
two-fold B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
binding B_MEASURE/B_DISEASE
affinity I_MEASURE/I_DISEASE
. O

glucocorticoid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
administration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O
a O
time-dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
number B_MEASURE/B_LOCATION
of O
lymphocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
glucocorticoid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
binding I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
sites I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
that O
is O
independent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
type B_MEASURE
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administered O
. O

This O
is O
the O
first B_SEQUENCE[MEASURE]
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
demonstration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modulate O
their O
own B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
man B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

immunoglobulin B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
localization B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
benign B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
malignant B_DISEASE
lesions I_DISEASE
of O
the O
human B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mammary I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gland I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Using O
direct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imunofluorescence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lesions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O
266 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
breast I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
studied O
for O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
IgA B_GENE
, O
IgM B_GENE/B_DISEASE
, O
or O
IgG B_GENE
localization I_GENE
. O

The O
lesions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
included O
benign B_DISEASE/B_PERSON
elements I_DISEASE/I_PERSON
from O
66 B_MEASURE/B_PERSON
subcutaneous I_MEASURE/I_PERSON
mastectomy I_MEASURE/I_PERSON
specimens I_MEASURE/I_PERSON
in O
which O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
simultaneous B_DISEASE
breast I_DISEASE
malignancy I_DISEASE
was O
documented O
, O
primary B_DISEASE
breast I_DISEASE
carcinomas I_DISEASE
from O
153 B_MEASURE/B_PERSON
mastectomy B_MEASURE/I_PERSON
specimens B_MEASURE/I_PERSON
, O
and O
47 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
biopsies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
containing O
metastatic B_DISEASE
breast I_DISEASE
cancer I_DISEASE
. O

A O
statistically O
significant O
association O
of O
IgA B_GENE/B_DISEASE
and O
IgM B_GENE
with O
benign O
lesions O
was O
contrasted O
to O
the O
association O
of O
IgG B_GENE
with O
malignant O
lesions O
. O

In O
both O
primary O
and O
metastatic O
lesions O
, O
IgG B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
localization O
was O
associated O
with O
estrogen-receptor-poor O
primary O
cancers O
as O
compared O
with O
estrogen-receptor-rich O
primary O
cancers O
. O

Among O
primary O
breast O
cancer O
patients O
, O
IgG B_GENE/B_DISEASE
localization O
in O
the O
tumor O
correlated O
with O
relative O
lymphopenia O
. O

A O
shorter O
disease-free O
interval O
was O
noted O
in O
association O
with O
IgG B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
localization O
among O
the O
metastatic O
breast O
lesions O
. O

No O
statistically O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
association I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
stage B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
disease B_DISEASE
and O
immunoglobulin B_DISEASE
presence I_DISEASE
was O
demonstrable B_DISEASE_ADJECTIVE[DISEASE]
. O

Moderate-to-severe O
intraductal O
epithelial O
hyperplasias O
were O
more O
often O
associated O
with O
immunoglobulin B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
G I_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
localization O
that O
were O
other O
benign O
lesions O
. O

correlation O
of O
steroid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
histologic O
differentiation O
in O
mammary O
carcinoma O
. O

A O
Singapore B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experience I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Cancer B_DISEASE/B_LOCATION
of O
the O
breast B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
is O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
tumor I_DISEASE_ADJECTIVE[DISEASE]
in O
females B_PERSON
in O
Singapore B_LOCATION
, O
with O
the O
rate B_MEASURE
of O
20.7 B_TIME[MEASURE]
per O
100 B_MEASURE
, O
000 B_MEASURE
per O
year B_TIME[MEASURE]/B_PERSON
( O
1977 B_MEASURE
estimate I_MEASURE
) O
, O
which O
is O
predicted O
to O
increase O
to O
29.8 B_TIME[MEASURE]
per O
100 B_MEASURE
, O
000 B_TIME[MEASURE]
women I_TIME[MEASURE]
per O
year B_TIME[MEASURE]/B_PERSON
by O
1995 B_TIME[MEASURE]
. O

A O
detailed O
histopathologic O
review O
of O
50 O
primary O
breast O
cancer O
tumors O
analyzed O
for O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
ER B_PROTEIN[GENE]/B_LOCATION
) O
level O
was O
carried O
out O
and O
a O
variety O
of O
morphologic O
features O
correlated O
with O
ER B_LOCATION/B_GENE
results O
to O
identify O
any O
factors O
that O
will O
improve O
the O
management O
and O
prognosis O
for O
breast O
cancer O
. O

cytosol B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
was O
incubated O
with O
3H-estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
absence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
cold B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diethylstilbestrol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
bound O
and O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
separated O
by O
Dextran-coated B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
charcoal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

tumors O
binding O
more O
than O
5 O
fmol/mg O
cytosol B_GENE
protein I_GENE
were O
classified O
as O
ER B_GENE
-positive O
. O

Progesterone B_GENE
receptor I_GENE
( O
PR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
level O
was O
analyzed O
in O
some O
specimens O
with O
the O
use O
of O
a O
similar O
method O
. O

Most B_NUMBER[MEASURE]/B_PERSON
of O
the O
patients B_PERSON
were O
Chinese B_LOCATION/B_PERSON
( O
90 B_LOCATION/B_PERSON
% I_LOCATION/I_PERSON
) O
. O

Three B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
were O
Malays B_LOCATION/B_PERSON
, O
one B_NUMBER[MEASURE]/B_PERSON
was O
Indian B_PERSON/B_LOCATION
, O
and O
one B_NUMBER[MEASURE]/B_PERSON
was O
European B_LOCATION/B_PERSON
in O
this O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Results O
indicated O
that O
there O
was O
strong O
correlation O
between O
ER B_GENE
level O
, O
age O
, O
and O
histologic O
grade O
of O
the O
tumors O
. O

No O
correlation O
existed O
between O
absence O
or O
presence O
of O
lymph O
node O
metastases O
and O
ER B_GENE/B_DISEASE
. O

Although O
there O
was O
a O
trend O
for O
ER B_GENE
-positive O
tumors O
to O
have O
a O
low-grade O
lymphocytic O
infiltration O
, O
the O
difference O
was O
not O
statistically O
significant O
. O

Mononuclear O
cells O
infiltrating O
human O
mammary O
carcinomas O
: O
immunohistochemical O
analysis O
with O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

breast O
carcinomas O
were O
examined O
by O
the O
immunoperoxidase O
technique O
using O
antisera O
specific O
for O
lymphocyte O
subsets O
, O
monocytes O
, O
NK O
cells O
and O
major B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
HLA-A B_GENE
, O
-B B_PROTEIN[GENE]/B_LOCATION
, O
-C O
; O
Ia-like B_DISEASE/B_PERSON
) O
. O

Sixty-four O
per O
cent B_SEQUENCE[MEASURE]
of O
the O
patients B_PERSON
had O
a O
moderate B_DISEASE_ADJECTIVE[DISEASE]
or O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mononuclear I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cell I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
infiltration I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
77 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
of O
the O
patients B_PERSON
without O
mononuclear B_DISEASE
cell I_DISEASE
infiltration I_DISEASE
had O
receptors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
estrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O
compared O
to O
51 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
patients B_PERSON/B_LOCATION
with O
infiltration B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
majority B_PERSON/B_MEASURE
of O
the O
infiltrating O
mononuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
were O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
; O
generally O
the O
OKT8 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
predominant B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
Leu B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3A/OKT8 B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratio B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
related O
to O
histological B_MEASURE/B_PERSON
type I_MEASURE/I_PERSON
, O
tumor B_MEASURE/B_PERSON
size I_MEASURE/I_PERSON
, O
age B_MEASURE/B_LOCATION
of O
the O
patient B_PERSON/B_DISEASE
or O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
metastases B_DISEASE
. O

Some O
of O
the O
T O
cells O
had O
the O
Ia B_GENE
antigen I_GENE
and O
were O
thus O
probably O
activated O
. O

The O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
either O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
less O
numerous B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
the O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
. O

There O
was O
no O
relation B_PERSON/B_DISEASE
between O
their O
distribution B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
the O
various B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
parameters I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
studied O
. O

A O
few O
monocytes O
were O
heterogeneous O
according O
to O
their O
markers O
( O
OKM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
acid O
phosphatase O
) O
. O

In O
6 O
cases O
only O
there O
was O
a O
strong O
infiltration O
of O
mononuclear O
cells O
positive O
for O
acid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
number B_MEASURE
of O
the O
natural B_PERSON
killer I_PERSON
cells I_PERSON
was O
also O
low B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Only O
a O
few B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
mononuclear I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
infiltrating O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
had O
receptors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
transferrin B_GENE
. O

There O
was O
a O
positive O
correlation O
between O
the O
inflammatory O
infiltration O
and O
the O
presence O
of O
HLA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
class-I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
antigens B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
on O
tumor O
cell O
s O
. O

Some O
of O
the O
antisera B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
specific I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
lymphocyte B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
subsets I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O
stained O
the O
breast B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
carcinoma I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
great B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
subsets B_MEASURE/B_LOCATION
of O
mononuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
in O
breast B_DISEASE/B_BIO
carcinomas I_DISEASE/I_BIO
may O
correspond O
to O
various B_DISEASE_ADJECTIVE[DISEASE]
systems I_DISEASE_ADJECTIVE[DISEASE]
of O
defense B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
against O
neoplasm B_DISEASE/B_BIO
. O

A O
case O
of O
male O
pseudohermaphroditism O
with O
normal O
androgen B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
receptor I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
binding O
and O
47 O
, O
XYY O
karyotype O
. O

A O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
male B_DISEASE/B_PERSON
pseudohermaphroditism I_DISEASE/I_PERSON
with O
47 B_MEASURE/B_PERSON
, O
XYY B_MEASURE/B_GENE
karyotype I_MEASURE/I_GENE
in O
blood B_BODY_PART_OR_ORGAN_COMPONENT
and O
cutaneous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fibroblasts I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
described O
. O

The O
plasma B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testosterone B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
HCG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
slightly O
below O
the O
normal B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
on O
two B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
occasions I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
suggesting O
a O
deficit B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
gonadal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
function I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

A O
study O
of O
the O
receptors O
for O
dihydrotestosterone O
in O
fibroblasts O
of O
genital O
and O
nongenital O
skin O
showed O
a O
normal O
concentration O
of O
receptors O
in O
genital O
skin O
; O
5-alpha-reductase B_GENE/B_PERSON
activity O
in O
fibroblasts O
of O
the O
genital O
skin O
was O
low O
, O
but O
the O
plasma O
relationship O
testosterone/dihydrotestosterone O
under O
HCG O
stimulation O
was O
normal O
. O

The O
diagnostic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possibility I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
testicular B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
feminization B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O
normal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
dihydrotestosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
commented O
on O
. O

1 O
, O
25-Dihydroxyvitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibits I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen-induced O
T B_DISEASE
cell I_DISEASE
activation I_DISEASE
. O

The O
proliferative O
response O
of O
murine O
spleen O
and O
thymus O
cells O
to O
antigen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
but O
not O
to O
lectin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
inhibited O
by O
the O
active O
metabolite O
of O
vitamin O
D3 O
, O
1 O
, O
25- O
( O
OH O
) O
2D3 O
. O

To O
directly O
examine O
the O
effect O
of O
1 O
, O
25- O
( O
OH O
) O
2D3 O
on O
T O
cell O
activation O
in O
the O
absence O
of O
other O
complicating O
interactions O
, O
we O
utilized O
a O
panel O
of O
cloned O
Ia-restricted O
T O
cell O
hybridomas O
that O
secrete O
IL B_GENE
2 I_GENE
on O
activation O
by O
cloned O
Ia-bearing O
stimulator O
cells O
( O
TA3 O
) O
or O
when O
stimulated O
by O
mitogen O
. O

physiologic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
concentrations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
1 B_MEASURE
, O
25- B_MEASURE
( O
OH O
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
0.01 B_MEASURE/B_LOCATION
to O
0.1 B_MEASURE
nm I_MEASURE
) O
inhibited O
the O
antigen-induced B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
secretion B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
IL B_GENE
2 I_GENE
by O
several B_NUMBER[MEASURE]/B_BIO
of O
these O
T B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hybridomas I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

This O
inhibition B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
dependent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
on O
the O
concentration B_MEASURE/B_LOCATION
of O
the O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
could O
be O
overcome O
by O
increasing O
the O
number B_MEASURE
of O
Ia-bearing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulator I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cells I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
used O
. O

Pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
T B_DISEASE/B_PROTEIN[GENE]
hybridoma B_DISEASE/I_PROTEIN[GENE]
but O
not O
the O
TA3 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
stimulator I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
with O
1 B_MEASURE
, O
25- B_MEASURE
( O
OH B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
resulted O
in O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
activation B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

These O
results O
are O
consistent O
with O
the O
finding O
that O
specific O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
25- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
OH I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2D3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
present O
on O
the O
T O
cell O
hybridomas O
but O
are O
lacking O
in O
TA3 O
cells O
. O

1 O
, O
25- O
( O
OH O
) O
2D3 O
failed O
, O
however O
, O
to O
inhibit O
the O
activation O
of O
the O
T O
cell O
hybridomas O
by O
lectin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
by O
an O
anti-Thy-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
1 B_MEASURE
, O
25- B_MEASURE
( O
OH O
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
may O
be O
interfering O
with O
early B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
events B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
antigen-induced B_DISEASE
T I_DISEASE
cell I_DISEASE
activation I_DISEASE
, O
perhaps O
by O
hindering O
T B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
recognition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
relevant B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
stimulator B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
surfaces I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

This O
system O
should O
prove O
useful O
in O
studying O
the O
molecular O
mechanisms O
by O
which O
1 O
, O
25- O
( O
OH O
) O
2D3 O
acts O
to O
inhibit O
T O
cell O
activation O
and O
subsequent O
IL B_GENE
2 I_GENE
production O
. O

Glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
steroid O
sensitivity O
in O
normal O
and O
neoplastic O
human O
lymphoid O
tissues O
: O
a O
review O
. O

The O
determination O
of O
estrogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
progesterone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
breast O
cancer O
has O
been O
shown O
to O
be O
useful O
in O
predicting O
the O
response O
to O
endocrine O
therapy O
. O

Given O
their O
well-known B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitory B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
lymphoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O
been O
used O
widely O
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
leukemia B_DISEASE/B_LOCATION
. O

Given O
these O
facts O
, O
over O
the O
last O
10 O
years O
, O
several O
investigators O
have O
measured O
the O
number O
of O
glucocorticoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
normal O
and O
neoplastic O
lymphoid O
tissue O
to O
see O
whether O
their O
number O
correlated O
with O
glucocorticoid O
responsiveness O
in O
vitro O
or O
in O
vivo O
. O

No O
clear O
correlation O
could O
be O
established O
between O
the O
level O
of O
glucocorticoid B_GENE
receptor I_GENE
and O
the O
in O
vitro O
action O
of O
steroids O
in O
normal O
and O
neoplastic O
lymphoid O
tissue O
. O

In O
contrast O
, O
attempts O
to O
correlate O
glucocorticoid B_GENE
receptor I_GENE
levels O
in O
acute O
lymphocytic O
leukemia O
to O
in O
vivo O
steroid O
responsiveness O
and O
immunological O
type O
using O
the O
whole-cell-binding O
assay O
for O
receptor O
determination O
and O
selecting O
the O
patients O
according O
to O
age O
and O
immunological O
criteria O
have O
been O
more O
successful O
. O

[ O
Glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
normal O
human O
lymphocytes O
] O
. O

glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
GC B_PROTEIN[GENE]/B_DISEASE
) O
receptors B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
studied O
in O
intact B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
11 B_PERSON/B_BIO
donors B_PERSON/I_BIO
. O

GC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
binding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
found O
to O
be O
highly O
reproducible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
repeated O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

It O
was O
shown O
that O
GC B_GENE
receptors I_GENE
in O
donors O
' O
lymphocytes O
could O
be O
distributed O
into O
two O
different O
classes O
similarly O
to O
the O
pattern O
seen O
in O
skin O
fibroblasts O
. O

Human O
lymphocytes O
are O
an O
adequate O
object O
for O
studying O
genetically O
determined O
variability O
of O
GC B_DISEASE/B_GENE
receptors I_DISEASE/I_GENE
and O
its O
clinical O
importance O
. O

specific O
estrogen B_GENE
binding I_GENE
sites I_GENE
in O
human O
lymphoid O
cells O
and O
thymic O
cells O
. O

The O
binding B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
preparations B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
mononuclear I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
well O
as O
by O
splenic B_BODY_PART_OR_ORGAN_COMPONENT
and O
thymic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O
demonstrated O
by O
three B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
approaches I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Dextran-coated B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
charcoal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whole B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
gel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
filtration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
a O
Sepharose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
4B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
column I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

Scatchard O
's O
analysis O
of O
[ O
3H O
] O
-moxestrol O
( O
R2858 O
) O
and O
[ O
3H O
] O
-estradiol O
binding O
proves O
the O
existence O
of O
a O
single O
class O
of O
receptor B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
having O
a O
dissociation O
constant O
of O
0.18-2.4 O
X O
10 O
( O
-9 O
) O
M O
. O

physicochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
properties I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
binder B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
binding B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
steroid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
specificity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
are O
quite O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
those O
reported O
for O
the O
thymus B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
small B_SPECIES[BIO]
mammalian I_SPECIES[BIO]
species I_SPECIES[BIO]
or O
human B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
thymoma I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Administration O
of O
fibroblast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
patients O
with O
advanced O
breast O
cancer O
: O
possible O
effects O
on O
skin O
metastasis O
and O
on O
hormone B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Eleven O
patients O
with O
metastasized O
breast O
cancer O
received O
8 O
intramuscular O
injections O
of O
6 O
x O
10 O
( O
6 O
) O
units O
of O
human B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fibroblast I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interferon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
over O
a O
period O
of O
40 O
days O
. O

The O
injections B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
cause O
local B_DISEASE
irritation I_DISEASE
or O
inflammation B_DISEASE/B_BACTERIUM[BIO]
. O

fever B_DISEASE
occurred O
in O
only O
1 B_NUMBER[MEASURE]
of O
the O
11 B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
. O

Although O
several B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
types I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
metastases B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
monitored O
, O
only O
skin B_NUMBER[MEASURE]
nodules I_NUMBER[MEASURE]
consistently O
( O
10 B_NUMBER[MEASURE]
out O
of O
11 B_TIME[MEASURE]
patients I_TIME[MEASURE]
) O
exhibited O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
were O
suggestive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
therapeutic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
either O
a O
simple B_DISEASE_ADJECTIVE[DISEASE]
decrease I_DISEASE_ADJECTIVE[DISEASE]
in O
size B_MEASURE
of O
some O
nodules B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
or O
central B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_DISEASE_ADJECTIVE[DISEASE]
accompanied O
by O
an O
inflammatory B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reaction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

NK-activity B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O
significantly O
increased O
after O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
first B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
the O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
subsequent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
injections I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
less O
clear B_DISEASE_ADJECTIVE[DISEASE]
. O

receptors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
for O
estrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
progestogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
increased O
in O
the O
tumor B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
biopsies I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
2 B_NUMBER[MEASURE]
out O
of O
2 B_NUMBER[MEASURE]
and O
5 B_NUMBER[MEASURE]
out O
of O
6 B_TIME[MEASURE]
patients I_TIME[MEASURE]
tested O
respectively O
. O

decreased O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O
in O
adrenal O
insufficiency O
. O

To O
examine O
the O
effect O
of O
glucocorticoid O
deficiency O
on O
the O
glucocorticoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
we O
examine O
the O
binding O
of O
[ O
3H O
] O
dexamethasone O
to O
lymphocytes O
in O
normal O
subjects O
and O
patients O
with O
adrenal O
insufficiency O
before O
and O
after O
glucocorticoid O
replacement O
therapy O
. O

Using O
a O
whole B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
competitive I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
normal B_PERSON/B_GENE
human I_PERSON/I_GENE
lymphocytes I_PERSON/I_GENE
had O
5977 B_MEASURE
+/- O
1487 B_MEASURE/B_LOCATION
( O
mean B_MEASURE
+/- O
SD B_LOCATION/B_DISEASE
) O
binding O
sites/cell B_LOCATION/B_MEASURE
and O
a O
dissociation B_MEASURE/B_LOCATION
constant I_MEASURE/I_LOCATION
of O
10 B_MEASURE
+/- I_MEASURE
2 I_MEASURE
nm I_MEASURE
. O

Lymphocytes O
from O
patients O
with O
untreated O
adrenal O
insufficiency O
had O
fewer O
binding B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sites I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
3364 O
+/-322 O
) O
and O
a O
2-fold O
increase O
in O
binding O
affinity O
( O
5.4 O
+/- O
0.9 O
mm O
) O
. O

The O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
conventional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
replacement I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
cortisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
months I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
caused O
no O
change B_MEASURE
in O
receptor B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
was O
associated O
with O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
binding B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toward O
normal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

After O
long B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
term I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
glucocorticoid I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replacement I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
binding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
those O
in O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

The O
physiological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
implications I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
decreased O
receptor B_MEASURE/B_DISEASE
number I_MEASURE/I_DISEASE
and O
increased O
binding B_MEASURE
affinity I_MEASURE
in O
adrenal B_DISEASE
insufficiency I_DISEASE
remain O
to O
be O
elucidated O
. O

Glucocorticoid B_GENE
receptor I_GENE
concentrations O
and O
terminal O
transferase B_ENZYME[GENE]/B_DISEASE
activity O
as O
indicators O
of O
prognosis O
in O
acute O
non-lymphocytic O
leukaemia O
. O

activity O
of O
terminal B_ENZYME[GENE]
deoxynucleotidyl I_ENZYME[GENE]
transferase I_ENZYME[GENE]
( O
TdT B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
adenosine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deaminase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
5'nucleotidase B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
the O
cellular O
concentration O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dexamethasone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
determined O
in O
25 O
patients O
with O
acute O
non-lymphocytic O
leukaemia O
. O

All O
patients B_PERSON
were O
treated O
according O
to O
a O
common B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

increased O
activity O
of O
TdT B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
greater O
than O
0.1 O
unit/microgram O
DNA O
) O
was O
found O
in O
11 O
patients O
. O

This O
group B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_BIO
was O
shown O
to O
have O
higher B_DISEASE_ADJECTIVE[DISEASE]
remission I_DISEASE_ADJECTIVE[DISEASE]
and O
survival B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_OTHER/B_MEASURE
= O
0.06 B_MEASURE
) O
compared O
with O
patients B_PERSON/B_ORGANIZATION
with O
low B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
TdT B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
glucocorticoid B_MEASURE/B_GENE
receptor I_MEASURE/I_GENE
concentration O
of O
the O
leukaemic O
blast O
cells O
ranged O
from O
0 O
to O
0.94 O
fmol/microgram O
DNA O
. O

Thirteen O
patients O
had O
blast O
cells O
with O
a O
glucocorticoid B_MEASURE/B_GENE
receptor I_MEASURE/I_GENE
concentration O
over O
0.22 O
fmol/microgram O
DNA O
. O

These O
patients B_PERSON/B_BIO
had O
significantly O
increased O
remission B_DISEASE
and O
survival B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_OTHER/B_MEASURE
= O
0.006 B_MEASURE
) O
compared O
with O
those O
with O
a O
low B_DISEASE/B_LOCATION
receptor I_DISEASE/I_LOCATION
concentration I_DISEASE/I_LOCATION
. O

This O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
not O
be O
explained O
by O
a O
difference B_MEASURE
in O
sensitivity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O
these O
were O
not O
used O
as O
therapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Adenosine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deaminase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
5'nucleotidase B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
activities O
both O
varied O
within O
two O
orders O
of O
magnitude O
. O

No O
correlation B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
found O
between O
activities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
enzymes B_ENZYME[GENE]
and O
remission B_DISEASE
or O
survival B_DISEASE_ADJECTIVE[DISEASE]
rate I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
results O
show O
that O
measurements O
of O
TdT B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
and O
the O
glucocorticoid B_GENE
receptor I_GENE
concentration O
yield O
valuable O
prognostic O
information O
in O
acute O
non-lymphocytic O
leukaemia O
. O

[ O
3H O
] O
cortivazol O
: O
a O
unique O
high O
affinity O
ligand O
for O
the O
glucocorticoid B_GENE
receptor I_GENE
. O

Cortivazol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CVZ B_LOCATION
) O
and O
deacylcortivazol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
dac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
are O
pyrazolosteroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
previous B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
work I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
showed O
that O
dac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
40-fold B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
more O
potent B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
DEX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
lysing O
leukemic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
lymphoblasts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O

To O
assess O
the O
interaction O
between O
these O
atypical O
steroids O
and O
the O
glucocorticoid B_GENE
receptor I_GENE
, O
we O
examined O
the O
binding O
of O
[ O
3H O
] O
CVZ O
to O
cytosol O
from O
glucocorticoid-sensitive O
and O
-resistant O
variants O
of O
the O
human O
leukemic O
cell O
line O
CEM O
C7 O
. O

In O
glucocorticoid-sensitive O
cells O
[ O
3H O
] O
CVZ O
causes O
a O
2-fold O
induction O
of O
glutamine B_ENZYME[GENE]
synthetase I_ENZYME[GENE]
and O
binds O
to O
a O
protein O
in O
the O
4.6 O
S O
region O
of O
high O
salt O
sucrose O
gradients O
. O

On O
DEAE-cellulose O
chromatography O
, O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CVZ-receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
a O
shift O
from O
high O
( O
0.25 O
M O
KP O
) O
to O
low O
salt O
( O
0.09 O
M O
KP O
) O
eluting O
forms O
upon O
activation O
. O

CVZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
competes O
for O
a O
97 B_MEASURE
, O
000-dalton B_MEASURE/B_PROTEIN[GENE]
protein I_MEASURE/I_PROTEIN[GENE]
labeled O
by O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dexamethasone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mesylate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Scatchard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CVZ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
glucocorticoid-sensitive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
a O
curvilinear B_MEASURE
plot I_MEASURE
which O
resolved O
into O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O
0.4 B_MEASURE/B_COLOR
nm I_MEASURE/I_COLOR
) O
and O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
11 B_MEASURE
nm I_MEASURE
) O
affinity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
components I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
receptor O
concentration O
of O
the O
low O
affinity O
site O
( O
0.30 O
pmol/mg O
protein O
) O
was O
approximately O
twice O
that O
of O
the O
high B_GENE/B_MEASURE
affinity I_GENE/I_MEASURE
site I_GENE/I_MEASURE
( O
0.14 O
pmol/mg O
protein O
) O
. O

dissociation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
dilution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and/or I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
excess I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
unlabeled I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CVZ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
supported O
the O
presence B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
independent B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast B_MEASURE
, O
the O
binding B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
DEX I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
C7 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cytosol I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
revealed O
a O
single B_MEASURE
class I_MEASURE
of O
binding O
sites B_LOCATION/B_ENT
( O
Kd B_PROTEIN[GENE]/B_LOCATION
= O
1.9 B_MEASURE/B_COLOR
nm I_MEASURE/I_COLOR
; O
receptor B_MEASURE/B_LOCATION
concentration I_MEASURE/I_LOCATION
, O
0.46 B_MEASURE/B_LOCATION
pmol/mg I_MEASURE/I_LOCATION
protein I_MEASURE/I_LOCATION
) O
. O

Examination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CVZ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
using O
10 B_NUMBER[MEASURE]/B_LOCATION
( O
-5 O
) O
M B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DEX I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
the O
competing O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
DEX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binds O
only O
to O
the O
low B_PROTEIN[GENE]/B_LOCATION
affinity I_PROTEIN[GENE]/I_LOCATION
site I_PROTEIN[GENE]/I_LOCATION
detected O
by O
[ B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CVZ I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

In O
cytosol O
from O
a O
glucocorticoid-resistant O
cell O
line O
with O
virtually O
no O
[ O
3H O
] O
Dex O
binding O
, O
[ O
3H O
] O
CVZ O
detected O
a O
single O
high B_PROTEIN[GENE]/B_LOCATION
affinity I_PROTEIN[GENE]/I_LOCATION
binding I_PROTEIN[GENE]/I_LOCATION
site I_PROTEIN[GENE]/I_LOCATION
that O
was O
similar O
in O
dissociation O
constant O
( O
0.8 O
nm O
) O
and O
receptor O
concentration O
( O
0.13 O
pmol/mg O
protein O
) O
to O
the O
high B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O
in O
the O
glucocorticoid-sensitive O
cell O
line O
C7 O
. O

A O
controlled O
pore O
glass O
bead O
assay O
for O
the O
measurement O
of O
cytoplasmic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

An O
assay O
for O
the O
quantitation O
of O
cytoplasmic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
lymphoid O
tissue O
has O
been O
developed O
using O
controlled O
pore O
glass O
( O
CPG O
) O
beads O
. O

soluble O
receptor B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
-- I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
3H-steroid I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
complex I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
cytosol O
or O
nuclear O
extract O
) O
is O
adsorbed O
quantitatively O
within O
the O
crevasses O
of O
porous O
glass O
beads O
. O

excess O
labeled O
steroid O
as O
well O
as O
most O
non-specifically O
bound O
steroid O
is O
easily O
washed O
away O
, O
leaving O
the O
hormone-receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complex I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
retained O
by O
the O
beads O
. O

bound O
3H-steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
eluted O
with O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
measured O
for O
radioactivity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
procedure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
is O
simple B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
highly O
reproducible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
carried O
out O
using O
frozen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
stable B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
many B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
containing O
as O
few B_NUMBER[MEASURE]/B_PERSON
as O
1 B_MEASURE
X O
10 B_NUMBER[MEASURE]
( O
7 B_MEASURE
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

A O
comparison O
of O
the O
CPG O
assay O
to O
dextran O
coated O
charcoal O
and O
a O
whole O
cell O
assay O
demonstrates O
that O
CPG O
and O
dextran O
coated O
charcoal O
give O
equivalent O
measurements O
of O
cytosolic B_GENE
receptor I_GENE
concentration O
, O
while O
the O
CPG O
and O
whole O
cell O
assays O
provide O
equivalent O
values O
for O
total O
receptor O
content O
. O

Plasmacytoid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blast B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
crisis B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
B-cell B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
chronic B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
lymphocytic B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
leukemia B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
: O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
and O
differentiation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
vitro B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Evolution O
of O
a O
case O
of O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
into O
blast O
crisis O
was O
found O
to O
be O
characterized O
by O
three O
unusual O
features O
( O
1 O
) O
the O
phenotype O
of O
the O
emerging O
blast O
cells O
was O
that O
of O
pre-plasmacytoid O
cells O
as O
shown O
by O
plasma O
cell O
morphology O
and O
an O
immunological O
phenotype O
corresponding O
partially O
with O
CLL- O
or O
intermediate O
B-cells O
, O
partially O
with O
plasma O
cells O
( O
terminal B_GENE/B_LOCATION
transferase I_GENE/I_LOCATION
- O
, O
common O
acute B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leukemia I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
, O
Ia+ B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
surface B_GENE
immunoglobulin I_GENE
heavy I_GENE
chains I_GENE
- O
, O
surface B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
+ O
, O
intracytoplasmic B_GENE/B_DISEASE
immunoglobulin I_GENE/I_DISEASE
A+ I_GENE/I_DISEASE
and I_GENE/I_DISEASE
G+ I_GENE/I_DISEASE
, O
BA-1+ B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
polyclonal O
gammaglobulin O
production O
) O
; O
( O
2 O
) O
cytogenetic O
analysis O
of O
spontaneous O
metaphases O
revealed O
that O
in O
addition O
to O
the O
typical O
CLL O
abnormality O
, O
trisomy O
12 O
, O
in O
all O
of O
the O
cells O
, O
an O
additional O
translocation O
between O
chromosomes B_DISEASE/B_GENE
14 I_DISEASE/I_GENE
and I_DISEASE/I_GENE
17 I_DISEASE/I_GENE
was O
present O
in O
40 O
% O
with O
a O
presumptive O
breakpoint O
on O
chromosome B_GENE/B_MEASURE
14 I_GENE/I_MEASURE
( O
q12-3 O
) O
never O
described O
before O
( O
commonly O
q32 O
) O
and O
( O
3 O
) O
the O
progression O
of O
the O
disease O
was O
associated O
with O
a O
striking O
increase O
in O
the O
expression O
by O
the O
transformed O
cells O
of O
specific O
binding O
sites O
for O
estradiol O
( O
E2 O
) O
due O
to O
an O
actual O
increase O
in O
total O
cellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
not O
to O
a O
change O
in O
receptor O
affinity O
for O
E2 O
. O

The O
functional O
status O
of O
the O
steroid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
confirmed O
by O
nuclear O
transfer O
of O
the O
cytoplasmic B_GENE
hormone-receptor I_GENE
complex I_GENE
upon O
temperature O
activation O
. O

Since O
the O
rise O
in O
E2-receptor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
display O
paralleled O
a O
large O
increase O
in O
the O
proliferative O
activity O
of O
the O
cells O
as O
well O
as O
a O
change O
in O
their O
maturation O
status O
the O
question O
was O
raised O
as O
to O
whether O
the O
E2-receptor B_PROTEIN[GENE]/B_MEASURE
should O
be O
considered O
as O
a O
physiological O
marker O
of O
growth O
rate O
or O
of O
cellular O
differentiation O
. O

Exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
patient B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
's I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blast I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
E2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
resulted O
in O
cessation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O
at O
least O
one B_TIME[MEASURE]
mitosis I_TIME[MEASURE]
after O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
inducer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
seen O
from O
the O
replacement B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
the O
large B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blasts B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
small B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
CLL-like B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
without O
definite B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
signs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
alteration B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
differentiation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
status B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

This O
suggests O
the O
association O
of O
E2-receptor B_GENE
expression O
with O
control O
of O
growth O
rather O
than O
cell O
maturation O
. O

Multiple O
forms O
and O
fragments O
of O
cytosolic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
human O
leukemic O
cells O
and O
normal O
lymphocytes O
. O

Therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
generally O
more O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
acute B_DISEASE/B_LOCATION
lymphoblastic I_DISEASE/I_LOCATION
leukemia I_DISEASE/I_LOCATION
than O
in O
other B_DISEASE/B_NUMBER[MEASURE]
types I_DISEASE/I_NUMBER[MEASURE]
of O
human B_DISEASE
leukemia I_DISEASE
. O

Previous O
studies O
, O
however O
, O
have O
not O
revealed O
any O
consistent O
relationship O
between O
clinical O
responsiveness O
and O
the O
cellular O
or O
cytosolic O
concentration O
of O
glucocorticoid-binding B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
objectives O
of O
this O
study O
were O
to O
determine O
whether O
there O
are O
intrinsic O
structural O
differences O
among O
the O
glucocorticoid B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
various O
types O
of O
leukemic O
cells O
and O
normal O
lymphocytes O
and O
to O
investigate O
the O
role O
of O
endogenous B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptidases I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
receptor O
degradation O
. O

Cytosols B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
were O
prepared O
from O
fresh B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
rapidly O
frozen B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leukocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
6 B_MEASURE
healthy I_MEASURE
adults I_MEASURE
and O
35 B_PERSON/B_BIO
high-risk I_PERSON/I_BIO
leukemia I_PERSON/I_BIO
patients I_PERSON/I_BIO
( O
median B_MEASURE/B_LOCATION
white I_MEASURE/I_LOCATION
blood I_MEASURE/I_LOCATION
cell I_MEASURE/I_LOCATION
count I_MEASURE/I_LOCATION
, O
150 B_MEASURE
, O
000 B_MEASURE
cells/microliter I_MEASURE
; O
median B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
, O
13 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
) O
. O

receptors B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
labeled O
with O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triamcinolone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
quantitated O
by O
charcoal-dextran B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
Sephadex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LH-20 O
chromatography B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Mean B_MEASURE/B_LOCATION
and O
median B_MEASURE
cytosolic I_MEASURE
receptor I_MEASURE
concentrations I_MEASURE
in O
12 B_MEASURE/B_DISEASE
acute I_MEASURE/I_DISEASE
lymphoblastic I_MEASURE/I_DISEASE
leukemia I_MEASURE/I_DISEASE
specimens I_MEASURE/I_DISEASE
lacking O
the O
standard B_GENE
B-cell I_GENE
or O
T-cell B_GENE
markers I_GENE
( O
null B_PROTEIN[GENE]/B_LOCATION
cells I_PROTEIN[GENE]/I_LOCATION
'' O
) O
were O
approximately O
4-fold B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
higher B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
in O
23 B_PERSON/B_BIO
other I_PERSON/I_BIO
leukemic I_PERSON/I_BIO
cell I_PERSON/I_BIO
specimens I_PERSON/I_BIO
. O

No O
other B_DISEASE_ADJECTIVE[DISEASE]
consistent I_DISEASE_ADJECTIVE[DISEASE]
differences I_DISEASE_ADJECTIVE[DISEASE]
in O
receptor B_DISEASE/B_GENE
content I_DISEASE/I_GENE
were O
observed O
. O

agarose B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
filtration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
ultracentrifugation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
hypotonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
buffers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
containing O
20 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mM I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Na2MoO4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O
complexes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
similar B_MEASURE/B_COLOR
size I_MEASURE/I_COLOR
and O
shape B_MEASURE
in O
all O
clinical B_NUMBER[MEASURE]
specimens I_NUMBER[MEASURE]
tested O
and O
two B_NUMBER[MEASURE]/B_LOCATION
established O
leukemic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lines I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

They O
had O
Stokes B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radii I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Rs B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
of O
8.1 B_MEASURE
+/- O
0.5 B_MEASURE
( O
S.D B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
) O
nm B_MEASURE/B_LOCATION
( O
n B_OTHER/B_MEASURE
= O
50 B_MEASURE
) O
, O
sedimentation B_MEASURE
coefficients I_MEASURE
of O
9.5 B_MEASURE
+/- I_MEASURE
0.3S I_MEASURE
( O
n B_OTHER/B_MEASURE
= O
40 B_MEASURE
) O
, O
molecular B_MEASURE/B_LOCATION
weights I_MEASURE/I_LOCATION
of O
approximately O
330 B_MEASURE
, O
000 B_MEASURE
, O
and O
axial B_MEASURE
ratios I_MEASURE
( O
a/b B_PROTEIN[GENE]/B_LOCATION
) O
of O
approximately O
12 B_NUMBER[MEASURE]/B_LOCATION
. O

In O
hypertonic O
, O
molybdate-free O
buffer O
, O
these O
oligomeric B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
dissociated O
into O
subunits O
with O
Rs O
of O
5.9 O
+/- O
0.3 O
nm O
( O
n O
= O
12 O
) O
and O
a/b O
of O
11 O
to O
12 O
, O
as O
observed O
previously O
for O
other O
receptors O
. O

Fragmentation O
of O
the O
oligomer B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
subunit B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
evident O
in O
some O
cytosols O
. O

High O
activities O
of O
peptidases B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
various O
specificities O
were O
detected O
in O
leukemic O
cell O
cytosols O
, O
as O
in O
other O
cytosols O
, O
by O
fluorometric O
assays O
with O
derivatives O
of O
7-amino-4-methylcoumarin O
. O

receptor O
cleavage O
by O
these O
and O
other O
endogenous B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzymes I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
account O
for O
previous O
observations O
of O
`` O
abnormal O
'' O
receptors O
in O
cytosols O
from O
some O
leukemic O
specimens O
. O

We O
conclude O
that O
intrinsic B_DISEASE_ADJECTIVE[DISEASE]
structural I_DISEASE_ADJECTIVE[DISEASE]
defects I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
receptors B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
unlikely B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
explanations I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
unresponsiveness B_DISEASE_ADJECTIVE[DISEASE]
of O
some O
types B_PERSON/B_LOCATION
of O
leukemia B_DISEASE
to O
steroid O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Glucocorticoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
number O
and O
intracellular O
water O
space O
. O

In O
order O
to O
elucidate O
the O
relationship O
between O
cell O
water O
content O
and O
number O
of O
glucocorticoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
eleven O
normal O
and O
malignant O
lymphoid O
or O
myelomonocytic O
cell O
types O
originating O
from O
mouse O
, O
rat O
and O
man O
were O
investigated O
. O

The O
cellular O
water O
space O
was O
measured O
with O
3H2O O
, O
and O
glucocorticoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
number O
was O
measured O
in O
a O
whole-cell O
binding O
assay O
with O
[ O
3H O
] O
dexamethasone O
at O
30 O
and O
37 O
degrees O
C O
. O

The O
intracellular O
water O
phase O
concentration O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
around O
40 O
nmol/l O
cell O
water O
) O
, O
and O
the O
dependence O
of O
receptor O
affinity O
on O
temperature O
were O
similar O
in O
normal O
and O
malignant O
rodent O
and O
human O
cells O
. O

It O
is O
concluded O
that O
comparisons O
of O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
are O
best O
made O
on O
the O
basis O
of O
intracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
concentrations O
. O

Covalent O
labeling O
of O
rat O
thymocyte O
and O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
lymphoid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
glucocorticoid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
receptor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

Lymphoid O
cells O
contain O
specific O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
glucocorticoids O
. O

We O
have O
used O
[ O
3H O
] O
dexamethasone-21-mesylate O
to O
label O
covalently O
glucocorticoid B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rat O
thymic O
lymphocytes O
and O
in O
neoplastic O
cells O
obtained O
from O
patients O
with O
acute O
lymphoblastic O
leukemia O
and O
malignant O
lymphoma O
. O

The O
covalently O
labeled O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
identified O
by O
polyacrylamide O
gel O
electrophoresis O
( O
in O
the O
presence O
of O
0.1 O
% O
sodium O
dodecyl O
sulfate O
) O
. O

In O
cytosolic O
fractions O
prepared O
from O
rat O
thymic O
lymphocytes O
, O
[ O
3H O
] O
-dexamethasone-21-mesylate O
labels O
a O
protein O
( O
Mr O
approximately O
equal O
to O
95 O
, O
000 O
) O
which O
was O
identified O
as O
the O
glucocorticoid B_GENE
receptor I_GENE
by O
the O
following O
criteria O
: O
( O
a O
) O
labeling O
of O
this O
moiety O
is O
inhibited O
by O
treatment O
with O
a O
100-fold O
molar O
excess O
of O
glucocorticoids O
, O
such O
as O
dexamethasone O
and O
triamcinolone O
acetonide O
; O
and O
( O
b O
) O
the O
covalently O
labeled O
Mr O
approximately O
equal O
to O
95 O
, O
000 O
protein O
is O
activated O
( O
by O
heating O
at O
20 O
degrees O
for O
30 O
min O
) O
to O
a O
form O
that O
binds O
to O
DNA-cellulose O
. O

When O
intact B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
thymocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
are O
treated O
with O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dexamethasone-21-mesylate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
an O
Mr B_PROTEIN[GENE]/B_MEASURE
approximately O
equal B_MEASURE
to O
95 B_MEASURE
, O
000 B_MEASURE/B_PERSON
moiety I_MEASURE/I_PERSON
is O
also O
labeled O
covalently O
. O

Approximately O
35 O
% O
of O
the O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
labeled O
covalently O
when O
intact O
thymocytes O
are O
treated O
with O
100 O
nm O
[ O
3H O
] O
dexamethasone-21-mesylate O
for O
30 O
min O
at O
4 O
degrees O
. O

Neoplastic B_PERSON/B_DISEASE
cells I_PERSON/I_DISEASE
from O
acute B_DISEASE
lymphoblastic I_DISEASE
leukemia I_DISEASE
and O
malignant B_DISEASE
lymphoma I_DISEASE
were O
treated O
with O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dexamethasone-21-mesylate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
all O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
an O
Mr B_PROTEIN[GENE]/B_MEASURE
approximately O
equal B_MEASURE
to O
95 B_MEASURE
, O
000 B_MEASURE/B_PERSON
moiety I_MEASURE/I_PERSON
was O
labeled O
covalently O
; O
labeling B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
inhibited O
by O
excess B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Smaller B_NUMBER[MEASURE]/B_PERSON
moieties I_NUMBER[MEASURE]/I_PERSON
were O
also O
identified O
by O
competition O
experiments O
; O
these O
may O
represent O
proteolytic B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
fragments I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
Mr O
approximately O
equal O
to O
95 O
, O
000 O
receptor O
. O

Thus O
, O
in O
rat O
and O
human O
lymphoid O
cells O
, O
[ O
3H O
] O
dexamethasone-21-mesylate O
can O
be O
used O
to O
label O
covalently O
the O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
association O
of O
cytosol O
oestrogen B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
progesterone I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
histological O
features O
of O
breast O
cancer O
and O
early O
recurrence O
of O
disease O
. O

Two O
hundred O
and O
eighty-eight O
primary O
breast O
tumours O
were O
examined O
for O
the O
presence O
or O
absence O
of O
oestrogen B_DISEASE/B_GENE
( I_DISEASE/I_GENE
REc I_DISEASE/I_GENE
) I_DISEASE/I_GENE
and I_DISEASE/I_GENE
progesterone I_DISEASE/I_GENE
( I_DISEASE/I_GENE
RPc I_DISEASE/I_GENE
) I_DISEASE/I_GENE
receptors I_DISEASE/I_GENE
. O

Analysis O
has O
shown O
a O
relative O
interdependence O
between O
the O
steroid B_GENE
receptor I_GENE
status O
of O
primary O
breast O
cancer O
and O
other O
prognostic O
variables O
such O
as O
histological O
grade O
, O
lymphocytic O
infiltration O
and O
tumour O
elastosis O
. O

There O
were O
significant O
associations O
between O
epithelial O
cellularity O
, O
stromal O
fibrosis O
and O
the O
value O
of O
REc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
those O
tumours O
in O
which O
the O
receptor O
was O
present O
. O

Cellularity O
and O
fibrosis O
were O
unrelated O
to O
the O
presence O
or O
absence O
of O
oestrogen B_DISEASE/B_GENE
receptor I_DISEASE/I_GENE
. O

By O
contrast O
, O
neither O
the O
presence O
or O
absence O
nor O
the O
value O
of O
RPc B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
related O
to O
cellularity O
or O
fibrosis O
. O

The O
value O
of O
REc B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
RPc B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O
as O
an O
indicator O
of O
prognosis O
was O
examined O
in O
a O
sub-group O
of O
175 O
patients O
receiving O
no O
additional O
treatment O
following O
mastectomy O
. O

Overall O
relapse-free O
survival O
( O
RFS O
) O
was O
no O
different O
for O
those O
patients O
with O
receptors O
compared O
to O
those O
without O
them O
( O
REc B_LOCATION
P O
= O
0.11 O
, O
RPc O
P O
= O
0.7 O
) O
. O

There O
was O
no O
difference B_MEASURE
in O
RFS B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
receptor B_DISEASE/B_GENE
positive I_DISEASE/I_GENE
and O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
tumours I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
when O
the O
axillary B_DISEASE/B_MEASURE
node B_DISEASE/I_MEASURE
status B_DISEASE/I_MEASURE
was O
taken O
into O
account B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Clinical O
implications O
of O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
human O
leukemia O
. O

Normal O
lymphoid O
cells O
contain O
glucocorticoid B_GENE
receptor I_GENE
. O

A O
variety B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
stimuli B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
activate O
these O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
also O
induce O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Similar O
glucocorticoid B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
detected O
in O
lymphoid O
cells O
from O
patients O
with O
acute O
lymphoblastic O
leukemia O
( O
All O
) O
. O

absence O
of O
the O
glucocorticoid B_GENE/B_DISEASE
receptor I_GENE/I_DISEASE
( O
usually O
found O
in O
treated O
patients O
) O
predicts O
lack O
of O
glucocorticoid O
responsiveness O
. O

Furthermore O
, O
in O
our O
hands O
, O
glucocorticoid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O
correlate O
with O
the O
duration O
of O
complete O
remission O
in O
All O
( O
though O
not O
in O
other O
forms O
of O
leukemia O
) O
. O

This O
association B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
independent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
cell B_MEASURE/B_DISEASE
type I_MEASURE/I_DISEASE
, O
age B_MEASURE/B_LOCATION
, O
sex B_PERSON/B_MEASURE
, O
or O
initial B_MEASURE/B_LOCATION
leukocyte B_MEASURE/I_LOCATION
count B_MEASURE/I_LOCATION
. O

The O
level B_MEASURE/B_LOCATION
of O
receptor B_GENE
shows O
a O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlation B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
increasing O
aggressiveness B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
the O
tumor B_DISEASE/B_PERSON
( O
null-cell B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
leukemia B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
greater B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O
T-cell B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
leukemia I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
greater I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O
Burkitt B_DISEASE
's I_DISEASE
lymphoma I_DISEASE
) O
. O

Corticosteroid-mediated B_PERSON/B_LOCATION
immunoregulation I_PERSON/I_LOCATION
in O
man B_DISEASE
. O

glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O
profound B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
human B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
the O
precise B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
corticosteroid-induced B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoregulation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
man B_DISEASE/B_BIO
have O
not O
been O
precisely O
defined O
. O

Intracytoplasmic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
corticosteroid-specific I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
receptors I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
appear O
to O
be O
an O
important O
common O
pathway O
for O
steroid-induced O
changes O
, O
but O
variations O
of O
receptor O
parameters O
do O
not O
account O
for O
the O
multifaceted O
effects O
on O
the O
immune O
system O
. O

Human B_PERSON/B_SPECIES[BIO]
circulating O
mononuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
redistribute O
out O
of O
the O
intravascular B_BODY_PART_OR_ORGAN_COMPONENT
compartment I_BODY_PART_OR_ORGAN_COMPONENT
following O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
corticosteroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Although O
certain B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
components I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O
this O
redistribution B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
phenomenon I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
well-characterized O
, O
the O
importance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
compartmental B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cellular I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
shift I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O
respect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
corticosteroid-induced B_DISEASE
immunoregulation I_DISEASE
are O
less O
well-defined B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
observations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
activated O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
may O
be O
sensitive B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
the O
lytic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effects I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
under O
certain B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
situations B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
elimination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
selected O
subsets B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
may O
be O
a O
relevant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanism I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
corticosteroid-mediated B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
immunoregulation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
man B_PERSON/B_BIO
. O

Corticosteroid-mediated B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
monocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanism I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
drug-induced B_DISEASE_ADJECTIVE[DISEASE]
immunoregulation I_DISEASE_ADJECTIVE[DISEASE]
in O
monocyte-dependent B_DISEASE/B_BIO
responses I_DISEASE/I_BIO
. O

In O
some O
experimental O
conditions O
, O
corticosteroids O
inhibit O
Interleukin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O
by O
monocytes O
. O

The O
immunoregulatory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
corticosteroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
lymphocyte B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
complex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
vitro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
corticosteroids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
appear O
to O
selectively O
affect O
early B_DISEASE_ADJECTIVE[DISEASE]
immunoregulatory I_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
as O
opposed O
to O
altering O
an O
established O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Multiple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
steroid-induced B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modulations B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
human B_DISEASE/B_GENE
B I_DISEASE/I_GENE
cell I_DISEASE/I_GENE
responses I_DISEASE/I_GENE
have O
been O
defined O
. O

Human B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lines I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
II B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Whole B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cytoplasmic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
properties B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
lymphoblastoid B_DISEASE
, O
leukaemia B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
lymphoma B_DISEASE
lines I_DISEASE
. O

The O
glucocorticoid B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
18 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
human I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
lymphoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
lines I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
HLCL B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
have O
been O
investigated O
. O

The O
specificity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
confirmed O
with O
various B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agonists I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
antagonists B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
gradation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
whole B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cytoplasmic B_MEASURE/B_BIO
glucocorticoid I_MEASURE/I_BIO
binding I_MEASURE/I_BIO
capacity I_MEASURE/I_BIO
was O
observed O
in O
the O
different B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cell I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
line I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
types I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
: O
lymphoblastoid B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
greater B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O
lymphoma B_DISEASE
greater I_DISEASE
than O
leukaemia B_DISEASE
. O

The O
cytoplasmic B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptors I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
of O
leukaemia O
and O
lymphoblastoid O
lines O
appeared O
to O
contain O
both O
proteinaceous O
and O
phospholipid O
components O
. O

Cytoplasmic B_PERSON/B_GENE
steroid-receptor I_PERSON/I_GENE
complexes I_PERSON/I_GENE
exhibited O
a O
wide O
range O
of O
sedimentation O
coefficients O
( O
8.5-11.3S O
) O
in O
low O
ionic O
strength O
buffer O
but O
there O
was O
no O
correlation O
with O
cell O
line O
type O
or O
glucocorticoid O
sensitivity O
. O

Activation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
these O
complexes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O
heat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
37 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
degrees I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
or O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
high B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ionic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strength I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
buffer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0.3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
M I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
NaCl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
induced O
nuclear B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
but O
only B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
high B_LOCATION/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
ionic B_LOCATION/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
strength B_LOCATION/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
buffer B_LOCATION/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
manifested O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
sedimentation B_MEASURE/B_DISEASE
coefficient I_MEASURE/I_DISEASE
. O

No O
correlation B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
between O
the O
level B_MEASURE/B_LOCATION
or O
nature B_MEASURE
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
the O
cytolethal B_BIO/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
cytostatic B_DISEASE_ADJECTIVE[DISEASE]
responsiveness I_DISEASE_ADJECTIVE[DISEASE]
of O
HLCL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
to O
glucocorticoid O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
vitro B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
resistance O
to O
cytolethal O
effects O
can O
not O
be O
ascribed O
to O
a O
failure O
of O
cells O
to O
take O
up O
and O
bind O
steroid O
or O
to O
significant O
differences O
in O
the O
molecular O
species O
of O
cytoplasmic B_PROTEIN[GENE]
receptors I_PROTEIN[GENE]
present O
. O

The O
molecular B_LOCATION
mechanisms I_LOCATION
by O
which O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
achieve O
cytolethal B_DISEASE_ADJECTIVE[DISEASE]
responses I_DISEASE_ADJECTIVE[DISEASE]
in O
human B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
lymphoid I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
cells I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

CD28 B_GENE
-mediated O
activation O
in O
CD45RA+ O
and O
CD45RO+ O
T O
cells O
: O
enhanced O
levels O
of O
reactive O
oxygen O
intermediates O
and O
c-Rel B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear O
translocation O
in O
CD45RA+ O
cells O
. O

We O
have O
analyzed O
the O
effect O
of O
complete O
T O
cell O
activation O
( O
anti-CD3 B_GENE
plus O
anti-CD28 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
on O
the O
activation O
of O
NF-kappaB B_GENE
in O
CD45RA+ O
( O
naive O
) O
and O
CD45RO+ O
( O
memory/effector O
) O
T O
cells O
. O

Long O
exposure O
( O
24 O
h O
) O
induced O
stronger O
NF-kappaB B_GENE
DNA O
binding O
in O
CD45RA+ O
cells O
than O
in O
CD45RO+ O
cells O
. O

Analysis O
of O
the O
nuclear B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
c-Rel B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
that O
after O
anti-CD3+anti-CD28 O
stimulation O
the O
level O
of O
c-Rel B_GENE
was O
higher O
in O
CD45RA+ O
cells O
. O

Analysis O
of O
the O
cytoplasmic O
inhibitor O
IkappaBalpha B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
that O
anti-CD3+anti-CD28 O
stimulation O
induced O
a O
long-lasting O
degradation O
in O
CD45RA+ O
cells O
but O
in O
CD45RO+ O
cells O
the O
degradation O
process O
was O
more O
rapid O
. O

Because O
the O
CD28 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
costimulus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
known O
to O
induce O
the O
production B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
reactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
oxygen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
intermediates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O
ROIs B_GENE/B_DISEASE
) O
, O
the O
intracellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ROI I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
CD45RA+ B_GENE/B_DISEASE
and O
CD45RO+ B_GENE/B_BIO
cells I_GENE/I_BIO
were O
compared O
by O
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

ROIs B_MEASURE/B_GENE
were O
produced O
in O
both O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
types I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
but O
more O
strongly O
in O
CD45RA+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
further O
emphasize O
the O
differences B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O
CD45RA+ B_GENE
and O
CD45RO+ B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
ROI-dependent B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O
pathways B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Ikaros B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O
hemopoietic O
lineage O
determination O
and O
homeostasis O
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
the O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O
control O
hemopoietic B_DISEASE/B_ORGANISM_FUNCTION
differentiation B_DISEASE/I_ORGANISM_FUNCTION
have O
focused O
on O
signaling O
cascades B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O
nuclear B_LOCATION/B_ORGANIZATION
effectors I_LOCATION/I_ORGANIZATION
that O
drive O
this O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developmental B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
regulated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fashion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Here O
we O
review O
the O
role O
of O
Ikaros B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
founding O
member O
of O
a O
unique O
family O
of O
zinc B_GENE/B_BIO
finger I_GENE/I_BIO
transcription I_GENE/I_BIO
factors I_GENE/I_BIO
in O
this O
developmental O
process O
. O

Studies O
on O
an O
Ikaros B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
null O
mutation O
have O
revealed O
an O
essential O
role O
for O
this O
factor O
in O
lymphoid O
cell O
fate O
determination O
and O
at O
subsequent O
branch O
points O
of O
the O
T O
cell O
differentiation O
pathway O
. O

differences O
in O
the O
phenotypes O
of O
a O
null O
and O
a O
dominant O
negative O
( O
DN O
) O
Ikaros O
mutation O
provide O
insight O
into O
a O
regulatory O
network O
through O
which O
Ikaros B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exert O
their O
effects O
in O
development O
. O

In O
addition O
a O
comparative O
analysis O
of O
the O
hemopoietic O
stem O
cell O
and O
precursor O
compartment O
resulting O
from O
the O
two O
Ikaros B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutations O
reveals O
a O
profound O
yet O
not O
absolute O
requirement O
for O
Ikaros B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
production O
and O
differentiation O
of O
these O
populations O
. O

Overexpression O
of O
p65 O
and O
c-Jun O
substitutes O
for O
B7-1 O
costimulation O
by O
targeting O
the O
CD28RE B_GENE/B_LOCATION
within O
the O
IL-2 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
role O
of O
Rel B_GENE/B_DISEASE
and O
activation B_GENE
protein-1 I_GENE
( O
AP-1 B_GENE/B_DISEASE
) O
in O
IL-2 B_GENE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoter B_GENE/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
in O
B7-1- O
and O
leukocyte O
function-associated O
Ag-3 O
( O
LFA. O
3 O
) O
-costimulated O
T O
cells O
has O
been O
evaluated O
. O

We O
demonstrate O
that O
overexpression O
of O
c-Jun B_GENE
but O
not O
c-Fos B_GENE
increases O
IL-2 B_GENE
promoter I_GENE
activity O
in O
both O
B7-1- O
and O
LFA-3-costimulated O
Jurkat O
T O
cells O
. O

Cotransfection O
of O
both O
c-Jun O
and O
c-Fos O
substitutes O
for O
B7-1 O
costimulation O
in O
driving O
an O
activation B_GENE/B_LOCATION
protein-1 I_GENE/I_LOCATION
response I_GENE/I_LOCATION
element I_GENE/I_LOCATION
but O
not O
for O
the O
IL-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Overexpression O
of O
Rel B_GENE
proteins I_GENE
demonstrated O
that O
p65-expressing O
Jurkat O
cells O
transcribed O
equally O
well O
a O
nuclear B_GENE/B_MEASURE
factor I_GENE/I_MEASURE
kappabeta I_GENE/I_MEASURE
reporter I_GENE/I_MEASURE
construct I_GENE/I_MEASURE
when O
costimulated O
with O
B7-1 B_GENE
or O
LFA-3 B_GENE
, O
but O
transcription O
of O
IL-2 B_GENE
promoter I_GENE
or O
CD28 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CD28RE I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-driven I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
superior O
in O
B7-1-costimulated O
cells O
. O

Combined O
expression O
of O
c-Jun B_GENE
and O
p65 B_GENE
induced O
vigorous O
transcription O
of O
IL-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CD28RE-driven I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
both O
LFA-3- O
and O
B7-1-costimulated O
Jurkat O
cells O
. O

Mutating O
the O
CD28RE B_GENE/B_LOCATION
but O
not O
the O
upstream B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappabeta-binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
IL-2 B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
reduced O
B7-1 B_GENE
-driven O
transcription O
> O
90 O
% O
. O

The O
results O
implicates O
a O
major O
role O
of O
the O
CD28RE B_GENE/B_LOCATION
in O
the O
integration O
of O
p65 B_GENE
/ O
c-Jun B_GENE
-mediated O
transcription O
within O
the O
IL-2 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
suggest O
that O
the O
transition O
from O
an O
autocrine O
LFA-3 B_GENE
-driven O
immune O
response O
to O
a O
B7 O
-- O
induced O
paracrine O
immune O
response O
involves O
the O
activation O
of O
c-Jun B_GENE
and O
p65 B_GENE
, O
which O
target O
the O
CD28RE B_GENE
region O
of O
the O
IL-2 B_GENE
promoter I_GENE
. O

defects B_DISEASE_ADJECTIVE[DISEASE]
in O
actin-cap B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
formation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
Vav-deficient B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mice B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
implicate O
an O
actin B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirement I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
lymphocyte B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
signal B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
transduction B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

Background O
: O
Antigen-receptor O
interactions O
on O
lymphocytes O
result O
in O
local O
clustering O
of O
actin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
receptors O
and O
signaling O
molecules O
into O
an O
asymmetric O
membrane O
structure O
termed O
a O
cap O
. O

Although O
actin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerization I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
known O
to O
be O
required O
, O
the O
mechanisms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
underlying O
cap B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
formation I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
unclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
studied O
the O
events O
underlying O
cap O
formation O
using O
mice O
bearing O
a O
null O
mutation O
in O
vav B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
vav B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-/- O
) O
, O
a O
gene O
that O
encodes O
a O
guanine-nucleotide B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
exchange I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
GTPase B_GENE
Rac I_GENE
. O

Results O
: O
Lymphocytes O
from O
vav B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-/- O
mice O
failed O
to O
form O
T-cell O
receptor O
caps O
following O
activation O
and O
had O
a O
defective O
actin O
cytoskeleton O
. O

The O
vav-/- B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
deficient B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
interleukin-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IL-2 B_GENE/B_MEASURE
) O
production B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
proliferation B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
and O
the O
peak B_MEASURE
of O
Ca2+ B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mobilization B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reduced O
although O
of O
normal B_TIME[MEASURE]
duration I_TIME[MEASURE]
. O

activation O
of O
Jun B_GENE/B_DISEASE
N-terminal I_GENE/I_DISEASE
kinase I_GENE/I_DISEASE
or O
stress-activated B_GENE
kinase I_GENE
( O
JNK B_GENE/B_LOCATION
or O
SAPK B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
mitogen-activated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MAPK B_GENE/B_LOCATION
) O
and O
the O
induction O
of O
the O
transcription B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-ATc1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
egr-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
normal O
. O

Despite O
the O
reduced O
Ca2+ O
mobilization O
, O
translocation O
of O
cytoplasmic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NF-ATc I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
nucleus O
was O
normal O
, O
reflecting O
that O
the O
lower O
levels O
of O
Ca2+ O
in O
vav-/- O
cells O
were O
still O
sufficient O
to O
activate O
calcineurin B_GENE
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
with O
cytochalasin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
blocks O
actin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerization I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
inhibited B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cap I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
produced O
defects B_DISEASE_ADJECTIVE[DISEASE]
in O
signaling O
and O
IL-2 B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
transcriptional B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
induction B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
response B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
antigen-receptor B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
were O
nearly O
identical B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
those O
seen O
in O
vav-/- B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
transfection O
studies O
, O
either O
constitutively O
active O
Vav B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O
Rac B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
complement O
constitutively O
active O
calcineurin B_GENE
to O
activate O
NF-AT-dependent O
transcription O
. O

conclusions O
: O
These O
results O
indicate O
that O
Vav B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
required O
for O
cap O
formation O
in O
lymphocytes O
. O

Furthermore O
, O
the O
correlation B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
cap B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
formation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
IL-2 O
production B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
proliferation B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
supports O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
an O
actin-dependent B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
a O
source B_LOCATION
of O
specialized B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulatory B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CD14 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O
activation O
of O
human O
endothelial O
cells O
by O
Bacteroides O
fragilis O
outer O
membrane O
. O

We O
studied O
the O
capacity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
isolated B_BACTERIUM[BIO]
Bacteriodes I_BACTERIUM[BIO]
fragilis O
outer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
membrane I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
B B_PROTEIN[GENE]/B_DISEASE
. O
fragilis B_BACTERIUM[BIO]
NCTC9343 I_BACTERIUM[BIO]
lipopolysaccharide I_BACTERIUM[BIO]
( O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
; O
endotoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
and O
B B_PROTEIN[GENE]/B_DISEASE
. O
fragilis B_BACTERIUM[BIO]/B_DISEASE
NCTC9343 I_BACTERIUM[BIO]/I_DISEASE
capsular I_BACTERIUM[BIO]/I_DISEASE
polysaccharides I_BACTERIUM[BIO]/I_DISEASE
to O
activate O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
umbilical I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
vein I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
endothelial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
HUVEC B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
) O
monolayers B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

To O
assess O
HUVEC O
activation O
, O
E-selectin B_GENE
expression O
was O
measured O
by O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
, O
Northern O
blot O
analysis O
for O
E-selectin-specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
electrophoretic O
gel O
mobility O
shift O
assay O
( O
EMSA O
) O
for O
NF-kappa B_GENE
B I_GENE
, O
a O
transcription B_GENE/B_MEASURE
factor I_GENE/I_MEASURE
necessary O
for O
E-selectin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
gene I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
activation O
. O

exposure O
of O
HUVECs O
to O
B. O
fragilis O
outer O
membrane O
fractions O
, O
separated O
from O
other O
components O
of O
the O
B. O
fragilis O
cell O
wall O
by O
isopycnic O
, O
sucrose O
gradient O
centrifugation O
, O
significantly O
increased O
surface O
expression O
of O
E-selectin B_GENE
and O
induced O
functional O
endothelial O
cell O
-dependent O
leukocyte O
adhesion O
. O

B. O
fragilis O
outer O
membranes O
induced O
translocation O
of O
NF-kappa B_GENE
B I_GENE
to O
HUVEC O
nuclei O
and O
accumulation O
of O
E-selectin B_GENE
mRNA I_GENE
in O
HUVEC O
cytoplasm O
. O

E-selectin B_DISEASE_ADJECTIVE[DISEASE]
expression I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
B B_PROTEIN[GENE]/B_DISEASE
. O
fragilis B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
outer I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
membranes I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
was O
not O
blocked O
by O
polymixin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
E-selectin B_DISEASE_ADJECTIVE[DISEASE]
expression I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
outer B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
fractions I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
purified O
from O
E B_OTHER/B_PERSON
. O
coli B_BACTERIUM[BIO]/B_PERSON
was O
competitively O
inhibited O
by O
polymixin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Neither O
purified O
B B_PROTEIN[GENE]/B_DISEASE
. O
fragilis B_BACTERIUM[BIO]/B_GENE
LPS I_BACTERIUM[BIO]/I_GENE
, O
a O
prominent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
constituent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
outer B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
membrane B_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
nor O
purified O
B B_PROTEIN[GENE]/B_DISEASE
. O
fragilis B_BACTERIUM[BIO]
capsular I_BACTERIUM[BIO]
polysaccharides I_BACTERIUM[BIO]
induced O
HUVEC B_DISEASE_ADJECTIVE[DISEASE]
activation I_DISEASE_ADJECTIVE[DISEASE]
. O

Two O
different O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
directed O
against O
human B_GENE
CD14 I_GENE
completely O
inhibited O
B. O
fragilis O
outer O
membrane-induced O
NF-kappa B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O
, O
E-selectin O
transcription O
, O
and O
E-selectin O
surface O
expression O
. O

We O
conclude O
that O
the O
outer O
membrane O
component O
of O
the O
B. O
fragilis O
cell O
wall O
contains O
a O
proinflammatory O
factor O
( O
s O
) O
, O
that O
is O
not O
LPS O
, O
which O
induces O
human O
endothelial O
cell O
activation O
by O
a O
soluble O
CD14 B_GENE
-dependent O
mechanism O
. O

NF-kappaB B_GENE
protects O
HIV-1-infected O
myeloid O
cells O
from O
apoptosis O
. O

HIV-1 O
infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
primary B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
myeloid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lines B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
sustained O
NF-kappaB B_DISEASE/B_GENE
activation I_DISEASE/I_GENE
. O

Recently O
, O
NF-kappaB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
induction I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
shown O
to O
play O
a O
role B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
protecting O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
programmed O
cell B_DISEASE
death I_DISEASE
. O

In O
the O
present O
study O
, O
we O
sought O
to O
investigate O
whether O
constitutive O
NF-kappaB B_GENE
activity O
in O
chronically O
HIV-1-infected O
promonocytic O
U937 O
( O
U9-IIIB O
) O
and O
myeloblastic O
PLB-985 O
( O
PLB-IIIB O
) O
cells O
affects O
apoptotic O
signaling O
. O

TNFalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
cycloheximide O
caused O
infected O
cells O
to O
undergo O
apoptosis O
more O
rapidly O
than O
parental O
U937 O
and O
PLB-985 O
cells O
. O

Inhibition O
of O
TNFalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O
NF-kappaB O
activation O
using O
the O
antioxidant O
N-acetylcysteine O
( O
NAC O
) O
resulted O
in O
increased O
apoptosis O
in O
both O
U937 O
and O
U9-IIIB O
cells O
, O
while O
preactivation O
of O
NF-kappaB B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O
the O
non-apoptotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inducer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IL-1beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
caused O
a O
relative O
decrease O
in O
apoptosis O
. O

Inhibition O
of O
constitutive O
NF-kappaB B_GENE
activity O
in O
U9-IIIB O
and O
PLB-IIIB O
cells O
also O
induced O
apoptosis O
, O
suggesting O
that O
NF-kappaB O
protects O
cells O
from O
a O
persistent O
apoptotic O
signal O
. O

TNFalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O
NAC O
treatment O
resulted O
in O
a O
marked O
decrease O
in O
Bcl-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O
in O
HIV-1-infected O
cells O
, O
coupled O
with O
an O
increase O
in O
Bax B_GENE/B_DISEASE
protein I_GENE/I_DISEASE
compared O
to O
uninfected O
cells O
, O
suggesting O
that O
the O
difference O
in O
susceptibility O
to O
TNFalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O
apoptosis O
may O
relate O
to O
the O
differences O
in O
relative O
levels O
of O
Bcl-2 B_GENE
and O
Bax B_GENE
. O

The O
protective O
role O
of O
NF-kappaB B_GENE
in O
blocking O
TNFalpha- O
and O
HIV-1-induced O
apoptosis O
was O
supported O
by O
studies O
in O
Jurkat O
T O
cells O
engineered O
to O
express O
IkappaB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repressor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutants I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TD-IkappaB B_PROTEIN[GENE]/B_LOCATION
) O
under O
the O
control O
of O
a O
tetracycline-responsive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

cells O
underwent O
apoptosis O
in O
response O
to O
TNFalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
only O
when O
NF-kappaB O
activation O
was O
inhibited O
by O
TD-IkappaB B_GENE
expression O
. O

As O
was O
observed O
for O
the O
U9-IIIB O
cells O
, O
TNFalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
treatment O
also O
induced O
a O
marked O
decrease O
in O
Bcl-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O
in O
TD-IkappaB O
expressing O
cells O
. O

These O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
that O
apoptotic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
perturbed O
in O
HIV-1-infected B_DISEASE
U9-IIIB I_DISEASE
cells I_DISEASE
and O
indicate O
that O
NF-kappaB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O
play O
an O
additional B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protective B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
HIV-1-induced B_DISEASE/B_GENE
apoptosis I_DISEASE/I_GENE
in O
myeloid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O

Human O
normal O
peripheral O
blood O
B-lymphocytes O
are O
deficient O
in O
DNA-dependent O
protein O
kinase O
activity O
due O
to O
the O
expression O
of O
a O
variant O
form O
of O
the O
Ku86 B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
heterodimeric O
Ku B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
comprises O
a O
86 B_MEASURE/B_PROTEIN[GENE]
kDa I_MEASURE/I_PROTEIN[GENE]
( I_MEASURE/I_PROTEIN[GENE]
Ku86 I_MEASURE/I_PROTEIN[GENE]
) I_MEASURE/I_PROTEIN[GENE]
amd O
a O
70 B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kDa I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ku70 I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunits I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
an O
abundant O
nuclear B_GENE
DNA-binding I_GENE
protein I_GENE
which O
binds O
in O
vitro O
to O
DNA B_GENE
termini I_GENE
without O
sequence O
specificity O
. O

Ku B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
DNA-targeting B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
component I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
large O
catalytic B_LOCATION/B_PERSON
sub-unit I_LOCATION/I_PERSON
of O
the O
DNA-dependent B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
complex I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
DNA-PK B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CS I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
that O
plays O
a O
critical O
role O
in O
mammalian O
double-strand O
break O
repair O
and O
lymphoid O
V O
( O
D O
) O
J O
recombination O
. O

By O
using O
electrophoretic O
mobility O
shift O
assays O
, O
we O
demonstrated O
that O
in O
addition O
to O
the O
major B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ku B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usually O
detected O
in O
cell O
line O
extracts O
, O
a O
second O
complex O
with O
faster O
electrophoretic O
mobility O
was O
observed O
in O
normal O
peripheral O
blood O
lymphocytes O
( O
PBL O
) O
extracts O
. O

The O
presence O
of O
this O
faster B_GENE
migrating I_GENE
complex I_GENE
was O
restricted O
to O
B O
cells O
among O
the O
circulating O
lymphocyte O
population O
. O

Western O
blot O
analysis O
revealed O
that O
B O
cells O
express O
a O
variant O
form O
of O
the O
Ku86 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
an O
apparent O
molecular O
weight O
of O
69 O
kDa O
, O
and O
not O
the O
86 B_GENE/B_MEASURE
kDa- I_GENE/I_MEASURE
full-length I_GENE/I_MEASURE
protein I_GENE/I_MEASURE
. O

Although O
the O
heterodimer B_GENE
Ku70/variant-Ku86 I_GENE
binds O
to O
DNA-ends B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
this O
altered O
form O
of O
the O
Ku B_GENE
heterodimer I_GENE
has O
a O
decreased O
ability O
to O
recruit O
the O
catalytic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
component I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
complex O
, O
DNA-PK B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CS I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
contributes O
to O
an O
absence O
of O
detectable O
DNA-PK O
activity O
in O
B O
cells O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O
a O
molecular B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basis B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
increased O
sensitivity B_DISEASE
of O
B B_DISEASE
cells I_DISEASE
to O
ionizing O
radiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
identify O
a O
new B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
regulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
DNA-PK B_DISEASE/B_GENE
activity B_DISEASE/I_GENE
that O
operates O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Co-stimulation O
of O
human O
peripheral O
blood O
mononuclear O
cells O
with O
IL-2 B_GENE
and O
anti-CD3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
induces O
phosphorylation O
of O
CREB B_GENE
. O

Phosphorylation O
of O
the O
cAMP-response B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CREB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
within O
1 O
h O
of O
CD2 B_GENE
but O
not O
CD3 B_GENE/B_MEASURE
cross-linking O
of O
human O
PBMC O
was O
recently O
demonstrated O
. O

The O
absence O
of O
P-CREB B_GENE
following O
CD3 O
cross-linking O
was O
unexpected O
, O
as O
other O
laboratories O
reported O
increased O
phosphorylation O
of O
CREB B_GENE
following O
CD3 O
cross-linking O
of O
the O
Jurkat O
lymphocyte O
cell O
line O
. O

Due O
to O
Jurkat O
T-cells O
being O
IL-2-independent O
, O
it O
was O
postulated O
that O
IL-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O
provide O
a O
necessary O
co-stimulus O
for O
phosphorylation O
of O
CREB B_GENE
in O
primary O
lymphocytes O
. O

Therefore O
, O
P-CREB B_GENE/B_DISEASE
was O
evaluated O
following O
co-stimulation O
of O
human O
PBMC O
through O
the O
IL-2 B_GENE
and I_GENE
CD2 I_GENE
or I_GENE
CD3 I_GENE
receptors I_GENE
. O

IL-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
further O
augment O
phosphorylation O
of O
CREB B_GENE
following O
CD2 O
cross-linking O
. O

However O
, O
while O
neither O
IL-2 B_GENE
nor O
CD3 O
cross-linking O
alone O
induced O
P-CREB B_GENE/B_DISEASE
, O
a O
4.5-fold O
increase O
in O
phosphorylation O
of O
CREB B_GENE
within O
1 O
h O
of O
IL-2/CD3 O
co-stimulation O
was O
observed O
. O

Phosphorylation O
was O
not O
associated O
with O
the O
induction O
of O
Camp O
, O
and O
inhibition O
of O
PKA O
signaling O
had O
no O
effect O
on O
P-CREB B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

consistent O
with O
signal O
transduction O
through O
p56lck B_GENE
or O
p59fyn B_GENE
, O
inhibition O
of O
PTK O
signaling O
reduced O
phosphorylation O
50 O
% O
. O

Interestingly O
, O
inhibiting O
PKC B_GENE
signaling O
with O
calphostin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
further I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
increased O
P-CREB B_DISEASE/B_GENE
levels I_DISEASE/I_GENE
3-fold I_DISEASE/I_GENE
over O
that O
observed O
in O
IL-2/CD3 B_GENE/B_PERSON
co-stimulated O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
not O
pretreated O
with O
a O
PKC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast O
to O
previous O
studies O
performed O
in O
the O
absence O
of O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
IL-2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
no O
increase O
in O
binding O
of O
CREB B_GENE
to O
a O
32P-labeled O
oligonucleotide O
probe O
was O
observed O
by O
electrophoretic O
mobility O
shift O
assay O
. O

These O
data O
suggest O
that O
the O
IL-2 B_GENE
and O
CD3 B_GENE
signaling O
pathways O
provide O
a O
necessary O
and O
co-operative O
stimulus O
promoting O
phosphorylation O
of O
CREB B_GENE
following O
receptor O
cross-linking O
. O

HIV-1 O
infection B_GENE/B_DISEASE
induces O
a O
selective B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
STAT5 B_DISEASE/B_GENE
protein B_DISEASE/I_GENE
expression B_DISEASE/I_GENE
. O

HIV-1 O
infection B_DISEASE/B_GENE
is O
accompanied O
by O
qualitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
quantitative B_DISEASE_ADJECTIVE[DISEASE]
defects I_DISEASE_ADJECTIVE[DISEASE]
in O
CD4+ B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Loss O
of O
immune O
function O
in O
HIV O
patients O
is O
usually O
associated O
with O
a O
profound O
dysregulation O
of O
cytokine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O
. O

To O
investigate O
whether O
cytokine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O
defects O
occur O
during O
HIV O
infection O
, O
PHA O
blasts O
from O
healthy O
human O
donors O
were O
infected O
with O
two O
strains O
of O
HIV-1 O
and O
screened O
for O
the O
expression O
of O
STAT B_GENE/B_BIO
proteins I_GENE/I_BIO
used O
in O
cytokine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O
. O

A O
selective O
decrease O
in O
STAT5B B_GENE/B_DISEASE
was O
seen O
8 O
days O
after O
infection O
with O
the O
BZ167 O
dual-tropic O
HIV O
isolate O
, O
but O
not O
with O
the O
Ba-L O
, O
M-tropic O
strain O
. O

Based O
on O
these O
findings O
, O
purified O
T O
cells O
from O
HIV-infected O
patients O
in O
different O
stages O
of O
disease O
were O
also O
tested O
for O
STAT O
expression O
; O
decreases O
in O
STAT5A B_GENE
, O
STAT5B B_GENE
, O
and O
STAT1alpha B_GENE
were O
observed O
in O
all O
patients O
. O

The O
reduction O
in O
STATs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
seen O
in O
vivo O
and O
in O
vitro O
after O
HIV O
infection O
may O
contribute O
to O
the O
loss O
of O
T O
cell O
function O
in O
HIV O
disease O
. O

Transcription B_GENE/B_LOCATION
factors I_GENE/I_LOCATION
that O
regulate O
monocyte O
/ O
macrophage O
differentiation O
. O

Although O
all O
the O
cells O
in O
an O
organism O
contain O
the O
same O
genetic O
information O
, O
differences O
in O
the O
cell O
phenotype O
arise O
from O
the O
expression O
of O
lineage-specific B_GENE/B_MEASURE
genes I_GENE/I_MEASURE
. O

During O
myelopoiesis O
, O
external O
differentiating O
signals O
regulate O
the O
expression O
of O
a O
set O
of O
transcription B_GENE
factors I_GENE
. O

The O
combined O
action O
of O
these O
transcription B_GENE
factors I_GENE
subsequently O
determines O
the O
expression O
of O
myeloid-specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
generation O
of O
monocytes O
and O
macrophages O
. O

In O
particular O
, O
the O
transcription B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
factor I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
PU.1 I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
has O
a O
critical O
role O
in O
this O
process O
. O

We O
review O
the O
contribution O
of O
several O
transcription B_GENE
factors I_GENE
to O
the O
control O
of O
macrophage O
development O
. O

Transcription B_GENE
factor I_GENE
LKLF I_GENE
is O
sufficient O
to O
program O
T O
cell O
quiescence O
via O
a O
c-Myc O
-- O
dependent O
pathway O
. O

T O
lymphocytes O
circulate O
in O
a O
quiescent O
state O
until O
they O
encounter O
cognate B_PROTEIN[GENE]
antigen I_PROTEIN[GENE]
bound O
to O
the O
surface O
of O
an O
antigen-presenting O
cell O
. O

The O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O
regulate O
T B_DISEASE
cell I_DISEASE
quiescence I_DISEASE
remain O
largely O
unknown B_DISEASE_ADJECTIVE[DISEASE]
. O

Here O
we O
show O
that O
forced O
expression O
of O
the O
lung B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Kruppel-like I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
LKLF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
Jurkat O
T O
cells O
is O
sufficient O
to O
program O
a O
quiescent O
phenotype O
characterized O
by O
decreased O
proliferation O
, O
reduced O
cell O
size O
and O
protein O
synthesis O
and O
decreased O
surface O
expression O
of O
activation O
markers O
. O

Conversely O
, O
LKLF-deficient B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
produced O
by O
gene B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
targeting B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O
increased O
proliferation B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
, O
increased O
cell B_MEASURE
size I_MEASURE
and O
enhanced B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
surface B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
markers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

LKLF B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O
to O
function O
, O
at O
least O
in O
part O
, O
by O
decreasing O
expression O
of O
the O
proto-oncogene B_GENE
encoding O
c-Myc B_GENE
. O

forced O
expression O
of O
LKLF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
associated O
with O
markedly O
decreased O
c-Myc B_GENE
expression O
. O

In O
addition O
, O
many O
effects O
of O
LKLF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
were O
mimicked O
by O
expression O
of O
the O
dominant-negative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MadMyc I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
rescued O
by O
overexpression O
of O
c-Myc B_GENE
. O

Thus O
, O
LKLF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
both O
necessary O
and O
sufficient O
to O
program O
quiescence O
in O
T O
cells O
and O
functions O
, O
in O
part O
, O
by O
negatively O
regulating O
a O
c-Myc O
-- O
dependent O
pathway O
. O

HTLV-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p12 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhances O
STAT5 O
activation O
and O
decreases O
the O
interleukin-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
requirement O
for O
proliferation O
of O
primary O
human O
peripheral O
blood O
mononuclear O
cells O
. O

The O
p12 B_GENE
( I_GENE
I I_GENE
) I_GENE
protein I_GENE
, O
encoded O
by O
the O
pX B_GENE
open I_GENE
reading I_GENE
frame I_GENE
I I_GENE
of O
the O
human O
T-lymphotropic O
virus O
type O
1 O
( O
HTLV-1 O
) O
, O
is O
a O
hydrophobic B_ENZYME[GENE]/B_MEASURE
protein I_ENZYME[GENE]/I_MEASURE
that O
localizes O
to O
the O
endoplasmic O
reticulum O
and O
the O
Golgi O
. O

Although O
p12 B_GENE/B_LOCATION
( I_GENE/I_LOCATION
I I_GENE/I_LOCATION
) I_GENE/I_LOCATION
contains O
4 O
minimal O
proline-rich O
, O
src B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
homology I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
3-binding I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
motifs I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PXXP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
a O
characteristic O
commonly O
found O
in O
proteins O
involved O
in O
signaling O
pathways O
, O
it O
has O
not O
been O
known O
whether O
p12 B_GENE/B_MEASURE
( I_GENE/I_MEASURE
I I_GENE/I_MEASURE
) I_GENE/I_MEASURE
has O
a O
role O
in O
modulating O
intracellular O
signaling O
pathways O
. O

This O
study O
demonstrated O
that O
p12 B_GENE
( I_GENE
I I_GENE
) I_GENE
binds O
to O
the O
cytoplasmic B_LOCATION/B_PERSON
domain I_LOCATION/I_PERSON
of O
the O
interleukin-2 B_GENE
receptor I_GENE
( I_GENE
IL-2R I_GENE
) I_GENE
beta I_GENE
chain I_GENE
that O
is O
involved O
in O
the O
recruitment O
of O
the O
Jak1 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Jak3 B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kinases B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

As O
a O
result O
of O
this O
interaction O
, O
p12 B_GENE
( I_GENE
I I_GENE
) I_GENE
increases O
signal B_GENE
transducers I_GENE
and I_GENE
activators I_GENE
of I_GENE
transcription I_GENE
5 I_GENE
( O
STAT5 B_GENE
) O
DNA O
binding O
and O
transcriptional O
activity O
and O
this O
effect O
depends O
on O
the O
presence O
of O
both O
IL-2R B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
Jak3 B_GENE
. O

Transduction O
of O
primary O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
with O
a O
human B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
immunodeficiency B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
virus B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
type B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1-based B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
retroviral B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
vector B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
expressing O
p12 B_GENE/B_DISEASE
( I_GENE/I_DISEASE
I I_GENE/I_DISEASE
) I_GENE/I_DISEASE
also O
resulted O
in O
increased O
STAT5 B_GENE
phosphorylation O
and O
DNA O
binding O
. O

However O
, O
p12 B_GENE/B_PERSON
( I_GENE/I_PERSON
I I_GENE/I_PERSON
) I_GENE/I_PERSON
could O
increase O
proliferation O
of O
human O
PBMCs O
only O
after O
stimulation O
of O
T-cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O
treatment O
of O
cells O
with O
low O
concentrations O
of O
alphaCD3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alphaCD28 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

In O
addition O
, O
the O
proliferative O
advantage O
of O
p12 O
( O
I O
) O
-transduced O
PBMCs O
was O
evident O
mainly O
at O
low O
concentrations O
of O
IL-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Together O
, O
these O
data O
indicate O
that O
p12 B_GENE
( I_GENE
I I_GENE
) I_GENE
may O
confer O
a O
proliferative O
advantage O
on O
HTLV-1-infected O
cells O
in O
the O
presence O
of O
suboptimal O
antigen O
stimulation O
and O
that O
this O
event O
may O
account O
for O
the O
clonal O
proliferation O
of O
infected O
T O
cells O
in O
vivo O
. O

( O
Blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O
2001 B_MEASURE
; O
98 B_MEASURE
: O
823-829 B_MEASURE
) O
. O

Single O
dose O
intranasal O
administration O
of O
retinal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
autoantigen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
generates O
a O
rapid O
accumulation O
and O
cell O
activation O
in O
draining O
lymph O
node O
and O
spleen O
: O
implications O
for O
tolerance O
therapy O
. O

BACKGROUND/AIMS O
: O
A O
single O
intranasal O
delivery O
of O
retinal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
autoantigen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suppresses O
effectively O
experimental O
autoimmune O
uveoretinitis O
( O
EAU O
) O
. O

To O
further O
unravel O
underlying O
mechanisms B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wished O
to O
determine O
, O
firstly O
, O
the O
kinetics B_MEASURE/B_DISEASE
of O
antigen B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
delivery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
, O
secondly O
, O
the O
early B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellular I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
responses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
involved O
in O
the O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nasal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mucosal I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tolerance I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

methods O
: O
Flow O
cytometry O
, O
cell O
proliferation O
assays O
, O
and O
microscopy O
were O
used O
to O
track O
antigen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
following O
a O
single O
, O
intranasal O
dose O
of O
Alexa-488 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
labelled I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
retinal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antigen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Results O
: O
A O
rapid O
accumulation O
of O
antigen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
both O
superficial O
cervical O
lymph O
nodes O
( O
SCLN O
) O
and O
spleen O
was O
observed O
after O
30 O
minutes O
. O

significant O
proliferative O
responses O
to O
IRBP O
were O
elicited O
by O
48 O
hours O
indicating O
that O
systemic O
priming O
of O
naive O
T O
cells O
to O
retinal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
had O
occurred O
. O

Cell O
activation O
was O
further O
confirmed O
by O
immunoprecipitation O
studies O
, O
which O
demonstrated O
phosphorylation O
of O
STAT4 B_GENE
but O
not O
STAT6 B_GENE
in O
both O
lymph O
nodes O
and O
spleen O
. O

However O
, O
at O
24 O
hours O
, O
STAT4 O
heterodimerisation O
with O
STAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
only O
observed O
in O
spleen O
. O

conclusions O
: O
The O
results O
provide O
novel O
evidence O
that O
following O
a O
single O
intranasal O
application O
rapid O
transfer O
of O
antigen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
occurs O
. O

resulting O
T B_DISEASE
cell I_DISEASE
proliferation I_DISEASE
develops O
consequent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
differential B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
signalling O
in O
SCLN B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
spleen B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
understanding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
underlying B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellular I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
is O
inferred O
by O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
the O
contribution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
local B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
versus B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
systemic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tolerance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
may O
assist O
in O
strategies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
clinically O
apply O
mucosal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tolerance I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
successfully O
. O

Regulation O
of O
interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-18 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
on O
CD4 O
( O
+ O
) O
T O
cells O
during O
T O
helper O
( O
th O
) O
1/Th2 O
differentiation O
. O

Critical O
downregulatory O
role O
of O
IL-4 B_PERSON/B_ENT
. O

Interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-18 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
well O
characterized O
as O
a O
costimulatory B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
induction O
of O
IL-12-mediated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
interferon I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IFN I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
production O
by O
T O
helper O
( O
th O
) O
1 O
cells O
, O
but O
also O
can O
induce O
IL-4 O
production O
and O
thus O
facilitate O
the O
differentiation O
of O
Th2 O
cells O
. O

To O
determine O
the O
mechanisms O
by O
which O
IL-18 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
might O
regulate O
these O
diametrically O
distinct O
immune O
responses O
, O
we O
have O
analyzed O
the O
role O
of O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
regulation O
of O
IL-18 B_GENE
receptor I_GENE
alpha I_GENE
chain I_GENE
( O
IL-18Ralpha B_PROTEIN[GENE]/B_LOCATION
) O
expression O
. O

The O
majority O
of O
peripheral O
CD4 O
( O
+ O
) O
T O
cells O
constitutively O
expressed O
the O
IL-18Ralpha B_GENE
. O

Upon O
antigen O
stimulation O
in O
the O
presence O
of O
IL-12 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
marked O
enhancement O
of O
IL-18Ralpha B_GENE
expression O
was O
observed O
. O

IL-12 B_GENE
-mediated O
upregulation O
of O
IL-18Ralpha B_GENE
required O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

activated O
CD4 O
( O
+ O
) O
T O
cells O
that O
expressed O
low O
levels O
of O
IL-18Ralpha B_GENE
could O
produce O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
when O
stimulated O
with O
the O
combination O
of O
IL-12 B_GENE
and O
IL-18 B_GENE
, O
while O
CD4 O
( O
+ O
) O
cells O
which O
expressed O
high O
levels O
of O
IL-18Ralpha B_GENE
could O
respond O
to O
IL-18 B_GENE
alone O
. O

In O
contrast O
, O
T O
cell O
stimulation O
in O
the O
presence O
of O
IL-4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O
in O
a O
downregulation O
of O
IL-18Ralpha B_GENE
expression O
. O

Both O
IL-4 O
( O
-/ O
) O
- O
and O
signal O
transducer O
and O
activator O
of O
transcription O
( O
Stat O
) O
6 O
( O
-/ O
) O
- O
T O
cells O
expressed O
higher O
levels O
of O
IL-18Ralpha B_GENE
after O
TCR O
stimulation O
. O

Furthermore O
, O
activated O
T O
cells O
from O
Stat6 O
( O
-/ O
) O
- O
mice O
produced O
more O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
response O
to O
IL-18 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
wild-type O
controls O
. O

Thus O
, O
positive/negative O
regulation O
of O
the O
IL-18Ralpha B_GENE
by O
the O
major O
inductive O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
IL-12 B_GENE
and O
IL-4 B_GENE
) O
determines O
the O
capacity O
of O
IL-18 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
to O
polarize O
an O
immune O
response O
. O

Glucocorticoid-regulated B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
transcription I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Glucocorticoids B_PERSON
are O
the O
most O
effective B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antiinflammatory I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drugs I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
used O
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
asthma B_DISEASE/B_LOCATION
. O

They O
act O
by O
binding O
to O
a O
specific O
receptor O
( O
GR B_GENE/B_DISEASE
) O
that O
, O
upon O
activation O
, O
translocates O
to O
the O
nucleus O
and O
either O
increases O
( O
transactivates O
) O
or O
decreases O
( O
transrepresses O
) O
gene O
expression O
. O

Inhibition O
of O
pro-inflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
such O
as O
activator B_GENE
protein I_GENE
( I_GENE
AP I_GENE
) I_GENE
-1 I_GENE
, O
signal B_GENE
transducers I_GENE
and I_GENE
activators I_GENE
of I_GENE
transcription I_GENE
( O
STATs B_GENE/B_LOCATION
) O
, O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
NFAT B_GENE/B_ORGANIZATION
) O
and O
nuclear B_GENE
factor I_GENE
( I_GENE
NF I_GENE
) I_GENE
-kappa I_GENE
B I_GENE
is O
thought O
to O
be O
a O
major O
action O
of O
glucocorticoids O
. O

Acetylation O
of O
histones B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allows O
unwinding O
of O
the O
local B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
structure I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
enables O
RNA B_GENE
polymerase I_GENE
II I_GENE
to O
enhance O
gene O
transcription O
. O

Histone O
acetylation O
is O
regulated O
by O
a O
balance O
between O
the O
activity O
of O
histone B_ENZYME[GENE]
acetyltransferases I_ENZYME[GENE]
( O
HATs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
and O
histone B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deacetylases I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
HDACs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

GR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acts O
as O
a O
direct O
inhibitor O
of O
NF-kappa O
B-induced O
Hat O
activity O
and O
also O
by O
recruiting O
HDAC2 B_GENE
to O
the O
NF-kappa B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
B/HAT B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complex B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

A O
sub-group O
of O
patients O
with O
glucocorticoid-insensitive O
asthma O
have O
an O
inability O
to O
induce O
histone O
acetylation O
in O
response O
to O
dexamethasone O
suggesting O
reduced O
expression O
of O
a O
GR-specific B_GENE/B_MEASURE
HAT I_GENE/I_MEASURE
. O

This O
suggests O
that O
pharmacological B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
manipulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
specific B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histone I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetylation I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
potentially O
useful B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
approach I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
inflammatory B_DISEASE
diseases I_DISEASE
. O

identification O
of O
the O
precise O
mechanism O
by O
which O
activated B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GR B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recruits O
HDAC2 B_GENE
may O
reveal O
new O
targets O
for O
the O
development O
of O
drugs O
that O
may O
dissociate O
the O
antiinflammatory O
actions O
of O
glucocorticoids O
from O
their O
side O
effects O
that O
are O
largely O
due O
to O
gene O
induction O
. O

Copyright B_LOCATION/B_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

Differential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
ultraviolet-B-induced I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
immunomodulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
XPA B_DISEASE/B_GENE
, O
XPC B_LOCATION/B_PERSON
, O
and O
CSB B_LOCATION/B_DISEASE
DNA I_LOCATION/I_DISEASE
repair-deficient I_LOCATION/I_DISEASE
mice I_LOCATION/I_DISEASE
. O

ultraviolet B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
B I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
irradiation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
has O
serious B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequences B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
cellular B_DISEASE/B_PERSON
immunity I_DISEASE/I_PERSON
and O
can O
suppress O
the O
rejection B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
skin B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tumors B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
the O
resistance B_DISEASE_ADJECTIVE[DISEASE]
to O
infectious B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diseases B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

DNA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
damage B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
plays O
a O
crucial B_PERSON/B_MEASURE
role I_PERSON/I_MEASURE
in O
these O
immunomodulatory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
ultraviolet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
impaired B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ultraviolet-B-induced B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
DNA B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
damage B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
has O
been O
shown O
to O
cause O
suppression B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cellular B_DISEASE
immunity I_DISEASE
. O

Ultraviolet-B-induced B_DISEASE/B_GENE
DNA B_DISEASE/I_GENE
damage B_DISEASE/I_GENE
is O
repaired O
by O
the O
nucleotide B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
excision I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
repair I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mechanism I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
very O
efficiently O
. O

nucleotide B_DISEASE/B_GENE
excision B_DISEASE/I_GENE
repair B_DISEASE/I_GENE
comprises O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
subpathways B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O
transcription-coupled B_GENE/B_LOCATION
and O
global B_GENE
genome I_GENE
repair I_GENE
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
immunologic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequences B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
specific B_DISEASE
nucleotide I_DISEASE
excision I_DISEASE
repair I_DISEASE
defects I_DISEASE
in O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mouse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
XPA B_DISEASE/B_PROTEIN[GENE]
, O
XPC B_DISEASE/B_LOCATION
, O
and O
CSB B_DISEASE
mutant I_DISEASE
mice I_DISEASE
, O
were O
investigated O
. O

XPA B_PERSON/B_BIO
mice I_PERSON/I_BIO
carry O
a O
total B_DISEASE/B_GENE
nucleotide I_DISEASE/I_GENE
excision I_DISEASE/I_GENE
repair I_DISEASE/I_GENE
defect I_DISEASE/I_GENE
, O
whereas O
XPC B_LOCATION/B_PERSON
and O
CSB B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
mice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
only O
lack O
global B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genome B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
transcription-coupled B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
excision I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repair I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
respectively O
. O

Our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
that O
cellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
immune B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
XPA B_DISEASE/B_PROTEIN[GENE]
, O
XPC B_LOCATION/B_PERSON
, O
and O
CSB B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
mice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
are O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
with O
their O
wild-type B_GENE/B_PERSON
( O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
littermates B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
may O
indicate O
that O
the O
reported B_DISEASE_ADJECTIVE[DISEASE]
altered O
cellular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responses I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
xeroderma B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pigmentosum I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
not O
constitutive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
but O
could O
be O
due B_DISEASE_ADJECTIVE[DISEASE]
to O
external B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
factors I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
ultraviolet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Upon O
exposure O
to O
ultraviolet O
B O
, O
only O
XPA O
mice O
are O
very O
sensitive O
to O
ultraviolet-B-induced O
inhibition O
of O
Th1-mediated O
contact O
hypersensitivity O
responses O
and O
interferon-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O
in O
skin O
draining O
lymph O
nodes O
. O

Lipopolysaccharide-stimulated O
tumor B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
necrosis B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factor B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
alpha B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
interleukin-10 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O
are O
significantly O
augmented O
in O
both O
XPA O
and O
CSB O
mice O
after O
ultraviolet O
B O
exposure O
. O

Lymph B_MEASURE/B_PERSON
node I_MEASURE/I_PERSON
cell I_MEASURE/I_PERSON
numbers I_MEASURE/I_PERSON
were O
increased O
very O
significantly O
in O
XPA B_DISEASE/B_PROTEIN[GENE]
, O
mildly O
increased O
in O
CSB B_DISEASE/B_PROTEIN[GENE]
, O
and O
not O
in O
XPC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
mice B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
general B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
XPC I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O
not O
exhibit O
any O
indication B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
enhanced B_DISEASE_ADJECTIVE[DISEASE]
ultraviolet I_DISEASE_ADJECTIVE[DISEASE]
B I_DISEASE_ADJECTIVE[DISEASE]
susceptibility I_DISEASE_ADJECTIVE[DISEASE]
with O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
immune B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
parameters I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analyzed O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
both O
global B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
genome I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
transcription-coupled B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
repair B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O
needed O
to O
prevent O
immunomodulation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
ultraviolet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
transcription-coupled B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repair I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
the O
major B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
DNA I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
repair I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
subpathway I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
nucleotide B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
excision I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O
prevents O
the O
acute B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ultraviolet-B-induced I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
erythema B_DISEASE
. O

Biomechanical O
strain O
induces O
class O
a O
scavenger B_GENE
receptor I_GENE
expression O
in O
human O
monocyte/macrophages O
and O
THP-1 O
cells O
: O
a O
potential O
mechanism O
of O
increased O
atherosclerosis O
in O
hypertension O
. O

Background B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Although O
hypertension B_DISEASE
is O
an O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
development B_DISEASE_ADJECTIVE[DISEASE]
of O
atherosclerosis B_DISEASE/B_LOCATION
, O
the O
mechanisms B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
this O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O
incompletely O
described O
. O

Previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
suggested O
that O
biomechanical B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strain I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulates O
macrophage B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phenotype I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
tested O
the O
hypothesis O
that O
biomechanical O
strain O
can O
induce O
expression O
of O
the O
class B_GENE
A I_GENE
scavenger I_GENE
receptor I_GENE
( O
SRA B_LOCATION/B_ORGANIZATION
) O
, O
an O
important O
lipoprotein B_GENE/B_PERSON
receptor I_GENE/I_PERSON
in O
atherogenesis O
. O

methods O
AND O
Results O
: O
Human O
monocyte/macrophages O
or O
THP-1 O
cells O
were O
cultured O
in O
a O
device O
that O
imposes O
uniform O
biaxial O
cyclic O
1-Hz O
strains O
of O
0 O
% O
, O
1 O
% O
, O
2 O
% O
, O
or O
3 O
% O
, O
and O
SRA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
was O
analyzed O
. O

Mechanical O
strains O
induced O
SRA B_GENE
mRNA I_GENE
( O
3.5+/-0.6-fold O
at O
3 O
% O
strain O
for O
48 O
hours O
, O
P O
< O
0.01 O
) O
and O
SRA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
THP-1 O
cells O
in O
an O
amplitude-dependent O
manner O
. O

This O
induction O
was O
accompanied O
by O
augmented O
expression O
of O
the O
class B_GENE
B I_GENE
scavenger I_GENE
receptor I_GENE
CD36 I_GENE
( O
2.8+/-0.3-fold O
, O
P O
< O
0.001 O
) O
but O
not O
by O
increased O
peroxisome B_GENE
proliferator-activated I_GENE
receptor-gamma I_GENE
expression O
. O

To O
evaluate O
this O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
apolipoprotein B_GENE
E I_GENE
( O
-/- B_PERSON/B_PROTEIN[GENE]
) O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
randomly O
assigned O
to O
receive O
standard B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chow I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
a O
high-cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
diet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
or O
a O
high-cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
hypertension B_DISEASE
induced O
by O
angiotensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
II I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
infusion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
8 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Immunohistochemistry O
revealed O
that O
among O
macrophages O
in O
atherosclerotic O
lesions O
of O
the O
aorta O
, O
the O
proportion O
of O
macrophages O
with O
SRA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
was O
highest O
in O
hypertensive O
animals O
on O
a O
high-cholesterol O
diet O
( O
43.9+/-0.7 O
% O
, O
versus O
12.0+/-2.0 O
% O
for O
normotensive O
animals O
on O
a O
high-cholesterol O
diet O
and O
4.7+/-4.7 O
% O
for O
animals O
on O
standard O
Chow O
; O
P O
< O
0.001 O
) O
. O

conclusions O
: O
Biomechanical O
strain O
induces O
SRA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
by O
monocyte/macrophages O
, O
suggesting O
a O
novel O
mechanism O
for O
promotion O
of O
atherosclerosis O
in O
hypertensive O
patients O
. O

High B_DISEASE/B_GENE
glucose B_DISEASE/I_GENE
induces O
MCP-1 O
expression B_GENE
partly O
via O
tyrosine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase-AP-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
peritoneal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mesothelial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
High B_DISEASE_ADJECTIVE[DISEASE]
glucose I_DISEASE_ADJECTIVE[DISEASE]
in O
peritoneal B_DISEASE/B_PERSON
dialysis I_DISEASE/I_PERSON
solutions I_DISEASE/I_PERSON
has O
been O
implicated O
in O
the O
pathogenesis B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
peritoneal B_DISEASE
fibrosis I_DISEASE
in O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ambulatory B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
peritoneal B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dialysis B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
CAPD B_DISEASE/B_GENE
) O
patients B_PERSON/B_DISEASE
. O

However O
, O
the O
mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
not O
very O
clear B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Peritoneal O
macrophages O
seem O
to O
participate O
in O
the O
process O
of O
peritoneal O
fibrosis O
and O
monocyte B_GENE
chemoattractant I_GENE
protein-1 I_GENE
( O
MCP-1 B_GENE/B_DISEASE
) O
plays O
a O
key O
role O
in O
the O
recruitment O
of O
monocytes O
toward O
the O
peritoneal O
cavity O
. O

However O
, O
little O
is O
known O
about O
the O
effect O
of O
high O
glucose O
on O
MCP-1 B_GENE
expression O
and O
its O
signal O
transduction O
pathway O
in O
human O
peritoneal O
mesothelial O
cells O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Mesothelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O
cultured O
with O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
5 B_MEASURE/B_LOCATION
to O
100 B_MEASURE
mmol/L I_MEASURE
) O
or O
mannitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chronically O
for O
up O
to O
seven B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
. O

MCP-1 B_GENE/B_MEASURE
expression O
of O
mRNA O
and O
protein O
was O
measured O
by O
Northern O
blot O
analysis O
and O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
. O

chemotactic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
high-glucose-conditioned B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
culture I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
supernatant I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O
measured O
by O
chemotactic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
examine O
the O
roles O
of O
the O
transcription B_GENE
factors I_GENE
activator I_GENE
protein-1 I_GENE
( O
AP-1 B_GENE/B_DISEASE
) O
and O
nuclear B_GENE
factor-kappaB I_GENE
( O
NF-kappaB B_GENE
) O
, O
electrophoretic O
mobility O
shift O
assay O
( O
EMSA O
) O
was O
performed O
. O

Results O
: O
glucose O
induced O
MCP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
in O
a O
time- O
and O
dose-dependent O
manner O
. O

MCP-1 B_DISEASE_ADJECTIVE[DISEASE]
protein I_DISEASE_ADJECTIVE[DISEASE]
in O
cell O
culture O
supernant O
was O
also O
increased O
. O

equivalent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
concentrations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
mannitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

High-glucose-conditioned O
supernatant O
possessed O
an O
increased O
chemotactic O
activity O
for O
monocytes O
, O
which O
was O
neutralized O
by O
anti-MCP-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

EMSA O
revealed O
that O
glucose O
increased O
the O
AP-1 B_GENE
binding O
activity O
in O
a O
time- O
and O
dose-dependent O
manner O
, O
but O
not O
NF-kappaB B_GENE
. O

Curcumin O
, O
an O
inhibitor O
of O
AP-1 B_GENE
, O
dose-dependently O
suppressed O
the O
induction O
of O
MCP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
high O
glucose O
. O

Tyrosine O
kinase O
inhibitors O
such O
as O
genistein O
( O
12.5 O
to O
50 O
micromol/L O
) O
and O
herbimycin O
A O
( O
0.1 O
to O
1 O
micromol/L O
) O
inhibited O
the O
high-glucose-induced O
MCP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
in O
a O
dose-dependent O
manner O
, O
and O
also O
suppressed O
the O
high-glucose-induced O
AP-1 B_GENE
binding O
activity O
. O

conclusions O
: O
: O
High O
glucose O
induced O
mesothelial O
MCP-1 B_GENE
expression O
partly O
via O
the O
tyrosine O
kinase- O
AP-1 B_GENE
pathway O
. O

Signal B_ORGANIZATION/B_TIME[MEASURE]
thresholds B_ORGANIZATION/I_TIME[MEASURE]
and O
modular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
synergy I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O
expression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
costimulatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
analyzed O
intracellular O
pathways O
modulating O
surface O
densities O
of O
CD80 B_GENE
and O
CD86 B_GENE
in O
B O
cells O
activated O
through O
ligation O
of O
the O
Ag B_GENE
receptor I_GENE
, O
and O
the O
adhesion B_GENE
molecule I_GENE
CD54 I_GENE
. O

Whereas O
B B_GENE
cell I_GENE
Ag I_GENE
receptor I_GENE
( O
BCR B_GENE/B_LOCATION
) O
cross-linking O
alone O
stimulated O
increased O
expression O
of O
CD86 B_GENE
, O
up-regulation O
of O
CD80 B_GENE
required O
dual O
stimulation O
with O
anti-IgM B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
anti-CD54 B_GENE
. O

The O
principal O
downstream O
component O
contributed O
by O
BCR B_GENE
signaling O
, O
toward O
both O
CD80 B_GENE
and O
CD86 B_GENE
induction O
, O
was O
the O
elevated O
concentration O
of O
free O
cytoplasmic O
ca O
( O
2+ O
) O
, O
recruited O
by O
way O
of O
capacitative O
influx O
. O

This O
alone O
was O
sufficient O
to O
generate O
an O
increase O
in O
CD86 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
. O

However O
, O
CD80 B_GENE/B_LOCATION
enhancement O
required O
the O
concerted O
action O
of O
both O
intracellular O
ca O
( O
2+ O
) O
concentration O
and O
CD54-initiated O
pathways O
. O

The O
nexus O
between O
anti-IgM O
and O
anti-CD54 O
stimulation O
, O
in O
the O
context O
of O
CD80 B_GENE
regulation O
, O
was O
identified O
to O
involve O
a O
self-propagating O
process O
of O
sequential O
synergy O
. O

The O
first O
step O
involved O
amplified O
accumulation O
of O
intracellular O
Camp O
, O
as O
a O
result O
of O
cross-talk O
between O
BCR B_GENE
-mobilized O
ca O
( O
2+ O
) O
and O
CD54-derived O
signals O
. O

This O
then O
facilitated O
a O
second O
synergistic O
interaction O
between O
ca O
( O
2+ O
) O
and O
Camp O
, O
culminating O
in O
CD80 B_GENE
expression O
. O

Our O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
distinct B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
signal I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
transducer I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
requirements I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
with O
the O
added B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequences B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cross-talk B_DISEASE/B_GENE
, O
offers O
an O
explanation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
variable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
costimulatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecule I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
diverse B_DISEASE
physiological I_DISEASE
stimuli I_DISEASE
. O

importantly O
, O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
also O
reveal O
how O
concentration B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
threshold I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
barriers I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
recruitment B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
second I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
messengers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
can O
be O
overcome O
by O
constructive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
convergence I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
signaling O
modules B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Epstein-Barr B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
virus B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
neoplastic B_DISEASE/B_LOCATION
transformation I_DISEASE/I_LOCATION
. O

In O
this O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
we O
focus O
on O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O
basic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O
translational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
relating O
to O
the O
Epstein-Barr B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
virus I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
EBV B_VIRUS[BIO]/B_DISEASE
) O
. O

Beside O
its O
well-known B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tropism B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
epithelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
EBV B_VIRUS[BIO]/B_DISEASE
also O
infects O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
granulocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

After O
primary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
EBV B_VIRUS[BIO]/B_DISEASE
persists O
throughout O
the O
life B_BODY_PART_OR_ORGAN_COMPONENT
span I_BODY_PART_OR_ORGAN_COMPONENT
in O
resting O
memory B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
B I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
, O
from O
where O
it O
is O
reactivated O
upon O
breakdown B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
immunity B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

In O
the O
process O
of O
neoplastic O
transformation O
, O
the O
EBV-encoded B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
latent B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
membrane B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
LMP1 B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
oncogene B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
represents O
the O
major O
driving O
force O
. O

LMP1 B_GENE
acts O
like O
a O
constitutively B_GENE/B_PERSON
activated I_GENE/I_PERSON
receptor I_GENE/I_PERSON
of O
the O
tumor B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
necrosis B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
family B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
allows O
the O
amplification O
or O
bypassing O
of O
physiological O
regulatory O
signals O
through O
direct O
and O
indirect O
interactions O
with O
proteins O
of O
the O
tumor B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
necrosis I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
factor I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
receptor-associated I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
factor I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
( I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
TRAF I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
) I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
family I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
. O

TRAF2 B_GENE
-mediated O
NF-kappaB B_GENE
activation O
, O
AP-1 B_GENE
induction O
and O
JAK3 B_GENE/B_LOCATION
/ O
STAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O
may O
result O
in O
sustained O
proliferation O
leading O
to O
lymphoma O
. O

The O
ability O
of O
LMP1 B_GENE
to O
suppress O
germinal O
center O
formation O
and O
its O
capacity O
to O
mediate O
its O
own O
transcriptional O
activation O
shed O
new O
light O
on O
the O
pathogenesis O
of O
EBV-associated O
latency O
type O
II O
lymphoproliferations O
like O
Hodgkin O
's O
disease O
and O
angioimmunoblastic O
lymphadenopathy O
. O

The O
carboxy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
terminus I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
LMP1 B_GENE
is O
also O
a O
reliable O
marker O
for O
individual O
EBV O
strain O
identification O
and O
thus O
offers O
new O
possibilities O
in O
tracing O
the O
molecular O
events O
leading O
to O
posttransplant O
lymphoproliferative O
disorders O
( O
PTLDs O
) O
. O

Cytotoxic O
T O
lymphocytes O
directed O
against O
well-characterized O
epitopes O
of O
EBV B_DISEASE/B_VIRUS[BIO]
latency B_DISEASE/I_VIRUS[BIO]
genes B_DISEASE/I_VIRUS[BIO]
represent O
an O
already O
successful O
and O
promising O
therapeutic O
approach O
to O
EBV-associated O
lymphomas O
, O
in O
particular O
PTLDs O
. O

Interferon-alpha B_DISEASE/B_GENE
drives O
T O
cell-mediated O
immunopathology O
in O
the O
intestine O
. O

The O
ability O
of O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
( B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
IFN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
) B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
-alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
to O
induce O
autoimmunity O
and O
exacerbate O
Th1 O
diseases O
is O
well O
known O
. O

We O
have O
recently O
described O
enhanced O
expression O
of O
IFN-alpha B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
mucosa O
of O
patients O
with O
celiac O
disease O
( O
CD O
) O
, O
a O
gluten-sensitive O
Th1-mediated O
enteropathy O
, O
characterized O
by O
villous O
atrophy O
and O
crypt O
cell O
hyperplasia O
. O

Previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O
this O
laboratory B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
shown O
that O
T B_DISEASE
cell I_DISEASE
activation I_DISEASE
in O
explant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cultures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
human B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
fetal B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
gut B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
can O
also O
result O
in O
villous B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
atrophy I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
crypt O
cell B_DISEASE/B_ORGANIZATION
hyperplasia I_DISEASE/I_ORGANIZATION
. O

We O
have O
, O
therefore O
, O
examined O
changes O
that O
take O
place O
in O
explant O
cultures O
of O
human O
fetal O
gut O
after O
activation O
of O
T O
cells O
with O
anti-CD3 B_GENE
and/or O
IFN-alpha B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
show O
that O
activation O
of O
T O
cells O
with O
anti-CD3 B_GENE
alone O
elicits O
a O
small O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response O
with O
no O
tissue O
injury O
. O

Similarly O
, O
no O
changes O
are O
seen O
in O
explants O
cultured O
with O
IFN-alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alone O
. O

However O
, O
addition O
of O
IFN-alpha B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
anti-CD3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
results O
in O
enhanced O
Th1 O
response O
and O
crypt O
cell O
hyperplasia O
. O

This O
is O
associated O
with O
enhanced O
phosphorylation O
of O
STAT1 B_GENE
, O
STAT3 B_GENE
, O
and O
Fyn B_GENE
, I_GENE
a I_GENE
Src I_GENE
homology I_GENE
tyrosine I_GENE
kinase I_GENE
, O
which O
interacts O
with O
both O
TCR O
and O
IFN-alpha O
signal O
components O
. O

Together O
these O
data O
indicate O
that O
IFN-alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
facilitate O
activation O
of O
Th1-reactive O
cells O
in O
the O
gut O
and O
drive O
immunopathology O
. O

suppression O
of O
tumor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
necrosis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
production O
by O
Camp O
in O
human O
monocytes O
: O
dissociation O
with O
mRNA O
level O
and O
independent O
of O
interleukin-10 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background O
: O
elevation O
of O
cellular O
Camp O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
-stimulated O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TNF-alpha B_GENE/B_LOCATION
) O
production O
and O
increases O
the O
expression O
of O
interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-10 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
mononuclear O
cells O
. O

TNF-alpha B_GENE
gene I_GENE
expression O
obligates O
activation O
of O
the O
transcription B_GENE
factor I_GENE
nuclear I_GENE
factor I_GENE
kappaB I_GENE
( O
NF-kappaB B_GENE
) O
. O

Exogenous O
IL-10 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibits O
NF-kappaB B_GENE
in O
monocytes O
and O
thus O
attenuates O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O
. O

We O
examined O
the O
role O
of O
endogenous O
IL-10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
regulation O
of O
NF-kappaB B_GENE
activation O
and O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O
in O
human O
monocytes O
by O
Camp O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
stimulated O
with O
Escherichia B_GENE/B_BACTERIUM[BIO]
coli I_GENE/I_BACTERIUM[BIO]
LPS I_GENE/I_BACTERIUM[BIO]
( O
100 B_LOCATION/B_MEASURE
ng/ml I_LOCATION/I_MEASURE
) O
with O
and O
without O
forskolin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
FSK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
50 B_NUMBER[MEASURE]/B_LOCATION
microM I_NUMBER[MEASURE]/I_LOCATION
) O
or O
dibutyryl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cyclic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
AMP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
dbcAMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
100 B_NUMBER[MEASURE]/B_LOCATION
microM I_NUMBER[MEASURE]/I_LOCATION
) O
. O

Cytokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
IL-10 B_GENE
) O
release O
was O
measured O
by O
immunoassay O
. O

TNF-alpha B_GENE
mRNA I_GENE
was O
measured O
by O
reverse O
transcription O
polymerase O
chain O
reaction O
, O
and O
NF-kappaB B_GENE
DNA O
binding O
activity O
was O
assessed O
by O
gel O
mobility O
shift O
assay O
. O

Results O
: O
cAMP-elevating O
agents O
inhibited O
LPS-stimulated O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
release O
( O
0.77 O
+/- O
0.13 O
ng/10 O
( O
6 O
) O
cells O
in O
LPS O
+ O
dbcAMP O
and O
0.68 O
+/- O
0.19 O
ng/10 O
( O
6 O
) O
cells O
in O
LPS O
+ O
FSK O
, O
both O
P O
< O
0.05 O
vs O
1.61 O
+/- O
0.34 O
ng/10 O
( O
6 O
) O
cells O
in O
LPS O
alone O
) O
. O

Conversely O
, O
Camp O
enhanced O
LPS-stimulated O
IL-10 B_GENE
release O
( O
100 O
+/- O
21.5 O
pg/10 O
( O
6 O
) O
cells O
in O
LPS O
+ O
dbcAMP O
and O
110 O
+/- O
25.2 O
pg/10 O
( O
6 O
) O
cells O
in O
LPS O
+ O
FSK O
, O
both O
P O
< O
0.05 O
vs O
53.3 O
+/- O
12.8 O
pg/10 O
( O
6 O
) O
cells O
in O
LPS O
alone O
) O
. O

Neither O
TNF-alpha B_GENE
mRNA I_GENE
expression O
nor O
NF-kappaB B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O
stimulated O
by O
LPS O
was O
inhibited O
by O
the O
cAMP-elevating O
agents O
. O

Neutralization O
of O
IL-10 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O
a O
specific O
antibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
attenuate O
the O
effect O
of O
cAMP-elevating O
agents O
on O
TNF-alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
production O
. O

conclusion O
: O
The O
results O
indicate O
that O
Camp O
inhibits O
LPS-stimulated O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O
through O
a O
posttranscriptional O
mechanism O
that O
is O
independent O
of O
endogenous O
IL-10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Copyright B_LOCATION/B_PERSON
2001 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

activation O
of O
the O
p21 B_GENE/B_LOCATION
( I_GENE/I_LOCATION
CIP1/WAF1 I_GENE/I_LOCATION
) I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
by O
bone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
morphogenetic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein-2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
mouse O
B O
lineage O
cells O
. O

BMPs B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exert O
a O
negative O
growth O
effect O
on O
various O
types O
of O
cells O
. O

We O
have O
previously O
reported O
that O
BMP-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O
the O
growth O
of O
HS-72 O
mouse O
hybridoma O
cells O
by O
inducing O
p21 O
( O
CIP1/WAF1 O
) O
expression O
. O

In O
the O
present O
study O
, O
we O
demonstrated O
that O
BMP-2 B_GENE
activated O
the O
mouse O
p21 B_GENE/B_LOCATION
( I_GENE/I_LOCATION
CIP1/WAF1 I_GENE/I_LOCATION
) I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
in O
HS-72 O
cells O
, O
and O
that O
a O
29-base B_MEASURE/B_LOCATION
pair I_MEASURE/I_LOCATION
( I_MEASURE/I_LOCATION
b I_MEASURE/I_LOCATION
) I_MEASURE/I_LOCATION
region I_MEASURE/I_LOCATION
of O
the O
promoter O
( O
-1928/-1900 O
relative O
to O
the O
TATA B_GENE/B_MEASURE
box I_GENE/I_MEASURE
) O
, O
conserved O
between O
mice O
and O
humans O
, O
was O
responsive O
to O
BMP-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O
well O
as O
expression O
of O
Smad1 B_GENE
, O
Smad4 B_GENE
, O
and O
constitutively O
active O
mutants O
of O
BMP B_GENE
type I_GENE
I I_GENE
receptors I_GENE
. O

Furthermore O
, O
an O
oligonucleotide O
containing O
the O
29-b B_GENE/B_LOCATION
region I_GENE/I_LOCATION
was O
found O
to O
be O
associated O
with O
Smad4 B_GENE
and O
phosphorylated B_GENE/B_MEASURE
Smad1 I_GENE/I_MEASURE
in O
the O
nuclear O
extract O
of O
BMP-2 B_GENE
-stimulated O
HS-72 O
cells O
. O

These O
results O
suggested O
that O
BMP-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
might O
activate O
p21 O
( O
CIP1/WAF1 O
) O
transcription O
by O
inducing O
a O
binding O
of O
Smad4 B_GENE
and O
Smad1 B_GENE/B_MEASURE
to O
the O
29-b B_LOCATION/B_BIO
region B_LOCATION/I_BIO
in O
HS-72 O
cells O
. O

dendritic B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
cell I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
development I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
from O
common B_BIO/B_DISEASE
myeloid I_BIO/I_DISEASE
progenitors I_BIO/I_DISEASE
. O

Dendritic O
cells O
( O
DCs O
) O
are O
professional O
antigen-presenting O
cells O
which O
both O
initiate O
adaptive O
immune O
responses O
and O
control O
tolerance O
to O
self-antigens B_DISEASE/B_BIO
. O

It O
has O
been O
suggested O
that O
these O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
responder B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
depend O
on O
subsets B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
DCs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
arising O
from O
either O
myeloid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
lymphoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
hematopoietic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
origins I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
CD8 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
alpha+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
Mac-1- I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
DCs I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O
supposed O
to O
be O
of O
lymphoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
while O
CD8 B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
alpha- I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Mac-1+ I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
DCs I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
supposed O
to O
be O
of O
myeloid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
origin I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O

Here O
we O
summarize O
our O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
both O
CD8 B_GENE
alpha+ I_GENE
and O
CD8 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
alpha- I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
DCs I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
can O
arise O
from O
clonogenic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
common I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
myeloid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
progenitors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CMPs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
in O
both O
thymus B_BODY_PART_OR_ORGAN_COMPONENT
and O
spleen O
. O

Therefore O
CD8 B_GENE/B_MEASURE
alpha I_GENE/I_MEASURE
expression O
DCs O
does O
not O
indicate O
a O
lymphoid O
origin O
and O
differences O
among O
CD8 O
alpha+ O
and O
CD8 O
alpha- O
DCs O
might O
rather O
reflect O
maturation O
status O
than O
ontogeny O
. O

On O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
transplantation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
it O
seems O
likely B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
that O
most B_MEASURE/B_DISEASE
of O
the O
DCs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
in O
secondary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lymphoid I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
organs I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
substantial B_MEASURE/B_PERSON
fraction I_MEASURE/I_PERSON
of O
thymic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
DCs I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
are O
myeloid-derived O
. O

Macrophage O
stimulation O
with O
Murabutide O
, O
an O
HIV-suppressive O
muramyl O
peptide O
derivative O
, O
selectively O
activates O
extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
C/EBPbeta B_GENE
and O
STAT1 B_GENE
: O
role O
of O
CD14 B_GENE
and O
Toll-like B_GENE
receptors I_GENE
2 I_GENE
and I_GENE
4 I_GENE
. O

The O
smallest B_MEASURE/B_PERSON
unit I_MEASURE/I_PERSON
of O
bacterial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
peptidoglycans I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
known O
to O
be O
endowed O
with O
biological B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activities I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
muramyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dipeptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
MDP B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

A O
clinically O
acceptable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
synthetic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
derivative I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
MDP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
namely O
murabutide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MB B_PROTEIN[GENE]/B_LOCATION
) O
, O
has O
been O
found O
to O
present O
interesting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pharmacological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
properties B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
to O
suppress O
HIV-1 B_DISEASE_ADJECTIVE[DISEASE]
replication I_DISEASE_ADJECTIVE[DISEASE]
in O
monocyte-derived B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MDM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

We O
have O
addressed O
the O
signaling O
events B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activated O
in O
MDM B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
either O
MB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
the O
potent B_LOCATION/B_ORGANIZATION
immunostimulant I_LOCATION/I_ORGANIZATION
LPS I_LOCATION/I_ORGANIZATION
. O

We O
also O
examined O
whether O
signaling O
by O
muramyl O
peptides O
involves O
the O
use O
of O
cell B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
surface I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
CD14 B_GENE
and O
Toll-like B_GENE/B_MEASURE
receptor I_GENE/I_MEASURE
2 I_GENE/I_MEASURE
( O
TLR2 B_GENE
) O
or O
TLR4 B_GENE/B_PERSON
that O
are O
known O
to O
be O
signal-transducing B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
other O
bacterial O
cell O
wall O
components O
. O

We O
demonstrate O
that O
, O
unlike O
LPS O
, O
the O
safe O
immunomodulator O
MB O
selectively O
activates O
extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Erk I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1/2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
the O
absence O
of O
detectable O
Jun B_GENE
N-terminal I_GENE
kinase I_GENE
( O
JNK B_GENE/B_LOCATION
) O
or O
p38 B_GENE
mitogen-activated I_GENE
kinase I_GENE
activation O
. O

Furthermore O
, O
STAT1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation O
but O
weak O
or O
no O
activation O
of O
STAT3 B_GENE
or O
STAT5 B_GENE
respectively O
, O
could O
be O
detected O
in O
MB-stimulated O
MDM O
. O

Using O
MonoMac6 O
cells O
, O
we O
observed O
high O
C/EBPbeta B_GENE
and O
AP-1 B_GENE
but O
weaker O
and O
transient O
NF-kappaB B_GENE
activation O
by O
MB O
. O

Moreover O
, O
the O
truncated O
form O
of O
C/EBPbeta B_GENE/B_LOCATION
, O
known O
to O
repress O
HIV-1 O
transcription O
, O
was O
detected O
in O
extracts O
from O
MB-treated O
THP-1 O
cells O
. O

surprisingly O
, O
neither O
MB O
nor O
MDP O
were O
able O
to O
transduce O
signals O
via O
CD14 B_GENE/B_LOCATION
and O
TLR2 B_GENE
or I_GENE
4 I_GENE
. O

These O
findings O
present O
major O
differences O
in O
the O
early O
cell O
activation O
process O
between O
LPS O
and O
muramyl O
peptides O
, O
and O
strongly O
argue O
for O
the O
implication O
of O
co-receptors B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
other O
than O
TLR2 B_GENE
and O
TLR4 B_GENE
in O
mediating O
the O
signaling O
events O
induced O
by O
defined O
subunits O
of O
bacterial O
peptidoglycans O
. O

Nuclear B_PERSON/B_GENE
peroxisome I_PERSON/I_GENE
proliferator-activated I_PERSON/I_GENE
receptors I_PERSON/I_GENE
alpha I_PERSON/I_GENE
and I_PERSON/I_GENE
gamma I_PERSON/I_GENE
have O
opposing O
effects O
on O
monocyte O
chemotaxis O
in O
endometriosis O
. O

The O
peroxisome B_GENE
proliferator-activated I_GENE
receptors I_GENE
( I_GENE
PPARs I_GENE
) I_GENE
alpha I_GENE
and I_GENE
gamma I_GENE
are O
nuclear B_GENE
receptors I_GENE
that O
play O
important O
roles O
in O
inflammatory O
diseases O
like O
ulcerative O
colitis O
and O
arthritis O
. O

In O
this O
study O
, O
we O
examined O
the O
possible O
role O
of O
PPARs B_GENE
in O
macrophage O
attraction O
into O
the O
peritoneal O
cavity O
of O
patients O
with O
endometriosis O
. O

We O
identified O
PPAR-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
messenger O
RNA O
by O
RT-PCR O
and O
protein O
by O
immunoblotting O
of O
lysates O
of O
peritoneal O
macrophages O
and O
monocytic O
U937 O
cells O
. O

Using O
immunocytochemistry O
, O
we O
localized O
PPAR-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
within O
the O
nuclei O
of O
both O
cell O
types O
. O

monocyte B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
chemotactic B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
activity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
peritoneal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fluid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
patients B_PERSON
with O
endometriosis B_DISEASE
was O
quantified O
in O
Boyden B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
chambers B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

migration B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
U937 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O
increased O
by O
WY B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
14643 B_LOCATION/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
reduced O
by O
rosiglitazone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Peritoneal O
fluid O
from O
patients O
with O
endometriosis O
activated O
U937 O
cells O
transiently O
transfected O
with O
a O
PPAR-alpha/GAL4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
luciferase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

By O
contrast O
, O
peritoneal O
fluid O
did O
not O
cause O
significant O
activation O
of O
PPAR-gamma/GAL4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
constructs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
U937 O
cells O
transiently O
transfected O
with O
a O
PPAR B_GENE
response I_GENE
element I_GENE
luciferase I_GENE
reporter I_GENE
showed O
disease O
stage-dependent O
up-regulation O
when O
treated O
with O
peritoneal O
fluid O
from O
patients O
with O
endometriosis O
. O

Treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
peritoneal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
fluid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O
healthy B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
down-regulated O
PPAR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transactivation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
conclude O
that O
peritoneal O
fluid O
of O
endometriosis O
patients O
contains O
activators O
of O
PPAR-alpha B_GENE
that O
stimulate O
macrophage O
chemotaxis O
. O

Inhibitors O
of O
PPAR-alpha B_GENE/B_DISEASE
or O
activators O
of O
PPAR-gamma B_GENE
could O
be O
developed O
for O
the O
treatment O
of O
inflammation O
associated O
with O
endometriosis O
. O

Long-term-impaired O
expression O
of O
nuclear B_GENE
factor-kappa I_GENE
B I_GENE
and O
I B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
peripheral O
blood O
mononuclear O
cells O
of O
trauma O
patients O
. O

Nuclear B_GENE
factor I_GENE
( I_GENE
NF I_GENE
) I_GENE
-kappa I_GENE
B I_GENE
expression O
and O
dimer O
characteristics O
were O
studied O
in O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
of O
major-trauma O
patients O
and O
healthy O
controls O
. O

Analysis O
of O
PBMCs O
on O
days O
1 O
, O
3 O
, O
5 O
, O
and O
10 O
after O
trauma O
revealed O
that O
expression O
of O
both O
p65p50 B_GENE
heterodimers I_GENE
and O
p50p50 B_GENE
homodimers I_GENE
was O
significantly O
reduced O
compared O
with O
that O
in O
controls O
. O

In O
vitro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
lipopolysaccharide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O
LPS B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
PBMCs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
induced O
NF-kappa B_DISEASE/B_GENE
B B_DISEASE/I_GENE
translocation B_DISEASE/I_GENE
. O

However O
, O
throughout O
the O
survey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
p65p50 B_DISEASE_ADJECTIVE[DISEASE]
activation I_DISEASE_ADJECTIVE[DISEASE]
remained O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
trauma B_PERSON/B_BIO
patients I_PERSON/I_BIO
than O
in O
controls B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

After O
LPS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
vitro B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
p65p50/p50p50 B_MEASURE
ratio I_MEASURE
was O
significantly O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
PBMCs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
trauma B_DISEASE/B_PERSON
patients I_DISEASE/I_PERSON
than O
from O
healthy B_PERSON/B_BIO
controls I_PERSON/I_BIO
. O

The O
ex O
vivo O
expression O
of O
I B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
higher O
in O
PBMCs O
of O
controls O
than O
of O
trauma O
patients O
. O

LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
did O
not O
induce O
I O
Kappa B_TIME[MEASURE]/B_LOCATION
B I_TIME[MEASURE]/I_LOCATION
expression I_TIME[MEASURE]/I_LOCATION
in O
PBMCs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
trauma B_PERSON/B_BIO
patients I_PERSON/I_BIO
, O
but O
strong B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
obtained O
with O
staphylococci B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
suggesting O
that O
this O
defect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
not O
universal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
depends O
on O
the O
nature B_MEASURE/B_DISEASE
of O
the O
activating O
signal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Although O
no O
direct O
correlation O
was O
found O
between O
levels O
of O
interleukin-10 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O
transforming B_GENE/B_MEASURE
growth B_GENE/I_MEASURE
factor-beta B_GENE/I_MEASURE
and O
NF-kappa B_GENE/B_DISEASE
B B_GENE/I_DISEASE
, O
these O
immunosuppressive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
significantly O
elevated O
in O
trauma O
patients O
by O
10 O
days O
after O
admission O
. O

The O
long-term O
low-basal O
and O
LPS-induced O
nuclear O
translocation O
of O
NF-kappa B_GENE
B I_GENE
recalled O
long-term O
immunoparalysis O
observed O
in O
patients O
with O
severe O
inflammatory O
stress O
such O
as O
trauma O
. O

Hepatic B_DISEASE_ADJECTIVE[DISEASE]
ischemia-reperfusion I_DISEASE_ADJECTIVE[DISEASE]
injury I_DISEASE_ADJECTIVE[DISEASE]
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
morbidity B_DISEASE
associated O
with O
liver B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
major B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
hepatic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
resections I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
is O
partly O
a O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ischemia-reperfusion B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Data B_MEASURE/B_ORGANIZATION
Sources I_MEASURE/I_ORGANIZATION
: O
The O
entire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
world I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
literature I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
the O
subject B_PERSON
was O
searched O
via O
Medline B_LOCATION/B_ORGANIZATION
. O

Keywords O
included O
reperfusion O
injury O
, O
transplantation O
, O
liver O
resection O
, O
nitric O
oxide O
, O
endothelin O
, O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
Kupffer O
cells O
, O
ischemic/ischaemic O
preconditioning O
, O
and O
nuclear B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factor-kappa I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
An O
imbalance B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
endothelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
results I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
failure B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
hepatic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
microcirculation I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
at O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of O
reperfusion B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

activation O
of O
nuclear B_GENE
factor-kappa I_GENE
B I_GENE
in O
the O
liver O
promotes O
proinflammatory B_DISEASE/B_GENE
cytokine I_DISEASE/I_GENE
and O
adhesion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
molecule I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
synthesis O
. O

These O
result O
in O
oxygen-derived O
free B_DISEASE_ADJECTIVE[DISEASE]
radical I_DISEASE_ADJECTIVE[DISEASE]
production I_DISEASE_ADJECTIVE[DISEASE]
and O
neutrophil B_DISEASE_ADJECTIVE[DISEASE]
recruitment I_DISEASE_ADJECTIVE[DISEASE]
, O
further O
contributing O
to O
cellular B_DISEASE
injury I_DISEASE
. O

Various B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapeutic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
modalities I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acting O
on O
the O
above B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mediators I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
successfully O
used O
to O
attenuate O
reperfusion B_DISEASE/B_GENE
injury I_DISEASE/I_GENE
in O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
hepatic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
resection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Application B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
the O
knowledge B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gained O
from O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hepatic B_DISEASE/B_GENE
ischemia-reperfusion I_DISEASE/I_GENE
to O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
setting I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
will O
improve O
the O
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
hepatic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

Down-regulation O
of O
IL-12 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p40 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
Plasmodium O
berghei-infected O
mice O
. O

We O
analyzed O
the O
mechanism O
that O
causes O
suppression O
of O
IL-12 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p40 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induction O
during O
Plasmodium O
berghei O
infection O
. O

Although O
IL-12 B_GENE
together O
with O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plays O
an O
important O
role O
in O
protection O
against O
pathogenic O
infection O
, O
the O
IL-12 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p70 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
production O
of O
infected O
macrophages O
is O
lower O
than O
that O
by O
the O
uninfected O
macrophages O
. O

We O
showed O
in O
the O
present O
study O
that O
the O
induction O
of O
IL-12 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p40 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
but O
not O
IL-12 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p35 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
macrophages O
of O
P. O
berghei-infected O
mice O
was O
profoundly O
inhibited O
. O

The O
inhibition O
was O
induced O
by O
interaction O
with O
macrophages O
that O
had O
contacted O
with O
P. O
berghei-infected O
erythrocytes O
and O
was O
mediated O
by O
a O
soluble O
factor O
, O
IL-10 B_GENE
. O

There O
was O
comparable O
activation O
of O
NF-kappaB B_GENE
in O
uninfected O
and O
infected O
cells O
. O

The O
induction O
of O
IFN-regulatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
comparable O
in O
transcription O
level O
in O
uninfected O
and O
infected O
cells O
, O
while O
the O
unidentified O
complex O
formation O
of O
IFN-regulatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
in O
infected O
cells O
. O

Therefore O
, O
the O
inhibition O
of O
the O
IL-12 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p40 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induction O
appeared O
to O
be O
regulated O
at O
transcriptional O
regulation O
level O
of O
the O
gene O
. O

The O
Friend B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GATA I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
U-shaped O
, O
FOG-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
FOG-2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O
as O
negative O
regulators O
of O
blood O
, O
heart O
, O
and O
eye O
development O
in O
Drosophila O
. O

Friend B_PERSON/B_GENE
of I_PERSON/I_GENE
GATA I_PERSON/I_GENE
( I_PERSON/I_GENE
FOG I_PERSON/I_GENE
) I_PERSON/I_GENE
proteins I_PERSON/I_GENE
regulate O
GATA O
factor-activated O
gene O
transcription O
. O

During O
vertebrate O
hematopoiesis O
, O
FOG B_BIO/B_GENE
and I_BIO/I_GENE
GATA I_BIO/I_GENE
proteins I_BIO/I_GENE
cooperate O
to O
promote O
erythrocyte O
and O
megakaryocyte O
differentiation O
. O

The O
Drosophila B_GENE
FOG I_GENE
homologue I_GENE
U-shaped I_GENE
( O
Ush B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
expressed O
similarly O
in O
the O
blood O
cell O
anlage O
during O
embryogenesis O
. O

During O
hematopoiesis B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
the O
acute B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myeloid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leukemia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homologue I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Lozenge I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
glial B_DISEASE/B_GENE
cells B_DISEASE/I_GENE
missing O
are O
required O
for O
the O
production B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
crystal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
plasmatocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O
respectively O
. O

However O
, O
additional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
factors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
been O
predicted O
to O
control O
crystal B_DISEASE
cell I_DISEASE
proliferation I_DISEASE
. O

In O
this O
report O
, O
we O
show O
that O
Ush B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
expressed O
in O
hemocyte O
precursors O
and O
plasmatocytes O
throughout O
embryogenesis O
and O
larval O
development O
, O
and O
the O
GATA B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
factor I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
Serpent I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
essential O
for O
Ush B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
embryonic O
expression O
. O

Furthermore O
, O
loss O
of O
ush O
function O
results O
in O
an O
overproduction O
of O
crystal O
cells O
, O
whereas O
forced O
expression O
of O
Ush B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O
this O
cell O
population O
. O

Murine B_PERSON/B_GENE
FOG-1 I_PERSON/I_GENE
and I_PERSON/I_GENE
FOG-2 I_PERSON/I_GENE
also O
can O
repress O
crystal O
cell O
production O
, O
but O
a O
mutant O
version O
of O
FOG-2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lacking O
a O
conserved O
motif O
that O
binds O
the O
corepressor B_GENE/B_LOCATION
C-terminal I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
fails O
to O
affect O
the O
cell O
lineage O
. O

The O
GATA B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Pannier I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Pnr B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
is O
required O
for O
eye O
and O
heart O
development O
in O
Drosophila O
. O

When O
Ush B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
FOG-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
FOG-2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
or O
mutant B_GENE/B_PERSON
FOG-2 I_GENE/I_PERSON
is O
coexpressed O
with O
Pnr B_GENE/B_PERSON
during O
these O
developmental O
processes O
, O
severe O
eye O
and O
heart O
phenotypes O
result O
, O
consistent O
with O
a O
conserved O
negative O
regulation O
of O
Pnr B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
function O
. O

These O
results O
indicate O
that O
the O
fly O
and O
mouse O
FOG B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
function O
similarly O
in O
three O
distinct O
cellular O
contexts O
in O
Drosophila O
, O
but O
may O
use O
different O
mechanisms O
to O
regulate O
genetic O
events O
in O
blood O
vs O
. O
cardial O
or O
eye O
cell O
lineages O
. O

The O
RING B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finger I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Siah-1 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulates O
the O
level O
of O
the O
transcriptional B_GENE
coactivator I_GENE
OBF-1 I_GENE
. O

The O
transcriptional B_GENE/B_MEASURE
coactivator I_GENE/I_MEASURE
OBF-1 I_GENE/I_MEASURE
, O
which O
interacts O
with O
Oct-1 B_GENE
and O
Oct-2 B_GENE
and O
the O
octamer B_GENE/B_BIO
site I_GENE/I_BIO
DNA I_GENE/I_BIO
, O
has O
been O
shown O
to O
be O
critical O
for O
development O
of O
a O
normal O
immune O
response O
and O
the O
formation O
of O
germinal O
centers O
in O
secondary O
lymphoid O
organs O
. O

Here O
we O
have O
identified O
the O
RING B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finger I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Siah-1 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
protein O
interacting O
specifically O
with O
OBF-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
interaction O
is O
mediated O
by O
the O
C-terminal B_LOCATION/B_PROTEIN[GENE]
part O
of O
Siah-1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
by O
residues O
in O
the O
N-terminus B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O
OBF-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
partly O
distinct O
from O
the O
residues O
required O
for O
formation O
of O
a O
complex O
with O
the O
Oct B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
POU I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
DNA O
. O

interaction O
between O
Siah-1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
OBF-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leads O
to O
downregulation O
of O
OBF-1 O
protein O
level O
but O
not O
mRNA O
, O
and O
to O
a O
corresponding O
reduction O
in O
octamer O
site-dependent O
transcription O
activation O
. O

Inhibition O
of O
the O
ubiquitin-proteasome O
pathway O
in O
B O
cells O
leads O
to O
elevated O
levels O
of O
OBF-1 B_GENE
protein I_GENE
. O

Furthermore O
, O
in O
immunized O
mice O
, O
OBF-1 B_GENE/B_MEASURE
protein I_GENE/I_MEASURE
amounts O
are O
dramatically O
increased O
in O
primary O
activated O
B O
cells O
, O
without O
concomitant O
increase O
in O
OBF-1 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mRNA B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

These O
data O
suggest O
that O
Siah-1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
part O
of O
a O
novel O
regulatory O
loop O
controlling O
the O
level O
of O
OBF-1 B_GENE
protein I_GENE
in O
B O
cells O
. O

The O
beta-catenin B_GENE
-- O
TCF-1 O
pathway B_LOCATION
ensures O
CD4 B_GENE
( O
+ B_DISEASE/B_GENE
) O
CD8 B_GENE
( O
+ B_DISEASE/B_PROTEIN[GENE]
) O
thymocyte B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
survival B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

The O
association O
of O
trans-acting B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TCFs B_GENE/B_LOCATION
) O
or O
lymphoid B_GENE/B_BIO
enhancer I_GENE/I_BIO
factor I_GENE/I_BIO
1 I_GENE/I_BIO
( O
LEF-1 B_GENE/B_LOCATION
) O
with O
their O
coactivator O
beta-catenin O
mediates O
transient O
transcriptional O
responses O
to O
extracellular O
Wnt O
signals O
. O

We O
show O
here O
that O
T O
cell O
maturation O
depends O
on O
the O
presence O
of O
the O
beta-catenin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
TCF-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
domain B_LOCATION/B_GENE
is O
necessary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
mediate O
the O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
immature B_GENE
CD4 I_GENE
( O
+ B_DISEASE/B_GENE
) O
CD8 B_GENE
( O
+ B_DISEASE/B_GENE
) O
double-positive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
DP B_PROTEIN[GENE]/B_DISEASE
) O
thymocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

accelerated O
spontaneous O
thymocyte O
death O
in O
the O
absence O
of O
TCF-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
correlates O
with O
aberrantly O
low O
expression O
of O
the O
anti-apoptotic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Bcl-x I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
L I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

increasing O
anti-apoptotic O
effectors O
in O
thymocytes O
by O
the O
use O
of O
a O
Bcl-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transgene B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rescued O
TCF-1-deficient O
DP O
thymocytes O
from O
apoptosis O
. O

Thus O
, O
TCF-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
upon O
association O
with O
beta-catenin O
, O
transiently O
ensures O
the O
survival O
of O
immature O
T O
cells O
, O
which O
enables O
them O
to O
generate O
and O
edit O
T B_GENE
cell I_GENE
receptor I_GENE
( I_GENE
TCR I_GENE
) I_GENE
alpha I_GENE
chains I_GENE
and O
attempt O
TCR B_GENE
-mediated O
positive O
selection O
. O

TRAIL/Apo2L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligand I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
selectively O
induces O
apoptosis O
and O
overcomes O
drug O
resistance O
in O
multiple O
myeloma O
: O
therapeutic O
applications O
. O

Multiple B_DISEASE
myeloma I_DISEASE
( O
MM B_LOCATION/B_DISEASE
) O
remains O
incurable B_DISEASE_ADJECTIVE[DISEASE]
and O
novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
urgently O
needed O
. O

Preclinical O
in O
vitro O
and O
in O
vivo O
evaluations O
were O
performed O
to O
assess O
the O
potential O
therapeutic O
applications O
of O
human O
recombinant O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TNF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-related I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
apoptosis-inducing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ligand/Apo2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ligand I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TRAIL/Apo2L B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
in O
mm O
. O

TRAIL/Apo2L B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
potently O
induced O
apoptosis O
of O
mm O
cells O
from O
patients O
and O
the O
majority O
of O
mm O
cell O
lines O
, O
including O
cells O
sensitive O
or O
resistant O
to O
dexamethasone O
( O
Dex O
) O
, O
doxorubicin O
( O
Dox O
) O
, O
melphalan O
, O
and O
mitoxantrone O
. O

TRAIL/Apo2L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O
overcame O
the O
survival O
effect O
of O
interleukin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
mm O
cells O
and O
did O
not O
affect O
the O
survival O
of O
peripheral O
blood O
and O
bone O
marrow O
mononuclear O
cells O
and O
purified O
B O
cells O
from O
healthy O
donors O
. O

The O
status O
of O
the O
TRAIL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
assessed O
by O
immunoblotting O
and O
flow O
cytometry O
) O
could O
not O
predict O
Trail O
sensitivity O
of O
mm O
cells O
. O

The O
anti-MM O
activity O
of O
TRAIL/Apo2L B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O
confirmed O
in O
nu/xid/bg O
mice O
xenografted O
with O
human O
mm O
cells O
; O
TRAIL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
500 O
microg O
intraperitoneally O
daily O
for O
14 O
days O
) O
was O
well O
tolerated O
and O
significantly O
suppressed O
the O
growth O
of O
plasmacytomas O
. O

Dox O
up-regulated O
the O
expression O
of O
the O
TRAIL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
death I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
DR5 B_GENE
) O
and O
synergistically O
enhanced O
the O
effect O
of O
TRAIL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
not O
only O
against O
mm O
cells O
sensitive O
to O
, O
but O
also O
against O
those O
resistant O
to O
, O
Dex- O
or O
Dox-induced O
apoptosis O
. O

Nuclear O
factor O
( O
NF O
) O
-kappaB O
inhibitors O
, O
such O
as O
SN50 O
( O
a O
cell-permeable O
inhibitor O
of O
the O
nuclear O
translocation O
and O
transcriptional O
activity O
of O
NF-kappaB B_GENE
) O
or O
the O
proteasome O
inhibitor O
PS-341 O
, O
enhanced O
the O
proapoptotic O
activity O
of O
TRAIL/Apo2L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
against O
TRAIL-sensitive O
mm O
cells O
, O
whereas O
SN50 O
reversed O
the O
Trail O
resistance O
of O
ARH-77 O
and O
IM-9 O
mm O
cells O
. O

importantly O
, O
normal O
B O
lymphocytes O
were O
not O
sensitized O
to O
TRAIL B_GENE/B_DISEASE
by O
either O
Dox O
, O
SN50 O
, O
or O
PS-341 O
. O

These O
preclinical O
studies O
suggest O
that O
TRAIL/Apo2L B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
overcome O
conventional O
drug O
resistance O
and O
provide O
the O
basis O
for O
clinical O
trials O
of O
TRAIL B_GENE
-based O
treatment O
regimens O
to O
improve O
outcome O
in O
patients O
with O
mm O
. O

( O
Blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O
2001 B_MEASURE
; O
98 B_MEASURE
: O
795-804 B_TIME[MEASURE]
) O
. O

CD28 B_GENE
costimulation O
is O
required O
not O
only O
to O
induce O
IL-12 B_GENE/B_DISEASE
receptor I_GENE/I_DISEASE
but O
also O
to O
render O
janus B_PERSON/B_GENE
kinases/STAT4 I_PERSON/I_GENE
responsive O
to O
IL-12 B_GENE
stimulation O
in O
TCR-triggered O
T O
cells O
. O

The O
activation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
resting O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
for O
the O
acquisition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
various B_DISEASE_ADJECTIVE[DISEASE]
functions I_DISEASE_ADJECTIVE[DISEASE]
depends O
on O
whether O
CD28 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
costimulatory I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
provided O
upon O
T B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
cell B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
receptor B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O

Here O
, O
we O
investigated O
how O
CD28 O
costimulation O
functions O
to O
allow O
TCR B_GENE/B_DISEASE
-triggered O
resting O
T O
cells O
to O
acquire O
IL-12 B_GENE/B_MEASURE
responsiveness O
. O

When O
T O
cells O
are O
stimulated O
with O
low O
doses O
of O
anti-CD3 B_GENE
mAb I_GENE
, O
CD28 O
costimulation O
was O
required O
for O
the O
optimal O
levels O
of O
IL-12 B_GENE
receptor I_GENE
( O
IL-12R B_PROTEIN[GENE]/B_LOCATION
) O
expression O
. O

However O
, O
stimulation O
of O
T O
cells O
with O
high O
doses O
of O
anti-CD3 B_GENE
alone O
induced O
comparable O
levels O
of O
IL-12R B_GENE
expression O
to O
those O
induced O
upon O
CD28 O
costimulation O
. O

Nevertheless O
, O
there O
was O
a O
substantial O
difference O
in O
IL-12 B_GENE/B_PERSON
responsiveness O
between O
these O
two O
groups O
of O
T O
cells O
: O
compared O
to O
anti-CD28-costimulated O
T O
cells O
, O
T O
cells O
that O
were O
not O
costimulated O
with O
anti-CD28 B_GENE
exhibited O
decreased O
levels O
of O
Janus B_GENE
kinases I_GENE
( O
JAK B_GENE
) O
JAK2/TYK2 B_GENE/B_MEASURE
and O
STAT4 B_GENE
phosphorylation O
and O
IFN-y O
production O
following O
IL-12 B_GENE
stimulation O
. O

importantly O
, O
STAT6 B_GENE/B_DISEASE
phosphorylation I_GENE/I_DISEASE
following O
IL-4 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
was O
not O
decreased O
in O
anti-CD28-uncostimulated B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

These O
resutls O
indicate O
that O
CD28 O
costimulation O
not O
only O
contributes O
to O
up-regulating O
IL-12R B_GENE
expression O
but O
is O
also O
required O
to O
render O
JAKs/STAT4 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
responsive O
to O
IL-12 B_GENE
stimulation O
. O

Constitutively O
activated O
Akt-1 B_GENE
is O
vital O
for O
the O
survival O
of O
human O
monocyte-differentiated O
macrophages O
. O

Role O
of O
Mcl-1 B_GENE
, O
independent O
of O
nuclear B_GENE
factor I_GENE
( I_GENE
NF I_GENE
) I_GENE
-kappaB I_GENE
, O
Bad B_GENE
, O
or O
caspase O
activation O
. O

Recent O
data O
from O
mice O
deficient O
for O
phosphatase B_GENE/B_DISEASE
and O
tensin B_GENE/B_LOCATION
homologue I_GENE/I_LOCATION
deleted O
from O
chromosome B_GENE
10 I_GENE
or O
src B_MEASURE
homology I_MEASURE
2 I_MEASURE
domain-containing I_MEASURE
5 I_MEASURE
' I_MEASURE
inositol I_MEASURE
phosphatase I_MEASURE
, O
phosphatases B_ENZYME[GENE]/B_BIO
that O
negatively O
regulate O
the O
phosphatidylinositol B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3-kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PI3K B_GENE/B_LOCATION
) O
pathway O
, O
revealed O
an O
increased O
number O
of O
macrophages O
in O
these O
animals O
, O
suggesting O
an O
essential O
role O
for O
the O
PI3K B_GENE
pathway O
for O
macro-phage O
survival O
. O

Here O
, O
we O
focused O
on O
the O
role O
of O
the O
PI3K-regulated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
serine/threonine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Akt-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
modulating O
macrophage O
survival O
. O

Akt-1 B_GENE
was O
constitutively O
activated O
in O
human O
macrophages O
and O
addition O
of O
the O
PI3K B_GENE
inhibitor O
, O
LY294002 O
, O
suppressed O
the O
activation O
of O
Akt-1 B_GENE
and O
induced O
cell O
death O
. O

Furthermore O
, O
suppression O
of O
Akt-1 B_GENE
by O
inhibition O
of O
PI3K B_GENE
or O
a O
dominant B_GENE
negative I_GENE
( I_GENE
DN I_GENE
) I_GENE
Akt-1 I_GENE
resulted O
in O
loss O
of O
mitochondrial O
transmembrane O
potential O
, O
activation O
of O
caspases-9 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
DNA O
fragmentation O
. O

The O
effects O
of O
PI3K B_GENE
inhibition O
were O
reversed O
by O
the O
ectopic O
expression O
of O
constitutively O
activated O
Akt-1 B_GENE
or O
Bcl-x B_GENE
( I_GENE
L I_GENE
) I_GENE
. O

Inhibition O
of O
PI3K B_GENE
/Akt-1 O
pathway O
either O
by O
LY294002 O
or O
DN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Akt-1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
had O
no O
effect O
on O
the O
constitutive O
or O
inducible O
activation O
of O
nuclear B_GENE
factor I_GENE
( I_GENE
NF I_GENE
) I_GENE
-kappaB I_GENE
in O
human O
macrophages O
. O

However O
, O
after O
inhibition O
of O
the O
PI3K B_GENE
/ O
Akt-1 B_GENE
pathway O
, O
a O
marked O
decrease O
in O
the O
expression O
of O
the O
antiapoptotic B_GENE
molecule I_GENE
Mcl-1 I_GENE
, O
but O
not O
other O
Bcl-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
members I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
, O
and O
Mcl-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
rescued O
macrophages O
from O
LY294002-induced O
cell O
death O
. O

Further O
, O
inhibition O
of O
Mcl-1 B_GENE
by O
antisense O
oligonucleotides O
, O
also O
resulted O
in O
macrophage O
apoptosis O
. O

Thus O
, O
our O
findings O
demonstrate O
that O
the O
constitutive O
activation O
of O
Akt-1 B_GENE
regulates O
macrophage O
survival O
through O
Mcl-1 B_GENE/B_DISEASE
, O
which O
is O
independent O
of O
caspases B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
NF-kappaB B_GENE
, O
or O
Bad B_GENE
. O

GRbeta B_GENE
expression I_GENE
in O
nasal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
polyp B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
inflammatory B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cells B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
its O
relationship B_PERSON
to O
the O
anti-inflammatory B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
intranasal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluticasone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Nasal B_DISEASE
polyposis I_DISEASE
disease I_DISEASE
is O
an O
inflammatory B_DISEASE/B_LOCATION
disorder I_DISEASE/I_LOCATION
with O
intense B_DISEASE
eosinophilic I_DISEASE
infiltration I_DISEASE
of O
respiratory B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mucosa I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O
is O
often O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
control O
with O
topical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
steroids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Recent O
evidence O
suggests O
that O
overexpression O
of O
the O
glucocorticoid B_GENE/B_LOCATION
receptor I_GENE/I_LOCATION
splice I_GENE/I_LOCATION
variant I_GENE/I_LOCATION
GRbeta I_GENE/I_LOCATION
in O
inflammatory O
cells O
might O
contribute O
to O
steroid O
insensitivity O
in O
diseases O
such O
as O
asthma O
. O

objective O
: O
The O
purposes O
of O
this O
investigation O
were O
to O
determine O
whether O
nasal O
polyp O
( O
NP O
) O
inflammatory O
cells O
overexpress O
GRbeta B_GENE
and O
to O
examine O
whether O
GRbeta B_GENE/B_PERSON
overexpression O
is O
associated O
with O
insensitivity O
to O
the O
potent O
topical O
steroid O
fluticasone O
propionate O
( O
FP O
) O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
biopsies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
obtained O
from O
10 B_PERSON/B_BIO
subjects I_PERSON/I_BIO
with O
NPs B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
and O
4 B_NUMBER[MEASURE]/B_ENT
weeks I_NUMBER[MEASURE]/I_ENT
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
intranasal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Middle B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
turbinates I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biopsies I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
6 B_PERSON
healthy I_PERSON
, O
nonallergic B_PERSON/B_BIO
subjects I_PERSON/I_BIO
served O
as O
normal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Biopsies O
were O
immunostained O
for O
inflammatory O
cell O
markers O
as O
well O
as O
GRbeta B_GENE
and O
probed O
for O
various O
cytokine B_GENE
mRNA I_GENE
. O

The O
anti-inflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
FP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
examined O
in O
relation B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
pretreatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
GRbeta B_GENE
expression I_GENE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
The O
total B_MEASURE
numbers I_MEASURE
of O
inflammatory B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O
increased O
in O
NPs B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
percentage O
of O
inflammatory O
cells O
expressing O
GRbeta B_GENE
was O
also O
increased O
( O
40.5 O
% O
+/- O
19.2 O
% O
vs O
16.1 O
% O
+/- O
4.0 O
% O
, O
P O
=.009 O
) O
. O

GRbeta B_GENE
expression O
in O
NPs O
was O
almost O
exclusive O
to O
T O
lymphocytes O
, O
eosinophils O
, O
and O
macrophages O
. O

An O
inverse O
correlation O
was O
observed O
between O
the O
baseline O
inflammatory O
cell O
GRbeta B_GENE/B_MEASURE
expression O
and O
the O
reduction O
after O
FP O
treatment O
in O
EG2-positive O
eosinophils O
, O
CD4-positive O
T O
lymphocytes O
, O
endothelial O
VCAM-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O
, O
and O
IL-4 O
mRNA-positive O
cells O
. O

NPs O
that O
were O
`` O
FP-insensitive O
'' O
in O
terms O
of O
suppression O
of O
eosinophil O
numbers O
( O
major B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
basic I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
-positive O
) O
had O
a O
significantly O
greater O
percentage O
of O
GRbeta-positive O
inflammatory O
cells O
, O
a O
higher O
ratio O
of O
GRbeta-positive/GRalpha-positive O
cells O
, O
and O
increased O
numbers O
of O
GRbeta-positive O
eosinophils O
and O
macrophages O
in O
comparison O
with O
those O
that O
were O
`` O
FP-sensitive. O
'' O
. O

`` O
FP-insensitive O
'' O
NPs O
also O
demonstrated O
a O
higher O
percentage O
of O
IL-5-positive O
inflammatory O
cells O
expressing O
GRbeta B_GENE
before O
and O
after O
FP O
treatment O
. O

conclusion O
: O
GRbeta B_GENE/B_LOCATION
expression O
appears O
to O
be O
a O
marker O
of O
steroid O
insensitivity O
in O
NPs O
. O

expression O
of O
GRbeta B_GENE
by O
NP O
inflammatory O
cells O
, O
particularly O
T O
cells O
and O
eosinophils O
, O
might O
render O
them O
resistant O
to O
suppression O
by O
topical O
steroids O
and O
thereby O
contribute O
to O
persistent O
NP O
inflammation O
. O

Transcriptional O
regulation O
of O
galectin-10 B_GENE/B_DISEASE
( O
eosinophil B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Charcot-Leyden I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
crystal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
: O
a O
GC B_GENE/B_LOCATION
box B_GENE/I_LOCATION
( O
-44 O
to O
-50 O
) O
controls O
butyric O
acid O
induction O
of O
gene O
expression O
. O

Galectin-10 B_GENE
( O
gal-10 B_GENE/B_DISEASE
, O
also O
known O
as O
Charcot-Leyden B_GENE/B_DISEASE
crystal I_GENE/I_DISEASE
protein I_GENE/I_DISEASE
) O
is O
a O
member O
of O
the O
galectin B_PERSON/B_BIO
family I_PERSON/I_BIO
of O
beta-galactoside B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
is O
expressed O
uniquely O
in O
eosinophilic O
and O
basophilic O
leukocytes O
. O

To O
gain O
a O
better O
understanding O
of O
galectin O
gene O
expression O
, O
we O
present O
an O
analysis O
of O
the O
transcriptional O
regulation O
of O
the O
gene O
encoding O
gal-10 B_GENE
. O

Analysis O
of O
the O
minimal B_GENE/B_LOCATION
promoter B_GENE/I_LOCATION
revealed O
nine O
consensus-binding B_LOCATION/B_PERSON
sites I_LOCATION/I_PERSON
for O
transcription B_GENE/B_MEASURE
factors I_GENE/I_MEASURE
, O
including O
several O
that O
are O
also O
found O
in O
the O
minimal B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
galectins B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
-1 I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
-2 I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
-3 I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
decrease O
in O
gal-10 O
promoter O
activity O
after O
disruption O
of O
either O
the O
GC B_GENE
box I_GENE
( O
-44 O
to O
-50 O
) O
or O
the O
Oct B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
-255 O
to O
-261 O
) O
suggests O
that O
these O
sites O
, O
along O
with O
the O
previously O
characterized O
GATA B_LOCATION/B_ORGANIZATION
and I_LOCATION/I_ORGANIZATION
EoTF I_LOCATION/I_ORGANIZATION
sites I_LOCATION/I_ORGANIZATION
, O
are O
necessary O
for O
full O
promoter O
activity O
. O

By O
supershift O
analysis O
, O
we O
demonstrate O
binding O
of O
the O
transcription B_GENE
factors I_GENE
Sp1 I_GENE
and O
Oct1 B_GENE/B_LOCATION
to O
the O
consensus B_GENE/B_LOCATION
GC I_GENE/I_LOCATION
box I_GENE/I_LOCATION
and O
the O
Oct B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
. O

Similar O
to O
gal-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
gal-10 O
expression O
is O
induced O
by O
butyric O
acid O
, O
an O
effect O
that O
is O
lost O
upon O
ablation O
of O
the O
GC B_GENE
box I_GENE
. O

Additionally O
, O
we O
demonstrate O
AML3 O
binding O
to O
the O
consensus B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AML I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
YY1 B_TIME[MEASURE]/B_GENE
binding I_TIME[MEASURE]/I_GENE
to O
the O
Inr B_LOCATION/B_GENE
sequence I_LOCATION/I_GENE
, O
both O
elements O
functioning O
as O
silencers O
in O
the O
gal-10 B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
promoter B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Tumour-stromal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Role B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
stroma B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
in O
mammary B_DISEASE
development I_DISEASE
. O

mammary B_DISEASE_ADJECTIVE[DISEASE]
development I_DISEASE_ADJECTIVE[DISEASE]
depends O
on O
branching O
morphogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O
namely O
the O
bifurcation B_DISEASE/B_ORGANIZATION
and O
extension B_TIME[MEASURE]/B_DISEASE
of O
ductal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
points I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
end B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
buds I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
and O
secretory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
lobules B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
into O
a O
more O
or O
less O
fatty B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
stroma I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O

Because O
breast B_DISEASE/B_PERSON
carcinomas I_DISEASE/I_PERSON
are O
overwhelmingly O
ductal B_BODY_PART_OR_ORGAN_COMPONENT
in O
origin B_DISEASE/B_LOCATION
, O
this O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
focuses O
on O
stromal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
influences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
guiding O
postnatal B_DISEASE/B_ORGANISM_FUNCTION
ductal I_DISEASE/I_ORGANISM_FUNCTION
development I_DISEASE/I_ORGANISM_FUNCTION
and O
there O
is O
only O
the O
briefest B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
account I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
embryonic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stroma I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
mesenchyme B_MEASURE/B_PROTEIN[GENE]
) O
. O

The O
stroma B_BODY_PART_OR_ORGAN_COMPONENT
as O
the O
necessary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
target I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O
endocrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
mammogens I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O
the O
source B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
stimulatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
growth I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
described O
and O
the O
importance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mammary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
epithelium-induced I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
modifications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
periductal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
stroma I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
emphasized O
. O

Evidence O
is O
presented O
that O
if O
they O
are O
to O
grow O
, O
end O
buds O
must O
condition O
proximal O
fatty O
stroma O
by O
recruiting O
white O
blood O
cells O
as O
well O
as O
inducing O
stromal O
cell O
division O
and O
, O
possibly O
, O
estrogen B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
induction B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
fibrous B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
stromal B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
tunic B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
around O
the O
end B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bud I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
described O
and O
its O
likely B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ductal B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
morphogen B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
discussed O
; O
a O
possible B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
growth B_DISEASE/B_ORGANISM_FUNCTION
inhibition B_DISEASE/I_ORGANISM_FUNCTION
is O
also O
considered O
. O

Although O
the O
signals O
governing O
fibrotic O
induction O
, O
ductal O
morphogenesis O
, O
and O
growth O
inhibition O
are O
unknown O
, O
a O
role O
for O
transforming O
growth B_GENE
factor-beta I_GENE
is O
highly O
likely O
and O
is O
discussed O
. O

Finally O
, O
a O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conceptual I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
experimental B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
approaches I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
understanding O
stromal-epithelial B_DISEASE
signaling I_DISEASE
is O
discussed O
. O

Adipophilin B_GENE
is O
a O
sensitive O
marker O
for O
lipid O
loading O
in O
human O
blood O
monocytes O
. O

Adipophilin B_GENE
, O
a O
marker O
of O
lipid O
accumulation O
initially O
described O
in O
adipocytes O
, O
was O
recently O
shown O
to O
be O
induced O
in O
macrophage O
foam O
cells O
. O

We O
found O
that O
even O
freshly O
isolated O
blood O
monocytes O
express O
adipophilin B_GENE
and O
that O
the O
amount O
of O
adipophilin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
variable O
in O
monocytes O
from O
different O
healthy O
individuals O
. O

However O
, O
the O
physiological O
expression O
of O
adipophilin B_GENE/B_DISEASE
does O
not O
correlate O
with O
the O
levels O
of O
free O
fatty O
acids O
, O
cholesterylesters O
or O
free O
cholesterol O
. O

Enzymatically B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
modified I_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
low-density I_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
lipoprotein I_GENE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
( O
E-LDL B_PROTEIN[GENE]/B_LOCATION
) O
induces O
rapid O
foam O
cell O
formation O
in O
monocytes O
and O
upregulates O
adipophilin B_GENE
mRNA O
and O
protein O
within O
2 O
h O
of O
incubation O
. O

This O
rapid O
induction O
of O
adipophilin B_GENE
is O
accompanied O
by O
a O
significant O
increase O
of O
free O
fatty O
acids O
in O
monocytes O
incubated O
with O
E-LDL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Adipophilin B_GENE/B_DISEASE
facilitates O
the O
uptake O
of O
free O
fatty O
acids O
, O
and O
here O
we O
demonstrate O
that O
free O
fatty O
acids O
increase O
is O
related O
to O
the O
early O
upregulation O
of O
adipophilin O
expression O
in O
blood O
monocytes O
. O

fatty O
acids O
are O
ligands O
for O
peroxisome B_GENE/B_LOCATION
proliferator-activated I_GENE/I_LOCATION
receptor-gamma I_GENE/I_LOCATION
( O
PPARgamma B_GENE
) O
, O
and O
the O
upregulation O
of O
adipophilin B_GENE
mRNA I_GENE
by O
PPARgamma B_GENE
agonists O
like O
15d-PGJ O
( O
2 O
) O
and O
ciglitazone O
indicates O
that O
PPARgamma B_GENE/B_PERSON
may O
mediate O
the O
induction O
of O
adipophilin O
expression O
in O
human O
blood O
monocytes O
. O

Constitutive O
expression O
of O
MHC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
melanoma O
cell O
lines O
results O
from O
the O
transcription O
of O
class B_GENE/B_LOCATION
II I_GENE/I_LOCATION
transactivator I_GENE/I_LOCATION
abnormally O
initiated O
from O
its O
B B_GENE/B_PERSON
cell-specific I_GENE/I_PERSON
promoter I_GENE/I_PERSON
. O

In O
melanoma O
cell O
lines O
, O
two O
different O
patterns O
of O
MHC O
class O
II O
expression O
have O
been O
described O
, O
either O
an O
IFN O
gamma-inducible O
expression O
of O
HLA-DR B_GENE
and O
HLA-DP B_PROTEIN[GENE]/B_LOCATION
, O
with O
a O
faint O
or O
null O
expression O
of O
HLA-DQ B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
resembling O
that O
described O
for O
melanocytes O
, O
or O
a O
constitutive O
expression O
, O
i.e. O
, O
IFN-gamma O
independent O
, O
of O
all O
three O
HLA-D B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isotypes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

As O
this O
latter B_DISEASE_ADJECTIVE[DISEASE]
phenotype I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
associated O
with O
a O
more O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
progression B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
melanoma B_DISEASE
tumors I_DISEASE
, O
we O
have O
analyzed O
in O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
melanoma B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cell B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
lines B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
the O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leading O
to O
this O
abnormal B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
MHC B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
class B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
II B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

In O
agreement O
with O
the O
evidence O
of O
a O
coordinate O
transcription O
of O
the O
HLA-D B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
these O
cell O
lines O
, O
we O
have O
shown O
the O
constitutive O
expression O
of O
CIITA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transactivator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
CIITA B_TIME[MEASURE]/B_LOCATION
being O
known O
as O
the O
master O
switch O
of O
MHC O
class O
II O
expression O
. O

unexpectedly O
, O
these O
transcripts O
initiate O
from O
promoter B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_LOCATION
III I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_LOCATION
of O
the O
CIITA B_GENE
gene I_GENE
, O
a O
promoter O
that O
is O
mainly O
used O
constitutively O
in O
B O
lymphocytes O
. O

This O
expression O
was O
further O
shown O
to O
occur O
through O
factor O
( O
s O
) O
acting O
on O
the O
enhancer O
located O
upstream O
of O
CIITA B_GENE
promoter I_GENE
III I_GENE
, O
which O
was O
previously O
described O
in O
epithelioid O
cells O
as O
an O
IFN-gamma-response O
sequence O
. O

The O
hypothesis B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
general B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
abnormality I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
IFN-gamma B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
transduction I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
dismissed O
. O

Constitutive O
transcription O
of O
CIITA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
promoter B_GENE
III I_GENE
having O
been O
observed O
in O
unrelated O
melanoma O
cell O
lines O
, O
we O
propose O
the O
hypothesis O
that O
this O
phenomenon O
might O
not O
be O
a O
random O
event O
, O
but O
could O
be O
linked O
to O
the O
neoplasic O
state O
of O
the O
melanoma O
cells O
. O

Caspase B_GENE
-mediated O
calcineurin O
activation O
contributes O
to O
IL-2 B_GENE
release O
during O
T O
cell O
activation O
. O

Calcineurin B_GENE
, O
a O
Ca B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2+ I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/calmodulin-dependent I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Ser/Thr I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2B I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
plays O
a O
critical O
role O
in O
IL-2 O
production O
during O
T O
cell O
activation O
. O

It O
has O
been O
previously O
reported O
that O
IL-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release O
in O
activated O
Jurkat O
T O
requires O
caspase-like O
activity O
( O
Posmantur O
et O
al. O
( O
1998 O
) O
Exp. O
Cell. O
Res. O
244 O
, O
302-309 O
) O
. O

We O
report O
here O
that O
the O
60-kDa B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
catalytic I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subunit I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
calcineurin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Cn B_LOCATION/B_PROTEIN[GENE]
A I_LOCATION/I_PROTEIN[GENE]
) O
was O
partially O
cleaved O
to O
a O
45-kDa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
form O
in O
phytohemagglutinin O
A O
( O
PHA O
) O
or O
phorbol O
ester O
+ O
ionomycin O
( O
P O
+ O
I O
) O
-activated O
Jurkat O
cells O
. O

In O
parallel O
, O
proteolytic O
activation O
of O
upstream O
caspases B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
caspase-8 O
and O
-9 O
) O
as O
well O
as O
effector B_GENE
caspase-3 I_GENE
was O
also O
observed O
. O

Cn B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cleavage O
was O
caspase O
mediated O
, O
since O
it O
was O
inhibitable O
by O
pan-caspase O
inhibitor O
Cbz-Asp-CH O
( O
2 O
) O
OC O
( O
O O
) O
-2 O
, O
6-dichlorobenzene O
( O
Z-D-DCB O
) O
. O

Cn B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
A I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cleavage O
was O
also O
observed O
when O
purified O
calcineurin B_GENE/B_DISEASE
was O
digested O
in O
vitro O
with O
caspase-3 B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Truncated B_DISEASE/B_MEASURE
Cn I_DISEASE/I_MEASURE
A I_DISEASE/I_MEASURE
was O
associated O
with O
enhanced O
phosphatase O
activity O
and O
reduced O
calmodulin O
sensitivity O
. O

Furthermore O
, O
in O
PHA O
or O
P O
+ O
I-activated O
Jurkat O
cells O
, O
dephosphorylation O
of O
calcineurin B_GENE
substrate O
NFATc B_GENE
( O
a O
transcription B_ENZYME[GENE]/B_MEASURE
factor I_ENZYME[GENE]/I_MEASURE
known O
to O
be O
involved O
in O
transactivation O
of O
the O
IL-2 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
) O
, O
was O
also O
suppressed O
by O
Z-D-DCB O
. O

taken O
together O
, O
our O
results O
suggest O
that O
caspase-mediated O
cleavage O
of O
Cn B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contributes O
to O
IL-2 O
production O
during O
T O
cell O
activation O
. O

Copyright B_LOCATION/B_PERSON
2001 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

maturation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
human B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dendritic B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
sulfasalazine B_DISEASE_ADJECTIVE[DISEASE]
target I_DISEASE_ADJECTIVE[DISEASE]
. O

Aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Sulfasalazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
a O
nonsteroidal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti-inflammatory I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
treating O
some O
autoimmune B_DISEASE
diseases I_DISEASE
, O
but O
its O
mechanism B_LOCATION
of O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O
unclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
determine O
whether O
dendritic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
could O
be O
a O
possible B_PERSON/B_LOCATION
target I_PERSON/I_LOCATION
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
studied O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sulfasalazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
its O
metabolites B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
aminosalicylate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sulfapyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
on O
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
maturation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
( O
terminal B_DISEASE/B_LOCATION
differentiation B_DISEASE/I_LOCATION
) O
of O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
myeloid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
dendritic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

methods O
: O
We O
prepared O
immature O
dendritic O
cells O
by O
incubating O
CD14-positive O
cells O
in O
the O
presence O
of O
granulocyte- B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
macrophage B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
interleukin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
cells O
were O
matured O
by O
addition O
of O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TNF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-a I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
IL-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
presence O
of O
sulfasalazine O
or O
its O
metabolites O
-- O
aminosalicylate O
and O
sulfapyridine O
, O
or O
their O
combinations O
. O

We O
quantified O
the O
effect O
of O
drugs O
on O
the O
dendritic O
cell O
characteristics O
, O
such O
as O
stimulation O
of O
autologous O
and O
allogeneic O
pan-T O
cell O
proliferation O
, O
surface O
marker O
phenotype O
, O
IL-12 O
p40 O
subunit O
secretion O
, O
and O
activation O
of O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
dendritic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
treated O
with O
sulfasalazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
1.25 B_MEASURE
micromol/L I_MEASURE
or O
2.5 B_MEASURE
micromol/L I_MEASURE
) O
could O
not O
stimulate O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
( O
p B_MEASURE
< I_MEASURE
0.028 I_MEASURE
, O
two-sided O
paired O
t-test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

In O
distinction O
to O
drug-free O
maturing O
dendritic O
cells O
, O
2.5 O
micromol/L O
sulfasalazine O
upregulated O
the O
levels O
of O
CD14 B_GENE
and O
CD68 B_GENE
and O
downregulated O
the O
levels O
of O
CD40 B_GENE
, O
CD80 B_GENE
, O
and O
CD83 B_GENE
( O
for O
all O
CD O
markers O
, O
p O
< O
0.03 O
for O
difference O
between O
measurements O
in O
the O
absence O
and O
the O
presence O
of O
sulfasalazine O
) O
. O

From O
concentration-dependent B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
CD83 B_GENE/B_MEASURE
expression B_GENE/I_MEASURE
, O
we O
found O
an O
apparent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ID50 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1.5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
micromol/L I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfasalazine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
apparent B_MEASURE
ID50 I_MEASURE
value I_MEASURE
for O
aminosalicylate-inhibited B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
maturation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
4 B_MEASURE
micromol/L I_MEASURE
. O

Sulfapyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O
no O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

At O
1.25 B_TIME[MEASURE]/B_PERSON
micromol/L I_TIME[MEASURE]/I_PERSON
, O
sulfasalazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
largely O
inhibited O
NF-kB B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
activation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
dendritic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Maturing O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
dendritic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
are O
hundred-fold B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
more O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
to O
sulfasalazine O
than O
T B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
NK B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
most O
sensitive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
described O
so O
far O
. O

Thus O
, O
dendritic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
maturation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sulfasalazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Because O
of O
the O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
dendritic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
( O
auto B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
immunity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
inhibition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
their O
maturation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
might O
provide O
a O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
for O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
optimization I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sulfasalazine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Defective O
function O
of O
the O
proteasome B_GENE
in O
autoimmunity O
: O
involvement O
of O
impaired O
NF-kappaB O
activation O
. O

Type O
1 O
diabetes O
( O
also O
known O
as O
insulin-dependent O
diabetes O
mellitus O
or O
juvenile-onset O
diabetes O
) O
is O
usually O
caused O
by O
T O
cell-mediated O
autoimmunity O
, O
with O
a O
prediabetic O
state O
characterized O
by O
the O
production O
of O
autoantibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
specific O
for O
proteins O
expressed O
by O
pancreatic O
beta O
cells O
. O

The O
nonobese O
patient O
with O
diabetes O
( O
nod O
) O
mouse O
is O
a O
spontaneous O
model O
of O
type O
1 O
diabetes O
with O
a O
strong O
genetic O
component O
that O
maps O
to O
the O
major B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
histocompatibility B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
complex B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
MHC B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
the O
genome B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

A O
specific O
proteasome B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
defect O
has O
been O
identified O
in O
nod O
mouse O
in O
select O
lymphocytic O
and O
monocytic O
lineages O
that O
results O
from O
down-regulation O
of O
expression O
of O
the O
proteasome B_GENE/B_MEASURE
subunit I_GENE/I_MEASURE
LMP2 I_GENE/I_MEASURE
, O
which O
is O
encoded O
by O
a O
gene O
in O
the O
MHC B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
genomic I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
region I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
defect O
prevents O
the O
proteolytic O
processing O
required O
for O
the O
production O
and O
activation O
of O
the O
transcription B_GENE
factor I_GENE
nuclear I_GENE
factor-kappaB I_GENE
( O
NF-kappaB B_GENE
) O
, O
which O
plays O
important O
roles O
in O
immune O
and O
inflammatory O
responses O
, O
as O
well O
as O
increases O
the O
susceptibility O
of O
the O
affected O
cells O
to O
apoptosis O
induced O
by O
tumor B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necrosis B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor-alpha B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
novel O
role O
of O
the O
proteasome B_BODY_PART_OR_ORGAN_COMPONENT/B_ENZYME[GENE]
in O
dysfunction O
in O
autoimmunity O
is O
presented O
and O
documented O
to O
be O
both O
tissue O
and O
developmental O
stage O
specific O
. O

We O
propose O
a O
role O
of O
the O
proteasome B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
as O
a O
step O
in O
disease O
pathogenesis O
and O
tissue O
targeting O
. O

Down-regulation O
of O
TDT O
transcription O
in O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocytes O
by O
Ikaros B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
direct O
competition O
with O
an O
Ets B_GENE/B_LOCATION
activator I_GENE/I_LOCATION
. O

Ikaros B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
a O
unique O
regulator O
of O
lymphopoiesis O
that O
associates O
with O
pericentromeric B_GENE
heterochromatin I_GENE
and O
has O
been O
implicated O
in O
heritable O
gene O
inactivation O
. O

binding O
and O
competition O
experiments O
demonstrate O
that O
Ikaros B_PERSON/B_GENE
dimers I_PERSON/I_GENE
compete O
with O
an O
Ets B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
occupancy O
of O
the O
lymphocyte-specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
TdT I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

mutations O
that O
selectively O
disrupt O
Ikaros O
binding O
to O
an O
integrated B_GENE/B_MEASURE
TdT I_GENE/I_MEASURE
promoter I_GENE/I_MEASURE
had O
no O
effect O
on O
promoter O
function O
in O
a O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocyte O
line O
. O

However O
, O
these O
mutations O
abolished O
down-regulation O
on O
differentiation O
, O
providing O
evidence O
that O
Ikaros B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plays O
a O
direct O
role O
in O
repression O
. O

reduced O
access B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
restriction B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cleavage I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
suggested O
that O
chromatin B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alterations I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accompany O
down-regulation B_DISEASE
. O

The O
Ikaros-dependent B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
down-regulation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
event I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O
the O
observed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alterations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
appear O
to O
precede O
pericentromeric B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repositioning I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Current O
models O
propose O
that O
the O
functions O
of O
Ikaros B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
should O
be O
disrupted O
by O
a O
small O
isoform B_GENE/B_LOCATION
that O
retains O
the O
dimerization B_GENE
domain I_GENE
and O
lacks O
the O
DNA-binding B_GENE
domain I_GENE
. O

surprisingly O
, O
in O
the O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
thymocyte O
line O
, O
overexpression O
of O
a O
small B_GENE
Ikaros I_GENE
isoform I_GENE
had O
no O
effect O
on O
differentiation O
or O
on O
the O
pericentromeric O
targeting O
and O
DNA-binding O
properties O
of O
Ikaros B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Rather O
, O
the O
small O
isoform B_GENE
assembled O
into O
multimeric B_LOCATION/B_BIO
complexes I_LOCATION/I_BIO
with O
DNA-bound B_GENE
Ikaros I_GENE
at O
the O
pericentromeric O
foci O
. O

The O
capacity O
for O
in O
vivo O
multimer O
formation O
suggests O
that O
interactions O
between O
Ikaros B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dimers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bound O
to O
the O
TdT B_GENE
promoter I_GENE
and O
those O
bound O
to O
pericentromeric B_GENE/B_MEASURE
repeat I_GENE/I_MEASURE
sequences I_GENE/I_MEASURE
may O
contribute O
to O
the O
pericentromeric O
repositioning O
of O
the O
inactive B_GENE
gene I_GENE
. O

Type B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferons I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IL-12 B_GENE/B_BIO
: O
convergence O
and O
cross-regulation O
among O
mediators O
of O
cellular O
immunity O
. O

therapeutic O
use O
of O
type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IFN I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
IFN-alpha/beta B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
has O
become O
common O
. O

Many B_NUMBER[MEASURE]/B_PERSON
of O
the O
diverse B_DISEASE
diseases I_DISEASE
targeted O
are O
marked O
by O
pathogenetic B_DISEASE_ADJECTIVE[DISEASE]
abnormalities I_DISEASE_ADJECTIVE[DISEASE]
in O
cell-mediated B_DISEASE
immunity I_DISEASE
( O
CMI B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
these O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
either O
causing O
injury B_DISEASE
to O
the O
host B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O
lacking O
sufficient B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
vigor I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
virus B_DISEASE/B_BIO
or O
tumor B_DISEASE/B_BIO
clearance B_DISEASE/I_BIO
, O
or O
both O
. O

In O
general B_PERSON/B_LOCATION
, O
therapeutic B_MEASURE/B_PERSON
efficacy B_MEASURE/I_PERSON
is O
limited O
. O

It O
is O
thus O
notable O
that O
the O
pleiotropic O
effects O
of O
type B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IFN B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
CMI O
remain O
poorly O
understood O
. O

We O
characterized O
the O
effects O
of O
type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IFN I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
production O
of O
IL-12 B_GENE
, O
the O
central B_PERSON/B_GENE
immunoregulatory I_PERSON/I_GENE
cytokine I_PERSON/I_GENE
of O
the O
CD4 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
+ I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
T I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cell I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
arm I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O
CMI O
. O

We O
show O
that O
type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
IFN I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
potent O
inhibitors O
of O
IL-12 O
production O
by O
human O
monocytes/macrophages O
. O

The O
underlying O
mechanism O
involves O
transcriptional O
inhibition O
of O
the O
IL-12p40 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
marked O
by O
down-regulation O
of O
PU.1 O
binding O
activity O
at O
the O
upstream B_LOCATION/B_MEASURE
Ets I_LOCATION/I_MEASURE
site I_LOCATION/I_MEASURE
of O
the O
IL-12p40 B_GENE
promoter I_GENE
. O

Type B_PERSON/B_GENE
I I_PERSON/I_GENE
IFN I_PERSON/I_GENE
have O
previously O
been O
shown O
to O
be O
able O
to O
substitute O
for O
IL-12 B_GENE
in O
driving O
IFN-gamma O
production O
from O
T O
and O
NK O
cells O
. O

The O
ability O
of O
IFN-alpha/beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
suppress O
IL-12 O
production O
while O
up-regulating O
IFN-gamma O
production O
suggests O
a O
possible O
mechanistic O
basis O
for O
the O
difficulties O
of O
employing O
these O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
diseases O
involving O
abnormalities O
of O
CMI O
. O

Nuclear B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
factor-kappaB B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
suppressive O
and O
inhibitor-kappaB B_GENE
stimulatory O
effects O
of O
troglitazone O
in O
obese O
patients O
with O
type O
2 O
diabetes O
: O
evidence O
of O
an O
antiinflammatory O
action O
. O

It O
has O
been O
shown O
recently O
that O
troglitazone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exerts O
an O
anti-inflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
vitro B_BIO/B_LOCATION
, O
and O
in O
experimental B_SPECIES[BIO]/B_ORGANIZATION
animals I_SPECIES[BIO]/I_ORGANIZATION
. O

To O
test O
these O
properties O
in O
humans O
, O
we O
investigated O
the O
effect O
of O
troglitazone O
on O
the O
proinflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-kappaB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
its O
inhibitory B_PROTEIN[GENE]
protein I_PROTEIN[GENE]
IkappaB I_PROTEIN[GENE]
in O
mononuclear O
cells O
( O
MNC O
) O
and O
plasma B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
soluble B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
intracellular B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
adhesion B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
molecule-1 B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
monocyte B_GENE
chemoattractant I_GENE
protein-1 I_GENE
, O
plasminogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
C-reactive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
also O
examined O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
troglitazone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
reactive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
species I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
p47 B_GENE
( O
phox B_GENE
) O
subunit B_GENE
expression I_GENE
, O
9-hydroxyoctadecadienoic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
9-HODE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
, O
13-HODE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
o-tyrosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
m-tyrosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
obese B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
type B_DISEASE
2 I_DISEASE
diabetes I_DISEASE
. O

Seven B_PERSON/B_BIO
obese I_PERSON/I_BIO
patients I_PERSON/I_BIO
with O
type B_DISEASE/B_LOCATION
2 I_DISEASE/I_LOCATION
diabetes I_DISEASE/I_LOCATION
were O
treated O
with O
troglitazone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
400 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg/day I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
for O
4 B_DISEASE
weeks I_DISEASE
. O

Blood B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
obtained O
at O
weekly B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
intervals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

Nuclear B_GENE
factor-kappaB I_GENE
binding O
activity O
in O
MNC O
nuclear O
extracts O
was O
significantly O
inhibited O
after O
troglitazone O
treatment O
at O
week O
1 O
and O
continued O
to O
be O
inhibited O
up O
to O
week O
4 O
. O

On O
the O
other B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
hand I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
IkappaB B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protein B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
increased O
significantly O
after O
troglitazone B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
at O
week B_TIME[MEASURE]/B_LOCATION
1 B_TIME[MEASURE]/I_LOCATION
, O
and O
this O
increase B_DISEASE_ADJECTIVE[DISEASE]
persisted O
throughout O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Plasma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocyte I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
chemoattractant I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
protein-1 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
soluble B_GENE
intracellular I_GENE
adhesion I_GENE
molecule-1 I_GENE
concentrations O
did O
not O
decrease O
significantly O
after O
troglitazone O
treatment O
, O
although O
there O
was O
a O
trend O
toward O
inhibition O
. O

reactive O
oxygen O
species O
generation O
by O
polymorphonuclear O
cells O
and O
MNC O
, O
p47 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phox I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subunit I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
quantities O
, O
plasminogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activator B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibitor-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
C-reactive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O
decreased O
significantly O
after O
troglitazone O
intake O
. O

13-HODE/linoleic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
9-HODE/linoleic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratios I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
decreased O
after O
troglitazone B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intake B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

However O
, O
o-tyrosine/phenylalanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
m-tyrosine/phenylalanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratios I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
change O
significantly O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O
that O
troglitazone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
has O
profound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiinflammatory I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
antioxidant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
obese B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
type B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
2 B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
diabetics B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O
these O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
relevant B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
recently O
described O
beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiatherosclerotic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
troglitazone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
at O
the O
vascular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
level I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

OX40 O
stimulation O
by O
gp34/OX40 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ligand B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhances O
productive O
human O
immunodeficiency O
virus O
type O
1 O
infection O
. O

OX40 B_GENE
is O
a O
member O
of O
the O
tumor B_GENE/B_PERSON
necrosis I_GENE/I_PERSON
factor I_GENE/I_PERSON
( I_GENE/I_PERSON
TNF I_GENE/I_PERSON
) I_GENE/I_PERSON
receptor I_GENE/I_PERSON
superfamily I_GENE/I_PERSON
and O
known O
to O
be O
an O
important O
costimulatory B_GENE
molecule I_GENE
expressed O
on O
activated O
T O
cells O
. O

To O
investigate O
the O
role O
of O
costimulation O
of O
OX40 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
infection O
by O
its O
natural O
ligand O
, O
gp34 B_GENE
, O
the O
OX40-transfected O
ACH-2 O
cell O
line O
, O
ACH-2/OX40 O
, O
chronically O
infected O
with O
HIV-1 O
, O
was O
cocultured O
with O
paraformaldehyde O
( O
PFA O
) O
-fixed O
gp34-transfected O
mouse O
cell O
line O
, O
SV-T2/gp34 O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
HIV-1 O
production B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
strongly O
induced O
. O

This O
was O
followed O
by O
apparent O
apoptosis O
, O
and O
both O
processes O
were O
specifically O
inhibited O
by O
the O
gp34 B_GENE
-specific O
neutralizing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
monoclonal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5A8 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Endogenous O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TNF-alpha B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
TNF-beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
production O
were O
not O
involved O
in O
the O
enhanced O
HIV-1 O
production O
. O

Furthermore O
, O
enhanced O
HIV-1 O
transcription O
in O
gp34 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-stimulated O
ACH-2/OX40 O
cells O
was O
dependent O
on O
the O
kappa B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
long I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeat I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
the O
OX40-gp34 O
interaction O
activated O
NF-kappa B_GENE
B I_GENE
consisting O
of O
p50 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p65 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

When O
primary B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activated O
CD4 B_GENE
( O
+ B_DISEASE/B_GENE
) O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
acutely O
infected O
with O
HIV-1 B_DISEASE/B_GENE
( O
NL4-3 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
CXCR4-using B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
T-cell-line-tropic B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
) O
were O
cocultured O
with O
PFA-fixed B_GENE
gp34 I_GENE
( O
+ B_DISEASE/B_GENE
) O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T-cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukemia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
type I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
1-bearing I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
MT-2 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
or O
SV-T2/gp34 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
HIV-1 O
production B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
markedly O
enhanced O
. O

The O
enhancement O
was O
again O
significantly O
inhibited O
by O
5A8 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
present O
study O
first O
shows O
that O
OX40-gp34 O
interaction O
stimulates O
HIV-1 O
expression O
and O
suggests O
that O
OX40 O
triggering O
by O
gp34 B_GENE
may O
play O
an O
important O
role O
in O
enhancing O
HIV-1 O
production O
in O
both O
acutely O
and O
latently O
infected O
CD4 O
( O
+ O
) O
T O
cells O
in O
vivo O
. O

Troglitazone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
a O
PPARgamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligand I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
inhibits O
osteopontin B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
gene B_DISEASE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
expression B_DISEASE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes/macrophage I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
THP-1 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Peroxizome B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proliferator-activated I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor-gamma I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PPARgamma B_GENE
) O
is O
a O
member O
of O
the O
nuclear B_GENE/B_PERSON
receptor I_GENE/I_PERSON
family I_GENE/I_PERSON
of O
transcription B_GENE/B_BIO
factors I_GENE/I_BIO
that O
regulate O
adipocyte O
differentiation O
. O

Recent O
studies O
indicate O
that O
liganded B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PPARgamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
not O
only O
promotes O
differentiation O
but O
also O
inhibits O
the O
activation O
of O
macrophages O
. O

Osteopontin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
a O
component O
of O
extracellular O
matrix O
, O
is O
synthesized O
by O
macrophages O
in O
atherosclerotic O
plaques O
. O

In O
this O
study O
, O
we O
examined O
whether O
PPARgamma B_GENE
ligand O
regulates O
osteopontin O
gene O
expression O
in O
THP-1 O
cells O
, O
a O
cell O
line O
derived O
from O
human O
monocytic O
leukemia O
cells O
which O
can O
differentiate O
to O
macrophage O
upon O
stimulation O
with O
phorbol O
ester O
PMA O
. O

Northern B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
that O
osteopontin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
markedly O
induced O
in O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
PMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Troglitazone O
, O
a O
PPARgamma B_GENE/B_DISEASE
ligand O
, O
dramatically O
attenuated O
the O
PMA-induced O
osteopontin O
expression O
. O

Transient O
transfection O
assays O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
osteopontin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter/luciferase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
construct I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
contains O
a O
5'-flanking B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
between O
-1500 O
and O
+87 O
relative O
to O
the O
transcription B_GENE/B_MEASURE
start I_GENE/I_MEASURE
site I_GENE/I_MEASURE
demonstrate O
that O
either O
treatment O
with O
troglitazone O
or O
cotransfection O
of O
PPARgamma B_GENE
expression I_GENE
vector I_GENE
inhibits O
osteopontin O
promoter O
activity O
. O

These O
data O
indicate O
that O
troglitazone O
reduces O
osteopontin O
gene O
expression O
at O
transcriptional O
level O
through O
PPARgamma B_GENE
activation O
, O
and O
suggest O
the O
role O
of O
troglitazone O
in O
inhibiting O
the O
ability O
of O
macrophages O
to O
produce O
extracellular O
matrix O
, O
which O
is O
particularly O
relevant O
to O
atherosclerotic O
plaque O
formation O
. O

Transcription B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulates O
Ig B_GENE
lambda I_GENE
light O
chain O
gene O
rearrangement O
. O

The O
tissue- O
and O
stage-specific O
assembly O
of O
Ig B_GENE
and I_GENE
TCR I_GENE
genes I_GENE
is O
mediated O
by O
a O
common O
V B_GENE/B_LOCATION
( I_GENE/I_LOCATION
D I_GENE/I_LOCATION
) I_GENE/I_LOCATION
J I_GENE/I_LOCATION
recombinase I_GENE/I_LOCATION
complex I_GENE/I_LOCATION
in O
precursor O
lymphocytes O
. O

Directed O
alterations O
in O
the O
accessibility O
of O
V B_GENE/B_LOCATION
, I_GENE/I_LOCATION
D I_GENE/I_LOCATION
, I_GENE/I_LOCATION
and I_GENE/I_LOCATION
J I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
segments I_GENE/I_LOCATION
target O
the O
recombinase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O
specific O
Ag B_GENE/B_LOCATION
receptor I_GENE/I_LOCATION
loci I_GENE/I_LOCATION
. O

Accessibility O
within O
a O
given O
locus B_GENE/B_LOCATION
is O
regulated O
by O
the O
functional O
interaction O
of O
transcription B_GENE
factors I_GENE
with O
cognate B_GENE
enhancer I_GENE
elements I_GENE
and O
correlates O
with O
the O
transcriptional O
activity O
of O
unrearranged O
gene B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
segments I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

As O
demonstrated O
in O
our O
prior O
studies O
, O
rearrangement O
of O
the O
Igkappa B_GENE
locus I_GENE
is O
regulated O
by O
the O
inducible B_GENE
transcription I_GENE
factor I_GENE
NF-kappaB I_GENE
. O

In O
contrast O
to O
the O
Igkappa B_GENE/B_BIO
locus I_GENE/I_BIO
, O
known O
transcriptional B_GENE
control I_GENE
elements I_GENE
in O
the O
Iglambda B_GENE/B_LOCATION
locus I_GENE/I_LOCATION
lack O
functional O
NF-kappaB B_GENE/B_MEASURE
binding I_GENE/I_MEASURE
sites I_GENE/I_MEASURE
. O

consistent O
with O
this O
observation O
, O
the O
expression O
of O
assembled O
Iglambda B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
mature O
B O
cells O
has O
been O
shown O
to O
be O
NF-kappaB B_GENE
independent O
. O

Nonetheless O
, O
we O
now O
show O
that O
specific O
repression O
of O
NF-kappaB B_GENE
inhibits O
germline O
transcription O
and O
recombination O
of O
Iglambda B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
segments I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
precursor O
B O
cells O
. O

Molecular O
analyses O
indicate O
that O
the O
block O
in O
NF-kappaB B_GENE
impairs O
Iglambda O
rearrangement O
at O
the O
level O
of O
recombinase B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
accessibility O
. O

In O
contrast O
, O
the O
activities O
of O
known O
Iglambda B_GENE/B_BIO
promoter I_GENE/I_BIO
and O
enhancer B_GENE
elements I_GENE
are O
unaffected O
in O
the O
same O
cellular O
background O
. O

These O
findings O
expand O
the O
range O
of O
NF-kappaB B_GENE
action O
in O
precursor O
B O
cells O
beyond O
Igkappa B_GENE/B_DISEASE
to O
include O
the O
control O
of O
recombinational O
accessibility O
at O
both O
L B_GENE/B_LOCATION
chain I_GENE/I_LOCATION
loci I_GENE/I_LOCATION
. O

Moreover O
, O
our O
results O
strongly O
suggest O
the O
existence O
of O
a O
novel O
Iglambda B_GENE/B_LOCATION
regulatory I_GENE/I_LOCATION
element I_GENE/I_LOCATION
that O
is O
either O
directly O
or O
indirectly O
activated O
by O
NF-kappaB B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
the O
early O
stages O
of O
B O
cell O
development O
. O

Transcription B_GENE
factor I_GENE
STAT5A I_GENE
is O
a O
substrate O
of O
Bruton B_GENE
's I_GENE
tyrosine I_GENE
kinase I_GENE
in O
B O
cells O
. O

STAT5A B_GENE
is O
a O
molecular O
regulator O
of O
proliferation O
, O
differentiation O
, O
and O
apoptosis O
in O
lymphohematopoietic O
cells O
. O

Here O
we O
show O
that O
STAT5A B_GENE
can O
serve O
as O
a O
functional O
substrate O
of O
Bruton B_GENE
's I_GENE
tyrosine I_GENE
kinase I_GENE
( O
BTK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

Purified B_GENE/B_PERSON
recombinant I_GENE/I_PERSON
BTK I_GENE/I_PERSON
was O
capable O
of O
directly O
binding O
purified B_GENE
recombinant I_GENE
STAT5A I_GENE
with O
high O
affinity O
( O
K O
( O
d O
) O
= O
44 O
nm O
) O
, O
as O
determined O
by O
surface O
plasmon O
resonance O
using O
a O
BIAcore O
biosensor O
system O
. O

BTK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O
also O
capable O
of O
tyrosine-phosphorylating O
ectopically O
expressed O
recombinant B_GENE
STAT5A I_GENE
on O
Tyr O
( O
694 O
) O
both O
in O
vitro O
and O
in O
vivo O
in O
a O
Janus B_GENE
kinase I_GENE
3 I_GENE
-independent O
fashion O
. O

BTK B_PERSON/B_GENE
phosphorylated O
the O
Y665F B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
, B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
Y668F B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
, B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
and B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
Y682F B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
, B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
Y683F B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
but O
not O
the O
Y694F B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutant I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
of O
STAT5A B_GENE
. O

STAT5A O
mutations O
in O
the O
Src B_GENE/B_BIO
homology I_GENE/I_BIO
2 I_GENE/I_BIO
( I_GENE/I_BIO
SH2 I_GENE/I_BIO
) I_GENE/I_BIO
and I_GENE/I_BIO
SH3 I_GENE/I_BIO
domains I_GENE/I_BIO
did O
not O
alter O
the O
BTK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-mediated O
tyrosine O
phosphorylation O
. O

Recombinant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
BTK I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
proteins I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
mutant O
pleckstrin O
homology O
, O
SH2 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
or I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
SH3 I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
domains I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
were O
capable O
of O
phosphorylating O
STAT5A B_GENE
, O
whereas O
recombinant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
BTK I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
proteins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
with O
SH1/kinase O
domain O
mutations O
were O
not O
. O

In O
pull-down O
experiments O
, O
only O
full-length B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
BTK I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
its O
SH1/kinase B_GENE/B_LOCATION
domain I_GENE/I_LOCATION
( O
but O
not O
the O
pleckstrin O
homology O
, O
SH2 B_PROTEIN[GENE]/B_LOCATION
, I_PROTEIN[GENE]/I_LOCATION
or I_PROTEIN[GENE]/I_LOCATION
SH3 I_PROTEIN[GENE]/I_LOCATION
domains I_PROTEIN[GENE]/I_LOCATION
) O
were O
capable O
of O
binding O
STAT5A B_GENE
. O

Ectopically O
expressed O
BTK B_GENE
kinase I_GENE
domain I_GENE
was O
capable O
of O
tyrosine-phosphorylating O
STAT5A B_GENE
both O
in O
vitro O
and O
in O
vivo O
. O

BTK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-mediated O
tyrosine O
phosphorylation O
of O
ectopically O
expressed O
wild O
type O
( O
but O
not O
Tyr B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
694 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutant I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) O
STAT5A B_GENE/B_LOCATION
enhanced O
its O
DNA O
binding O
activity O
. O

In O
BTK B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
-competent O
chicken O
B O
cells O
, O
anti-IgM-stimulated O
tyrosine O
phosphorylation O
of O
STAT5 B_GENE
protein I_GENE
was O
prevented O
by O
pretreatment O
with O
the O
BTK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor O
LFM-A13 O
but O
not O
by O
pretreatment O
with O
the O
JAK3 O
inhibitor O
HI-P131 O
. O

B O
cell O
antigen O
receptor O
ligation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5 B_GENE
in O
BTK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-deficient O
chicken O
B O
cells O
reconstituted O
with O
wild B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
type I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
human I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
BTK I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
but O
not O
in O
BTK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-deficient O
chicken O
B O
cells O
reconstituted O
with O
kinase-inactive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BTK I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Similarly O
, O
anti-IgM O
stimulation O
resulted O
in O
enhanced O
tyrosine O
phosphorylation O
of O
STAT5A B_GENE
in O
BTK B_DISEASE/B_GENE
-competent O
B O
cells O
from O
wild O
type O
mice O
but O
not O
in O
BTK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-deficient O
B O
cells O
from O
XID O
mice O
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
from O
XID B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
from O
JAK3 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
knockout I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mice I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
showed O
a O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
STAT5A I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
phosphorylation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
response I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
anti-IgM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

These O
findings O
provide O
unprecedented O
experimental O
evidence O
that O
BTK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plays O
a O
nonredundant O
and O
pivotal O
role O
in O
B O
cell O
antigen O
receptor-mediated O
STAT5A O
activation O
in O
B O
cells O
. O

Role O
of O
T-bet B_GENE
in O
commitment O
of O
TH1 O
cells O
before O
IL-12 B_GENE
-dependent O
selection O
. O

How O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
control O
differentiation O
of O
helper O
T O
( O
th O
) O
cells O
is O
controversial O
. O

We O
show O
that O
T-bet B_GENE
, O
without O
apparent O
assistance O
from O
interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
12 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-12 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
STAT4 B_GENE/B_MEASURE
, O
specifies O
TH1 O
effector O
fate O
by O
targeting O
chromatin O
remodeling O
to O
individual O
interferon-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IFN-gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alleles I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
by O
inducing O
IL-12 B_GENE
receptor I_GENE
beta2 I_GENE
expression O
. O

Subsequently O
, O
it O
appears O
that O
IL-12 B_GENE/B_LOCATION
/ O
STAT4 B_MEASURE/B_GENE
serves O
two O
essential O
functions O
in O
the O
development O
of O
TH1 O
cells O
: O
as O
growth B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
inducing O
survival O
and O
cell O
division O
; O
and O
as O
trans-activator B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
prolonging O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthesis O
through O
a O
genetic O
interaction O
with O
the O
coactivator B_GENE/B_PERSON
, O
CREB-binding B_GENE
protein I_GENE
. O

These O
results O
suggest O
that O
a O
cytokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O
not O
simply O
induce O
th O
fate O
choice O
but O
instead O
may O
act O
as O
an O
essential O
secondary O
stimulus O
that O
mediates O
selective O
survival O
of O
a O
lineage O
. O

Stat6 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
necessary O
and O
sufficient O
for O
IL-4 O
's O
role O
in O
Th2 O
differentiation O
and O
cell O
expansion O
. O

IL-4 B_GENE
plays O
a O
critical O
role O
in O
the O
differentiation O
of O
T O
CR-stimulated O
naive O
CD4 O
T O
cells O
to O
the O
Th2 O
phenotype O
. O

In O
response O
to O
IL-4 B_GENE/B_DISEASE
, O
the O
IL-4R B_GENE
activates O
a O
set O
of O
phosphotyrosine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain-containing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
insulin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
substrate I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1/2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
Shc B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
IL-4R B_GENE
interacting I_GENE
protein I_GENE
, O
as O
well O
as O
Stat6 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Stat6 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
shown O
to O
be O
required O
for O
Th2 O
differentiation O
. O

To O
determine O
the O
roles O
of O
the O
phosphotyrosine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adaptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
Th2 O
differentiation O
, O
we O
prepared O
a O
retrovirus O
containing O
a O
mutant O
of O
the O
human B_GENE
( I_GENE
h I_GENE
) I_GENE
IL-4R I_GENE
alpha-chain I_GENE
, O
Y497F B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
is O
unable O
to O
recruit O
these O
adaptors O
. O

The O
mutant B_GENE
hIL-4Ralpha I_GENE
, O
as O
well O
as O
the O
wild-type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
WT I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hIL-4Ralpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
was O
introduced O
into O
naive O
CD4 O
T O
cells O
. O

Upon O
hIL-4 O
stimulation O
, O
Y497F B_GENE/B_PERSON
worked O
as O
well O
as O
the O
WT B_GENE
hIL-4Ralpha I_GENE
in O
driving O
Th2 O
differentiation O
, O
as O
measured O
by O
Gata3 O
up-regulation O
and O
IL-4 O
production O
. O

Furthermore O
, O
IL-4-driven O
cell O
expansion O
was O
also O
normal O
in O
the O
cells O
infected O
with O
Y497F B_DISEASE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
although O
cells O
infected O
with O
Y497F B_DISEASE/B_VIRUS[BIO]
were O
not O
capable O
of O
phosphorylating O
insulin B_GENE
receptor I_GENE
substrate I_GENE
2 I_GENE
. O

These O
results O
suggest O
that O
the O
signal O
pathway O
mediated O
by O
Y497 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
dispensable O
for O
both O
IL-4 B_GENE
-driven O
Th2 O
differentiation O
and O
cell O
expansion O
. O

Both O
WT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Y497F I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
hIL-4Ralpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lose O
the O
ability O
to O
drive O
Th2 O
differentiation O
and O
cell O
expansion O
in O
Stat6-knockout O
CD4 O
T O
cells O
. O

A O
constitutively O
activated O
form O
of O
Stat6 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
introduced O
into O
CD4 O
T O
cells O
resulted O
in O
both O
Th2 O
differentiation O
and O
enhanced O
cell O
expansion O
. O

Thus O
, O
activated B_GENE
Stat6 I_GENE
is O
necessary O
and O
sufficient O
to O
mediate O
both O
IL-4 B_GENE
-driven O
Th2 O
differentiation O
and O
cell O
expansion O
in O
CD4 O
T O
cells O
. O

The O
effect O
of O
HIV-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulatory B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
cellular O
genes O
: O
derepression O
of O
the O
IL-2 B_GENE
promoter I_GENE
by O
Tat B_GENE
. O

In O
HIV-infected B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
individuals I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
dysregulation I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
the O
immune B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
characterized O
by O
severe B_DISEASE_ADJECTIVE[DISEASE]
disorders I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
cytokine B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
network I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

increase O
secretion O
of O
IL-2 B_GENE
, O
the O
major O
T O
cell O
growth O
and O
differentiation O
cytokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
may O
play O
a O
decisive O
role O
in O
sensitization O
of O
T O
cells O
for O
activation O
induced O
apoptosis O
and O
indirect O
death O
of O
activated O
T O
cells O
through O
augmented O
virus O
replication O
. O

We O
investigated O
the O
cause O
of O
enhanced O
IL-2 O
secretion O
and O
found O
that O
the O
HIV B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tat B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O
this O
effect O
. O

We O
demonstrate O
that O
increased O
IL-2 O
secretion O
is O
due O
to O
Tat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-enhanced O
IL-2 B_GENE
promoter I_GENE
activation O
. O

Tat B_GENE
derepresses O
and O
activates O
the O
distal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
AP-1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
position B_LOCATION/B_PROTEIN[GENE]
-185 I_LOCATION/I_PROTEIN[GENE]
to I_LOCATION/I_PROTEIN[GENE]
-177 I_LOCATION/I_PROTEIN[GENE]
) O
in O
the O
IL-2 B_GENE
promoter I_GENE
. O

In O
nonstimulated O
T O
cells O
a O
repressor O
complex O
containing O
NF-IL6 B_GENE
, O
JunB B_GENE/B_BACTERIUM[BIO]
, O
c-Fos B_GENE
and O
Fra-1 B_GENE
is O
formed O
on O
the O
AP-1 B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
( B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
IL-2/d B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
) B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
site B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
represses O
IL-2 B_GENE
promoter I_GENE
activity O
. O

After O
T O
cell O
activation O
, O
a O
heterodimeric B_LOCATION
activator I_LOCATION
containing O
p65 B_GENE
and O
c-Jun B_GENE
binds O
to O
the O
AP-1 B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
IL-2/d I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
site I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

HIV B_GENE/B_DISEASE
Tat I_GENE/I_DISEASE
enhances O
activation O
of O
NF-kappaB B_GENE
and O
consequently O
, O
activates O
the O
AP-1 B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
IL-2/d I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
site I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Our O
data O
provide O
evidence O
for O
a O
novel O
mechanism O
by O
which O
HIV B_DISEASE
Tat I_DISEASE
dysregulates O
IL-2 O
production O
and O
therefore O
may O
contribute O
to O
the O
HIV-1 O
infection O
in O
a O
way O
yet O
to O
be O
clarified O
. O

Transforming B_GENE
growth I_GENE
factor-beta1 I_GENE
interferes O
with O
thrombopoietin-induced O
signal O
transduction O
in O
megakaryoblastic O
and O
erythroleukemic O
cells O
. O

objective O
: O
Thrombopoietin B_GENE
( O
TPO B_PROTEIN[GENE]/B_DISEASE
) O
and O
transforming B_GENE
growth I_GENE
factor-beta I_GENE
( I_GENE
1 I_GENE
) I_GENE
( O
TGF-beta B_GENE/B_MEASURE
( I_GENE/I_MEASURE
1 I_GENE/I_MEASURE
) I_GENE/I_MEASURE
) O
have O
been O
shown O
to O
exert O
opposite O
effects O
on O
proliferation O
and O
megakaryocytic O
differentiation O
of O
hematopoietic O
cells O
. O

To O
determine O
whether O
TGF-beta B_GENE
( I_GENE
1 I_GENE
) I_GENE
interferes O
directly O
with O
TPO B_GENE
-induced O
signal O
transduction O
in O
hematopoietic O
cells O
, O
we O
compared O
the O
regulatory O
effects O
in O
the O
TPO B_GENE
-responsive O
cell O
lines O
Mo-7e O
and O
HEL O
. O

Materials O
AND O
methods O
: O
The O
cells O
were O
stimulated O
by O
100 O
ng/mL O
TPO B_GENE
and/or O
100 O
ng/mL O
TGF-beta1 B_GENE
and O
analyzed O
for O
proliferation O
( O
3H O
thymidine O
incorporation O
) O
, O
viability O
( O
trypan O
blue O
exclusion O
) O
, O
and O
protein O
expression O
and O
phosphorylation O
( O
Western O
blot O
) O
. O

Results O
: O
TPO B_GENE/B_DISEASE
enhanced O
the O
proliferation O
of O
Mo-7e O
cells O
as O
determined O
by O
3H-thymidine O
incorporation O
, O
whereas O
TGF-beta1 B_GENE
suppressed O
baseline O
cell O
growth O
and O
antagonized O
the O
proliferative O
effect O
of O
TPO B_GENE
. O

TPO B_PROTEIN[GENE]/B_DISEASE
-induced O
proliferation O
also O
was O
reduced O
by O
a O
specific O
inhibitor O
of O
the O
mitogen-activated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MAPK B_GENE
) O
pathway O
( O
PD098059 O
) O
, O
which O
inhibits O
activation O
of O
the O
MAPK B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
extracellular B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
signal-regulated B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
kinases B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
ERK B_GENE/B_LOCATION
) O
ERK1 B_GENE
and O
ERK2 B_GENE/B_LOCATION
, O
and O
AG490 O
, O
an O
inhibitor O
of O
Janus B_GENE
kinase-2 I_GENE
, O
which O
completely O
blocked O
TPO B_GENE
-induced O
proliferation O
. O

As O
demonstrated O
by O
Western O
blotting O
, O
TGF-beta1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduced O
the O
TPO B_GENE
-stimulated O
ERK1 B_GENE
/ O
ERK2 B_GENE
and O
STAT5 O
phosphorylation O
in O
Mo-7e O
and O
HEL O
cells O
. O

This O
effect O
was O
completely O
reversed O
by O
preincubation O
with O
a O
tyrosine O
phosphatase O
inhibitor O
( O
Na3VO4 O
) O
, O
which O
suggests O
that O
TGF-beta1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activated O
a O
phosphatase B_GENE/B_LOCATION
. O

Although O
STAT3 B_GENE
also O
was O
activated O
by O
TPO B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
STAT3 B_GENE/B_MEASURE
activation O
remained O
unaltered O
by O
TGF-beta1 B_GENE
. O

conclusion O
: O
taken O
together O
, O
these O
data O
suggest O
that O
TGF-beta1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
modulates O
TPO B_GENE
-mediated O
effects O
on O
megakaryocytic O
proliferation O
by O
interfering O
with O
TPO B_GENE
-induced O
signal O
transduction O
, O
particularly O
by O
reducing O
the O
activities O
of O
MAPK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ERK1/ERK2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
STAT5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Invariant B_GENE
chain I_GENE
induces O
B O
cell O
maturation O
by O
activating O
a O
TAF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
105-NF-kappaB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-dependent O
transcription O
program O
. O

Early B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stages B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
B B_DISEASE/B_ORGANISM_FUNCTION
cell I_DISEASE/I_ORGANISM_FUNCTION
development I_DISEASE/I_ORGANISM_FUNCTION
occur O
in O
the O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
marrow I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
resulting O
in O
formation B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
immature B_DISEASE/B_GENE
B I_DISEASE/I_GENE
cells I_DISEASE/I_GENE
. O

From O
there O
these O
immature B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
migrate O
to O
the O
spleen B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
where O
they O
differentiate O
to O
mature O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

This O
final O
maturation O
step O
is O
crucial O
for O
the O
B O
cells O
to O
become O
responsive O
to O
antigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
to O
participate O
in O
the O
immune O
response O
. O

Recently O
, O
invariant B_GENE
chain I_GENE
( O
Ii B_PROTEIN[GENE]/B_DISEASE
) O
, O
a O
major B_GENE
histocompatibility I_GENE
complex I_GENE
class I_GENE
II I_GENE
chaperone I_GENE
, O
as O
well O
as O
the O
transcription B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Rel I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
p65/RelA B_GENE
, O
were O
found O
to O
play O
a O
role O
in O
the O
final O
antigen-independent O
differentiation O
stage O
of O
B O
cells O
in O
the O
spleen O
. O

In O
this O
study O
, O
we O
investigated O
a O
possible O
link O
between O
Ii B_GENE/B_DISEASE
-dependent O
B O
cell O
maturation O
and O
the O
NF-kappaB O
pathway O
. O

Our O
studies O
indicate O
that O
Ii B_DISEASE/B_GENE
-induced O
B O
cell O
maturation O
involves O
activation O
of O
transcription O
mediated O
by O
the O
NF-kappaB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p65/RelA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homodimer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
requires O
the O
B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell-enriched I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coactivator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TBP-associated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
105 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Androgens B_PERSON/B_LOCATION
indirectly O
accelerate O
thymocyte B_DISEASE/B_ORGANISM_FUNCTION
apoptosis I_DISEASE/I_ORGANISM_FUNCTION
. O

apoptotic B_DISEASE
processes I_DISEASE
, O
or O
the O
disturbance B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
natural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
processes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
may O
be O
involved O
in O
the O
pathogenesis B_DISEASE
of O
autoimmune B_DISEASE/B_LOCATION
diseases I_DISEASE/I_LOCATION
( O
aid B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Women B_PERSON/B_BIO
are O
, O
in O
general B_PERSON/B_TIME[MEASURE]
, O
more O
susceptible B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
men B_PERSON
to O
develop O
aid B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
like O
rheumatoid B_DISEASE
arthritis I_DISEASE
. O

androgens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
in O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
oestrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
have O
favourable B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
Aid B_PERSON/B_BIO
models B_PERSON/I_BIO
as O
well O
as O
in O
human B_PERSON/B_ORGANIZATION
Aid I_PERSON/I_ORGANIZATION
. O

It O
is O
known O
that O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
, O
used O
for O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
aid B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
increase O
apoptosis B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
thymus B_BODY_PART_OR_ORGAN_COMPONENT
resulting O
in O
decreased O
numbers B_MEASURE
of O
CD4+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
CD8+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
thymocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

It O
was O
asked O
whether O
androgens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
in O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
oestrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
exert O
their O
favourable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
aid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O
a O
mechanism B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comparable I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
that O
described O
for O
GC B_DISEASE
by O
eliminating O
the O
apoptosis B_DISEASE_ADJECTIVE[DISEASE]
prone I_DISEASE_ADJECTIVE[DISEASE]
CD4+ I_DISEASE_ADJECTIVE[DISEASE]
CD8+ I_DISEASE_ADJECTIVE[DISEASE]
population I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
thymus B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Although O
both O
androgens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
oestrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proved O
thymolytic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
significantly O
decreased B_MEASURE
percentage I_MEASURE
of O
CD4+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
CD8+ I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
thymocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
was O
observed O
by O
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
androgen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyltestosterone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
with O
the O
oestrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ethinylestradiol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
investigate O
whether O
the O
observed O
thymolytic O
effects O
were O
due O
to O
the O
presence O
of O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
thymocytes O
, O
cells O
were O
isolated O
from O
the O
thymus O
and O
incubated O
with O
androgens O
or O
oestrogens O
to O
measure O
apoptosis O
. O

Several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
used O
to O
determine O
thymocyte B_DISEASE/B_GENE
apoptosis I_DISEASE/I_GENE
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
but O
no O
enhanced B_DISEASE_ADJECTIVE[DISEASE]
apoptotic I_DISEASE_ADJECTIVE[DISEASE]
signal I_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
. O

Using O
the O
very O
sensitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
TUNEL I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
assay I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
no O
direct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
androgens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
thymocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
could O
be O
observed O
. O

This O
is O
in O
sharp B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
contrast I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
the O
high B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
signal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
observed O
with O
GC B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Therefore O
, O
upon O
in O
vivo O
androgen O
treatment O
, O
other O
cells O
containing O
androgen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
than O
thymocytes O
are O
probably O
involved O
in O
inducing O
the O
increase O
in O
thymic O
apoptosis O
. O

To O
study O
the O
role O
of O
the O
androgen B_GENE
receptor I_GENE
on O
thymocyte O
apoptosis O
, O
androgen B_NUMBER[MEASURE]
receptor I_NUMBER[MEASURE]
mutant O
( O
Tfm/Y O
) O
mice O
were O
treated O
with O
androgens O
. O

No O
alterations O
of O
thymocyte O
subpopulations O
were O
seen O
, O
suggesting O
that O
changes O
in O
the O
percentage O
of O
CD4+ O
CD8+ O
thymocytes O
after O
administration O
of O
androgens O
depend O
on O
the O
presence O
of O
functional O
androgen B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Thus O
, O
it O
is O
concluded O
that O
androgens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indirectly O
accelerate O
thymocyte B_DISEASE/B_ORGAN_OR_TISSUE_FUNCTION[ORGANISM_FUNCTION]
apoptosis B_DISEASE/I_ORGAN_OR_TISSUE_FUNCTION[ORGANISM_FUNCTION]
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Inhibition O
of O
the O
transcription B_GENE/B_LOCATION
factors I_GENE/I_LOCATION
AP-1 I_GENE/I_LOCATION
and O
NF-kappaB B_GENE
in O
CD4 O
T O
cells O
by O
peroxisome B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proliferator-activated I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ligands I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
peroxisome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator-activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PPARgamma B_GENE
) O
, O
a O
member O
of O
the O
nuclear B_GENE/B_BIO
hormone I_GENE/I_BIO
receptor I_GENE/I_BIO
superfamily I_GENE/I_BIO
, O
is O
essential O
for O
adipocyte O
differentiation O
and O
glucose O
homeostasis O
. O

PPARgamma B_GENE
has O
been O
found O
recently O
to O
regulate O
macrophage O
activation O
in O
response O
to O
mitogens B_DISEASE
and O
inflammation O
. O

Our O
study O
shows O
PPARgamma B_GENE
to O
be O
preferentially O
expressed O
in O
the O
nuclei O
of O
resting O
T O
cells O
and O
to O
increase O
upon O
activation O
of O
T O
cells O
by O
either O
anti-CD3 B_GENE
and O
anti-CD28 B_GENE
or O
phorbol O
myristyl O
acetate O
( O
PMA O
) O
. O

We O
also O
found O
the O
PPARgamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligand I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ciglitizone O
to O
attenuate O
the O
activation O
of O
T O
cells O
by O
inhibiting O
cytokine O
gene O
expression O
and O
anti-CD3 B_GENE
and O
anti-CD28 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
PMA-induced O
proliferative O
responses O
. O

Inhibition O
of O
both O
the O
proliferative O
response O
and O
inflammatory O
cytokine O
expression O
in O
CD4 O
T O
cells O
was O
correlated O
with O
suppression O
of O
the O
activated O
transcription B_GENE/B_LOCATION
factors I_GENE/I_LOCATION
AP1 I_GENE/I_LOCATION
and O
NF-kappaB B_GENE
. O

PPARgamma B_PERSON/B_DISEASE
ligands I_PERSON/I_DISEASE
also O
strongly O
inhibited O
SEA-induced O
Vbeta3 O
T O
cell O
activation O
in O
vivo O
. O

These O
results O
, O
together O
with O
previous O
findings O
of O
the O
inhibitory O
effect O
of O
PPARgamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligands B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
activated O
macrophages O
, O
provide O
clear O
evidence O
for O
PPARgamma B_GENE
as O
a O
negative B_GENE/B_PERSON
regulator I_GENE/I_PERSON
of O
the O
inflammatory O
activation O
of O
both O
macrophage O
and O
T O
cells O
. O

PPARgamma B_GENE
may O
thus O
be O
a O
potential O
therapeutic O
target O
for O
the O
treatment O
of O
autoimmunity O
. O

A O
prominent O
role O
for O
activator B_GENE
protein-1 I_GENE
in O
the O
transcription O
of O
the O
human B_GENE
2B4 I_GENE
( I_GENE
CD244 I_GENE
) I_GENE
gene I_GENE
in O
NK O
cells O
. O

The O
cell B_GENE/B_PERSON
surface I_GENE/I_PERSON
glycoprotein I_GENE/I_PERSON
2B4 I_GENE/I_PERSON
( O
CD244 B_GENE
) O
of O
the O
Ig B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
superfamily I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
is O
involved O
in O
the O
regulation O
of O
NK O
and O
T O
lymphocyte O
functions O
. O

We O
have O
recently O
identified O
CD48 B_GENE
as O
the O
high B_GENE/B_PERSON
affinity I_GENE/I_PERSON
counterreceptor I_GENE/I_PERSON
for O
2B4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
both O
mice O
and O
humans O
. O

The O
cytoplasmic B_GENE
domain I_GENE
of O
2B4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associates O
with O
src B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homology I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain-containing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O
signaling B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphocyte I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecule-associated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
whose O
mutation O
is O
the O
underlying O
genetic O
defect O
in O
the O
X-linked O
lymphoproliferative O
syndrome O
. O

In O
this O
study O
, O
we O
report O
the O
molecular O
cloning O
and O
characterization O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2B4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
h2B4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Through O
primer O
extension O
analysis O
, O
we O
found O
that O
the O
transcription O
of O
the O
h2B4 B_GENE
gene I_GENE
initiates O
at O
multiple O
start O
sites O
. O

We O
isolated O
h2B4 B_GENE
genomic I_GENE
clones I_GENE
and O
PCR O
amplified O
the O
5 B_GENE/B_LOCATION
' I_GENE/I_LOCATION
untranslated I_GENE/I_LOCATION
region I_GENE/I_LOCATION
containing O
the O
promoter B_GENE
elements I_GENE
. O

We O
have O
identified O
a O
functional O
AP-1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O
lies O
between O
( O
-106 O
to O
-100 O
) O
through O
transient O
transfection O
analysis O
in O
YT O
cells O
, O
a O
human O
NK O
cell O
line O
. O

EMSAs O
with O
Abs B_GENE
specific O
for O
various O
protein B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
AP-1 B_GENE/B_LOCATION
family I_GENE/I_LOCATION
revealed O
that O
multiple O
members O
of O
the O
Jun B_PERSON/B_ORGANIZATION
family I_PERSON/I_ORGANIZATION
are O
involved O
in O
the O
regulation O
of O
the O
h2B4 B_GENE
gene I_GENE
. O

mutation O
of O
the O
AP-1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
not O
only O
abolishes O
protein/DNA O
interactions O
but O
also O
promoter O
activity O
. O

These O
results O
demonstrate O
a O
significant O
role O
for O
AP-1 B_GENE
in O
the O
transcriptional O
regulation O
of O
the O
h2B4 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
. O

functional O
correction O
of O
FA-C O
cells O
with O
FANCC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
suppresses O
the O
expression O
of O
interferon B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gamma-inducible I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Because O
hematopoietic O
cells O
derived O
from O
Fanconi O
anemia O
( O
FA O
) O
patients O
of O
the O
C-complementation O
group O
( O
FA-C O
) O
are O
hypersensitive O
to O
the O
inhibitory O
effects O
of O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
IFNgamma B_PROTEIN[GENE]/B_LOCATION
) O
, O
the O
products O
of O
certain O
IFNgamma-inducible B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
known O
to O
influence O
hematopoietic O
cell O
survival O
were O
quantified O
. O

High O
constitutive O
expression O
of O
the O
IFNgamma-inducible B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
IFN-stimulated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunit I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ISGF3gamma B_GENE/B_DISEASE
) O
, O
IFN B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulatory I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
IRF-1 B_GENE/B_DISEASE
) O
, O
and O
the O
cyclin-dependent B_GENE/B_PERSON
kinase I_GENE/I_PERSON
inhibitor I_GENE/I_PERSON
p21 I_GENE/I_PERSON
( O
WAF1 B_GENE/B_DISEASE
) O
was O
found O
in O
FANCC B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
mutant O
B O
lymphoblasts O
, O
low-density O
bone O
marrow O
cells O
, O
and O
murine O
embryonic O
fibroblasts O
. O

Paradoxically O
, O
these O
cells O
do O
not O
activate B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
signal I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
transducer I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
activator I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
of I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
( I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
STAT I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
properly O
. O

In O
an O
attempt O
to O
clarify O
mechanisms O
by O
which O
FA-C O
cells O
overexpress O
IFNgamma-inducible B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
face O
of O
defective O
STAT1 O
phosphorylation O
, O
it O
was O
reasoned O
that O
decreased O
levels O
of O
activated B_GENE
STAT1 I_GENE
might O
result O
in O
reduced O
expression O
of O
a O
hematopoietic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IFNgamma-responsive I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
normally O
modulates O
expression O
of O
other O
IFNgamma-responsive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

levels O
of O
the O
IFNgamma B_GENE
-inducible O
factor O
IFN B_PROTEIN[GENE]/B_MEASURE
consensus I_PROTEIN[GENE]/I_MEASURE
sequence I_PROTEIN[GENE]/I_MEASURE
binding I_PROTEIN[GENE]/I_MEASURE
protein I_PROTEIN[GENE]/I_MEASURE
( O
ICSBP B_DISEASE/B_GENE
) O
, O
a O
negative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
trans-acting I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
some O
IFNgamma-inducible B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
were O
quantified O
. O

ICSBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
levels O
were O
reduced O
in O
FA-C O
B O
lymphoblasts O
and O
MEFs O
. O

However O
, O
enforced O
expression O
of O
ICSBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
failed O
to O
down-regulate O
IRF-1 B_GENE
, O
ISGF3gamma B_GENE
, O
and O
p21 B_GENE
( I_GENE
WAF1 I_GENE
) I_GENE
. O

Thus O
, O
the O
FANCC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
functions O
to O
modulate O
expression O
of O
a O
family O
of O
genes O
that O
in O
normal O
cells O
are O
inducible O
only O
by O
specific O
environmental O
cues O
for O
apoptosis O
or O
mitogenic O
inhibition O
, O
but O
it O
does O
so O
independently O
of O
the O
classic O
IFN-STAT1 O
pathway O
and O
is O
not O
the O
direct O
result O
of O
reduced O
ICSBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O
. O

A O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
investigation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
E2A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
function B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
lymphocyte B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
development I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
are O
derived O
from O
hematopoietic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
HSC B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
) O
following O
a O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
regulated B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
differentiation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
events I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Multipotent B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
HSCs I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
become O
committed O
to O
the O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lineage I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
bone B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
marrow I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
lineage I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
in O
the O
thymus B_BODY_PART_OR_ORGAN_COMPONENT
after O
receiving O
appropriate B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
signals I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
corresponding B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
microenvironment I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O

These O
committed O
lymphoid O
cells O
must O
then O
undergo O
V O
( O
D O
) O
J O
recombination O
at O
the O
immunoglobulin B_GENE
gene I_GENE
or O
T B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
resulting O
in O
clonal O
production O
of O
functional O
B O
or O
T O
lymphocytes O
, O
respectively O
. O

Lymphocyte O
commitment O
and O
differentiation O
are O
accompanied O
by O
programmed O
gene O
expression O
or O
repression O
events O
which O
are O
driven O
by O
lineage B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stage I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
specific I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
basic-helix-loop-helix B_GENE
( I_GENE
bHLH I_GENE
) I_GENE
transcription I_GENE
factors I_GENE
encoded O
by O
the O
E2A B_GENE
gene I_GENE
are O
involved O
in O
several O
differentiation O
events O
during O
B O
and O
T O
cell O
development O
, O
including O
lineage O
commitment O
, O
initiation O
of O
V O
( O
D O
) O
J O
recombination O
, O
and O
antigen O
receptor O
mediated O
proliferation O
and O
differentiation O
. O

Several B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recent I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
provided O
a O
comprehensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
discussion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
E2A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
lymphocyte B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
development I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
( O
1 B_MEASURE
, O
2 B_MEASURE
) O
. O

Here O
, O
we O
only O
discuss O
some O
of O
the O
genetic O
approaches O
our O
laboratory O
( O
except O
where O
it O
is O
noted O
) O
has O
undertaken O
to O
investigate O
the O
molecular O
pathways O
mediated O
by O
E2A B_GENE
transcription I_GENE
factors I_GENE
in O
lymphocyte O
development O
. O

D609 B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibits I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ionizing O
radiation-induced O
oxidative B_DISEASE/B_GENE
damage I_DISEASE/I_GENE
by O
acting O
as O
a O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antioxidant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Tricyclodecan-9-yl-xanthogenate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
D609 B_LOCATION/B_PROTEIN[GENE]
) O
has O
been O
extensively O
studied O
in O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
and O
exhibits O
a O
variety B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
biological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
functions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
antiviral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
antitumor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
anti-inflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activities I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Most O
of O
these O
activities O
have O
been O
largely O
attributed O
to O
the O
inhibitory O
effect O
of O
D609 O
on O
phosphatidylcholine-specific O
phospholipase B_ENZYME[GENE]
C I_ENZYME[GENE]
. O

However O
, O
as O
a O
xanthate B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivative I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
D609 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
strong B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrolyte I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
readily O
dissociates O
to O
xanthate O
anions B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cations B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
alkali B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
metals I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Xanthate B_PERSON/B_LOCATION
anions I_PERSON/I_LOCATION
and O
protonated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
xanthic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contain O
a O
free B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
thiol I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
moiety I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
are O
highly O
reductive B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
implies O
that O
D609 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
xanthate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derivatives I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O
function O
as O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antioxidants I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Indeed O
, O
we O
found O
that O
D609 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O
the O
Fenton B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
reaction-induced B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
oxidation B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
dihydrorhodamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
123 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
a O
dose-dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manner I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
similar I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
that O
of O
pyrrolidinedithiocarbamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
well O
known O
antioxidant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
D609 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
inhibited O
the O
formation B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
alpha-phenyl-tert-butylnitrone-free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
radical I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
spin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
adducts I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
lipid B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
peroxidation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
synaptosomal B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
membranes B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
the O
Fenton B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
reagents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Furthermore O
, O
preincubation O
of O
lymphocytes O
with O
D609 O
resulted O
in O
a O
significant O
diminution O
of O
ionizing O
radiation O
( O
IR O
) O
-induced O
1 O
) O
production O
of O
reactive O
oxygen O
species O
; O
2 O
) O
decrease O
in O
intracellular O
reduced O
glutathione O
; O
3 O
) O
oxidative O
damage O
to O
proteins O
and O
lipids O
; O
and O
4 O
) O
activation O
of O
nuclear B_GENE
factor-kappaB I_GENE
. O

Moreover O
, O
when O
D609 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
50 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mg/kg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
i.v B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O
) O
was O
administered O
to O
mice O
10 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
min I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
prior I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
to O
total B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
body I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
IR I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
6.5 B_MEASURE
and O
8.5 B_MEASURE/B_LOCATION
Gy I_MEASURE/I_LOCATION
) O
, O
it O
protected O
the O
mice B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
IR-induced B_DISEASE
lethality I_DISEASE
. O

Thus O
, O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
D609 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
a O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antioxidant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
has O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
inhibit O
IR-induced B_DISEASE/B_GENE
cellular B_DISEASE/I_GENE
oxidative B_DISEASE/I_GENE
stress B_DISEASE/I_GENE
. O

Inhibition O
of O
AP-1 B_GENE
by O
the O
glucocorticoid-inducible O
protein B_GENE/B_LOCATION
GILZ I_GENE/I_LOCATION
. O

The O
immunosuppressive O
effects O
of O
glucocorticoids O
arise O
largely O
by O
inhibition O
of O
cytokine O
gene O
expression O
, O
which O
has O
been O
ascribed O
to O
interference O
between O
the O
glucocorticoid B_GENE
receptor I_GENE
and O
transcription B_GENE
factors I_GENE
such O
as O
AP-1 B_GENE
and O
NF-kappa B_GENE
B I_GENE
as O
well O
as O
by O
competition O
for O
common O
coactivators O
. O

Here O
we O
show O
that O
glucocorticoid-induced O
inhibition O
of O
interleukin-2 O
mRNA O
expression O
in O
activated O
normal O
T O
cells O
required O
new O
protein O
synthesis O
, O
suggesting O
that O
this O
phenomenon O
is O
secondary O
to O
expression O
of O
glucocorticoid-regulated O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One O
of O
the O
most O
prominent O
glucocorticoid-induced O
genes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
glucocorticoid-induced B_GENE
leucine I_GENE
zipper I_GENE
( O
GILZ B_PROTEIN[GENE]/B_LOCATION
) O
, O
which O
has O
been O
reported O
to O
inhibit O
activation-induced O
up-regulation O
of O
Fas B_GENE
ligand I_GENE
( I_GENE
FasL I_GENE
) I_GENE
mRNA I_GENE
. O

Indeed O
, O
transient O
expression O
of O
GILZ B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Jurkat O
T O
cells O
blocked O
induction O
of O
a O
reporter B_GENE/B_LOCATION
construct I_GENE/I_LOCATION
driven O
by O
the O
FasL B_GENE
promoter I_GENE
. O

This O
could O
be O
accounted O
for O
by O
GILZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-mediated O
inhibition O
of O
Egr-2 B_GENE
and O
Egr-3 B_GENE
, O
NFAT/AP-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-inducible O
transcription B_GENE
factors I_GENE
that O
bind O
a O
regulatory B_GENE/B_LOCATION
element I_GENE/I_LOCATION
in O
the O
FasL B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
and O
up-regulate O
FasL O
expression O
. O

GILZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O
potently O
inhibited O
AP-1-driven B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter-driven I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
recombinant O
GILZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
specifically O
interacted O
with O
c-Fos B_GENE
and O
c-Jun B_GENE/B_LOCATION
in O
vitro O
and O
inhibited O
the O
binding O
of O
active B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AP-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
its O
target O
DNA O
. O

Whereas O
homodimerization O
of O
GILZ B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O
the O
presence O
of O
its O
leucine B_GENE/B_PERSON
zipper I_GENE/I_PERSON
, O
the O
interaction O
with O
c-Fos B_GENE
and O
c-Jun B_GENE
occurred O
through O
the O
N-terminal B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
60-amino B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
GILZ B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
, O
GILZ B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represents O
a O
glucocorticoid-induced O
gene O
product O
that O
can O
inhibit O
a O
variety O
of O
activation-induced O
events O
, O
at O
least O
in O
part O
by O
direct O
interference O
with O
AP-1 B_GENE
, O
and O
is O
therefore O
a O
candidate O
for O
a O
mediator O
of O
glucocorticoid-induced O
immunosuppression O
. O

Pharmacokinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
a O
T B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell-tolerizing I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
T B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell-activating I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
peptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Vaccination O
with O
a O
peptide O
representing O
a O
CTL O
epitope O
from O
the O
human O
papillomavirus O
( O
HPV O
) O
16 O
E7 B_GENE
protein I_GENE
induces O
a O
specific O
CTL O
response O
that O
prevents O
the O
outgrowth O
of O
HPV16 O
E7-expressing O
tumors O
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
vaccination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
a O
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
encoding O
an O
adenovirus B_VIRUS[BIO]/B_DISEASE
type I_VIRUS[BIO]/I_DISEASE
5 I_VIRUS[BIO]/I_DISEASE
( O
Ad5 B_PROTEIN[GENE]/B_SPECIES[BIO]
) O
E1A B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CTL I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epitope I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
CTL B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tolerance I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
enhanced B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
growth I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
an O
Ad5 B_DISEASE
E1A-expressing I_DISEASE
tumor I_DISEASE
. O

It O
is O
unclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
why O
these O
peptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induce O
such B_DISEASE
opposite I_DISEASE
effects I_DISEASE
. O

To O
determine O
whether O
a O
difference B_MEASURE
in O
pharmacokinetics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O
explain O
the O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contrasts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
tritiated O
Ad5 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
E1A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
HPV16 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
E7 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
peptides I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
injected O
into O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O
that O
the O
tolerizing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
peptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
spread O
through O
the O
body B_BODY_PART_OR_ORGAN_COMPONENT
16 I_BODY_PART_OR_ORGAN_COMPONENT
times I_BODY_PART_OR_ORGAN_COMPONENT
faster O
than O
the O
activating O
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
was O
cleared O
at O
least O
2 B_TIME[MEASURE]
times I_TIME[MEASURE]
faster O
. O

The O
HPV16 O
E7 O
peptide O
kinetics O
correlated O
with O
the O
kinetics O
of O
HPV16 B_VIRUS[BIO]/B_PROTEIN[GENE]
E7 B_VIRUS[BIO]/I_PROTEIN[GENE]
-specific O
CTL O
induction O
. O

In O
contrast O
, O
Ad5 O
E1A O
peptide O
injection O
resulted O
in O
physical O
deletion O
of O
preexisting O
Ad5 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
E1A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-specific O
CTLs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
within O
24 O
h O
after O
injection O
. O

This O
tolerization B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
occurred O
at O
the O
time B_TIME[MEASURE]/B_LOCATION
when O
the O
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reached O
its O
maximum B_MEASURE/B_LOCATION
peptide B_MEASURE/I_LOCATION
concentration B_MEASURE/I_LOCATION
in O
the O
organs B_BODY_PART_OR_ORGAN_COMPONENT
. O

These O
data O
suggest O
that O
ubiquitous O
expression O
of O
the O
tolerizing O
Ad5 O
E1A O
peptide O
within O
a O
short O
period O
of O
time O
causes O
activation-induced O
cell O
death O
of O
Ad5 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
E1A I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
-specific O
CTLs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Therefore O
, O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
the O
pharmacokinetics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
peptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
vital B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
peptide-based B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vaccines I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Smad3 B_GENE
and O
Smad4 B_GENE
mediate O
transforming B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor-beta1 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O
IgA O
expression O
in O
murine O
B O
lymphocytes O
. O

Transforming B_GENE/B_DISEASE
growth I_GENE/I_DISEASE
factor I_GENE/I_DISEASE
( I_GENE/I_DISEASE
TGF I_GENE/I_DISEASE
) I_GENE/I_DISEASE
-beta1 I_GENE/I_DISEASE
is O
well O
established O
as O
a O
critical O
IgA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isotype I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
switching I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
Smad B_GENE/B_MEASURE
molecules I_GENE/I_MEASURE
have O
been O
reported O
to O
act O
as O
transducers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
transcriptional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
expression O
of O
TGF-beta1 B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
-targeted O
genes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

We O
examined O
the O
involvement O
of O
Smad B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
TGF-beta1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O
IgA O
expression O
. O

First O
, O
we O
found O
that O
TGF-beta1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O
increases O
endogenous B_DISEASE_ADJECTIVE[DISEASE]
germ-line I_DISEASE_ADJECTIVE[DISEASE]
( I_DISEASE_ADJECTIVE[DISEASE]
GL I_DISEASE_ADJECTIVE[DISEASE]
) I_DISEASE_ADJECTIVE[DISEASE]
alpha I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_DISEASE_ADJECTIVE[DISEASE]
by O
LPS-stimulated O
CH12.LX.4933 O
( O
Mu O
( O
+ O
) O
) O
B O
lymphoma O
cells O
. O

To O
investigate O
its O
signaling O
mechanisms O
, O
the O
lymphoma O
cell O
line O
was O
transfected O
with O
pFL3 B_GENE
that O
contains O
the O
TGF-beta-responsive B_GENE/B_LOCATION
element I_GENE/I_LOCATION
of O
the O
GLalpha B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
, O
and O
stimulated O
with O
TGF-beta1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Similar O
to O
endogenous B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GLalpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
TGF-beta1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O
GLalpha B_GENE/B_MEASURE
promoter I_GENE/I_MEASURE
activity O
and O
overexpression O
of O
Smad3 B_GENE
markedly O
enhances O
the O
promoter O
activity O
. O

This O
activity O
is O
further O
augmented O
by O
cotransfected B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Smad4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

On O
the O
other O
hand O
, O
Smad7 B_GENE
substantially O
abrogates O
the O
synergistic O
effect O
of O
Smad3/4 B_GENE
on O
GLalpha B_GENE
promoter I_GENE
activity O
. O

In O
addition O
, O
overexpression O
of O
Smad3/4 B_GENE
enhances O
TGF-beta1 B_GENE
-induced O
endogenous B_DISEASE/B_GENE
GLalpha I_DISEASE/I_GENE
transcripts I_DISEASE/I_GENE
in O
normal O
spleen O
B O
cell O
s O
. O

Finally O
, O
in O
the O
presence O
of O
TGF-beta1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
overexpression O
of O
Smad3/4 B_GENE
selectively O
increases O
both O
surface O
IgA O
expression O
and O
IgA O
production O
. O

The O
results O
from O
the O
present O
study O
indicate O
that O
Smad3 B_GENE
, O
Smad4 B_GENE
, O
and O
Smad7 B_GENE
, O
at O
least O
in O
part O
, O
serve O
as O
mediators O
linking O
TGF-beta1 B_GENE/B_LOCATION
to O
transcriptional O
regulation O
of O
IgA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
switching I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
regulation O
of O
IgA O
class O
switching O
. O

The O
translesion B_GENE
DNA I_GENE
polymerase I_GENE
zeta I_GENE
plays O
a O
major O
role O
in O
Ig O
and O
bcl-6 O
somatic O
hypermutation O
. O

Ig O
somatic O
mutations O
would O
be O
introduced O
by O
a O
polymerase B_GENE
( O
pol B_PROTEIN[GENE]/B_DISEASE
) O
while O
repairing O
DNA O
outside O
main O
DNA O
replication O
. O

We O
show O
that O
human O
B O
cells O
constitutively O
express O
the O
translesion B_GENE/B_DISEASE
pol I_GENE/I_DISEASE
zeta I_GENE/I_DISEASE
, O
which O
effectively O
extends O
DNA O
past O
mismatched O
bases O
( O
mispair O
extender O
) O
, O
and O
pol B_PROTEIN[GENE]
eta I_PROTEIN[GENE]
, O
which O
bypasses O
DNA O
lesions O
in O
an O
error-free O
fashion O
. O

Upon O
B B_GENE
cell I_GENE
receptor I_GENE
( O
BCR B_PROTEIN[GENE]/B_LOCATION
) O
engagement O
and O
coculture O
with O
activated O
CD4+ O
T O
cells O
, O
these O
lymphocytes O
upregulated O
pol B_GENE
zeta I_GENE
, O
downregulated O
pol B_GENE
eta I_GENE
, O
and O
mutated O
the O
Ig B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bcl-6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Inhibition O
of O
the O
pol B_GENE
zeta I_GENE
REV3 I_GENE
catalytic I_GENE
subunit I_GENE
by O
specific O
phosphorothioate-modified O
oligonucleotides O
impaired O
Ig O
and O
bcl-6 O
hypermutation O
and O
UV O
damage-induced O
DNA O
mutagenesis O
, O
without O
affecting O
cell O
cycle O
or O
viability O
. O

Thus O
, O
pol B_GENE
zeta I_GENE
plays O
a O
critical O
role O
in O
Ig O
and O
bcl-6 O
hypermutation O
, O
perhaps O
facilitated O
by O
the O
downregulation O
of O
pol B_GENE
eta I_GENE
. O

Molecular O
mechanism O
of O
cell O
cycle O
progression O
induced O
by O
the O
oncogene B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
product B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Tax B_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
human O
T-cell O
leukemia O
virus O
type O
I O
. O

The O
trans-activator B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Tax I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
human O
T-cell O
leukemia O
virus O
type O
I O
( O
HTLV-I O
) O
plays O
an O
important O
role O
in O
the O
development O
of O
adult O
T-cell O
leukemia O
through O
, O
at O
least O
in O
part O
, O
its O
ability O
to O
stimulate O
cell O
growth O
. O

We O
previously O
reported O
that O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O
cell O
cycle O
progression O
from O
G0/G1 O
phase O
to O
S O
and O
G2/M O
phases O
in O
human O
T-cell O
line O
Kit O
225 O
cells O
. O

To O
elucidate O
molecular O
mechanism O
of O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
-induced O
cell O
cycle O
progression O
, O
we O
systematically O
examined O
the O
effects O
of O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
biochemical O
events O
associated O
with O
cell O
cycle O
progression O
. O

Introduction O
of O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
into O
resting O
Kit O
225 O
cells O
induced O
activation O
of O
the O
G1/S O
transition O
regulation O
Cascade O
consisting O
of O
activation O
of O
cyclin B_GENE
dependent I_GENE
kinase I_GENE
2 I_GENE
( O
CDK2 B_GENE
) O
and O
CDK4 B_GENE
, O
phosphorylation O
of O
the O
Rb B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
an O
increase O
in O
free O
E2F B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
kinase O
activation O
was O
found O
to O
result O
from O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O
expression O
of O
genes O
for O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cycle B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
regulatory B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
molecules B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
including O
cyclin B_GENE
D2 I_GENE
, O
cyclin B_GENE
E I_GENE
, O
E2F1 B_GENE
, O
CDK2 B_GENE
, O
CDK4 B_GENE
and O
CDK6 B_GENE/B_MEASURE
, O
and O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O
reduction O
of O
CDK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p19 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
INK4d B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
p27 B_GENE
( I_GENE
Kip1 I_GENE
) I_GENE
. O

These O
modulations O
by O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
always O
paralleled O
the O
ability O
of O
Tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
activate O
the O
NF-kappaB O
transcription O
pathway O
. O

These O
results O
indicate O
the O
important O
role O
of O
Tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-mediated O
trans-activation O
of O
the O
genes O
for O
cell B_GENE/B_ORGANIZATION
cycle I_GENE/I_ORGANIZATION
regulatory I_GENE/I_ORGANIZATION
molecules I_GENE/I_ORGANIZATION
in O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-induced O
cell O
cycle O
progression O
. O

Cot B_GENE
kinase I_GENE
induces O
cyclooxygenase-2 O
expression O
in O
T O
cells O
through O
activation O
of O
the O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Cyclooxygenase-2 B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
COX-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
is O
induced O
in O
human O
T O
lymphocytes O
upon O
T B_GENE/B_DISEASE
cell I_GENE/I_DISEASE
receptor I_GENE/I_DISEASE
triggering O
. O

Here O
we O
report O
that O
Cot B_GENE
kinase I_GENE
, O
a O
mitogen-activated B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
involved O
in O
T O
cell O
activation O
, O
up-regulates O
COX-2 B_GENE
gene I_GENE
expression O
in O
Jurkat O
T O
cells O
. O

induction O
of O
COX-2 O
promoter O
activity O
by O
Cot B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kinase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
occurred O
mainly O
through O
activation O
of O
the O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
NFAT B_GENE/B_LOCATION
) O
. O

mutation O
of O
the O
distal B_LOCATION
( I_LOCATION
-105/-97 I_LOCATION
) I_LOCATION
and O
proximal B_LOCATION/B_GENE
( B_LOCATION/I_GENE
-76/-61 B_LOCATION/I_GENE
) B_LOCATION/I_GENE
NFAT B_LOCATION/I_GENE
response B_LOCATION/I_GENE
elements B_LOCATION/I_GENE
in O
the O
COX-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
abolished O
the O
activation O
induced O
by O
Cot B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Even O
more O
, O
coexpression O
of O
a O
dominant O
negative O
version O
of O
NFAT B_GENE
inhibited O
Cot B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-mediated O
COX-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O
, O
whereas O
cotransfection O
of O
a O
constitutively O
active O
version O
of O
the O
calcium-dependent B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
calcineurin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synergizes O
with O
Cot B_GENE
kinase I_GENE
in O
the O
up-regulation O
of O
COX-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-driven O
transcription O
. O

Strikingly O
, O
Cot B_GENE/B_PERSON
kinase I_GENE/I_PERSON
increased O
transactivation O
mediated O
by O
a O
GAL4-NFAT B_GENE/B_LOCATION
fusion I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
containing O
the O
N-terminal B_GENE/B_LOCATION
transactivation I_GENE/I_LOCATION
domain I_GENE/I_LOCATION
of O
NFATp B_GENE
. O

In O
contrast O
to O
phorbol O
ester O
plus O
calcium O
ionophore O
A23187 O
, O
Cot B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
kinase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
increases O
both O
COX-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
and O
NFAT B_GENE
-mediated O
transactivation O
in O
a O
cyclosporin O
A-independent O
manner O
. O

These O
data O
indicate O
that O
Cot B_GENE
kinase I_GENE
up-regulates O
COX-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-driven O
transcription O
through O
the O
NFAT B_GENE/B_LOCATION
response I_GENE/I_LOCATION
elements I_GENE/I_LOCATION
, O
being O
the O
Cot B_GENE
kinase I_GENE
-induced O
NFAT B_GENE
-dependent O
transactivation O
presumably O
implicated O
in O
this O
up-regulation O
. O

positive O
and O
negative O
roles O
of O
the O
trans-acting B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
T I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
cell I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
factor-1 I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
for O
the O
acquisition O
of O
distinct O
Ly-49 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MHC B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
NK O
cells O
. O

Members O
of O
the O
Ly-49 B_GENE/B_PERSON
gene I_GENE/I_PERSON
family I_GENE/I_PERSON
code O
for O
class B_GENE
I I_GENE
MHC-specific I_GENE
receptors I_GENE
that O
regulate O
NK O
cell O
function O
. O

Due O
to O
a O
combinatorial O
distribution O
of O
Ly-49 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
NK O
cells O
display O
considerable O
clonal O
heterogeneity O
. O

The O
acquisition O
of O
one O
Ly-49 B_GENE
receptor I_GENE
, O
Ly-49A B_GENE/B_MEASURE
is O
strictly O
dependent O
on O
the O
transcriptional B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
trans-acting I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cell-specific I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TCF-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Indeed O
, O
TCF-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binds O
to O
two O
sites O
in O
the O
Ly-49a B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
and O
regulates O
its O
activity O
, O
suggesting O
that O
the O
Ly-49a B_GENE/B_PERSON
gene I_GENE/I_PERSON
is O
a O
direct O
TCF-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O
. O

TCF-1 B_MEASURE/B_PERSON
deficiency O
resulted O
in O
the O
altered O
usage O
of O
additional O
Ly-49 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
show O
in O
this O
study O
, O
using O
TCF-1 B_GENE/B_NUMBER[MEASURE]
beta I_GENE/I_NUMBER[MEASURE]
( I_GENE/I_NUMBER[MEASURE]
2 I_GENE/I_NUMBER[MEASURE]
) I_GENE/I_NUMBER[MEASURE]
-microglobulin I_GENE/I_NUMBER[MEASURE]
double-deficient O
mice O
, O
that O
these O
repertoire O
alterations O
are O
not O
due O
to O
Ly-49/MHC O
class O
I O
interactions O
. O

Our O
findings O
rather O
suggest O
a O
TCF-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O
, O
cell O
autonomous O
effect O
on O
the O
acquisition O
of O
multiple O
Ly-49 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Besides O
reduced O
receptor O
usage O
( O
Ly-49A B_PROTEIN[GENE]/B_LOCATION
and I_PROTEIN[GENE]/I_LOCATION
D I_PROTEIN[GENE]/I_LOCATION
) O
, O
we O
also O
observed O
no O
effect O
( O
Ly-49C B_PROTEIN[GENE]/B_LOCATION
) O
and O
significantly O
expanded O
( O
Ly-49G B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
receptor O
usage O
in O
the O
absence O
of O
TCF-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

These O
effects O
did O
not O
in O
all O
cases O
correlate O
with O
the O
presence O
of O
TCF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
respective O
proximal B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Therefore O
, O
besides O
TCF-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O
to O
the O
proximal B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
, O
Ly-49 O
acquisition O
may O
also O
be O
regulated O
by O
TCF-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O
to O
more O
distant O
cis-acting B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
elements B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and/or O
by O
regulating O
the O
expression O
of O
additional O
trans-acting B_GENE/B_LOCATION
factors I_GENE/I_LOCATION
. O

consistent O
with O
the O
observed O
differential O
, O
positive O
or O
negative O
role O
of O
TCF-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Ly-49 B_GENE/B_DISEASE
receptor I_GENE/I_DISEASE
acquisition O
, O
reporter O
gene O
assays O
revealed O
the O
presence O
of O
an O
inducing O
as O
well O
as O
a O
repressing O
TCF B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
certain O
proximal O
Ly-49 B_GENE/B_LOCATION
promoters I_GENE/I_LOCATION
. O

These O
findings O
reveal O
an O
important O
role O
of O
TCF-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
formation O
of O
the O
NK B_GENE
cell I_GENE
receptor I_GENE
repertoire O
. O

Ligation O
of O
CD11b B_GENE
and O
CD11c B_GENE
beta I_GENE
( I_GENE
2 I_GENE
) I_GENE
integrins I_GENE
by O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
soluble B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CD23 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O
macrophage B_GENE
inflammatory I_GENE
protein I_GENE
1alpha I_GENE
( O
MIP-1alpha B_GENE
) O
and O
MIP-1beta B_GENE
production O
in O
primary O
human O
monocytes O
through O
a O
pathway O
dependent O
on O
nuclear B_GENE
factor-kappaB I_GENE
. O

Chemokines B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
adhesion B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
such O
as O
integrins B_GENE/B_DISEASE
play O
a O
major O
part O
in O
the O
trafficking O
, O
extravasation O
, O
and O
recruitment O
of O
leukocytes O
to O
inflammatory O
sites O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
investigated O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_NUMBER[MEASURE]
) O
integrin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
engagement B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
chemokine B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
production B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
by O
freshly O
isolated O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
found O
that O
ligation O
of O
CD11b B_GENE
or O
CD11c B_GENE
but O
not O
CD11a B_GENE/B_MEASURE
alpha I_GENE/I_MEASURE
chains I_GENE/I_MEASURE
of O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
integrins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
soluble B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CD23 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sCD23 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fusion B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rapidly O
induced O
transcription O
and O
secretion O
of O
interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
8 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
macrophage B_MEASURE/B_GENE
inflammatory I_MEASURE/I_GENE
protein I_MEASURE/I_GENE
( I_MEASURE/I_GENE
MIP I_MEASURE/I_GENE
) I_MEASURE/I_GENE
1alpha I_MEASURE/I_GENE
, O
and O
MIP-1beta B_GENE
. O

Because O
the O
promoters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
these O
chemokine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contain O
kappaB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
assessed O
the O
possible O
role O
of O
nuclear B_GENE
factor-kappaB I_GENE
( O
NF-kappaB B_GENE
) O
in O
controlling O
induction O
of O
the O
genes O
through O
beta O
( O
2 O
) O
integrin O
engagement O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
sCD23 B_GENE
or O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
CD11b B_GENE
or O
to O
CD11c B_GENE
up-regulated O
DNA-binding O
activity O
of O
NF-kappaB B_GENE
. O

activation O
of O
NF-kappaB B_GENE
was O
accompanied O
by O
degradation O
of O
its O
cytosolic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IkappaB-alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

blockade O
of O
depletion O
of O
IkappaB-alpha B_GENE
by O
proteasome O
inhibitors O
( O
proteasome O
inhibitor O
I O
or O
acetyl-leucinyl-leucinyl-norleucinal O
) O
led O
to O
concomitant O
inhibition O
of O
NF-kappaB O
DNA-binding O
activity O
and O
expression O
of O
MIP-1alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MIP-1beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
messenger I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
beta O
( O
2 O
) O
integrin O
ligation O
. O

These O
results O
suggest O
that O
triggering O
of O
CD11b B_GENE
or O
CD11c B_GENE
beta I_GENE
( I_GENE
2 I_GENE
) I_GENE
integrin O
on O
primary O
human O
monocytes O
provides O
activation O
signals O
leading O
to O
nuclear O
translocation O
of O
NF-kappaB B_GENE
and O
subsequent O
secretion O
of O
MIP-1alpha B_GENE
and O
MIP-1beta B_GENE
that O
may O
have O
an O
important O
role O
in O
recruitment O
of O
other O
inflammatory O
cells O
during O
initiation O
of O
an O
inflammatory O
response O
. O

Synergistic O
transcriptional O
activation O
of O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Acyl-coenzyme I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cholesterol I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acyltransterase-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
interferon-gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
all-trans-retinoic O
acid O
THP-1 O
cells O
. O

Acyl-coenzyme B_GENE/B_ORGANIZATION
A I_GENE/I_ORGANIZATION
: I_GENE/I_ORGANIZATION
cholesterol I_GENE/I_ORGANIZATION
acyltransferase I_GENE/I_ORGANIZATION
( O
ACAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
is O
an O
intracellular B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involved O
in O
cellular O
cholesterol O
homeostasis O
and O
in O
atherosclerotic O
foam O
cell O
formation O
. O

Human B_GENE/B_LOCATION
ACAT-1 I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
contains O
two O
promoters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
P1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
P7 B_PROTEIN[GENE]
) O
, O
each O
located O
in O
a O
different O
chromosome B_LOCATION/B_PERSON
( I_LOCATION/I_PERSON
1 I_LOCATION/I_PERSON
and I_LOCATION/I_PERSON
7 I_LOCATION/I_PERSON
) I_LOCATION/I_PERSON
( O
Li O
, O
B. O
L. O
, O
Li O
, O
X. O
L. O
, O
Duan O
, O
Z. O
J. O
, O
Lee O
, O
O. O
, O
Lin O
, O
S. O
, O
Ma O
, O
Z. O
M. O
, O
Chang O
, O
C. O
C. O
, O
Yang O
, O
X. O
Y. O
, O
Park O
, O
J. O
P. O
, O
Mohandas O
, O
T. O
K. O
, O
Noll O
, O
W. O
, O
Chan O
, O
L. O
, O
and O
Chang O
, O
T. O
Y. O
( O
1999 O
) O
J. O
Biol O
Chem. O
274 O
, O
11060-11071 O
) O
. O

Interferon-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
IFN-gamma B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
a O
cytokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
exerts O
many O
pro-atherosclerotic O
effects O
in O
vivo O
, O
causes O
up-regulation O
of O
ACAT-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
human O
blood O
monocyte-derived O
macrophages O
and O
macrophage-like O
cells O
but O
not O
in O
other O
cell O
types O
. O

To O
examine O
the O
molecular O
nature O
of O
this O
observation O
, O
we O
identified O
within O
the O
ACAT-1 B_GENE/B_MEASURE
P1 I_GENE/I_MEASURE
promoter I_GENE/I_MEASURE
a O
159-base B_GENE/B_MEASURE
pair I_GENE/I_MEASURE
core I_GENE/I_MEASURE
region I_GENE/I_MEASURE
. O

This O
region O
contains O
4 O
Sp1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
an O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
GAS B_GENE/B_BACTERIUM[BIO]
) O
that O
overlaps O
with O
the O
second O
Sp1 B_GENE/B_LOCATION
element I_GENE/I_LOCATION
. O

In O
the O
monocytic O
cell O
line O
THP-1 O
cell O
, O
the O
combination O
of O
IFN-gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
all-trans-retinoic O
acid O
( O
a O
known O
differentiation O
agent O
) O
enhances O
the O
ACAT-1 B_GENE
P1 I_GENE
promoter I_GENE
but O
not O
the O
P7 B_GENE
promoter I_GENE
. O

Additional O
experiments O
showed O
that O
all-trans-retinoic O
acid O
causes O
large O
induction O
of O
the O
transcription B_GENE
factor I_GENE
STAT1 I_GENE
, O
while O
IFN-gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
causes O
activation O
of O
STAT1 B_GENE
such O
that O
it O
binds O
to O
the O
GAS/Sp1 B_GENE/B_MEASURE
site I_GENE/I_MEASURE
in O
the O
ACAT-1 B_GENE
P1 I_GENE
promoter I_GENE
. O

Our O
work O
provides O
a O
molecular O
mechanism O
to O
account O
for O
the O
effect O
of O
IFN-gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
causing O
transcriptional O
activation O
of O
ACAT-1 B_GENE
in O
macrophage-like O
cells O
. O

inhaled O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
down-regulates O
intrapulmonary B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
nitric B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
oxide B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
production B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
lipopolysaccharide-induced B_DISEASE/B_BIO
acute I_DISEASE/I_BIO
lung I_DISEASE/I_BIO
injury I_DISEASE/I_BIO
. O

objective O
: O
To O
examine O
whether O
inhaled O
nitric O
oxide O
( O
NO O
) O
affected O
the O
intrapulmonary O
production O
of O
NO O
, O
reactive O
oxygen O
species O
, O
and O
nuclear B_GENE
factor-kappaB I_GENE
in O
a O
lipopolysaccharide O
( O
LPS O
) O
-induced O
model O
of O
acute O
lung O
injury O
. O

Design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
randomized O
, O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

setting B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Experimental B_LOCATION/B_PERSON
laboratory I_LOCATION/I_PERSON
at O
a O
biomedical B_LOCATION/B_MEASURE
institute I_LOCATION/I_MEASURE
. O

subjects B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Twenty B_PERSON
male I_PERSON
rabbits I_PERSON
weighing O
2.5-3.5 B_NUMBER[MEASURE]/B_LOCATION
kg I_NUMBER[MEASURE]/I_LOCATION
. O

Interventions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
or O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
5 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg/kg B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
body B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
was O
administered O
intravenously O
with O
or O
without O
NO O
inhalation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ppm I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
in O
each O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
five B_PERSON/B_SPECIES[BIO]
rabbits I_PERSON/I_SPECIES[BIO]
. O

Measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
AND O
Main B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
RESULTS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increased O
the O
lung B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leak B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
index B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
the O
neutrophils B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
NO O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
bronchoalveolar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lavage I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fluid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
NO O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
produced O
by O
resting B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
stimulated O
alveolar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

inhaled O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
decreased O
the O
lung B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leak B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
index B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
the O
neutrophils B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
NO O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O
measured O
by O
nitrite B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
lavage B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluid I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
NO O
produced O
by O
the O
resting B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
stimulated O
alveolar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

inhaled O
NO O
also O
blocked O
the O
activities O
of O
reactive O
oxygen O
species O
and O
nuclear B_GENE
factor-kappaB I_GENE
binding O
to O
DNA O
in O
lavage O
cells O
and O
in O
alveolar O
macrophages O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
inhaled O
NO O
attenuates B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
LPS-induced O
acute B_DISEASE/B_GENE
lung I_DISEASE/I_GENE
injury I_DISEASE/I_GENE
, O
possibly O
by O
decreasing O
NO O
production B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
lungs B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

The O
mechanism O
of O
reducing O
NO O
production O
resulting O
from O
inhaled O
NO O
may O
involve O
, O
in O
part O
, O
the O
activities O
of O
reactive O
oxygen O
species O
and/or O
nuclear B_GENE
factor-kappaB I_GENE
. O

Treatment O
of O
allergic O
airway O
inflammation O
and O
hyperresponsiveness O
by O
antisense-induced O
local O
blockade O
of O
GATA-3 B_GENE
expression O
. O

Recent O
studies O
in O
transgenic O
mice O
have O
revealed O
that O
expression O
of O
a O
dominant O
negative O
form O
of O
the O
transcription B_GENE/B_LOCATION
factor I_GENE/I_LOCATION
GATA-3 I_GENE/I_LOCATION
in O
T O
cells O
can O
prevent O
T O
helper O
cell O
type O
2 O
( O
Th2 O
) O
-mediated O
allergic O
airway O
inflammation O
in O
mice O
. O

However O
, O
it O
remains O
unclear O
whether O
GATA-3 B_GENE
plays O
a O
role O
in O
the O
effector O
phase O
of O
allergic O
airway O
inflammation O
and O
whether O
antagonizing O
the O
expression O
and/or O
function O
of O
GATA-3 B_GENE
can O
be O
used O
for O
the O
therapy O
of O
allergic O
airway O
inflammation O
and O
hyperresponsiveness O
. O

Here O
, O
we O
analyzed O
the O
effects O
of O
locally O
antagonizing O
GATA-3 B_GENE
function O
in O
a O
murine O
model O
of O
asthma O
. O

We O
could O
suppress O
GATA-3 O
expression O
in O
interleukin B_GENE
( I_GENE
IL I_GENE
) I_GENE
-4 I_GENE
-producing O
T O
cells O
in O
vitro O
and O
in O
vivo O
by O
an O
antisense O
phosphorothioate O
oligonucleotide O
overlapping O
the O
translation B_LOCATION/B_ORGANIZATION
start I_LOCATION/I_ORGANIZATION
site I_LOCATION/I_ORGANIZATION
of O
GATA-3 B_GENE
, O
whereas O
nonsense O
control O
oligonucleotides O
were O
virtually O
inactive O
. O

In O
a O
murine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
asthma B_DISEASE/B_LOCATION
associated O
with O
allergic B_DISEASE
pulmonary I_DISEASE
inflammation I_DISEASE
and O
hyperresponsiveness B_DISEASE
in O
ovalbumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
OVA B_DISEASE/B_LOCATION
) O
-sensitized O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
local B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intranasal I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
fluorescein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
isothiocyanate-labeled I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
GATA-3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antisense I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oligonucleotides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
led O
to O
DNA B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
uptake I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
lung B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
intracellular B_DISEASE/B_GENE
GATA-3 I_DISEASE/I_GENE
expression I_DISEASE/I_GENE
. O

Such B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intrapulmonary B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
blockade B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
GATA-3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
caused O
an O
abrogation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
signs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
lung B_DISEASE/B_GENE
inflammation I_DISEASE/I_GENE
including O
infiltration B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
eosinophils B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
Th2 B_DISEASE
cytokine I_DISEASE
production I_DISEASE
. O

Furthermore O
, O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
antisense B_GENE
but O
not O
nonsense B_GENE
oligonucleotides I_GENE
induced O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
airway B_DISEASE
hyperresponsiveness I_DISEASE
in O
OVA-sensitized B_DISEASE/B_BIO
mice I_DISEASE/I_BIO
to O
levels B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparable I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
saline-treated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mice I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
as O
assessed O
by O
both O
enhanced O
pause B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
PenH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
pulmonary B_DISEASE_ADJECTIVE[DISEASE]
resistance I_DISEASE_ADJECTIVE[DISEASE]
determined O
by O
body B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
plethysmography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

These O
data O
indicate O
a O
critical O
role O
for O
GATA-3 B_GENE
in O
the O
effector O
phase O
of O
a O
murine O
asthma O
model O
and O
suggest O
that O
local O
delivery O
of O
GATA-3 O
antisense O
oligonucleotides O
may O
be O
a O
novel O
approach O
for O
the O
treatment O
of O
airway O
hyperresponsiveness O
such O
as O
in O
asthma O
. O

This O
approach O
has O
the O
potential O
advantage O
of O
suppressing O
the O
expression O
of O
various O
proinflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Th2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
simultaneously O
rather O
than O
suppressing O
the O
activity O
of O
a O
single O
cytokine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

T B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
helper-cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phenotype I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulates O
atherosclerosis B_DISEASE/B_GENE
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O
conditions B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
mild B_DISEASE
hypercholesterolemia I_DISEASE
. O

Background B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
T B_GENE
cells I_GENE
are O
implicated O
in O
atherosclerosis B_DISEASE/B_LOCATION
, O
but O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
about O
the O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
especially O
under O
conditions B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
mild B_DISEASE
hypercholesterolemia I_DISEASE
. O

methods O
AND O
Results O
: O
BALB/c O
mice O
, O
making O
a O
CD4+ O
Th2 O
( O
IL-4+ O
) O
cell O
response O
, O
express O
both O
MHC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
IA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
IE B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
d I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
and O
are O
atherosclerosis-resistant O
. O

C57Bl/6 O
mice O
produce O
a O
CD4+ O
Th1 O
( O
interferon O
[ O
IFN O
] O
gamma+ O
) O
response O
, O
express O
IA B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
b I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
no O
IE B_DISEASE/B_GENE
, O
and O
are O
atherosclerosis-prone O
. O

To O
evaluate O
T B_DISEASE_ADJECTIVE[DISEASE]
helper-cell I_DISEASE_ADJECTIVE[DISEASE]
phenotype I_DISEASE_ADJECTIVE[DISEASE]
in O
fatty B_DISEASE
streak I_DISEASE
formation I_DISEASE
, O
wild-type O
C57Bl/6 B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
mice I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
IA B_PROTEIN[GENE]/B_DISEASE
( O
b O
) O
+IE- B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
transgenic B_BIO/B_GENE
mice I_BIO/I_GENE
, O
either O
AB B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
o B_PROTEIN[GENE]/B_LOCATION
) O
, O
IA B_DISEASE/B_PROTEIN[GENE]
( O
b O
) O
-IE- O
; O
ABEalpha B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
IA-IE B_LOCATION/B_PROTEIN[GENE]
( O
k B_MEASURE/B_PROTEIN[GENE]
) O
+ B_PROTEIN[GENE]/B_DISEASE
; O
or O
BL B_LOCATION
: O
TG B_PROTEIN[GENE]/B_MEASURE
: O
Ealpha B_PROTEIN[GENE]/B_LOCATION
, O
IA B_PROTEIN[GENE]/B_DISEASE
( O
b O
) O
+IE B_LOCATION/B_PROTEIN[GENE]
( O
k B_MEASURE/B_PROTEIN[GENE]
) O
+ B_PROTEIN[GENE]/B_DISEASE
, O
were O
fed O
a O
high-cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
16 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
and O
evaluated O
histomorphometrically O
for O
aortic B_DISEASE
lesions I_DISEASE
. O

Lesion B_MEASURE/B_PERSON
size B_MEASURE/I_PERSON
in O
AB B_LOCATION/B_PERSON
( O
o B_PROTEIN[GENE]/B_LOCATION
) O
, O
ABEalpha B_LOCATION
, O
and O
BL B_LOCATION
: O
TG B_LOCATION
: O
Ealpha B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
strains I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
decreased O
by O
54 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
79 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
and O
82 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
respectively O
, O
compared O
with O
wild-type B_GENE
, O
correlating O
with O
decreased O
Th1 B_GENE
and O
increased O
Th2 O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
suggesting O
that O
T B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
helper-cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phenotype I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
fatty B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesion I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

decreasing O
Th1 O
cells O
by O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
alpha-CD4 B_GENE
) O
or O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
IL-4 B_GENE
) O
also O
caused O
> O
/=80 O
% O
reductions O
in O
lesion O
size O
. O

Immunohistology O
revealed O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
IL-4 B_GENE
, O
colocalized O
with O
activated O
macrophages O
. O

confirming O
these O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mouse I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
strain I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
BALB/c B_PERSON/B_GENE
Stat I_PERSON/I_GENE
6 I_PERSON/I_GENE
knockout I_PERSON/I_GENE
mice I_PERSON/I_GENE
( O
Th2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell-deficient I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
developed O
aortic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesions I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparable I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
C57Bl/6 B_PERSON/B_BIO
mice I_PERSON/I_BIO
on O
the O
same B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diet I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
In O
mildly O
hypercholesterolemic O
C57Bl/6 O
mice O
, O
presence O
of O
IA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
b B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O
absence O
of O
IE B_DISEASE/B_GENE
regulated O
CD4+ O
T O
helper-cell O
phenotype O
; O
fatty O
lesions O
were O
proportional O
to O
IFNgamma+ O
Th1 O
cells O
in O
both O
C57Bl/6 O
and O
BALB/c O
strains O
. O

IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
may O
participate O
through O
macrophage O
activation O
, O
whereas O
IL-4 B_GENE
may O
act O
to O
limit O
Th1-cell O
response O
. O

requirement O
for O
p38 B_GENE
and O
p44/p42 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
RAGE B_GENE
-mediated O
nuclear B_GENE
factor-kappaB I_GENE
transcriptional O
activation O
and O
cytokine O
secretion O
. O

Advanced O
glycation O
end O
product O
( O
Age O
) O
activation O
of O
the O
signal-transducing B_GENE/B_DISEASE
receptor I_GENE/I_DISEASE
for I_GENE/I_DISEASE
AGE I_GENE/I_DISEASE
( O
RAGE B_GENE/B_DISEASE
) O
has O
been O
linked O
to O
a O
proinflammatory O
phenotypic O
change O
within O
cells O
. O

However O
, O
the O
precise B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intracellular I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O
pathways B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
involved O
have O
not O
been O
elucidated O
. O

We O
demonstrate O
here O
that O
human O
serum O
albumin O
modified O
with O
N O
( O
varepsilon O
) O
- O
( O
carboxymethyl O
) O
lysine O
( O
CML O
) O
, O
a O
major O
Age O
adduct O
that O
progressively O
accumulates O
with O
aging O
, O
diabetes O
, O
and O
renal O
failure O
, O
induced O
nuclear B_GENE/B_DISEASE
factor I_GENE/I_DISEASE
( I_GENE/I_DISEASE
NF I_GENE/I_DISEASE
) I_GENE/I_DISEASE
-kappaB I_GENE/I_DISEASE
-driven O
reporter O
gene O
expression O
in O
human O
monocytic O
THP-1 O
cells O
. O

The O
NF-kappaB O
response O
was O
blocked O
with O
a O
synthetic O
peptide O
corresponding O
to O
the O
putative B_LOCATION
ligand-binding I_LOCATION
domain I_LOCATION
of O
RAGE B_GENE
, O
with O
anti- O
RAGE B_GENE
antiserum O
, O
and O
by O
coexpression O
of O
truncated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lacking O
the O
intracellular B_LOCATION/B_PERSON
domain B_LOCATION/I_PERSON
. O

Signal O
transduction O
from O
RAGE B_GENE
to O
NF-kappaB B_GENE
involved O
the O
generation O
of O
reactive O
oxygen O
species O
, O
since O
reporter O
gene O
expression O
was O
blocked O
with O
the O
antioxidant O
N-acetyl-L-cysteine O
. O

CML-modified B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
albumin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
produced O
rapid O
transient O
activation O
of O
tyrosine O
phosphorylation O
, O
extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
p38 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MAPK B_GENE
) O
, O
but O
not O
c-Jun B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NH I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-terminal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

RAGE B_GENE
-mediated O
NF-kappaB O
activation O
was O
suppressed O
by O
the O
selective O
p38 B_GENE
MAPK I_GENE
inhibitor O
SB203580 O
and O
by O
coexpression O
of O
a O
kinase-dead O
p38 O
dominant-negative O
mutant O
. O

activation O
of O
NF-kappaB B_GENE
by O
CML-modified B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
albumin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
increased O
secretion O
of O
proinflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
interleukin-1beta B_GENE
, O
and O
monocyte B_GENE
chemoattractant I_GENE
protein-1 I_GENE
) O
severalfold O
, O
and O
inhibition O
of O
p38 B_GENE
MAPK I_GENE
blocked O
these O
increases O
. O

These O
results O
indicate O
that O
p38 B_GENE
MAPK I_GENE
activation O
mediates O
RAGE B_GENE
-induced O
NF-kappaB B_GENE
-dependent O
secretion O
of O
proinflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
suggest O
that O
accelerated O
inflammation O
may O
be O
a O
consequence O
of O
cellular O
activation O
induced O
by O
this O
receptor O
. O

Antigen-receptor O
cross-linking O
and O
lipopolysaccharide O
trigger O
distinct O
phosphoinositide B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3-kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-dependent O
pathways O
to O
NF-kappa O
B O
activation O
in O
primary O
B O
cells O
. O

The O
NF-kappaB/Rel B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
play O
an O
important O
role O
in O
the O
expression O
of O
genes O
involved O
in O
B O
cell O
development O
, O
differentiation O
and O
function O
. O

Nuclear B_GENE
NF-kappaB I_GENE
is O
induced O
in O
B O
cells O
by O
engagement O
of O
either O
the O
BCR B_GENE
or O
CD40 B_GENE/B_LOCATION
or O
by O
stimulation O
with O
lipopolysaccharide O
( O
LPS O
) O
. O

Despite O
the O
importance O
of O
NF-kappaB B_GENE
to O
B O
cell O
function O
, O
little O
is O
known O
about O
the O
signaling O
pathways O
leading O
to O
NF-kappaB O
activation O
. O

In O
this O
report O
we O
address O
the O
role O
of O
phosphoinositide B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3'-kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PI B_GENE/B_LOCATION
3-kinase I_GENE/I_LOCATION
) O
in O
BCR B_GENE
- O
and O
LPS-induced O
NF-kappaB O
activation O
using O
populations O
of O
primary O
murine O
resting O
B O
cells O
. O

Using O
the O
specific O
pharmacological O
inhibitors O
of O
PI B_GENE
3-kinase I_GENE
, O
Wortmannin O
and O
LY294002 O
, O
we O
demonstrate O
that O
PI B_GENE
3-kinase I_GENE
activity O
is O
vital O
for O
BCR B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O
NF-kappaB B_GENE
DNA-binding O
activity O
. O

Furthermore O
, O
we O
show O
that O
this O
is O
achieved O
via O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-dependent O
degradation O
of O
IkappaBalpha B_GENE
. O

Similar O
analyses O
reveal O
that O
PI B_GENE
3-kinase I_GENE
is O
also O
critical O
in O
triggering O
NF-kappaB B_GENE
DNA-binding O
activity O
and O
IkappaBalpha B_GENE
degradation O
following O
LPS O
stimulation O
. O

Interestingly O
, O
a O
PKC O
inhibitor O
which O
blocked O
the O
BCR B_GENE
-induced O
IkappaBalpha B_GENE
degradation O
had O
no O
effect O
on O
the O
degradation O
of O
IkappaBalpha B_GENE
after O
LPS O
stimulation O
. O

taken O
together O
, O
our O
results O
indicate O
the O
involvement O
of O
PI B_GENE
3-kinase I_GENE
in O
at O
least O
two O
distinct O
signaling O
pathways O
leading O
to O
activation O
of O
NF-kappaB B_GENE
in O
B O
cells O
. O

Tetramer-guided O
epitope O
mapping O
: O
rapid O
identification O
and O
characterization O
of O
immunodominant O
CD4+ O
T O
cell O
epitopes O
from O
complex O
antigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

T O
cell O
responses O
to O
Ags B_DISEASE/B_VIRUS[BIO]
involve O
recognition O
of O
selected O
peptide B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
epitopes I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
contained O
within O
the O
antigenic B_PROTEIN[GENE]
protein I_PROTEIN[GENE]
. O

In O
this O
report O
, O
we O
describe O
a O
new O
approach O
for O
direct O
identification O
of O
CD4+ O
T O
cell O
epitopes O
of O
complex O
Ags B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O
uses O
human B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
class I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
II I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tetramers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
identify O
reactive O
cells O
. O

With O
a O
panel O
of O
60 O
overlapping O
peptides O
covering O
the O
entire O
sequence O
of O
the O
VP16 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
major O
Ag B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
HSV-2 O
, O
we O
generated O
a O
panel O
of O
class B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MHC B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetramers B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loaded O
with O
peptide O
pools O
that O
were O
used O
to O
stain O
peripheral O
lymphocytes O
of O
an O
HSV-2 O
infected O
individual O
. O

With O
this O
approach O
, O
we O
identified O
four O
new O
DRA1*0101/DRB1*0401- O
and O
two O
DRA1*0101/DRB1*0404-restricted O
, O
VP16-specific B_LOCATION/B_PERSON
epitopes I_LOCATION/I_PERSON
. O

By O
using O
tetramers B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
sort O
individual O
cells O
, O
we O
easily O
obtained O
a O
large O
number O
of O
clones O
specific O
to O
these O
epitopes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
DRA1*0101/DRB1*0401 O
and O
DRA1*0101/DRB1*0404 O
are O
structurally O
very O
similar O
, O
nonoverlapping O
VP16 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
epitopes B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O
identified O
, O
illustrating O
high O
selectivity O
of O
individual O
allele O
polymorphisms O
within O
common O
MHC O
variants O
. O

This O
rapid O
approach O
to O
detecting O
CD4+ O
T O
cell O
epitopes O
from O
complex O
Ags B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
be O
applied O
to O
any O
known O
Ag B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
gives O
a O
T O
cell O
response O
. O

localized O
pancreatic B_DISEASE
NF-kappaB I_DISEASE
activation I_DISEASE
and O
inflammatory B_DISEASE/B_GENE
response I_DISEASE/I_GENE
in O
taurocholate-induced B_DISEASE
pancreatitis I_DISEASE
. O

Transcription B_GENE
factor I_GENE
nuclear I_GENE
factor-kappaB I_GENE
( O
NF-kappaB B_GENE
) O
is O
activated O
in O
cerulein O
pancreatitis O
and O
mediates O
cytokine O
expression O
. O

The O
role B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
transcription B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
pancreatitis B_DISEASE
has O
not O
been O
established O
. O

Here O
we O
report O
upregulation O
of O
NF-kappaB B_GENE
and O
inflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
their O
correlation O
with O
local O
pancreatic O
injury O
, O
in O
a O
model O
of O
severe O
pancreatitis O
. O

rats B_BIO/B_PERSON
received O
intraductal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
taurocholate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
pancreatic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
head I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
tail B_BODY_PART_OR_ORGAN_COMPONENT
were O
analyzed O
separately O
. O

NF-kappaB B_GENE
and O
activator B_GENE/B_LOCATION
protein-1 I_GENE/I_LOCATION
( O
AP-1 B_GENE
) O
activation O
were O
assessed O
by O
gel O
shift O
assay O
, O
and O
mRNA O
expression O
of O
interleukin-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
tumor B_GENE/B_LOCATION
necrosis I_GENE/I_LOCATION
factor-alpha I_GENE/I_LOCATION
, O
KC O
, O
monocyte B_GENE/B_LOCATION
chemoattractant I_GENE/I_LOCATION
protein-1 I_GENE/I_LOCATION
, O
and O
inducible B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nitric I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oxide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
assessed O
by O
semiquantitative O
RT-PCR O
. O

Morphological O
damage O
and O
trypsin O
activation O
were O
much O
greater O
in O
the O
pancreatic O
head O
than O
tail O
, O
in O
parallel O
with O
a O
stronger O
activation O
of O
NF-kappaB B_GENE
and I_GENE
cytokine I_GENE
mRNA I_GENE
. O

Saline B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mildly O
affected O
these O
parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

AP-1 B_GENE
was O
strongly O
activated O
in O
both O
pancreatic O
segments O
after O
either O
taurocholate O
or O
saline O
infusion O
. O

NF-kappaB B_GENE
inhibition O
with O
N-acetylcysteine O
ameliorated O
the O
local O
inflammatory O
response O
. O

correlation O
between O
localized O
NF-kappaB B_GENE
activation O
, O
cytokine O
upregulation O
, O
and O
tissue O
damage O
suggests O
a O
key O
role O
for O
NF-kappaB B_GENE
in O
the O
development O
of O
the O
inflammatory O
response O
of O
acute O
pancreatitis O
. O

CD45 B_GENE
tyrosine I_GENE
phosphatase I_GENE
controls O
common O
gamma-chain B_GENE
cytokine I_GENE
-mediated O
STAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
extracellular O
signal-related O
kinase O
phosphorylation O
in O
activated O
human O
lymphoblasts O
: O
inhibition O
of O
proliferation O
without O
induction O
of O
apoptosis O
. O

The O
objective B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
test O
whether O
CD45 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
influence O
signaling O
processes B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
activated O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoblasts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
this O
end O
, O
we O
generated O
lymphoblasts O
which O
proliferate O
in O
response O
to O
common O
gamma-chain B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokines B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
readily O
undergo O
apoptosis O
after O
cytokine O
withdrawal O
. O

In O
experiments O
with O
the O
CD45R0 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mAb B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
UCHL-1 B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
control B_GENE/B_TIME[MEASURE]
CD45 I_GENE/I_TIME[MEASURE]
mAbs I_GENE/I_TIME[MEASURE]
, O
we O
found O
significant O
inhibition O
of O
proliferation O
. O

Interestingly O
, O
the O
pan-CD45 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mAb B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GAP8.3 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
is O
most O
effective O
in O
inhibition O
of O
OKT-3-mediated O
proliferation O
in O
quiescent O
lymphocytes O
, O
was O
ineffective O
in O
lymphoblasts O
. O

addition O
of O
CD3 B_GENE
mAb I_GENE
OKT-3 I_GENE
had O
no O
influence O
on O
IL-2-mediated O
proliferation O
( O
with O
or O
without O
UCHL-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
. O

In O
contrast O
, O
after O
addition O
of O
OKT-3 B_GENE
to O
IL-4 B_GENE
- O
and O
IL-7 B_GENE
-stimulated O
proliferation O
assays O
, O
UCHL-1 B_GENE/B_PERSON
signals O
could O
not O
significantly O
alter O
cellular O
proliferation O
. O

We O
did O
not O
find O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
apoptosis B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
following O
CD45R0 B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
signaling B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
Western O
blots O
using O
mAbs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
detecting O
phosphorylated B_GENE
STAT-3 I_GENE
, I_GENE
STAT-5 I_GENE
, I_GENE
STAT-6 I_GENE
, O
or O
extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-related I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1/2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
found O
that O
CD45R0 O
signaling O
could O
effectively O
diminish O
phosphorylation O
of O
these O
intracellular O
signaling O
components O
. O

Using O
RT-PCR O
, O
we O
found O
that O
CD45R0 O
signaling O
inhibited O
IL-2 O
mRNA O
production O
without O
major O
influence O
on O
IL-13 B_GENE
, O
IL-5 B_GENE
, O
or O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O
. O

Costimulation O
with O
OKT-3 B_GENE
and O
IL-2 B_GENE/B_LOCATION
optimally O
induced O
secretion O
of O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
IL-5 B_GENE
, O
which O
was O
not O
decreased O
by O
CD45 O
signals O
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
we O
illustrate O
that O
CD45R0 B_GENE
signals I_GENE
control O
early B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor-associated O
signaling O
processes B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
mRNA B_GENE
and O
DNA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
synthesis B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
activated O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoblasts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Furthermore O
, O
we O
show O
the O
existence O
of O
CD45 B_GENE/B_BIO
epitopes I_GENE/I_BIO
( O
GAP8.3 B_GENE/B_LOCATION
) O
, O
which O
are O
active O
and O
critical O
for O
signaling O
in O
quiescent O
lymphocytes O
, O
but O
are O
nonfunctional O
in O
activated O
human O
lymphoblasts O
. O

Pax5 B_GENE/B_LOCATION
determines O
the O
identity O
of O
B O
cells O
from O
the O
beginning O
to O
the O
end O
of O
B-lymphopoiesis O
. O

Despite O
being O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
most O
intensively O
studied O
cell B_DISEASE
types I_DISEASE
, O
the O
molecular B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
basis I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
B B_DISEASE
cell I_DISEASE
specification I_DISEASE
is O
largely O
unknown B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
Pax5 B_GENE
gene I_GENE
encoding O
the O
transcription B_GENE/B_MEASURE
factor I_GENE/I_MEASURE
BSAP I_GENE/I_MEASURE
is O
required O
for O
progression O
of O
B-lymphopoiesis O
beyond O
the O
pro-B O
cell O
stage O
. O

Pax5-deficient B_PERSON
pro-B I_PERSON
cells I_PERSON
are O
, O
however O
, O
not O
yet O
committed B_PERSON
to O
the O
B-lymphoid B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lineage I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
instead O
have O
a O
broad B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphomyeloid I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developmental I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pax5 B_GENE
appears O
to O
mediate O
B-lineage O
commitment O
by O
repressing O
the O
transcription O
of O
non-B-lymphoid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
by O
simultaneously O
activating O
the O
expression O
of O
B-lineage-specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Pax5 B_GENE
thus O
functions O
both O
as O
a O
transcriptional O
repressor O
and O
activator O
, O
depending O
on O
its O
interactions O
with O
corepressors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
Groucho B_GENE/B_LOCATION
protein I_GENE/I_LOCATION
family I_GENE/I_LOCATION
or O
with O
positive O
regulators O
such O
as O
the O
TATA-binding B_GENE
protein I_GENE
. O

Once O
committed O
to O
the O
B-lineage O
, O
B O
cells O
require O
Pax5 B_GENE/B_MEASURE
function O
to O
maintain O
their O
B-lymphoid O
identity O
throughout O
B O
cell O
development O
. O

Partners O
in O
transcription O
: O
NFAT B_GENE
and O
AP-1 B_GENE
. O

Combinatorial O
regulation O
is O
a O
powerful O
mechanism O
that O
enables O
tight O
control O
of O
gene O
expression O
, O
via O
integration O
of O
multiple O
signaling O
pathways O
that O
induce O
different O
transcription B_GENE/B_LOCATION
factors I_GENE/I_LOCATION
required O
for O
enhanceosome O
assembly O
. O

The O
four O
calcium-regulated O
transcription B_GENE/B_BIO
factors I_GENE/I_BIO
of O
the O
NFAT B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
family B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
act O
synergistically O
with O
AP-1 B_GENE/B_BIO
( I_GENE/I_BIO
Fos/Jun I_GENE/I_BIO
) I_GENE/I_BIO
proteins I_GENE/I_BIO
on O
composite O
DNA O
elements O
which O
contain O
adjacent O
NFAT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AP-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
where O
they O
form O
highly O
stable O
ternary O
complexes O
to O
regulate O
the O
expression O
of O
diverse O
inducible O
genes O
. O

Concomitant O
induction O
of O
NFAT B_GENE
and O
AP-1 B_GENE
requires O
concerted O
activation O
of O
two O
different O
signaling O
pathways O
: O
calcium/calcineurin O
, O
which O
promotes O
NFAT O
dephosphorylation O
, O
nuclear O
translocation O
and O
activation O
; O
and O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PKC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/Ras I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
promotes O
the O
synthesis O
, O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Fos B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Jun I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
families I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
transcription B_GENE/B_DISEASE
factors I_GENE/I_DISEASE
. O

A O
fifth O
member O
of O
the O
NFAT B_GENE/B_BIO
family I_GENE/I_BIO
, O
NFAT5 B_GENE/B_LOCATION
, O
controls O
the O
cellular O
response O
to O
osmotic O
stress O
, O
by O
a O
mechanism O
that O
requires O
dimer O
formation O
and O
is O
independent O
of O
calcineurin B_GENE
or O
of O
interaction O
with O
AP-1 B_GENE
. O

Pharmacological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interference I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
theNFAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
AP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
interaction I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
selective B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
manipulation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
immune B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

balanced O
activation O
of O
NFAT B_GENE
and O
AP-1 B_GENE
is O
known O
to O
be O
required O
for O
productive O
immune O
responses O
, O
but O
the O
role O
of O
NFAT O
: O
AP-1 O
interactions O
in O
other O
cell O
types O
and O
biological O
processes O
remains O
to O
be O
understood O
. O

cytokine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
production I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
by O
Vgamma B_GENE
( O
+ B_PROTEIN[GENE]/B_DISEASE
) O
-T-cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
subsets I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
is O
an O
important B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
determining O
CD4 B_GENE
( O
+ B_DISEASE/B_GENE
) O
-Th-cell B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
phenotype I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O
susceptibility B_DISEASE
of O
BALB/c B_SPECIES[BIO]/B_PERSON
mice I_SPECIES[BIO]/I_PERSON
to O
coxsackievirus O
B3-induced B_DISEASE_ADJECTIVE[DISEASE]
myocarditis I_DISEASE_ADJECTIVE[DISEASE]
. O

Two O
coxsackievirus O
B3 O
( O
CVB3 O
) O
variants O
( O
H3 O
and O
H310A1 O
) O
differ O
by O
a O
single O
amino O
acid O
mutation O
in O
the O
VP2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
capsid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

H3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O
severe B_DISEASE/B_GENE
myocarditis I_DISEASE/I_GENE
in O
BALB/c B_SPECIES[BIO]
mice I_SPECIES[BIO]
, O
but O
H310A1 B_DISEASE/B_GENE
is O
amyocarditic B_DISEASE_ADJECTIVE[DISEASE]
. O

infection O
with O
H3 O
, O
but O
not O
H310A1 O
, O
preferentially O
activates O
Vgamma4 O
Vdelta4 O
cells O
, O
which O
are O
strongly O
positive O
for O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
IFN-gamma B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
whereas O
Vgamma1 O
Vdelta4 O
cells O
are O
increased O
in O
both O
H3 O
and O
H310A1 O
virus-infected O
animals O
. O

Depletion O
of O
Vgamma1 O
( O
+ O
) O
cells O
using O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
anti-Vgamma1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
enhanced O
myocarditis O
and O
CD4 O
( O
+ O
) O
- O
, O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
+ O
) O
-cell O
responses O
in O
both O
H3- O
and O
H310A1-infected O
mice O
yet O
decreased O
the O
CD4 O
( O
+ O
) O
- O
, O
IL-4 O
( O
+ O
) O
-cell O
response O
. O

Depleting B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Vgamma4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
+ B_GENE/B_DISEASE
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
suppressed O
myocarditis B_DISEASE/B_GENE
and O
reduced O
CD4 B_GENE
( O
+ B_GENE/B_DISEASE
) O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
+ B_DISEASE/B_GENE
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
but O
increased O
CD4 B_GENE
( O
+ B_GENE/B_DISEASE
) O
IL-4 B_GENE
( O
+ B_OTHER/B_DISEASE
) O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

The O
role O
of O
cytokine O
production O
by O
Vgamma1 O
( O
+ O
) O
and O
Vgamma4 O
( O
+ O
) O
T O
cells O
was O
investigated O
by O
adoptively O
transferring O
these O
cells O
isolated O
from O
H3-infected O
BALB/c O
Stat4 O
knockout O
( O
Stat4ko O
) O
( O
defective O
in O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O
) O
or O
BALB/c O
Stat6ko O
( O
defective O
in O
IL-4 O
expression O
) O
mice O
into O
H3 O
virus-infected O
wild-type O
BALB/c O
recipients O
. O

Vgamma4 O
and O
Vgamma1 O
( O
+ O
) O
T O
cells O
from O
Stat4ko O
mice O
expressed O
IL-4 B_GENE
but O
no O
or O
minimal O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
whereas O
these O
cell O
populations O
derived O
from O
Stat6ko O
mice O
expressed O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
but O
no O
IL-4 B_GENE
. O

Stat4ko B_GENE/B_MEASURE
Vgamma1 I_GENE/I_MEASURE
( O
+ B_DISEASE/B_GENE
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O
IL-4 B_GENE
( O
+ B_GENE/B_DISEASE
) O
) O
suppress O
myocarditis B_DISEASE/B_GENE
. O

Stat6ko B_GENE
Vgamma1 I_GENE
( O
+ B_GENE/B_DISEASE
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
+ B_DISEASE/B_PROTEIN[GENE]
) O
) O
were O
not O
inhibitory B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

Stat6ko B_GENE/B_MEASURE
Vgamma4 I_GENE/I_MEASURE
( O
+ B_GENE/B_DISEASE
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
+ B_DISEASE/B_GENE
) O
) O
significantly O
enhanced O
myocarditis B_DISEASE
. O

Stat4ko B_GENE
Vgamma4 I_GENE
( O
+ B_DISEASE/B_GENE
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
IL-4 B_GENE
( O
+ B_GENE/B_DISEASE
) O
) O
neither O
inhibited O
nor O
enhanced B_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
that O
distinct B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gammadelta-T-cell B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subsets B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
control O
myocarditis B_DISEASE
susceptibility I_DISEASE
and O
bias O
the O
CD4 B_GENE
( O
+ B_GENE/B_DISEASE
) O
-Th-cell B_MEASURE/B_LOCATION
response I_MEASURE/I_LOCATION
. O

The O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
produced O
by O
the O
Vgamma O
subpopulation O
have O
a O
significant O
influence O
on O
the O
CD4 B_GENE
( O
+ O
) O
-Th-cell O
phenotype O
. O

Plasmin B_GENE
-induced O
expression O
of O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
tissue B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
human O
monocytes O
involves O
AP-1 B_GENE
and O
IKKbeta B_GENE
-mediated O
NF-kappaB O
activation O
. O

It O
was O
previously O
shown O
that O
plasmin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activates O
human O
peripheral O
monocytes O
in O
terms O
of O
lipid O
mediator O
release O
and O
chemotactic O
migration O
. O

Here O
it O
is O
demonstrated O
that O
plasmin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
proinflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
release O
and O
tissue B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TF B_PROTEIN[GENE]
) O
expression O
by O
monocytes O
. O

Plasmin B_GENE/B_MEASURE
0.043 O
to O
1.43 O
CTA O
U/mL O
, O
but O
not O
active B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
site-blocked I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
triggered O
concentration-dependent O
expression O
of O
mRNA O
for O
interleukin-1alpha B_GENE
( O
IL-1alpha B_GENE
) O
, O
IL-1beta B_GENE
, O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
and O
TF B_GENE
with O
maximum O
responses O
after O
4 O
hours O
. O

Plasmin B_GENE
-mediated O
mRNA O
expression O
was O
inhibited O
in O
a O
concentration-dependent O
manner O
by O
the O
lysine O
analogue O
trans-4- O
( O
aminomethyl O
) O
cyclohexane-1-carboxylic O
acid O
( O
t-AMCA O
) O
. O

increases O
in O
mRNA O
levels O
were O
followed O
by O
concentration- O
and O
time-dependent O
release O
of O
IL-1alpha B_GENE
, O
IL-1beta B_GENE
and O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
by O
TF B_GENE
expression O
on O
monocyte O
surfaces O
. O

Neither O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nor O
TF B_GENE
could O
be O
detected O
when O
monocytes O
were O
preincubated O
with O
actinomycin O
D O
or O
cycloheximide O
. O

Electrophoretic O
mobility O
shift O
assays O
indicated O
plasmin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O
activation O
of O
NF-kappaB B_GENE
; O
DNA-binding B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
complexes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
composed O
of O
p50 B_GENE
, O
p65 B_GENE
, O
and O
c-Rel B_GENE
, O
as O
shown O
by O
supershift O
experiments O
. O

Nuclear O
translocation O
of O
NF-kappaB/Rel B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
coincided O
with O
IkappaBalpha O
degradation O
. O

At O
variance O
with O
endotoxic O
lipopolysaccharide O
, O
plasmin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elicited O
the O
rapid O
degradation O
of O
another O
cytoplasmic B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
NF-kappaB I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
p105 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Proteolysis O
of O
NF-kappaB O
inhibitors O
was O
apparently O
due O
to O
transient O
activation O
of O
IkappaB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IKK I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
reached O
maximum O
activity O
at O
1 O
hour O
after O
plasmin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O
. O

In O
addition O
, O
AP-1 O
binding O
was O
increased O
in O
plasmin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-treated O
monocytes O
, O
with O
most O
complexes O
composed O
of O
JunD B_GENE/B_DISEASE
, O
c-Fos B_GENE/B_LOCATION
, O
and O
FosB B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
findings O
further O
substantiate O
the O
role O
of O
plasmin B_GENE
as O
a O
proinflammatory O
activator O
of O
human O
monocytes O
and O
reveal O
an O
important O
new O
link O
between O
the O
plasminogen-plasmin O
system O
and O
inflammation O
. O

( O
Blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O
2001 B_MEASURE
; O
97 B_MEASURE
: O
3941-3950 B_MEASURE/B_LOCATION
) O
. O

STAT3 B_GENE
is O
constitutively O
active O
in O
some O
patients O
with O
Polycythemia O
rubra O
Vera O
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Polycythemia B_DISEASE/B_GENE
vera I_DISEASE/I_GENE
is O
a O
clonal B_DISEASE
stem I_DISEASE
cell I_DISEASE
disorder I_DISEASE
characterized O
by O
hyperproliferation B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
erythroid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O
myeloid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
megakaryocytic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lineages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

While O
it O
has O
been O
shown O
that O
progenitor O
cells O
of O
P. O
Vera O
patients O
are O
hypersensitive O
to O
several O
growth O
factors O
including O
erythropoietin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
insulin-like B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
thrombopoietin B_GENE
, O
interleukin-3 B_GENE
, O
and O
granulocyte/monocyte B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
molecular O
pathogenesis O
of O
this O
disease O
remains O
unknown O
. O

Growth B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
hypersensitivity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
could O
be O
mediated O
by O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
signal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transduction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pathways I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
therefore O
investigated O
a O
common O
downstream O
effector O
of O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
signal B_GENE
transducers I_GENE
and I_GENE
activators I_GENE
of I_GENE
transcription I_GENE
( O
STATs B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

A O
constitutive O
activation O
of O
STAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
explain O
the O
increased O
proliferation O
of O
P. O
Vera O
cells O
even O
in O
the O
absence O
of O
growth O
factor O
stimulation O
. O

methods O
: O
peripheral O
granulocytes O
from O
patients O
with O
P. O
Vera O
and O
from O
healthy O
volunteers O
were O
assayed O
for O
STAT1 B_GENE
, I_GENE
3 I_GENE
, I_GENE
and I_GENE
5 I_GENE
DNA O
binding O
by O
electrophoretic O
mobility O
shift O
assay O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
Four B_NUMBER[MEASURE]
of O
14 B_LOCATION/B_PERSON
P B_LOCATION/I_PERSON
. O
vera B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
analyzed O
showed O
constitutive B_DISEASE_ADJECTIVE[DISEASE]
STAT3 I_DISEASE_ADJECTIVE[DISEASE]
DNA I_DISEASE_ADJECTIVE[DISEASE]
binding I_DISEASE_ADJECTIVE[DISEASE]
in O
unstimulated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
peripheral I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
granulocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O
while O
none B_PERSON/B_NUMBER[MEASURE]
of O
the O
17 B_PERSON
healthy I_PERSON
volunteers I_PERSON
tested O
did O
. O

None O
of O
the O
subjects O
showed O
constitutive O
STAT1 B_GENE
or O
STAT5 B_GENE
activity O
. O

Western O
blotting O
demonstrated O
that O
, O
in O
the O
three O
patients O
, O
STAT3 B_GENE
is O
constitutively O
phosphorylated O
on O
Tyr O
705 O
, O
whereas O
it O
is O
unphosphorylated O
in O
the O
other O
patients O
and O
in O
controls O
. O

Interestingly O
, O
constitutive O
STAT3 B_GENE
activity O
did O
not O
correlate O
with O
the O
duration O
of O
disease O
or O
the O
treatment O
regimen O
. O

It O
was O
observed O
in O
a O
recently O
diagnosed O
patient B_PERSON/B_DISEASE
and O
in O
two B_PERSON
patients I_PERSON
treated O
only O
with O
phlebotomy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

conclusion O
: O
Our O
data O
suggest O
that O
constitutive O
phosphorylation O
and O
activation O
of O
STAT3 B_GENE
is O
not O
a O
secondary O
event O
induced O
by O
mutagenizing O
agents O
or O
by O
prolonged O
hyperproliferation O
of O
hematopoietic O
cells O
, O
but O
rather O
represents O
a O
primary O
molecular O
aberration O
. O

Constitutively B_GENE/B_PERSON
active I_GENE/I_PERSON
STAT3 I_GENE/I_PERSON
may O
contribute O
to O
the O
growth O
factor O
hypersensitivity O
of O
P. O
Vera O
cells O
. O

identification O
of O
phosphorylation B_ENZYME[GENE]/B_LOCATION
sites I_ENZYME[GENE]/I_LOCATION
for O
Bruton B_GENE
's I_GENE
tyrosine I_GENE
kinase I_GENE
within O
the O
transcriptional B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
regulator I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
BAP/TFII-I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

Bruton B_GENE
's I_GENE
tyrosine I_GENE
kinase I_GENE
( O
Btk B_LOCATION/B_ORGANIZATION
) O
, O
a O
member O
of O
the O
Tec B_GENE/B_LOCATION
family I_GENE/I_LOCATION
of I_GENE/I_LOCATION
cytosolic I_GENE/I_LOCATION
kinases I_GENE/I_LOCATION
, O
is O
essential O
for O
B O
cell O
development O
and O
function O
. O

BAP/TFII-I B_GENE
, O
a O
protein O
implicated O
in O
transcriptional O
regulation O
, O
is O
associated O
with O
Btk B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
B O
cells O
and O
is O
transiently O
phosphorylated O
on O
tyrosine O
following O
B O
cell O
receptor O
engagement O
. O

BAP/TFII-I B_GENE
is O
a O
substrate O
for O
Btk B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vitro O
and O
is O
hyperphosphorylated O
on O
tyrosine O
upon O
coexpression O
with O
Btk B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mammalian O
cells O
. O

In O
an O
effort O
to O
understand O
the O
physiologic O
consequences O
of O
BAP/TFII-I B_GENE
tyrosine O
phosphorylation O
following O
B O
cell O
receptor O
stimulation O
, O
site-directed O
mutagenesis O
and O
phosphopeptide O
mapping O
were O
used O
to O
locate O
the O
predominant O
sites O
of O
BAP/TFII-I B_GENE
phosphorylation O
by O
Btk B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vitro O
. O

These O
residues O
, O
Tyr248 O
, O
Tyr357 O
, O
and O
Tyr462 O
, O
were O
also O
found O
to O
be O
the O
major O
sites O
for O
Btk B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O
phosphorylation O
of O
BAP/TFII-I B_GENE
in O
vivo O
. O

residues O
Tyr357 O
and O
Tyr462 O
are O
contained O
within O
the O
loop B_LOCATION/B_ORGANIZATION
regions I_LOCATION/I_ORGANIZATION
of O
adjacent O
helix-loop-helix-like B_LOCATION/B_BIO
repeats B_LOCATION/I_BIO
within O
BAP/TFII-I B_GENE
. O

mutation O
of O
either O
Tyr248 O
, O
Tyr357 O
, O
or O
Tyr462 O
to O
phenylalanine O
reduced O
transcription O
from O
a O
c-fos B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
relative O
to O
wild-type B_GENE/B_TIME[MEASURE]
BAP/TFII-I I_GENE/I_TIME[MEASURE]
in O
transfected O
COS-7 O
cells O
, O
consistent O
with O
the O
interpretation O
that O
phosphorylation O
at O
these O
sites O
contributes O
to O
transcriptional O
activation O
. O

Phosphorylation O
of O
BAP/TFII-I B_GENE
by O
Btk B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
link O
engagement O
of O
receptors O
such O
as O
surface O
immunoglobulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
modulation O
of O
gene O
expression O
. O

expression O
of O
interferon B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
consensus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O
potent O
immunity O
against O
BCR/ABL-induced O
leukemia O
. O

mice O
deficient O
in O
the O
interferon B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
consensus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
ICSBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
develop O
a O
disease O
resembling O
chronic O
myeloid O
leukemia O
( O
CML O
) O
, O
which O
in O
humans O
is O
caused O
by O
the O
BCR/ABL B_GENE/B_DISEASE
oncoprotein I_GENE/I_DISEASE
. O

Interferon-alpha B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
IFN-alpha B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
induces O
ICSBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O
and O
is O
an O
effective O
therapy O
for O
CML O
. O

This O
study O
examined O
whether O
enforced O
expression O
of O
ICSBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
might O
antagonize O
BCR/ABL-induced O
leukemia O
; O
results O
demonstrated O
that O
ICSBP-modified O
cells O
generated O
a O
protective O
CD8 O
( O
+ O
) O
cytotoxic O
T-cell O
response O
against O
BCR/ABL-transformed O
BaF3 O
cells O
in O
a O
murine O
leukemia O
model O
. O

ICSBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O
represents O
a O
novel O
means O
of O
stimulating O
a O
host O
immune O
response O
to O
BCR/ABL O
( O
+ O
) O
leukemia O
cells O
and O
a O
potential O
strategy O
for O
immunotherapy O
of O
CML O
. O

( O
Blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O
2001 B_MEASURE
; O
97 B_MEASURE
: O
3491-3497 B_MEASURE
) O
. O

A O
transcriptional O
block O
in O
the O
IL-2 B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
at O
the O
-150 B_GENE/B_MEASURE
AP-1 I_GENE/I_MEASURE
site I_GENE/I_MEASURE
in O
effector O
CD8+ O
T O
cells O
. O

Both O
CD4+ O
and O
CD8+ O
T O
cells O
that O
produce O
IL-2 B_GENE
in O
response O
to O
AG O
recognition O
have O
been O
isolated O
. O

However O
, O
most O
effector O
CD8+ O
T O
cells O
recovered O
after O
exposure O
to O
Ag B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O
not O
produce O
sufficient O
IL-2 B_GENE
to O
sustain O
growth O
, O
and O
depend O
on O
CD4+ O
T O
helper O
cells O
for O
this O
obligate O
growth O
factor O
. O

IL-2 O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
CD4+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O
primarily O
controlled O
at O
the O
level B_MEASURE/B_LOCATION
of O
transcription B_GENE
, O
but O
mechanisms B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
restricting O
IL-2 O
production B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
CD8+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
have O
not O
been O
elucidated O
. O

To O
evaluate O
transcriptional O
regulation O
of O
the O
IL-2 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
in O
CD8+ O
T O
cells O
, O
we O
stably O
transfected O
reporter B_GENE/B_PERSON
genes I_GENE/I_PERSON
into O
Ag B_VIRUS[BIO]/B_GENE
-specific O
CD8+ O
T O
cell O
clones O
. O

CD28+ O
CD8 O
( O
+ O
) O
T O
cells O
unable O
to O
transcribe O
the O
IL-2 B_GENE
gene I_GENE
in O
response O
to O
antigenic O
stimulation O
had O
a O
block O
in O
transactivation O
of O
the O
-150 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CD28 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CD28RE I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/AP-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
IL-2 B_GENE
promoter I_GENE
, O
but O
did O
transactivate O
the O
composite O
NFAT/AP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
OCT/AP-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
a O
consensus B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AP-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motif I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

mutation O
of O
the O
nonconsensus B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-150 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AP-1 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
consensus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
AP-1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
or O
insertion O
of O
a O
CD28RE/AP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
consensus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
upstream O
of O
the O
native O
-150 B_GENE/B_LOCATION
CD28RE/AP-1 I_GENE/I_LOCATION
site I_GENE/I_LOCATION
restored O
transactivation O
of O
the O
altered O
promoter B_GENE/B_LOCATION
. O

These O
results O
suggest O
that O
the O
defect O
at O
the O
-150 B_PERSON/B_GENE
site B_PERSON/I_GENE
may O
reflect O
the O
absence O
or O
inactivity O
of O
a O
required O
factor O
rather O
than O
repression O
of O
the O
IL-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Stem B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
interleukin-3 B_GENE
induce O
stepwise O
generation O
of O
erythroid O
precursor O
cells O
from O
a O
basic O
fibroblast B_GENE
growth I_GENE
factor I_GENE
-dependent O
hematopoietic O
stem O
cell O
line O
, O
A-6 O
. O

A O
m O
ultipotent O
immature O
myeloid O
cell O
population O
was O
produced O
from O
a O
basic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fibroblast I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
bFGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
-dependent O
hematopoietic O
stem O
cell O
line O
, O
A-6 O
, O
when O
cultured O
with O
stem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
SCF B_GENE/B_LOCATION
) O
replacing O
bFGF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Those O
cells O
were O
positive O
for O
stem B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
markers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
c-kit B_GENE
and O
CD34 B_GENE
, O
and O
a O
myeloid B_GENE/B_MEASURE
cell I_GENE/I_MEASURE
marker I_GENE/I_MEASURE
, I_GENE/I_MEASURE
F4/80 I_GENE/I_MEASURE
. O

Some O
cell O
fractions O
were O
also O
positive O
for O
Mac-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
a I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
macrophage I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
marker I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O
Gr-1 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
a I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
granulocytic I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
maker I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
but O
negative O
for O
an O
erythroid B_GENE
marker I_GENE
TER119 I_GENE
. O

They O
also O
showed O
the O
expression O
of O
mRNA O
for O
the O
myeloid-specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PU.1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
but O
did O
not O
that O
for O
the O
erythroid-specific B_GENE
GATA-1 I_GENE
. O

Among O
various O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
interleukin-3 B_GENE
( O
IL-3 B_GENE
) O
induced O
erythroid O
precursor O
cells O
that O
expressed O
the O
erythroid-specific B_GENE
GATA-1 I_GENE
and O
beta-major B_GENE
globin I_GENE
. O

The O
quantitative O
analysis O
showed O
that O
erythroid O
precursor O
cells O
were O
newly O
produced O
from O
the O
immature O
myeloid O
cells O
by O
cultivation O
with O
IL-3 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

SCF B_GENE/B_BIO
and O
IL-3 B_GENE/B_LOCATION
induced O
stepwise O
generation O
of O
erythroid O
precursor O
cells O
from O
an O
A-6 O
hematopoietic O
stem O
cell O
line O
. O

Copyright B_LOCATION/B_PERSON
2001 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

distinct O
BMI-1 B_GENE
and O
EZH2 B_GENE
expression O
patterns O
in O
thymocytes O
and O
mature O
T O
cells O
suggest O
a O
role O
for O
Polycomb B_GENE/B_MEASURE
genes I_GENE/I_MEASURE
in O
human O
T O
cell O
differentiation O
. O

BMI-1 B_GENE/B_DISEASE
and O
EZH2 B_GENE/B_DISEASE
Polycomb-group I_GENE/I_DISEASE
( I_GENE/I_DISEASE
PcG I_GENE/I_DISEASE
) I_GENE/I_DISEASE
proteins I_GENE/I_DISEASE
belong O
to O
two O
distinct O
protein O
complexes O
involved O
in O
the O
regulation O
of O
hematopoiesis O
. O

Using O
unique O
PcG-specific O
antisera O
and O
triple O
immunofluorescence O
, O
we O
found O
that O
mature O
resting O
peripheral O
T O
cells O
expressed O
BMI-1 B_GENE
, O
whereas O
dividing O
blasts O
were O
EZH2 O
( O
+ O
) O
. O

By O
contrast O
, O
subcapsular O
immature O
double-negative O
( O
DN O
) O
( O
CD4 O
( O
- O
) O
/CD8 O
( O
- O
) O
) O
T O
cells O
in O
the O
thymus O
coexpressed O
BMI-1 B_GENE
and O
EZH2 B_GENE
or O
were O
BMI-1 O
single O
positive O
. O

Their O
descendants O
, O
double-positive O
( O
DP O
; O
CD4 O
( O
+ O
) O
/CD8 O
( O
+ O
) O
) O
cortical O
thymocytes O
, O
expressed O
EZH2 B_GENE
without O
BMI-1 B_TIME[MEASURE]
. O

Most B_GENE
EZH2 I_GENE
( O
+ B_DISEASE/B_GENE
) O
DN B_PROTEIN[GENE]/B_DISEASE
and O
DP B_LOCATION
thymocytes I_LOCATION
were O
dividing O
, O
while O
DN B_GENE/B_LOCATION
BMI-1 I_GENE/I_LOCATION
( O
+ B_DISEASE/B_GENE
) O
/EZH2 B_GENE
( O
- O
) O
thymocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
resting O
and O
proliferation B_TIME[MEASURE]/B_DISEASE
was O
occasionally O
noted O
in O
DN B_GENE
BMI-1 I_GENE
( O
+ B_DISEASE/B_GENE
) O
/EZH2 B_GENE
( O
+ B_DISEASE/B_PROTEIN[GENE]
) O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Maturation O
of O
DP O
cortical O
thymocytes O
to O
single-positive O
( O
CD4 O
( O
+ O
) O
/CD8 O
( O
- O
) O
or O
CD8 O
( O
+ O
) O
/CD4 O
( O
- O
) O
) O
medullar O
thymocytes O
correlated O
with O
decreased O
detectability O
of O
EZH2 B_GENE
and O
continued O
relative O
absence O
of O
BMI-1 B_GENE
. O

Our O
data O
show O
that O
BMI-1 B_GENE
and O
EZH2 B_GENE
expression O
in O
mature O
peripheral O
T O
cells O
is O
mutually O
exclusive O
and O
linked O
to O
proliferation O
status O
, O
and O
that O
this O
pattern O
is O
not O
yet O
established O
in O
thymocytes O
of O
the O
cortex O
and O
medulla O
. O

T O
cell O
stage-specific O
PcG O
expression O
profiles O
suggest O
that O
PcG B_GENE/B_BIO
genes I_GENE/I_BIO
contribute O
to O
regulation O
of O
T O
cell O
differentiation O
. O

They O
probably O
reflect O
stabilization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
type-specific B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gene B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
irreversibility B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
lineage B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
choice I_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
difference B_MEASURE
in O
PcG B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O
medullar B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
thymocytes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
mature O
interfollicular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
indicates O
that O
additional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
maturation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
processes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
occur O
after O
thymocyte B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transportation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
the O
thymus B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

Stepwise B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lineage I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
restriction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
progenitors B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O
lympho-myelopoiesis B_DISEASE/B_BIO
. O

It O
has O
long O
been O
controversial B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
whether O
hematopoiesis B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGANISM_FUNCTION
progresses O
through O
ordered O
stages B_DISEASE/B_LOCATION
of O
determination B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
in O
embryonic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
development I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

This O
is O
due O
to O
the O
absence B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
methodology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
capable I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
exactly O
determining O
the O
developmental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
hematopoietic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem/progenitor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
multilineage B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
progenitor I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MLP B_LOCATION/B_ORGANIZATION
) O
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
enabled O
us O
to O
discriminate O
among O
seven B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
types I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
hematopoietic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
progenitors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
are O
multipotent B_DISEASE_ADJECTIVE[DISEASE]
progenitor I_DISEASE_ADJECTIVE[DISEASE]
p-MTB I_DISEASE_ADJECTIVE[DISEASE]
( O
capable B_PERSON/B_LOCATION
of O
generating B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
myeloid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
bipotent B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
progenitors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p-MT I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
p-MB B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
p-TB B_DISEASE/B_PROTEIN[GENE]
, O
and O
unipotent B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
progenitors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
p-M I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
p-T O
and O
p-B O
. O

Among O
these O
seven B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
types I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
the O
p-TB B_SEQUENCE[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
type I_SEQUENCE[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
progenitor I_SEQUENCE[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O
found O
to O
be O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
indicate O
that O
the O
process B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
lineage B_DISEASE/B_ORGANISM_FUNCTION
commitment I_DISEASE/I_ORGANISM_FUNCTION
proceeds I_DISEASE/I_ORGANISM_FUNCTION
through O
an O
ordered O
but O
not O
random B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

By O
extending O
the O
area B_LOCATION/B_MEASURE
of O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
include O
the O
erythroid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lineage B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
more O
convincing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
the O
ordered O
process B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
obtained O
. O

Detailed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
exact B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
illustration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
process B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
hematopoiesis B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_ORGAN_OR_TISSUE_FUNCTION[ORGANISM_FUNCTION]
will O
provide O
an O
opportunity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
revive O
hematopoiesis B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
as O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
most O
fascinating B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
targets I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O
developmental B_DISEASE/B_BIO
biology I_DISEASE/I_BIO
. O

Epstein-Barr O
virus O
and O
its O
glycoprotein-350 B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
upregulate O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
human O
B-lymphocytes O
via O
CD21 B_GENE/B_LOCATION
, O
involving O
activation O
of O
NF-kappaB B_GENE/B_DISEASE
and O
different O
signaling O
pathways O
. O

Epstein-Barr B_DISEASE/B_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
( O
EBV B_VIRUS[BIO]/B_DISEASE
) O
is O
a O
ubiquitous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
highly O
immunotropic B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
gamma I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
herpesvirus I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
that O
infects O
more B_MEASURE/B_PERSON
than O
90 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
humans B_PERSON/B_BIO
worldwide O
. O

Its O
pathogenicity B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
leads O
to O
a O
number B_MEASURE/B_LOCATION
of O
diseases B_DISEASE
including O
tumors B_DISEASE/B_PERSON
that O
result O
from O
EBV B_DISEASE
's I_DISEASE
ability I_DISEASE
to O
readily O
transform O
B-lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
, O
to O
a O
lesser B_MEASURE/B_DISEASE
extent I_MEASURE/I_DISEASE
, O
epithelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

EBV O
utilizes O
CD21/CR2 B_GENE
as O
its O
receptor O
on O
B O
cells O
to O
initiate O
the O
infection O
process O
. O

EBV O
binds O
to O
CR2 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
its O
major B_GENE/B_BIO
envelope I_GENE/I_BIO
glycoprotein-350 I_GENE/I_BIO
( O
gp350 B_GENE
) O
and O
is O
also O
a O
remarkable O
immunomodulating O
agent O
. O

We O
had O
previously O
shown O
that O
EBV O
is O
capable O
of O
modulating O
the O
synthesis O
of O
a O
number O
of O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
now O
show O
that O
while O
both O
purified O
recombinant B_GENE/B_VIRUS[BIO]
gp350 B_GENE/I_VIRUS[BIO]
( O
rgp350 B_GENE
) O
and O
EBV O
upregulate O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthesis O
in O
B O
cells O
, O
EBV-induced O
IL-6 O
gene O
activation O
occurs O
for O
a O
significantly O
longer O
period O
of O
time O
( O
i.e. O
12 O
hours O
for O
EBV O
as O
compared O
to O
6 O
hours O
for O
rgp350 B_GENE/B_VIRUS[BIO]
) O
. O

Moreover O
, O
the O
half-life O
of O
EBV-induced O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
also O
significantly O
longer O
( O
10 O
hours O
) O
than O
that O
of O
mRNA O
induced O
by O
rgp350 B_GENE/B_VIRUS[BIO]
( O
about O
6 O
hours O
) O
. O

Both O
EBV O
and O
gp350 B_GENE/B_VIRUS[BIO]
enhance O
the O
binding O
of O
the O
NF-kappaB B_GENE
transcription I_GENE
factor I_GENE
, O
as O
determined O
by O
band-shift O
and O
augment O
NF-kappaB B_GENE/B_MEASURE
-mediated O
activation O
of O
a O
CAT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
reporter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Furthermore O
, O
we O
demonstrate O
that O
while O
the O
activation O
of O
IL-6 O
gene O
expression O
by O
gp350 B_GENE/B_VIRUS[BIO]
is O
mediated O
primarily O
by O
the O
protein O
kinase O
C O
pathway O
, O
EBV O
can O
mediate O
its O
effects O
through O
multiple O
signaling O
pathways O
. O

To O
our O
knowledge O
this O
is O
the O
first O
report O
showing O
that O
the O
binding O
of O
a O
herpesvirus B_GENE
envelope I_GENE
glycoprotein I_GENE
to O
CR2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
human O
B O
cells O
results O
in O
the O
activation O
of O
the O
NF-kappaB B_GENE
transcription I_GENE
factor I_GENE
leading O
to O
the O
upregulation O
of O
IL-6 O
gene O
expression O
in O
these O
lymphocytes O
. O

Copyright B_LOCATION/B_PERSON
2001 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

Gene- B_TIME[MEASURE]/B_PERSON
and O
tissue-specificity B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
mutation B_DISEASE/B_GENE
in O
big B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
Blue B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
treated O
with O
the O
hepatocarcinogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N-hydroxy-2-acetylaminofluorene I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
a O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
we O
found O
that O
treating O
transgenic B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
big I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blue I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
hepatocarcinogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N-hydroxy-2-acetylaminofluorene I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
N-OH-AAF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
produced O
the O
same B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
major I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adduct I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
target B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
liver I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
nontarget B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
spleen I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
bone B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
marrow I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
induced O
lacI B_DISEASE
mutants I_DISEASE
in O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
and O
induced O
much O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
frequencies B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
l B_GENE/B_DISEASE
acI I_GENE/I_DISEASE
and O
hprt B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
spleen B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

In O
the O
present O
study O
, O
sequence O
analysis O
was O
conducted O
on O
lacI B_SPECIES[BIO]/B_GENE
DNA B_SPECIES[BIO]/I_GENE
and O
hprt B_GENE
cDNA I_GENE
from O
the O
mutants O
, O
to O
determine O
the O
mutational O
specificity O
of O
N-OH-AAF O
in O
the O
rat O
. O

All O
the O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spectra B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
N-OH-AAF-treated B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
rats I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
differed O
significantly O
from O
corresponding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mutation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
profiles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O
untreated B_PERSON/B_BIO
animals I_PERSON/I_BIO
( O
P B_OTHER/B_LOCATION
= O
0.02 B_MEASURE
to O
P B_MEASURE
< I_MEASURE
0.0001 I_MEASURE
) O
. O

Although O
there O
were O
similarities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
among O
the O
mutational B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
patterns B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
derived O
from O
N-OH-AAF-treated B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
rats I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
e.g B_DISEASE/B_PROTEIN[GENE]
. O
, O
G B_OTHER/B_LOCATION
: O
C B_MEASURE/B_GENE
-- O
> B_MEASURE/B_LOCATION
T I_MEASURE/I_LOCATION
: O
A O
transversion B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
was O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
mutation I_DISEASE_ADJECTIVE[DISEASE]
in O
all O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sets I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
) O
, O
there O
were O
significant B_MEASURE
differences I_MEASURE
in O
the O
patterns B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
basepair B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
substitution B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
frameshift B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
spleen B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lymphocyte I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lacI I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
mutants I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
P B_PROTEIN[GENE]/B_LOCATION
= O
0.02 B_MEASURE
) O
and O
between O
the O
spleen B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
lymphocyte B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
lacI B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
hprt B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
mutants I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O
P B_PROTEIN[GENE]/B_LOCATION
= O
0.04 B_MEASURE
) O
. O

Also O
, O
multiplex O
PCR O
analysis O
of O
genomic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
hprt O
mutants O
indicated O
that O
12 O
% O
of O
mutants O
from O
treated O
rats O
had O
major O
deletions O
in O
the O
hprt B_GENE
gene I_GENE
; O
no O
corresponding O
incidence O
of O
large O
deletions O
was O
evident O
among O
lacI O
mutations O
. O

All O
the O
mutation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
profiles I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reflect O
the O
general B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutational B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
specificity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
major B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adduct I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
formed O
by O
N-OH-AAF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
differences O
between O
N-OH-AAF O
mutation O
in O
the O
endogenous B_GENE/B_BIO
gene I_GENE/I_BIO
and O
transgene B_GENE
can O
be O
partially O
explained O
by O
the O
structures O
of O
the O
two O
genes O
. O

The O
tissue-specificity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
mutation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spectra I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O
contribute O
to O
targeting O
tumor B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Environ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
Mol B_PERSON/B_LOCATION
. O
Mutagen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
37 B_MEASURE
: O
203-214 B_MEASURE
, O
2001 B_MEASURE/B_LOCATION
. O

Published O
2001 B_PERSON/B_ENT
Wiley-Liss I_PERSON/I_ENT
, O
Inc B_ORGANIZATION/B_PERSON
. O

Caspase B_GENE
-dependent O
cleavage O
of O
the O
hematopoietic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
specific I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adaptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Gads I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alters O
signalling O
from O
the O
T B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
cell B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

Gads B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
a O
SH2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
SH3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
domain I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-containing O
, O
hematopoietic-specific B_GENE
adaptor I_GENE
protein I_GENE
that O
functions O
in O
signalling O
from O
the O
T B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
cell B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
receptor B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Gads B_PERSON/B_GENE
acts O
by O
linking O
SLP-76 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
bound O
by O
the O
carboxy-terminal B_GENE
Gads I_GENE
SH3 I_GENE
domain I_GENE
, O
to O
tyrosine B_GENE/B_LOCATION
phosphorylated I_GENE/I_LOCATION
LAT I_GENE/I_LOCATION
which O
contains O
binding O
sites O
for O
the O
Gads B_PROTEIN[GENE]
SH2 I_PROTEIN[GENE]
domain I_PROTEIN[GENE]
. O

Gads B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
distinguished O
from O
Grb2 B_GENE/B_BIO
and O
the O
closely O
related O
Grap B_GENE/B_BIO
protein I_GENE/I_BIO
by O
the O
presence O
of O
a O
120 B_LOCATION/B_MEASURE
amino I_LOCATION/I_MEASURE
acid I_LOCATION/I_MEASURE
unique I_LOCATION/I_MEASURE
region I_LOCATION/I_MEASURE
between O
the O
SH2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
carboxy B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
terminal I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SH3 I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Here O
we O
demonstrate O
that O
the O
unique O
region O
of O
Gads B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
contains O
a O
capase B_LOCATION/B_GENE
cleavage I_LOCATION/I_GENE
site I_LOCATION/I_GENE
. O

induction O
of O
apoptosis O
in O
lymphocytes O
results O
in O
detectable O
Gads B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cleavage O
by O
60 O
min O
. O

Gads B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cleavage O
is O
blocked O
in O
vivo O
by O
treating O
cells O
with O
a O
caspase O
3 O
inhibitor O
. O

A O
putative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
caspase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cleavage I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
identified O
within O
the O
unique O
region O
and O
mutation O
of O
this O
site O
prevented O
Gads B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
cleavage O
in O
vitro O
, O
and O
in O
vivo O
. O

The O
Gads B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
cleavage O
products O
retained O
the O
predicted O
binding O
specificity O
for O
SLP-76 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
LAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

expression O
of O
the O
Gads B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cleavage O
products O
in O
Jurkat O
T O
cells O
inhibited O
NFAT O
activation O
following O
TCR O
cross O
linking O
. O

These O
findings O
indicate O
that O
cleavage O
of O
Gads B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
vivo O
could O
function O
to O
alter O
signalling O
downstream O
of O
the O
T B_GENE/B_LOCATION
cell I_GENE/I_LOCATION
receptor I_GENE/I_LOCATION
by O
disrupting O
cross O
talk O
between O
SLP-76 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
LAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

targeting O
of O
p300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
interleukin-2 B_GENE
promoter I_GENE
via O
CREB-Rel O
cross-talk O
during O
mitogen B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
oncogenic O
molecular O
signaling O
in O
activated O
T-cells O
. O

In O
this O
report O
, O
we O
explore O
the O
mechanisms O
of O
targeting O
of O
p300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
interleukin-2 B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
( B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
IL-2 B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
) B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
promoter B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O
response O
to O
mitogenic O
and O
oncogenic O
molecular O
signals O
. O

recruitment O
of O
p300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
cAMP-responsive B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
element-binding I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
protein-Rel I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cross-talk O
at O
the O
composite B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CD28 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
CD28RE B_GENE/B_LOCATION
) O
- O
TRE B_MEASURE/B_LOCATION
element B_MEASURE/I_LOCATION
of O
the O
IL-2 B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
is O
essential O
for O
promoter O
inducibility O
during O
T-cell O
activation O
, O
and O
CD28RE-TRE B_GENE/B_LOCATION
is O
the O
exclusive O
target O
of O
the O
human O
T-cell O
lymphotropic O
virus O
type O
I O
oncoprotein B_GENE/B_DISEASE
Tax I_GENE/I_DISEASE
. O

The O
intrinsic O
histone O
acetyltransferase O
activity O
of O
p300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
dispensable O
for O
activation O
of O
the O
IL-2 B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
, O
and O
the O
N-terminal B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
743 B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
residues B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contain O
the O
minimal O
structural O
requirements O
for O
synergistic O
transactivation O
of O
the O
CD28RE-TRE B_GENE/B_LOCATION
, O
the O
IL-2 B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
, O
and O
endogenous O
IL-2 B_GENE
gene I_GENE
expression O
. O

Mutational O
analysis O
of O
p300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O
differential O
structural O
requirements O
for O
the O
N-terminal O
p300 O
module O
by O
individual O
cis-elements B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
within O
the O
IL-2 B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
. O

These O
findings O
provide O
evidence O
that O
p300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assembles O
at O
the O
IL-2 B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
promoter B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
to O
form O
an O
enhanceosome-like O
signal O
transduction O
target O
that O
is O
centrally O
integrated O
at O
the O
CD28RE-TRE B_LOCATION
element I_LOCATION
of O
the O
IL-2 B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
through O
specific O
protein O
module-targeted O
associations O
in O
activated O
T-cells O
. O

Regulation O
of O
cytokine O
production O
in O
T-cell O
responses O
to O
inhalant O
allergen O
: O
GATA-3 B_GENE/B_PERSON
expression O
distinguishes O
between O
Th1- O
and O
Th2-polarized O
immunity O
. O

Background B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
The O
precise B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
nature I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
allergen-specific B_DISEASE
cytokine I_DISEASE
responses I_DISEASE
in O
atopics B_BIO/B_DISEASE
versus I_BIO/I_DISEASE
non-atopics I_BIO/I_DISEASE
, O
in O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
'Th1 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
polarity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
' O
of O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
non-atopics B_DISEASE/B_BIO
, O
remains O
controversial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
is O
due B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
relative B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
insensitivity I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
cytokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
associated B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
kinetics B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
cytokine B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
production B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
catabolism B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
in O
vitro B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

As O
an O
alternative O
to O
cytokine O
measurement O
, O
this O
study O
focuses O
on O
expression O
of O
the O
transcription B_GENE
factor I_GENE
GATA-3 I_GENE
for O
analysis O
of O
allergen-specific O
th O
cell O
responses O
. O

methods O
: O
cord O
blood O
mononuclear O
cells O
were O
Th1- O
or O
Th2-polarized O
by O
culture O
in O
IL-12- O
or O
IL-4-employing O
established O
methods O
; O
PBMC O
from O
house O
dust O
mite O
( O
HDM O
) O
-sensitive O
atopics O
and O
controls O
were O
stimulated O
overnight O
with O
HDM O
; O
cytokine O
production O
was O
measured O
by O
ELISA O
and O
GATA-3 B_GENE/B_DISEASE
mRNA I_GENE/I_DISEASE
expression O
by O
PCR O
. O

Results O
: O
Cytokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-driven O
Th2 O
polarization O
of O
naive O
T O
cells O
is O
associated O
with O
marked O
upregulation O
of O
GATA-3 B_GENE
expression O
, O
whereas O
a O
reciprocal O
expression O
pattern O
accompanies O
differentiation O
towards O
the O
Th1 O
cytokine O
phenotype O
. O

In O
T O
cells O
from O
HDM O
skin O
prick O
test-positive O
( O
HDM-SPT+/HDM-IgE+ O
) O
volunteers O
, O
overnight O
stimulation O
results O
in O
marked O
upregulation O
of O
GATA-3 B_GENE
expression O
, O
compared O
to O
an O
equally O
marked O
downregulation O
of O
expression O
in O
T O
cells O
from O
SPT-/IgE- O
subjects O
. O

In O
subjects O
who O
are O
HDM-SPT+ O
but O
IgE- O
, O
GATA-3 B_GENE/B_DISEASE
expression O
levels O
remained O
relatively O
stable O
during O
culture O
with O
HDM O
. O

conclusions O
: O
Upregulation O
of O
GATA-3 B_GENE
expression O
in O
PBMC O
is O
a O
hallmark O
of O
the O
early O
phase O
of O
Th2 O
recall O
responses O
to O
specific O
allergen O
in O
atopics O
. O

The O
reciprocal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
expression I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
observed O
in O
HDM-specific B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
recall I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
responses I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
non-atopics B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
provides O
independent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
confirmation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
underlying O
Th1-like B_DISEASE
immunity I_DISEASE
in O
these O
subjects B_PERSON/B_BIO
. O

The O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
neonatal B_MEASURE/B_PERSON
T I_MEASURE/I_PERSON
cells I_MEASURE/I_PERSON
suggest O
that O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
may O
be O
utilized O
for O
monitoring O
the O
progress B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
allergen-specific B_DISEASE
Th1/Th2 I_DISEASE
memory I_DISEASE
development I_DISEASE
during O
early B_DISEASE/B_ORGANISM_FUNCTION
childhood B_DISEASE/I_ORGANISM_FUNCTION
, O
and O
hence O
in O
assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
risk B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O
future B_DISEASE
allergic I_DISEASE
disease I_DISEASE
. O

Copyright B_MEASURE/B_PERSON
2001 I_MEASURE/I_PERSON
S I_MEASURE/I_PERSON
. O
Karger B_PERSON
AG I_PERSON
, O
Basel B_LOCATION/B_ORGANIZATION
. O

The O
heat O
shock O
response O
reduces O
myelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
oligodendrocyte I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
glycoprotein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
-induced O
experimental O
autoimmune O
encephalomyelitis O
in O
mice O
. O

The O
stress O
response O
( O
SR O
) O
can O
block O
inflammatory O
gene O
expression O
by O
preventing O
activation O
of O
transcription B_GENE
factor I_GENE
nuclear I_GENE
factor-kappa I_GENE
B I_GENE
( O
NF-kappaB B_GENE
) O
. O

As O
inflammatory B_DISEASE/B_LOCATION
gene B_DISEASE/I_LOCATION
expression B_DISEASE/I_LOCATION
contributes O
to O
the O
pathogenesis B_DISEASE_ADJECTIVE[DISEASE]
of O
demyelinating O
diseases B_DISEASE/B_LOCATION
, O
we O
tested O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
SR B_GENE/B_DISEASE
on O
the O
progression B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
demyelinating O
disease B_DISEASE
experimental I_DISEASE
autoimmune I_DISEASE
encephalomyelitis I_DISEASE
( O
EAE B_DISEASE/B_LOCATION
) O
. O

EAE O
was O
actively O
induced O
in O
C57BL/6 O
mice O
using O
an O
encephalitogenic O
myelin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oligodendrocyte B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glycoprotein B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MOG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
35-55 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
peptide O
. O

Whole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
body I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hyperthermia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
used O
to O
induce O
a O
heat B_DISEASE
shock I_DISEASE
response I_DISEASE
( O
HSR B_DISEASE/B_PROTEIN[GENE]
) O
in O
immunized O
mice B_SPECIES[BIO]/B_PERSON
2 I_SPECIES[BIO]/I_PERSON
days I_SPECIES[BIO]/I_PERSON
after O
the O
booster B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
MOG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
35-55 B_TIME[MEASURE]/B_LOCATION
) O
peptide B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

The O
HSR B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduced O
the O
incidence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
EAE B_DISEASE
by O
70 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
, O
delayed O
disease B_DISEASE_ADJECTIVE[DISEASE]
onset I_DISEASE_ADJECTIVE[DISEASE]
by O
6 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
, O
and O
attenuated O
disease B_DISEASE
severity I_DISEASE
. O

The O
HSR O
attenuated O
leukocyte O
infiltration O
into O
CNS O
assessed O
by O
quantitation O
of O
perivascular O
infiltrates O
, O
and O
by O
reduced O
staining O
for O
CD4 B_GENE
and O
CD25 B_GENE
immunopositive O
T-cells O
. O

T-cell O
activation O
, O
assessed O
by O
the O
production O
of O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
IFNgamma B_PROTEIN[GENE]/B_LOCATION
) O
in O
response O
to O
MOG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
35-55 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
was O
also O
decreased O
by O
the O
HSR O
. O

The O
HSR O
reduced O
inflammatory O
gene O
expression O
in O
the O
brain O
that O
normally O
occurs O
during O
EAE O
, O
including O
the O
early O
increase O
in O
RANTES B_GENE
( O
regulated B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
on I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
activation I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
normal I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
T-cell I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
expressed I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
secreted I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O
expression O
, O
and O
the O
later O
expression O
of O
the O
inducible O
form O
of O
nitric B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
early O
activation O
of O
transcription B_GENE
factor I_GENE
NF-kappaB I_GENE
was O
also O
blocked O
by O
the O
HSR O
. O

The O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
the O
SR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reduces O
inflammation B_DISEASE/B_BACTERIUM[BIO]
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
the O
clinical B_DISEASE_ADJECTIVE[DISEASE]
severity I_DISEASE_ADJECTIVE[DISEASE]
of O
EAE B_DISEASE/B_LOCATION
opens O
a O
novel B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
therapeutic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
approach I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O
prevention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
autoimmune B_DISEASE
diseases I_DISEASE
. O

In O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
developing O
thymocytes B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

Information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
regarding O
the O
intracellular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
occur O
during O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
T B_DISEASE/B_GENE
cells I_DISEASE/I_GENE
has O
largely O
been O
obtained O
with O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
transgenic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mouse I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
models I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
which O
although O
providing O
invaluable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
information I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
time B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
consuming I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
costly B_DISEASE_ADJECTIVE[DISEASE]
. O

To O
this O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
we O
have O
developed O
a O
novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O
facilitates O
the O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
signal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transduction I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O
T-lymphocyte B_DISEASE/B_ORGANISM_FUNCTION
development I_DISEASE/I_ORGANISM_FUNCTION
. O

This O
approach O
uses O
reporter-plasmids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
the O
detection O
of O
intracellular O
signals O
mediated O
by O
the O
mitogen-activated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O
cyclic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AMP-dependent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Reporter-plasmids B_PERSON/B_GENE
are O
transfected O
into O
thymocytes O
in O
fetal O
thymic O
organ O
culture O
by O
accelerated O
DNA/particle O
bombardment O
( O
gene O
gun O
) O
, O
and O
the O
activation O
of O
a O
signaling O
pathway O
is O
determined O
in O
the O
form O
of O
a O
standard O
luciferase O
assay O
. O

importantly O
, O
this O
powerful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
technique I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
preserves O
the O
structural B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
integrity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
thymus B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
, O
and O
will O
provide O
an O
invaluable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tool I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
study O
how O
thymocytes O
respond O
to O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
environmental B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimuli B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encountered O
during O
differentiation B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
within O
the O
thymic B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
milieu I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O

Thus O
, O
this O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
allows O
for O
the O
monitoring B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
signals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
occur O
in O
a O
biological B_MEASURE/B_BIO
time B_MEASURE/I_BIO
frame B_MEASURE/I_BIO
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
during O
differentiation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
within O
the O
natural B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
environment I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
differentiating O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Core-binding B_GENE
factor I_GENE
beta I_GENE
( O
CBFbeta B_GENE
) O
, O
but O
not O
CBFbeta-smooth B_GENE
muscle I_GENE
myosin I_GENE
heavy I_GENE
chain I_GENE
, O
rescues O
definitive O
hematopoiesis O
in O
CBFbeta B_GENE
-deficient O
embryonic O
stem O
cells O
. O

Core-binding B_PROTEIN[GENE]
factor I_PROTEIN[GENE]
beta I_PROTEIN[GENE]
( O
CBFbeta B_GENE/B_DISEASE
) O
is O
the O
non-DNA-binding B_GENE/B_MEASURE
subunit I_GENE/I_MEASURE
of O
the O
heterodimeric B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
CBFs I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Genes B_GENE/B_DISEASE
encoding I_GENE/I_DISEASE
CBFbeta I_GENE/I_DISEASE
( O
CBFB B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
and O
one O
of O
the O
DNA-binding B_GENE/B_NUMBER[MEASURE]
CBFalpha I_GENE/I_NUMBER[MEASURE]
subunits I_GENE/I_NUMBER[MEASURE]
, I_GENE/I_NUMBER[MEASURE]
Runx1 I_GENE/I_NUMBER[MEASURE]
( O
also O
known O
as O
CBFalpha2 B_GENE/B_DISEASE
, O
AML1 B_GENE
, O
and O
PEBP2alphaB B_GENE/B_DISEASE
) O
, O
are O
required O
for O
normal O
hematopoiesis O
and O
are O
also O
frequent O
targets O
of O
chromosomal O
translocations O
in O
acute O
leukemias O
in O
humans O
. O

Homozygous O
disruption O
of O
either O
the O
Runx1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Cbfb I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
mice O
results O
in O
embryonic O
lethality O
at O
midgestation O
due O
to O
hemorrhaging O
in O
the O
central O
nervous O
system O
, O
and O
severely O
impairs O
fetal O
liver O
hematopoiesis O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
that O
Cbfb-deficient B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mouse B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
embryonic B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stem B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
es B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
can O
differentiate O
into O
primitive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
erythroid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
colonies I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
but O
are O
impaired O
in O
their O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
produce O
definitive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
erythroid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
and O
myeloid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
colonies I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
mimicking O
the O
in O
vivo B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defect B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

definitive O
hematopoiesis O
is O
restored O
by O
ectopic O
expression O
of O
full-length B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Cbfb I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transgenes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
well O
as O
by O
a O
transgene O
encoding O
only O
the O
heterodimerization B_GENE/B_LOCATION
domain I_GENE/I_LOCATION
of O
CBFbeta B_GENE
. O

In O
contrast O
, O
the O
CBFbeta B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
smooth B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
muscle I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
myosin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heavy I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
SMMHC I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fusion I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generated O
by O
the O
inv B_GENE/B_DISEASE
( B_GENE/I_DISEASE
16 B_GENE/I_DISEASE
) B_GENE/I_DISEASE
associated O
with O
acute O
myeloid O
leukemias O
( O
M4Eo O
) O
can O
not O
rescue O
definitive O
hematopoiesis O
by O
Cbfb-deficient O
es O
cells O
. O

sequences O
responsible O
for O
the O
inability O
of O
CBFbeta B_PROTEIN[GENE]/B_DISEASE
-SMMHC O
to O
rescue O
definitive O
hematopoiesis O
reside O
in O
the O
SMMHC B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
portion I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
fusion B_GENE/B_LOCATION
protein I_GENE/I_LOCATION
. O

Results O
also O
show O
that O
the O
CBFbeta-SMMHC B_GENE
fusion I_GENE
protein I_GENE
transdominantly O
inhibits O
definitive O
hematopoiesis O
, O
but O
not O
to O
the O
same O
extent O
as O
homozygous O
loss O
of O
Runx1 B_GENE
or O
Cbfb B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CBFbeta-SMMHC B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preferentially O
inhibits O
the O
differentiation O
of O
myeloid O
lineage O
cells O
, O
while O
increasing O
the O
number O
of O
blastlike O
cells O
in O
culture O
. O

The O
latency O
pattern O
of O
Epstein-Barr O
virus O
infection O
and O
viral O
IL-10 B_GENE
expression O
in O
cutaneous O
natural O
killer/T-cell O
lymphomas O
. O

The O
nasal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
extranodal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
natural B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
killer B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O
T B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
NK/T B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
-cell B_DISEASE
lymphoma I_DISEASE
is O
usually O
associated O
with O
latent B_DISEASE/B_VIRUS[BIO]
Epstein-Barr B_DISEASE/I_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
( O
EBV B_VIRUS[BIO]/B_DISEASE
) O
infection B_DISEASE
. O

In O
order B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
elucidate O
the O
EBV B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
examined O
eight B_PERSON
patients I_PERSON
with O
cutaneous B_DISEASE/B_GENE
EBV-related I_DISEASE/I_GENE
NK/T-cell I_DISEASE/I_GENE
lymphomas I_DISEASE/I_GENE
, O
including O
six B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
with O
a O
NK-cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phenotype B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
two B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
with O
a O
T-cell B_DISEASE/B_GENE
phenotype I_DISEASE/I_GENE
. O

The O
implication O
of O
EBV O
in O
the O
skin O
lesions O
was O
determined O
by O
the O
presence O
of O
EBV-DNA B_VIRUS[BIO]/B_GENE
, O
EBV-encoded B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
nuclear B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
RNA B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
EBER B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
a O
clonality O
of O
EBV-DNA B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
fragments I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
containing O
the O
terminal B_GENE/B_DISEASE
repeats I_GENE/I_DISEASE
. O

Transcripts O
of O
EBV-encoded B_DISEASE/B_BIO
genes I_DISEASE/I_BIO
were O
screened O
by O
reverse O
transcription- O
polymerase O
chain O
reaction O
( O
RT-PCR O
) O
, O
and O
confirmed O
by O
Southern O
blot O
hybridization O
. O

The O
expression O
of O
EBV-related B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigens I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
examined O
by O
immunostaining O
using O
paraffin-embedded O
tissue O
sections O
and O
cell O
pellets O
of O
EBV-positive O
cell O
lines O
. O

Our O
study O
demonstrated O
that O
all O
samples O
from O
the O
patients O
contained O
EBV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigen I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
EBNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
was O
transcribed O
using O
the O
Q B_GENE
promoter I_GENE
, O
whereas O
both O
the O
Q B_PROTEIN[GENE]/B_LOCATION
promoter I_PROTEIN[GENE]/I_LOCATION
and O
another O
upstream B_GENE
promoter I_GENE
( O
Cp/Wp B_PROTEIN[GENE]
) O
were O
used O
in O
EBV-positive O
cell O
lines O
, O
B95.8 O
, O
Raji O
and O
Jiyoye O
. O

Latent B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LMP-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
detected O
in O
seven O
of O
eight O
patients O
and O
all O
cell O
lines O
, O
whereas O
EBNA-2 B_GENE/B_PERSON
transcripts I_GENE/I_PERSON
were O
found O
only O
in O
the O
cell O
lines O
. O

Immunostaining O
showed O
no O
LMP-1 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
EBNA-2 I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ZEBRA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antigens I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
paraffin-embedded O
tissue O
sections O
, O
although O
they O
were O
positive O
in O
the O
cell O
line O
cells O
. O

Latent B_GENE/B_PERSON
BHRF1 I_GENE/I_PERSON
transcripts I_GENE/I_PERSON
encoding O
bcl-2 B_GENE/B_VIRUS[BIO]
homologue B_GENE/I_VIRUS[BIO]
and O
BCRF1 B_GENE/B_BIO
transcripts I_GENE/I_BIO
encoding O
viral B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interleukin I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vIL I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-10 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
detected O
in O
one O
and O
two O
of O
eight O
patients O
, O
respectively O
. O

A O
patient B_PERSON/B_BIO
with O
NK-cell B_DISEASE
lymphoma I_DISEASE
expressing O
both O
transcripts B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
died O
of O
rapid B_DISEASE_ADJECTIVE[DISEASE]
progression I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
illness B_DISEASE
. O

Our O
results O
indicate O
that O
the O
restricted O
expression O
of O
the O
latency-associated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
EBV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
production O
of O
vIL-10 B_GENE
and I_GENE
bcl-2 I_GENE
homologue I_GENE
may O
favour O
tumour O
growth O
, O
evading O
the O
host O
immune O
surveillance O
. O

Copyright B_ENT/B_LOCATION
2001 I_ENT/I_LOCATION
Cancer I_ENT/I_LOCATION
Research I_ENT/I_LOCATION
Campaign I_ENT/I_LOCATION
. O

Oxidized B_NUMBER[MEASURE]/B_PERSON
alkyl B_NUMBER[MEASURE]/I_PERSON
phospholipids B_NUMBER[MEASURE]/I_PERSON
are O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
high B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affinity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
peroxisome I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
proliferator-activated I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ligands I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
agonists B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

synthetic B_NUMBER[MEASURE]/B_GENE
high I_NUMBER[MEASURE]/I_GENE
affinity I_NUMBER[MEASURE]/I_GENE
peroxisome I_NUMBER[MEASURE]/I_GENE
proliferator-activated O
receptor B_GENE
( O
PPAR B_LOCATION/B_ORGANIZATION
) O
agonists B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
known O
, O
but O
biologic B_NUMBER[MEASURE]/B_ORGANIZATION
ligands I_NUMBER[MEASURE]/I_ORGANIZATION
are O
of O
low B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
affinity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Oxidized B_PROTEIN[GENE]
low I_PROTEIN[GENE]
density I_PROTEIN[GENE]
lipoprotein I_PROTEIN[GENE]
( O
oxLDL B_GENE/B_LOCATION
) O
is O
inflammatory O
and O
signals O
through O
PPARs B_GENE
. O

We O
showed O
, O
by O
phospholipase O
A O
( O
1 O
) O
digestion O
, O
that O
PPARgamma O
agonists O
in O
oxLDL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
arise O
from O
the O
small O
pool O
of O
alkyl O
phosphatidylcholines O
in O
LDL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

We O
identified O
an O
abundant O
oxidatively O
fragmented O
alkyl O
phospholipid O
in O
oxLDL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
hexadecyl O
azelaoyl O
phosphatidylcholine O
( O
azPC O
) O
, O
as O
a O
high O
affinity O
ligand O
and O
agonist O
for O
PPARgamma B_GENE/B_LOCATION
. O

[ O
( O
3 O
) O
H O
] O
azPC O
bound O
recombinant B_GENE
PPARgamma I_GENE
with O
an O
affinity O
( O
K O
( O
d O
) O
( O
( O
app O
) O
) O
approximately O
40 O
nm O
) O
that O
was O
equivalent O
to O
rosiglitazone O
( O
BRL49653 O
) O
, O
and O
competition O
with O
rosiglitazone O
showed O
that O
binding O
occurred O
in O
the O
ligand-binding B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pocket B_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

azPC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O
PPRE B_DISEASE/B_GENE
reporter B_DISEASE/I_GENE
gene B_DISEASE/I_GENE
expression B_DISEASE/I_GENE
, O
as O
did O
rosiglitazone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
with O
a O
half-maximal B_MEASURE/B_LOCATION
effect B_MEASURE/I_LOCATION
at O
100 B_TIME[MEASURE]/B_PERSON
nm I_TIME[MEASURE]/I_PERSON
. O

Overexpression O
of O
PPARalpha B_GENE/B_LOCATION
or O
PPARgamma B_GENE
revealed O
that O
azPC O
was O
a O
specific O
PPARgamma O
agonist O
. O

The O
scavenger B_GENE/B_MEASURE
receptor I_GENE/I_MEASURE
CD36 I_GENE/I_MEASURE
is O
encoded O
by O
a O
PPRE-responsive B_GENE
gene I_GENE
, O
and O
azPC O
enhanced O
expression O
of O
CD36 B_GENE
in O
primary O
human O
monocytes O
. O

We O
found O
that O
anti-CD36 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O
azPC O
uptake O
, O
and O
it O
inhibited O
PPRE O
reporter O
induction O
. O

Results O
with O
a O
small O
molecule O
phospholipid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flippase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mimetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
azPC O
acts O
intracellularly O
and O
that O
cellular O
azPC O
accumulation O
was O
efficient O
. O

Thus O
, O
certain O
alkyl O
phospholipid O
oxidation O
products O
in O
oxLDL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
are O
specific O
, O
high O
affinity O
extracellular O
ligands O
and O
agonists O
for O
PPARgamma B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
induce O
PPAR-responsive B_DISEASE/B_GENE
genes B_DISEASE/I_GENE
. O

Regulation O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
MAT2B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
encoding O
the O
regulatory B_PROTEIN[GENE]/B_PERSON
beta I_PROTEIN[GENE]/I_PERSON
subunit I_PROTEIN[GENE]/I_PERSON
of O
methionine B_GENE
adenosyltransferase I_GENE
, O
MAT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
II B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Methionine B_GENE
adenosyltransferase I_GENE
( O
MAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
catalyzes O
the O
biosynthesis O
of O
S-adenosylmethionine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
AdoMet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O
, O
a O
key O
molecule O
in O
transmethylation O
reactions O
and O
polyamine O
biosynthesis O
. O

The O
MAT B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
II I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
isozyme I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
consists O
of O
a O
catalytic B_PROTEIN[GENE]
alpha2 I_PROTEIN[GENE]
and I_PROTEIN[GENE]
a I_PROTEIN[GENE]
regulatory I_PROTEIN[GENE]
beta I_PROTEIN[GENE]
subunit I_PROTEIN[GENE]
. O

Down-regulation O
of O
the O
MAT B_GENE
II I_GENE
beta I_GENE
subunit I_GENE
expression O
causes O
a O
6-10-fold O
increase O
in O
intracellular O
AdoMet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
. O

To O
understand O
the O
mechanism O
by O
which O
the O
beta B_GENE
subunit I_GENE
expression O
is O
regulated O
, O
we O
cloned O
the O
MAT2B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
determined O
its O
organization O
, O
characterized O
its O
5'-flanking B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
elucidated O
the O
in O
vitro O
and O
in O
vivo O
regulation O
of O
its O
promoter B_GENE
. O

transcription O
of O
the O
MAT2B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
initiates O
at O
position O
-203 O
relative O
to O
the O
translation B_PERSON/B_ORGANIZATION
start I_PERSON/I_ORGANIZATION
site I_PERSON/I_ORGANIZATION
. O

Promoter B_PERSON
deletion I_PERSON
analysis I_PERSON
defined O
a O
minimal B_GENE/B_LOCATION
promoter B_GENE/I_LOCATION
between O
positions B_NUMBER[MEASURE]/B_LOCATION
+52 I_NUMBER[MEASURE]/I_LOCATION
and I_NUMBER[MEASURE]/I_LOCATION
+93 I_NUMBER[MEASURE]/I_LOCATION
base O
pairs O
, O
a O
GC-rich B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
region B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

inclusion O
of O
the O
sequences O
between O
-4 O
and O
+52 O
enhanced O
promoter O
activity O
; O
this O
was O
primarily O
because O
of O
an O
Sp1 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
recognition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
site I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O
+9/+15 O
. O

The O
inclusion O
of O
sequences O
up O
to O
position O
-115 O
provided O
full O
activity O
; O
this O
was O
attributed O
to O
a O
TATA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
-32 O
. O

The O
Sp1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O
position O
+9 O
was O
key O
for O
the O
formation O
of O
protein.DNA O
complexes O
. O

mutation O
of O
both O
the O
Sp1 B_GENE/B_LOCATION
site I_GENE/I_LOCATION
at O
+9 O
and O
the O
TATA B_GENE/B_MEASURE
at O
-32 O
reduced O
promoter O
activity O
to O
its O
minimal O
level O
. O

Supershift O
assays O
showed O
no O
effect O
of O
the O
anti-Sp1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
complex O
formation O
, O
whereas O
the O
anti-Sp3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
a O
strong O
effect O
on O
protein.DNA O
complex O
formation O
, O
suggesting O
that O
Sp3 B_GENE
is O
one O
of O
the O
main O
factors O
binding O
to O
this O
Sp1 B_GENE/B_LOCATION
site I_GENE/I_LOCATION
. O

Chromatin O
immunoprecipitation O
assays O
supported O
the O
involvement O
of O
both O
Sp1 B_GENE/B_DISEASE
and O
Sp3 B_GENE
in O
complexes O
formed O
on O
the O
MAT2B B_GENE
promoter I_GENE
. O

The O
data O
show O
that O
the O
5'-untranslated B_GENE
sequences I_GENE
play O
an O
important O
role O
in O
regulating O
the O
MAT2B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
identifies O
the O
Sp1 B_GENE/B_LOCATION
site I_GENE/I_LOCATION
at O
+9 O
as O
a O
potential O
target O
for O
modulating O
MAT2B O
expression O
, O
a O
process O
that O
can O
have O
a O
major O
effect O
on O
intracellular O
AdoMet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
. O

Molecular O
pathogenesis O
of O
influenza O
A O
virus O
infection O
and O
virus-induced O
regulation O
of O
cytokine B_GENE
gene I_GENE
expression O
. O

Despite O
vaccines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
antiviral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
substances I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
influenza I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
still O
causes O
significant B_DISEASE_ADJECTIVE[DISEASE]
morbidity I_DISEASE_ADJECTIVE[DISEASE]
and O
mortality B_DISEASE/B_LOCATION
world I_DISEASE/I_LOCATION
wide O
. O

Better B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
understanding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
influenza B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
virus I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replication I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
pathogenesis B_DISEASE
and O
host B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immune I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
required O
for O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
more O
efficient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
means I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
prevention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
influenza B_DISEASE/B_LOCATION
. O

Influenza B_DISEASE/B_MEASURE
A O
virus B_VIRUS[BIO]/B_DISEASE
, O
which O
replicates O
in O
epithelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
leukocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
regulates O
host B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
translational B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
activates B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
as O
well O
as O
downregulates B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
apoptotic B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Influenza O
A O
virus O
infection O
results O
in O
the O
production O
of O
chemotactic O
( O
RANTES B_GENE/B_LOCATION
, O
MIP-1 B_LOCATION/B_ORGANIZATION
alpha I_LOCATION/I_ORGANIZATION
, O
MCP-1 B_GENE/B_LOCATION
, O
MCP-3 B_GENE
, O
and O
IP-10 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
pro-inflammatory O
( O
IL-1 B_GENE
beta I_GENE
, O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
IL-18 B_GENE
, O
and O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
and O
antiviral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IFN-alpha/beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Cytokine O
gene O
expression O
is O
associated O
with O
the O
activation O
of O
NF-kappa B_GENE
B I_GENE
, O
AP-1 B_GENE
, O
STAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IRF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transducing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
influenza O
A O
virus-infected O
cells O
. O

In O
addition O
of O
upregulating O
cytokine B_GENE
gene I_GENE
expression O
, O
influenza O
A O
virus O
infection O
activates O
caspase-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
is O
involved O
in O
the O
proteolytic O
processing O
of O
proIL-1 B_GENE
beta I_GENE
and O
proIL-18 B_GENE
into O
their O
biologically O
active O
forms O
. O

Influenza O
A O
virus-induced O
IFN-alpha/beta B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
essential O
in O
host O
's O
antiviral O
defence O
by O
activating O
the O
expression O
of O
antiviral B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Mx I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
PKR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oligoadenylate I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthetase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

IFN-alpha/beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O
prolongs O
T O
cell O
survival O
, O
upregulates O
IL-12 O
and O
IL-18 O
receptor O
gene O
expression O
and O
together O
with O
IL-18 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulates O
NK O
and O
T O
cell O
IFN-gamma O
production O
and O
the O
development O
of O
Th1-type O
immune O
response O
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hprt B_GENE
and O
lacI B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
frequency B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
DNA B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
adduct I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
formation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
N-hydroxy-2-acetylaminofluorene-treated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
big I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
Blue I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
rats I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

N-Hydroxy-2-acetylaminofluorene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
N-OH-AAF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
the O
proximate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
carcinogenic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
metabolite I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
powerful B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rat I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
liver I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
carcinogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2-acetylaminofluorene I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
transgenic B_LOCATION/B_DISEASE
Big I_LOCATION/I_DISEASE
Blue I_LOCATION/I_DISEASE
( O
R B_OTHER/B_COLOR
) O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
used O
to O
examine O
the O
relationship B_PERSON/B_MEASURE
between O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutagenicity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
DNA B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adduct I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
formation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
N-OH-AAF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
target B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
liver I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
compared O
with O
that O
in O
nontarget B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
tissues I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Male B_PERSON/B_BIO
rats I_PERSON/I_BIO
were O
given O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
two B_NUMBER[MEASURE]/B_PERSON
, O
or O
four B_NUMBER[MEASURE]/B_PERSON
doses I_NUMBER[MEASURE]/I_PERSON
of O
25 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N-OH-AAF/kg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
body I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
i.p B_TIME[MEASURE]/B_LOCATION
. O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
at O
4-day B_TIME[MEASURE]/B_LOCATION
intervals I_TIME[MEASURE]/I_LOCATION
, O
and O
groups B_ORGANIZATION/B_MEASURE
of O
treated O
and O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
rats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
euthanized O
up O
to O
10 B_NUMBER[MEASURE]/B_ENT
weeks I_NUMBER[MEASURE]/I_ENT
after O
beginning O
the O
dosing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

mutant O
frequencies O
were O
measured O
in O
the O
spleen B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
lymphocyte I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
hprt I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
gene I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
, O
and O
lacI O
mutant O
frequencies O
were O
determined O
in O
the O
liver O
and O
spleen O
lymphocytes O
. O

At O
6 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
after O
beginning O
the O
dosing B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
the O
hprt B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutant B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
frequency B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
spleen B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
from O
the O
four-dose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O
16.5 B_MEASURE
x I_MEASURE
10 I_MEASURE
( O
-6 B_MEASURE
) O
compared O
with O
3.2 B_MEASURE
x O
10 B_MEASURE
( O
-6 O
) O
in O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Also O
at O
6 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
one B_NUMBER[MEASURE]/B_PERSON
, O
two B_NUMBER[MEASURE]/B_PERSON
, O
or O
four B_NUMBER[MEASURE]/B_PERSON
doses I_NUMBER[MEASURE]/I_PERSON
of O
N-OH-AAF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
lacI O
mutant B_MEASURE/B_LOCATION
frequencies B_MEASURE/I_LOCATION
in O
the O
liver B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
of O
97.6 B_MEASURE
, O
155.6 B_MEASURE
, O
and O
406.8 B_MEASURE
x O
10 B_NUMBER[MEASURE]
( O
-6 B_MEASURE
) O
, O
respectively O
, O
compared O
with O
a O
control B_MEASURE
frequency I_MEASURE
of O
25.7 B_TIME[MEASURE]
x O
10 B_NUMBER[MEASURE]
( O
-6 O
) O
; O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
four B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
had O
lacI O
mutant B_MEASURE/B_LOCATION
frequencies B_MEASURE/I_LOCATION
in O
spleen B_BODY_PART_OR_ORGAN_COMPONENT
lymphocytes I_BODY_PART_OR_ORGAN_COMPONENT
of O
55.8 B_TIME[MEASURE]
x O
10 B_NUMBER[MEASURE]
( O
-6 B_MEASURE
) O
compared O
with O
a O
control B_MEASURE/B_LOCATION
frequency I_MEASURE/I_LOCATION
of O
20.4 B_MEASURE
x O
10 B_NUMBER[MEASURE]
( O
-6 B_NUMBER[MEASURE]/B_LOCATION
) O
. O

Additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
rats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
evaluated O
for O
DNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adduct I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
formation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
spleen B_BODY_PART_OR_ORGAN_COMPONENT
lymphocytes I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
marrow I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
by O
( O
32 B_MEASURE
) O
P-postlabeling B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
. O

adduct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
conducted O
1 B_TIME[MEASURE]/B_LOCATION
day I_TIME[MEASURE]/I_LOCATION
after O
one B_NUMBER[MEASURE]/B_DISEASE
, O
two B_NUMBER[MEASURE]/B_PERSON
, O
and O
four B_NUMBER[MEASURE]/B_LOCATION
treatments I_NUMBER[MEASURE]/I_LOCATION
with O
N-OH-AAF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
5 B_NUMBER[MEASURE]/B_ENT
days I_NUMBER[MEASURE]/I_ENT
after O
one B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
9 B_NUMBER[MEASURE]/B_ENT
days I_NUMBER[MEASURE]/I_ENT
after O
two B_NUMBER[MEASURE]/B_PERSON
treatments I_NUMBER[MEASURE]/I_PERSON
. O

N- O
( O
Deoxyguanosin-8-yl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
-2-aminofluorene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
the O
major B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
DNA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
adduct I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
identified O
in O
all O
the O
tissues B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examined O
. O

Adduct B_MEASURE/B_PERSON
concentrations I_MEASURE/I_PERSON
increased O
with O
total B_MEASURE/B_PERSON
dose I_MEASURE/I_PERSON
to O
maximum B_MEASURE
values I_MEASURE
in O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
taken O
1 B_TIME[MEASURE]/B_LOCATION
day B_TIME[MEASURE]/I_LOCATION
after O
two B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
and O
remained O
essentially O
the O
same B_MEASURE/B_LOCATION
after O
four B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
doses B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
taken O
after O
four B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
adduct B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
103 B_MEASURE
, O
28 B_MEASURE
, O
and O
7 B_MEASURE
fmol/microg I_MEASURE
of O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
spleen B_BODY_PART_OR_ORGAN_COMPONENT
lymphocytes I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
marrow I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
respectively O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
the O
extent B_DISEASE/B_MEASURE
of O
both O
DNA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
adduct I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
formation I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
mutant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
correlates I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
the O
organ B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
specificity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
N-OH-AAF B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carcinogenesis B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
rat B_SPECIES[BIO]/B_GENE
. O

Environ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
Mol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
Mutagen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
37 B_MEASURE
: O
195-202 B_MEASURE
, O
2001 B_MEASURE/B_LOCATION
. O

Published O
2001 B_PERSON/B_ENT
Wiley-Liss I_PERSON/I_ENT
, O
Inc B_ORGANIZATION/B_PERSON
. O

expression O
of O
Mad1 B_GENE/B_BIO
in O
T O
cells O
leads O
to O
reduced O
thymic O
cellularity O
and O
impaired O
mitogen-induced O
proliferation O
. O

To O
investigate O
Mad1 B_GENE/B_PERSON
function O
in O
vivo O
, O
transgenic O
mice O
were O
generated O
that O
express O
a O
Mad1 B_GENE
transgene I_GENE
in O
T O
lineage O
cells O
under O
the O
control O
of O
the O
proximal B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
lck I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
promoter I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Thymus B_MEASURE/B_PERSON
size B_MEASURE/I_PERSON
in O
lck-Mad1 B_DISEASE/B_PERSON
transgenic I_DISEASE/I_PERSON
mice I_DISEASE/I_PERSON
is O
drastically O
reduced O
although O
representation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
various B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
thymocyte I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
sub I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
populations I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
appears O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
investigate O
more O
closely O
any O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
Mad1 B_GENE
expression I_GENE
on O
thymocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O
we O
examined O
thymic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
selection I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
MHC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I-restricted O
H-Y-TCR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transgenic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mice I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Mad1 B_GENE
expression I_GENE
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
reduces O
the O
efficiency B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
positive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
selection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Furthermore O
, O
thymocytes O
and O
splenic O
T O
cells O
from O
lck-Mad1 O
transgenic O
mice O
display O
a O
profound O
proliferative O
defect O
in O
response O
to O
activation O
with O
either O
PMA/Ionomycin O
or O
immobilized B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
anti-CD3/CD28 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

This O
proliferative O
defect O
is O
not O
reversed O
by O
addition O
of O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
IL-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
is O
p53-independent O
. O

The O
growth O
inhibition O
caused O
by O
Mad1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O
overcome O
by O
expression O
of O
active B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
c-Myc I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

differential O
requirement O
for O
the O
transcription B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
factor I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
PU.1 I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
generation O
of O
natural O
killer O
cells O
versus O
B O
and O
T O
cells O
. O

PU.1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
a O
member O
of O
the O
Ets B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
required O
for O
the O
development O
of O
various O
lymphoid O
and O
myeloid O
cell O
lineages O
, O
but O
its O
role O
in O
natural O
killer O
( O
NK O
) O
cell O
development O
is O
not O
known O
. O

The O
study O
shows O
that O
PU.1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
expressed O
in O
NK O
cells O
and O
that O
, O
on O
cell O
transfer O
into O
alymphoid O
Rag2/gammac O
( O
-/- O
) O
mice O
, O
hematopoietic O
progenitors O
of O
PU.1 O
( O
-/- O
) O
fetal O
liver O
cells O
could O
generate O
functional O
NK O
cells O
but O
not O
B O
or O
T O
cells O
. O

Nevertheless O
, O
the O
numbers B_MEASURE
of O
bone B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
marrow I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
NK I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
precursors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
splenic B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
mature O
NK B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
reduced O
compared O
to O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Moreover O
, O
PU.1 O
( O
-/- O
) O
NK O
cells O
displayed O
reduced O
expression O
of O
the O
receptors O
for O
stem B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
interleukin B_GENE
( I_GENE
IL I_GENE
) I_GENE
-7 I_GENE
, O
suggesting O
a O
nonredundant O
role O
for O
PU.1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
regulating O
the O
expression O
of O
these O
cytokine B_GENE
receptor I_GENE
genes I_GENE
during O
NK O
cell O
development O
. O

PU.1 O
( O
-/- O
) O
NK O
cells O
also O
showed O
defective O
expression O
of O
inhibitory O
and O
activating O
members O
of O
the O
Ly49 B_GENE/B_PERSON
family I_GENE/I_PERSON
and O
failed O
to O
proliferate O
in O
response O
to O
IL-2 B_GENE
and O
IL-12 B_GENE
. O

Thus O
, O
despite O
the O
less O
stringent O
requirement O
for O
PU.1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
NK O
cell O
development O
compared O
to O
B O
and O
T O
cells O
, O
PU.1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulates O
NK O
cell O
differentiation O
and O
homeostasis O
. O

Benzene-extracted O
components O
are O
important O
for O
the O
major O
activity O
of O
diesel O
exhaust O
particles O
: O
effect O
on O
interleukin-8 B_GENE
gene I_GENE
expression O
in O
human O
bronchial O
epithelial O
cells O
. O

epidemiologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
suggest O
that O
diesel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exhaust I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
DEPs B_DISEASE
) O
may O
be O
related O
to O
increasing O
respiratory B_DISEASE_ADJECTIVE[DISEASE]
mortality I_DISEASE_ADJECTIVE[DISEASE]
and O
morbidity B_DISEASE
. O

We O
have O
shown O
that O
DEPs O
augmented O
the O
production O
of O
inflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
human O
airway O
epithelial O
cells O
in O
vitro O
. O

To O
better O
understand O
the O
mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
their O
proinflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
studied O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
several B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
components I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
extracted O
from O
DEPs B_DISEASE/B_BIO
on O
interleukin B_GENE
( O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
-8 O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
human B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
bronchial I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
epithelial I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
line I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
BEAS-2B I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
normal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_NUMBER[MEASURE]
human I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_NUMBER[MEASURE]
airway I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_NUMBER[MEASURE]
epithelial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_NUMBER[MEASURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_NUMBER[MEASURE]
obtained O
from O
very O
peripheral B_PERSON/B_TIME[MEASURE]
Airways B_PERSON/I_TIME[MEASURE]
by O
an O
ultrathin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bronchoscope I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
used O
several O
agents O
active O
on O
signal O
transduction O
pathways O
in O
cytokine O
expression O
, O
such O
as O
the O
protein O
kinase O
C O
inhibitor O
staurosporin O
, O
antioxidant O
agents O
including O
N-acetyl O
cysteine O
( O
NAC O
) O
and O
pyrrolidine O
dithiocarbamate O
( O
PDTC O
) O
, O
and O
p38 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MAPK B_GENE/B_LOCATION
) O
inhibitor O
SB203580 O
. O

Benzene-extracted O
components O
showed O
effects O
mimicking O
DEPs O
on O
IL-8 O
gene O
expression O
, O
release O
of O
several O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
IL-8 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
; O
granulocyte B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
macrophage I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
and O
regulated O
on O
activation O
, O
normal O
T O
cells O
expressed O
and O
secreted O
) O
and O
nuclear O
factor O
( O
NF O
) O
-kappa O
B O
activation O
. O

We O
also O
found O
that O
NAC O
, O
PDTC O
, O
and O
SB203580 O
suppressed O
the O
activities O
of O
DEPs O
and O
their O
benzene O
extracts O
, O
suggesting O
the O
roles O
of O
oxidants-mediated O
NF-kappa O
B O
activation O
and O
p38MAPK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathways O
. O

Finally O
, O
benzo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
[ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
a O
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pyrene I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
important B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
in O
the O
benzene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
component I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
replicated O
the O
activities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
shown O
by O
DEPs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
nuclear B_GENE/B_LOCATION
receptor I_GENE/I_LOCATION
PPAR I_GENE/I_LOCATION
gamma I_GENE/I_LOCATION
is O
expressed O
by O
mouse O
T O
lymphocytes O
and O
PPAR O
gamma O
agonists O
induce O
apoptosis O
. O

Peroxisome B_GENE/B_LOCATION
proliferator-activated I_GENE/I_LOCATION
receptor I_GENE/I_LOCATION
( I_GENE/I_LOCATION
PPAR I_GENE/I_LOCATION
) I_GENE/I_LOCATION
-gamma I_GENE/I_LOCATION
is O
a O
nuclear B_GENE
hormone I_GENE
receptor I_GENE
that O
serves O
as O
a O
trans O
factor O
to O
regulate O
lipid O
metabolism O
. O

intense O
interest O
is O
focused O
on O
PPAR-gamma B_GENE
and O
its O
ligands O
owing O
to O
its O
putative O
role O
in O
adipocyte O
differentiation O
. O

Little O
is O
known O
, O
however O
, O
about O
the O
functions O
of O
PPAR-gamma B_GENE
in O
the O
immune O
system O
, O
especially O
in O
T O
lymphocytes O
. O

We O
demonstrate O
that O
both O
naive O
and O
activated O
ovalbumin-specific O
T O
cells O
from O
DO11.10-transgenic O
mice O
express O
PPAR-gamma B_GENE
mRNA O
and O
protein O
. O

In O
order O
to O
determine O
the O
function O
of O
PPAR-gamma B_GENE
, O
T O
cells O
were O
stimulated O
with O
phorbol O
12-myristate O
13-acetate O
and O
ionomycin O
or O
antigen O
and O
antigen-presenting O
cells O
. O

Simultaneous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
PPAR-gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligands I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
e.g B_MEASURE/B_DISEASE
. O
15-deoxy-Delta B_GENE/B_MEASURE
( O
12 B_MEASURE
, O
14 B_MEASURE
) O
-prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
J B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O
2 B_NUMBER[MEASURE]
) O
, O
troglitazone B_MEASURE
) O
showed O
drastic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
proliferation B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
significant B_DISEASE_ADJECTIVE[DISEASE]
decreases I_DISEASE_ADJECTIVE[DISEASE]
in O
cell B_DISEASE_ADJECTIVE[DISEASE]
viability I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
decrease O
in O
cell O
viability O
was O
due O
to O
apoptosis O
of O
the O
T O
lymphocytes O
, O
and O
occurred O
only O
when O
cells O
were O
treated O
with O
PPAR-gamma B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
not O
PPAR-alpha O
agonists O
, O
revealing O
specificity O
of O
this O
response O
for O
PPAR-gamma B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
PPAR-gamma B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
agonists B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
play O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
regulating O
T B_OTHER/B_GENE
cell-mediated O
immune B_DISEASE_ADJECTIVE[DISEASE]
responses I_DISEASE_ADJECTIVE[DISEASE]
by O
inducing O
apoptosis B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

T B_DISEASE/B_GENE
cell B_DISEASE/I_GENE
death B_DISEASE/I_GENE
via O
PPAR-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ligation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O
act O
as O
a O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anti-inflammatory I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
signal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
immune B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
ligands B_PERSON/B_LOCATION
could O
possibly O
be O
used O
to O
control O
disorders B_DISEASE/B_LOCATION
in O
which O
excessive B_DISEASE
inflammation I_DISEASE
occurs O
. O

suppression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
lung B_DISEASE/B_GENE
inflammation I_DISEASE/I_GENE
in O
rats B_BIO/B_DISEASE
by O
prevention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
NF-kappaB B_DISEASE/B_GENE
activation I_DISEASE/I_GENE
in O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

activation O
of O
NF-kappaB B_GENE
and O
production O
of O
NF-kappaB B_GENE
-dependent O
chemokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
thought O
to O
be O
involved O
in O
the O
pathogenesis O
of O
neutrophilic O
lung O
inflammation O
. O

Calpain-1 O
inhibitor O
( O
CI-1 O
) O
blocks O
activation O
of O
NF-kappaB B_GENE
by O
preventing O
proteolysis O
of O
the O
inhibitory O
protein O
IkappaB-alpha B_GENE
by O
the O
ubiquitin/proteasome O
pathway O
. O

We O
hypothesized O
that O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
proteasome B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
CI-1 O
would O
block O
NF-kappaB B_DISEASE
activation I_DISEASE
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
after O
intraperitoneal B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
i.p B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O
) O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
bacterial B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lipopolysaccharide B_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LPS B_LOCATION/B_ORGANIZATION
) O
, O
and O
that O
NF-kappaB B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
inhibition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
would O
be O
associated O
with O
suppression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
chemokine B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
attenuation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
neutrophilic B_DISEASE
alveolitis I_DISEASE
. O

We O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
a O
single B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
i.p B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
CI-1 O
( O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg/kg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
two B_MEASURE/B_ENT
hours I_MEASURE/I_ENT
prior I_MEASURE/I_ENT
to O
i.p B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
7 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg/kg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
. O

Treatment O
with O
Cl-1 O
prevented O
degradation O
of O
IkappaB-alpha B_GENE
and O
activation O
of O
NF-kappaB B_GENE
in O
the O
liver O
in O
response O
to O
LPS O
; O
however O
, O
Cl-1 O
treatment O
had O
no O
detected O
effect O
on O
NF-kappaB O
activation O
in O
lung O
tissue O
. O

CI-1 O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prior I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resulted O
in O
40 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
% B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
lower B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
MIP-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
concentration B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
lung B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lavage I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
fluid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
compared O
to O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
with O
vehicle B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prior I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
502 B_MEASURE/B_LOCATION
+/- I_MEASURE/I_LOCATION
112 I_MEASURE/I_LOCATION
pg/ml I_MEASURE/I_LOCATION
vs I_MEASURE/I_LOCATION
. O
859 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+/-144 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pg/ml I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
P B_MEASURE
< I_MEASURE
0.05 I_MEASURE
) O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
CI-1 O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
substantially O
inhibited O
LPS-induced B_DISEASE
neutrophilic I_DISEASE
alveolitis I_DISEASE
( O
2.7+ B_MEASURE
/- O
1.2 B_MEASURE
x O
10 B_MEASURE
( O
5 B_MEASURE
) O
vs B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O
43.7 B_TIME[MEASURE]
+/- O
12.2 B_MEASURE
x O
10 B_NUMBER[MEASURE]
( O
5 B_NUMBER[MEASURE]
) O
lung B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lavage I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neutrophils I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
P B_MEASURE
< I_MEASURE
0.01 I_MEASURE
) O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
NF-kappaB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibition I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
can O
alter O
lung B_DISEASE_ADJECTIVE[DISEASE]
inflammation I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
systemic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
LPS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
suggest O
that O
a O
liver-lung O
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contributes O
to O
the O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
lung B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Notch1 B_GENE
regulates O
maturation O
of O
CD4+ O
and O
CD8+ O
thymocytes O
by O
modulating O
TCR O
signal O
strength O
. O

Notch B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulates O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
fate I_DISEASE_ADJECTIVE[DISEASE]
decisions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
lineages B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
. O

We O
demonstrate O
in O
this O
report O
that O
retroviral O
expression O
of O
activated O
Notch1 B_GENE
in O
mouse O
thymocytes O
abrogates O
differentiation O
of O
immature O
CD4+CD8+ O
thymocytes O
into O
both O
CD4 O
and O
CD8 O
mature O
single-positive O
T O
cells O
. O

The O
ability O
of O
Notch1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
inhibit O
T O
cell O
development O
was O
observed O
in O
vitro O
and O
in O
vivo O
with O
both O
normal O
and O
TCR O
transgenic O
thymocytes O
. O

Notch1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-mediated O
developmental O
arrest O
was O
dose O
dependent O
and O
was O
associated O
with O
impaired O
thymocyte O
responses O
to O
TCR O
stimulation O
. O

Notch1 B_PERSON/B_PROTEIN[GENE]
also O
inhibited O
TCR-mediated O
signaling O
in O
Jurkat O
T O
cells O
. O

These O
data O
indicate O
that O
constitutively O
active O
Notch1 B_GENE/B_LOCATION
abrogates O
CD4+ O
and O
CD8+ O
maturation O
by O
interfering O
with O
TCR O
signal O
strength O
and O
provide O
an O
explanation O
for O
the O
physiological O
regulation O
of O
notch O
expression O
during O
thymocyte O
development O
. O

expression O
of O
SART3 B_GENE
antigen I_GENE
and O
induction O
of O
CTLs O
by O
SART3-derived O
peptides O
in O
breast O
cancer O
patients O
. O

We O
recently O
reported O
the O
SART3 B_BIO/B_DISEASE
tumour-rejection I_BIO/I_DISEASE
antigen I_BIO/I_DISEASE
as O
possessing O
tumour O
epitopes O
capable O
of O
inducing O
HLA-class O
I-restricted O
cytotoxic O
T O
lymphocytes O
( O
CTLs O
) O
. O

This O
study O
investigated O
expression O
of O
the O
SART3 B_GENE
antigen I_GENE
in O
breast O
cancer O
to O
explore O
an O
appropriate O
molecule O
for O
use O
in O
specific O
immunotherapy O
of O
breast O
cancer O
patients O
. O

The O
SART3 B_GENE
antigen I_GENE
was O
detected O
in O
all O
of O
the O
breast O
cancer O
cell O
lines O
tested O
, O
30 O
of O
40 O
( O
75 O
% O
) O
breast O
cancer O
tissue O
samples O
, O
and O
0 O
of O
3 O
non-tumourous O
breast O
tissue O
samples O
. O

SART3 O
derived O
peptides O
at O
positions B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
109-118 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
315-323 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
HLA-A24 O
restricted O
CTLs O
that O
reacted O
to O
breast O
cancer O
cells O
from O
the O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
of O
breast O
cancer O
patients O
. O

Therefore O
, O
the O
SART3 B_GENE
antigen I_GENE
and O
its O
peptides O
could O
be O
an O
appropriate O
molecule O
for O
use O
in O
specific O
immunotherapy O
of O
the O
majority O
of O
HLA-A24-positive O
breast O
cancer O
patients O
. O

Autostimulation O
of O
the O
Epstein-Barr O
virus O
BRLF1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
mediated O
through O
consensus O
Sp1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Sp3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

As O
an O
essential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
step B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
in O
the O
lytic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cascade B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
Rta B_BIO/B_GENE
homologues I_BIO/I_GENE
of O
gammaherpesviruses B_BACTERIUM[BIO]/B_GENE
all O
activate O
their O
own B_GENE
expression I_GENE
. O

consistent O
with O
this O
biologic O
function O
, O
the O
Epstein-Barr O
virus O
( O
EBV O
) O
Rta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
powerfully O
stimulates O
the O
promoter B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
its O
own O
gene O
, O
Rp B_GENE/B_DISEASE
, O
in O
EBV-positive O
B O
cells O
in O
transient-transfection O
reporter-based O
assays O
. O

We O
analyzed O
the O
activity O
of O
RpCAT B_GENE/B_BACTERIUM[BIO]
in O
response O
to O
Rta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
deletional O
and O
site-directed O
mutagenesis O
. O

Two O
cognate B_LOCATION/B_BIO
Sp1 I_LOCATION/I_BIO
binding I_LOCATION/I_BIO
sites I_LOCATION/I_BIO
located O
at O
-279 O
and O
-45 O
relative O
to O
the O
transcriptional B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
start I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
site I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
proved O
crucial O
for O
Rta-mediated O
activation O
. O

Previously O
described O
binding O
sites O
for O
the O
cellular O
transcription B_GENE/B_BIO
factor I_GENE/I_BIO
Zif268 I_GENE/I_BIO
and O
the O
viral B_GENE/B_BIO
transactivator I_GENE/I_BIO
ZEBRA I_GENE/I_BIO
were O
found O
to O
be O
dispensable O
for O
activation O
of O
RpCAT B_GENE/B_BACTERIUM[BIO]
by O
Rta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

gel O
shift O
analysis O
, O
using O
extracts O
of O
B O
cells O
in O
latency O
or O
induced O
into O
the O
lytic O
cycle O
, O
identified O
Sp1 B_GENE/B_LOCATION
and O
Sp3 B_GENE
as O
the O
predominant O
cellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bound O
to O
Rp B_PROTEIN[GENE]/B_DISEASE
near O
-45 O
. O

During O
the O
lytic O
cycle O
, O
ZEBRA B_PERSON/B_GENE
bound O
Rp B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
near O
the O
Sp1/Sp3 B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
site B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
binding O
of O
Sp1 B_GENE/B_LOCATION
and O
Sp3 B_GENE/B_DISEASE
to O
Rp B_GENE/B_DISEASE
correlated O
with O
the O
reporter O
activities O
in O
the O
mutagenesis O
study O
, O
establishing O
a O
direct O
link O
between O
transcriptional O
activation O
of O
Rp B_GENE/B_DISEASE
by O
Rta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
DNA O
binding O
by O
Sp1 B_GENE/B_LOCATION
and/or O
Sp3 B_GENE/B_LOCATION
. O

The O
relative O
abundance O
or O
functional O
state O
of O
the O
cellular O
Sp1 B_GENE/B_LOCATION
and O
Sp3 B_GENE
transcription I_GENE
factors I_GENE
may O
be O
altered O
in O
response O
to O
stimuli O
that O
induce O
the O
BRLF1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
thereby O
contribute O
to O
the O
activation O
of O
the O
viral O
lytic O
cycle O
. O

Gene O
transfer O
of O
antisense O
hypoxia B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
inducible I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhances O
the O
therapeutic O
efficacy O
of O
cancer O
immunotherapy O
. O

Solid B_DISEASE/B_PERSON
tumors I_DISEASE/I_PERSON
meet O
their O
demands B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
nascent B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vessels B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
increased O
glycolysis B_ORGAN_OR_TISSUE_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE
, O
to O
combat O
hypoxia B_DISEASE
, O
by O
activating O
multiple B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
involved O
in O
angiogenesis B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
glucose B_DISEASE
metabolism I_DISEASE
. O

Hypoxia B_GENE/B_MEASURE
inducible I_GENE/I_MEASURE
factor-1 I_GENE/I_MEASURE
( O
HIF-1 B_GENE/B_DISEASE
) O
is O
a O
constitutively O
expressed O
basic O
helix-loop-helix B_GENE
transcription I_GENE
factor I_GENE
, O
formed O
by O
the O
assembly O
of O
HIF-1alpha B_GENE
and O
HIF-1beta B_GENE
( O
Arnt B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
, O
that O
is O
stablized O
in O
response O
to O
hypoxia O
, O
and O
rapidly O
degraded O
under O
normoxic O
conditions O
. O

It O
activates O
the O
transcription B_GENE
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
important I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
maintaining O
oxygen B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
homeostasis B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

Here O
, O
we O
demonstrate O
that O
engineered O
down-regulation O
of O
HIF-1alpha B_GENE
by O
intratumoral O
gene O
transfer O
of O
an O
antisense B_GENE
HIF-1alpha I_GENE
plasmid I_GENE
leads O
to O
the O
down-regulation O
of O
VEGF B_GENE/B_DISEASE
, O
and O
decreased O
tumor O
microvessel O
density O
. O

antisense B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
HIF-1alpha I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
monotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
resulted O
in O
the O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
permanent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rejection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
0.1 B_MEASURE
cm I_MEASURE
in O
diameter B_MEASURE/B_LOCATION
) O
EL-4 O
tumors B_DISEASE
, O
which O
is O
unusual B_DISEASE_ADJECTIVE[DISEASE]
for O
an O
anti-angiogenic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
agent I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
where O
transient B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suppression B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
tumor B_DISEASE
growth I_DISEASE
is O
the O
norm B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
induced O
NK B_DISEASE_ADJECTIVE[DISEASE]
cell I_DISEASE_ADJECTIVE[DISEASE]
-dependent I_DISEASE_ADJECTIVE[DISEASE]
rejection I_DISEASE_ADJECTIVE[DISEASE]
of O
tumors B_DISEASE
, O
but O
failed O
to O
stimulate O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
-mediated O
anti-tumor B_DISEASE
immunity I_DISEASE
, O
and O
synergized O
with O
B7-1-mediated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
immunotherapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
cause O
the O
NK B_DISEASE_ADJECTIVE[DISEASE]
cell I_DISEASE_ADJECTIVE[DISEASE]
and O
CD8 B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
T I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cell I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
-dependent I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rejection I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
larger B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
EL-4 O
tumors B_DISEASE
( O
0.4 B_MEASURE
cm I_MEASURE
in O
diameter B_MEASURE/B_LOCATION
) O
that O
were O
refractory B_DISEASE_ADJECTIVE[DISEASE]
to O
monotherapies B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

mice B_BIO/B_PERSON
cured O
of O
their O
tumors B_DISEASE
by O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
resisted O
a O
rechallenge B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
with O
parental B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tumor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
cells I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
indicating O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antitumor I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
immunity I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
had O
been O
achieved O
. O

In O
summary O
, O
whilst O
intensive O
investigations O
are O
in O
progress O
to O
target O
the O
many O
HIF-1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
effectors O
, O
the O
results O
herein O
indicate O
that O
blocking O
hypoxia-inducible O
pathways O
and O
enhancing O
NK-mediated O
antitumor O
immunity O
by O
targeting O
HIF-1 B_GENE/B_DISEASE
itself O
may O
be O
advantageous O
, O
especially O
when O
combined O
with O
cancer O
immunotherapy O
. O

Runx2 B_GENE
: O
a O
novel O
oncogenic O
effector O
revealed O
by O
in O
vivo O
complementation O
and O
retroviral O
tagging O
. O

The O
Runx2 B_GENE
( O
Cbfa1 B_GENE
, O
Pebp2alphaA B_GENE/B_DISEASE
, O
Aml3 B_GENE
) O
gene O
was O
previously O
identified O
as O
a O
frequent O
target O
for O
transcriptional O
activation O
by O
proviral O
insertion O
in O
T-cell O
lymphomas O
of O
CD2-MYC O
transgenic O
mice O
. O

We O
have O
recently O
shown O
that O
over-expression O
of O
the O
full-length O
, O
most O
highly O
expressed O
Runx2 B_GENE
isoform O
in O
the O
thymus O
perturbs O
T-cell O
development O
, O
leads O
to O
development O
of O
spontaneous O
lymphomas O
at O
low O
frequency O
and O
is O
strongly O
synergistic O
with O
Myc B_DISEASE/B_SPECIES[BIO]
. O

To O
gain O
further O
insight O
into O
the O
relationship O
of O
Runx2 B_GENE
to O
other O
lymphomagenic O
pathways O
, O
we O
tested O
the O
effect O
of O
combining O
the O
CD2-Runx2 B_GENE
transgene I_GENE
either O
with O
a O
Pim1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transgene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
E B_GENE
( I_GENE
mu I_GENE
) I_GENE
-Pim1 I_GENE
) O
or O
with O
the O
p53 B_GENE/B_MEASURE
null O
genotype O
, O
as O
each O
of O
these O
displays O
independent O
synergy O
with O
Myc B_GENE/B_SPECIES[BIO]
. O

In O
both O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
observed O
synergistic B_DISEASE
tumour I_DISEASE
development I_DISEASE
. O

However O
, O
Runx2 B_GENE/B_MEASURE
appeared O
to O
have O
a O
dominant O
effect O
on O
the O
tumour O
phenotype O
in O
each O
case O
, O
with O
most O
tumours O
conforming O
to O
the O
CD3 O
( O
+ O
) O
, O
CD8 O
( O
+ O
) O
, O
CD4 O
( O
+/- O
) O
phenotype O
seen O
in O
CD2-Runx2 O
mice O
. O

Neonatal B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
CD2-Runx2 B_PERSON/B_SPECIES[BIO]
mice I_PERSON/I_SPECIES[BIO]
with O
Moloney B_VIRUS[BIO]/B_LOCATION
murine I_VIRUS[BIO]/I_LOCATION
leukaemia I_VIRUS[BIO]/I_LOCATION
virus I_VIRUS[BIO]/I_LOCATION
( O
Moloney B_VIRUS[BIO]/B_LOCATION
MLV B_VIRUS[BIO]/I_LOCATION
) O
also O
led O
to O
a O
dramatic B_DISEASE_ADJECTIVE[DISEASE]
acceleration I_DISEASE_ADJECTIVE[DISEASE]
of O
tumour B_DISEASE/B_ORGANISM_FUNCTION
onset I_DISEASE/I_ORGANISM_FUNCTION
. O

Analysis O
of O
known O
Moloney B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
MLV I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
target I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
these O
lymphomas O
showed O
a O
high O
frequency O
of O
rearrangement O
at O
c-Myc B_GENE/B_DISEASE
or O
N-Myc B_GENE
( O
82 O
% O
) O
, O
and O
a O
significant O
number O
at O
Pim1 B_GENE
or O
Pim2 B_GENE
( O
23 O
% O
) O
, O
and O
at O
Pal1/Gfi1 B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
18 O
% O
) O
. O

These O
results O
indicate O
that O
Runx2 B_GENE
makes O
a O
distinct O
contribution O
to O
T-cell O
lymphoma O
development O
which O
does O
not O
coincide O
with O
any O
of O
the O
oncogene O
complementation O
groups O
previously O
identified O
by O
retroviral O
tagging O
. O

The O
involvement O
of O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-related O
apoptosis-inducing O
ligand O
in O
the O
enhanced O
cytotoxicity O
of O
IFN-beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-stimulated O
human O
dendritic O
cells O
to O
tumor O
cells O
. O

TNF-alpha B_DISEASE/B_GENE
-related O
apoptosis-inducing O
ligand O
( O
Trail O
) O
is O
characterized O
by O
its O
preferential O
induction O
of O
apoptosis O
of O
tumor O
cells O
but O
not O
normal O
cells O
. O

dendritic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
DCs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
) O
, O
besides O
their O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
APCs B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
now O
have O
been O
demonstrated O
to O
exert O
cytotoxicity B_DISEASE_ADJECTIVE[DISEASE]
or O
cytostasis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
some O
tumor B_DISEASE
cells I_DISEASE
. O

Here O
, O
we O
report O
that O
both O
human B_GENE
CD34 I_GENE
( O
+ B_OTHER/B_DISEASE
) O
stem B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
-derived O
DCs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O
CD34DCs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
) O
and O
human B_GENE
CD14 I_GENE
( O
+ B_GENE/B_DISEASE
) O
monocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
-derived O
DCs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O
MoDCs B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
express O
TRAIL B_GENE
and O
exhibit B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cytotoxicity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
some O
types B_MEASURE/B_DISEASE
of O
tumor B_DISEASE
cells I_DISEASE
partially O
through O
TRAIL B_GENE
. O

Moderate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
TRAIL B_GENE
appeared O
on O
CD34DCs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
the O
8th B_TIME[MEASURE]/B_LOCATION
day B_TIME[MEASURE]/I_LOCATION
of O
culture B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
and O
was O
also O
seen O
on O
freshly O
isolated O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

The O
level B_MEASURE
of O
TRAIL B_GENE
expression I_GENE
remained O
constant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
until O
DC B_TIME[MEASURE]/B_LOCATION
maturation I_TIME[MEASURE]/I_LOCATION
. O

Trail O
expression O
on O
immature O
CD34DCs O
or O
MoDCs O
was O
greatly O
up-regulated O
after O
IFN-beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O
. O

Moreover O
, O
IFN-beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
could O
strikingly O
enhance O
the O
ability O
of O
CD34DCs O
or O
MoDCs O
to O
kill O
TRAIL-sensitive O
tumor O
cells O
, O
but O
LPS O
did O
not O
have O
such O
an O
effect O
. O

The O
up-regulation O
of O
Trail O
on O
IFN-beta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-stimulated O
DCs O
partially O
contributed O
to O
the O
increased O
cytotoxicity O
of O
DCS O
: O
Pretreatment O
of O
TRAIL-sensitive O
tumor O
cells O
with O
caspase-3 O
inhibitor O
could O
significantly O
increase O
their O
resistance O
to O
the O
cytotoxicity O
of O
IFN-beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-stimulated O
DCS O
: O
In O
contrast O
, O
NF-kappaB O
inhibitor O
could O
significantly O
increase O
the O
sensitivity O
of O
tumor O
cells O
to O
the O
killing O
by O
nonstimulated O
or O
LPS-stimulated O
DCS O
: O
Our O
studies O
demonstrate O
that O
IFN-beta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-stimulated O
DCs O
are O
functionally O
cytotoxic O
. O

Thus O
, O
an O
innate B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
DC-mediated B_DISEASE
antitumor I_DISEASE
immunity I_DISEASE
might O
exist O
in O
vivo B_PERSON/B_DISEASE
in O
which O
DCs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
act I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
effectors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
directly O
kill O
tumor B_DISEASE
cells I_DISEASE
partially O
via O
TRAIL B_GENE
. O

Subsequently O
, O
DCs O
act O
as O
APCs O
involved O
in O
the O
uptake O
, O
processing O
, O
and O
presentation O
of O
apoptotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
tumor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
Ags B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
to O
cross-prime O
CD8 O
( O
+ O
) O
CTL O
cells O
. O

tumor B_PERSON/B_DISEASE
cells I_PERSON/I_DISEASE
regulate O
the O
lytic B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
tumor-specific B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cytotoxic I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
t O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
by O
modulating O
the O
inhibitory B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
natural I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
killer I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Tumor-infiltrating O
p58+ O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O
a O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
tumor B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
specifically O
expanded O
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
tumor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
cloned O
. O

These O
p58+ O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
were O
found O
to O
express O
a O
memory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phenotype I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
corresponded O
to O
clonal O
TCRBV3 B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
T-cell B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
expansion B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

Functionally O
, O
p58 B_NUMBER[MEASURE]/B_PERSON
( O
+ O
) O
CTLs B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
displayed O
a O
low B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lytic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
HLA-A2 B_DISEASE
tumor I_DISEASE
and O
normal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O

However O
, O
this O
lytic O
activity O
was O
significantly O
increased O
after O
blockade O
of O
p58 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O
specific O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Interestingly O
, O
we O
demonstrated O
that O
stimulation O
by O
tumor O
cells O
was O
required O
to O
trigger O
the O
inhibitory O
effect O
of O
p58 B_GENE
on O
the O
lytic O
activity O
of O
antigen-specific O
CTLs O
and O
that O
stimulation O
of O
the O
inhibitory O
function O
of O
p58 B_GENE
by O
tumor O
cells O
correlated O
with O
an O
inhibition O
of O
nuclear O
factor-kappaB O
activation O
in O
p58+ O
tumor-specific O
CTLS O
. O

T-cell B_GENE
factor-1 I_GENE
expression O
during O
human O
natural O
killer O
cell O
development O
and O
in O
circulating O
CD56 B_GENE/B_LOCATION
( I_GENE/I_LOCATION
+ I_GENE/I_LOCATION
) I_GENE/I_LOCATION
bright O
natural O
killer O
cells O
. O

Transcription B_GENE/B_PERSON
factors I_GENE/I_PERSON
are O
essential O
to O
govern O
differentiation O
along O
the O
lymphoid O
lineage O
from O
uncommitted O
hematopoietic O
stem O
cells O
. O

Although O
many O
of O
these O
transcription B_GENE/B_BIO
factors I_GENE/I_BIO
have O
putative O
roles O
based O
on O
murine O
knockout O
experiments O
, O
their O
function O
in O
human O
lymphoid O
development O
is O
less O
known O
and O
was O
studied O
further O
. O

Transcription B_DISEASE_ADJECTIVE[DISEASE]
factor I_DISEASE_ADJECTIVE[DISEASE]
expression I_DISEASE_ADJECTIVE[DISEASE]
in O
fresh B_TIME[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
cultured B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adult I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marrow I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
umbilical B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cord I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
progenitors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O
evaluated O
. O

We O
found O
that O
fresh O
CD34 O
( O
+ O
) O
Lin O
( O
- O
) O
cells O
that O
are O
human O
leukocyte O
antigen O
( O
HLA O
) O
-DR O
( O
- O
) O
or O
CD38 O
( O
- O
) O
constitutively O
express O
GATA-3 B_GENE
but O
not O
T-cell B_GENE/B_DISEASE
factor-1 I_GENE/I_DISEASE
( O
TCF-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
Id-3 B_GENE
. O

Culture O
with O
the O
murine O
fetal O
liver O
cell O
line O
AFT024 O
and O
defined O
cytokines B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
was O
capable O
of O
inducing O
TCF-1 B_GENE/B_DISEASE
mRNA I_GENE/I_DISEASE
. O

However O
, O
no O
T-cell B_GENE
receptor I_GENE
gene I_GENE
rearrangement O
was O
identified O
in O
cultured O
progeny O
. O

Id-3 B_GENE/B_LOCATION
, O
a O
basic B_GENE/B_MEASURE
helix I_GENE/I_MEASURE
loop I_GENE/I_MEASURE
helix I_GENE/I_MEASURE
factor I_GENE/I_MEASURE
with O
dominant O
negative O
function O
for O
T-cell O
differentiation O
transcription B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
also O
was O
upregulated O
and O
may O
explain O
unsuccessful O
T-cell O
maturation O
. O

To O
better O
understand O
the O
developmental B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
link I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
between O
natural B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
killer B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
NK B_LOCATION/B_PERSON
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
derived O
from O
progenitors B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
we O
studied O
NK B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
cell I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
subsets I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
circulating O
in O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
. O

CD56 O
( O
+bright O
) O
, O
but O
not O
CD56 O
( O
+dim O
) O
, O
NK O
cells O
constitutively O
express O
TCF-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
reverse O
transcriptase O
polymerase O
chain O
reaction O
and O
Western O
blot O
analysis O
. O

The O
TCF-1 B_GENE
isoform I_GENE
found O
in O
CD56 O
( O
+bright O
) O
cells O
, O
which O
express O
lectin B_GENE
but O
not O
immunoglobulin B_GENE/B_LOCATION
class I_GENE/I_LOCATION
I I_GENE/I_LOCATION
recognizing O
inhibitory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
was O
identical O
to O
that O
induced O
in O
NK O
cell O
differentiation O
culture O
and O
was O
distinctly O
different O
from O
isoforms O
in O
T O
cells O
. O

These O
results O
suggest O
that O
TCF-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O
not O
target O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
killer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
immunoglobulin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
TCF-1 B_LOCATION
is O
uniquely O
expressed O
in O
circulating O
CD56 O
( O
+bright O
) O
NK O
cells O
, O
and O
specific O
TCF-1 B_GENE/B_BIO
isoforms I_GENE/I_BIO
may O
play O
an O
important O
role O
in O
regulating O
NK O
differentiation O
from O
a O
common O
NK/T-cell O
progenitor O
. O

Transcriptional O
activation O
by O
a O
matrix B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associating B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region-binding B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

contextual O
requirements O
for O
the O
function O
of O
bright B_PERSON/B_ORGANIZATION
. O

Bright B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
regulator I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
IgH I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
is O
a O
B O
cell O
-specific O
, O
matrix B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
associating I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region-binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
transactivates O
gene O
expression O
from O
the O
IgH B_GENE
intronic I_GENE
enhancer I_GENE
( O
E B_PROTEIN[GENE]/B_PERSON
mu I_PROTEIN[GENE]/I_PERSON
) O
. O

We O
show O
here O
that O
Bright B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
has O
multiple O
contextual O
requirements O
to O
function O
as O
a O
transcriptional B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Bright B_PERSON/B_GENE
can O
not O
transactivate O
via O
out O
of O
context O
, O
concatenated B_LOCATION
binding I_LOCATION
sites I_LOCATION
. O

transactivation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
maximal B_DISEASE_ADJECTIVE[DISEASE]
on O
integrated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substrates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two O
of O
the O
three O
previously O
identified O
binding B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
E B_GENE
mu I_GENE
are O
required O
for O
full O
Bright B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
transactivation O
. O

The O
Bright B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
DNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
binding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
domain I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
defined O
a O
new O
family O
, O
which O
includes O
SWI1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
a O
component O
of O
the O
SWI.SNF B_LOCATION/B_BIO
complex I_LOCATION/I_BIO
shown O
to O
have O
high O
mobility O
group-like O
DNA O
binding O
characteristics O
. O

Similar O
to O
one O
group O
of O
high B_BIO/B_GENE
mobility I_BIO/I_GENE
group I_BIO/I_GENE
box I_BIO/I_GENE
proteins I_BIO/I_GENE
, O
Bright B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
distorts O
E B_GENE/B_LOCATION
mu I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
site I_GENE/I_LOCATION
-containing O
DNA O
on O
binding O
, O
supporting O
the O
concept O
that O
it O
mediates O
E B_GENE
mu I_GENE
remodeling O
. O

Transfection O
studies O
further O
implicate O
Bright B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
in O
facilitating O
spatially O
separated O
promoter-enhancer O
interactions O
in O
both O
transient O
and O
stable O
assays O
. O

Finally O
, O
we O
show O
that O
overexpression O
of O
Bright B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
leads O
to O
enhanced O
DNase O
I O
sensitivity O
of O
the O
endogenous O
E B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
mu B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
matrix O
associating O
regions O
. O

These O
data O
further O
suggest O
that O
Bright B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
may O
contribute O
to O
increased O
gene O
expression O
by O
remodeling O
the O
immunoglobulin B_GENE
locus I_GENE
during O
B O
cell O
development O
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
BCL-6 B_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
in O
classic B_DISEASE
Hodgkin I_DISEASE
disease I_DISEASE
of O
the O
B- B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
T-cell B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
type B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

BCL-6 B_GENE
is O
essential O
for O
germinal O
center O
formation O
and O
thus O
for O
affinity O
maturation O
of O
immunoglobulin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
( I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
Ig I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
) I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
genes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O
somatic O
mutations O
. O

The O
5'-noncoding B_GENE/B_LOCATION
region I_GENE/I_LOCATION
of O
the O
BCL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
even O
a O
target O
for O
the O
mutation O
machinery O
. O

Translocations O
of O
the O
BCL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
heterologous B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
mutations O
of O
its O
5'-noncoding B_GENE/B_MEASURE
regulatory I_GENE/I_MEASURE
region I_GENE/I_MEASURE
were O
reported O
to O
be O
potential O
mechanisms O
for O
deregulating O
BCL-6 B_GENE
expression O
and O
for O
playing O
a O
role O
in O
the O
Genesis O
of O
non-Hodgkin O
lymphoma O
. O

In O
line B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
this O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
B-cell B_DISEASE/B_PERSON
lymphoma I_DISEASE/I_PERSON
with O
somatic B_DISEASE/B_GENE
mutations I_DISEASE/I_GENE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
diffuse B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
large I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
B-cell I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
lymphoma I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
follicular B_DISEASE/B_GENE
lymphoma I_DISEASE/I_GENE
, O
also O
carry O
BCL-6 B_DISEASE/B_GENE
mutations I_DISEASE/I_GENE
, O
some O
of O
which O
are O
recurrently O
detectable B_DISEASE_ADJECTIVE[DISEASE]
. O

classic B_DISEASE/B_GENE
Hodgkin B_DISEASE/I_GENE
disease B_DISEASE/I_GENE
( O
cHD B_LOCATION/B_ORGANIZATION
) O
is O
also O
derived O
from O
B B_DISEASE/B_BIO
cells I_DISEASE/I_BIO
with O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loads B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
somatic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutations I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
thus O
a O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
candidate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
BCL-6 B_DISEASE
mutations I_DISEASE
. O

To O
determine O
the O
presence O
and O
potential O
role O
of O
BCL-6 O
mutations O
in O
cHD O
, O
the O
5'-noncoding B_GENE/B_MEASURE
BCL-6 B_GENE/I_MEASURE
proportion O
of O
single O
Hodgkin O
and O
Reed-Sternberg O
( O
HRS O
) O
cells O
from O
6 O
cases O
of O
cHD O
and O
6 O
cases O
of O
HD-derived O
cell O
lines O
was O
analyzed O
. O

All O
B-cell-derived B_DISEASE/B_BIO
HD I_DISEASE/I_BIO
cases I_DISEASE/I_BIO
and O
cell B_DISEASE/B_PERSON
lines I_DISEASE/I_PERSON
harbored O
BCL-6 B_DISEASE/B_GENE
mutations B_DISEASE/I_GENE
. O

In O
contrast B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
both O
T-cell-derived B_DISEASE/B_BIO
HD I_DISEASE/I_BIO
cases I_DISEASE/I_BIO
and O
cell B_DISEASE/B_ORGANIZATION
lines I_DISEASE/I_ORGANIZATION
were O
devoid B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O
BCL-6 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

With O
only O
one O
exception O
, O
there O
were O
no O
lymphoma-specific O
recurrent O
BCL-6 O
mutations O
detected O
, O
and O
BCL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
absent O
from O
the O
HRS O
cells O
of O
most O
cases O
. O

In O
conclusion O
, O
( O
1 O
) O
somatic O
BCL-6 O
mutations O
are O
restricted O
to O
cHD O
cases O
of O
B-cell O
origin O
, O
and O
( O
2 O
) O
the O
BCL-6 O
mutations O
represent O
mostly O
irrelevant O
somatic O
base O
substitutions O
without O
consequences O
for O
BCL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
and O
the O
pathogenesis O
of O
cHD O
. O

Gadd45gamma B_GENE
is O
dispensable O
for O
normal O
mouse O
development O
and O
T-cell O
proliferation O
. O

Gadd45gamma B_GENE
, O
a O
family O
member O
of O
the O
growth B_GENE/B_BIO
arrest I_GENE/I_BIO
and I_GENE/I_BIO
DNA I_GENE/I_BIO
damage-inducible I_GENE/I_BIO
gene I_GENE/I_BIO
family I_GENE/I_BIO
45 I_GENE/I_BIO
( O
Gadd45 B_GENE
) O
, O
is O
strongly O
induced O
by O
interleukin-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IL-2 B_GENE
) O
in O
peripheral O
T O
cells O
. O

While O
in O
most O
tissues O
all O
Gadd45 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
family I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
members I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
are O
expressed O
, O
Gadd45gamma B_GENE
is O
the O
only O
member O
that O
is O
induced O
by O
IL-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Here O
we O
show O
that O
the O
IL-2 B_GENE
-induced O
expression O
of O
Gadd45gamma B_GENE
is O
dependent O
on O
a O
signaling O
pathway O
mediated O
by O
the O
tyrosine B_GENE
kinase I_GENE
Jak3 I_GENE
and O
the O
transcription B_GENE
factors I_GENE
Stat5a I_GENE
and O
Stat5b B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
signal B_GENE/B_MEASURE
transducer I_GENE/I_MEASURE
and I_GENE/I_MEASURE
activator I_GENE/I_MEASURE
of I_GENE/I_MEASURE
transcription I_GENE/I_MEASURE
) O
. O

Previous O
studies O
with O
ectopically O
overexpressed O
Gadd45gamma B_GENE
in O
various O
cell O
lines O
implicated O
its O
function O
in O
negative O
growth O
control O
. O

To O
analyze O
the O
physiological O
role O
of O
Gadd45gamma B_GENE/B_BIO
we O
used O
homologous O
recombination O
to O
generate O
mice O
lacking O
Gadd45gamma B_GENE
. O

Gadd45gamma B_GENE/B_DISEASE
-deficient O
mice O
develop O
normally O
, O
are O
indistinguishable O
from O
their O
littermates O
, O
and O
are O
fertile O
. O

Furthermore O
, O
hematopoiesis O
in O
mice O
lacking O
Gadd45gamma B_GENE
is O
not O
impaired O
and O
Gadd45gamma B_GENE
-deficient O
T O
lymphocytes O
show O
normal O
responses O
to O
IL-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
data O
demonstrate O
that O
Gadd45gamma B_GENE
is O
not O
essential O
for O
normal O
mouse O
development O
and O
hematopoiesis O
, O
possibly O
due O
to O
functional O
redundancy O
among O
the O
Gadd45 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
family I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
members I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Gadd45gamma B_GENE
is O
also O
dispensable O
for O
IL-2 B_GENE
-induced O
T-cell O
proliferation O
. O

decreased O
expression O
of O
c-myc B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
thymuses O
from O
myasthenia O
gravis O
patients O
. O

The O
thymus B_BODY_PART_OR_ORGAN_COMPONENT
is O
a O
critical B_LOCATION/B_PERSON
organ I_LOCATION/I_PERSON
for O
the O
elimination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
autoreactive B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
T B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cells B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
by O
apoptosis B_DISEASE
. O

We O
studied O
the O
expression O
of O
apoptosis-associated O
genes O
, O
bcl-xL B_GENE
, O
bad B_GENE/B_DISEASE
, O
caspase-3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
c-myc B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
myasthenia O
gravis O
( O
MG O
) O
thymuses O
. O

We O
observed O
that O
the O
mRNA O
levels O
of O
myc B_GENE
family I_GENE
genes I_GENE
, O
c-myc B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
max B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
were O
markedly O
reduced O
in O
MG O
thymuses O
. O

These O
results O
indicate O
that O
c-myc B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-mediated O
signaling O
is O
abnormal O
in O
MG O
thymuses O
. O

The O
levels O
of O
molecules O
whose O
expressions O
are O
associated O
with O
myc B_DISEASE/B_SPECIES[BIO]
, O
such O
as O
STAM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
prothymosin-alpha B_GENE/B_LOCATION
, O
and O
NFkappaB B_GENE
. O

Immunohistochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
interferon-gamma-producing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
dermatophytosis B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Skin O
lesions O
of O
dermatophytosis O
are O
thought O
to O
be O
a O
result O
of O
a O
T O
cell O
-dependent O
inflammatory O
response O
that O
is O
mediated O
by O
various O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
examined O
whether O
IFN-gamma-positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
as O
expression B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
Th1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
were O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
skin B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lesions B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
dermatophytosis B_DISEASE/B_LOCATION
in O
situ B_PERSON/B_SPECIES[BIO]
by O
immunohistochemical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

mixtures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
CD4-positive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
CD8-positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
found O
to O
be O
present B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
dermal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infiltrates B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
lesions B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

considerable B_MEASURE/B_LOCATION
numbers B_MEASURE/I_LOCATION
of O
CD1a-positive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
detected O
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
dermis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
epidermis B_BODY_PART_OR_ORGAN_COMPONENT
. O

A O
marked B_LOCATION/B_MEASURE
accumulation I_LOCATION/I_MEASURE
of O
CD68-positive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
found O
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
dermis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

IFN-gamma-positive B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
dermis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
lesions B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
pattern O
of O
IFN-gamma B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
staining O
appeared O
to O
be O
intracellular O
in O
mononuclear O
lymphoid O
cells O
. O

The O
staining O
was O
considered O
to O
be O
highly O
specific O
because O
it O
could O
be O
completely O
blocked O
by O
preabsorption O
with O
recombinant B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IFN-gamma B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
the O
skin B_DISEASE_ADJECTIVE[DISEASE]
lesions I_DISEASE_ADJECTIVE[DISEASE]
of O
dermatophytosis B_DISEASE/B_LOCATION
may O
be O
associated O
with O
a O
Th1 B_DISEASE/B_BIO
response I_DISEASE/I_BIO
. O

Th1 O
response O
, O
which O
is O
characterized O
by O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
release O
, O
is O
thought O
to O
be O
involved O
in O
the O
host O
defense O
against O
dermatophytes O
and O
to O
reflect O
cutaneous O
reaction O
in O
dermatophytosis O
. O

Regulation O
of O
the O
helix-loop-helix B_GENE/B_BIO
proteins I_GENE/I_BIO
, O
E2A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Id3 B_GENE
, O
by O
the O
Ras B_GENE/B_DISEASE
- O
ERK B_GENE
MAPK I_GENE
Cascade O
. O

activation O
of O
mitogen-activated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MAPK B_GENE
) O
pathways O
leads O
to O
cellular O
differentiation O
and/or O
proliferation O
in O
a O
wide O
variety O
of O
cell O
types O
, O
including O
developing O
thymocytes O
. O

The O
basic B_PROTEIN[GENE]
helix-loop-helix I_PROTEIN[GENE]
( I_PROTEIN[GENE]
bHLH I_PROTEIN[GENE]
) I_PROTEIN[GENE]
proteins I_PROTEIN[GENE]
E12 I_PROTEIN[GENE]
and O
E47 B_PROTEIN[GENE]
and O
an O
inhibitor B_PROTEIN[GENE]
HLH I_PROTEIN[GENE]
protein I_PROTEIN[GENE]
, O
Id3 B_GENE
, O
play O
key O
roles O
in O
thymocyte O
differentiation O
. O

We O
show O
here O
that O
E2A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
DNA O
binding O
is O
lowered O
in O
primary O
immature O
thymocytes O
consequent O
to O
T O
cell O
receptor O
( O
TCR O
) O
-mediated O
ligation O
. O

Whereas O
expression O
of O
E2A O
mRNA O
and O
protein O
are O
unaltered O
, O
Id3 B_GENE/B_PERSON
transcripts I_GENE/I_PERSON
are O
rapidly O
induced O
upon O
signaling O
from O
the O
TCR B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

activation O
of O
Id3 O
transcription O
is O
regulated O
in O
a O
dose-dependent O
manner O
by O
the O
extracellular O
signal-regulated O
kinase O
( O
ERK B_GENE
) O
MAPK B_GENE/B_LOCATION
module O
. O

These O
observations O
directly O
connect O
the O
ERK B_GENE
MAPK I_GENE
Cascade O
and O
HLH B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
linear O
pathway O
. O

retinoic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
acid I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
up-regulates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
myeloid O
ICAM-3 B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
expression B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
cell-specific B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
fashion B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
-- O
evidence B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
retinoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
signaling O
pathways B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O
the O
mast B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lineage I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Investigation O
of O
mast O
cell O
responsiveness O
toward O
retinoic O
acid O
( O
RA O
) O
revealed O
selective O
promotion O
of O
ICAM-3 B_GENE
expression O
in O
the O
human O
mast O
cell O
line O
HMC-1 O
. O

This O
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
dose- B_MEASURE
and O
time-dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
detectable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
ELISA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
Northern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

ICAM-3 B_GENE/B_MEASURE
modulation O
was O
found O
to O
be O
cell-type O
dependent O
, O
detectable O
also O
for O
HL-60 O
cells O
and O
monocytes O
but O
not O
U-937 O
and O
only O
weakly O
for O
KU812 O
cells O
. O

Terminally O
differentiated O
skin O
mast O
cells O
also O
failed O
to O
up-modulate O
their O
ICAM-3 B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
suggesting O
the O
requirement O
for O
some O
degree O
of O
immaturity O
for O
the O
process O
. O

RA-mediated O
effects O
on O
ICAM-1 B_GENE
expression O
, O
studied O
in O
parallel O
, O
were O
clearly O
distinct O
from O
those O
on O
ICAM-3 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Investigation O
of O
retinoid B_GENE/B_LOCATION
receptor I_GENE/I_LOCATION
expression O
, O
known O
to O
mediate O
intracellular O
RA O
signaling O
, O
revealed O
presence O
of O
RAR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RAR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RXR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RXR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
all O
cell O
lines O
studied O
, O
and O
HMC-1 O
cells O
were O
the O
only O
line O
lacking O
RXR B_GENE/B_MEASURE
alpha I_GENE/I_MEASURE
. O

RAR B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
not O
expressed O
at O
baseline O
, O
was O
induced O
by O
RA O
in O
a O
fashion O
obviously O
correlating O
with O
ICAM-3 B_GENE/B_LOCATION
up-regulation O
. O

increased O
ICAM-3 B_GENE
expression O
was O
of O
functional O
significance O
, O
such O
that O
processes O
stimulated O
or O
co-stimulated O
via O
ICAM-3 B_GENE
( O
homotypic O
aggregation O
, O
IL-8 O
secretion O
) O
were O
clearly O
enhanced O
upon O
RA O
pretreatment O
, O
suggesting O
that O
RA O
may O
contribute O
via O
hitherto O
unrecognized O
pathways O
to O
immune O
function O
and O
host O
defense O
. O

CD28 B_GENE
and O
T O
cell O
co-stimulation O
. O

Over O
the O
last B_TIME[MEASURE]/B_LOCATION
decade I_TIME[MEASURE]/I_LOCATION
the O
concept B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
T B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
co-stimulation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O
emerged O
to O
take O
a O
central B_LOCATION/B_PERSON
role I_LOCATION/I_PERSON
in O
the O
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
T B_DISEASE
cell I_DISEASE
activation I_DISEASE
. O

However O
, O
the O
exact B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
definition I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
co-stimulation B_DISEASE/B_LOCATION
is O
still O
unclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
we O
re-examine O
the O
concept B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
co-stimulation B_DISEASE/B_PERSON
. O

We O
suggest O
that O
while O
co-stimulation B_DISEASE/B_GENE
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
there O
is O
little B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
link O
co-stimulation B_DISEASE/B_GENE
with O
T B_DISEASE
cell I_DISEASE
anergy I_DISEASE
. O

We O
then O
suggest O
a O
framework B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
studying O
co-stimulation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

focusing O
on O
recent O
advances O
in O
our O
understanding O
of O
CD28 B_GENE/B_DISEASE
, O
we O
discuss O
four O
areas O
of O
T O
cell O
activation O
where O
co-stimulation O
may O
play O
a O
role O
. O

Regulation O
of O
activator B_GENE
protein-1 I_GENE
and O
NF-kappa B_GENE
B I_GENE
in O
CD8+ O
T O
cells O
exposed O
to O
peripheral B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
self-antigens B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
transcriptional O
events O
that O
control O
T O
cell O
tolerance O
to O
peripheral B_DISEASE
self I_DISEASE
Ags I_DISEASE
are O
still O
unknown O
. O

In O
this O
study O
, O
we O
analyzed O
the O
regulation O
of O
AP-1 B_GENE/B_LOCATION
- O
and O
NF-kappa B_GENE
B I_GENE
-mediated O
transcription O
during O
in O
vivo O
induction O
of O
tolerance O
to O
a O
self B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Ag I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expressed O
exclusively O
on O
hepatocytes O
. O

naive O
CD8 O
( O
+ O
) O
Desire O
( O
Des O
) O
( O
+ O
) O
T O
cells O
isolated O
from O
the O
Des O
TCR-transgenic O
mice O
that O
are O
specific O
for O
the O
H-2K B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
b I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ag I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
transferred O
into O
Alb-K O
( O
b O
) O
-transgenic O
mice O
that O
express O
the O
H-2K B_GENE/B_LOCATION
( I_GENE/I_LOCATION
b I_GENE/I_LOCATION
) I_GENE/I_LOCATION
Ag I_GENE/I_LOCATION
on O
hepatocytes O
only O
. O

tolerance B_DISEASE
develops O
in O
these O
mice B_BIO/B_PERSON
. O

We O
found O
that O
the O
self-reactive B_GENE
CD8 I_GENE
( O
+ B_DISEASE/B_GENE
) O
Des B_GENE/B_DISEASE
( O
+ B_GENE/B_DISEASE
) O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O
transiently O
activated O
, O
then O
became O
unresponsive B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O
were O
further O
deleted O
. O

In O
contrast O
to O
CD8 O
( O
+ O
) O
Des O
( O
+ O
) O
T O
cells O
activated O
in O
vivo O
with O
APCs O
, O
which O
express O
high O
AP-1 B_GENE
and O
high O
NF-kappa B_GENE
B I_GENE
transcriptional O
activity O
, O
the O
unresponsive O
CD8 O
( O
+ O
) O
Des O
( O
+ O
) O
T O
cells O
expressed O
no O
AP-1 B_GENE
and O
only O
weak O
NF-kappa B_GENE
B I_GENE
transcriptional O
activity O
. O

The O
differences O
in O
NF-kappa B_GENE/B_DISEASE
B I_GENE/I_DISEASE
transcriptional O
activity O
correlated O
with O
the O
generation O
of O
distinct O
NF-kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Indeed O
, O
in O
vivo O
primed O
T O
cells O
predominantly O
express O
p50/p50 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p65/p50 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dimers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
whereas O
these O
p50-containing B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complexes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O
barely O
detectable O
in O
tolerant O
T O
cells O
that O
express O
p65- B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Rel-containing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
observations O
suggest O
that O
fine O
regulation O
of O
NF-kappa B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
B B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complex B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
formation O
may O
determine O
T O
cell O
fate O
. O

transcriptional B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulation B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
have O
been O
used O
to O
investigate O
many B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellular I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
lineage B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
commitment B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O
differentiation B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
, O
proliferation B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
apoptosis B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

The O
transcription B_GENE
factors I_GENE
that O
mediate O
these O
processes O
are O
often O
expressed O
broadly O
in O
many O
cell O
types O
. O

The O
emerging O
theme O
is O
one O
of O
cell-type-specific O
regulation O
, O
affecting O
not O
only O
the O
functional O
activation O
of O
transcription B_GENE
factors I_GENE
but O
also O
their O
access O
to O
appropriate O
regions O
of O
DNA O
. O

existence O
of O
retinoic B_GENE
acid-receptor I_GENE
-independent O
retinoid B_GENE
X-receptor I_GENE
-dependent O
pathway O
in O
myeloid O
cell O
function O
. O

We O
previously O
reported O
that O
ER-27191 O
( O
4- O
[ O
4 O
, O
5 O
, O
7 O
, O
8 O
, O
9 O
, O
10-hexahydro-7 O
, O
7 O
, O
10 O
, O
10-tetramethyl-1- O
( O
3-pyridylmethyl O
) O
anthra O
[ O
1 O
, O
2-b O
] O
pyrrol-3-yl O
] O
benzoic O
acid O
) O
is O
a O
potent O
antagonist O
of O
retinoic B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
RAR B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
and O
ER-35795 O
( O
( O
2E O
, O
4E O
, O
6E O
) O
-7- O
[ O
1- O
( O
1-methylethyl O
) O
-8-chloro-1 O
, O
2 O
, O
3 O
, O
4-tetrahydroquinolin-6-yl O
] O
-6-fluoro-3-methyl-2 O
, O
4 O
, O
6-nonatrienoic O
acid O
) O
is O
a O
novel O
retinoid B_GENE/B_MEASURE
X B_GENE/I_MEASURE
receptor B_GENE/I_MEASURE
( O
RXR B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
-specific O
agonist O
. O

By O
using O
these O
compounds O
, O
we O
investigated O
whether O
distinct O
RAR B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O
and O
RXR B_PROTEIN[GENE]/B_LOCATION
-dependent O
pathways O
operate O
to O
mediate O
the O
diverse O
activities O
of O
retinoids O
, O
particularly O
, O
the O
effects O
of O
the O
RXR B_GENE/B_LOCATION
pathway O
on O
cellular O
function O
. O

ER-27191 O
completely O
antagonized O
HL60 B_DISEASE
cell I_DISEASE
differentiation I_DISEASE
induced O
by O
all-trans-retinoic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
atRA B_LOCATION/B_ORGANIZATION
) O
. O

However O
, O
the O
differentiation O
induced O
by O
the O
ER-35795 O
was O
not O
antagonized O
at O
all O
by O
the O
RAR B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O
, O
but O
was O
inhibited O
by O
an O
RXR B_GENE/B_LOCATION
homodimer I_GENE/I_LOCATION
antagonist O
( O
LGD100754 O
, O
( O
2E O
, O
4E O
, O
6Z O
) O
-7- O
( O
3-n-propoxy-5 O
, O
6 O
, O
7 O
, O
8-tetrahydro-5 O
, O
5 O
, O
8 O
, O
8-tetramethylnaphthalen-2-yl O
) O
-3-methylocta-2 O
, O
4 O
, O
6-trienoic O
acid O
) O
. O

Its O
agonistic O
action O
on O
RXR/RAR B_GENE/B_LOCATION
heterodimer I_GENE/I_LOCATION
, O
on O
the O
other O
hand O
, O
was O
neutralized O
by O
the O
RAR B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O
. O

During O
HL60 O
cell O
differentiation O
, O
atRA O
induced O
RARbeta B_GENE/B_DISEASE
mRNA I_GENE/I_DISEASE
, O
while O
the O
RXR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
had O
no O
effect O
. O

Interestingly O
, O
a O
functional O
RXR B_GENE/B_LOCATION
-pathway O
was O
also O
seen O
in O
lipopolysaccharide-induced O
inhibition O
of O
mouse O
splenocyte O
proliferation O
. O

These O
results O
strongly O
suggest O
the O
existence O
of O
a O
pharmacological O
RXR B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-dependent O
pathway O
that O
is O
activated O
by O
a O
ligand O
that O
can O
bind O
to O
RXR B_GENE/B_LOCATION
. O

targeting O
Src B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homology I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain-containing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
SHP-1 B_GENE/B_DISEASE
) O
into O
lipid O
rafts O
inhibits O
CD3 B_GENE
-induced O
T O
cell O
activation O
. O

To O
study O
the O
mechanism O
by O
which O
protein B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatases I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PTPs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
regulate O
CD3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O
tyrosine O
phosphorylation O
, O
we O
investigated O
the O
distribution O
of O
PTPs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
subdomains O
of O
plasma O
membrane O
. O

We O
report O
here O
that O
the O
bulk O
PTP B_ENZYME[GENE]
activity O
associated O
with O
T O
cell O
membrane O
is O
present O
outside O
the O
lipid O
rafts O
, O
as O
determined O
by O
sucrose O
density O
gradient O
sedimentation O
. O

In O
Jurkat O
T O
cells O
, O
approximately O
5 O
-- O
10 O
% O
of O
Src B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homology I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
domain-containing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
SHP-1 B_GENE/B_DISEASE
) O
is O
constitutively O
associated O
with O
plasma O
membrane O
, O
and O
nearly O
50 O
% O
of O
SHP-2 B_GENE/B_BIO
is O
translocated O
to O
plasma O
membrane O
after O
vanadate O
treatment O
. O

Similar O
to O
transmembrane B_GENE
PTP I_GENE
, O
CD45 B_GENE/B_TIME[MEASURE]
, O
the O
membrane-associated O
populations O
of O
SHP-1 B_GENE
and O
SHP-2 B_GENE
are O
essentially O
excluded O
from O
lipid O
rafts O
, O
where O
other O
signaling B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
molecules I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such O
as O
Lck B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
linker I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
CD3 B_GENE
zeta I_GENE
are O
enriched O
. O

We O
further O
demonstrated O
that O
CD3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O
tyrosine O
phosphorylation O
of O
these O
substrates O
is O
largely O
restricted O
to O
lipid O
rafts O
, O
unless O
PTPs B_GENE/B_PERSON
are O
inhibited O
. O

It O
suggests O
that O
a O
restricted O
partition O
of O
PTPs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
among O
membrane O
subdomains O
may O
regulate O
protein O
tyrosine O
phosphorylation O
in O
T O
cell O
membrane O
. O

To O
test O
this O
hypothesis O
, O
we O
targeted O
SHP-1 B_GENE
into O
lipid O
rafts O
by O
using O
the O
N-terminal B_GENE
region I_GENE
of I_GENE
Lck I_GENE
( O
residues B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
14 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
results O
indicate O
that O
the O
expression O
of O
Lck/SHP-1 B_GENE
chimera I_GENE
inside O
lipid O
rafts O
profoundly O
inhibits O
CD3 B_GENE
-induced O
tyrosine O
phosphorylation O
of O
CD3 B_GENE
zeta/epsilon I_GENE
, O
IL-2 O
generation O
, O
and O
nuclear O
mobilization O
of O
NF-AT B_GENE
. O

collectively O
, O
these O
results O
suggest O
that O
the O
exclusion O
of O
PTPs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
from O
lipid O
rafts O
may O
be O
a O
mechanism O
that O
potentiates O
TCR B_GENE
/ O
CD3 B_GENE/B_LOCATION
activation O
. O

An O
instructive O
component O
in O
T O
helper O
cell O
type O
2 O
( O
Th2 O
) O
development O
mediated O
by O
GATA-3 B_GENE
. O

Although O
interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-12 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
IL-4 B_MEASURE/B_GENE
polarize O
naive O
CD4 O
( O
+ O
) O
T O
cells O
toward O
T O
helper O
cell O
type O
1 O
( O
Th1 O
) O
or O
Th2 O
phenotypes O
, O
it O
is O
not O
known O
whether O
cytokines B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
instruct O
the O
developmental O
fate O
in O
uncommitted O
progenitors O
or O
select O
for O
outgrowth O
of O
cells O
that O
have O
stochastically O
committed O
to O
a O
particular O
fate O
. O

To O
distinguish O
these O
instructive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
selective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
we O
used O
surface B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
affinity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
matrix I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
technology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
isolate O
committed B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
progenitors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
based O
on O
cytokine B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretion B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenotype B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
developed O
retroviral-based B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tagging O
approaches B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O
directly O
monitor O
individual B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
progenitor B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fate B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
decisions B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O
the O
clonal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
population B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

We O
observe O
IL-4 B_GENE/B_MEASURE
-dependent O
redirection O
of O
phenotype O
in O
cells O
that O
have O
already O
committed O
to O
a O
non-IL-4-producing O
fate O
, O
inconsistent O
with O
predictions O
of O
the O
selective O
model O
. O

Further O
, O
retroviral O
tagging O
of O
naive O
progenitors O
with O
the O
Th2-specific B_GENE
transcription I_GENE
factor I_GENE
GATA-3 I_GENE
provided O
direct O
evidence O
for O
instructive O
differentiation O
, O
and O
no O
evidence O
for O
the O
selective O
outgrowth O
of O
cells O
committed O
to O
either O
the O
Th1 O
or O
Th2 O
fate O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
would O
seem O
to O
exclude O
selection B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O
an O
exclusive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Th1 B_LOCATION/B_PERSON
/ O
Th2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
support O
an O
instructive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
cytokine-driven B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programming I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fate B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
decisions B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
vitro-activated O
human O
lupus O
T O
cells O
express O
normal O
estrogen B_GENE
receptor I_GENE
proteins I_GENE
which O
bind O
to O
the O
estrogen B_GENE/B_LOCATION
response I_GENE/I_LOCATION
element I_GENE/I_LOCATION
. O

We O
have O
shown O
that O
estrogen B_GENE/B_NUMBER[MEASURE]
receptor I_GENE/I_NUMBER[MEASURE]
( O
ERalpha B_GENE/B_LOCATION
, O
ERbeta B_GENE/B_LOCATION
) O
transcripts O
are O
expressed O
in O
SLE O
and O
normal O
T O
cells O
. O

In O
this O
study O
, O
T O
cell O
nuclear O
extracts O
from O
female O
lupus O
patients O
and O
normal O
donors O
were O
tested O
for O
biologically O
active O
ER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
capable O
of O
binding O
to O
the O
human B_GENE
estrogen I_GENE
response I_GENE
element I_GENE
( O
hERE B_GENE/B_BIO
) O
by O
electrophoretic O
mobility O
shift O
assays O
. O

When O
peripheral O
blood O
T O
cells O
were O
stimulated O
with O
17beta-estradiol O
( O
E2 O
) O
, O
PMA O
and O
ionomycin O
, O
two O
major O
retarded O
bands O
in O
T O
cell O
nuclear O
extracts O
exhibited O
a O
migration O
pattern O
similar O
to O
slow O
migrating O
protein-ERE B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
complexes B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
human O
breast O
cancer O
cell O
extracts O
. O

T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cultured O
only O
with O
E2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
did O
not O
have O
these O
complexes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
formation O
of O
the O
complexes O
was O
inhibited O
by O
competition O
with O
the O
Here O
cold O
oligonucleotide O
and O
partially O
with O
anti-ERalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

There O
was O
no O
notable O
difference O
in O
the O
migration O
pattern O
of O
ERE-binding B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
between O
the O
SLE O
and O
normal O
T O
cell O
extracts O
. O

Together O
, O
these O
results O
suggest O
that O
activated O
human O
T O
cells O
, O
whether O
lupus-derived O
or O
normal-derived O
, O
contain O
biologically O
active O
ERalpha B_GENE
proteins I_GENE
. O

Other B_PERSON/B_GENE
factors I_PERSON/I_GENE
may O
be O
responsible B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
differential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
sensitivity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
lupus B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
to O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

mechanism O
of O
the O
inhibitory O
effect O
of O
protease O
inhibitor O
on O
tumor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
production O
of O
monocytes O
. O

If O
the O
inflammatory B_DISEASE/B_MEASURE
response I_DISEASE/I_MEASURE
becomes O
excessive B_DISEASE_ADJECTIVE[DISEASE]
or O
uncontrolled B_DISEASE_ADJECTIVE[DISEASE]
by O
some O
stimuli B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
inappropriate B_DISEASE/B_PERSON
inflammatory I_DISEASE/I_PERSON
responses I_DISEASE/I_PERSON
occur O
. O

Monocytes O
are O
extremely O
important O
cells O
for O
regulating O
the O
cytokine O
network O
and O
tumor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
necrosis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
TNFalpha B_GENE/B_LOCATION
) O
and O
interleukin- B_GENE
( I_GENE
IL I_GENE
) I_GENE
10 I_GENE
, O
which O
are O
mainly O
synthesized O
by O
monocytes O
, O
are O
representative O
cytokines B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
play O
a O
central O
role O
in O
the O
cytokine O
network O
. O

protease B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O
gabexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mesilate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GM B_ORGANIZATION/B_LOCATION
) O
and O
ulinastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
UTI B_ORGANIZATION/B_LOCATION
) O
have O
been O
shown O
to O
have O
various B_DISEASE_ADJECTIVE[DISEASE]
beneficial I_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
by O
inhibiting O
the O
activation B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
leukocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
but O
the O
mechanism B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
this O
has O
yet O
to O
be O
fully O
elucidated O
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O
investigated O
the O
mechanism B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
inhibitory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
protease B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
proinflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
cytokine B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
production B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
lipopolysaccharide- B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
stimulated O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

LPS-stimulated B_PERSON
monocytes I_PERSON
were O
treated O
with O
GM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O
UTI B_DISEASE/B_PROTEIN[GENE]
. O

The O
value O
of O
TNFalpha B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IL-10 B_GENE
in O
the O
culture O
medium O
of O
monocytes O
was O
measured O
and O
each O
mRNA O
expression O
was O
assayed O
. O

The O
inhibitory O
effect O
of O
protease O
inhibitors O
on O
the O
activity O
of O
intracellular O
signal O
transduction O
pathways O
such O
as O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PKC B_GENE
) O
and O
nuclear B_GENE
factor I_GENE
kappa I_GENE
B I_GENE
( O
NFkappaB B_GENE
) O
were O
also O
evaluated O
. O

GM O
decreased O
the O
TNFalpha B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O
of O
LPS-stimulated O
monocytes O
as O
shown O
by O
the O
inhibition O
of O
mRNA O
expression O
and O
increased O
the O
IL-10 B_GENE
production O
of O
LPS-stimulated O
monocytes O
. O

GM O
also O
suppressed O
the O
NFkappaB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activity O
of O
LPS-stimulated O
monocytes O
. O

UTI O
decreased O
the O
TNFalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O
of O
LPS-stimulated O
monocytes O
, O
but O
did O
not O
inhibit O
the O
TNFalpha B_GENE
mRNA I_GENE
expression O
. O

The O
present O
study O
shows O
that O
the O
inhibitory O
effect O
of O
GM O
on O
the O
TNFalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O
of O
activated O
human O
monocytes O
is O
mediated O
by O
the O
suppression O
of O
NFkappaB B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O
, O
while O
the O
mechanism O
of O
UTI O
inhibiting O
TNFalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O
of O
human O
monocytes O
may O
be O
due O
to O
the O
inhibition O
of O
either O
the O
translation O
or O
secretion O
of O
TNFalpha B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Homocysteine O
stimulates O
the O
expression O
of O
monocyte B_GENE
chemoattractant I_GENE
protein-1 I_GENE
in O
endothelial O
cells O
leading O
to O
enhanced O
monocyte O
chemotaxis O
. O

Hyperhomocysteinemia B_DISEASE
has O
been O
identified O
as O
an O
independent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factor B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
atherosclerosis B_DISEASE
. O

The O
infiltration B_DISEASE/B_TIME[MEASURE]
of O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
into O
the O
arterial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wall I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
key B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
events I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
during O
atherogenesis B_DISEASE/B_LOCATION
. O

Monocyte B_GENE
chemoattractant I_GENE
protein-1 I_GENE
( O
MCP-1 B_GENE/B_DISEASE
) O
is O
a O
potent O
chemokine B_GENE
that O
stimulates O
the O
migration O
of O
monocytes O
into O
the O
intima O
of O
the O
arterial O
wall O
. O

The O
mechanism B_LOCATION
by O
which O
increased O
monocyte B_DISEASE
infiltration I_DISEASE
occurs O
in O
atherosclerotic B_DISEASE
lesions I_DISEASE
in O
patients B_PERSON/B_BIO
with O
hyperhomocysteinemia B_DISEASE/B_LOCATION
has O
not O
been O
delineated O
. O

The O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effect O
of O
homocysteine O
on O
MCP-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O
in O
endothelial O
cells O
. O

cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
incubated O
with O
homocysteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
secretion O
of O
MCP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
significantly O
increased O
( O
195 O
% O
as O
compared O
to O
the O
control O
) O
in O
cells O
treated O
with O
pathological O
concentrations O
of O
homocysteine O
. O

Such O
effect O
was O
accompanied O
by O
an O
increased O
expression O
of O
MCP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
176 O
% O
as O
compared O
to O
the O
control O
) O
in O
endothelial O
cells O
which O
resulted O
in O
enhanced O
monocyte O
chemotaxis O
. O

The O
p38 B_GENE
MAP I_GENE
kinase I_GENE
as O
well O
as O
other O
members O
of O
the O
p38 O
Map O
kinase O
pathway O
, O
including O
MKK3 B_GENE
, O
MKK6 B_GENE
, O
ATF-2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Elk-1 B_GENE
, O
were O
activated O
in O
homocysteine-treated O
cells O
. O

Homocysteine-induced O
MCP-1 B_GENE
expression O
and O
subsequent O
monocyte O
chemotaxis O
were O
blocked O
by O
a O
p38 B_GENE
MAP I_GENE
kinase I_GENE
inhibitor O
( O
SB203580 O
) O
suggesting O
that O
the O
p38 B_GENE
MAP I_GENE
kinase I_GENE
pathway O
might O
be O
involved O
in O
homocysteine-induced O
MCP-1 B_GENE
expression O
in O
endothelial O
cells O
. O

In O
contrast O
, O
staurosporine O
, O
a O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor O
, O
had O
no O
effect O
on O
homocysteine-induced O
MCP-1 B_GENE
expression O
. O

In O
conclusion O
, O
our O
results O
indicate O
that O
homocysteine O
stimulates O
MCP-1 B_GENE
expression O
in O
endothelial O
cells O
leading O
to O
enhanced O
monocyte O
chemotaxis O
. O

inducible B_DISEASE_ADJECTIVE[DISEASE]
resistance I_DISEASE_ADJECTIVE[DISEASE]
to O
Fas-mediated B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
apoptosis B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
B B_DISEASE
cells I_DISEASE
. O

Apoptosis O
produced O
in O
B O
cells O
through O
Fas B_GENE/B_DISEASE
( O
APO-1 B_GENE/B_LOCATION
, O
CD95 B_PROTEIN[GENE]/B_LOCATION
) O
triggering O
is O
regulated O
by O
signals O
derived O
from O
other O
surface O
receptors O
: O
CD40 O
engagement O
produces O
upregulation O
of O
Fas B_GENE
expression O
and O
marked O
susceptibility O
to O
Fas B_GENE/B_DISEASE
-induced O
cell O
death O
, O
whereas O
antigen O
receptor O
engagement O
, O
or O
IL-4R O
engagement O
, O
inhibits O
Fas B_GENE/B_PERSON
killing O
and O
in O
so O
doing O
induces O
a O
state O
of O
Fas B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-resistance O
, O
even O
in O
otherwise O
sensitive O
, O
CD40 B_GENE
-stimulated O
targets O
. O

Surface B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunoglobulin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
IL-4R B_GENE
utilize O
at O
least O
partially O
distinct O
pathways O
to O
produce O
Fas B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-resistance O
that O
differentially O
depend O
on O
PKC B_GENE
and O
STAT6 B_GENE
, O
respectively O
. O

Further O
, O
surface O
immunoglobulin O
signaling O
for O
inducible O
Fas B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-resistance O
bypasses O
Btk B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
requires O
NF-kappaB B_GENE
, O
and O
entails O
new O
macromolecular O
synthesis O
. O

Terminal O
effectors O
of O
B O
cell O
Fas B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-resistance O
include O
the O
known O
anti-apoptotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
products B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
Bcl-xL B_GENE/B_LOCATION
and O
FLIP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
a O
novel O
anti-apoptotic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
encodes O
FAIM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Fas B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Apoptosis I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Inhibitory I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Molecule I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

faim B_PERSON/B_GENE
was O
identified O
by O
differential O
display O
and O
exists O
in O
two O
alternatively O
spliced O
forms O
; O
faim-S B_PERSON/B_PROTEIN[GENE]
is O
broadly O
expressed O
, O
but O
faim-L O
expression O
is O
tissue-specific O
. O

The O
FAIM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
highly O
evolu- O
tionarily O
conserved O
, O
suggesting O
an O
important O
role O
for O
this O
molecule O
throughout O
phylogeny O
. O

Inducible O
resistance O
to O
Fas B_GENE/B_PERSON
killing O
is O
hypothesized O
to O
protect O
foreign O
antigen-specific O
B O
cells O
during O
potentially O
hazardous O
interactions O
with O
FasL-bearing O
T O
cells O
, O
whereas O
autoreactive O
B O
cells O
fail O
to O
become O
Fas B_GENE/B_DISEASE
-resistant O
and O
are O
deleted O
via O
Fas B_GENE
-dependent O
cytotoxicity O
. O

Inadvertent O
or O
aberrant O
acquisition O
of O
Fas B_GENE/B_DISEASE
-resistance O
may O
permit O
autoreactive O
B O
cells O
to O
escape O
Fas B_GENE/B_LOCATION
deletion O
, O
and O
malignant O
lymphocytes O
to O
impede O
anti-tumor O
immunity O
. O

Stromal B_GENE
cell-derived I_GENE
factor I_GENE
1 I_GENE
alpha I_GENE
-induced O
chemotaxis O
in O
T O
cells O
is O
mediated O
by O
nitric O
oxide O
signaling O
pathways O
. O

Stromal B_GENE
cell-derived I_GENE
factor I_GENE
1 I_GENE
alpha I_GENE
( O
SDF1 B_GENE
alpha I_GENE
) O
and O
its O
cognate O
chemokine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CXCR4 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
act O
as O
potent O
chemoattractants O
and O
regulate O
trafficking O
and O
homing O
of O
hematopoietic O
progenitor O
cells O
and O
lymphocytes O
. O

However O
, O
the O
molecular O
mechanisms O
regulating O
SDF1 B_GENE
alpha I_GENE
-driven O
cell O
migration O
are O
not O
well O
defined O
. O

In O
this O
study O
, O
we O
have O
explored O
the O
roles O
of O
the O
second O
messenger O
NO O
and O
the O
transcription B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
SDF1 B_GENE
alpha I_GENE
-induced O
T O
cell O
migration O
. O

SDF1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
treatment O
of O
Jurkat O
T O
cells O
increased O
the O
activity O
of O
NO B_GENE
synthase I_GENE
, O
which O
catalyzes O
the O
generation O
of O
NO O
. O

We O
observed O
that O
pretreatment O
of O
Jurkat O
cells O
or O
activated O
PBLs O
with O
several O
NO O
donors O
significantly O
enhanced O
the O
SDF1 B_GENE
alpha I_GENE
-induced O
migration O
, O
whereas O
various O
inhibitors O
of O
NO B_GENE
synthase I_GENE
markedly O
abrogated O
the O
chemotactic O
response O
in O
a O
concentration-dependent O
manner O
. O

Furthermore O
, O
we O
observed O
that O
inhibitors O
of O
the O
transcription B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
is O
linked O
to O
NO O
signaling O
pathways O
, O
also O
significantly O
blocked O
the O
SDF1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O
chemotactic O
response O
. O

However O
, O
these O
compounds O
did O
not O
have O
a O
significant O
effect O
on O
SDF1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-induced O
mitogen-activated O
protein O
kinase O
activity O
. O

In O
addition O
, O
the O
MAP/Erk O
kinase O
kinase O
inhibitor O
PD98059 O
did O
not O
abrogate O
SDF1 B_GENE
alpha I_GENE
-induced O
chemotaxis O
. O

AKT B_GENE
, O
which O
has O
been O
shown O
to O
mediate O
NO O
production O
, O
was O
also O
phosphorylated O
upon O
SDF1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation O
. O

These O
studies O
suggest O
that O
NO-related O
signaling O
pathways O
may O
mediate O
SDF1 B_GENE
alpha I_GENE
-induced O
chemotaxis O
, O
but O
not O
mitogen-activated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
activation O
. O

The O
lack B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
NF-kappa B_GENE
B I_GENE
transactivation I_GENE
and O
PKC B_GENE
epsilon I_GENE
expression I_GENE
in O
CD4 B_GENE
( O
+ B_DISEASE/B_GENE
) O
CD8 B_GENE
( O
+ B_DISEASE/B_PROTEIN[GENE]
) O
thymocytes B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlates I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
negative B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
selection I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Deletion O
of O
autoreactive O
thymocytes O
at O
the O
DP O
stage O
is O
the O
basis O
for O
tolerance O
to O
thymus-expressed B_DISEASE
self I_DISEASE
antigens I_DISEASE
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O
investigated O
whether O
distinct B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
induced O
in O
DP B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
thymocytes I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
as O
compared O
to O
mature O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
upon O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
antigen B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Using O
triple O
transgenic O
mice O
expressing O
a O
TCR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transgene B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
dominant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
negative I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ras/Mek I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
reporter B_GENE
gene I_GENE
construct I_GENE
with O
AP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
showed O
a O
complete O
lack O
of O
transcriptional O
activity O
of O
NF-kappa B_GENE
B I_GENE
but O
not O
AP-1 B_GENE
in O
DP O
thymocytes O
, O
whereas O
both O
were O
transcriptionally O
active O
in O
mature O
T O
cells O
after O
antigenic O
stimulation O
. O

lack O
of O
NF-kappa B_GENE/B_DISEASE
B I_GENE/I_DISEASE
induction O
correlated O
with O
increased O
death O
in O
response O
to O
antigen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

AP-1 B_GENE/B_DISEASE
induction O
was O
dependent O
on O
the O
integrity O
of O
the O
ras/Mek O
pathway O
indicating O
that O
this O
pathway O
was O
activated O
in O
the O
DP O
thymocytes O
. O

In O
contrast O
, O
we O
found O
a O
complete O
lack O
of O
constitutive O
expression O
of O
the O
epsilon B_PROTEIN[GENE]
isoform I_PROTEIN[GENE]
of I_PROTEIN[GENE]
Protein I_PROTEIN[GENE]
Kinase I_PROTEIN[GENE]
C I_PROTEIN[GENE]
( O
PKC B_GENE
) O
in O
DP O
thymocytes O
, O
although O
it O
was O
present O
in O
mature O
thymocytes O
and O
peripheral O
T O
cells O
. O

taken O
together O
the O
results O
suggest O
that O
the O
lack O
of O
PKC B_GENE
epsilon I_GENE
in O
DP O
thymocytes O
could O
lead O
to O
the O
absence O
of O
NF-kappa B_GENE
B I_GENE
activity O
after O
antigenic O
stimulation O
contributing O
to O
negative O
selection O
. O

Cell B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Death B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
differentiation B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
( O
2000 B_NUMBER[MEASURE]
) O
7 B_MEASURE
, O
1253 B_MEASURE
- O
1262 B_MEASURE
. O

CD2 O
stimulation O
leads O
to O
the O
delayed O
and O
prolonged O
activation O
of O
STAT1 B_GENE
in O
T O
cells O
but O
not O
NK O
cells O
. O

objective O
: O
T O
lymphocytes O
can O
be O
activated O
by O
soluble O
factors O
such O
as O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O
through O
direct O
cell-cell O
interactions O
. O

Although O
cytokine B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
are O
known O
to O
signal O
through O
STAT B_GENE
family I_GENE
transcription I_GENE
factors I_GENE
, O
the O
mechanisms O
by O
which O
other O
cell-surface B_GENE/B_BIO
molecules I_GENE/I_BIO
, O
such O
as O
CD2 B_GENE
, O
transduce O
signals O
is O
unclear O
. O

The O
goal O
of O
this O
study O
was O
to O
determine O
whether O
stimulation O
of O
T O
cells O
through O
CD2 B_GENE
recapitulates O
aspects O
of O
cytokine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O
T-cell O
activation O
by O
use O
of O
STAT B_GENE
transcription I_GENE
factors I_GENE
. O

Materials O
AND O
methods O
: O
T O
cells O
were O
treated O
with O
anti-CD2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O
cells O
bearing O
the O
natural O
CD2 B_GENE
ligand I_GENE
CD58 I_GENE
, O
after O
which O
signaling O
through O
STAT B_GENE
transcription I_GENE
factors I_GENE
was O
assessed O
. O

Results O
: O
stimulation O
of O
CD2 B_GENE
on O
primary O
T O
lymphocytes O
leads O
to O
the O
tyrosine O
phosphorylation O
, O
nuclear O
translocation O
, O
and O
DNA O
binding O
of O
STAT1 B_GENE
. O

In O
contrast O
to O
stimulation O
by O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
activation O
of O
STAT1 B_GENE
in O
response O
to O
CD2 O
ligation O
is O
delayed O
and O
does O
not O
involve O
Jak B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Furthermore O
, O
while O
STAT O
phosphorylation O
induced O
by O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O
generally O
transient O
, O
STAT1 O
phosphorylation O
following O
CD2 O
stimulation O
persists O
for O
a O
period O
of O
days O
. O

transcription O
of O
key O
target O
genes O
such O
as O
IRF1 B_GENE
and O
c-fos B_GENE
proceeds O
with O
delayed O
kinetics O
following O
CD2 O
stimulation O
, O
suggesting O
that O
this O
unique O
pattern O
of O
STAT O
activation O
may O
lead O
to O
a O
distinct O
cellular O
response O
following O
CD2 O
ligation O
. O

This O
pathway O
appears O
to O
be O
restricted O
to O
T O
cells O
, O
as O
stimulation O
of O
CD2 B_GENE
on O
NK O
cells O
does O
not O
lead O
to O
STAT1 O
activation O
. O

conclusion O
: O
stimulation O
of O
T O
cells O
through O
cell-surface B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
such O
as O
CD2 B_GENE
involves O
activation O
of O
STAT B_GENE
transcription I_GENE
factors I_GENE
, O
thus O
recapitulating O
elements O
of O
cytokine O
signaling O
. O

NFATc1 B_GENE
and O
NFATc2 B_GENE
together O
control O
both O
T O
and O
B O
cell O
activation O
and O
differentiation O
. O

NFAT B_GENE/B_PERSON
transcription I_GENE/I_PERSON
factors I_GENE/I_PERSON
play O
critical O
roles O
in O
gene O
transcription O
during O
immune O
responses O
. O

To O
investigate O
further O
the O
two O
most O
prominent O
NFAT B_GENE/B_PERSON
family I_GENE/I_PERSON
members I_GENE/I_PERSON
, O
NFATc1 B_GENE
and O
NFATc2 B_GENE
, O
we O
generated O
mice O
bearing O
lymphoid O
systems O
devoid O
of O
both O
. O

Doubly O
deficient O
T O
cells O
displayed O
cell O
surface O
markers O
of O
activation O
yet O
were O
significantly O
deficient O
in O
the O
development O
of O
multiple O
effector O
functions O
, O
including O
Th B_GENE
cytokine I_GENE
production O
, O
surface B_GENE
effector I_GENE
molecule I_GENE
expression O
, O
and O
cytolytic O
activity O
. O

Nevertheless O
, O
doubly O
deficient O
B O
cells O
were O
hyperactivated O
, O
as O
evidenced O
by O
extremely O
elevated O
serum O
IgG1 B_GENE
and O
IgE B_GENE/B_DISEASE
, O
as O
well O
as O
plasma O
cell O
expansion O
and O
infiltration O
of O
end O
organs O
. O

Thus O
, O
in O
T O
cells O
, O
NFATc1 B_GENE
and O
NFATc2 B_GENE
are O
dispensable O
for O
inflammatory O
reactivity O
but O
are O
required O
for O
effector O
differentiation O
, O
while O
in O
B O
cells O
, O
NFATs B_GENE/B_PERSON
regulate O
both O
normal O
homeostasis O
and O
differentiation O
. O

Epstein-barr O
virus O
immediate-early B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BZLF1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
SUMO-1 O
modified O
and O
disrupts O
promyelocytic O
leukemia O
bodies O
. O

Although O
the O
immediate-early B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteins B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O
both O
herpes O
simplex O
virus O
( O
HSV O
) O
and O
cytomegalovirus O
( O
CMV O
) O
are O
known O
to O
modify O
promyelocytic O
leukemia O
( O
PML O
) O
( O
ND10 O
) O
bodies O
in O
the O
nucleus O
of O
the O
host O
cell O
, O
it O
has O
been O
unclear O
whether O
lytic O
infection O
with O
gamma O
herpesviruses O
induces O
a O
similar O
effect O
. O

The O
PML B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
induced O
by O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
involved O
in O
major B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
histocompatibility B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complex B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
class B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
presentation O
, O
and O
necessary O
for O
certain O
types O
of O
apoptosis O
. O

Therefore O
, O
it O
is O
likely B_DISEASE_ADJECTIVE[DISEASE]
that O
PML B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
bodies I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
function O
in O
an O
antiviral B_MEASURE/B_LOCATION
capacity B_MEASURE/I_LOCATION
. O

SUMO-1 O
modification O
of O
PML B_GENE/B_DISEASE
is O
known O
to O
be O
required O
for O
the O
formation O
of O
PML O
bodies O
. O

To O
examine O
whether O
Epstein-Barr O
virus O
( O
EBV O
) O
lytic O
replication O
interferes O
with O
PML O
bodies O
, O
we O
expressed O
the O
EBV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immediate-early I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BZLF1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Z I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
BRLF1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
R I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
EBV-positive O
cell O
lines O
and O
examined O
PML B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
localization O
. O

Both O
Z O
and O
R O
expression O
resulted O
in O
PML B_DISEASE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
dispersion O
in O
EBV-positive O
cells O
. O

Z B_OTHER/B_LOCATION
but O
not O
R B_PROTEIN[GENE]/B_LOCATION
expression I_PROTEIN[GENE]/I_LOCATION
is O
sufficient B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
disrupt O
PML B_DISEASE/B_GENE
bodies I_DISEASE/I_GENE
in O
EBV-negative B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lines B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
show O
that O
dispersion O
of O
PML O
bodies O
by O
Z B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requires O
a O
portion O
of O
the O
transcriptional B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Z B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
not O
the O
DNA-binding O
function O
. O

As O
was O
previously O
reported O
for O
the O
HSV-1 B_DISEASE/B_BIO
ICP0 I_DISEASE/I_BIO
and I_DISEASE/I_BIO
CMV I_DISEASE/I_BIO
IE1 I_DISEASE/I_BIO
proteins I_DISEASE/I_BIO
, O
Z B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduces O
the O
amount O
of O
SUMO-1-modified B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PML I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
also O
found O
that O
Z B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
itself O
is O
SUMO-1 O
modified O
( O
through O
amino O
acid O
12 O
) O
and O
that O
Z B_OTHER/B_PROTEIN[GENE]
competes O
with O
PML B_GENE/B_DISEASE
for O
limiting O
amounts O
of O
SUMO-1 B_GENE
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
disruption B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
PML B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bodies I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
efficient B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
lytic I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
replication I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
EBV B_VIRUS[BIO]/B_DISEASE
. O

Furthermore O
, O
Z B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O
potentially O
alter O
the O
function O
of O
a O
variety O
of O
cellular O
proteins O
by O
inhibiting O
SUMO-1 O
modification O
. O

suppression O
of O
nuclear B_GENE/B_DISEASE
factor-kappaB I_GENE/I_DISEASE
and O
stimulation O
of O
inhibitor B_GENE
kappaB I_GENE
by O
troglitazone O
: O
evidence O
for O
an O
anti-inflammatory O
effect O
and O
a O
potential O
antiatherosclerotic O
effect O
in O
the O
obese O
. O

To O
elucidate O
whether O
troglitazone O
exerts O
an O
antiinflammatory O
effect O
in O
humans O
, O
in O
vivo O
, O
we O
investigated O
the O
suppression O
of O
nuclear B_GENE
factor I_GENE
kappaB I_GENE
( O
NFkappaB B_GENE
) O
in O
mononuclear O
cells O
( O
MNC O
) O
by O
this O
drug O
. O

We O
measured O
intranuclear B_GENE/B_DISEASE
NFkappaB I_GENE/I_DISEASE
, O
total O
cellular B_GENE
NFkappaB I_GENE
, O
inhibitor B_GENE
kappaB I_GENE
( I_GENE
IkappaB I_GENE
) I_GENE
alpha I_GENE
, O
reactive O
oxygen O
species O
( O
ROS O
) O
generation O
, O
and O
p47 B_GENE
( I_GENE
phox I_GENE
) I_GENE
subunit I_GENE
( O
a O
key O
component O
protein O
of O
nicotinamide B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adenine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dinucleotide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphate I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oxidase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
in O
MNC O
. O

Plasma B_MEASURE/B_LOCATION
tumor I_MEASURE/I_LOCATION
necrosis I_MEASURE/I_LOCATION
factor I_MEASURE/I_LOCATION
( I_MEASURE/I_LOCATION
TNF I_MEASURE/I_LOCATION
) I_MEASURE/I_LOCATION
-alpha I_MEASURE/I_LOCATION
, O
soluble B_GENE
intercellular I_GENE
adhesion I_GENE
molecule-1 I_GENE
( O
sICAM-1 B_GENE/B_LOCATION
) O
, O
monocyte B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chemoattractant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MCP-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
plasminogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activator B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibitor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
PAI-1 B_GENE/B_LOCATION
) O
, O
C-reactive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CRP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
interleukin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
-10 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
antiinflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
concentrations O
were O
also O
measured O
as O
mediators O
of O
inflammatory O
activity O
that O
are O
regulated O
by O
the O
proinflammatory B_GENE
transcription I_GENE
factor I_GENE
NFkappaB I_GENE
. O

Seven B_PERSON
nondiabetic I_PERSON
obese I_PERSON
patients I_PERSON
were O
given O
400 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
troglitazone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
daily O
for O
4 B_TIME[MEASURE]/B_DISEASE
weeks B_TIME[MEASURE]/I_DISEASE
. O

Blood B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
collected O
before O
and O
at O
weekly B_TIME[MEASURE]/B_LOCATION
intervals B_TIME[MEASURE]/I_LOCATION
thereafter O
. O

MNC O
were O
separated O
; O
and O
the O
levels O
of O
intranuclear B_GENE
NFkappaB I_GENE
, O
total O
cellular B_GENE
NFkappaB I_GENE
, O
IkappaBalpha B_GENE
, O
and O
p47 B_GENE/B_LOCATION
( I_GENE/I_LOCATION
phox I_GENE/I_LOCATION
) I_GENE/I_LOCATION
subunit I_GENE/I_LOCATION
and O
ROS O
generation O
were O
determined O
. O

plasma O
was O
used O
to O
measure O
insulin O
glucose O
, O
TNFalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
sICAM B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
MCP-1 B_GENE
, O
PAI-1 B_GENE
, O
CRP B_GENE
, O
and O
IL-10 B_GENE
. O

Plasma B_GENE
insulin I_GENE
concentrations I_GENE
fell O
significantly O
at O
week B_TIME[MEASURE]
1 I_TIME[MEASURE]
, O
from O
31.2 B_MEASURE
+/- O
29.1 B_MEASURE
to O
14.2 B_MEASURE
+/- O
11.4 B_MEASURE
mU/L I_MEASURE
( O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
0.01 I_MEASURE/I_LOCATION
) O
and O
remained O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
throughout O
4 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

plasma B_MEASURE/B_PERSON
glucose B_MEASURE/I_PERSON
concentrations B_MEASURE/I_PERSON
did O
not O
alter O
significantly O
. O

There O
was O
a O
fall O
in O
intranuclear B_GENE
NFkappaB I_GENE
, O
total O
cellular B_GENE
NFkappaB I_GENE
, O
and O
p47 B_GENE
( I_GENE
phox I_GENE
) I_GENE
subunit I_GENE
, O
with O
an O
increase O
in O
cellular O
IkappaBalpha B_GENE
at O
week O
2 O
, O
which O
persisted O
until O
week O
4 O
. O

There O
was O
a O
parallel B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fall B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
ROS B_DISEASE/B_GENE
generation I_DISEASE/I_GENE
by O
MNC B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
at O
week B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O
this O
progressed O
and O
persisted O
until O
week B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
4 I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
P B_MEASURE
< I_MEASURE
0.001 I_MEASURE
) O
. O

plasma O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
sICAM-1 B_GENE
, O
MCP-1 B_GENE
, O
and O
PAI-1 B_GENE
concentrations O
fell O
significantly O
at O
week O
4 O
. O

plasma O
IL-10 B_GENE
concentration O
increased O
significantly O
, O
whereas O
plasma B_GENE
CRP I_GENE
concentrations O
decreased O
. O

We O
conclude O
that O
troglitazone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
has O
an O
antiinflammatory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
may O
contribute O
to O
its O
putative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
antiatherosclerotic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
effects I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Tyrosine O
phosphorylation-dependent O
activation O
of O
NF-kappa B_GENE
B I_GENE
. O

requirement O
for O
p56 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
LCK I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
ZAP-70 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Phosphorylation O
of O
the O
N-terminal B_GENE/B_MEASURE
domain I_GENE/I_MEASURE
of O
I B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibitory I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O
activation O
of O
the O
transcription B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
B I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
serine O
phosphorylation O
has O
been O
shown O
to O
induce O
ubiquitination O
and O
subsequent O
proteasome-mediated O
degradation O
of O
I B_GENE
kappa I_GENE
B-alpha I_GENE
, O
little O
is O
known O
about O
the O
mechanisms O
that O
lead O
to O
release O
of O
active O
NF-kappa B_GENE
B I_GENE
in O
T O
cells O
as O
a O
consequence O
of O
tyrosine O
phosphorylation O
of O
I B_GENE
kappa I_GENE
B-alpha I_GENE
[ O
Imbert O
, O
V. O
, O
Rupec O
, O
R.A. O
, O
Livolsi O
, O
A. O
, O
Pahl O
, O
H.L. O
, O
Traenckner O
, O
B.M. O
, O
Mueller-Dieckmann O
, O
C. O
, O
Farahifar O
, O
D. O
, O
Rossi O
, O
B. O
, O
Auberger O
, O
P. O
, O
Baeuerle O
, O
P. O
& O
Peyron O
, O
J.F. O
( O
1996 O
) O
Cell O
86 O
, O
787 O
-- O
798 O
] O
. O

The O
involvement O
of O
the O
tyrosine B_GENE
kinases I_GENE
p56 I_GENE
( I_GENE
lck I_GENE
) I_GENE
and O
ZAP-70 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
reaction O
is O
demonstrated O
here O
using O
specific O
pharmacological O
inhibitors O
and O
Jurkat O
mutants O
unable O
to O
express O
these O
kinases B_ENZYME[GENE]
. O

Although O
the O
inhibitors O
prevented O
both O
pervanadate-induced O
phosphorylation O
of O
I B_GENE
kappa I_GENE
B-alpha I_GENE
on O
Tyr42 O
and O
NF-kappa B_GENE
B I_GENE
activation O
, O
we O
observed O
that O
, O
in O
p56 O
( O
lck O
) O
-deficient O
Jurkat O
mutants O
, O
NF-kappa B_GENE
B I_GENE
could O
still O
associate O
with O
I B_GENE
kappa I_GENE
B-alpha I_GENE
despite O
phosphorylation O
on O
Tyr42 O
. O

Furthermore O
, O
the O
SH2 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
p56 B_GENE
( I_GENE
lck I_GENE
) I_GENE
appeared O
to O
be O
required O
for O
pervanadate-induced O
NF-kappa B_GENE
B I_GENE
activation O
but O
not O
for O
Tyr42 O
phosphorylation O
. O

These O
results O
show O
that O
p56 B_GENE
( I_GENE
lck I_GENE
) I_GENE
and O
ZAP-70 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
key O
components O
of O
the O
signaling O
pathway O
that O
leads O
to O
phosphotyrosine-dependent O
NF-kappa B_GENE
B I_GENE
activation O
in O
T O
cells O
and O
confirm O
that O
tyrosine B_GENE
kinases I_GENE
must O
control O
at O
least O
two O
different O
steps O
to O
induce O
activation O
of O
NF-kappa B_GENE
B I_GENE
. O

Finally O
, O
we O
show O
that O
H O
( O
2 O
) O
O O
( O
2 O
) O
, O
which O
stimulates O
p56 B_GENE
( I_GENE
lck I_GENE
) I_GENE
and O
ZAP-70 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
T O
cells O
, O
is O
an O
activator O
of O
NF-kappa B_GENE/B_DISEASE
B I_GENE/I_DISEASE
through O
tyrosine O
phosphorylation O
of O
I B_GENE
kappa I_GENE
B-alpha I_GENE
. O

specific O
missense O
mutations O
in O
NEMO B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
result O
in O
hyper-IgM O
syndrome O
with O
hypohydrotic O
ectodermal O
dysplasia O
. O

The O
gene O
that O
encodes O
nuclear B_GENE/B_LOCATION
factor I_GENE/I_LOCATION
kappaB I_GENE/I_LOCATION
( I_GENE/I_LOCATION
NF-kappaB I_GENE/I_LOCATION
) I_GENE/I_LOCATION
essential I_GENE/I_LOCATION
modulator I_GENE/I_LOCATION
( O
or O
NEMO B_ENZYME[GENE]/B_PERSON
, O
also O
known O
as O
IKKgamma B_GENE/B_LOCATION
) O
is O
required O
for O
activation O
of O
the O
transcription B_GENE/B_LOCATION
factor I_GENE/I_LOCATION
NF-kappaB I_GENE/I_LOCATION
. O

We O
describe O
mutations O
in O
the O
putative B_GENE/B_LOCATION
zinc-finger I_GENE/I_LOCATION
domain I_GENE/I_LOCATION
of O
NEMO B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
result O
in O
an O
X-linked O
primary O
immunodeficiency O
characterized O
by O
hyper-IgM O
syndrome O
and O
hypohydrotic O
ectodermal O
dysplasia O
( O
XHM-ED O
) O
. O

These O
mutations O
prevent O
CD40 B_GENE
ligand I_GENE
( O
CD40L B_GENE
) O
-mediated O
degradation O
of O
inhibitor O
of O
NF-kappaB B_GENE
alpha I_GENE
( O
IkappaB-alpha B_GENE/B_DISEASE
) O
and O
account O
for O
the O
following O
observations O
: O
B O
cells O
from O
XHM-ED O
patients O
are O
unable O
to O
undergo O
immunoglobulin O
class-switch O
recombination O
and O
antigen-presenting O
cells O
( O
APCs O
) O
are O
unable O
to O
synthesize O
the O
NF-kappaB-regulated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
interleukin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
12 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
IL-12 B_GENE/B_MEASURE
) O
or O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
when O
stimulated O
with O
CD40L B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nevertheless O
, O
innate O
immunity O
is O
preserved O
in O
XHM-ED O
patients O
because O
APCs O
retain O
the O
capacity O
to O
respond O
to O
stimulation O
by O
lipopolysaccharide O
or O
Staphylococcus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
aureus I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
Cowan I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
's I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
antigen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O
SAC B_MEASURE/B_DISEASE
) O
. O

Overall O
, O
the O
phenotype O
observed O
in O
XHM-ED O
patients O
shows O
that O
the O
putative B_GENE_EXPRESSION_ADJECTIVE[GENE]
zinc-finger I_GENE_EXPRESSION_ADJECTIVE[GENE]
domain I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
NEMO B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
a O
regulatory O
function O
and O
demonstrates O
the O
definite O
requirement O
of O
CD40 B_GENE
-mediated O
NF-kappaB O
activation O
for O
B O
cell O
immunoglobulin O
class-switching O
. O

Granulocytic B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_DISEASE_ADJECTIVE[DISEASE]
of O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
NB4 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
promyelocytic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukemia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
all-trans B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
retinoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
metabolites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
metabolism B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
all-trans B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
retinoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
ATRA B_LOCATION/B_ORGANIZATION
) O
has O
been O
reported O
to O
be O
partly O
responsible B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
in O
vivo B_DISEASE_ADJECTIVE[DISEASE]
resistance I_DISEASE_ADJECTIVE[DISEASE]
to O
ATRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seen O
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
human B_DISEASE/B_PERSON
acute I_DISEASE/I_PERSON
promyelocytic I_DISEASE/I_PERSON
leukemia I_DISEASE/I_PERSON
( O
APL B_DISEASE
) O
. O

However O
, O
ATRA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
metabolism I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
appears O
to O
be O
involved O
in O
the O
growth B_DISEASE/B_ORGANISM_FUNCTION
inhibition I_DISEASE/I_ORGANISM_FUNCTION
of O
several B_DISEASE
cancer I_DISEASE
cell I_DISEASE
lines I_DISEASE
in O
vitro B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
in O
vitro O
activity O
of O
the O
principal O
metabolites O
of O
ATRA O
[ O
4-hydroxy-retinoic O
acid O
( O
4-OH-RA O
) O
, O
18-hydroxy-retinoic O
acid O
( O
18-OH-RA O
) O
, O
4-oxo-retinoic O
acid O
( O
4-oxo-RA O
) O
, O
and O
5 O
, O
6-epoxy-retinoic O
acid O
( O
5 O
, O
6-epoxy-RA O
) O
] O
in O
NB4 O
, O
a O
human O
promyelocytic O
leukemia O
cell O
line O
that O
exhibits O
the O
APL O
diagnostic O
t O
( O
15 O
; O
17 O
) O
chromosomal O
translocation O
and O
expresses O
the O
PML-RAR B_GENE/B_DISEASE
alpha I_GENE/I_DISEASE
fusion I_GENE/I_DISEASE
protein I_GENE/I_DISEASE
. O

We O
established O
that O
the O
four B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ATRA I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
metabolites I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
indeed O
formed O
by O
the O
NB4 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
vitro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

NB4 B_DISEASE/B_GENE
cell B_DISEASE/I_GENE
growth B_DISEASE/I_GENE
was O
inhibited O
( O
69-78 B_MEASURE
% I_MEASURE
at O
120 B_MEASURE
h O
) O
and O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycle B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
progression B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
G1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
82-85 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
at O
120 B_MEASURE
h O
) O
was O
blocked O
by O
ATRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
all O
of O
the O
metabolites B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
1 B_TIME[MEASURE]/B_DISEASE
microM I_TIME[MEASURE]/I_DISEASE
concentration I_TIME[MEASURE]/I_DISEASE
. O

ATRA O
and O
its O
metabolites O
could O
induce O
NB4 O
cells O
differentiation O
with O
similar O
activity O
, O
as O
evaluated O
by O
cell O
morphology O
, O
by O
the O
nitroblue O
tetrazolium O
reduction O
test O
( O
82-88 O
% O
at O
120 O
h O
) O
or O
by O
the O
expression O
of O
the O
maturation B_GENE
specific I_GENE
cell I_GENE
surface I_GENE
marker I_GENE
CD11c I_GENE
. O

In O
addition O
, O
nuclear O
body O
reorganization O
to O
macropunctated O
structures O
, O
as O
well O
as O
the O
degradation O
of O
PML-RAR B_GENE
alpha I_GENE
, O
was O
found O
to O
be O
similar O
for O
ATRA O
and O
all O
of O
its O
metabolites O
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
relative B_MEASURE/B_LOCATION
potency I_MEASURE/I_LOCATION
of O
the O
retinoids B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
using O
the O
nitroblue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tetrazolium I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
reduction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
test I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O
effective B_MEASURE/B_LOCATION
concentrations B_MEASURE/I_LOCATION
required O
to O
differentiate O
50 B_LOCATION/B_MEASURE
% B_LOCATION/I_MEASURE
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
in O
72 B_NUMBER[MEASURE]
h O
as O
follows O
: O
ATRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
15.8 B_MEASURE
+/- I_MEASURE
1.7 I_MEASURE
nm I_MEASURE
; O
4-oxo-RA B_LOCATION/B_ORGANIZATION
, O
38.3 B_MEASURE
+/- I_MEASURE
1.3 I_MEASURE
nm I_MEASURE
; O
18-OH-RA B_LOCATION/B_ORGANIZATION
, O
55.5 B_MEASURE
+/- I_MEASURE
1.8 I_MEASURE
nm I_MEASURE
; O
4-OH-RA B_LOCATION/B_PERSON
, O
79.8 B_MEASURE
+/- O
1.8 B_MEASURE/B_LOCATION
nM I_MEASURE/I_LOCATION
; O
and O
5 B_MEASURE/B_LOCATION
, O
6-epoxy-RA B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
99.5 B_MEASURE/B_LOCATION
+/- I_MEASURE
1.5 I_MEASURE
nm I_MEASURE
. O

The O
ATRA O
metabolites O
were O
found O
to O
exert O
their O
differentiation O
effects O
via O
the O
RAR B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
nuclear I_GENE/I_LOCATION
receptors I_GENE/I_LOCATION
, O
because O
the O
RAR O
alpha-specific O
antagonist O
BMS614 O
blocked O
metabolite-induced O
CD11c O
expression O
in O
NB4 O
cells O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
that O
the O
principal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ATRA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Phase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
elicit O
leukemia B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
differentiation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
through O
the O
RAR B_GENE
alpha I_GENE
signaling O
pathway B_LOCATION/B_ORGANIZATION
, O
and O
they O
suggest O
that O
these O
metabolites B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O
play O
a O
role B_TIME[MEASURE]/B_PERSON
in O
ATRA B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antileukemic I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

expression O
of O
oestrogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
progesterone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
mast O
cells O
alone O
, O
but O
not O
lymphocytes O
, O
macrophages O
or O
other O
immune O
cells O
in O
human O
upper O
Airways O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Nasal B_DISEASE/B_LOCATION
polyposis I_DISEASE/I_LOCATION
often O
coexists O
with O
asthma B_DISEASE
in O
airway B_DISEASE/B_PERSON
inflammatory I_DISEASE/I_PERSON
conditions I_DISEASE/I_PERSON
characterised O
by O
the O
infiltration B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
range B_LOCATION/B_MEASURE
of O
immune B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
potentially O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
role I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
ovarian B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hormones I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
implicated O
in O
airway B_DISEASE/B_ORGANISM_FUNCTION
inflammation I_DISEASE/I_ORGANISM_FUNCTION
but O
the O
cellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
such B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
not O
known O
. O

methods O
: O
expression O
of O
oestrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
ER B_LOCATION/B_ORGANIZATION
) O
and O
progesterone B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PR B_LOCATION/B_ORGANIZATION
) O
was O
examined O
using O
immunohistochemistry O
in O
formalin O
fixed O
nasal O
polyp O
tissues O
from O
47 O
subjects O
. O

The O
cells O
positive O
for O
ER B_LOCATION
or O
PR B_LOCATION
were O
confirmed O
by O
spatial O
location O
, O
dual O
immunolabelling O
, O
and O
histochemical O
staining O
. O

Results O
: O
consistent O
with O
the O
known O
features O
of O
nasal O
polyps O
, O
CD4+ O
( O
T O
helper/inducer O
) O
, O
CD8+ O
( O
cytotoxic/suppressor O
) O
, O
CD68+ O
( O
macrophages O
) O
, O
mast O
cells O
, O
eosinophils O
and O
neutrophils O
were O
all O
clearly O
detected O
by O
their O
relevant O
monoclonal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
appropriate O
histochemical O
staining O
, O
but O
only O
mast O
cells O
tested O
positive O
for O
ER B_LOCATION
/PR O
labelling O
with O
their O
polyclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
frequencies B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
expression B_DISEASE/B_GENE
were O
61.7 B_MEASURE
% I_MEASURE
for O
ER B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
positive I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
59.6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
for O
PR B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
positive I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cells I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

The O
expression O
of O
ER B_PROTEIN[GENE]/B_LOCATION
/ O
PR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O
independent O
of O
patient O
sex O
and O
age O
but O
was O
highly O
correlated O
with O
the O
numbers O
of O
mast O
cells O
( O
r O
= O
0.973 O
, O
p O
< O
0.001 O
for O
ER B_PROTEIN[GENE]/B_LOCATION
; O
r O
= O
0.955 O
, O
p O
< O
0.001 O
for O
PR B_LOCATION
) O
. O

fewer O
than O
5 O
% O
of O
mast O
cells O
were O
found O
to O
be O
negative O
for O
ER B_LOCATION
/ O
PR B_LOCATION
expression O
. O

conclusions O
: O
mast O
cells O
alone O
, O
but O
not O
lymphocytes O
, O
macrophages O
, O
or O
other O
immune O
cells O
, O
express O
ER B_LOCATION
/ O
PR B_LOCATION
in O
human O
upper O
Airways O
. O

Numerous B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ER/PR I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
positive I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mast I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cells I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
exist O
in O
nasal B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
polyps I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
indicating O
that O
this O
may O
be O
a O
major B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
route I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
involvement B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sex B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hormones B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
airway B_DISEASE/B_BIO
inflammation I_DISEASE/I_BIO
when O
exposed O
to O
the O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
varying O
concentration B_MEASURE
of O
oestrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
characteristic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
females B_PERSON/B_BIO
. O

NF B_GENE
kappa I_GENE
b O
signaling B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
posthypoxic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
endothelial B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
: O
relevance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
E-selectin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
neutrophil B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
adhesion B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

Our O
previous O
studies O
have O
implicated O
the O
nuclear O
transcription O
factor O
Kappa O
B O
( O
NF B_GENE
kappa I_GENE
B I_GENE
) O
in O
the O
regulation O
of O
adhesion B_GENE
molecule I_GENE
expression O
in O
endothelial O
cells O
exposed O
to O
anoxia-reoxygenation O
( O
A/R O
) O
or O
a O
redox O
imbalance O
. O

The O
objectives O
of O
this O
study O
were O
( O
1 O
) O
to O
define O
the O
kinetics O
of O
NF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kappa B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O
by O
examining O
I O
Kappa O
B O
alpha O
degradation O
and O
the O
nuclear O
translocation O
of O
p65 B_GENE
in O
response O
to O
A/R O
or O
redox O
imbalance O
( O
induced O
by O
treatment O
of O
cells O
with O
diamide O
and O
buthionine O
sulfoximine O
) O
and O
( O
2 O
) O
to O
determine O
whether O
the O
signal O
for O
I O
Kappa O
B O
alpha O
degradation O
, O
nuclear O
translocation O
of O
p65 B_GENE
, O
and O
E-selectin B_GENE
-mediated O
neutrophil O
adhesion O
is O
related O
to O
the O
activity O
of O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PTK B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
, O
protein B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PTPase B_GENE/B_LOCATION
) O
and/or O
protein B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
C I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PKC B_GENE/B_DISEASE
) O
. O

The O
results O
demonstrate O
that O
both O
A/R O
and O
redox O
imbalance O
led O
to O
I O
Kappa O
B O
alpha O
degradation O
within O
30 O
min O
and O
the O
concomitant O
appearance O
of O
p65 B_GENE
in O
the O
nucleus O
, O
consistent O
with O
rapid O
cytosolic O
activation O
of O
NF B_GENE
kappa I_GENE
B I_GENE
and O
subsequent O
nuclear O
translocation O
of O
the O
activated B_GENE
p65 I_GENE
subunit I_GENE
. O

Inhibition O
of O
PKC B_GENE
blocked O
I B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degradation O
and O
p65 B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
translocation O
in O
A/R-challenged O
, O
but O
not O
redox-altered O
, O
endothelial O
cells O
. O

However O
, O
both O
A/R- O
and O
redox-induced O
NF O
Kappa O
B O
activation O
was O
blocked O
by O
inhibition O
of O
PTK B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Similarly O
, O
A/R-induced O
E-selectin O
expression O
and O
neutrophil-endothelial O
cell O
adhesion O
were O
blocked O
by O
inhibition O
of O
PKC B_GENE/B_LOCATION
or O
PTK B_LOCATION/B_GENE
, O
while O
only O
PTK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O
the O
redox-induced O
adhesion O
response O
. O

Pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
with O
N-acetyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cysteine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effectively O
blocked O
A/R- B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
redox-induced O
I O
kappa B_DISEASE_ADJECTIVE[DISEASE]
B I_DISEASE_ADJECTIVE[DISEASE]
degradation I_DISEASE_ADJECTIVE[DISEASE]
and O
significantly O
attenuated O
the O
respective B_DISEASE_ADJECTIVE[DISEASE]
neutrophil I_DISEASE_ADJECTIVE[DISEASE]
adhesion I_DISEASE_ADJECTIVE[DISEASE]
responses I_DISEASE_ADJECTIVE[DISEASE]
. O

collectively O
, O
these O
findings O
indicate O
that O
A/R-induced O
E-selectin O
expression O
and O
neutrophil-endothelial O
cell O
adhesion O
are O
mediated O
by O
both O
PKC B_GENE
and O
PTK B_GENE/B_LOCATION
, O
which O
signal O
rapid O
activation O
of O
NF B_GENE
kappa I_GENE
B I_GENE
. O

This O
A/R-induced O
NF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O
response O
appears O
to O
be O
mediated O
, O
at O
least O
in O
part O
, O
by O
intracellular O
redox O
imbalance O
. O

Copyright B_MEASURE/B_PERSON
2001 I_MEASURE/I_PERSON
S I_MEASURE/I_PERSON
. O
Karger B_PERSON
AG I_PERSON
, O
Basel B_LOCATION/B_ORGANIZATION
. O

Induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
apoptosis B_DISEASE/B_GENE
in O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O
the O
herbicide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
4-dichlorophenoxyacetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

Dimethylammonium B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
salt B_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
2 B_NUMBER[MEASURE]
, O
4-dichlorophenoxyacetic B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DMA-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
4-D B_MEASURE
) O
is O
a O
widely O
used O
herbicide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
is O
considered O
moderately O
toxic B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O
found O
that O
DMA-2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
4-D B_NUMBER[MEASURE]/B_LOCATION
is O
able B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
cause O
apoptosis B_DISEASE
in O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
healthy B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
individuals I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O
Jurkat B_PERSON/B_DISEASE
T I_PERSON/I_DISEASE
cells I_PERSON/I_DISEASE
. O

Apoptosis O
induced O
by O
DMA-2 O
, O
4-D O
was O
dose O
and O
time O
dependent O
, O
independent O
of O
Fas B_GENE
, O
TNF B_GENE
receptor I_GENE
1 I_GENE
or O
the O
aromatic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hydrocarbon I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
involved O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
activation O
of O
caspase-9 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

ZVAD-FMK O
, O
a O
broad-spectrum O
inhibitor O
of O
caspases B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
blocked O
DMA-2 O
, O
4-D-induced O
apoptosis O
completely O
. O

While O
an O
inhibitor O
of O
caspase-9 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
as O
well O
as O
caspase-9 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
caspase-3 O
inhibitors O
in O
combination O
, O
strongly O
blocked O
DMA-2 O
, O
4-D-induced O
apoptosis O
, O
an O
inhibitor O
of O
caspase-3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
had O
a O
moderate O
inhibitory O
effect O
. O

Unlike O
Fas B_GENE
-mediated O
apoptosis O
, O
the O
initiator B_PERSON/B_ENZYME[GENE]
caspase I_PERSON/I_ENZYME[GENE]
, O
caspase-8 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
was O
not O
involved O
in O
DMA-2 O
, O
4-D-induced O
apoptosis O
. O

Transfection O
of O
Jurkat O
cells O
with O
Bcl-2 B_GENE
prevented O
DMA-2 O
, O
4-D-induced O
disruption O
of O
the O
mitochondrial O
transmembrane O
potential O
and O
led O
to O
a O
complete O
blockage O
of O
apoptosis O
. O

Our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
DMA-2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
4-D B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kills O
human B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
initiating O
apoptosis B_DISEASE
via O
a O
direct B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
mitochondria B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

The O
activation O
of O
caspases B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
occurs O
downstream O
of O
mitochondrial O
damage O
, O
and O
the O
dysfunction O
of O
mitochondria O
appears O
to O
be O
sufficient O
for O
triggering O
all O
downstream O
events O
leading O
to O
apoptosis O
. O

Inhibition O
of O
Th1 O
differentiation O
by O
IL-6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
mediated O
by O
SOCS1 B_GENE
. O

Interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
is O
a O
cytokine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
by O
immune O
and O
nonimmune O
cells O
and O
exhibits O
functional O
pleiotropy O
and O
redundancy O
. O

IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
plays O
an O
important O
role O
in O
the O
differentiation O
of O
several O
cell O
types O
. O

Here O
, O
we O
describe O
a O
novel O
function O
of O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
: O
the O
negative O
regulation O
of O
CD4 B_GENE
+ O
Th1 O
cell O
differentiation O
. O

While O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-directed O
CD4 B_GENE/B_DISEASE
+ O
Th2 O
differentiation O
is O
mediated O
by O
IL-4 B_GENE
, O
inhibition O
of O
Th1 O
differentiation O
by O
IL-6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
independent O
of O
IL-4 B_GENE
. O

IL-6 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upregulates O
suppressor B_GENE
of I_GENE
cytokine I_GENE
signaling I_GENE
1 I_GENE
( O
SOCS1 B_GENE/B_LOCATION
) O
expression O
in O
activated O
CD4+ O
T O
cells O
, O
thereby O
interfering O
with O
signal B_GENE
transducer I_GENE
and I_GENE
activator I_GENE
of I_GENE
transcription I_GENE
1 I_GENE
( O
STAT1 B_GENE
) O
phosphorylation O
induced O
by O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
IFNgamma B_PROTEIN[GENE]/B_LOCATION
) O
. O

Inhibition O
of O
IFNgamma B_GENE/B_LOCATION
receptor-mediated O
signals O
by O
IL-6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prevents O
autoregulation O
of O
IFNgamma B_GENE
gene I_GENE
expression O
by O
IFNgamma B_GENE
during O
CD4+ O
T O
cell O
activation O
, O
thereby O
preventing O
Th1 O
differentiation O
. O

Thus O
, O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promotes O
CD4 B_GENE/B_LOCATION
+ O
Th2 O
differentiation O
and O
inhibits O
Th1 O
differentiation O
by O
two O
independent O
molecular O
mechanisms O
. O

interaction O
between O
CCAAT/enhancer B_GENE
binding I_GENE
protein I_GENE
and O
cyclic B_GENE
AMP I_GENE
response I_GENE
element I_GENE
binding I_GENE
protein I_GENE
1 I_GENE
regulates O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
in O
cells O
of O
the O
monocyte/macrophage O
lineage O
. O

Recent O
observations O
have O
shown O
two O
CCAAT/enhancer B_GENE/B_LOCATION
binding I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
( I_GENE/I_LOCATION
C/EBP I_GENE/I_LOCATION
) I_GENE/I_LOCATION
binding I_GENE/I_LOCATION
sites I_GENE/I_LOCATION
to O
be O
critically O
important O
for O
efficient O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
replication O
within O
cells O
of O
the O
monocyte/macrophage O
lineage O
, O
a O
cell O
type O
likely O
involved O
in O
transport O
of O
the O
virus O
to O
the O
brain O
. O

Additionally O
, O
sequence O
variation O
at O
C/EBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
lies O
immediately O
upstream O
of O
the O
distal B_GENE/B_DISEASE
nuclear I_GENE/I_DISEASE
factor I_GENE/I_DISEASE
kappa I_GENE/I_DISEASE
B I_GENE/I_DISEASE
site I_GENE/I_DISEASE
and O
immediately O
downstream O
of O
a O
binding O
site O
for O
activating B_GENE
transcription I_GENE
factor I_GENE
( O
ATF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
/ O
cyclic B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
AMP I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
response I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
element I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CREB B_GENE/B_LOCATION
) O
, O
has O
been O
shown O
to O
affect O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
long I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeat I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
LTR B_GENE/B_DISEASE
) O
activity O
. O

Given O
that O
C/EBP B_GENE/B_PERSON
proteins I_GENE/I_PERSON
have O
been O
shown O
to O
interact O
with O
many O
other O
transcription B_GENE/B_BIO
factors I_GENE/I_BIO
including O
members O
of O
the O
ATF/CREB B_GENE/B_MEASURE
family I_GENE/I_MEASURE
, O
we O
proceeded O
to O
determine O
whether O
an O
adjacent O
ATF/CREB B_GENE/B_LOCATION
binding I_GENE/I_LOCATION
site I_GENE/I_LOCATION
could O
affect O
C/EBP B_GENE
protein I_GENE
binding O
to O
C/EBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Electrophoretic O
mobility O
shift O
analyses O
indicated O
that O
selected O
ATF/CREB B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
site B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variants B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
assisted O
in O
the O
recruitment O
of O
C/EBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
an O
adjacent O
, O
naturally O
occurring O
, O
low-affinity O
C/EBP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

This O
biophysical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O
to O
occur O
via O
at O
least O
two B_MEASURE/B_BIO
mechanisms B_MEASURE/I_BIO
. O

First O
, O
low O
amounts O
of O
CREB-1 B_GENE
and O
C/EBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
appear O
to O
heterodimerize O
and O
bind O
to O
a O
site O
consisting O
of O
a O
half O
site O
from O
both O
the O
ATF/CREB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C/EBP I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition O
, O
CREB-1 B_GENE/B_BIO
homodimers I_GENE/I_BIO
bind O
to O
the O
ATF/CREB B_GENE
site I_GENE
and O
recruit O
C/EBP B_GENE/B_BIO
dimers I_GENE/I_BIO
to O
their O
cognate O
weak B_LOCATION/B_GENE
binding I_LOCATION/I_GENE
sites I_LOCATION/I_GENE
. O

This O
interaction O
is O
reciprocal O
, O
since O
C/EBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dimer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding O
to O
a O
strong O
C/EBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leads O
to O
enhanced O
CREB-1 B_GENE
recruitment O
to O
ATF/CREB B_GENE/B_LOCATION
sites I_GENE/I_LOCATION
that O
are O
weakly O
bound O
by O
CREB B_GENE
. O

sequence O
variation O
at O
both O
C/EBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ATF/CREB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
affects O
the O
molecular O
interactions O
involved O
in O
mediating O
both O
of O
these O
mechanisms O
. O

Most O
importantly O
, O
sequence O
variation O
at O
the O
ATF/CREB B_GENE/B_LOCATION
binding I_GENE/I_LOCATION
site I_GENE/I_LOCATION
affected O
basal O
LTR B_GENE/B_DISEASE
activity O
as O
well O
as O
LTR B_GENE/B_DISEASE
function O
following O
interleukin-6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stimulation O
, O
a O
treatment O
that O
leads O
to O
increases O
in O
C/EBP O
activation O
. O

Thus O
, O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ATF/CREB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequence O
variation O
may O
modulate O
cellular O
signaling O
at O
the O
viral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
through O
the O
C/EBP O
pathway O
. O

Selective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
inhibition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
interleukin-4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicated O
that O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
acetylsalicylic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
ASA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
can O
have O
profound B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
immunomodulatory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
by O
regulating O
cytokine B_GENE
gene I_GENE
expression I_GENE
in O
several B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
types B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
cells B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

This O
study O
is O
the O
first O
in O
which O
concentrations O
of O
ASA O
in O
the O
therapeutic O
range O
were O
found O
to O
significantly O
reduce O
interleukin B_GENE
( I_GENE
IL I_GENE
) I_GENE
-4 I_GENE
secretion O
and O
RNA O
expression O
in O
freshly O
isolated O
and O
mitogen-primed O
human O
CD4+ O
T O
cells O
. O

In O
contrast O
, O
ASA O
did O
not O
affect O
IL-13 B_GENE
, O
interferon-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
IL-2 B_GENE
expression O
. O

ASA O
inhibited O
IL-4 B_GENE
, O
but O
not O
IL-2 B_GENE
, O
promoter-driven O
chloramphenicol O
acetyltransferase O
expression O
in O
transiently O
transfected O
Jurkat O
T O
cells O
. O

The O
structurally O
unrelated O
nonsteroidal O
anti-inflammatory O
drugs O
indomethacin O
and O
flurbiprofen O
did O
not O
affect O
cytokine O
gene O
expression O
in O
T O
cells O
, O
whereas O
the O
weak O
cyclo-oxygenase O
inhibitor O
salicylic O
acid O
was O
at O
least O
as O
effective O
as O
ASA O
in O
inhibiting O
IL-4 B_GENE/B_PERSON
expression O
and O
promoter O
activity O
. O

The O
inhibitory O
effect O
of O
ASA O
on O
IL-4 O
transcription O
was O
not O
mediated O
by O
decreased O
nuclear O
expression O
of O
the O
known O
salicylate B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
target I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-kappaB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
was O
accompanied O
by O
reduced O
binding O
of O
an O
inducible O
factor O
to O
an O
IL-4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
upstream O
of O
, O
but O
not O
overlapping O
, O
the O
NF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappaB-binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
is O
concluded O
that O
anti-inflammatory O
salicylates O
, O
by O
means O
of O
a O
previously O
unrecognized O
mechanism O
of O
action O
, O
can O
influence O
the O
nature O
of O
adaptive O
immune O
responses O
by O
selectively O
inhibiting O
the O
expression O
of O
IL-4 B_GENE
, O
a O
critical O
effector O
of O
these O
responses O
, O
in O
CD4+ O
T O
cells O
. O

Molecular O
and O
cellular O
mediators O
of O
interleukin-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-dependent O
acute O
inflammatory O
arthritis O
. O

objective O
: O
To O
examine O
the O
molecular O
and O
cellular O
mechanisms O
in O
a O
model O
of O
acute O
inflammatory O
monarticular O
arthritis O
induced O
by O
methylated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bovine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
serum I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
albumin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
mBSA B_LOCATION/B_ORGANIZATION
) O
and O
interleukin-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
IL-1 B_GENE
) O
. O

methods O
: O
mice O
were O
injected O
intraarticularly O
with O
mBSA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
day O
0 O
and O
subcutaneously O
with O
recombinant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
human I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IL-1beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
days O
0-2 O
. O

At O
day B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
7 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
knee B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
joints B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
removed O
and O
assessed O
histologically O
. O

Flow O
cytometry O
and O
RNase O
protection O
were O
used O
to O
analyze O
IL-1 B_GENE/B_MEASURE
-dependent O
events O
. O

Results O
: O
C57BL/6 O
( O
B6 O
) O
, O
129/Sv O
, O
and O
( O
B6 O
x O
129/ O
SV O
) O
F1 O
hybrid O
mice O
, O
all O
H-2b O
strains O
, O
were O
susceptible O
to O
mBSA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/IL-1-induced O
arthritis O
, O
whereas O
C3H/HeJ O
( O
H-2k O
) O
mice O
were O
not O
. O

B6 O
mice O
lacking O
T O
and O
B O
cells O
( O
RAG1-/- O
) O
or O
major B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
histocompatibility B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complex B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MHC B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
class B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
II B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
antigens B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
MHCII-/- O
) O
, O
and O
B6 O
mice O
treated O
with O
a O
CD4+ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
T I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
cell-depleting I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
monoclonal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
were O
resistant O
to O
disease O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
B B_GENE/B_PERSON
cell-deficient I_GENE/I_PERSON
( O
muMT/ B_PROTEIN[GENE]/B_LOCATION
muMT I_PROTEIN[GENE]/I_LOCATION
) O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O
arthritis B_DISEASE
at O
an O
incidence B_MEASURE/B_LOCATION
and O
severity B_MEASURE/B_PERSON
similar I_MEASURE/I_PERSON
to O
that O
of O
controls B_DISEASE/B_PERSON
. O

RelB-deficient B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
RelB-/- O
) O
bone B_SPECIES[BIO]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
marrow I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chimeric I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mice I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
had O
arthritis B_DISEASE
that O
was O
significantly O
reduced O
in O
incidence B_MEASURE
and O
severity B_MEASURE
. O

In O
B6 O
mice O
, O
flow O
cytometry O
demonstrated O
an O
IL-1-dependent O
leukocyte O
infiltration O
into O
the O
synovial O
compartment O
and O
RNase O
protection O
assays O
revealed O
induction O
of O
messenger B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
mRNA B_GENE
) O
for O
the O
chemokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
monocyte I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chemoattractant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
macrophage B_PROTEIN[GENE]/B_MEASURE
inhibitory I_PROTEIN[GENE]/I_MEASURE
protein I_PROTEIN[GENE]/I_MEASURE
2 I_PROTEIN[GENE]/I_MEASURE
( O
MIP-2 B_GENE/B_DISEASE
) O
, O
RANTES B_GENE
, O
MIP-1alpha B_GENE
, O
and O
MIP-1beta B_GENE
, O
in O
vivo O
and O
in O
vitro O
. O

conclusion O
: O
Arthritis O
induced O
by O
mBSA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
IL-1 B_LOCATION/B_PERSON
is O
strain O
specific O
and O
dependent O
on O
CD4+ O
T O
lymphocytes O
and O
at O
least O
partially O
on O
RelB B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
on O
B O
lymphocytes O
or O
antibody B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

IL-1 B_GENE/B_LOCATION
contributes O
to O
leukocyte O
recruitment O
to O
the O
synovium O
and O
directly O
induces O
chemokine O
mRNA O
production O
by O
synovial O
cells O
. O

This O
model O
of O
acute O
monarticular O
arthritis O
is O
particularly O
suitable O
for O
further O
investigations O
into O
cell-mediated O
immunity O
in O
arthritis O
and O
the O
role O
of O
IL-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

positive O
and O
negative O
regulation O
of O
granulopoiesis O
by O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RARalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

acute O
promyelocytic O
leukemia O
( O
APL O
) O
is O
always O
associated O
with O
chromosomal O
translocations O
that O
disrupt O
the O
retinoic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RARalpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Whether O
these O
translocations O
relate O
to O
a O
role O
for O
endogenous B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RARalpha I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
normal O
granulopoiesis O
remains O
uncertain O
because O
most O
studies O
addressing O
this O
question O
have O
used O
non-physiological O
overexpression O
systems O
. O

Granulocyte O
differentiation O
in O
cells O
derived O
from O
RARalpha-deficient O
( O
RARalpha O
( O
-/- O
) O
) O
mice O
was O
studied O
and O
evaluated O
in O
the O
context O
of O
agonist-bound B_DISEASE/B_GENE
and I_DISEASE/I_GENE
ligand-free I_DISEASE/I_GENE
RARalpha I_DISEASE/I_GENE
. O

Our O
results O
demonstrate O
that O
RARalpha B_GENE
is O
dispensable O
for O
granulopoiesis O
, O
as O
RARalpha O
( O
-/- O
) O
mice O
have O
a O
normal O
granulocyte O
population O
despite O
an O
impaired O
ability O
to O
respond O
to O
retinoids O
. O

However O
, O
although O
it O
is O
not O
absolutely O
required O
, O
RARalpha B_GENE
can O
bidirectionally O
modulate O
granulopoiesis O
. O

RARalpha B_GENE
stimulates O
differentiation O
in O
response O
to O
exogenous O
retinoic O
acid O
. O

Furthermore O
, O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
retinoids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
control O
granulopoiesis B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
either O
vitamin B_PERSON/B_BIO
A-deficient I_PERSON/I_BIO
mice I_PERSON/I_BIO
or O
animals B_BIO/B_PERSON
treated O
with O
an O
RAR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
accumulate O
more O
immature B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
granulocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
in O
their O
bone B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
marrow I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Conversely O
, O
RARalpha B_GENE
acts O
to O
limit O
differentiation O
in O
the O
absence O
of O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
because O
granulocyte O
precursors O
from O
RARalpha O
( O
-/- O
) O
mice O
differentiate O
earlier O
in O
culture O
. O

Thus O
, O
the O
block O
in O
granulopoiesis O
exerted O
by O
RARalpha B_GENE/B_LOCATION
fusion I_GENE/I_LOCATION
proteins I_GENE/I_LOCATION
expressed O
in O
APL O
cells O
may O
correspond O
to O
an O
amplification O
of O
a O
normal O
function O
of O
unliganded B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
RARalpha B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

expression O
and O
function O
of O
a O
stem B_GENE/B_PERSON
cell I_GENE/I_PERSON
promoter I_GENE/I_PERSON
for O
the O
murine B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
CBFalpha2 B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
gene B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
: O
distinct O
roles O
and O
regulation O
in O
natural O
killer O
and O
T O
cell O
development O
. O

The O
Runt B_GENE/B_MEASURE
family I_GENE/I_MEASURE
transcription I_GENE/I_MEASURE
factor I_GENE/I_MEASURE
CBFalpha2 I_GENE/I_MEASURE
( O
AML1 B_GENE/B_DISEASE
, O
PEBP2alphaB B_GENE/B_DISEASE
, O
or O
Runx1 B_GENE/B_DISEASE
) O
is O
required O
by O
hematopoietic O
stem O
cells O
and O
expressed O
at O
high O
levels O
in O
T-lineage O
cells O
. O

In O
human O
T O
cells O
CBFalpha2 B_GENE
is O
usually O
transcribed O
from O
a O
different B_MEASURE/B_BIO
promoter I_MEASURE/I_BIO
( O
distal B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
promoter I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
) O
than O
in O
myeloid O
cells O
( O
proximal B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
, O
but O
the O
developmental O
and O
functional O
significance O
of O
this O
promoter O
switch O
has O
not O
been O
known O
. O

Here O
, O
we O
report O
that O
both O
coding B_LOCATION/B_PERSON
and I_LOCATION/I_PERSON
noncoding I_LOCATION/I_PERSON
sequences I_LOCATION/I_PERSON
of O
the O
distal B_GENE
5 I_GENE
' I_GENE
end I_GENE
are O
highly O
conserved O
between O
the O
human B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
murine I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
distal B_GENE
promoter I_GENE
is O
responsible O
for O
the O
overwhelming O
majority O
of O
CBFalpha2 O
expression O
in O
murine O
hematopoietic O
stem O
cells O
as O
well O
as O
in O
T O
cells O
. O

distal B_GENE
promoter I_GENE
activity I_GENE
is O
maintained O
throughout O
T B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cell B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O
at O
lower B_MEASURE/B_LOCATION
levels I_MEASURE/I_LOCATION
in O
B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
development B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
but O
downregulated O
in O
natural B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
killer B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
development B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
distal B_PROTEIN[GENE]
N-terminal I_PROTEIN[GENE]
isoform I_PROTEIN[GENE]
binds O
to O
functionally O
important O
regulatory B_GENE/B_LOCATION
sites I_GENE/I_LOCATION
from O
known O
target B_GENE
genes I_GENE
with O
two- O
to O
threefold O
higher O
affinity O
than O
the O
proximal B_LOCATION/B_GENE
N-terminal I_LOCATION/I_GENE
isoform I_LOCATION/I_GENE
. O

Neither O
full-length B_GENE
isoform I_GENE
alters O
growth O
of O
a O
myeloid O
cell O
line O
under O
nondifferentiating O
conditions O
, O
but O
the O
proximal B_GENE
isoform I_GENE
selectively O
delays O
mitotic O
arrest O
of O
the O
cell O
line O
under O
differentiating O
conditions O
, O
resulting O
in O
the O
generation O
of O
greater O
numbers O
of O
neutrophils O
. O

constitutive B_GENE
PI3-K I_GENE
activity I_GENE
is O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
proliferation B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
but O
not O
survival B_DISEASE_ADJECTIVE[DISEASE]
, O
of O
Theileria B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
parva-transformed O
B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Theileria B_DISEASE/B_BACTERIUM[BIO]
is O
an O
intracellular B_SPECIES[BIO]/B_DISEASE
parasite I_SPECIES[BIO]/I_DISEASE
that O
causes O
lymphoproliferative B_DISEASE
disorders I_DISEASE
in O
cattle B_BIO/B_PERSON
, O
and O
infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
leucocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
induces O
a O
transformed B_DISEASE/B_LOCATION
phenotype I_DISEASE/I_LOCATION
similar I_DISEASE/I_LOCATION
to O
tumour B_DISEASE
cells I_DISEASE
, O
but O
the O
mechanisms B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O
which O
the O
parasite B_SPECIES[BIO]/B_DISEASE
induces O
this O
phenotype B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
not O
understood O
. O

Here O
, O
we O
show O
that O
infected O
B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
display I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constitutive I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphoinositide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3-kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PI3-K B_GENE
) O
activity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
, O
which O
appears O
to O
be O
necessary B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
proliferation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
but O
not O
survival B_DISEASE_ADJECTIVE[DISEASE]
. O

importantly O
, O
we O
demonstrate O
that O
one O
mechanism O
by O
which O
PI3-K B_GENE/B_VIRUS[BIO]
mediates O
the O
proliferation O
of O
infected O
B O
lymphocytes O
is O
through O
the O
induction O
of O
a O
granulocyte-monocyte B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
GM-CSF B_LOCATION/B_PERSON
) O
-dependent O
autocrine O
loop O
. O

PI3-K B_PERSON
induction O
of O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appears O
to O
be O
at O
the O
transcriptional O
level O
and O
, O
consistently O
, O
we O
demonstrate O
that O
PI3-K B_GENE
is O
also O
involved O
in O
the O
constitutive O
induction O
of O
AP-1 B_GENE
and O
NF-kappaB B_GENE
, O
which O
characterizes O
Theileria-infected O
leucocytes O
. O

taken O
together O
, O
our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
highlight O
a O
novel B_LOCATION
strategy I_LOCATION
exploited O
by O
the O
intracellular B_SPECIES[BIO]
parasite I_SPECIES[BIO]
Theileria I_SPECIES[BIO]
to O
induce O
continued B_DISEASE
proliferation I_DISEASE
of O
its O
host B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leucocyte I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Lymphokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dependence O
of O
STAT3 O
activation O
produced O
by O
surface O
immunoglobulin O
cross-linking O
and O
by O
phorbol O
ester O
plus O
calcium O
ionophore O
treatment O
in O
B O
cells O
. O

stimulation O
of O
B O
cells O
by O
surface B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoglobulin B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
sIg B_PROTEIN[GENE]/B_LOCATION
) O
triggering O
, O
or O
through O
the O
mitogenic O
combination O
of O
phorbol O
ester O
and O
calcium O
ionophore O
, O
is O
accompanied O
by O
activation O
of O
STAT B_GENE
transcription I_GENE
factors I_GENE
. O

The O
mechanism O
responsible O
for O
the O
delayed O
nuclear O
accumulation O
of O
phosphorylated B_GENE/B_DISEASE
STAT3 I_GENE/I_DISEASE
was O
examined O
in O
detail O
, O
focusing O
on O
the O
role O
of O
B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell-derived I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lymphokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

sIg B_GENE
-induced O
activation O
of O
STAT3 B_GENE
was O
partially O
inhibited O
in O
B O
cells O
obtained O
from O
IL-6- O
or O
IL-10-deficient O
mice O
, O
and O
was O
partially O
blocked O
by O
neutralizing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
directed O
against O
either O
of O
these O
lymphokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

sIg B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O
STAT3 O
activation O
was O
completely O
inhibited O
by O
combining O
IL-6- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
IL-10-specific I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
neutralizing I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
or O
by O
adding O
individual O
neutralizing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
B O
cells O
obtained O
from O
lymphokine-deficient O
animals O
. O

In O
contrast O
, O
IL-10 B_GENE
alone O
appeared O
to O
account O
for O
STAT3 O
activation O
resulting O
from O
B O
cell O
stimulation O
with O
phorbol O
ester O
and O
calcium O
ionophore O
. O

In O
keeping O
with O
these O
results O
, O
soluble O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
IL-10 B_GENE
were O
found O
in O
supernatant O
fluid O
obtained O
from O
stimulated O
B O
cells O
. O

This O
work O
indicates O
that O
a O
lymphokine O
pathway O
is O
responsible O
for O
STAT3 O
activation O
that O
occurs O
late O
after O
B O
cell O
stimulation O
, O
and O
points O
out O
differences O
in O
B O
cell O
activation O
that O
result O
from O
stimulation O
through O
the O
antigen B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
receptor I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
through O
pharmacological O
mimicry O
of O
signaling B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mediators I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Transcription B_GENE
factor I_GENE
AP-4 I_GENE
is O
a O
ligand B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
immunoglobulin-kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E-box I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Immunoglobulin B_GENE/B_BIO
( I_GENE/I_BIO
Ig I_GENE/I_BIO
) I_GENE/I_BIO
-kappa I_GENE/I_BIO
promoters I_GENE/I_BIO
from O
humans O
and O
mice O
share O
conserved B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
octamer B_LOCATION/B_MEASURE
element I_LOCATION/I_MEASURE
is O
common O
to O
all O
Ig B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
pivotal O
for O
their O
function O
. O

However O
, O
other O
conserved B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequence I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
motifs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
that O
differ O
between O
Ig B_GENE/B_BIO
variable I_GENE/I_BIO
gene I_GENE/I_BIO
families I_GENE/I_BIO
, O
are O
required O
for O
normal O
promoter O
function O
. O

These O
conserved O
motifs O
do O
not O
stimulate O
transcription O
in O
the O
absence O
of O
an O
octamer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

One O
example O
is O
an O
E-box B_GENE
of O
the O
E47/E12 B_GENE/B_MEASURE
type I_GENE/I_MEASURE
( I_GENE/I_MEASURE
5'-CAGCTG-3 I_GENE/I_MEASURE
' I_GENE/I_MEASURE
) I_GENE/I_MEASURE
, O
which O
is O
found O
in O
all O
promoters O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
murine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ig-kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subgroups/families I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
with O
the O
exception O
of O
subgroups O
II O
and O
VI O
and O
their O
related O
murine B_LOCATION/B_GENE
families I_LOCATION/I_GENE
. O

In O
the O
present O
study O
we O
show O
that O
the O
ubiquitously O
expressed O
transcription B_GENE
factor I_GENE
AP-4 I_GENE
, O
and O
not O
E47 B_GENE
, O
interacts O
specifically O
with O
the O
kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E-boxes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
when O
tested O
in O
electrophoretic O
mobility-shift O
assays O
using O
nuclear O
extracts O
derived O
from O
human O
and O
murine O
B-cell O
lines O
. O

Furthermore O
, O
AP-4 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
unlike O
E47 B_GENE
, O
did O
not O
act O
as O
a O
transactivator B_GENE
, O
which O
is O
in O
agreement O
with O
previous O
studies O
on O
intact O
kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
showing O
that O
transcription O
is O
absent O
when O
the O
octamer B_GENE/B_LOCATION
element I_GENE/I_LOCATION
has O
been O
mutated O
. O

Based O
on O
these O
data O
, O
and O
the O
conservation O
of O
the O
5'-CAGCTG-3 B_GENE/B_MEASURE
' I_GENE/I_MEASURE
motif I_GENE/I_MEASURE
among O
human B_GENE/B_PERSON
and I_GENE/I_PERSON
murine I_GENE/I_PERSON
kappa I_GENE/I_PERSON
promoters I_GENE/I_PERSON
, O
we O
propose O
that O
AP-4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
major B_PERSON/B_LOCATION
ligand I_PERSON/I_LOCATION
for O
Ig-kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E-boxes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
16-mer B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
RQIKIWFQNRRMKWKK B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
from O
antennapedia B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
preferentially O
targets O
the O
Class B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I O
pathway O
. O

Translocation O
of O
antigenic O
peptides O
into O
the O
cytosol O
of O
antigen O
presenting O
cells O
facilitates O
proteosomal O
processing O
and O
loading O
into O
Class B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
for O
MHC O
presentation O
on O
the O
cell O
surface O
. O

The O
DNA B_GENE/B_MEASURE
binding I_GENE/I_MEASURE
domain I_GENE/I_MEASURE
of O
the O
Drosophila B_GENE
transcription I_GENE
factor I_GENE
( O
Antennapedia B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
a O
60 B_GENE
amino I_GENE
acid I_GENE
protein I_GENE
, O
is O
rapidly O
taken O
up O
by O
cells O
and O
has O
been O
fused O
to O
selected O
antigens B_GENE/B_DISEASE
to O
enhance O
their O
immunogenicity O
. O

We O
now O
demonstrate O
that O
a O
16 B_PROTEIN[GENE]
amino I_PROTEIN[GENE]
acid I_PROTEIN[GENE]
peptide I_PROTEIN[GENE]
from O
antennapedia B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
can O
facilitate O
the O
cytoplasmic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
uptake I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O
CTL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
epitope I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
9-mer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
peptides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

synthetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
peptides I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
made O
containing O
the O
16-mer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
antennapedia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
linked O
in O
tandem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
the O
ovalbumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
SIINFEKL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CTL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
peptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
complex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O
shown O
to O
rapidly O
internalise O
into O
APCs B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
by O
confocal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
CTL B_DISEASE/B_GENE
in O
C57BL/6 B_SPECIES[BIO]/B_PERSON
mice I_SPECIES[BIO]/I_PERSON
and O
protected O
them O
against O
growth B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
an O
ovalbumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expressing O
tumour B_DISEASE
cell I_DISEASE
line I_DISEASE
( O
E.G7-OVA B_DISEASE/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

The O
ability O
of O
the O
hybrid O
peptide O
to O
be O
processed O
and O
presented O
by O
APCs O
was O
similar O
, O
whether O
the O
SIINFEKL O
sequence O
was O
appended O
at O
the O
C-terminus B_LOCATION/B_MEASURE
or O
N-terminus B_LOCATION
of O
the O
Antennapedia O
peptide O
. O

The O
production B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
synthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
other B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CTL I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
peptide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
epitopes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
useful B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
priming O
CTLs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
vitro B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
. O

Bone B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
marrow I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promote O
TH2 B_DISEASE
polarization I_DISEASE
and O
inhibit O
virus-specific B_DISEASE/B_GENE
CTL I_DISEASE/I_GENE
generation I_DISEASE/I_GENE
. O

This O
laboratory B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recently O
reported O
that O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marrow I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
BMC B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
inhibit O
the O
generation B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
virus-specific B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CTL B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
culture B_LOCATION/B_SPECIES[BIO]
. O

The O
culture O
supernatants O
contained O
increased O
levels O
of O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
PGE I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
shown O
to O
favor O
TH2 O
cell O
development O
) O
and O
also O
inhibited O
EBV-CTL O
effector O
cell O
development O
. O

In O
this O
study O
, O
we O
obtained O
PBL O
from O
Epstein-Barr O
virus O
( O
EBV O
) O
IgG B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive O
kidney O
transplant O
recipients O
( O
R O
) O
and O
their O
living-related O
donors O
( O
LRD O
) O
one O
year O
after O
renal O
transplantation O
. O

EBV-specific B_DISEASE/B_PERSON
CTL I_DISEASE/I_PERSON
were O
then O
generated O
in O
vitro B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
stimulating O
PBL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
with O
autologous B_DISEASE/B_PROTEIN[GENE]
EBV-transformed B_DISEASE/I_PROTEIN[GENE]
B B_DISEASE/I_PROTEIN[GENE]
cells B_DISEASE/I_PROTEIN[GENE]
( O
EBV-B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
in O
the O
presence B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
absence B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
autologous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
BMC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
addition O
of O
BMC O
to O
the O
EBV-CTL O
generation O
cultures O
increased O
the O
intracellular O
expression O
in O
CD3+ O
cells O
of O
IL-4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-10 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-13 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
CD3+ O
cells O
also O
expressed O
increased O
levels O
of O
the O
TH2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
associated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CCR3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
was O
even O
observed O
by O
preparing O
EBV-CTL B_DISEASE/B_MEASURE
generating O
cultures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
trans-wells B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
separated O
the O
autologous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
BMC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
the O
PBL B_GENE
+ O
EBV-B B_DISEASE/B_LOCATION
. O

It O
was O
then O
observed O
that O
CD3+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
obtained O
after O
7 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
culture B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
in O
the O
presence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
autologous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
BMC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
could O
be O
used O
as O
inhibitors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
EBV-CTL B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
generation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Protein B_GENE
Kinase I_GENE
A I_GENE
( O
PKA B_GENE/B_LOCATION
) O
, O
a O
cAMP B_ENZYME[GENE]/B_LOCATION
kinase I_ENZYME[GENE]/I_LOCATION
that O
is O
involved O
in O
the O
upregulation O
of O
TH2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
, O
was O
increased O
in O
EBV-CTL O
cultures O
by O
the O
presence O
of O
BMC O
. O

Additionally O
, O
IL-4-mediated O
signal O
transduction O
and O
activation O
of O
transcription O
( O
STAT-6 B_GENE/B_LOCATION
) O
phosphorylation O
was O
slightly O
increased O
. O

These O
results O
show O
that O
the O
BMC O
inhibition O
is O
mediated O
by O
soluble B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
that O
cell-cell O
contact O
in O
this O
autologous O
system O
is O
not O
required O
, O
so O
that O
BMC O
( O
at O
least O
partially O
, O
via O
cytokine O
production O
) O
promote O
TH2 O
polarization O
in O
culture O
. O

Moreover O
, O
TH2 O
cells O
induced O
by O
culturing O
with O
autologous O
BMC O
directly O
inhibit O
EBV-CTL O
generation O
, O
and O
TH2 B_LOCATION/B_PERSON
associated O
PKA B_GENE
, O
CCR3 B_GENE/B_LOCATION
, O
and O
STAT-6 B_GENE
phosphorylation O
are O
enhanced O
by O
BMC O
. O

reduction O
in O
DNA O
binding O
activity O
of O
the O
transcription B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Pax-5a I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
B O
lymphocytes O
of O
aged O
mice O
. O

Aging B_DISEASE/B_LOCATION
has O
been O
associated O
with O
intrinsic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
humoral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
immune I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
response I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
may O
lead O
to O
an O
increased O
occurrence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
autoimmune B_DISEASE/B_BIO
disorders I_DISEASE/I_BIO
and O
pathogenic B_DISEASE
susceptibility I_DISEASE
. O

The O
transcription B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
factor I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
Pax-5 I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
is O
a O
key O
regulator O
of O
B O
cell O
development O
. O

Pax-5a/B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell-specific I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
an O
alternatively B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
spliced I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoform I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Pax-5d I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
may O
have O
opposing O
functions O
in O
transcriptional O
regulation O
due O
to O
the O
lack O
of O
a O
transactivation B_GENE/B_LOCATION
domain I_GENE/I_LOCATION
in O
Pax-5d B_GENE/B_SPECIES[BIO]
. O

To O
study O
B O
cell O
-specific O
changes O
that O
occur O
during O
the O
aging O
process O
, O
we O
investigated O
expression O
patterns O
of O
Pax-5a B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5d I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mature O
B O
cells O
of O
young O
and O
aged O
mice O
. O

RNase O
protection O
assays O
showed O
a O
similar O
transcriptional O
pattern O
for O
both O
age O
groups O
that O
indicates O
that O
aging O
has O
no O
affect O
on O
transcription O
initiation O
or O
alternative O
splicing O
for O
either O
isoform B_GENE/B_LOCATION
. O

In O
contrast O
, O
a O
significant O
reduction O
in O
the O
DNA O
binding O
activity O
of O
Pax-5a B_GENE
but O
not O
Pax-5d B_GENE
protein O
was O
observed O
in O
aged O
B O
cells O
in O
vitro O
, O
while O
Western O
blot O
analyses O
showed O
that O
similar O
levels O
of O
Pax-5a B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5d I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins O
were O
present O
in O
both O
age O
groups O
. O

The O
observed O
decrease O
in O
Pax-5a B_GENE
binding O
activity O
correlated O
with O
changes O
in O
expression O
of O
two O
Pax-5 B_GENE/B_LOCATION
target I_GENE/I_LOCATION
genes I_GENE/I_LOCATION
in O
aged O
B O
cells O
. O

expression O
of O
the O
Ig B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
J I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
secreted O
form O
of O
Ig B_GENE
mu I_GENE
, O
which O
are O
both O
known O
to O
be O
suppressed O
by O
Pax-5a B_GENE
in O
mature O
B O
cells O
, O
were O
increased O
in O
B O
cells O
of O
aged O
mice O
. O

Together O
, O
our O
studies O
suggest O
that O
changes O
associated O
with O
the O
aging O
phenotype O
cause O
posttranslational O
modification O
( O
s O
) O
of O
Pax-5a B_GENE
but O
not O
Pax-5d B_GENE
, O
which O
may O
lead O
to O
an O
abnormal O
B O
cell O
phenotype O
in O
aged O
mice O
, O
associated O
with O
elevated O
levels O
of O
J B_GENE
chain I_GENE
, O
and O
secretion O
of O
IgM B_GENE
. O

NF-kappa B_PERSON/B_LOCATION
B/Rel I_PERSON/I_LOCATION
participation O
in O
the O
lymphokine-dependent O
proliferation O
of O
T O
lymphoid O
cells O
. O

Proliferative O
responses O
of O
lymphoid O
cells O
to O
IL-2 B_GENE
and O
IL-4 B_GENE
depend O
on O
activation O
of O
the O
cells O
, O
but O
the O
mechanism O
( O
s O
) O
by O
which O
activation O
enhances O
cellular O
competence O
to O
respond O
to O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
not O
fully O
understood O
. O

The O
NF-kappaB/Rel B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
represents O
one O
signal O
transduction O
pathway O
induced O
during O
such O
activation O
. O

We O
show O
in O
this O
study O
that O
inhibition O
of O
NF-kappaB B_GENE
through O
the O
expression O
of O
an O
IkappaBalpha B_GENE/B_DISEASE
( O
inhibitory B_PROTEIN[GENE]
protein I_PROTEIN[GENE]
that O
dissociates O
from O
NF-kappaB B_GENE
) O
mutant O
refractory O
to O
signal-induced O
degradation O
( O
IkappaBalpha B_GENE/B_DISEASE
( I_GENE/I_DISEASE
DeltaN I_GENE/I_DISEASE
) I_GENE/I_DISEASE
) O
interfered O
with O
the O
acquisition O
of O
competence O
to O
proliferate O
in O
response O
to O
IL-4 B_GENE
as O
well O
as O
IL-2 B_GENE
. O

Thymocytes O
and O
T O
cells O
from O
IkappaBalpha B_GENE/B_PERSON
( I_GENE/I_PERSON
DeltaN I_GENE/I_PERSON
) I_GENE/I_PERSON
transgenic O
mice O
expressed O
normal O
levels O
of O
IL-2R B_GENE
subunits I_GENE
. O

However O
, O
transgenic O
cells O
exhibited O
a O
dramatic O
defect O
in O
Stat5A O
activation O
treatment O
with O
IL-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
a O
similar O
defect O
was O
observed O
for O
IL-4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O
Stat5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

In O
contrast O
, O
T O
lymphoid O
cells O
with O
inhibition O
of O
NF-kappaB B_GENE
showed O
normal O
insulin O
receptor O
substrate-2 O
phosphorylation O
and O
only O
a O
modest O
decrease O
in O
Stat6 O
activation O
and O
insulin O
receptor O
substrate-1 O
phosphorylation O
after O
IL-4 O
stimulation O
. O

These O
results O
indicate O
that O
the O
NF-kappaB/Rel/IkappaBalpha O
system O
can O
regulate O
cytokine B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
receptor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
capacitation O
through O
effects O
on O
the O
induction O
of O
downstream O
signaling O
by O
the O
Stat B_GENE
transcription I_GENE
factor I_GENE
family I_GENE
. O

BMS-189453 O
, O
a O
novel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
retinoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
is O
a O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testicular I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

BMS-189453 O
is O
a O
synthetic O
retinoid O
that O
acts O
as O
an O
antagonist O
at O
retinoic B_GENE/B_DISEASE
acid I_GENE/I_DISEASE
receptors I_GENE/I_DISEASE
alpha I_GENE/I_DISEASE
, I_GENE/I_DISEASE
beta I_GENE/I_DISEASE
, I_GENE/I_DISEASE
and I_GENE/I_DISEASE
gamma I_GENE/I_DISEASE
. O

In O
Sprague O
Dawley O
rats O
at O
daily O
oral O
doses O
of O
15 O
, O
60 O
, O
or O
240 O
mg/kg O
for O
1 O
month O
, O
BMS-189453 O
produced O
increases O
in O
leukocyte O
counts O
, O
alkaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
phosphatase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
and O
alanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
aminotransferase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
levels O
, O
and O
marked O
testicular O
degeneration O
and O
atrophy O
at O
all O
doses O
. O

Significant B_DISEASE_ADJECTIVE[DISEASE]
overt I_DISEASE_ADJECTIVE[DISEASE]
signs I_DISEASE_ADJECTIVE[DISEASE]
of O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
deaths B_DISEASE
occurred O
at O
240 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
mg/kg I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
, O
whereas O
body-weight B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
food-consumption B_DISEASE
decreases I_DISEASE
occurred O
at O
60 B_MEASURE
and O
240 B_MEASURE/B_LOCATION
mg/kg I_MEASURE/I_LOCATION
. O

When O
BMS-189453 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
administered O
to O
male B_SPECIES[BIO]/B_PERSON
rats I_SPECIES[BIO]/I_PERSON
at O
daily B_MEASURE/B_LOCATION
doses I_MEASURE/I_LOCATION
ranging O
from O
12.5 B_TIME[MEASURE]
to O
100 B_MEASURE
mg/kg I_MEASURE
for O
1 B_TIME[MEASURE]/B_PERSON
week B_TIME[MEASURE]/I_PERSON
, O
only O
minimal B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testicular I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O
at O
all O
doses B_TIME[MEASURE]/B_LOCATION
, O
shortly O
after O
the O
dosing B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
period I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

However O
, O
after O
a O
1-month B_TIME[MEASURE]
drug-free I_TIME[MEASURE]
observation I_TIME[MEASURE]
period I_TIME[MEASURE]
, O
marked O
testicular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
atrophy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
all O
doses B_TIME[MEASURE]/B_LOCATION
. O

BMS-189453 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
then O
administered O
at O
doses B_MEASURE
of O
2 B_NUMBER[MEASURE]
, O
10 B_MEASURE
, O
or O
50 B_MEASURE
mg/kg I_MEASURE
to O
male B_SPECIES[BIO]/B_PERSON
rats I_SPECIES[BIO]/I_PERSON
for O
1 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
, O
or O
7 B_NUMBER[MEASURE]/B_LOCATION
consecutive I_NUMBER[MEASURE]/I_LOCATION
days I_NUMBER[MEASURE]/I_LOCATION
. O

Dose- B_TIME[MEASURE]/B_PERSON
and O
duration-dependent B_DISEASE
testicular I_DISEASE
toxicity I_DISEASE
that O
occurred O
after O
a O
1-month B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
did O
not O
recover O
, O
and O
, O
in O
some O
cases B_PERSON/B_LOCATION
, O
was O
more O
severe B_DISEASE_ADJECTIVE[DISEASE]
4 I_DISEASE_ADJECTIVE[DISEASE]
months I_DISEASE_ADJECTIVE[DISEASE]
after O
the O
last B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
rabbits B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administered O
BMS-189453 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
oral B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
2 B_NUMBER[MEASURE]
, O
10 B_MEASURE
, O
or O
50 B_MEASURE
mg/kg I_MEASURE
for O
1 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
week B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
testicular B_DISEASE
degeneration I_DISEASE
and O
atrophy B_DISEASE/B_ORGANISM_FUNCTION
were O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
high-dose B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
1 B_TIME[MEASURE]
month I_TIME[MEASURE]
following O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

These O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O
that O
retinoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonists I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
selectively O
produce O
progressive B_DISEASE_ADJECTIVE[DISEASE]
and O
prolonged B_DISEASE
testicular I_DISEASE
toxicity I_DISEASE
after O
single B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
repeated O
oral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O
are O
otherwise O
well O
tolerated O
. O

Sequential O
involvement O
of O
NFAT B_GENE
and O
Egr B_GENE
transcription I_GENE
factors I_GENE
in O
FasL O
regulation O
. O

The O
critical O
function O
of O
NFAT B_GENE
proteins I_GENE
in O
maintaining O
lymphoid O
homeostasis O
was O
revealed O
in O
mice O
lacking O
both O
NFATp B_GENE
and O
NFAT4 B_GENE
( O
DKO O
) O
. O

DKO O
mice O
exhibit O
increased O
lymphoproliferation O
, O
decreased O
activation-induced O
cell O
death O
, O
and O
impaired O
induction O
of O
FasL B_GENE
. O

The O
transcription B_GENE
factors I_GENE
Egr2 I_GENE
and O
Egr3 B_GENE
are O
potent O
activators O
of O
FasL O
expression O
. O

Here O
we O
find O
that O
Egr2 B_GENE
and O
Egr3 B_GENE
are O
NFAT B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
target I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
genes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

activation O
of O
FasL B_GENE
occurs O
via O
the O
NFAT B_GENE
-dependent O
induction O
of O
Egr3 B_GENE
, O
as O
demonstrated O
by O
the O
ability O
of O
exogenously O
provided O
NFATp B_GENE
to O
restore O
Egr B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-dependent O
FasL O
promoter O
activity O
in O
DKO O
lymph O
node O
cells O
. O

Further O
, O
Egr3 B_GENE
expression O
is O
enriched O
in O
Th1 O
cells O
, O
suggesting O
a O
molecular O
basis O
for O
the O
known O
preferential O
expression O
of O
FasL B_GENE
in O
the O
Th1 O
versus O
Th2 O
subset O
. O

mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
clinical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
relevance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
nongenomic B_DISEASE
glucocorticoid I_DISEASE
actions I_DISEASE
. O

glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O
profound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti-inflammatory I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
immunosuppressive B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
actions I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
when O
used O
therapeutically O
. O

The O
therapeutic B_MEASURE/B_DISEASE
dose I_MEASURE/I_DISEASE
is O
quite O
variable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
depends O
on O
the O
disease B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
ranges O
from O
very O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
extremely O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

The O
rationale B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
various B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dosage I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
regimens I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
specific B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indications I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
existence B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
three B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
distinct I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
therapeutically O
relevant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
genomic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nongenomic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
unspecific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nongenomic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Genomic O
effects O
are O
mediated O
by O
cytosolic B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O
alter O
expression O
of O
specific O
genes O
. O

specific O
nongenomic O
effects O
occur O
within O
a O
few O
minutes O
and O
are O
mediated O
by O
steroid-selective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Unspecific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
nongenomic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
occur O
within O
seconds B_MEASURE/B_BIO
, O
but O
only O
at O
high B_TIME[MEASURE]/B_LOCATION
glucocorticoid I_TIME[MEASURE]/I_LOCATION
dosages I_TIME[MEASURE]/I_LOCATION
, O
and O
seem O
to O
result O
from O
direct B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
biological B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
membranes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

For O
unspecific B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nongenomic I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
methylprednisolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
shown O
to O
inhibit O
cation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
cycling I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
across O
the O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
to O
have O
little B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
synthesis B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

Thus O
, O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
diminish O
or O
prevent O
the O
acute B_DISEASE
immune I_DISEASE
response I_DISEASE
by O
interfering O
with O
processes B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
the O
rise B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
intracellular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Ca2+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
concentration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

It O
is O
proposed O
that O
the O
additional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapeutic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
benefit I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
higher B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
obtained O
via O
these O
nongenomic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

High O
glucose-induced O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
( O
ICAM-1 B_GENE/B_DISEASE
) O
expression O
through O
an O
osmotic O
effect O
in O
rat O
mesangial O
cells O
is O
PKC-NF-kappa O
B-dependent O
. O

AIMS/HYPOTHESIS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
infiltration B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
mononuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
and O
glomerular B_DISEASE
enlargement I_DISEASE
accompanied O
by O
glomerular B_DISEASE/B_GENE
cell I_DISEASE/I_GENE
proliferation I_DISEASE/I_GENE
are O
very O
early B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
pathophysiology B_DISEASE
of O
diabetes B_DISEASE
. O

To O
clarify O
the O
mechanism B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
early B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
diabetic B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nephropathy B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
we O
measured O
[ O
3H B_MEASURE/B_BIO
] B_MEASURE/I_BIO
-thymidine B_MEASURE/I_BIO
incorporation B_MEASURE/I_BIO
and O
cell B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
numbers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
show O
the O
influence B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ambient B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
osmotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
rat B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mesangial B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
proliferation B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
also O
measured O
the O
effect O
of O
high O
glucose O
on O
the O
expression O
of O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
and O
vascular B_GENE
adhesion I_GENE
molecule-1 I_GENE
by O
flow O
cytometry O
and O
semiquantitative O
RT-PCR O
in O
mesangial O
cells O
and O
the O
adhesion O
of O
leukocytes O
to O
mesangial O
cells O
. O

METHODS/RESULTS O
: O
cells O
exposed O
to O
high O
D-glucose O
( O
30 O
mmol/l O
) O
caused O
an O
increase O
in O
[ O
3H O
] O
-thymidine O
incorporation O
and O
cell O
numbers O
at O
24 O
and O
48 O
h O
and O
normalized O
at O
72 O
h O
( O
p O
< O
0.05 O
) O
, O
whereas O
these O
changes O
were O
not O
found O
in O
high O
mannitol O
( O
30 O
mmol/l O
) O
, O
IL-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
or O
TNF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-stimulated O
mesangial O
cells O
. O

cells O
exposed O
to O
high-glucose O
( O
15 O
, O
30 O
, O
or O
60 O
mmol/l O
) O
or O
osmotic O
agents O
( O
L-glucose O
, O
raffinose O
and O
mannitol O
) O
showed O
that O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
expression O
began O
to O
increase O
after O
24 O
h O
, O
reached O
its O
maximum O
at O
24 O
and O
48 O
h O
and O
gradually O
decreased O
afterwards O
. O

The O
stimulatory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
high B_DISEASE_ADJECTIVE[DISEASE]
glucose I_DISEASE_ADJECTIVE[DISEASE]
and O
high B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mannitol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
mRNA B_CELL_FUNCTION[ORGANISM_FUNCTION]/B_GENE
expression I_CELL_FUNCTION[ORGANISM_FUNCTION]/I_GENE
were O
observed O
as O
early O
as O
6 B_MEASURE
h O
and O
reached O
its O
maximum B_MEASURE/B_LOCATION
at O
12 B_MEASURE
h O
. O

Up-regulation O
of O
ICAM-1 B_GENE
protein O
and O
mRNA O
was O
also O
found O
in O
IL-1-beta B_DISEASE_ADJECTIVE[DISEASE]
and O
TNF-alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
-stimulated O
mesangial O
cells O
. O

Neither O
vascular B_GENE
adhesion I_GENE
molecule-1 I_GENE
protein O
nor O
mRNA O
expression O
was O
, O
however O
, O
affected O
by O
high O
glucose O
and O
high O
mannitol O
. O

notably O
, O
the O
protein O
kinase O
C O
inhibitors O
calphostin O
C O
and O
staurosporine O
reduced O
high O
glucose- O
or O
high O
mannitol-induced O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
mRNA O
expression O
and O
high O
glucose-induced O
proliferation O
. O

Furthermore O
, O
the O
NF-kappa O
B O
inhibitor O
N-tosyl-L-phenylalanine O
chloromethyl O
ketone O
reduced O
high O
glucose- O
or O
high O
mannitol-induced O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
mRNA O
expression O
and O
high O
glucose-induced O
proliferation O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O
that O
high B_DISEASE_ADJECTIVE[DISEASE]
glucose I_DISEASE_ADJECTIVE[DISEASE]
( O
15 B_MEASURE
, O
30 B_MEASURE
mmol/l I_MEASURE
) O
or O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
concentrations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
osmotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
remarkably O
increased O
the O
number B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
adherent B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leukocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
mesangial B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_MEASURE/B_LOCATION
< B_MEASURE/I_LOCATION
0.01 B_MEASURE/I_LOCATION
) O
compared O
with O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mmol/l I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D-glucose I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

functional O
blocking O
of O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
on O
mesangial O
cells O
with O
rat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
intercellular I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecule-1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monoclonal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
calphostin O
C O
, O
staurosporine O
, O
or O
N-tosyl-L-phenylalanine O
chloromethyl O
ketone O
significantly O
inhibited O
high O
glucose- O
or O
high O
mannitol-induced O
increase O
in O
leukocyte O
adhesion O
( O
p O
< O
< O
0.05 O
) O
. O

CONCLUSION/INTERPRETATION O
: O
These O
results O
suggest O
that O
high O
glucose O
can O
upregulate O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
protein O
and O
mRNA O
expression O
but O
not O
vascular O
adhesion O
molecule-1 O
expression O
in O
mesangial O
cells O
and O
promote O
leukocyte O
adhesion O
through O
up-regulation O
of O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
through O
osmotic O
effect O
, O
possibly O
depending O
on O
the O
protein B_GENE/B_LOCATION
kinase I_GENE/I_LOCATION
C I_GENE/I_LOCATION
nuclear I_GENE/I_LOCATION
factor-kappa I_GENE/I_LOCATION
B I_GENE/I_LOCATION
( O
PKC B_GENE
- O
NF-kappa B_PROTEIN[GENE]/B_LOCATION
B I_PROTEIN[GENE]/I_LOCATION
) O
pathway O
. O

High B_DISEASE/B_GENE
glucose B_DISEASE/I_GENE
itself O
can O
also O
promote O
mesangial B_DISEASE/B_GENE
cell I_DISEASE/I_GENE
proliferation I_DISEASE/I_GENE
through O
the O
PKC-NF-kappa B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
B B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

We O
conclude O
that O
hyperglycaemia B_DISEASE
in O
itself O
seems O
to O
be O
an O
important B_DISEASE_ADJECTIVE[DISEASE]
factor I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
early B_DISEASE
diabetic I_DISEASE
nephropathy I_DISEASE
. O

Combined O
corticosteroid/ O
granulocyte B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
colony-stimulating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
G-CSF B_LOCATION/B_GENE
) O
therapy O
in O
the O
treatment O
of O
severe O
congenital O
neutropenia O
unresponsive O
to O
G-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
activated O
glucocorticoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synergize O
with O
G-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
signals O
. O

More O
than O
90 O
% O
of O
patients O
with O
severe O
congenital O
neutropenia O
( O
SCN O
) O
respond O
to O
granulocyte B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
G-CSF B_LOCATION/B_ORGANIZATION
) O
therapy O
. O

The O
basis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
refractory B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
state B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
remaining O
patients B_PERSON/B_BIO
is O
unknown B_DISEASE_ADJECTIVE[DISEASE]
. O

To O
address O
this O
issue O
, O
we O
studied O
a O
child O
with O
SCN O
who O
was O
totally O
unresponsive O
to O
G-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
had O
a O
novel O
point O
mutation O
in O
the O
extracellular B_GENE
domain I_GENE
of O
the O
G-CSF B_GENE
receptor I_GENE
( O
GCSF-R B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

marrow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stromal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
support I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
granulopoiesis B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
evaluated O
by O
plating O
CD34 B_GENE
( O
+ B_OTHER/B_DISEASE
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
on O
preformed B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stromal B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
layers B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nonadherent B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
were O
harvested O
and O
assayed O
in O
clonogenic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
granulocytic B_DISEASE_ADJECTIVE[DISEASE]
colony I_DISEASE_ADJECTIVE[DISEASE]
production I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
in O
vitro O
effect O
of O
G-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
corticosteroids O
on O
granulopoiesis O
was O
evaluated O
in O
clonogenic O
assays O
of O
marrow O
mononuclear O
cells O
, O
by O
proliferation O
studies O
of O
the O
murine O
myeloid O
cell O
line O
32D O
expressing O
the O
patient O
's O
mutated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
G-CSFR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
by O
measuring O
STAT5 O
activation O
in O
nuclear O
extracts O
from O
stimulated O
cells O
. O

patient B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
's I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stroma I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supported O
granulopoiesis B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
derived O
from O
control B_GENE
marrow I_GENE
CD34 I_GENE
( O
+ B_OTHER/B_DISEASE
) O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
a O
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
manner I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Normal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
stroma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
however O
, O
failed O
to O
induce O
granulopoiesis B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
patient B_GENE
's I_GENE
CD34 I_GENE
( O
+ B_OTHER/B_DISEASE
) O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Clonogenic O
assays O
of O
the O
patient O
's O
marrow O
mononuclear O
cells O
incorporating O
either O
G-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
hydrocortisone O
produced O
little O
neutrophil O
growth O
. O

In O
contrast O
, O
inclusion O
of O
both O
G-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
hydrocortisone O
in O
the O
cytokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
`` I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocktail I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
'' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markedly O
increased O
the O
neutrophil O
numbers O
. O

proliferation O
of O
32D O
cells O
expressing O
the O
mutated B_GENE
receptor I_GENE
and O
STAT5 O
activation O
were O
improved O
by O
a O
combination O
of O
G-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dexamethasone O
. O

When O
small O
daily O
doses O
of O
oral O
prednisone O
were O
then O
administered O
to O
the O
patient O
with O
conventional O
doses O
of O
subcutaneous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G-CSF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
patient O
responded O
with O
increased O
neutrophil O
numbers O
and O
with O
a O
complete O
reversal O
of O
the O
infectious O
problems O
. O

These O
data O
provide O
insight O
into O
SCN O
unresponsive O
to O
standard O
G-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
and O
to O
the O
potential O
corrective O
action O
of O
combined O
treatment O
with O
G-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
corticosteroids O
through O
synergistic O
activation O
of O
STAT5 B_GENE
. O

Human B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
renal I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mesangial I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
a O
target B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
anti-inflammatory B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
action I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
9-cis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retinoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Mesangial B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
cells I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
play O
an O
active B_DISEASE_ADJECTIVE[DISEASE]
role I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
inflammatory B_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
to O
glomerular B_DISEASE
injury I_DISEASE
. O

We O
have O
studied O
in O
cultured O
human O
mesangial O
cells O
( O
CHMC O
) O
several O
effects O
of O
9-cis O
retinoic O
acid O
( O
9-cRA O
) O
, O
an O
activator O
of O
both O
retinoic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
RARs B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
retinoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
RXRs B_LOCATION/B_ORGANIZATION
) O
. O

9-cRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O
foetal B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
calf I_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
serum-induced O
CHMC B_DISEASE_ADJECTIVE[DISEASE]
proliferation I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
also O
prevented O
CHMC B_DISEASE/B_GENE
death I_DISEASE/I_GENE
induced O
by O
the O
inflammatory B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
mediator I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
H I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
( O
2 B_NUMBER[MEASURE]/B_LOCATION
) O
O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_NUMBER[MEASURE]/B_LOCATION
) O
. O

This O
preventive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
due O
to O
any O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
H B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 B_MEASURE/B_LOCATION
) O
O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_NUMBER[MEASURE]/B_LOCATION
) O
catabolism B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
it O
persisted O
even O
when O
both O
catalase B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
glutathione B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
inhibited O
. O

Finally O
, O
9-cRA B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diminished B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monocyte B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adhesion B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
FCS-stimulated B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CHMC B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Interestingly O
, O
the O
retinoid O
also O
inhibited O
in O
FCS-stimulated O
cells O
the O
protein O
expression O
of O
two O
mesangial B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adhesion I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
fibronectin B_GENE
and O
osteopontin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
but O
it O
did O
not O
modify O
the O
protein O
expression O
of O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
and O
vascular B_GENE
adhesion I_GENE
molecule-1 I_GENE
. O

All O
major O
RARs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RXRs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isotypes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
expressed O
in O
CHMC O
regardless O
of O
the O
presence O
or O
absence O
of O
9-cRA O
. O

Transcripts O
to O
RAR-alpha B_GENE
, O
RAR-beta B_GENE
and O
RXR-alpha B_GENE/B_LOCATION
increased O
after O
incubation O
with O
9-cRA O
whereas O
RXR-gamma B_GENE
was O
inhibited O
, O
suggesting O
a O
major O
role O
for O
RARs B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
RXRs B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
9-cRA-anti-inflammatory O
effects O
. O

9-cRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
toxic B_DISEASE_ADJECTIVE[DISEASE]
only O
at O
50 B_NUMBER[MEASURE]
microM O
( O
a O
concentration B_MEASURE
50 I_MEASURE
- O
5000 B_MEASURE
times I_MEASURE
higher I_MEASURE
than O
required O
for O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
above O
) O
. O

Cell B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
death I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
occurred O
by O
apoptosis B_DISEASE/B_GENE
, O
whose O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
associated O
with O
a O
pronounced B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
catalase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
reduced B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
glutathione B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
content B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
being O
more O
effectively O
induced O
by O
all-trans B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
retinoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

modulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
oxidant/antioxidant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
balance I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
failed O
to O
inhibit O
apoptosis B_DISEASE
. O

We O
conclude O
that O
mesangial B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
might O
be O
a O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
for O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
inflammatory B_DISEASE
glomerulopathies I_DISEASE
with O
9-cRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

expression O
of O
mammalian B_GENE
defensin I_GENE
genes I_GENE
. O

Antimicrobial B_PERSON/B_DISEASE
peptides I_PERSON/I_DISEASE
are O
a O
prevalent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanism I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
host B_DISEASE
defense I_DISEASE
found O
throughout O
nature B_BIO/B_DISEASE
. O

In O
mammals O
, O
defensins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
are O
among O
the O
most O
abundant O
of O
these O
broad-spectrum O
antibiotics O
, O
and O
are O
expressed O
in O
epithelial O
and O
hematopoietic O
cells O
. O

The O
defensin B_GENE/B_BIO
peptides I_GENE/I_BIO
are O
especially O
abundant B_DISEASE_ADJECTIVE[DISEASE]
in O
neutrophils B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O
however O
, O
gene B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
limited O
to O
the O
promyelocyte B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
stage I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
epithelial O
cells O
, O
defensin B_GENE/B_BIO
genes I_GENE/I_BIO
are O
found O
as O
both O
constitutively O
expressed O
and O
inducible O
. O

Induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
has O
been O
observed O
in O
vitro B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
bacterial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
lipopolysaccharide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
as O
well O
as O
inflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mediators I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
vivo O
, O
up-regulation O
of O
several O
defensin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
occurs O
in O
both O
infectious O
and O
inflammatory O
states O
. O

Gene O
regulation O
occurs O
via O
signal O
transduction O
pathways O
common O
to O
other O
innate O
immune O
responses O
, O
utilizing O
transcription B_GENE
factors I_GENE
such O
as O
nuclear B_GENE
factor I_GENE
( I_GENE
NF I_GENE
) I_GENE
-kappaB I_GENE
and O
NF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interleukin-6 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Together O
, O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
suggest O
a O
broad-based B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
innate I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
host I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
defense I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
whereby O
potent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
antimicrobial B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
peptides B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
present B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
prevent O
initial B_DISEASE_ADJECTIVE[DISEASE]
colonization I_DISEASE_ADJECTIVE[DISEASE]
by O
pathogenic B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
microorganisms I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
recognition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
bacteria B_BIO/B_DISEASE
coupled O
with O
a O
nascent B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
inflammatory B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
response B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
can O
bolster O
this O
defense B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
a O
coordinated B_MEASURE
up-regulation I_MEASURE
of O
the O
peptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Multiple O
signals O
required O
for O
cyclic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AMP-responsive I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
CREB B_GENE/B_LOCATION
) O
binding O
protein O
interaction O
induced O
by O
CD3/CD28 O
costimulation O
. O

The O
optimal O
activation O
of O
cAMP-responsive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
CREB B_GENE/B_LOCATION
) O
, O
similar O
to O
the O
full O
activation O
of O
T O
lymphocytes O
, O
requires O
the O
stimulation O
of O
both O
CD3 B_GENE
and O
CD28 B_GENE
. O

Using O
a O
reporter O
system O
to O
detect O
interaction O
of O
CREB B_GENE
and O
CREB-binding B_GENE
protein I_GENE
( O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
in O
this O
study O
we O
found O
that O
CREB B_GENE
binds O
to O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
by O
engagement O
of O
both O
CD3 B_GENE
and O
CD28 B_GENE
. O

CD3/CD28 B_GENE
-promoted O
CREB B_GENE/B_LOCATION
- O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O
was O
dependent O
on O
p38 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MAPK B_GENE/B_LOCATION
) O
and O
calcium/calmodulin-dependent B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CaMK I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
addition O
to O
the O
previously O
identified O
extracellular O
signal-regulated O
kinase O
pathway O
. O

Extracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signal-regulated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CaMKIV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
p38 B_GENE
MAPK I_GENE
were O
also O
the O
kinases O
involved O
in O
CREB B_GENE
Ser O
( O
133 O
) O
phosphorylation O
induced O
by O
CD3/CD28 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
reconstitution O
experiment O
illustrated O
that O
optimum O
CREB B_GENE
- O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O
and O
CREB B_GENE
trans-activation O
were O
attained O
when O
these O
three O
kinase O
pathways O
were O
simultaneously O
activated O
in O
T O
cells O
. O

Our O
results O
demonstrate O
that O
coordinated O
activation O
of O
different O
kinases B_GENE/B_LOCATION
leads O
to O
full O
activation O
of O
CREB B_GENE
. O

notably O
, O
CD28 O
ligation O
activated O
p38 B_GENE
MAPK I_GENE
and O
CaMKIV B_GENE
, O
the O
kinases B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O
by O
CD3 O
engagement O
, O
suggesting O
that O
CD28 B_GENE
acts O
by O
increasing O
the O
activation O
extent O
of O
p38 B_GENE
MAPK I_GENE
and O
CaMKIV B_GENE
. O

These O
results O
support O
the O
model O
of O
a O
minimum O
activation O
threshold O
for O
CREB B_GENE
- O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction O
that O
can O
be O
reached O
only O
when O
both O
CD3 B_GENE
and O
CD28 B_GENE
are O
stimulated O
. O

The O
murine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL-2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O
distal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulatory I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
responsive O
to O
the O
Ah B_GENE
receptor I_GENE
, O
a O
member O
of O
the O
evolutionarily O
conserved O
bHLH-PAS B_GENE/B_LOCATION
transcription I_GENE/I_LOCATION
factor I_GENE/I_LOCATION
family I_GENE/I_LOCATION
. O

signaling O
through O
the O
TCR B_GENE
and O
costimulatory O
signals O
primarily O
control O
transcription O
of O
the O
IL-2 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
in O
naive O
T O
cells O
. O

The O
minimal B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
necessary O
for O
this O
expression O
lies O
proximal O
, O
between O
-300 O
and O
the O
transcription B_GENE/B_LOCATION
start B_GENE/I_LOCATION
site B_GENE/I_LOCATION
. O

We O
had O
previously O
shown O
that O
activation O
of O
the O
arylhydrocarbon B_GENE/B_PERSON
receptor I_GENE/I_PERSON
( O
AHR B_LOCATION/B_ORGANIZATION
) O
, O
a O
member O
of O
the O
bHLH-PAS B_GENE/B_MEASURE
family I_GENE/I_MEASURE
of I_GENE/I_MEASURE
transcription I_GENE/I_MEASURE
factors I_GENE/I_MEASURE
, O
leads O
to O
increased O
mRNA O
expression O
of O
IL-2 B_GENE
in O
murine O
fetal O
thymocytes O
. O

The O
AHR B_GENE/B_DISEASE
is O
abundant O
in O
the O
thymus O
and O
may O
play O
a O
role O
for O
the O
development O
of O
the O
immune O
system O
. O

Moreover O
, O
its O
overactivation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
chemicals B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
such I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O
dioxins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
leads O
to O
immunosuppression B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
thymic B_DISEASE
involution I_DISEASE
. O

binding O
motifs O
for O
the O
liganded B_GENE/B_BACTERIUM[BIO]
AHR I_GENE/I_BACTERIUM[BIO]
can O
be O
identified O
in O
the O
distal B_LOCATION/B_BIO
region I_LOCATION/I_BIO
-1300 I_LOCATION/I_BIO
to I_LOCATION/I_BIO
-800 I_LOCATION/I_BIO
of O
the O
mouse B_GENE/B_LOCATION
IL-2 I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
. O

We O
show O
here O
that O
these O
DNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
motifs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
so-called O
dioxin B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elements I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
after O
binding O
to O
the O
liganded B_GENE/B_BACTERIUM[BIO]
AHR I_GENE/I_BACTERIUM[BIO]
are O
sufficient O
to O
transactivate O
luciferase O
expression O
in O
a O
reporter O
gene O
system O
. O

The O
IL-2 B_GENE/B_DISEASE
gene I_GENE/I_DISEASE
can O
be O
induced O
by O
the O
AHR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O
in O
thymocytes O
in O
vivo O
after O
injection O
of O
2 O
, O
3 O
, O
7 O
, O
8-tetrachlorodibenzo-p-dioxin O
, O
a O
potent O
ligand O
of O
the O
AHR B_GENE/B_DISEASE
. O

The O
AHR B_GENE/B_DISEASE
mediates O
the O
IL-2 O
induction O
as O
shown O
with O
AHR B_GENE/B_DISEASE
-deficient O
mice O
. O

However O
, O
in O
spleen O
cells O
in O
vitro O
costimulation O
via O
the O
TCR B_GENE
is O
necessary O
for O
optimal O
IL-2 B_GENE
gene I_GENE
induction O
. O

Thus O
, O
the O
IL-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O
novel O
distal B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
regulatory B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
elements B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O
can O
be O
addressed O
by O
the O
AHR B_DISEASE/B_GENE
to O
induce O
IL-2 B_GENE/B_DISEASE
and O
can O
cooperate O
with O
the O
proximal B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
. O

Visualization O
of O
Syk-antigen B_GENE/B_BIO
receptor I_GENE/I_BIO
interactions O
using O
green B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
differential O
roles O
for O
Syk B_GENE/B_PERSON
and O
Lyn B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
regulation O
of O
receptor O
capping O
and O
internalization O
. O

The O
cross-linking O
of O
the O
B B_GENE
cell I_GENE
Ag I_GENE
receptor I_GENE
( O
BCR B_LOCATION/B_ORGANIZATION
) O
is O
coupled O
to O
the O
stimulation O
of O
multiple O
intracellular O
signal O
transduction O
cascades O
via O
receptor-associated O
, O
protein B_GENE/B_BIO
tyrosine I_GENE/I_BIO
kinases I_GENE/I_BIO
of O
both O
the O
Src B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
Syk I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
families I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

To O
monitor O
changes O
in O
the O
subcellular O
distribution O
of O
Syk B_GENE/B_BACTERIUM[BIO]
in O
B O
cells O
responding O
to O
BCR B_GENE
cross-linking O
, O
we O
expressed O
in O
Syk B_GENE/B_BACTERIUM[BIO]
-deficient O
DT40 O
B O
cells O
a O
fusion B_GENE
protein I_GENE
consisting O
of O
Syk B_GENE/B_BACTERIUM[BIO]
coupled O
to O
green B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Treatment O
of O
these O
cells O
with O
anti-IgM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Abs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
leads O
to O
the O
recruitment O
of O
the O
kinase B_GENE
from O
cytoplasmic O
and O
nuclear O
compartments O
to O
the O
site O
of O
the O
cross-linked B_GENE
receptor I_GENE
at O
the O
plasma O
membrane O
. O

The O
Syk-receptor B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
aggregate O
into O
membrane O
patches O
that O
redistribute O
to O
form O
a O
cap O
at O
one O
pole O
of O
the O
cell O
. O

Syk B_GENE/B_BACTERIUM[BIO]
is O
not O
demonstrably O
associated O
with O
the O
internalized B_DISEASE/B_GENE
receptor I_DISEASE/I_GENE
. O

Catalytically O
active O
Syk B_GENE/B_BACTERIUM[BIO]
promotes O
and O
stabilizes O
the O
formation O
of O
tightly B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
capped I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
BCR I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
complexes I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O
the O
plasma O
membrane O
. O

Lyn B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
not O
required O
for O
the O
recruitment O
of O
Syk B_GENE/B_BACTERIUM[BIO]
to O
the O
cross-linked B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O
but O
is O
required O
for O
the O
internalization O
of O
the O
clustered O
BCR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
absence O
of O
Lyn B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
receptor-Syk B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complexes B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
at O
the O
plasma O
membrane O
are O
long O
lived O
, O
and O
the O
receptor-mediated O
activation O
of O
the O
NF-AT B_GENE
transcription I_GENE
factor I_GENE
is O
enhanced O
. O

Thus O
, O
Lyn B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appears O
to O
function O
to O
negatively O
regulate O
aspects O
of O
BCR B_GENE
-dependent O
signaling O
by O
stimulating O
receptor O
internalization O
and O
down-regulation O
. O

Renal O
interstitial O
fibrosis O
is O
reduced O
in O
angiotensin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1a I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-deficient O
mice O
. O

unilateral B_DISEASE
ureteral I_DISEASE
obstruction I_DISEASE
( O
UUO B_LOCATION/B_ORGANIZATION
) O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
tubulointerstitial B_DISEASE_ADJECTIVE[DISEASE]
fibrosis I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
affected O
kidney B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
by O
stimulating O
the O
renin-angiotensin B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
study O
established O
a O
UUO O
model O
in O
angiotensin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1a I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
AT1a B_PROTEIN[GENE]/B_LOCATION
) O
deficient O
( O
mutant O
) O
mice O
to O
elucidate O
the O
role O
of O
angiotensin B_DISEASE/B_GENE
II B_DISEASE/I_GENE
through O
AT1a B_GENE
on O
the O
fibrosis O
of O
the O
obstructed O
kidney O
( O
OBK O
) O
. O

The O
relative O
volume O
of O
the O
tubulointerstitium O
was O
measured O
by O
an O
image O
analyzer O
; O
deposition O
of O
collagen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
types I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
III I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
monocyte O
/ O
macrophage O
infiltration O
were O
histologically O
examined O
using O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Also O
determined O
were O
the O
mRNA O
levels O
of O
transforming B_GENE
growth I_GENE
factor-beta I_GENE
by O
Northern O
blot O
analysis O
. O

Nuclear B_GENE
factor-kappaB I_GENE
activity O
was O
assessed O
by O
gel O
shift O
assay O
. O

UUO O
in O
wild O
mice O
resulted O
in O
a O
marked O
expansion O
of O
relative O
volume O
of O
the O
tubulointerstitium O
, O
together O
with O
increased O
deposition O
of O
collagen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
types I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
III I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
number O
of O
infiltrated O
monocytes O
/ O
macrophages O
in O
the O
interstitium O
, O
relative O
to O
sham-operated O
mice O
. O

In O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
these O
changes B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
significantly O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
mutant B_PERSON/B_MEASURE
mice I_PERSON/I_MEASURE
with O
UUO B_DISEASE
. O

The O
mRNA O
level O
of O
transforming B_GENE
growth I_GENE
factor-beta I_GENE
was O
significantly O
higher O
in O
the O
OBK O
of O
wild O
mice O
with O
UUO O
compared O
with O
sham-operated O
mice O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
mRNA B_MEASURE
level I_MEASURE
in O
the O
OBK B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mutant B_BIO/B_GENE
mice I_BIO/I_GENE
was O
significantly O
less B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
in O
wild B_BIO/B_PERSON
mice I_BIO/I_PERSON
. O

Finally O
, O
UUO O
resulted O
in O
activation O
of O
nuclear B_GENE
factor-kappaB I_GENE
in O
wild O
mice O
but O
was O
inhibited O
in O
the O
OBK O
of O
mutant O
mice O
. O

The O
results O
provide O
direct O
evidence O
that O
angiotensin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acting O
via O
the O
AT1a B_PROTEIN[GENE]/B_LOCATION
plays O
a O
pivotal O
role O
in O
the O
development O
of O
tubulointerstitial O
fibrosis O
in O
UUO O
. O

HLA-DQ B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
tetramers I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
identify O
epitope-specific O
T O
cells O
in O
peripheral O
blood O
of O
herpes O
simplex O
virus O
type O
2-infected O
individuals O
: O
direct O
detection O
of O
immunodominant O
antigen-responsive O
cells O
. O

Ag-specific B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CD4+ B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
peripheral B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
blood I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
in O
low B_DISEASE/B_BIO
frequency I_DISEASE/I_BIO
, O
where O
they O
undergo O
recruitment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
expansion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
during O
immune B_DISEASE/B_ORGANISM_FUNCTION
responses I_DISEASE/I_ORGANISM_FUNCTION
and O
in O
the O
pathogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
numerous B_DISEASE/B_LOCATION
autoimmune I_DISEASE/I_LOCATION
diseases I_DISEASE/I_LOCATION
. O

MHC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tetramers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
which O
constitute O
a O
labeled B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
MHC-peptide I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
ligand I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
suitable O
for O
binding O
to O
the O
Ag-specific B_GENE
receptor I_GENE
on O
T O
cells O
, O
provide O
a O
novel O
approach O
for O
the O
detection O
and O
characterization O
of O
such O
rare O
cells O
. O

In O
this O
study O
, O
we O
utilized O
this O
technology O
to O
identify O
HLA B_GENE
DQ I_GENE
-restricted O
Ag-specific O
T O
cells O
in O
the O
peripheral O
blood O
of O
human O
subjects O
and O
to O
identify O
immunodominant O
epitopes O
associated O
with O
viral O
infection O
. O

Peptides O
representing O
potential O
epitope B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
VP16 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
HSV-2 O
were O
loaded O
onto O
recombinant B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DQ0602 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecules B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
generate O
a O
panel O
of O
Ag-specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DQ0602 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetramers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

VP16 B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Ag I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
-specific O
DQ-restricted O
T O
cells O
were O
identified O
and O
expanded O
from O
the O
peripheral O
blood O
of O
HSV-2-infected O
individuals O
, O
representing O
two O
predominant O
epitope O
specificities O
. O

Although O
the O
VP16 O
369-380 O
peptide O
has O
a O
lower O
binding O
affinity O
for O
DQ0602 B_GENE
molecules I_GENE
than O
the O
VP16 O
33-52 O
peptide O
, O
T O
cells O
that O
recognized O
the O
VP16 O
369-380 O
peptide O
occurred O
at O
a O
much O
higher O
frequency O
than O
those O
that O
were O
specific O
for O
the O
VP16 O
33-52 O
peptide O
. O

Down-regulation O
of O
BOB.1/OBF.1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Oct2 B_GENE
in O
classical O
Hodgkin O
disease O
but O
not O
in O
lymphocyte O
predominant O
Hodgkin O
disease O
correlates O
with O
immunoglobulin O
transcription O
. O

In O
contrast O
to O
the O
tumor O
cells O
( O
L O
& O
H O
cells O
) O
of O
lymphocyte O
predominant O
Hodgkin O
disease O
( O
LPHD O
) O
, O
Hodgkin O
and O
Reed-Sternberg O
( O
HRS O
) O
cells O
of O
classical O
Hodgkin O
disease O
( O
cHD O
) O
are O
unable O
to O
transcribe O
immunoglobulin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
despite O
the O
presence O
of O
rearranged B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
immunoglobulin B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
genes B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Although O
initial O
studies O
have O
suggested O
crippling O
immunoglobulin O
gene O
mutations O
to O
be O
the O
cause O
of O
absent O
immunoglobulin O
expression O
in O
cHD O
, O
recent O
work O
of O
our O
group O
has O
demonstrated O
an O
impaired O
activation O
of O
the O
immunoglobulin B_GENE
promoter I_GENE
as O
a O
superior O
mechanism O
. O

As O
immunoglobulin O
transcription O
is O
mainly O
regulated O
by O
the O
B-cell B_GENE
transcription I_GENE
factors I_GENE
Oct2 I_GENE
and O
BOB.1/OBF.1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
analyzed O
35 O
cases O
of O
LPHD O
, O
32 O
cases O
of O
cHD O
, O
and O
2 O
Hodgkin O
disease O
cell O
lines O
for O
the O
expression O
of O
these O
transcription B_GENE
factors I_GENE
and O
also O
in O
parallel O
for O
immunoglobulin O
expression O
. O

Our O
results O
demonstrate O
an O
absence O
of O
Oct2 B_GENE/B_DISEASE
and/or O
BOB.1/OBF.1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cHD O
and O
a O
striking O
overexpression O
of O
Oct2 B_GENE
in O
LPHD O
. O

immunoglobulin B_GENE/B_DISEASE
expression B_GENE/I_DISEASE
was O
lacking O
in O
CHD B_DISEASE
but O
present B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
LPHD B_DISEASE
. O

Furthermore O
, O
the O
reintroduction O
of O
BOB.1/OBF.1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Oct2 B_GENE
into O
cultured O
HRS O
cells O
restored O
the O
activity O
of O
cotransduced O
immunoglobulin B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
constructs B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Our O
findings O
dismiss O
the O
concept O
that O
the O
different O
immunoglobulin O
expression O
in O
cHD O
and O
LPHD O
is O
due O
to O
disrupting O
mutations O
of O
immunoglobulin B_GENE
V I_GENE
genes I_GENE
in O
cHD O
but O
is O
most O
likely O
due O
to O
a O
down-regulation O
of O
Oct2 B_GENE
and/or O
BOB.1/OBF.1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
study O
further O
revealed O
Oct2 B_GENE
as O
a O
new O
and O
valuable O
marker O
for O
the O
identification O
of O
L O
& O
H O
cells O
and O
their O
distinction O
from O
HRS O
cells O
. O

The O
impairment O
of O
immunoglobulin O
transcription O
with O
a O
down-regulated O
synthesis O
of O
Oct2 B_GENE
and O
BOB.1/OBF.1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
first O
established O
general O
recurrent O
defect O
found O
in O
HRS O
cells O
. O

Constitutive O
expression O
of O
NF-kappa B_GENE
B I_GENE
is O
a O
characteristic O
feature O
of O
mycosis O
fungoides O
: O
implications O
for O
apoptosis O
resistance O
and O
pathogenesis O
. O

The O
NF-kappa B_GENE
B I_GENE
family I_GENE
of I_GENE
transcription I_GENE
factors I_GENE
is O
an O
important O
regulator O
of O
genes O
expressed O
during O
inflammatory O
responses O
, O
immunoglobulin O
( O
Ig O
) O
class O
switching O
, O
cellular O
differentiation O
, O
and O
apoptosis O
. O

Recently O
, O
members O
of O
the O
NF-kappaB B_GENE/B_BIO
family I_GENE/I_BIO
, O
including O
p65 B_GENE
( I_GENE
Rel I_GENE
A I_GENE
) I_GENE
, O
have O
been O
implicated O
in O
promoting O
survival O
of O
various O
hematopoeitic O
neoplasms O
, O
including O
T O
cell O
malignancies O
such O
as O
adult O
T O
cell O
leukemia-lymphoma O
. O

We O
investigated O
the O
expression O
of O
active B_GENE
NF-kappa I_GENE
B I_GENE
p65 I_GENE
( I_GENE
Rel I_GENE
A I_GENE
) I_GENE
in O
cases O
of O
mycosis O
fungoides O
( O
MF O
) O
and O
the O
effect O
of O
chemical O
inhibitors O
of O
NF-kappa B_GENE
B I_GENE
on O
apoptosis O
in O
cutaneous O
T O
cell O
lymphoma O
( O
CTCL O
) O
cell O
lines O
. O

Paraffin-embedded O
tissues O
from O
23 O
cutaneous O
lesions O
and O
a O
single O
lymph O
node O
biopsy O
from O
patients O
diagnosed O
with O
MF O
were O
evaluated O
for O
p65 O
( O
Rel O
A O
) O
expression O
by O
using O
a O
monoclonal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mouse I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibody I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
detects O
the O
activated O
form O
of O
p65 B_GENE
( I_GENE
Rel I_GENE
A I_GENE
) I_GENE
. O

Apoptosis B_DISEASE/B_GENE
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
the O
NF-kappa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gliotoxin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
MG132 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
bay B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
11-7082 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
bay B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
11-7085 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
quantitatively O
measured O
in O
the O
CTCL B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lines B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
HuT-78 O
and O
HH B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
by O
propidium B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
iodide I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PI B_PROTEIN[GENE]
) O
/cell B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
a O
hypodiploid B_DISEASE_ADJECTIVE[DISEASE]
( O
sub-G B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE/B_LOCATION
) O
) O
population B_PERSON/B_LOCATION
and O
by O
determination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
increased O
annexin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
V/7-amino-actinomycin I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
7-AAD B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
extracts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
CTCL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
before O
and O
after O
chemical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
inhibition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
were O
analyzed O
for O
NF-kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA-binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
electrophoretic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mobility I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shift I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
EMSA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
with O
quantitative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
densitometry I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Nuclear O
expression O
of O
p65 B_GENE
( I_GENE
Rel I_GENE
A I_GENE
) I_GENE
before O
and O
after O
treatment O
with O
the O
various O
inhibitory O
compounds O
was O
measured O
by O
immunofluorescence O
staining O
in O
each O
CTCL O
cell O
line O
. O

Neoplastic O
T O
lymphocytes O
from O
22 O
of O
24 O
cases O
of O
MF O
showed O
strong O
nuclear O
and O
cytoplasmic O
expression O
of O
active B_GENE
p65 I_GENE
( I_GENE
Rel I_GENE
A I_GENE
) I_GENE
. O

Compared O
with O
untreated B_PERSON/B_BIO
control I_PERSON/I_BIO
cells I_PERSON/I_BIO
, O
a O
marked B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
apoptosis B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
NF-kappa B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
B B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DNA-binding B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activity B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
and O
a O
marked O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
nuclear B_GENE
p65 I_GENE
( O
Rel B_GENE/B_DISEASE
A I_GENE/I_DISEASE
) O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
seen O
in O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
from O
both O
CTCL B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
cell I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
lines I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
after O
chemical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
B I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
inhibition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
data O
show O
that O
the O
active O
form O
of O
NF-kappa B_GENE
B I_GENE
p65 I_GENE
( I_GENE
Rel I_GENE
A I_GENE
) I_GENE
is O
commonly O
expressed O
in O
neoplastic O
T O
lymphocytes O
in O
patients O
with O
MF O
. O

In O
CTCL O
cell O
lines O
, O
the O
significant O
decrease O
in O
nuclear O
NF-kappa O
B O
expression O
and O
the O
marked O
increase O
in O
spontaneous O
apoptosis O
caused O
by O
chemical O
NF-kappa O
B O
inhibition O
suggest O
a O
critical O
role O
for O
NF-kappa B_GENE
B I_GENE
in O
the O
pathogenesis O
and O
tumor O
cell O
maintenance O
of O
CTCLs O
. O

hum B_TIME[MEASURE]
PATHOL I_TIME[MEASURE]
31 I_TIME[MEASURE]
: O
1482-1490 B_MEASURE/B_PERSON
. O

Human O
T-cell O
leukemia O
virus O
type O
1 O
tax B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activates O
transcription O
through O
AP-1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O
inducing O
DNA O
binding O
activity O
in O
T O
cells O
. O

Human O
T-cell O
leukemia O
virus O
type O
1 O
( O
HTLV-1 O
) O
Tax B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B_GENE/B_LOCATION
factor I_GENE/I_LOCATION
AP-1 I_GENE/I_LOCATION
, O
such O
as O
c-Jun B_GENE
, O
JunD B_GENE/B_DISEASE
, O
c-Fos B_GENE
, O
and O
Fra-1 B_GENE
, O
at O
the O
level O
of O
RNA O
expression O
in O
T O
cells O
. O

We O
examined O
the O
activity O
of O
Tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
transcription O
through O
AP-1-binding B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
AP-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
T O
cells O
. O

Transient O
transfection O
studies O
showed O
that O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activated O
the O
expression O
of O
a O
luciferase B_GENE/B_MEASURE
gene I_GENE/I_MEASURE
regulated O
by O
two O
copies O
of O
an O
AP-1 B_GENE/B_MEASURE
site I_GENE/I_MEASURE
in O
the O
human O
Jurkat O
T-cell O
line O
. O

Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activates O
the O
expression O
of O
viral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cellular I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
through O
two O
different O
enhancers O
: O
a O
cAMP-responsive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CRE I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-like I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
kappaB B_GENE/B_LOCATION
element I_GENE/I_LOCATION
. O

Two O
Tax B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentially O
activated O
expression O
of O
these O
two O
elements O
. O

Tax703 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preferentially O
activated O
the O
kappaB B_GENE/B_LOCATION
element I_GENE/I_LOCATION
but O
not O
the O
CRE-like O
one O
, O
whereas O
TaxM22 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O
the O
reverse O
. O

In O
addition O
, O
Tax703 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
TaxM22 B_GENE
, O
converted O
cell O
growth O
of O
a O
mouse O
T-cell O
line O
from O
being O
interleukin O
( O
IL O
) O
-2-dependent O
to O
being O
IL-2-independent O
. O

Unlike O
the O
wild-type B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tax I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Tax703 B_GENE/B_ORGANIZATION
and O
TaxM22 B_GENE/B_MEASURE
only O
weakly O
activated O
the O
AP-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
T-cell O
line O
. O

Thus O
, O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
seems O
to O
activate O
the O
AP-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O
mechanisms O
distinct O
from O
those O
of O
kappaB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CRE-like I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
the O
activation O
of O
the O
AP-1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
dispensable O
for O
IL-2-independent O
growth O
of O
CTLL-2 O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
Tax B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
strong O
binding O
activity O
to O
an O
AP-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
CTLL-2 O
, O
whereas O
Tax703 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
, O
indicating O
that O
the O
induction O
of O
binding O
activity O
to O
the O
AP-1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
essential O
for O
the O
transcriptional O
activation O
by O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
binding B_GENE/B_LOCATION
complex I_GENE/I_LOCATION
induced O
by O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
CTLL-2 O
contained O
JunD B_GENE/B_DISEASE
and O
Fra-2 B_GENE/B_LOCATION
. O

Other O
AP-1 B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
undetectable O
. O

activation O
of O
transcription O
through O
the O
AP-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Jurkat O
cells O
by O
JunD B_GENE/B_DISEASE
and/or O
Fra-2 B_GENE
was O
weak O
. O

c-Jun B_GENE
, O
JunB B_GENE/B_BACTERIUM[BIO]
, O
and O
c-Fos B_GENE
activation O
was O
greater O
, O
although O
the O
level O
was O
still O
less O
than O
that O
with O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Thus O
, O
the O
induction O
of O
AP-1 B_GENE
mRNA I_GENE
by O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O
not O
be O
sufficient O
for O
a O
complete O
activation O
of O
AP-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
Tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
results O
suggest O
that O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activates O
the O
transcription O
of O
cellular B_GENE/B_LOCATION
genes I_GENE/I_LOCATION
with O
AP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O
inducing O
the O
DNA-binding O
activity O
of O
AP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
T O
cells O
, O
a O
mechanism O
distinct O
from O
those O
of O
CRE-like B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappaB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Copyright B_LOCATION/B_PERSON
2001 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

strict B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
human B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
immunodeficiency B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
virus B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
type B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
replication B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
by O
a O
genetic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
switch I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O
Tet B_GENE/B_BACTERIUM[BIO]
for O
Tat B_GENE
. O

Live-attenuated B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunodeficiency B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
virus B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
HIV-1 B_DISEASE/B_GENE
) O
variants B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
shown O
great B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promise I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
AIDS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
vaccines I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
but O
continued B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replication I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
lead O
to O
the O
selection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
faster-replicating O
variants B_DISEASE/B_BIO
that O
are O
pathogenic B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
therefore O
designed O
HIV-1 B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
genomes B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
that O
replicate O
exclusively O
upon O
addition O
of O
the O
nontoxic O
effector O
doxycycline O
( O
dox O
) O
. O

This O
was O
achieved O
by O
replacement B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
viral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
TAR-Tat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
transcriptional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
activation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
by O
the O
Escherichia B_BACTERIUM[BIO]/B_GENE
coli-derived B_BACTERIUM[BIO]/I_GENE
Tet B_BACTERIUM[BIO]/I_GENE
system B_BACTERIUM[BIO]/I_GENE
for O
inducible B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
designer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
HIV-rtTA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
'' O
viruses B_DISEASE/B_GENE
replicate O
in O
a O
strictly O
dox-dependent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
manner B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
both O
in O
a O
T-cell B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
line B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O
in O
primary B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
rate B_MEASURE/B_LOCATION
of O
replication B_TIME[MEASURE]/B_DISEASE
can O
be O
fine-tuned O
by O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
dox B_MEASURE/B_BIO
concentration B_MEASURE/I_BIO
. O

These O
HIV-rtTA B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
viruses B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O
a O
tool B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
to O
perform O
genetics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
e.g B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
, O
selection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
optimization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
experiments I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O
with O
the O
E B_OTHER/B_LOCATION
. O
coli-derived B_SPECIES[BIO]/B_GENE
Tet I_SPECIES[BIO]/I_GENE
reagents I_SPECIES[BIO]/I_GENE
in O
a O
eukaryotic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Furthermore O
, O
such B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
viruses I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
may O
represent O
improved B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vaccine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
candidates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
because O
their O
replication B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
can O
be O
turned O
on O
and O
off O
at O
will B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Synovial O
fluid O
induced O
nuclear B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
factor-kappaB I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DNA O
binding O
in O
a O
monocytic O
cell O
line O
. O

objective O
: O
To O
determine O
the O
effects O
of O
synovial O
fluids O
( O
SF O
) O
on O
DNA O
binding O
activity O
of O
transcription B_GENE
factor I_GENE
nuclear I_GENE
factor-kappaB I_GENE
( O
NF-kappaB B_GENE
) O
in O
the O
Mono O
Mac O
6 O
monocytic/macrophage O
cell O
line O
as O
a O
model O
for O
the O
interaction O
between O
SF O
and O
synovial O
tissue O
macrophages O
in O
arthritis O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
: O
mono B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Mac I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
6 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
incubated O
with O
SF B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
knee B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
joints I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
human B_PERSON
subjects I_PERSON
with O
rheumatoid B_DISEASE
arthritis I_DISEASE
( O
RA B_LOCATION
) O
, O
undifferentiated B_DISEASE
seronegative I_DISEASE
oligoarthritis I_DISEASE
, O
and O
osteoarthritis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
OA B_LOCATION
) O
. O

Nuclear O
extracts O
prepared O
from O
the O
Mono O
Mac O
6 O
cells O
and O
RA O
synovial O
tissue O
were O
analyzed O
by O
electrophoretic O
mobility O
shift O
analysis O
( O
EMSA O
) O
for O
NF-kappaB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
: O
induction O
of O
NF-kappaB B_GENE
DNA O
binding O
by O
the O
p65 B_GENE
( I_GENE
RelA I_GENE
) I_GENE
/p50 I_GENE
heterodimer I_GENE
was O
observed O
in O
response O
to O
incubation O
of O
Mono O
Mac O
6 O
cells O
with O
SF O
( O
20 O
% O
in O
culture O
medium O
) O
from O
5 O
of O
8 O
subjects O
with O
RA O
, O
4 O
of O
5 O
with O
OA O
, O
and O
none O
of O
3 O
with O
undifferentiated O
seronegative O
oligoarthritis O
. O

Incubation O
of O
SF O
with O
neutralizing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
against O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TNF-alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
against O
interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
significantly O
reduced O
the O
induction O
of O
p65/p50 O
binding O
activity O
in O
SF O
from O
subjects O
with O
RA O
and O
OA O
. O

unexpectedly O
, O
a O
slowly O
migrating O
SF O
inducible O
NF-kappaB B_GENE
-binding O
complex O
was O
observed O
in O
EMSA O
of O
Mono O
Mac O
6 O
cells O
after O
incubation O
with O
SF O
from O
5 O
of O
8 O
RA O
and O
2 O
of O
5 O
OA O
subjects O
. O

The O
induction O
of O
this O
complex O
by O
SF O
was O
not O
affected O
by O
neutralization O
of O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
SF O
, O
and O
the O
complex O
was O
not O
inducible O
by O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
IL-1beta O
, O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O
IL-1beta B_GENE
, O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
platelet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
derived I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
growth I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
lipopolysaccharide O
, O
or O
tetradecanoyl O
phorbol O
acetate O
. O

The O
slowly O
migrating B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
could O
not O
be O
supershifted O
with O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O
NF-kappaB B_GENE
, O
Jun B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
the O
transcriptional O
coactivators O
p300 B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
CBP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
NF-kappaB-binding B_PROTEIN[GENE]/B_MEASURE
complex I_PROTEIN[GENE]/I_MEASURE
with O
similar O
slow O
mobility O
was O
observed O
in O
nuclear O
extracts O
prepared O
from O
fresh O
human O
RA O
synovial O
tissue O
. O

conclusion O
: O
Biological O
activity O
of O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
SF O
from O
RA O
and O
OA O
subjects O
is O
capable O
of O
inducing O
p65/p50 B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
NF-kappaB I_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
DNA O
binding O
activity O
in O
macrophages O
. O

A O
property O
of O
SF O
that O
is O
independent O
of O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
other O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
responsible O
for O
the O
induction O
of O
a O
novel O
slowly O
migrating O
NF-kappaB-binding B_DISEASE/B_GENE
complex I_DISEASE/I_GENE
. O

soluble O
mediators O
in O
SF O
of O
subjects O
with O
RA O
and O
OA O
can O
therefore O
modulate O
binding O
of O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
NF-kappaB B_GENE
binding I_GENE
site I_GENE
in O
macrophages O
and O
may O
play O
a O
role O
in O
inflammatory O
gene O
expression O
in O
arthritis O
. O

Peroxisome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor-gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
agonists O
and O
15-deoxy-Delta O
( O
12 O
, O
14 O
) O
( O
12 O
, O
14 O
) O
-PGJ O
( O
2 O
) O
induce O
apoptosis O
in O
normal O
and O
malignant O
B-lineage O
cells O
. O

The O
research O
described O
herein O
evaluates O
the O
expression O
and O
functional O
significance O
of O
peroxisome B_GENE
proliferator I_GENE
activator I_GENE
receptor-gamma I_GENE
( I_GENE
PPAR-gamma I_GENE
) I_GENE
on O
B-lineage O
cells O
. O

Normal O
mouse O
B O
cells O
and O
a O
variety O
of O
B O
lymphoma O
cells O
reflective O
of O
stages O
of O
B O
cell O
differentiation O
( O
e.g. O
, O
70Z/3 O
, O
CH31 O
, O
WEHI-231 O
, O
CH12 O
, O
and O
J558 O
) O
express O
PPAR-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
, O
by O
Western O
blot O
analysis O
, O
the O
67-kDa B_GENE
PPAR-gamma I_GENE
protein I_GENE
. O

15-Deoxy-Delta O
( O
12 B_MEASURE
, O
14 B_MEASURE
) O
-PGJ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
2 B_NUMBER[MEASURE]
) O
( O
15d-PGJ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
2 B_NUMBER[MEASURE]
) O
) O
, O
a O
PPAR-gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
agonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
has O
a O
dose-dependent B_DISEASE_ADJECTIVE[DISEASE]
antiproliferative I_DISEASE_ADJECTIVE[DISEASE]
and O
cytotoxic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
malignant B_DISEASE
B I_DISEASE
cells I_DISEASE
as O
shown O
by O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 B_NUMBER[MEASURE]
) O
H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
thymidine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
3- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
[ O
4 B_NUMBER[MEASURE]
, O
5-dimethylthiazol-2-yl B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-2 O
, O
5-diphenyltetrazolium B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bromide I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Only O
PPAR-gamma O
agonists O
( O
thiazolidinediones O
) O
, O
and O
not O
PPAR-alpha O
agonists O
, O
mimicked O
the O
effect O
of O
15d-PGJ O
( O
2 O
) O
on O
B-lineage O
cells O
, O
indicating O
that O
the O
mechanism O
by O
which O
15d-PGJ O
( O
2 O
) O
negatively O
affects O
B-lineage O
cells O
involves O
in O
part O
PPAR-gamma B_GENE
. O

The O
mechanism B_LOCATION
by O
which O
PPAR-gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agonists I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induce O
cytotoxicity B_DISEASE/B_GENE
is O
via O
apoptosis B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
as O
shown O
by O
annexin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
V I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
as O
confirmed O
by O
DNA B_DISEASE_ADJECTIVE[DISEASE]
fragmentation I_DISEASE_ADJECTIVE[DISEASE]
detected O
using O
the O
TUNEL B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Interestingly O
, O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
PGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2alpha B_PROTEIN[GENE]/B_MEASURE
) O
, O
which O
was O
not O
known O
to O
affect O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O
dramatically O
attenuated O
the O
deleterious B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
PPAR-gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agonists I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphomas B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

surprisingly O
, O
15d-PGJ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
2 B_NUMBER[MEASURE]
) O
induced O
a O
massive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
nuclear B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mitogen-activated B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
kinase B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
and O
pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
with O
PGF B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2alpha B_PROTEIN[GENE]/B_MEASURE
) O
blunted O
the O
mitogen-activated B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
is O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
evaluating O
PPAR-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
its O
significance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
B B_DISEASE/B_LOCATION
lymphocytes I_DISEASE/I_LOCATION
. O

PPAR-gamma B_PERSON/B_LOCATION
agonists I_PERSON/I_LOCATION
may O
serve O
as O
a O
counterbalance B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
the O
stimulating B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PGs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
namely O
PGE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
2 B_NUMBER[MEASURE]/B_LOCATION
) O
, O
which O
promotes O
B B_DISEASE
cell I_DISEASE
differentiation I_DISEASE
. O

Finally O
, O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
PGs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
15d-PGJ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
2 B_NUMBER[MEASURE]/B_LOCATION
) O
, O
and O
synthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PPAR-gamma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
agonists I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
induce O
apoptosis B_DISEASE/B_GENE
in O
B-lineage B_DISEASE/B_BIO
cells I_DISEASE/I_BIO
may O
lead O
to O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
novel B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
fatal B_DISEASE/B_LOCATION
B I_DISEASE/I_LOCATION
lymphomas I_DISEASE/I_LOCATION
. O

Inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
STAT3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leads O
to O
apoptosis B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
leukemic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
large I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
granular I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
decreased O
Mcl-1 B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O

Large B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
granular B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocyte B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
LGL B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
leukemia B_DISEASE
is O
characterized O
by O
the O
expansion B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
antigen-activated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytotoxic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
leukemic O
cells O
are O
resistant O
to O
Fas-mediated O
apoptosis O
despite O
expressing O
high O
levels O
of O
Fas B_GENE
. O

We O
found O
that O
leukemic O
LGL O
from O
19 O
patients O
displayed O
high O
levels O
of O
activated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
STAT3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Treatment O
of O
leukemic O
LGL O
with O
the O
JAK-selective O
tyrosine O
kinase O
inhibitor O
AG-490 O
induced O
apoptosis O
with O
a O
corresponding O
decrease O
in O
STAT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-DNA O
binding O
activity O
. O

Moreover O
, O
using O
an O
antisense B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oligonucleotide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
approach I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
diminish O
STAT3 B_GENE/B_DISEASE
expression I_GENE/I_DISEASE
, O
we O
found O
that O
Fas B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sensitivity I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
restored O
in O
leukemic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
LGL B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

AG-490-induced B_DISEASE/B_GENE
apoptosis I_DISEASE/I_GENE
in O
leukemic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
LGL B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
independent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
Bcl-xL B_GENE
or O
Bcl-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
we O
found O
that O
the O
Bcl-2-family B_DISEASE_ADJECTIVE[DISEASE]
protein I_DISEASE_ADJECTIVE[DISEASE]
Mcl-1 I_DISEASE_ADJECTIVE[DISEASE]
was O
significantly O
reduced O
by O
AG-490 O
treatment O
. O

Activated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
STAT3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
shown O
to O
bind O
an O
SIE-related B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
murine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mcl-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Using O
a O
luciferase O
reporter O
assay O
, O
we O
demonstrated O
that O
v-src O
overexpression O
in O
NIH3T3 O
induced O
STAT3 B_GENE
-dependent O
transcriptional O
activity O
from O
the O
mcl-1 B_GENE
promoter I_GENE
and O
increased O
endogenous O
Mcl-1 O
protein O
levels O
. O

We O
conclude O
that O
STAT3 B_GENE
activation O
contributed O
to O
accumulation O
of O
the O
leukemic O
LGL O
clones O
. O

These O
findings O
suggest O
that O
investigation O
should O
focus O
on O
novel O
strategies O
targeting O
STAT3 B_GENE
in O
the O
treatment O
of O
LGL O
leukemia O
. O

decreased O
immediate O
inflammatory B_GENE/B_DISEASE
gene I_GENE/I_DISEASE
induction O
in O
activating B_GENE/B_PERSON
transcription I_GENE/I_PERSON
factor-2 I_GENE/I_PERSON
mutant O
mice O
. O

Transcription B_GENE
factor I_GENE
activating I_GENE
transcription I_GENE
factor I_GENE
( I_GENE
ATF I_GENE
) I_GENE
-2 I_GENE
is O
activated O
by O
inflammatory O
signals O
transduced O
by O
the O
JNK O
and O
p38 O
Map O
kinase O
pathways O
. O

To O
better O
define O
the O
role O
of O
ATF-2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
inflammation O
, O
adult O
mice O
expressing O
small O
amounts O
of O
a O
mutant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ATF-2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
challenged O
with O
lipopolysaccharide O
( O
LPS O
) O
, O
anti-CD3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
antibody B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
or O
virus O
. O

Within O
3 O
h O
of O
challenge O
by O
LPS O
, O
ATF-2 O
mutant O
mice O
had O
decreased O
induction O
of O
the O
adhesion B_GENE
molecules I_GENE
E-selectin I_GENE
, O
P-selectin B_GENE
and O
VCAM-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
as O
well O
as O
the O
cytokines B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumor I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necrosis I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor-alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
IL-1beta B_GENE
and O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
compared O
with O
control O
mice O
. O

stimulation O
of O
T O
lymphocytes O
by O
anti-CD3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O
showed O
less O
induction O
of O
IL-1 B_GENE
and O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
ATF-2 O
mutant O
tissues O
. O

ATF-2 O
mutant O
thymocytes O
treated O
with O
anti-CD3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
vitro O
demonstrated O
reduced O
induction O
of O
c-Jun B_GENE
, O
JunB B_GENE/B_BACTERIUM[BIO]
, O
JunD B_GENE/B_DISEASE
and O
Fra-2 B_GENE
. O

However O
, O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
what O
was O
observed O
after O
p38 B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
kinase B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibition B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
normal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
relative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ATF-2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
deficiency I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
did O
not O
prevent O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
mononuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
infiltrate O
in O
the O
week B_BODY_PART_OR_ORGAN_COMPONENT
following O
an O
inflammatory B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulus I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

ATF-2 O
mutant B_BIO/B_PERSON
mice I_BIO/I_PERSON
proved O
more O
susceptible B_DISEASE_ADJECTIVE[DISEASE]
to O
death B_DISEASE
than O
control B_PERSON/B_BIO
mice I_PERSON/I_BIO
from O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
plus O
D-galactosamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
injection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
Coxsackievirus B_DISEASE
B3 I_DISEASE
infection I_DISEASE
and O
had O
a O
higher B_MEASURE/B_DISEASE
incidence I_MEASURE/I_DISEASE
of O
mononuclear B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pulmonary I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infiltrates I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
herpes B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simplex B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
virus-1 B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

ATF-2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
essential O
for O
maximal O
immediate O
induction O
of O
adhesion B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
cytokine B_GENE/B_DISEASE
genes I_GENE/I_DISEASE
, O
but O
at O
later O
time O
points O
may O
even O
protect O
against O
overactive O
immune O
responses O
. O

LIGHT B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
TNF-like B_GENE
molecule I_GENE
, O
costimulates O
T O
cell O
proliferation O
and O
is O
required O
for O
dendritic O
cell O
-mediated O
allogeneic O
T O
cell O
response O
. O

LIGHT B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
recently O
identified O
member O
of O
the O
TNF B_GENE/B_BIO
superfamily I_GENE/I_BIO
and O
its O
receptors O
, O
herpesvirus B_GENE
entry I_GENE
mediator I_GENE
and O
lymphotoxin B_GENE
beta I_GENE
receptor I_GENE
, O
are O
found O
in O
T O
cells O
and O
stromal O
cells O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
LIGHT B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
selectively O
expressed O
on O
immature O
dendritic O
cells O
( O
DCs O
) O
generated O
from O
human O
PBMCs O
. O

In O
contrast O
, O
LIGHT B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
detectable O
in O
DCs O
either O
freshly O
isolated O
from O
PBMCs O
or O
rendered O
mature O
in O
vitro O
by O
LPS O
treatment O
. O

blockade O
of O
LIGHT B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
its O
soluble B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
lymphotoxin B_GENE/B_LOCATION
beta I_GENE/I_LOCATION
receptor-Ig I_GENE/I_LOCATION
or O
HVEM-Ig B_GENE
, O
inhibits O
the O
induction O
of O
DC O
-mediated O
primary O
allogeneic O
T O
cell O
response O
. O

Furthermore O
, O
engagement O
of O
LIGHT B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
costimulates O
human O
T O
cell O
proliferation O
, O
amplifies O
the O
NF-kappaB O
signaling O
pathway O
, O
and O
preferentially O
induces O
the O
production O
of O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
IL-4 B_GENE
, O
in O
the O
presence O
of O
an O
antigenic O
signal O
. O

Our O
results O
suggest O
that O
LIGHT B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
costimulatory B_GENE/B_LOCATION
molecule I_GENE/I_LOCATION
involved O
in O
DC O
-mediated O
cellular O
immune O
responses O
. O

suppression O
of O
HIV O
type O
1 O
replication O
by O
a O
dominant-negative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Ets-1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mutant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

activity O
of O
the O
distal B_GENE/B_BIO
region I_GENE/I_BIO
of O
the O
human O
immunodeficiency O
virus O
( O
HIV-1 O
) O
long B_GENE
terminal I_GENE
repeat I_GENE
( O
LTR B_GENE/B_DISEASE
) O
, O
which O
contains O
binding B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
Ets-1 B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
USF-1 I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
is O
integral O
for O
HIV-1 O
replication O
. O

The O
Ets-1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
USF-1 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
play O
a O
critical O
role O
in O
the O
activity O
of O
the O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
distal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
indicated O
by O
the O
potent O
dominant O
negative O
effect O
of O
a O
mutant B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Ets-1 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
lacking B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
trans-activation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
domains B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
on O
the O
transcriptional O
activity O
of O
the O
LTR B_GENE/B_DISEASE
. O

To O
determine O
the O
biological O
relevance O
of O
the O
Ets-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
USF-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
HIV-1 O
replication O
, O
we O
examined O
the O
effect O
of O
expression O
of O
the O
dominant-negative O
mutant O
of O
Ets-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
dnEts-1 B_PROTEIN[GENE]
) O
on O
HIV-1 O
infection O
of O
T O
cells O
. O

We O
demonstrated O
that O
expression O
of O
dnEts B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markedly O
suppressed O
HIV-1 O
infection O
of O
a O
T O
cell O
line O
. O

This O
finding O
indicates O
that O
formation O
of O
a O
transcriptionaly B_GENE/B_LOCATION
active B_GENE/I_LOCATION
USF-1/Ets-1 B_GENE/I_LOCATION
complex B_GENE/I_LOCATION
is O
important O
in O
the O
productive O
infection O
of O
cells O
by O
HIV-1 O
, O
and O
suggests O
that O
inhibition O
of O
the O
interaction O
between O
USF-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Ets-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O
provide O
a O
new O
target O
for O
anti-HIV-1 O
gene O
therapy O
. O

Human O
eosinophils O
constitutively O
express O
nuclear B_GENE
factor I_GENE
of I_GENE
activated I_GENE
T I_GENE
cells I_GENE
p I_GENE
and I_GENE
c I_GENE
. O

Background O
: O
Eosinophils O
are O
now O
known O
to O
produce O
a O
variety O
of O
proinflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokines B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
although O
the O
molecular O
factors O
that O
regulate O
their O
production O
are O
poorly O
understood O
. O

The O
expression O
of O
almost O
all O
of O
the O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
produced O
by O
eosinophils O
, O
including O
the O
proallergic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
is O
now O
known O
to O
be O
regulated O
at O
the O
level O
of O
transcription O
by O
members O
of O
the O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
NFAT B_GENE/B_LOCATION
) O
family O
of O
transcription O
factors O
. O

objective O
: O
We O
sought O
to O
characterize O
the O
expression O
of O
different O
NFAT B_GENE
proteins I_GENE
in O
resting O
and O
activated O
eosinophils O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Nuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
whole B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
extracts I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
obtained O
from O
both O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
eosinophils I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
and O
those O
obtained O
from O
bronchoalveolar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lavage I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fluid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
asthmatic B_PERSON/B_BIO
subjects I_PERSON/I_BIO
after O
endobronchial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
allergen B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
challenge B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

NFAT B_GENE
expression O
was O
determined O
by O
using O
immunoprecipitation O
and O
Western O
blot O
analysis O
, O
DNA-binding O
assays O
, O
and O
RT-PCR O
analysis O
of O
eosinophil B_GENE
mRNA I_GENE
. O

Results O
: O
Both O
peripheral O
blood O
and O
bronchoalveolar O
lavage O
fluid O
eosinophils O
expressed O
NFATp B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NFATc I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Unlike O
activated O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
which O
express O
multiple B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NFATc I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
eosinophils B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
preferentially O
express O
the O
approximately O
85-kd B_PROTEIN[GENE]/B_MEASURE
isoform I_PROTEIN[GENE]/I_MEASURE
. O

In O
addition O
, O
eosinophils O
were O
found O
to O
constitutively O
express O
NFATc B_GENE
mRNA I_GENE
. O

A O
brief O
incubation O
with O
the O
T B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
H I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
IL-5 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
sufficient O
to O
induce O
the O
nuclear O
translocation O
of O
NFATc B_GENE
. O

Eosinophil O
nuclear O
extracts O
contain O
multiple O
factors O
that O
can O
specifically O
recognize O
the O
IL-4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
P1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NFAT I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
DNA-binding O
assays O
, O
including O
NFATp B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusion O
: O
NFATp B_GENE
and O
NFATc B_GENE
can O
regulate O
the O
expression O
of O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
other O
genes O
in O
eosinophils O
but O
appear O
to O
be O
regulated O
by O
a O
novel O
signal O
transduction O
mechanism O
in O
these O
cells O
. O

BLyS B_GENE/B_DISEASE
binds O
TO O
B O
cells O
With O
High O
affinity O
AND O
INDUCES O
activation O
OF O
THE O
TRANSCRIPTION B_LOCATION/B_GENE
FACTORS I_LOCATION/I_GENE
NF-kappaB I_LOCATION/I_GENE
AND O
ELF-1 B_GENE
. O

B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphocyte I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stimulator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
BLyS B_LOCATION/B_DISEASE
) O
is O
a O
novel O
member O
of O
the O
TNF B_GENE/B_LOCATION
family I_GENE/I_LOCATION
of I_GENE/I_LOCATION
proteins I_GENE/I_LOCATION
expressed O
by O
myeloid O
cells O
as O
membrane-bound O
and O
soluble O
forms O
. O

BLyS B_GENE/B_DISEASE
was O
shown O
to O
act O
specifically O
on O
B O
cells O
, O
inducing O
proliferation O
and O
immunoglobulin O
production O
both O
in O
vitro O
and O
in O
vivo O
. O

The O
present O
study O
was O
undertaken O
to O
characterize O
binding O
of O
radiolabeled B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
BLyS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
its O
cognate B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
human O
B O
lymphocytes O
and O
examine O
intracellular O
events O
initiated O
by O
BLyS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
binding O
. O

Similar O
to O
other O
TNF B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
family B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
members B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
BLyS B_GENE/B_DISEASE
is O
present O
in O
solution O
as O
a O
homotrimer B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
determined O
by O
gel O
filtration O
chromatography O
and O
light O
scattering O
analysis O
. O

BLyS B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
binding O
to O
B O
cells O
is O
specific O
as O
other O
TNF B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tested O
did O
not O
compete O
for O
( O
125 O
) O
I- O
BLyS B_GENE/B_DISEASE
binding O
. O

Analysis O
of O
equilibrium O
binding O
of O
( B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
125 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
I-labeled I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
BLyS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
purified O
human O
tonsillar O
B O
cells O
demonstrated O
saturable O
binding O
. O

Scatchard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
binding O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
revealed O
a O
single B_MEASURE/B_LOCATION
class I_MEASURE/I_LOCATION
of O
high-affinity B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
B I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O
approximately O
2600 B_NUMBER[MEASURE]
binding O
sites B_LOCATION/B_ENT
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
and O
an O
apparent B_MEASURE/B_LOCATION
dissociation I_MEASURE/I_LOCATION
constant I_MEASURE/I_LOCATION
( O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
) O
of O
about O
0.1 B_MEASURE
nm I_MEASURE
. O

In O
addition O
we O
report O
that O
BLyS B_GENE/B_DISEASE
binding O
to O
B O
cells O
results O
in O
the O
activation O
of O
NF-kappaB B_GENE
and O
the O
Ets B_GENE/B_PERSON
family I_GENE/I_PERSON
transcription I_GENE/I_PERSON
factor I_GENE/I_PERSON
, O
ELF-1 B_GENE
, O
and O
in O
the O
induction O
of O
mRNA O
for O
Polo-like B_GENE
kinase I_GENE
( O
PLK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

Copyright B_LOCATION/B_PERSON
2001 I_LOCATION/I_PERSON
Academic I_LOCATION/I_PERSON
Press I_LOCATION/I_PERSON
. O

Design O
and O
use O
of O
an O
inducibly O
activated O
human O
immunodeficiency O
virus O
type O
1 O
Nef B_BIO/B_GENE
to O
study O
immune O
modulation O
. O

The O
Nef B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
has O
been O
shown O
to O
enhance O
the O
infectivity O
of O
virus O
particles O
, O
downmodulate O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
surface B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
and O
associate O
with O
many O
intracellular B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
proteins B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O
are O
thought O
to O
facilitate O
HIV O
infection O
. O

One O
of O
the O
challenges O
in O
defining O
the O
molecular O
events O
regulated O
by O
Nef B_GENE/B_BACTERIUM[BIO]
has O
been O
obtaining O
good O
expression O
of O
Nef B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
T O
cells O
. O

This O
has O
been O
attributed O
to O
effects O
of O
Nef B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
on O
cell O
proliferation O
and O
apoptosis O
. O

We O
have O
designed O
a O
Nef B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
is O
readily O
expressed O
in O
T-cell O
lines O
and O
whose O
function O
is O
inducibly O
activated O
. O

It O
is O
composed O
of O
a O
fusion O
between O
full-length B_GENE
Nef I_GENE
and O
the O
estrogen B_PROTEIN[GENE]/B_LOCATION
receptor I_PROTEIN[GENE]/I_LOCATION
hormone-binding I_PROTEIN[GENE]/I_LOCATION
domain I_PROTEIN[GENE]/I_LOCATION
( O
Nef-ER B_GENE/B_DISEASE
) O
. O

The O
Nef-ER B_ENZYME[GENE]/B_LOCATION
is O
kept O
in O
an O
inactive O
state O
due O
to O
steric O
hindrance O
, O
and O
addition O
of O
the O
membrane-permeable O
drug O
4-hydroxytamoxifen O
( O
4-HT O
) O
, O
which O
binds O
to O
the O
ER B_GENE
domain I_GENE
, O
leads O
to O
inducible O
activation O
of O
Nef-ER B_GENE/B_LOCATION
within O
cells O
. O

We O
demonstrate O
that O
Nef-ER B_GENE
inducibly O
associates O
with O
the O
62-kDa B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
Ser/Thr B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
kinase B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
is O
localized O
to O
specific O
membrane O
microdomains O
( O
lipid O
rafts O
) O
only O
after O
activation O
. O

Using O
this O
inducible O
Nef B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
also O
compared O
the O
specific O
requirements O
for O
CD4 B_GENE
and O
HLA-A2 B_GENE
downmodulation O
in O
a O
SupT1 O
T-cell O
line O
. O

Half-maximal O
downmodulation O
of O
cell B_GENE
surface I_GENE
CD4 I_GENE
required O
very O
little O
active O
Nef-ER B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
occurred O
as O
early O
as O
4 O
h O
after O
addition O
of O
4-HT O
. O

In O
contrast O
, O
50 O
% O
downmodulation O
of O
HLA-A2 B_GENE
by O
Nef B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
required O
16 O
to O
24 O
h O
and O
about O
50- O
to O
100-fold-greater O
concentrations O
of O
4-HT O
. O

These O
data O
suggest O
that O
HLA-A2 B_GENE
downmodulation O
may O
require O
certain O
threshold O
levels O
of O
active O
Nef B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O

The O
differential O
timing O
of O
CD4 B_GENE/B_DISEASE
and O
HLA-A2 B_GENE
downmodulation O
may O
have O
implications O
for O
HIV O
pathogenesis O
and O
immune O
evasion O
. O

Regulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chemokine B_GENE
mRNA I_GENE
expression I_GENE
in O
a O
rat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
vanadium-induced B_DISEASE
pulmonary I_DISEASE
inflammation I_DISEASE
. O

Environmental B_ORGANIZATION/B_PERSON
and O
occupational B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exposure B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
vanadium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dusts I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
results I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
toxic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mainly O
confined O
to O
the O
respiratory B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Using O
a O
rat O
model O
of O
acute O
lung O
inflammation O
induced O
by O
intratracheal O
instillation O
of O
sodium O
metavanadate O
( O
NaVO3 O
) O
at O
the O
dose O
of O
200 O
microg O
V/kg O
, O
we O
investigated O
the O
relationship O
between O
the O
cytologic O
characterization O
of O
pulmonary O
inflammation O
and O
the O
expression O
of O
chemokine B_GENE
mRNA I_GENE
. O

Significant B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
polymorphonuclear I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukocyte I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PMN B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
influx B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0.01 B_MEASURE
) O
into O
the O
lung B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O
noted O
4 B_MEASURE/B_LOCATION
h O
after O
NaVO3 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
instillation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
whereas O
alveolar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
AMs B_LOCATION/B_ORGANIZATION
) O
in O
bronchoalveolar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
lavage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
BAL B_LOCATION
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appeared O
to O
decrease O
significantly O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
neither O
PMNs B_LOCATION
nor O
AMs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
changed O
substantially O
1 B_MEASURE/B_LOCATION
h O
after O
NaVO3 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
instillation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

By O
Northern O
analysis O
, O
macrophage B_GENE
inflammatory I_GENE
protein I_GENE
( I_GENE
MIP I_GENE
) I_GENE
-2 I_GENE
mRNA I_GENE
in O
BAL O
cells O
increased O
markedly O
1 O
h O
after O
NaVO3 O
instillation O
and O
reduced O
a O
little O
bit O
at O
4 O
h O
, O
whereas O
MIP-1alpha B_GENE/B_LOCATION
mRNA I_GENE/I_LOCATION
in O
BAL O
cells O
was O
expressed O
relatively O
high O
1 O
h O
after O
NaVO3 O
instillation O
, O
although O
a O
basal O
expression O
was O
detected O
in O
control O
group O
, O
and O
returned O
rapidly O
nearly O
to O
control O
level O
at O
4 O
h O
. O

Since O
MIP-2 B_GENE
is O
a O
potent O
PMN O
chemoattractant O
and O
MIP-1alpha B_GENE
is O
a O
potent O
macrophage/monocyte O
chemoattractant O
has O
been O
well O
known O
. O

The O
facts O
that O
PMN O
influx O
was O
preceded O
by O
increased O
MIP-2 O
mRNA O
expression O
, O
suggesting O
that O
MIP-2 B_LOCATION/B_ORGANIZATION
is O
involved O
in O
the O
development O
of O
NaVO3-induced O
pulmonary O
inflammation O
, O
whereas O
increased O
MIP-1alpha B_GENE/B_LOCATION
mRNA I_GENE/I_LOCATION
expression O
was O
followed O
by O
decreased O
AMs O
in O
BAL O
cells O
, O
suggesting O
AMs O
might O
be O
activated O
by O
MIP-1alpha B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
adherent O
to O
the O
lining O
surface O
of O
the O
Airways O
and O
then O
resistant O
to O
be O
washed O
out O
. O

To O
delineate O
the O
mechanisms O
of O
transcriptional O
activation O
, O
we O
recently O
cloned O
the O
5'-flanking B_GENE/B_LOCATION
region I_GENE/I_LOCATION
of O
the O
MIP-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
promotor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O
consensus B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for O
transcription B_GENE
factor I_GENE
nuclear I_GENE
factor I_GENE
kappaB I_GENE
( O
NF-kappaB B_GENE
) O
and O
activator B_GENE
protein-1 I_GENE
( O
AP-1 B_GENE/B_DISEASE
) O
. O

Using O
electrophoretic O
mobility O
shift O
assay O
, O
increased O
nuclear O
NF-kappaB B_GENE
, O
not O
AP-1 B_GENE
, O
binding O
activity O
was O
detected O
1 O
h O
after O
NaVO3 O
instillation O
, O
which O
correlated O
with O
the O
induction O
of O
MIP-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

p65 B_GENE
( I_GENE
Rel I_GENE
A I_GENE
) I_GENE
and O
p50 B_GENE/B_BIO
protein I_GENE/I_BIO
appears O
to O
be O
involved O
in O
MIP-2 O
NF-kappaB B_GENE
binding O
. O

taken O
together O
, O
our O
studies O
suggest O
that O
MIP-2 B_GENE
is O
an O
important O
mediator O
of O
NaVO3-induced O
pulmonary O
inflammation O
in O
the O
rat O
model O
. O

In O
addition O
, O
elevated O
MIP-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O
are O
accompanied O
by O
increased O
NF-kappaB B_GENE
binding O
activity O
in O
BAL O
cells O
, O
suggesting O
possible O
MIP-2 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcriptional O
regulation O
through O
NF-kappaB B_GENE
. O

Activation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
signal B_GENE
transduction I_GENE
and O
apoptosis B_DISEASE/B_GENE
in O
healthy B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphomonocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
exposed O
to O
bystander O
HIV-1-infected B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cells B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Persistent B_DISEASE_ADJECTIVE[DISEASE]
activation I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
immune B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
system I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
hallmarks B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
HIV-1 B_DISEASE
infection I_DISEASE
. O

In O
this O
study O
we O
analysed O
the O
induction O
of O
factors O
involved O
in O
cytokine O
signal O
transduction O
, O
such O
as O
STAT B_GENE
1 I_GENE
proteins I_GENE
and O
IRF-1 B_GENE
mRNA I_GENE
, O
in O
normal O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
exposed O
to O
HIV-infected O
cells O
, O
and O
the O
induction O
of O
apoptosis O
. O

Western O
blot O
analyses O
and O
reverse O
transcriptase-polymerase O
chain O
reaction O
results O
indicate O
that O
both O
cells O
infected O
with O
a O
X4 O
strain O
and O
cells O
infected O
with O
a O
R5 O
strain O
are O
able O
to O
increase O
intracellular O
levels O
of O
STAT B_GENE/B_PERSON
1alpha I_GENE/I_PERSON
and I_GENE/I_PERSON
beta I_GENE/I_PERSON
proteins O
as O
well O
as O
IRF-1 B_GENE
mRNA I_GENE
. O

This O
effect O
was O
prevented O
by O
neutralizing O
antibodies O
against O
interferon-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
IFN-alpha B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

HIV-1-infected O
cells O
dose-dependently O
induced O
apoptotic O
commitment O
in O
normal O
PBMC O
, O
as O
revealed O
by O
DNA O
fragmentation O
analysis O
, O
but O
this O
was O
not O
accompanied O
by O
an O
increase O
of O
caspase-3 O
activity O
, O
even O
if O
a O
slight O
up-regulation O
of O
IL-1beta-converting B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
detected O
. O

Apoptosis O
induction O
could O
be O
abrogated O
mainly O
by O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
tumour B_GENE
necrosis I_GENE
factor-alpha I_GENE
( O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
, O
to O
a O
lesser O
extent O
, O
by O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
against O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

All O
these O
findings O
suggest O
that O
uninfected O
PBMC O
can O
undergo O
activation O
of O
signal O
transduction O
and O
apoptosis O
after O
exposure O
to O
bystander O
HIV-infected O
cells O
, O
subsequent O
to O
the O
induction O
of O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
such O
as O
IFNs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
physical O
association O
of O
protein B_GENE
kinase I_GENE
C I_GENE
theta I_GENE
with O
a O
lipid O
raft-associated O
inhibitor O
of O
kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IKK I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plays O
a O
role O
in O
the O
activation O
of O
the O
NF-kappa O
B O
Cascade O
by O
TCR B_GENE
and O
CD28 B_GENE
. O

We O
investigated O
the O
role O
of O
protein B_GENE
kinase I_GENE
C I_GENE
theta I_GENE
( O
PKCtheta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
the O
activation O
of O
the O
NF-kappaB B_GENE/B_DISEASE
Cascade O
in O
primary O
human O
CD4 O
( O
+ O
) O
lymphocytes O
. O

Among O
six O
or O
so O
PKC B_GENE
isoforms I_GENE
expressed O
in O
T O
cells O
, O
only O
PKCtheta B_NUMBER[MEASURE]/B_ORGANIZATION
participates O
in O
the O
assembly O
of O
the O
supramolecular O
activation O
clusters O
at O
the O
contact O
site O
of O
the O
TCR B_GENE
with O
Ag B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

signaling O
via O
both O
the O
TCR B_GENE
and O
CD28 B_GENE
is O
required O
for O
optimal O
activation O
of O
the O
multisubunit B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IkappaB I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IKK I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
primary O
human O
T O
lymphocytes O
; O
this O
activation O
could O
be O
inhibited O
by O
a O
ca O
( O
2+ O
) O
-independent O
PKC O
isoform O
inhibitor O
, O
rottlerin O
. O

Moreover O
, O
endogenous O
PKCtheta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
physically O
associates O
with O
activated O
IKK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
CD3/CD28-costimulated O
primary O
CD4 O
( O
+ O
) O
T O
cells O
. O

The O
same O
set O
of O
stimuli O
also O
induced O
relocation O
of O
endogenous O
PKCtheta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IKKs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O
a O
GM1 O
ganglioside-enriched O
, O
detergent-insoluble O
membrane O
compartment O
in O
primary O
T O
cells O
. O

IKKs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
recruited O
to O
these O
lipid O
rafts O
were O
capable O
of O
phosphorylating O
a O
recombinant O
IkappaBalpha O
sustrate O
. O

Confocal O
microscopy O
further O
demonstrated O
that O
exogenously O
expressed O
PKCtheta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
IKKss B_GENE
colocalize O
in O
the O
membrane O
of O
CD3/CD28-costimulated O
Jurkat O
T O
cells O
. O

Constitutively O
active O
but O
not O
kinase-inactive B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
PKCtheta I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activated O
IKKbeta B_GENE
in O
Jurkat O
T O
cells O
. O

expression O
of O
dominant-active B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PKCtheta I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O
had O
stimulatory O
effects O
on O
the O
CD28 B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
IL-2 B_GENE
promoter I_GENE
. O

taken O
together O
, O
these O
data O
show O
that O
the O
activation O
of O
PKCtheta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
the O
TCR B_GENE
and O
CD28 B_GENE
plays O
an O
important O
role O
in O
the O
assembly O
and O
activation O
of O
IKK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
T O
cell O
membrane O
. O

T-cell O
-mediated O
regulation O
of O
osteoclastogenesis O
by O
signalling O
cross-talk O
between O
RANKL B_GENE
and O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Bone O
resorption O
is O
regulated O
by O
the O
immune O
system O
, O
where O
T-cell O
expression O
of O
RANKL B_GENE
( O
receptor B_GENE/B_DISEASE
activator I_GENE/I_DISEASE
of I_GENE/I_DISEASE
nuclear I_GENE/I_DISEASE
factor I_GENE/I_DISEASE
( I_GENE/I_DISEASE
NF I_GENE/I_DISEASE
) I_GENE/I_DISEASE
-kappaB I_GENE/I_DISEASE
ligand I_GENE/I_DISEASE
) O
, O
a O
member O
of O
the O
tumour-necrosis B_GENE/B_BIO
factor I_GENE/I_BIO
family I_GENE/I_BIO
that O
is O
essential O
for O
osteoclastogenesis O
, O
may O
contribute O
to O
pathological O
conditions O
, O
such O
as O
autoimmune O
arthritis O
. O

However O
, O
whether O
activated O
T O
cells O
maintain O
bone O
homeostasis O
by O
counterbalancing O
the O
action O
of O
RANKL B_GENE
remains O
unknown O
. O

Here O
we O
show O
that O
T-cell O
production O
of O
interferon B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IFN I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
strongly O
suppresses O
osteoclastogenesis O
by O
interfering O
with O
the O
RANKL B_GENE
-RANK O
signalling O
pathway O
. O

IFN-gamma B_DISEASE/B_GENE
induces O
rapid O
degradation O
of O
the O
RANK B_ENZYME[GENE]/B_PERSON
adapter I_ENZYME[GENE]/I_PERSON
protein I_ENZYME[GENE]/I_PERSON
, O
TRAF6 B_GENE
( O
tumour B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor-associated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
6 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
which O
results O
in O
strong O
inhibition O
of O
the O
RANKL B_GENE
-induced O
activation O
of O
the O
transcription B_GENE
factor I_GENE
NF-kappaB I_GENE
and O
JNK B_GENE
. O

This O
inhibition O
of O
osteoclastogenesis O
is O
rescued O
by O
overexpressing O
TRAF6 B_GENE
in O
precursor O
cells O
, O
which O
indicates O
that O
TRAF6 B_GENE
is O
the O
target O
critical O
for O
the O
IFN-gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
action O
. O

Furthermore O
, O
we O
provide O
evidence O
that O
the O
accelerated O
degradation O
of O
TRAF6 B_GENE
requires O
both O
its O
ubiquitination O
, O
which O
is O
initiated O
by O
RANKL B_GENE
, O
and O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-induced O
activation O
of O
the O
ubiquitin-proteasome O
system O
. O

Our O
study O
shows O
that O
there O
is O
cross-talk O
between O
the O
tumour B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
IFN B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
families I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
through O
which O
IFN-gamma B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O
a O
negative O
link O
between O
T-cell O
activation O
and O
bone O
resorption O
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
offer O
a O
therapeutic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
approach I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
treat O
the O
inflammation-induced B_DISEASE_ADJECTIVE[DISEASE]
tissue I_DISEASE_ADJECTIVE[DISEASE]
breakdown I_DISEASE_ADJECTIVE[DISEASE]
. O

Stromal-derived B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
thrombopoietin B_GENE
regulate O
distinct O
aspects O
of O
human O
megakaryopoiesis O
. O

The O
role O
of O
the O
chemokine B_GENE
binding O
stromal-derived B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
SDF-1 B_GENE
) O
in O
normal O
human O
megakaryopoiesis O
at O
the O
cellular O
and O
molecular O
levels O
and O
its O
comparison O
with O
that O
of O
thrombopoietin B_GENE
( O
TPO B_PROTEIN[GENE]
) O
have O
not O
been O
determined O
. O

In O
this O
study O
it O
was O
found O
that O
SDF-1 B_GENE/B_LOCATION
, O
unlike O
TPO B_GENE
, O
does O
not O
stimulate O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cell O
proliferation O
or O
differentiation O
or O
have O
an O
antiapoptotic O
effect O
. O

However O
, O
it O
does O
induce O
chemotaxis O
, O
trans-Matrigel O
migration O
, O
and O
secretion O
of O
matrix O
metalloproteinase B_ENZYME[GENE]
9 I_ENZYME[GENE]
( O
MMP-9 B_TIME[MEASURE]/B_GENE
) O
and O
vascular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
endothelial I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
VEGF B_GENE
) O
by O
these O
cells O
, O
and O
both O
SDF-1 B_GENE
and O
TPO B_GENE
increase O
the O
adhesion O
of O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
to O
fibrinogen B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
vitronectin B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

investigating O
the O
intracellular O
signaling O
pathways O
induced O
by O
SDF-1 B_GENE
and O
TPO B_GENE/B_DISEASE
revealed O
some O
overlapping O
patterns O
of O
protein O
phosphorylation/activation O
( O
mitogen-activated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
[ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MAPK I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p42/44 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
MAPK B_GENE
p38 I_GENE
, O
and O
AKT B_GENE
[ I_GENE
protein I_GENE
kinase I_GENE
B I_GENE
] I_GENE
) O
and O
some O
that O
were O
distinct O
for O
TPO B_GENE/B_DISEASE
( O
eg O
, O
JAK-STAT B_GENE
) O
and O
for O
SDF-1 B_GENE
( O
eg O
, O
NF-kappa B_GENE
B I_GENE
) O
. O

It O
was O
also O
found O
that O
though O
inhibition O
of O
phosphatidyl-inositol B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3-kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PI-3K B_GENE
) O
by O
LY294002 O
in O
alpha O
( O
IIb O
) O
beta O
( O
3 O
) O
( O
+ O
) O
cells O
induced O
apoptosis O
and O
inhibited O
chemotaxis O
adhesion O
and O
the O
secretion O
of O
MMP-9 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
VEGF B_GENE
, O
the O
inhibition O
of O
MAPK B_GENE
p42/44 I_GENE
( O
by O
the O
MEK O
inhibitor O
U0126 O
) O
had O
no O
effect O
on O
the O
survival O
, O
proliferation O
, O
and O
migration O
of O
these O
cells O
. O

Hence O
, O
it O
is O
suggested O
that O
the O
proliferative O
effect O
of O
TPO B_GENE
is O
more O
related O
to O
activation O
of O
the O
JAK-STAT O
pathway O
( O
unique O
to O
TPO B_GENE
) O
, O
and O
the O
PI-3K-AKT O
axis O
is O
differentially O
involved O
in O
TPO- O
and O
SDF-1-dependent O
signaling O
. O

Accordingly O
, O
PI-3K B_GENE
is O
involved O
in O
TPO B_GENE
-mediated O
inhibition O
of O
apoptosis O
, O
TPO- O
and O
SDF-1-regulated O
adhesion O
to O
fibrinogen B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
vitronectin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
SDF-1 B_GENE
-mediated O
migration O
. O

This O
study O
expands O
the O
understanding O
of O
the O
role O
of O
SDF-1 B_GENE/B_LOCATION
and O
TPO B_GENE/B_LOCATION
in O
normal O
human O
megakaryopoiesis O
and O
indicates O
the O
molecular O
basis O
of O
the O
observed O
differences O
in O
cellular O
responses O
. O

( O
Blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O
2000 B_MEASURE
; O
96 B_MEASURE
: O
4142-4151 B_MEASURE/B_LOCATION
) O
. O

Adhesion O
of O
immature O
and O
mature O
T O
cells O
induces O
in O
human O
thymic O
epithelial O
cells O
( O
TEC O
) O
activation O
of O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
trascription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
NF-kappaB B_GENE
and O
NF-IL6 B_GENE
) O
and O
IL-6 O
gene O
expression O
: O
role O
of O
alpha3beta1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha6beta4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
integrins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
precursors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
homed O
to O
thymus O
develop O
in O
close B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
contact I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
with O
stromal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Among O
them O
, O
thymic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
epithelial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
TEC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
are O
known O
to O
exert O
dominant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
roles I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
their O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
and O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
shaping B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

Key O
molecules O
mediating O
TEC O
/ O
thymocytes O
interactions O
include O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
growth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
secreted O
by O
the O
two O
cell O
types O
and O
adhesion B_GENE/B_BIO
receptors I_GENE/I_BIO
mediating O
cell O
contact O
. O

signaling O
events B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
triggered O
in O
thymocytes B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
by O
adhesion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
epithelial B_DISEASE/B_GENE
cells B_DISEASE/I_GENE
have O
been O
extensively O
investigated O
, O
whereas O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
on O
the O
opposite B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
phenomenon I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
have O
previously O
investigated O
this O
issue B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
a O
co-culture B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
system I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
composed O
of O
TEC B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cultures I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
derived O
from O
human B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
normal I_SPECIES[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
thymus I_SPECIES[BIO]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
heterologous B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
thymocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
demonstrated O
that O
thymocytes O
adhere O
to O
TEC O
involving O
beta1 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
beta4 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
integrins I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O
induce O
the O
clustering O
of O
alpha3beta1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha6beta4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
at O
the O
TEC O
surface O
. O

In O
addition O
thymocyte O
adhesion O
was O
followed O
by O
activation O
of O
NF-kappaB B_GENE
and O
NF-IL6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
enhanced O
IL-6 O
production O
. O

The O
two O
latter O
phenomena O
were O
reproduced O
by O
the O
cross-linking O
of O
the O
alpha3 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
alpha6 B_PROTEIN[GENE]/B_MEASURE
, O
beta1 B_GENE
and I_GENE
beta4 I_GENE
integrins I_GENE
, O
thus O
implying O
that O
the O
alpha3beta1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha6beta4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O
signal O
during O
thymocyte O
adhesion O
. O

We O
have O
extended O
our O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
work I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigating O
in O
the O
same B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
experimental I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
setting O
the O
inducing O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
non B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O
or O
activated O
policlonal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
or O
clonal B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mature O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
as O
representative B_PERSON/B_LOCATION
of O
the O
more O
mature B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
thymocyte I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
subset I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O

We O
found O
that O
adhesion O
of O
unstimulated O
T O
cell O
i O
) O
involved O
beta1 O
, O
but O
not O
beta4 O
integrin O
functions O
at O
the O
surface O
ii O
) O
induced O
the O
clustering O
of O
alpha3beta1 B_GENE
, O
but O
not O
alpha2beta1 B_GENE
heterodimers I_GENE
at O
the O
TEC O
surface O
and O
III O
) O
up-regulated O
the O
nuclear O
binding O
activity O
of O
NF-kappaB B_GENE
transcription I_GENE
factor I_GENE
and O
the O
IL-6 O
secretion O
. O

We O
propose O
that O
alpha3beta1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha6beta4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
induced O
to O
cluster O
at O
the O
TEC O
surface O
recognizing O
yet O
unknown O
cellular B_BIO/B_LOCATION
ligands I_BIO/I_LOCATION
differentially O
expressed O
during O
T O
cell O
development O
. O

identification O
and O
characterization O
of O
SKAT-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
novel O
Th2-specific B_GENE/B_PERSON
zinc I_GENE/I_PERSON
finger I_GENE/I_PERSON
gene I_GENE/I_PERSON
. O

We O
have O
identified O
a O
novel O
Kruppel-type B_GENE/B_PERSON
zinc I_GENE/I_PERSON
finger I_GENE/I_PERSON
( I_GENE/I_PERSON
ZF I_GENE/I_PERSON
) I_GENE/I_PERSON
gene I_GENE/I_PERSON
, O
SKAT-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
is O
selectively O
expressed O
by O
murine O
Th2 O
cells O
. O

The O
protein O
encoded O
by O
this O
gene O
has O
14 O
C2H2-type O
ZF O
tandemly O
arrayed O
at O
its O
C B_PROTEIN[GENE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
terminus B_PROTEIN[GENE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
N-terminal B_PROTEIN[GENE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SCAN I_PROTEIN[GENE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
box I_PROTEIN[GENE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
KRAB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

SKAT-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
tissue O
restricted O
in O
expression O
at O
the O
RNA O
level O
, O
detectable O
only O
in O
brain O
and O
at O
low O
levels O
in O
kidney O
and O
spleen O
and O
few O
hematopoietic O
cell O
lines O
. O

By O
in O
situ O
hybridization O
, O
SKAT-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O
was O
found O
to O
peak O
in O
antigen-stimulated O
CD4 O
( O
+ O
) O
T O
cells O
after O
2-3 O
days O
of O
culture O
under O
Th2 O
but O
not O
Th1 O
biasing O
conditions O
. O

This O
pattern O
of O
expression O
closely O
mirrored O
that O
of O
GATA-3 B_GENE
in O
the O
same O
cells O
. O

In O
transient O
transfection O
experiments O
in O
phorbol O
12-myristate O
13-acetate/ionomycin-stimulated O
EL4 O
cells O
, O
SKAT-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
to O
up-regulate O
the O
activity O
of O
the O
IL-4 B_GENE
but I_GENE
not I_GENE
the I_GENE
IL-5 I_GENE
promoter I_GENE
, O
contrasting O
with O
the O
ability O
of O
GATA-3 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
activate O
both O
promoters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

This O
result O
was O
confirmed O
using O
clones O
of O
EL4 O
cells O
stably O
expressing O
an O
inducible O
form O
of O
SKAT-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
thus O
SKAT-2 B_LOCATION/B_PERSON
is O
a O
novel O
Th2-specific B_GENE/B_PERSON
gene I_GENE/I_PERSON
that O
may O
play O
a O
role O
in O
selective O
regulation O
of O
cytokine B_GENE/B_DISEASE
genes I_GENE/I_DISEASE
in O
T O
cells O
. O

hsp70 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interacting B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Hip B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O
not O
affect O
glucocorticoid B_GENE
receptor I_GENE
folding O
by O
the O
hsp90-based O
chaperone O
machinery O
except O
to O
oppose O
the O
effect O
of O
BAG-1 B_GENE
. O

Reticulocyte O
lysate O
contains O
a O
chaperone O
system O
that O
assembles O
glucocorticoid B_DISEASE_ADJECTIVE[DISEASE]
receptor I_DISEASE_ADJECTIVE[DISEASE]
( I_DISEASE_ADJECTIVE[DISEASE]
GR I_DISEASE_ADJECTIVE[DISEASE]
) I_DISEASE_ADJECTIVE[DISEASE]
.hsp90 I_DISEASE_ADJECTIVE[DISEASE]
heterocomplexes I_DISEASE_ADJECTIVE[DISEASE]
. O

Using O
purified B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
proteins I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
we O
have O
prepared O
a O
five-protein O
heterocomplex O
assembly O
system O
consisting O
of O
two O
proteins O
essential O
for O
heterocomplex O
assembly- O
hsp90 B_GENE
and O
hsp70 B_GENE
-and O
three O
proteins O
that O
act O
as O
co-chaperones O
to O
enhance O
assembly- O
Hop B_DISEASE/B_GENE
, O
hsp40 B_GENE
, O
p23 B_GENE
[ O
Morishima O
, O
Y. O
, O
Kanelakis O
, O
K. O
C. O
, O
Silverstein O
, O
A. O
M. O
, O
Dittmar O
, O
K. O
D. O
, O
Estrada O
, O
L. O
, O
and O
Pratt O
, O
W. O
B. O
( O
2000 O
) O
J. O
Biol. O
Chem. O
275 O
, O
6894-6900 O
] O
. O

The O
hsp70 B_GENE
co-chaperone I_GENE
Hip I_GENE
has O
been O
recovered O
in O
receptor.hsp90 B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
heterocomplexes I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
at O
an O
intermediate O
stage O
of O
assembly O
in O
reticulocyte O
lysate O
, O
and O
Hip B_DISEASE/B_GENE
is O
also O
thought O
to O
be O
an O
intrinsic O
component O
of O
the O
assembly O
machinery O
. O

Here O
we O
show O
that O
immunodepletion O
of O
Hip B_GENE/B_DISEASE
from O
reticulocyte O
lysate O
or O
addition O
of O
high O
levels O
of O
Hip B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
the O
purified O
five-protein O
system O
does O
not O
affect O
GR.hsp90 O
heterocomplex O
assembly O
or O
the O
activation O
of O
steroid O
binding O
activity O
that O
occurs O
with O
assembly O
. O

Despite O
the O
fact O
that O
Hip B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O
not O
affect O
assembly O
, O
it O
is O
recovered O
in O
GR.hsp90 B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
heterocomplexes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assembled O
by O
both O
systems O
. O

In O
the O
five-protein O
system O
, O
Hip B_GENE/B_DISEASE
prevents O
inhibition O
of O
assembly O
by O
the O
hsp70 B_GENE
co-chaperone I_GENE
BAG-1 I_GENE
, O
and O
cotransfection O
of O
Hip B_GENE/B_DISEASE
with O
BAG-1 B_GENE
opposes O
BAG-1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
reduction O
of O
steroid O
binding O
activity O
in O
COS O
cells O
. O

We O
conclude O
that O
Hip B_GENE/B_DISEASE
is O
not O
a O
component O
of O
the O
assembly O
machinery O
but O
that O
it O
could O
play O
a O
regulatory O
role O
in O
opposition O
to O
BAG-1 B_GENE/B_DISEASE
. O

cutting O
edge B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
STAT6-deficient B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
mice I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
have O
enhanced O
tumor B_DISEASE/B_MEASURE
immunity I_DISEASE/I_MEASURE
to O
primary B_DISEASE_ADJECTIVE[DISEASE]
and O
metastatic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mammary I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
carcinoma I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

STAT4 B_GENE
and O
STAT6 B_GENE
are O
essential O
for O
the O
development O
of O
CD4 O
( O
+ O
) O
Th1 O
and O
Th2 O
development O
, O
respectively O
. O

tumor B_PERSON/B_ORGANIZATION
immunologists I_PERSON/I_ORGANIZATION
have O
hypothesized O
that O
Th1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
critical B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O
tumor B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
immunity I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O
they O
facilitate O
differentiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
CD8 B_GENE
( O
+ B_DISEASE/B_GENE
) O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
which O
are O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti-tumor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effectors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
used O
STAT4 B_GENE
( O
-/- O
) O
and O
STAT6 B_GENE
( O
-/- O
) O
mice B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
test O
this O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

BALB/c B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
knockout B_SPECIES[BIO]/B_GENE
mice I_SPECIES[BIO]/I_GENE
were O
challenged O
in O
the O
mammary B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
gland I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
with O
the O
highly O
malignant B_DISEASE_ADJECTIVE[DISEASE]
and O
spontaneously O
metastatic B_DISEASE_ADJECTIVE[DISEASE]
BALB/c-derived I_DISEASE_ADJECTIVE[DISEASE]
4T1 I_DISEASE_ADJECTIVE[DISEASE]
mammary I_DISEASE_ADJECTIVE[DISEASE]
carcinoma I_DISEASE_ADJECTIVE[DISEASE]
. O

Primary B_DISEASE_ADJECTIVE[DISEASE]
tumor I_DISEASE_ADJECTIVE[DISEASE]
growth I_DISEASE_ADJECTIVE[DISEASE]
and O
metastatic B_DISEASE
disease I_DISEASE
are O
reduced O
in O
STAT6 B_GENE
( O
-/- B_PERSON/B_PROTEIN[GENE]
) O
mice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
relative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
BALB/c B_GENE/B_PERSON
and O
STAT4 B_GENE
( O
-/- O
) O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Ab B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
depletions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
demonstrate O
that O
the O
effect B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
mediated O
by O
CD8 B_GENE
( O
+ B_DISEASE/B_GENE
) O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
and O
immunized O
STAT6 B_GENE
( O
-/- O
) O
mice B_BIO/B_PERSON
have O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
levels B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
4T1-specific B_DISEASE/B_GENE
CTL I_DISEASE/I_GENE
than O
BALB/c B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
STAT4 B_GENE
( O
-/- O
) O
mice B_BIO/B_PERSON
. O

surprisingly O
, O
Th1 B_GENE/B_LOCATION
or O
Th2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
not O
involved O
, O
because O
CD4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
depletion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
does O
not O
diminish O
the O
anti-tumor B_DISEASE
effect I_DISEASE
. O

Therefore O
, O
deletion O
of O
the O
STAT6 B_GENE
gene I_GENE
facilitates O
development O
of O
potent O
anti-tumor O
immunity O
via O
a O
CD4 O
( O
+ O
) O
-independent O
pathway O
. O

activation O
of O
oncogenic B_GENE
transcription I_GENE
factor I_GENE
AP-1 I_GENE
in O
T O
cells O
infected O
with O
human O
T O
cell O
leukemia O
virus O
type O
1 O
. O

Human O
T O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV-1 O
) O
Tax B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
protein I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
transforms O
primary O
human O
T O
cells O
in O
vitro O
. O

We O
previously O
showed O
that O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
the O
expression O
of O
various O
family O
members O
of O
the O
transcription B_GENE/B_LOCATION
factor I_GENE/I_LOCATION
AP-1 I_GENE/I_LOCATION
such O
as O
c-Jun B_GENE
, O
JunD B_GENE/B_DISEASE
, O
c-Fos B_GENE
, O
and O
Fra-1 B_GENE
at O
the O
mRNA O
level O
in O
T O
cells O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
ability O
of O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
activate O
transcription O
through O
the O
AP-1-binding B_GENE/B_LOCATION
site I_GENE/I_LOCATION
( O
AP-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
site B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
. O

A O
transient O
transfection O
study O
showed O
that O
Tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
activate O
transcription O
through O
the O
AP-1-binding B_GENE/B_LOCATION
site I_GENE/I_LOCATION
in O
a O
human O
T O
cell O
line O
, O
whereas O
any O
combination O
of O
AP-1 B_GENE/B_BIO
proteins I_GENE/I_BIO
did O
so O
much O
less O
than O
Tax B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
indicating O
that O
the O
activation O
of O
the O
AP-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
Tax B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O
require O
a O
mechanism O
other O
than O
the O
induction O
of O
AP-1 B_GENE
mRNA I_GENE
. O

Fresh B_NUMBER[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
peripheral I_NUMBER[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood I_NUMBER[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leukemia I_NUMBER[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_NUMBER[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
all O
surveyed O
ATL B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
displayed O
constitutive B_DISEASE_ADJECTIVE[DISEASE]
AP-1 O
DNA-binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
whereas O
no O
normal B_PERSON/B_BIO
individuals I_PERSON/I_BIO
did O
. O

However O
, O
the O
HTLV-1 B_GENE/B_MEASURE
genes I_GENE/I_MEASURE
, O
including O
tax B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
are O
not O
significantly O
expressed O
in O
fresh O
leukemia O
cells O
from O
ATL O
patients O
. O

Our O
present O
results O
suggest O
that O
activation O
of O
AP-1 B_GENE
occurs O
through O
Tax-dependent O
and O
-independent O
mechanisms O
in O
HTLV-1-infected O
T O
cells O
, O
which O
may O
play O
some O
roles O
in O
dysregulated O
phenotypes O
of O
HTLV-1-infected O
cells O
. O

2 B_MEASURE
, O
2 B_NUMBER[MEASURE]
' O
, O
4 B_NUMBER[MEASURE]
, O
6 B_NUMBER[MEASURE]
, O
6'-pentachlorobiphenyl B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O
apoptosis B_DISEASE
in O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Polychlorinatedbiphenyls B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
PCBs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
are O
a O
group B_ORGANIZATION/B_MEASURE
of O
persistent B_DISEASE_ADJECTIVE[DISEASE]
and O
widely O
dispersed O
environmental B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pollutants I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
some O
of O
which O
may O
be O
immunotoxic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
investigated O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PCBs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
immune B_DISEASE
system I_DISEASE
by O
assessing O
apoptotic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cell B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
death B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
U937 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Among O
the O
various B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
congeners I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tested O
, O
2 B_NUMBER[MEASURE]
, O
2 B_NUMBER[MEASURE]
' O
, O
4 B_NUMBER[MEASURE]
, O
6 B_NUMBER[MEASURE]
, O
6'-pentachlorobiphenyl B_TIME[MEASURE]
( O
PeCB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
, O
a O
highly O
ortho-substituted B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
congener I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
specifically O
induced O
DNA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
fragmentation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
a O
hallmark B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
apoptosis B_DISEASE/B_GENE
, O
while O
the O
other B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
examined O
di- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
tri- O
, O
tetra- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
and O
pentachlorobiphenyls B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
did O
not O
. O

To O
further O
study O
the O
2 B_NUMBER[MEASURE]
, O
2 B_NUMBER[MEASURE]
' O
, O
4 B_NUMBER[MEASURE]
, O
6 B_NUMBER[MEASURE]
, O
6'-PeCB-induced B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
death I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
various B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
apoptosis B_DISEASE
were O
examined O
. O

2 B_MEASURE
, O
2 B_NUMBER[MEASURE]
' O
, O
4 B_NUMBER[MEASURE]
, O
6 B_NUMBER[MEASURE]
, O
6'-PeCB B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
viability B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
induced O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
morphologic B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
features O
characteristic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
apoptosis B_DISEASE
such I_DISEASE
as O
chromatin B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
aggregation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
apoptotic B_DISEASE_ADJECTIVE[DISEASE]
bodies I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition O
, O
caspase-3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
an O
executioner O
of O
apoptosis O
, O
was O
activated O
and O
its O
substrate O
, O
poly B_GENE
( I_GENE
ADP-ribose I_GENE
) I_GENE
polymerase I_GENE
( O
PARP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
, O
was O
cleaved O
during O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6'-PeCB-induced O
apoptosis O
. O

In O
contrast O
, O
3 O
, O
3 O
' O
, O
4 O
, O
4 O
' O
, O
5-PeCB O
, O
a O
congener O
of O
coplanar O
structure O
, O
as O
well O
as O
2 O
, O
3 O
, O
7 O
, O
8-TCDD O
did O
not O
induce O
apoptosis O
in O
these O
human O
monocytic O
cells O
, O
although O
they O
potently O
induced O
CYP B_DISEASE/B_GENE
1A1 I_DISEASE/I_GENE
in O
human O
hepatoma O
Hep O
G2 O
cells O
. O

taken O
together O
, O
the O
data O
indicate O
that O
2 O
, O
2 O
' O
, O
4 O
, O
6 O
, O
6'-PeCB O
induces O
apoptosis O
in O
human O
monocytic O
cells O
through O
a O
mechanism O
that O
is O
independent O
of O
the O
arylhydrocarbon B_GENE
receptor I_GENE
. O

This O
suggests O
a O
possibly O
separate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mechanism B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
by O
which O
PCBs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cause O
immunosuppression B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Effects O
of O
deregulated O
RAF O
activation O
on O
integrin B_GENE/B_DISEASE
, O
cytokine-receptor O
expression O
and O
the O
induction O
of O
apoptosis O
in O
hematopoietic O
cells O
. O

The O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
deregulated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Raf I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
activation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
growth B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
differentiation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
hematopoietic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
were O
investigated O
. O

The O
cytokine-dependent O
murine O
myeloid O
FDC-P1 O
and O
human O
erythroleukemic O
TF-1 O
cell O
lines O
were O
transformed O
to O
grow O
in O
response O
to O
deregulated O
RAF O
expression O
in O
the O
absence O
of O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
conditionally O
active O
Raf B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
regulated O
by O
beta-estradiol O
as O
cDNAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
containing O
the O
Raf B_GENE
catalytic I_GENE
, O
but O
lacking O
negative-regulatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
domains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
were O
ligated O
to O
the O
hormone B_GENE/B_LOCATION
binding I_GENE/I_LOCATION
domain I_GENE/I_LOCATION
of O
the O
estrogen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
deltaRaf B_GENE/B_LOCATION
: I_GENE/I_LOCATION
ER I_GENE/I_LOCATION
) O
. O

continuous O
deltaRaf B_GENE/B_LOCATION
expression O
prevented O
apoptosis O
in O
the O
absence O
of O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokines I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
altered O
the O
morphology O
of O
the O
FD/deltaRaf O
: O
ER O
cells O
as O
they O
grew O
in O
large O
aggregated O
masses O
( O
> O
100 O
cells O
) O
whereas O
the O
parental O
cytokine-dependent O
FDC-P1 O
cells O
grew O
in O
smaller O
grape-like O
clusters O
( O
< O
10 O
cells O
) O
. O

FD/deltaRaf-1 O
: O
ER O
cells O
growing O
in O
response O
to O
RAF O
activation O
displayed O
decreased O
levels O
of O
the O
Mac-2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
Mac-3 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
their O
cell O
surface O
. O

In O
contrast O
, O
when O
these O
cells O
were O
cultured O
in O
IL-3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
higher O
levels O
of O
these O
adhesion B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
detected O
. O

expression O
of O
activated O
Raf B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oncoproteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O
abrogated O
cytokine O
dependency O
and O
prevented O
apoptosis O
of O
TF-1 O
cells O
. O

Moreover O
, O
the O
differentiation O
status O
of O
these O
Raf-responsive O
cells O
was O
more O
immature O
upon O
RAF O
activation O
as O
culture O
with O
the O
differentiation-inducing O
agent O
phorbol O
12 O
myristate O
13-acetate O
( O
PMA O
) O
and O
beta-estradiol O
resulted O
in O
decreased O
levels O
of O
the O
CD11b B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
CD18 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
integrin I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
cell O
surface O
. O

In O
contrast O
when O
the O
Raf-responsive O
cells O
were O
induced O
to O
differentiate O
with O
PMA O
and O
GM-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
in O
the O
absence O
of O
deltaRaf B_GENE
: I_GENE
ER I_GENE
activation O
, O
increased O
levels O
of O
the O
CD11b B_GENE/B_MEASURE
and I_GENE/I_MEASURE
CD18 I_GENE/I_MEASURE
molecules I_GENE/I_MEASURE
were O
detected O
. O

Retinoic O
acid O
( O
RA O
) O
inhibited O
3H-thymidine O
incorporation O
in O
response O
to O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Interestingly O
, O
Raf B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
counterbalanced O
the O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
DNA B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
synthesis B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
caused O
by O
RA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
not O
PMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Thus O
deregulated O
Raf B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O
alter O
cytokine B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dependency B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
integrin B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
expression B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
the O
stage B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
differentiation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

These O
Raf-responsive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lines I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
will O
be O
useful B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
elucidating O
the O
roles B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
MAP B_GENE
kinase I_GENE
cascade I_GENE
on O
hematopoietic B_DISEASE/B_ORGANISM_FUNCTION
cell I_DISEASE/I_ORGANISM_FUNCTION
differentiation I_DISEASE/I_ORGANISM_FUNCTION
and O
malignant B_DISEASE/B_ORGANISM_FUNCTION
transformation I_DISEASE/I_ORGANISM_FUNCTION
. O

Cyclic O
AMP O
activates O
p38 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
Th2 O
cells O
: O
phosphorylation O
of O
GATA-3 B_GENE
and O
stimulation O
of O
Th2 O
cytokine O
gene O
expression O
. O

cAMP B_GENE
is O
an O
important B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
second I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
messenger I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O
immunomodulatory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
properties I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

elevation O
of O
intracellular O
Camp O
in O
T O
cells O
, O
induced O
by O
agents O
such O
as O
IL-1alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
PGs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
inhibits O
T O
cell O
activation O
. O

In O
effector O
T O
cells O
, O
an O
increase O
in O
the O
level O
of O
intracellular O
Camp O
inhibits O
cytokine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
production O
in O
Th1 O
cells O
but O
stimulates O
cytokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O
in O
Th2 O
cells O
. O

Here O
we O
report O
that O
cAMP-induced O
effects O
in O
Th2 O
cells O
occur O
independently O
of O
the O
protein B_GENE
kinase I_GENE
A I_GENE
pathway O
, O
which O
is O
the O
major O
mediator O
of O
cAMP-induced O
signaling O
events O
in O
most O
cell O
types O
. O

Instead O
, O
Camp O
stimulates O
activation O
of O
p38 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
Th2 O
cells O
. O

This O
appears O
to O
be O
a O
Th2 O
-selective O
event O
because O
Camp O
barely O
increased O
p38 B_GENE
phosphorylation O
in O
Th1 O
cells O
. O

We O
show O
that O
in O
Th2 O
cells O
, O
Camp O
promotes O
the O
production O
of O
both O
IL-5 B_GENE
and O
IL-13 B_GENE
, O
which O
play O
distinct O
but O
critical O
roles O
in O
asthma O
pathogenesis O
. O

Our O
data O
also O
show O
that O
Camp O
causes O
increased O
phosphorylation O
of O
the O
transcription B_GENE
factor I_GENE
GATA-3 I_GENE
, O
which O
we O
have O
shown O
is O
a O
critical O
regulator O
of O
Th2 O
cytokine O
gene O
expression O
and O
, O
in O
turn O
, O
of O
airway O
inflammation O
in O
mice O
. O

Thus O
, O
Th2 O
-specific O
GATA-3 B_GENE
expression O
and O
p38 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mitogen-activated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O
together O
provide O
a O
molecular O
basis O
for O
the O
differential O
effects O
of O
Camp O
in O
the O
two O
T O
helper O
cell O
subsets O
. O

characterization O
of O
IL-4 B_GENE
and O
IL-13 B_GENE
signals O
dependent O
on O
the O
human B_GENE/B_LOCATION
IL-13 I_GENE/I_LOCATION
receptor I_GENE/I_LOCATION
alpha I_GENE/I_LOCATION
chain I_GENE/I_LOCATION
1 I_GENE/I_LOCATION
: O
redundancy O
of O
requirement O
of O
tyrosine O
residue O
for O
STAT3 O
activation O
. O

IL-4 B_GENE
and O
IL-13 B_GENE/B_MEASURE
are O
pleiotropic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
whose O
biological O
activities O
overlap O
with O
each O
other O
. O

IL-13 B_GENE
receptor I_GENE
alpha I_GENE
chain I_GENE
1 I_GENE
( O
IL-13R B_PROTEIN[GENE]
alpha I_PROTEIN[GENE]
1 I_PROTEIN[GENE]
) O
is O
necessary O
for O
binding O
to O
IL-13 B_GENE
, O
and O
the O
heterodimer O
composed O
of O
IL-13R B_GENE
alpha I_GENE
1 I_GENE
and O
IL-4R B_PROTEIN[GENE]/B_MEASURE
alpha I_PROTEIN[GENE]/I_MEASURE
chain I_PROTEIN[GENE]/I_MEASURE
transduces O
IL-13 B_GENE
and O
IL-4 B_GENE
signals O
; O
however O
, O
the O
functional O
mapping O
of O
the O
intracellular B_LOCATION
domain I_LOCATION
of O
IL-13R B_GENE
alpha I_GENE
1 I_GENE
is O
not O
fully O
understood O
. O

In O
this O
study O
, O
we O
constructed O
wild O
and O
mutated O
types O
of O
human B_GENE/B_BIO
IL-13R I_GENE/I_BIO
alpha I_GENE/I_BIO
1 I_GENE/I_BIO
, O
and O
analyzed O
IL-4 B_GENE/B_DISEASE
and O
IL-13 B_GENE
signals O
using O
an O
IL-13R B_GENE
alpha I_GENE
1 I_GENE
-transfected O
human O
B O
cell O
line O
. O

expression O
of O
IL-13R B_GENE
alpha I_GENE
1 I_GENE
evoked O
STAT3 B_GENE/B_LOCATION
activation O
by O
IL-4 B_GENE
and O
IL-13 B_GENE
, O
and O
in O
stimulated O
human O
B O
cells O
, O
on O
which O
IL-13R B_GENE
alpha I_GENE
1 I_GENE
was O
highly O
expressed O
, O
IL-4 B_GENE
and O
IL-13 B_GENE/B_MEASURE
induced O
STAT3 B_GENE
activation O
. O

replacement O
of O
the O
two O
tyrosine O
residues O
completely O
abolished O
STAT3 B_GENE
activation O
, O
although O
replacing O
either O
tyrosine O
residue O
alone O
retained O
it O
. O

Furthermore O
, O
we O
found O
that O
the O
Box1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
region B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
the O
C-terminal B_GENE/B_LOCATION
tail I_GENE/I_LOCATION
of O
IL-13R B_GENE
alpha I_GENE
1 I_GENE
were O
critical O
for O
binding O
to O
Tyk2 B_GENE
, O
and O
activation O
of O
Jak1 B_GENE
, O
Tyk2 B_GENE
, O
the O
insulin B_GENE
receptor I_GENE
substrate-1 I_GENE
and O
STAT6 B_GENE
respectively O
. O

These O
results O
suggest O
that O
STAT3 B_GENE
activation O
is O
involved O
with O
IL-4 B_GENE
and O
IL-13 B_GENE
signals O
in O
human O
B O
cells O
along O
with O
the O
activation O
of O
STAT6 B_GENE
, O
and O
that O
there O
is O
a O
unique O
sequence O
in O
IL-13R B_GENE/B_BIO
alpha I_GENE/I_BIO
1 I_GENE/I_BIO
to O
activate O
STAT3 B_GENE
. O

Functional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
uncoupling I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
Janus B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3-Stat5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
malignant B_DISEASE/B_ORGANISM_FUNCTION
growth I_DISEASE/I_ORGANISM_FUNCTION
of O
human B_DISEASE/B_LOCATION
T I_DISEASE/I_LOCATION
cell I_DISEASE/I_LOCATION
leukemia I_DISEASE/I_LOCATION
virus I_DISEASE/I_LOCATION
type I_DISEASE/I_LOCATION
1-transformed I_DISEASE/I_LOCATION
human I_DISEASE/I_LOCATION
T I_DISEASE/I_LOCATION
cells I_DISEASE/I_LOCATION
. O

Human O
T O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV-1 O
) O
transforms O
cytokine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O
T O
lymphocytes O
and O
causes O
adult O
T O
cell O
leukemia O
. O

Janus B_GENE
tyrosine I_GENE
kinase I_GENE
( I_GENE
Jak I_GENE
) I_GENE
3 I_GENE
and O
transcription B_PROTEIN[GENE]/B_MEASURE
factors I_PROTEIN[GENE]/I_MEASURE
Stat5a I_PROTEIN[GENE]/I_MEASURE
and O
Stat5b B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
essential O
for O
the O
proliferation O
of O
normal O
T O
cells O
and O
are O
constitutively O
hyperactivated O
in O
both O
HTLV-1-transformed O
human O
T O
cell O
lines O
and O
lymphocytes O
isolated O
from O
HTLV-1-infected O
patients O
; O
therefore O
, O
a O
critical O
role O
for O
the O
Jak3-Stat5 O
pathway O
in O
the O
progression O
of O
this O
disease O
has O
been O
postulated O
. O

We O
recently O
reported O
that O
tyrphostin O
AG-490 O
selectively O
blocked O
IL-2 O
activation O
of O
Jak3/Stat5 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
growth O
of O
murine O
T O
cell O
lines O
. O

Here O
we O
demonstrate O
that O
disruption B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Jak3/Stat5a/b B_GENE
signaling O
with O
AG-490 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
50 B_TIME[MEASURE]/B_LOCATION
& O
mgr B_MEASURE/B_PERSON
; O
M B_MEASURE
) O
blocked O
the O
proliferation B_DISEASE/B_ORGANISM_FUNCTION
of O
primary B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
human I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
but O
paradoxically O
failed O
to O
inhibit O
the O
proliferation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
HTLV-1-transformed B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
human I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lines I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
HuT-102 O
and O
MT-2 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Structural B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
homologues I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
AG-490 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
inhibited O
the O
proliferation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
primary B_DISEASE_ADJECTIVE[DISEASE]
human I_DISEASE_ADJECTIVE[DISEASE]
T I_DISEASE_ADJECTIVE[DISEASE]
cells I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
HTLV-1-infected O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

disruption O
of O
constitutive O
Jak3/Stat5 O
activation O
by O
AG-490 O
was O
demonstrated O
by O
inhibition O
of O
1 O
) O
tyrosine O
phosphorylation O
of O
Jak3 B_GENE
, O
Stat5a B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Tyr O
( O
694 O
) O
) O
, O
and O
Stat5b B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Tyr O
( O
699 O
) O
) O
; O
2 O
) O
serine O
phosphorylation O
of O
Stat5a B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Ser O
( O
726 O
) O
) O
as O
determined O
by O
a O
novel O
phosphospecific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Ab I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
; O
and O
3 O
) O
Stat5a/b O
DNA O
binding O
to O
the O
Stat5-responsive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
beta-casein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast O
, O
AG-490 O
had O
no O
effect O
on O
DNA O
binding O
by O
p50/p65 B_GENE/B_MEASURE
components I_GENE/I_MEASURE
of O
NF-kappaB B_GENE
, O
a O
transcription B_GENE/B_LOCATION
factor I_GENE/I_LOCATION
activated O
by O
the O
HTLV-1-encoded B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phosphoprotein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Tax I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

collectively O
, O
these O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
the O
Jak3-Stat5 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
HTLV-1-transformed B_DISEASE
T I_DISEASE
cells I_DISEASE
has O
become O
functionally O
redundant B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
proliferation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

reversal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uncoupling B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
required O
before O
Jak3/Stat5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
will O
be O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
this O
malignancy B_DISEASE
. O

The O
Epstein-Barr B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
initiating O
B-cell O
transformation O
is O
activated O
by O
RFX B_GENE
proteins I_GENE
and O
the O
B-cell-specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BSAP/Pax5 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Epstein-Barr O
virus O
( O
EBV O
) O
-induced O
B-cell O
growth O
transformation O
, O
a O
central O
feature O
of O
the O
virus O
' O
strategy O
for O
colonizing O
the O
human O
B-cell O
system O
, O
requires O
full O
virus O
latent O
gene O
expression O
and O
is O
initiated O
by O
transcription O
from O
the O
viral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Wp I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Interestingly O
, O
when O
EBV B_VIRUS[BIO]/B_GENE
accesses O
other B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
types B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
this O
growth-transforming B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
not O
activated O
. O

The O
present O
work O
focuses O
on O
a O
region O
of O
Wp B_GENE/B_DISEASE
which O
in O
reporter O
assays O
confers O
B-cell O
-specific O
activity O
. O

Bandshift O
studies O
indicate O
that O
this O
region O
contains O
three O
factor O
binding O
sites O
, O
termed O
sites B_GENE/B_DISEASE
B I_GENE/I_DISEASE
, I_GENE/I_DISEASE
C I_GENE/I_DISEASE
, I_GENE/I_DISEASE
and I_GENE/I_DISEASE
D I_GENE/I_DISEASE
, O
in O
addition O
to O
a O
previously O
characterized O
CREB B_LOCATION/B_NUMBER[MEASURE]
site I_LOCATION/I_NUMBER[MEASURE]
. O

Here O
we O
show O
that O
site B_PROTEIN[GENE]
C I_PROTEIN[GENE]
binds O
members O
of O
the O
ubiquitously O
expressed O
RFX B_GENE/B_BIO
family I_GENE/I_BIO
of I_GENE/I_BIO
proteins I_GENE/I_BIO
, O
notably O
RFX1 B_GENE/B_DISEASE
, O
RFX3 B_GENE/B_DISEASE
, O
and O
the O
associated O
factor O
MIBP1 B_GENE
, O
whereas O
sites B_LOCATION/B_PERSON
B B_LOCATION/I_PERSON
and B_LOCATION/I_PERSON
D B_LOCATION/I_PERSON
both O
bind O
the O
B-cell-specific B_GENE/B_BIO
activator I_GENE/I_BIO
protein I_GENE/I_BIO
BSAP/Pax5 I_GENE/I_BIO
. O

In O
reporter O
assays O
with O
mutant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Wp I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
loss O
of O
factor O
binding O
to O
any O
one O
of O
these O
sites O
severely O
impaired O
promoter O
activity O
in O
B O
cells O
, O
while O
the O
wild-type B_SEQUENCE[MEASURE]/B_PERSON
promoter I_SEQUENCE[MEASURE]/I_PERSON
could O
be O
activated O
in O
non-B O
cells O
by O
ectopic O
BSAP O
expression O
. O

We O
suggest O
that O
Wp B_GENE/B_DISEASE
regulation O
by O
BSAP B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
helps O
to O
ensure O
the O
B-cell O
specificity O
of O
EBV O
's O
growth-transforming O
function O
. O

activation O
of O
the O
Lck B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
by O
the O
Herpesvirus O
saimiri O
tip B_GENE
protein I_GENE
involves O
two O
binding O
interactions O
. O

The O
Tip B_GENE
protein I_GENE
of O
Herpesvirus O
saimiri O
strain O
484C O
binds O
to O
and O
activates O
the O
Lck B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Two O
sequences O
in O
the O
Tip B_GENE/B_LOCATION
protein I_GENE/I_LOCATION
were O
previously O
shown O
to O
be O
involved O
in O
binding O
to O
Lck B_GENE/B_BACTERIUM[BIO]
. O

A O
proline-rich B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
region B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
residues O
132-141 O
, O
binds O
to O
the O
SH3 B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
domain I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
Lck B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
show O
here O
that O
the O
other O
Lck-binding B_LOCATION/B_PROTEIN[GENE]
domain B_LOCATION/I_PROTEIN[GENE]
, O
residues O
104-113 O
, O
binds O
to O
the O
carboxyl-terminal B_LOCATION/B_MEASURE
half I_LOCATION/I_MEASURE
of O
Lck B_GENE/B_BACTERIUM[BIO]
and O
that O
this O
binding O
does O
not O
require O
the O
Lck B_GENE
SH3 I_GENE
domain I_GENE
. O

Mutated O
Tip B_PROTEIN[GENE]
containing O
only O
one O
functional O
Lck-binding B_LOCATION/B_MEASURE
domain I_LOCATION/I_MEASURE
can O
bind O
stably O
to O
Lck B_GENE/B_BACTERIUM[BIO]
, O
although O
not O
as O
strongly O
as O
wild-type B_GENE
Tip I_GENE
. O

interaction O
of O
Tip B_GENE
with O
Lck B_GENE/B_BACTERIUM[BIO]
through O
either O
Lck-binding B_LOCATION
domain I_LOCATION
increases O
the O
activity O
of O
Lck B_GENE/B_BACTERIUM[BIO]
in O
vivo O
. O

simultaneous O
binding O
of O
both O
domains O
is O
required O
for O
maximal O
activation O
of O
Lck B_GENE/B_BACTERIUM[BIO]
. O

The O
transient O
expression O
of O
Tip B_GENE
in O
T O
cells O
was O
found O
to O
stimulate O
both O
Stat3 B_GENE
-dependent O
and O
NF-AT B_GENE
-dependent O
transcription O
. O

mutant O
forms O
of O
Tip B_GENE
lacking O
one O
or O
the O
other O
of O
the O
two O
Lck-binding B_GENE/B_LOCATION
domains I_GENE/I_LOCATION
retained O
the O
ability O
to O
stimulate O
Stat3 B_GENE
-dependent O
transcription O
. O

Tip B_PROTEIN[GENE]/B_LOCATION
lacking O
the O
proline-rich O
Lck-binding B_LOCATION/B_GENE
domain I_LOCATION/I_GENE
exhibited O
almost O
wild-type O
activity O
in O
this O
assay O
. O

In O
contrast O
, O
ablation O
of O
either O
Lck-binding B_GENE/B_LOCATION
domain I_GENE/I_LOCATION
abolished O
the O
ability O
of O
Tip B_GENE
to O
stimulate O
NF-AT B_GENE
-dependent O
transcription O
. O

Full O
biological O
activity O
of O
Tip B_GENE
, O
therefore O
, O
appears O
to O
require O
both O
Lck-binding B_LOCATION
domains I_LOCATION
. O

accumulation O
of O
RXR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
during O
activation O
of O
cycling O
human O
T O
lymphocytes O
: O
modulation O
of O
RXRE O
transactivation O
function O
by O
mitogen-activated O
protein O
kinase O
pathways O
. O

We O
have O
previously O
reported O
that O
the O
activation O
of O
resting O
human O
immature O
peripheral O
blood O
T O
( O
PBT O
) O
lymphocytes O
is O
associated O
with O
the O
loss O
of O
retinoid B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
RXRalpha B_GENE
) O
expression O
. O

In O
the O
present O
study O
, O
we O
have O
demonstrated O
that O
, O
unlike O
resting O
cells O
, O
activation O
of O
cycling O
human O
mature O
PBT O
lymphocytes O
, O
and O
T O
lymphocyte O
leukemia O
cell O
lines O
is O
accompanied O
by O
the O
accumulation O
of O
RXRalpha B_GENE
mRNA O
and O
protein O
. O

Interestingly O
, O
cyclosporin O
A O
further O
augmented O
RXRalpha B_GENE
expression O
, O
indicating O
the O
involvement O
of O
calcineurin O
pathways O
in O
the O
process O
. O

9-cis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
retinoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibited O
the O
accumulation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
suggesting O
that O
retinoids B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
can O
regulate O
the O
synthesis B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
their O
own B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
T B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cell B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
activation B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

Transfection O
analysis O
in O
Jurkat O
cells O
, O
using O
RXRE-dependent O
reporter O
assays O
, O
showed O
that O
RXRalpha B_GENE/B_LOCATION
accumulated O
during O
T O
cell O
activation O
was O
transcriptionally O
inactive O
. O

To O
investigate O
the O
mechanism O
of O
such O
inhibition O
, O
the O
role O
of O
two O
mitogen-activated O
protein O
kinase O
pathways O
, O
c-Jun B_GENE
N-terminal I_GENE
kinase I_GENE
( O
JNK B_GENE/B_LOCATION
) O
and O
extracellular B_GENE
signal-regulated I_GENE
kinase I_GENE
( O
ERK B_GENE/B_LOCATION
) O
, O
in O
modulating O
RXRE-dependent O
transcription O
, O
was O
explored O
. O

The O
expression O
of O
constitutively O
active O
MAP/ERK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
MEKK1 B_GENE
) O
inhibited O
RXRE-dependent O
transcription O
, O
whereas O
dominant B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
negative B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MEKK1 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O
the O
transcription O
, O
indicating O
the O
involvement O
of O
JNK B_GENE/B_PERSON
signaling O
pathways O
in O
the O
process O
. O

In O
contrast O
, O
expression O
of O
constitutively B_GENE
active I_GENE
MEK1 I_GENE
, O
which O
activates O
ERK B_GENE
pathway O
, O
enhanced O
RXRE-dependent O
activation O
. O

When O
both O
were O
activated O
simultaneously O
, O
JNK B_GENE
pathway O
was O
dominant O
over O
ERK B_GENE
pathway O
and O
resulted O
in O
inhibition O
of O
RXRE-mediated O
transcription O
. O

These O
data O
demonstrate O
a O
dual O
regulatory O
control O
of O
RXRalpha B_GENE
expression O
during O
the O
activation O
of O
resting O
and O
cycling O
T O
lymphocytes O
and O
indicate O
a O
dynamic O
balance O
between O
JNK O
and O
ERK O
pathways O
in O
modulating O
RXRE-mediated O
transactivation O
. O

The O
proteasome B_ENZYME[GENE]/B_LOCATION
regulates O
receptor-mediated O
endocytosis O
of O
interleukin-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Recent O
studies O
have O
increasingly O
implicated O
the O
proteasome B_GENE
in O
the O
regulation O
of O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
surface B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
receptors B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
role O
of O
the O
proteasome B_GENE
for O
ligand-dependent O
endocytosis O
and O
degradation O
of O
the O
interleukin-2 B_GENE
( I_GENE
IL-2 I_GENE
) I_GENE
-interleukin-2 I_GENE
receptor I_GENE
( I_GENE
IL-2R I_GENE
) I_GENE
complex I_GENE
. O

Proteasome O
inhibitors O
impaired O
internalization O
of O
IL-2.IL-2R B_GENE
and O
prevented O
the O
lysosomal O
degradation O
of O
this O
cytokine B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Based O
on O
time-course O
studies O
, O
proteasome B_GENE
activity O
is O
primarily O
required O
after O
initial O
endocytosis O
of O
the O
IL-2.IL-2R B_GENE
. O

Proteasome O
function O
was O
also O
necessary O
for O
the O
lysosomal O
degradation O
of O
IL-2 B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
internalized O
by O
IL-2R B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
were O
comprised O
of O
cytoplasmic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tailless I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-subunits I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
suggesting O
that O
the O
target O
protein O
for O
the O
proteasome B_ENZYME[GENE]
is O
independent O
of O
either O
the O
cytoplasmic B_MEASURE/B_LOCATION
tail B_MEASURE/I_LOCATION
of O
the O
IL-2R B_GENE
beta- I_GENE
or I_GENE
gamma I_GENE
c-subunits I_GENE
and O
their O
associated O
signaling O
components O
. O

Therefore O
, O
a O
functional O
proteasome B_GENE/B_LOCATION
is O
required O
for O
optimal O
endocytosis O
of O
the O
IL-2R/ligand B_GENE
complex I_GENE
and O
is O
essential O
for O
the O
subsequent O
lysosomal O
degradation O
of O
IL-2 B_GENE
, O
possibly O
by O
regulating O
trafficking O
to O
the O
lysosome O
. O

functional O
characterization O
of O
the O
two O
alternative O
promoters O
of O
human B_GENE
p45 I_GENE
NF-E2 I_GENE
gene I_GENE
. O

objective O
: O
The O
transcription B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-E2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
heterodimeric B_GENE/B_LOCATION
protein I_GENE/I_LOCATION
complex I_GENE/I_LOCATION
composed O
of O
p45 B_GENE/B_MEASURE
and O
small O
Maf B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
family I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
is O
considered O
crucial O
for O
the O
proper O
differentiation O
of O
erythrocytes O
and O
megakaryocytes O
in O
vivo O
. O

We O
report O
the O
results O
of O
studies O
aimed O
at O
understanding O
the O
regulatory O
mechanisms O
controlling O
p45 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
in O
erythroid O
cells O
. O

Materials O
AND O
methods O
: O
Human B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
p45 I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
have O
two O
alternative O
isoforms O
, O
aNF-E2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
fNF-E2 B_GENE
, O
and O
these O
isoforms O
are O
transcribed O
from O
the O
alternative B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
promoters B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
investigated O
lineage-specific B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
both O
isomers B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
erythroid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
megakaryocytic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O
reverse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
transcriptase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
polymerase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
or O
Northern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

For O
functional O
characterization O
of O
both O
promoters O
, O
plasmids O
in O
which O
reporter B_BIO/B_GENE
genes I_BIO/I_GENE
were O
placed O
under O
the O
control O
of O
a O
series O
of O
truncated O
or O
mutated O
promoter B_GENE/B_LOCATION
fragments I_GENE/I_LOCATION
were O
transfected O
to O
human O
hematopoietic O
cell O
lines O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
When O
CD34 B_GENE
( O
+ B_OTHER/B_DISEASE
) O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
isolated O
from O
human B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cord I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
induced O
to O
unilineage B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
erythroid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
or O
megakaryocytic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
liquid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
suspension I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
culture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
both O
transcripts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
although O
barely O
detected O
at O
day B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
were O
induced O
in O
both O
erythroid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
and O
megakaryocytic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cultures I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

fNF-E2 B_GENE
mRNA I_GENE
was O
found O
to O
be O
more O
abundant O
in O
erythroid O
cells O
than O
megakaryocytic O
cells O
at O
day O
7 O
of O
culture O
. O

Although O
both O
isomers O
were O
expressed O
in O
human O
erythroid-megakaryocytic O
cell O
lines O
, O
megakaryocytic O
maturation O
with O
loss O
of O
erythroid O
phenotype O
induced O
by O
phorbol O
12-myristate O
13-acetate O
( O
PMA O
) O
resulted O
in O
exclusive O
downregulation O
of O
fNF-E2 B_GENE
, O
suggesting O
that O
fNF-E2 B_GENE
promoter I_GENE
is O
more O
erythroid O
specific O
. O

functional O
analysis O
of O
fNF-E2 B_GENE
promoter I_GENE
showed O
that O
the O
promoter O
is O
active O
only O
in O
erythroid-megakaryocytic O
cells O
and O
that O
the O
double B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
GATA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
e O
in O
the O
proximal O
region O
is O
necessary O
for O
its O
efficient O
activity O
. O

conclusion O
: O
These O
results O
suggest O
that O
GATA B_GENE
proteins I_GENE
, O
which O
govern O
the O
differentiation O
of O
erythroid O
lineage O
cells O
, O
are O
required O
for O
full O
promoter O
activity O
of O
the O
p45 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Transcriptional O
activation O
of O
heme B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
its O
functional O
significance O
in O
acetaminophen-induced O
hepatitis O
and O
hepatocellular O
injury O
in O
the O
rat O
. O

BACKGROUND/AIM O
: O
Glutathione O
depletion O
contributes O
to O
acetaminophen O
hepatotoxicity O
and O
is O
known O
to O
induce O
the O
oxidative O
stress O
reactant O
heme B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
metabolites B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
heme B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
biliverdin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
carbon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
monoxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
iron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
may O
modulate O
acetaminophen B_DISEASE
toxicity I_DISEASE
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
cell-type O
specific O
expression O
of O
heme B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
its O
impact O
on O
liver O
injury O
and O
microcirculatory O
disturbances O
in O
a O
model O
of O
acetaminophen-induced O
hepatitis O
. O

methods O
: O
Gene O
expression O
of O
heme B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
studied O
by O
Northern- O
and O
Western O
analysis O
as O
well O
as O
immunohistochemistry O
. O

The O
time O
course O
of O
heme B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
cytokine-induced B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
neutrophil I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chemoattractant-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
was O
studied O
by O
Northern O
analysis O
. O

DNA-binding O
activity O
of O
nuclear B_GENE
factor-kappaB I_GENE
was O
determined O
by O
electrophoretic O
mobility O
shift O
assay O
. O

sinusoidal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
perfusion I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
and O
leukocyte-endothelial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
interactions I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
assessed O
by O
intravital B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
Acetaminophen O
caused O
a O
moderate O
sinusoidal O
perfusion O
failure O
( O
-15 O
% O
) O
and O
infiltration O
of O
neutrophils O
along O
with O
activation O
of O
nuclear B_GENE
factor-kappaB I_GENE
and O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
and O
cytokine-induced B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
neutrophil I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chemoattractant-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs O
. O

induction O
of O
heme B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA O
and O
protein O
( O
approximately O
30-fold O
) O
in O
hepatocytes O
and O
non-parenchymal O
cells O
paralleled O
the O
inflammatory O
response O
. O

blockade O
of O
heme O
oxygenase O
activity O
with O
tin-protoporphyrin-IX O
abrogated O
acetaminophen-induced O
hepatic O
neutrophil O
accumulation O
and O
nuclear B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor-kappaB B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O
, O
but O
failed O
to O
affect O
sinusoidal O
perfusion O
and O
liver O
injury O
. O

conclusions O
: O
The O
inflammatory O
response O
associated O
with O
acetaminophen O
hepatotoxicity O
is O
modulated O
by O
the O
parallel O
induction O
of O
the O
heme B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
heme B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O
no O
permissive O
effect O
on O
sinusoidal O
perfusion O
and O
does O
not O
affect O
liver O
injury O
in O
this O
model O
. O

These O
data O
argue O
against O
a O
central O
role O
of O
nuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
factor-kappaB I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
activation O
and O
neutrophil O
infiltration O
as O
perpetuating O
factors O
of O
liver O
injury O
in O
acetaminophen O
toxicity O
. O

Tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-induced O
proliferation O
requires O
synthesis O
of O
granulocyte-macrophage B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

objective O
: O
Tumor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
necrosis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
induces O
a O
variety O
of O
cellular O
responses O
, O
some O
of O
them O
being O
at O
least O
seemingly O
contradictory O
. O

Thus O
, O
we O
set O
out O
to O
find O
differences O
in O
the O
modes O
of O
proliferative O
and O
apoptotic O
responses O
to O
TNF- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Materials O
AND O
methods O
: O
We O
screened O
a O
panel O
of O
acute O
myeloid O
leukemia-derived O
cell O
lines O
for O
TNF- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
-responsiveness O
. O

In O
two O
lines O
( O
OCI-AML-1 O
, O
OCI-AML-11 O
) O
, O
TNF- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acted O
as O
an O
apoptotic O
agent O
; O
in O
others O
( O
HU-3 O
, O
M-07e O
, O
TF-1 O
) O
, O
it O
had O
the O
opposite O
effect O
, O
preventing O
apoptosis O
and O
inducing O
proliferation O
. O

Direct O
and O
indirect O
signaling O
mechanisms O
, O
including O
NF-kappaB B_GENE
activation O
and O
cytokine O
synthesis O
, O
were O
analyzed O
. O

Results O
: O
All O
cell O
lines O
tested O
expressed O
TNF- B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
responded O
to O
TNF- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O
upregulation O
of O
intercellular B_GENE
adhesion I_GENE
molecule-1 I_GENE
. O

In O
contrast O
to O
granulocyte-macrophage B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GM-CSF B_ORGANIZATION/B_LOCATION
) O
, O
TNF- B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
did O
not O
activate O
the O
MAP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
p70S6 O
kinase O
pathways O
. O

Nevertheless O
, O
inhibitors O
of O
these O
pathways O
clearly O
reduced O
the O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-induced O
cell O
growth O
, O
indicating O
that O
TNF- O
alpha-proliferative O
cells O
produced O
a O
growth O
factor O
that O
induced O
proliferation O
upon O
stimulation O
of O
the O
above O
pathways O
. O

Anti-GM-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibited O
the O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-induced O
growth O
, O
suggesting O
the O
presence O
of O
an O
autocrine O
loop O
for O
cell O
proliferation O
mediated O
by O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Supporting O
this O
notion O
, O
TNF-alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
-induced O
upregulation O
of O
GM-CSF B_GENE
mRNA I_GENE
levels O
and O
protein O
secretion O
in O
the O
TNF-alpha B_DISEASE/B_GENE
-proliferative O
, O
but O
not O
in O
the O
TNF-alpha-apoptotic O
cell O
lines O
. O

conclusion O
: O
These O
data O
identify O
GM-CSF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synthesis O
as O
an O
early O
and O
essential O
step O
in O
TNF- O
alpha-induced O
proliferation O
. O

We O
show O
for O
the O
first O
time O
that O
TNF-alpha-treated O
cell O
lines O
producing O
no O
or O
only O
minimal O
amounts O
of O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
demonstrate O
an O
apoptotic O
phenotype O
, O
while O
cell O
lines O
with O
high O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression O
rates O
can O
escape O
from O
growth O
arrest O
or O
even O
apoptosis O
. O

In O
this O
context O
, O
we O
discuss O
arguments O
pointing O
at O
NF-kappaB B_GENE
as O
regulator O
of O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synthesis O
and O
thus O
indirectly O
as O
regulator O
for O
the O
escape O
of O
TNF-alpha B_DISEASE/B_GENE
-induced O
apoptosis O
. O

Glucocorticoid B_GENE/B_MEASURE
receptor I_GENE/I_MEASURE
content O
of O
T O
lymphocytes O
: O
evidence O
for O
heterogeneity O
. O

Glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
measured O
in O
T O
lymphocytes O
that O
were O
isolated O
from O
peripheral O
blood O
by O
either O
nylon O
wool O
filtration O
or O
E-rosette O
sedimentation O
. O

T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
isolated O
by O
nylon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wool I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
filtration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
specifically O
bind O
6.7 B_MEASURE
+/- O
0.2 B_MEASURE/B_LOCATION
fmol I_MEASURE/I_LOCATION
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
per O
million B_MEASURE/B_BIO
cells I_MEASURE/I_BIO
( O
equivalent B_MEASURE/B_ORGANIZATION
to O
4000 B_MEASURE
+/- I_MEASURE
200 I_MEASURE
receptors I_MEASURE
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
) O
, O
whereas O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
isolated O
by O
E-rosette B_MEASURE
sedimentation I_MEASURE
bind I_MEASURE
12.0 I_MEASURE
+/- O
0.7 B_MEASURE/B_LOCATION
fmol I_MEASURE/I_LOCATION
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
per O
million B_MEASURE/B_PERSON
cells I_MEASURE/I_PERSON
( O
equivalent B_MEASURE/B_ORGANIZATION
to O
7200 B_MEASURE
+/- I_MEASURE
400 I_MEASURE
receptors I_MEASURE
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

This O
difference B_MEASURE
in O
the O
amount B_MEASURE/B_LOCATION
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bound O
by O
the O
two B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
preparations B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
p B_MEASURE
less I_MEASURE
than O
.001 B_NUMBER[MEASURE]/B_LOCATION
) O
and O
was O
present B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immediately O
after O
cell B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
isolation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
binding O
affinities B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
different B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
T I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cell I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
preparations I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
that O
are O
isolated O
by O
a O
combination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
nylon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wool I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
filtration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
followed O
by O
E-rosette B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sedimentation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
bind O
the O
same B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amount I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
isolated O
by O
nylon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wool I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
filtration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alone O
. O

T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
isolated O
by O
a O
combination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
E-rosette B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sedimentation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
following O
by O
nylon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
wool I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
filtration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
bind I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
less I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dexamethasone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
than O
do O
T B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
isolated O
by O
E-rosette B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sedimentation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alone O
. O

These O
findings O
suggest O
that O
T O
cells O
are O
heterogeneous O
with O
respect O
to O
their O
quantity O
of O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

isolation O
of O
T O
cells O
by O
E-rosette O
sedimentation O
enriches O
for O
T O
cells O
that O
have O
a O
greater O
number O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
isolation O
of O
T O
cells O
by O
nylon O
wool O
filtration O
enriches O
for O
T O
cells O
that O
have O
a O
lesser O
number O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

Glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O
glucocorticoid O
sensitivity O
of O
human O
leukemic O
cells O
. O

We O
have O
established O
optimal O
conditions O
for O
the O
measurement O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
GR B_LOCATION/B_ORGANIZATION
) O
in O
human O
white O
cells O
using O
a O
whole-cell O
binding O
assay O
with O
[ O
3H O
] O
dexamethasone O
as O
the O
ligand O
, O
and O
the O
subsequent O
determination O
of O
the O
GR B_PROTEIN[GENE]/B_DISEASE
content O
in O
normal O
human O
lymphocytes O
and O
in O
leukemic O
cells O
of O
patients O
with O
various O
forms O
of O
acute O
and O
chronic O
leukemia O
. O

A O
number O
of O
leukemia O
cell O
lines O
in O
continuous O
culture O
were O
also O
subjected O
to O
the O
GR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assay O
, O
and O
the O
results O
were O
correlated O
with O
the O
sensitivity O
of O
these O
cell O
lines O
to O
glucocorticoid O
steroids O
in O
vitro O
. O

The O
GR B_PROTEIN[GENE]/B_DISEASE
content O
of O
normal O
human O
lymphocytes O
amounted O
to O
4 O
, O
850 O
+/- O
1 O
, O
340 O
( O
mean O
+/- O
SD O
) O
receptors/cell O
. O

The O
mean O
equilibrium O
dissociation O
constant O
( O
KD O
) O
of O
the O
interaction O
of O
[ O
3H O
] O
dexamethasone O
with O
the O
GR B_PROTEIN[GENE]/B_DISEASE
was O
1.2 O
x O
10 O
( O
-8 O
) O
M O
. O

steroidal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
compounds I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
a O
known O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
potency I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
effectively O
competed O
for O
the O
binding B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
devoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
e.g B_DISEASE/B_PROTEIN[GENE]
. O
estradiol-17 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
ineffective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
GR B_PROTEIN[GENE]/B_DISEASE
content O
of O
the O
blast O
cells O
obtained O
from O
eight O
patients O
suffering O
from O
acute O
leukemia O
and O
four O
patients O
with O
a O
blast O
crisis O
of O
chronic O
myelocytic O
leukemia O
was O
found O
to O
be O
highly O
variable O
( O
3 O
, O
230-29 O
, O
900 O
receptors/cell O
) O
, O
while O
the O
lymphocytes O
of O
six O
patients O
with O
chronic O
lymphatic O
leukemia O
contained O
a O
rather O
stable O
GR B_PROTEIN[GENE]/B_DISEASE
content O
( O
2 O
, O
930-5 O
, O
120 O
receptors/cell O
) O
, O
which O
was O
comparable O
with O
that O
of O
normal O
lymphocytes O
. O

GR B_GENE/B_DISEASE
was O
identified O
in O
all O
the O
12 O
malignant O
continuous O
white O
cell O
lines O
studied O
. O

Large O
cells O
contained O
more O
GR B_GENE/B_DISEASE
than O
the O
smaller O
ones O
. O

There O
was O
no O
apparent O
correlation O
between O
the O
GR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O
and O
the O
sensitivity O
of O
the O
cells O
in O
vitro O
to O
glucocorticoids O
as O
judged O
by O
[ O
3H O
] O
thymidine O
incorporation O
studies O
. O

Distribution O
of O
the O
surface O
markers O
in O
the O
leukemic O
cell O
lines O
did O
not O
relate O
to O
the O
GR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O
. O

We O
conclude O
that O
the O
presence O
of O
GR B_GENE/B_DISEASE
is O
probably O
a O
universal O
feature O
of O
the O
leukemic O
cells O
, O
and O
, O
from O
a O
clinical O
standpoint O
, O
probably O
does O
not O
alone O
imply O
steroid O
responsiveness O
. O

Evidence O
for O
a O
steroid B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
receptor I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
rheumatoid O
synovial O
tissue O
cells O
. O

One O
mechanism O
by O
which O
glucocorticoids O
could O
exert O
their O
anti-inflammatory O
action O
is O
via O
rapidly O
saturable O
, O
stereo-specific B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
cytoplasmic B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
protein B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
receptors B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

This O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
of O
an O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
into O
such O
a O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
synovial B_LOCATION
cells I_LOCATION
. O

Synovium O
, O
obtained O
from O
knee O
joints O
of O
rheumatoid O
patients O
undergoing O
surgery O
, O
was O
incubated O
with O
clostridiopeptidase B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
trypsin-EDTA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
to O
obtain O
cell O
suspensions O
. O

These O
, O
together O
with O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
obtained O
from O
synovial B_BODY_PART_OR_ORGAN_COMPONENT
fluid I_BODY_PART_OR_ORGAN_COMPONENT
aspirated O
from O
patients B_PERSON/B_BIO
with O
rheumatoid B_DISEASE/B_LOCATION
arthritis I_DISEASE/I_LOCATION
, O
were O
identified O
by O
electron B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Duplicate B_NUMBER[MEASURE]/B_PERSON
samples I_NUMBER[MEASURE]/I_PERSON
of O
these O
cell B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
suspensions I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
incubated O
with O
increasing O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
H3Dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
1 B_MEASURE
x O
10 B_MEASURE
( O
-10 B_MEASURE
) O
M-1 O
x O
10 B_MEASURE
( O
-9 B_MEASURE
) O
M B_MEASURE/B_OTHER
) O
for O
30 B_TIME[MEASURE]
minutes I_TIME[MEASURE]
at O
37 B_MEASURE/B_LOCATION
degrees I_MEASURE/I_LOCATION
C I_MEASURE/I_LOCATION
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
proportion B_MEASURE/B_LOCATION
of O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O
to O
whole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
rapidly O
saturable B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
receptors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
obtained O
from O
synovial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
this O
was O
not O
found O
in O
synovial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fluid I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Electron B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
micrographs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
that O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
obtained O
from O
synovial B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consisted O
of O
synovial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibroblast I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
and O
macrophage-types B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O
monocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
macrophages B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Polymorphonuclear B_PERSON
leucocytes I_PERSON
appeared O
to O
be O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

However O
, O
in O
synovial B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fluid I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
type I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
polymorphonuclear I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
leucocytes I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
the O
predominant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cell B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
type B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

We O
concluded O
from O
this O
, O
that O
one O
or O
more O
of O
the O
cell O
types O
present O
in O
synovial O
tissue O
contain O
a O
specific B_GENE
steroid I_GENE
receptor I_GENE
, O
but O
that O
this O
is O
lacking O
in O
synovial O
fluid O
polymorphonuclear O
leucocytes O
. O

Clinical O
implications O
of O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
human O
leukemia O
. O

Glucorticoid B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
studied O
in O
various O
populations O
of O
normal O
human O
peripheral O
blood O
lymphocytes O
and O
leukemic O
lymphoblasts O
. O

Normal O
lymphocytes O
contain O
low O
levels O
of O
glucocorticoid B_GENE
receptor I_GENE
( O
approximately O
2 O
, O
500 O
sites/cell O
) O
which O
are O
identical O
in O
T- O
and O
non-T-fractions O
. O

Phytohemagglutinin B_BIO/B_TIME[MEASURE]
treatment O
increases O
levels O
about O
3-fold O
. O

Leukemic B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphoblasts I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
contain O
larger B_MEASURE/B_LOCATION
numbers I_MEASURE/I_LOCATION
of O
receptor B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
sites I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

Presence B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
receptor B_GENE/B_DISEASE
is O
correlated O
with O
in O
vitro B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivitiy I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
in O
vivo B_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
to O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

quantity B_TIME[MEASURE]/B_PERSON
of O
receptor B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
also O
correlated O
with O
complete B_DISEASE
remission I_DISEASE
duration I_DISEASE
independently O
of O
leukemic B_TIME[MEASURE]/B_DISEASE
cell I_TIME[MEASURE]/I_DISEASE
type I_TIME[MEASURE]/I_DISEASE
( O
T B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O
null B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
, O
initial B_MEASURE
WBC I_MEASURE
, O
or O
age B_MEASURE
of O
patient B_PERSON/B_DISEASE
. O

quantitative O
determination O
of O
glucocorticoid B_GENE
receptor I_GENE
levels O
in O
acute O
lymphoblastic O
leukemia O
may O
be O
of O
value O
both O
as O
an O
independent O
prognostic O
variable O
and O
in O
suggesting O
which O
patients O
should O
receive O
glucocorticoid O
therapy O
. O

functional O
and O
physical O
interaction O
of O
protein-tyrosine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Fyn I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Csk I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
T-cell O
signaling O
system O
. O

The O
Src-like B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein-tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Fyn I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
associated O
with O
T-cell B_DISEASE/B_GENE
antigen I_DISEASE/I_GENE
receptor I_DISEASE/I_GENE
. O

Transient O
expression O
of O
actively O
mutated O
Fyn B_GENE
, O
having O
Phe-528 O
instead O
of O
Tyr-528 O
or O
Thr-338 O
instead O
of O
Ile-338 O
, O
in O
Jurkat O
T-cells O
stimulated B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SRE B_GENE/B_DISEASE
) O
, O
12-O-tetradecanoyl-phorbol-13-acetate B_GENE/B_LOCATION
response I_GENE/I_LOCATION
element I_GENE/I_LOCATION
, O
cyclic B_GENE
AMP I_GENE
response I_GENE
element I_GENE
, O
and O
c-fos B_GENE
promoter I_GENE
. O

The O
stimulation O
of O
SRE B_DISEASE/B_GENE
was O
particularly O
prominent O
not O
only O
with O
active O
Fyn B_GENE/B_DISEASE
but O
also O
with O
normal B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wild-type B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fyn B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

SRE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
also O
stimulated O
by O
both O
normal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
active I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Lck I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Furthermore O
, O
normal B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
active I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fyn I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O
transcription O
from O
the O
IL-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
when O
transfected O
cells O
were O
stimulated O
by O
concanavalin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
plus O
12-O-tetradecanoylphorbol-13-acetate O
. O

Under O
the O
same O
conditions O
, O
Lck B_GENE/B_BACTERIUM[BIO]
did O
not O
stimulate O
IL-2 B_GENE
promoter I_GENE
unless O
it O
was O
activated O
by O
mutation O
. O

Interestingly O
, O
a O
mutant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Fyn I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
has O
deletions O
within O
the O
SH2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
so O
is O
able O
to O
transform O
chicken O
embryo O
fibroblasts O
, O
did O
not O
stimulate O
either O
the O
c-fos B_GENE
or I_GENE
IL-2 I_GENE
promoter I_GENE
, O
suggesting O
the O
importance O
of O
this O
region O
in O
T-cell O
signaling O
. O

Csk B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
which O
phosphorylates O
tyrosine O
residues O
in O
the O
negative O
regulatory O
sites O
of O
Src B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
down-regulated O
Fyn- O
and O
Lck-mediated O
stimulation O
of O
the O
serum B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
element I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Fyn-mediated O
enhancement O
of O
IL-2 B_GENE
promoter I_GENE
activity O
. O

These O
data O
suggest O
that O
Fyn B_GENE/B_LOCATION
and O
Lck B_GENE/B_BACTERIUM[BIO]
, O
whose O
activities O
are O
regulated O
by O
Csk B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
are O
involved O
in O
different O
phases O
of O
T-cell O
activation O
. O

A O
novel O
NF-kappa B_GENE/B_LOCATION
B I_GENE/I_LOCATION
complex I_GENE/I_LOCATION
containing O
p65 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homodimers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O
implications O
for O
transcriptional O
control O
at O
the O
level O
of O
subunit O
dimerization O
. O

The O
predominant O
inducible O
form O
of O
the O
NF-kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
a O
heteromeric B_LOCATION
complex I_LOCATION
containing O
two O
Rel-related B_GENE/B_LOCATION
DNA-binding I_GENE/I_LOCATION
subunits I_GENE/I_LOCATION
, O
termed B_GENE
p65 I_GENE
and O
p50 B_GENE
. O

Prior O
transfection O
studies O
have O
shown O
that O
when O
these O
p65 B_GENE
and I_GENE
p50 I_GENE
subunits I_GENE
are O
expressed O
independently O
as O
stable B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homodimers I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
p65 B_GENE
stimulates O
Kappa O
B-directed O
transcription O
, O
whereas O
p50 B_MEASURE/B_GENE
functions O
as O
a O
Kappa O
B-specific O
repressor O
. O

While O
authentic O
p50 B_GENE
homodimers I_GENE
( O
previously O
termed O
KBF1 B_GENE
) O
have O
been O
detected O
in O
nuclear O
extracts O
from O
nontransfected O
cells O
, O
experimental O
evidence O
supporting O
the O
existence O
of O
p65 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
homodimers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
vivo O
was O
lacking O
. O

We O
now O
provide O
direct O
biochemical O
evidence O
for O
the O
presence O
of O
an O
endogenous O
pool O
of O
inducible O
p65 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
homodimers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
intact O
human O
T O
cells O
. O

As O
with O
the O
prototypical O
NF-kappa B_GENE/B_MEASURE
B I_GENE/I_MEASURE
p50-p65 I_GENE/I_MEASURE
heterodimer I_GENE/I_MEASURE
, O
this O
novel O
p65 B_MEASURE/B_LOCATION
homodimeric I_MEASURE/I_LOCATION
form I_MEASURE/I_LOCATION
of O
NF-kappa B_GENE/B_LOCATION
B I_GENE/I_LOCATION
is O
functionally O
sequestered O
in O
the O
cytoplasm O
but O
rapidly O
appears O
in O
the O
nuclear O
compartment O
following O
cellular O
stimulation O
. O

Site-directed O
mutagenesis O
studies O
indicate O
that O
the O
homodimerization O
function O
of O
p65 B_GENE
is O
dependent O
upon O
the O
presence O
of O
cysteine O
216 O
and O
a O
conserved O
recognition O
motif O
for O
protein B_GENE
kinase I_GENE
A I_GENE
( O
RRPS B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O
amino O
acids O
273 O
to O
276 O
) O
, O
both O
of O
which O
reside O
within O
a O
91-amino-acid O
segment O
of O
the O
Rel B_GENE
homology I_GENE
domain I_GENE
that O
mediates O
self-association O
. O

In O
contrast O
, O
mutations O
at O
these O
two O
sites O
do O
not O
affect O
heterodimerization O
of O
p65 B_GENE
with O
p50 B_GENE
or O
its O
functional O
interaction O
with O
I O
Kappa O
B O
alpha O
. O

These O
later O
findings O
indicate O
that O
neither O
homo- O
nor O
heterodimer O
formation O
is O
an O
absolute O
prerequisite O
for O
I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kappa B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
recognition O
of O
p65 B_GENE
. O

taken O
together O
with O
prior O
in O
vivo O
transcription O
studies O
, O
these O
results O
suggest O
that O
the O
biological O
activities O
of O
p65 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p50 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
homodimers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
independently O
regulated O
, O
thereby O
providing O
an O
integrated O
and O
flexible O
control O
mechanism O
for O
the O
rapid O
activation O
and O
repression O
of O
NF-kappa B_GENE/B_LOCATION
B I_GENE/I_LOCATION
/ O
Rel B_GENE/B_DISEASE
-directed O
gene O
expression O
. O

carrier B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
X-linked B_DISEASE/B_GENE
agammaglobulinemia B_DISEASE/I_GENE
using O
X B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inactivation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
purified O
B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
report O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
relatively O
quick B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
simple B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
method I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
for O
the O
assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
X B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inactivation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
status I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
carrier B_PERSON
determination I_PERSON
in O
families B_PERSON/B_SOCIAL_CIRCUMSTANCES
affected O
by O
X-linked B_DISEASE/B_GENE
agammaglobulinemia I_DISEASE/I_GENE
( O
XLA B_DISEASE/B_LOCATION
) O
. O

This O
method O
utilises O
an O
immunomagnetic O
separation O
technique O
for O
B O
cell O
purification O
and O
a O
polymerase O
chain O
reaction O
( O
PCR O
) O
based O
assay O
for O
the O
determination O
of O
methylation O
status O
at O
the O
androgen B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
AR I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
assess O
whether O
X O
inactivation O
is O
random O
or O
non-random O
at O
this O
locus O
. O

We O
report O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
have O
obtained O
using O
this O
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
investigate O
females B_PERSON/B_BIO
known O
to O
be O
carriers B_PERSON
of O
various B_DISEASE/B_GENE
X-linked I_DISEASE/I_GENE
immunodeficiency I_DISEASE/I_GENE
disorders I_DISEASE/I_GENE
. O

In O
addition B_MEASURE/B_LOCATION
, O
we O
investigated O
four B_PERSON/B_BIO
females I_PERSON/I_BIO
from O
different B_PERSON/B_LOCATION
families I_PERSON/I_LOCATION
affected O
by O
XLA B_DISEASE
, O
two B_NUMBER[MEASURE]/B_PERSON
of O
whom O
were O
of O
unknown B_PERSON/B_DISEASE
carrier I_PERSON/I_DISEASE
status I_PERSON/I_DISEASE
, O
and O
we O
discuss O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O
with O
this O
and O
other B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
X-inactivation I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
assays I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assay I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O
recently O
been O
described O
by O
Allen B_PERSON/B_LOCATION
et I_PERSON/I_LOCATION
al I_PERSON/I_LOCATION
. O
( O
1992 B_MEASURE
) O
and O
applied O
to O
members B_PERSON/B_BIO
of O
one B_PERSON/B_ENT
family I_PERSON/I_ENT
affected O
by O
XLA B_DISEASE/B_GENE
. O

Effects O
of O
IL-4 B_GENE
and O
Fc B_GENE/B_LOCATION
gamma I_GENE/I_LOCATION
receptor I_GENE/I_LOCATION
II I_GENE/I_LOCATION
engagement O
on O
Egr-1 B_GENE
expression O
during O
stimulation O
of O
B O
lymphocytes O
by O
membrane O
immunoglobulin O
crosslinking O
. O

Egr-1 B_GENE
is O
an O
immediate B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
early I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
is O
rapidly O
upregulated O
in O
response O
to O
mitogenic O
signals O
induced O
by O
antigen O
receptor O
crosslinking O
on O
murine O
B O
lymphocytes O
. O

It O
has O
been O
shown O
that O
levels O
of O
Egr-1 B_GENE
expression O
are O
closely O
correlated O
with O
B O
cell O
proliferation O
in O
several O
models O
of O
B O
cell O
activation O
and O
tolerance O
. O

We O
compared O
the O
expression O
of O
Egr-1 B_GENE
during O
B O
cell O
stimulation O
with O
Fab'2 B_GENE
and O
IgG B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
anti-immunoglobulin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
anti-Ig B_GENE/B_LOCATION
) O
, O
since O
it O
is O
known O
that O
Fab'2 B_GENE
anti-Ig I_GENE
is O
mitogenic O
while O
IgG B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
anti-Ig I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
not O
, O
owing O
to O
a O
dominant O
inhibitory O
effect O
of O
crosslinking O
the O
B B_GENE
cell I_GENE
Fc I_GENE
gamma I_GENE
RII I_GENE
to O
membrane B_GENE
Ig I_GENE
. O

While O
mitogenic O
doses O
of O
Fab'2 B_GENE
anti-Ig I_GENE
induce O
large O
and O
rapid O
increases O
in O
Egr-1 O
expression O
, O
IgG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti-Ig I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
results O
in O
smaller O
increases O
in O
Egr-1 B_GENE
mRNA I_GENE
, O
comparable O
to O
that O
seen O
with O
submitogenic O
concentrations O
of O
Fab'2 B_GENE
anti-Ig I_GENE
. O

However O
, O
the O
correlation O
between O
Egr-1 O
expression O
and O
B O
cell O
proliferation O
breaks O
down O
when O
IL-4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
added O
as O
a O
co-mitogen O
to O
induce O
B O
cell O
proliferation O
with O
IgG B_DISEASE_ADJECTIVE[DISEASE]
anti-Ig I_DISEASE_ADJECTIVE[DISEASE]
or O
submitogenic O
concentrations O
of O
Fab'2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
anti-Ig I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

No O
corresponding O
increases O
in O
Egr-1 B_GENE
mRNA I_GENE
levels O
are O
observed O
when O
IL-4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
added O
. O

Therefore O
, O
IL-4 B_LOCATION/B_PERSON
overcomes O
FC O
receptor-mediated O
inhibition O
of O
B O
cell O
proliferation O
without O
affecting O
inhibition O
of O
Egr-1 B_GENE
mRNA I_GENE
induction O
, O
as O
demonstrated O
earlier O
for O
c-myc B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mRNA B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
this O
system O
. O

identification O
of O
a O
novel O
cyclosporin-sensitive B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
human B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
tumor B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
necrosis B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factor B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
alpha B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
gene B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
promoter B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
TNF-alpha B_GENE/B_LOCATION
) O
, O
a O
cytokine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
with O
pleiotropic O
biological O
effects O
, O
is O
produced O
by O
a O
variety O
of O
cell O
types O
in O
response O
to O
induction O
by O
diverse O
stimuli O
. O

In O
this O
paper O
, O
TNF-alpha B_GENE/B_LOCATION
mRNA I_GENE/I_LOCATION
is O
shown O
to O
be O
highly O
induced O
in O
a O
murine O
T O
cell O
clone O
by O
stimulation O
with O
T B_GENE
cell I_GENE
receptor I_GENE
( O
TCR B_PROTEIN[GENE]/B_LOCATION
) O
ligands O
or O
by O
calcium O
ionophores O
alone O
. O

Induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
does O
not O
require O
de B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
novo I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
synthesis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
is O
completely O
blocked O
by O
the O
immunosuppressant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclosporin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CsA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

We O
have O
identified O
a O
human B_GENE/B_PERSON
TNF-alpha I_GENE/I_PERSON
promoter I_GENE/I_PERSON
element I_GENE/I_PERSON
, O
kappa B_PROTEIN[GENE]/B_LOCATION
3 I_PROTEIN[GENE]/I_LOCATION
, O
which O
plays O
a O
key O
role O
in O
the O
calcium-mediated O
inducibility O
and O
CsA O
sensitivity O
of O
the O
gene O
. O

In O
electrophoretic O
mobility O
shift O
assays O
, O
an O
oligonucleotide O
containing O
kappa B_GENE
3 I_GENE
forms O
two O
DNA O
protein O
complexes O
with O
proteins O
that O
are O
present O
in O
extracts O
from O
unstimulated O
T O
cells O
. O

These O
complexes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
appear O
in O
nuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
extracts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
only O
after O
T B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
stimulation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

induction O
of O
the O
inducible O
nuclear B_GENE
complexes I_GENE
is O
rapid O
, O
independent O
of O
protein O
synthesis O
, O
and O
blocked O
by O
CsA O
, O
and O
thus O
, O
exactly O
parallels O
the O
induction O
of O
TNF-alpha B_GENE
mRNA I_GENE
by O
TCR O
ligands O
or O
by O
calcium O
ionophore O
. O

Our O
studies O
indicate O
that O
the O
kappa B_PROTEIN[GENE]/B_MEASURE
3 I_PROTEIN[GENE]/I_MEASURE
binding I_PROTEIN[GENE]/I_MEASURE
factor I_PROTEIN[GENE]/I_MEASURE
resembles O
the O
preexisting O
component O
of O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
activated O
T O
cells O
. O

Thus O
, O
the O
TNF-alpha B_GENE
gene I_GENE
is O
an O
immediate O
early O
gene O
in O
activated O
T O
cells O
and O
provides O
a O
new O
model O
system O
in O
which O
to O
study O
CsA-sensitive B_GENE/B_DISEASE
gene I_GENE/I_DISEASE
induction O
in O
activated O
T O
cells O
. O

differences O
in O
expression O
of O
transcription B_GENE
factor I_GENE
AP-1 I_GENE
in O
human O
promyelocytic O
HL-60 O
cells O
during O
differentiation O
towards O
macrophages O
versus O
granulocytes O
. O

commitment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
HL-60 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O
macrophage B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
granulocytic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O
achieved O
by O
incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta-phorbol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12-myristate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
13-acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
for O
30-60 B_TIME[MEASURE]
min I_TIME[MEASURE]
or O
with O
dimethyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulphoxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DMSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
for O
24 B_MEASURE
h O
respectively O
. O

The O
commitment O
stage O
towards O
PMA-induced O
macrophage O
differentiation O
was O
associated O
with O
increases O
in O
Jun O
B O
and O
c-fos O
mRNA O
levels O
, O
as O
well O
as O
with O
an O
increase O
in O
the O
binding O
activity O
of O
transcription B_GENE
factor I_GENE
AP-1 I_GENE
. O

Nevertheless O
, O
gel O
retardation O
analysis O
indicated O
that O
the O
AP-1 B_GENE
activity O
detected O
in O
untreated O
cells O
was O
drastically O
reduced O
during O
the O
commitment O
stage O
of O
DMSO-induced O
HL-60 O
differentiation O
towards O
granulocytes O
. O

When O
HL-60 O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
treated O
with O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
butyrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
induced O
monocytic B_DISEASE
differentiation I_DISEASE
, O
a O
remarkable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
AP-1 O
binding B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
detected O
. O

Treatment O
of O
HL-60 O
cells O
with O
1 O
alpha O
, O
25-dihydroxyvitamin O
D3 O
, O
another O
monocytic O
differentiation O
agent O
, O
induced O
a O
weak O
, O
but O
appreciable O
, O
increase O
in O
AP-1 B_GENE
activity O
. O

Furthermore O
, O
addition O
of O
sodium O
butyrate O
or O
1 O
alpha O
, O
25-dihydroxyvitamin O
D3 O
to O
HL-60 O
cells O
induced O
the O
expression O
of O
c-fos B_GENE
, I_GENE
c-jun I_GENE
, I_GENE
jun I_GENE
B I_GENE
and I_GENE
jun I_GENE
D I_GENE
proto-oncogenes I_GENE
. O

In O
contrast O
, O
when O
HL-60 O
cells O
were O
treated O
with O
retinoic O
acid O
, O
a O
granulocytic O
differentiation O
inducer O
, O
no O
enhanced O
AP-1 O
binding O
activity O
was O
observed O
, O
and O
only O
a O
weak O
increase O
in O
jun B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
D I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
level O
was O
detected O
. O

These O
data O
indicate O
that O
formation O
of O
AP-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
required O
for O
the O
induction O
of O
HL-60 O
differentiation O
towards O
granulocytes O
, O
whereas O
induction O
of O
monocytic O
differentiation O
is O
correlated O
with O
an O
increase O
in O
AP-1 B_GENE
activity O
. O

The O
differential O
expression O
of O
AP-1 B_GENE
activity O
may O
be O
critical O
in O
the O
differentiation O
of O
HL-60 O
cells O
towards O
monocytic O
or O
granulocytic O
lineages O
. O

Glucocorticoid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
receptors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
sensitivity O
in O
leukemias O
. O

In O
an O
attempt O
to O
investigate O
the O
utility O
of O
glucocorticoid B_GENE/B_MEASURE
receptor I_GENE/I_MEASURE
determination O
to O
predict O
clinical O
responsiveness O
in O
human O
leukemias O
we O
have O
studied O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
leukemic O
cells O
from O
46 O
patients O
and O
in O
the O
lymphocytes O
from O
18 O
normal O
donors O
. O

In O
the O
normal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
there O
were O
3 B_MEASURE
, O
875 B_MEASURE
( O
Median B_MEASURE
) O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding I_MEASURE
sites I_MEASURE
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
blasts O
from O
17 O
patients O
with O
ANLL O
had O
on O
average O
higher O
levels O
of O
binding B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
per O
cell O
( O
median O
= O
7 O
, O
250 O
, O
range O
: O
0 O
to O
15 O
, O
295 O
) O
than O
the O
other O
leukemias O
. O

Of O
the O
15 B_PERSON
patients I_PERSON
with O
CLL B_DISEASE/B_LOCATION
, O
six B_NUMBER[MEASURE]
had O
received O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
3 B_NUMBER[MEASURE]/B_LOCATION
to O
5 B_TIME[MEASURE]
years I_TIME[MEASURE]
. O

Their O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
had O
lower B_MEASURE
number I_MEASURE
of O
receptors B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
median B_LOCATION/B_MEASURE
= O
2 B_MEASURE
, O
000 B_MEASURE
) O
than O
the O
other B_NUMBER[MEASURE]/B_PERSON
cases I_NUMBER[MEASURE]/I_PERSON
which O
were O
newly O
diagnosed O
( O
median B_LOCATION/B_MEASURE
= O
4 B_MEASURE
, O
500 B_MEASURE
) O
. O

Four B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
had O
ALL/AUL O
, O
three B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
had O
blast B_DISEASE/B_GENE
crisis I_DISEASE/I_GENE
as O
terminal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
CML B_DISEASE
, O
and O
seven B_NUMBER[MEASURE]/B_PERSON
had O
leukemic B_DISEASE/B_GENE
Non-Hodgkin I_DISEASE/I_GENE
lymphomas I_DISEASE/I_GENE
( O
Median B_MEASURE/B_LOCATION
= O
3 B_MEASURE
, O
500 B_MEASURE
sites/cell I_MEASURE
) O
. O

In O
24 B_TIME[MEASURE]/B_PERSON
patients I_TIME[MEASURE]/I_PERSON
we O
have O
also O
studied O
the O
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sensitivity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
leukemic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O
dexamethasone O
. O

There O
was O
no O
marked O
correlation O
between O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
and O
in O
vitro O
sensitivity O
. O

An O
attempt O
to O
correlate O
receptor O
levels O
with O
clinical O
responsiveness O
demonstrated O
that O
glucocorticoid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
determination O
might O
be O
of O
value O
in O
patients O
with O
lymphoid O
malignancies O
but O
probably O
not O
in O
patients O
with O
other O
leukemias O
. O

'Activation-labile B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
' I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
glucocorticoid-receptor I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
complexes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
a O
steroid-resistant O
variant O
of O
CEM-C7 O
human O
lymphoid O
cells O
. O

For O
cytoplasmic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid-receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
enter O
and O
accumulate O
in O
the O
nucleus O
a O
temperature-dependent O
event O
, O
'activation O
' O
is O
required O
. O

activation O
can O
be O
achieved O
in O
vitro O
by O
increased O
ionic O
strength O
, O
dilution O
or O
gel O
filtration O
and O
is O
manifested O
by O
an O
increased O
affinity O
of O
steroid-receptor B_GENE
complex I_GENE
for O
DNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
an O
altered O
elution O
profile O
from O
ion-exchange O
resins O
. O

Munck O
and O
Foley O
have O
shown O
that O
activated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isolated O
from O
thymocytes O
elute O
from O
DEAE-cellulose O
in O
a O
manner O
identical O
to O
complexes O
activated O
in O
vitro O
. O

We O
report O
here O
that O
DEAE-cellulose O
chromatography O
of O
steroid-receptor B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complexes B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
from O
CEM-C7 O
, O
a O
cloned O
human O
leukaemic O
T-cell O
line O
sensitive O
to O
the O
cytolytic O
action O
of O
glucocorticoids O
, O
and O
its O
steroid-resistant O
subclone O
4R4 O
demonstrated O
that O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
clone O
4R4 O
can O
not O
form O
stable O
activated O
complexes O
. O

This O
defines O
a O
new B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
defect I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
receptor B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
activation B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
lability I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
r+act1 B_LOCATION/B_ORGANIZATION
) O
, O
which O
is O
unlike O
either O
the O
r- B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
r+nt- O
, O
or O
r+nti B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotypes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
previously O
described O
for O
mouse B_DISEASE/B_BIO
lymphoid I_DISEASE/I_BIO
variants I_DISEASE/I_BIO
. O

granulocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O
the O
endometrium B_BODY_PART_OR_ORGAN_COMPONENT
of O
post-partum B_DISEASE/B_BIO
women I_DISEASE/I_BIO
. O

endometrial B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
women B_PERSON/B_SPECIES[BIO]
at O
various B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
stages B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
of O
gonadal B_ORGANISM_FUNCTION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_ORGANISM_FUNCTION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
parturition B_ORGANISM_FUNCTION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
examined O
for O
the O
presence B_MEASURE/B_DISEASE
and O
numbers B_MEASURE/B_LOCATION
of O
endometrial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
granulocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

Although O
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
at O
all O
the O
stages B_TIME[MEASURE]/B_DISEASE
contained O
significant B_MEASURE/B_LOCATION
numbers I_MEASURE/I_LOCATION
of O
the O
granulocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
( O
i.e B_MEASURE/B_GENE
. O
greater B_LOCATION/B_MEASURE
than O
7/high-power B_MEASURE
field I_MEASURE
) O
, O
the O
100 B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
late-proliferative B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
adaptation B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hyperplasia I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
values B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
the O
resting B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
81.8 B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
% B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
early O
( O
82.4 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O
and O
mid- B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
87.9 B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
% I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O
proliferative B_DISEASE_ADJECTIVE[DISEASE]
and O
secretory B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
( O
83.3 B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
% B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O
phases B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
suggest O
that O
this O
correlates B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
suggestion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
the O
granulocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
constitute O
a O
receptor B_GENE/B_LOCATION
system B_GENE/I_LOCATION
for O
oestrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Interaction B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
with O
macrophages B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

identification O
of O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
monocytes O
and O
macrophages O
. O

glucocorticoid B_GENE
binding I_GENE
was O
measured O
in O
resident B_PERSON/B_BIO
and O
thioglycollate-elicited B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mouse B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
peritoneal B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
macrophages B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
rabbit B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
alveolar I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
macrophages I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Two O
assays O
of O
binding O
were O
used O
-- O
an O
assay O
with O
intact O
cells O
in O
suspension O
or O
monolayers O
, O
and O
an O
assay O
of O
cytosol O
and O
nuclear O
forms O
of O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
mononuclear O
phagocytes O
contained O
approximately O
equal O
to O
4 O
-- O
10 O
X O
10 O
( O
3 O
) O
high B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
affinity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
per O
cell O
, O
with O
dissociation O
constants O
of O
approximately O
equal O
to O
2 O
-- O
8 O
nm O
dexamethasone O
. O

The O
binding O
to O
the O
saturable B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
specific O
for O
steroids O
with O
glucocorticoid O
or O
antiglucocorticoid O
activity O
. O

cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
corticosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
competed O
with O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
binding O
, O
whereas O
estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
dihydrotestosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
11-epicortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
competed O
very O
little B_DISEASE_ADJECTIVE[DISEASE]
. O

binding O
of O
dexamethasone O
to O
cytosol O
and O
nuclear O
forms O
of O
the O
receptor B_GENE
complex I_GENE
and O
temperature-sensitive O
translocation O
of O
cytosol O
forms O
to O
nuclear O
forms O
were O
shown O
. O

At O
37 O
degrees O
C O
the O
predominant O
form O
of O
the O
hormone-receptor B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
nuclear O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
that O
corticosteroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interact O
with O
macrophages B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
physiological B_MEASURE/B_LOCATION
concentrations B_MEASURE/I_LOCATION
. O

Nitric O
oxide O
signaling O
: O
a O
possible O
role O
for O
G B_GENE/B_DISEASE
proteins I_GENE/I_DISEASE
. O

We O
have O
previously O
reported O
various B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inductive B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
effects B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
PBMC I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
describe O
a O
novel O
and O
potentially O
important O
mechanism O
of O
nitric O
oxide O
signaling-through O
direct O
activation O
of O
guanine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide-binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
G B_GENE/B_DISEASE
proteins I_GENE/I_DISEASE
) O
. O

We O
have O
found O
that O
nitric B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
oxide I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
membranes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
isolated O
from O
fresh B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
human I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
PBMC I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
enhances O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
these O
membranes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
hydrolyze O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gamma-32P I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
GTP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
bind O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
gamma-35S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
GTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
whole B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
yielded O
membranes B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
enhanced B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
GTPase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Furthermore O
, O
the O
GTPase O
activity O
of O
pure O
, O
recombinant O
Gs B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Gi B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
p21ras B_GENE
was O
greatly O
enhanced O
by O
nitric O
oxide O
. O

In O
support O
of O
the O
existence O
of O
this O
pathway O
in O
whole O
cells O
, O
we O
found O
that O
the O
G O
protein O
inhibitor O
, O
GDP-beta-S O
, O
blocked O
NF-kappa B_GENE
B I_GENE
translocation O
induced O
by O
nitric O
oxide O
or O
LPS O
in O
permeabilized O
cells O
. O

In O
addition O
, O
nitric O
oxide O
greatly O
reduced O
the O
pertussis O
toxin-mediated O
ADP-ribosylation O
of O
45- B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
41-kDa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
membranes O
of O
these O
cells O
. O

Because O
G B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
play O
a O
central O
role O
in O
many O
diverse O
signaling O
systems O
, O
activation O
by O
an O
endogenous O
and O
inducible O
oxidant O
may O
represent O
a O
novel O
signaling O
pathway O
. O

The O
granulocyte-macrophage B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cis-acting I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CLE0 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mediates O
induction O
signals O
in O
T O
cells O
and O
is O
recognized O
by O
factors O
related O
to O
AP1 B_GENE
and O
NFAT B_GENE
. O

expression O
of O
the O
granulocyte-macrophage B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GM-CSF I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
T O
cells O
is O
activated O
by O
the O
combination O
of O
phorbol O
ester O
( O
phorbol O
myristate O
acetate O
) O
and O
calcium O
ionophore O
( O
A23187 O
) O
, O
which O
mimic O
antigen O
stimulation O
through O
the O
T-cell B_GENE
receptor I_GENE
. O

We O
have O
previously O
shown O
that O
a O
fragment O
containing O
bp B_GENE/B_LOCATION
-95 B_GENE/I_LOCATION
to B_GENE/I_LOCATION
+27 B_GENE/I_LOCATION
of O
the O
mouse B_GENE/B_LOCATION
GM-CSF I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
can O
confer O
inducibility O
to O
reporter B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
human O
Jurkat O
T-cell O
line O
. O

Here O
we O
use O
an O
in O
vitro O
transcription O
system O
to O
demonstrate O
that O
a O
cis-acting B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
element I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
positions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
-54 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
to B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
-40 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
, O
referred O
to O
as O
CLE0 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
a O
target O
for O
the O
induction O
signals O
. O

We O
observed O
induction O
with O
templates O
containing O
intact O
CLE0 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
not O
with O
templates O
with O
deleted B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutated I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CLE0 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
also O
observed O
that O
two O
distinct O
signals O
were O
required O
for O
the O
stimulation O
through O
CLE0 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
since O
only O
extracts O
from O
cells O
treated O
with O
both O
phorbol O
myristate O
acetate O
and O
A23187 O
supported O
optimal O
induction O
. O

stimulation O
probably O
was O
mediated O
by O
CLE0-binding B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
because O
depletion O
of O
these O
proteins O
specifically O
reduced O
GM-CSF B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transcription O
. O

One O
of O
the O
binding B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
possessed O
biochemical O
and O
immunological O
features O
identical O
to O
those O
of O
the O
transcription B_GENE/B_BIO
factor I_GENE/I_BIO
AP1 I_GENE/I_BIO
. O

Another O
factor O
resembled O
the O
T-cell-specific B_GENE/B_PERSON
factor I_GENE/I_PERSON
NFAT I_GENE/I_PERSON
. O

The O
characteristics B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
these O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
their O
involvement B_PERSON/B_DISEASE
in O
GM-CSF B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
presence O
of O
CLE0-like B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
promoters B_LOCATION/B_ORGANIZATION
of O
interleukin-3 B_GENE/B_BIO
( I_GENE/I_BIO
IL-3 I_GENE/I_BIO
) I_GENE/I_BIO
, I_GENE/I_BIO
IL-4 I_GENE/I_BIO
, I_GENE/I_BIO
IL-5 I_GENE/I_BIO
, I_GENE/I_BIO
GM-CSF I_GENE/I_BIO
, I_GENE/I_BIO
and I_GENE/I_BIO
NFAT I_GENE/I_BIO
sites I_GENE/I_BIO
in O
the O
IL-2 B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
promoter I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
suggests O
that O
the O
factors O
we O
detected O
, O
or O
related O
factors O
that O
recognize O
these O
sites O
, O
may O
account O
for O
the O
coordinate O
induction O
of O
these O
genes O
during O
T-cell O
activation O
. O

identification O
and O
characterization O
of O
an O
Alu-containing B_GENE
, I_GENE
T-cell-specific I_GENE
enhancer I_GENE
located O
in O
the O
last O
intron B_GENE/B_LOCATION
of O
the O
human B_GENE
CD8 I_GENE
alpha I_GENE
gene I_GENE
. O

expression O
of O
the O
human B_GENE
CD8 I_GENE
alpha I_GENE
gene I_GENE
is O
restricted O
to O
cells O
of O
the O
lymphoid O
lineage O
and O
developmentally O
regulated O
during O
thymopoiesis O
. O

As O
an O
initial O
step O
towards O
understanding O
the O
molecular O
basis O
for O
tissue-specific O
expression O
of O
this O
gene O
, O
we O
surveyed O
the O
surrounding O
chromatin O
structure O
for O
potential O
cis-acting B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulatory B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
DNase B_GENE
I I_GENE
hypersensitivity O
mapping O
and O
found O
four O
hypersensitive O
sites O
, O
three O
of O
which O
were O
T O
cell O
restricted O
. O

By O
using O
a O
reporter-based O
expression O
approach O
, O
a O
T-cell-specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
identified O
by O
its O
close O
association O
with O
a O
prominent O
T-cell-restricted B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
hypersensitive B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sites B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
last O
intron O
of O
the O
CD8 B_GENE/B_LOCATION
alpha I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
. O

Deletion B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
that O
the O
minimal B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancer I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
adjacent B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O
a O
negative B_GENE/B_LOCATION
regulatory I_GENE/I_LOCATION
element I_GENE/I_LOCATION
. O

DNA O
sequence O
analysis O
of O
the O
minimal B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancer I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
a O
striking O
cluster O
of O
consensus B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
binding B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sites B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
for O
Ets-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TCF-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CRE I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GATA-3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LyF-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
were O
verified O
by O
electrophoretic O
mobility O
shift O
assays O
. O

In O
addition O
, O
the O
5 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
enhancer B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
composed O
of O
an O
Alu O
repeat O
which O
contained O
the O
GATA-3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LyF-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Site-directed O
mutation O
of O
the O
Ets-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
GATA-3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dramatically O
reduced O
enhancer O
activity O
. O

The O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
importance I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
other B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
binding B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sites B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
only O
became O
apparent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
combinations B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
mutations B_DISEASE/B_GENE
were O
analyzed O
. O

taken O
together O
, O
these O
results O
suggest O
that O
the O
human B_GENE
CD8 I_GENE
alpha I_GENE
gene I_GENE
is O
regulated O
by O
the O
interaction O
of O
multiple O
T-cell B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
a O
transcriptional O
enhancer O
located O
in O
the O
last O
intron B_GENE/B_LOCATION
of O
the O
gene O
. O

comparison O
of O
the O
CD8 B_GENE
alpha I_GENE
enhancer I_GENE
with O
other O
recently O
identified O
T-cell-specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulatory I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
suggests O
that O
a O
common O
set O
of O
transcription B_GENE/B_LOCATION
factors I_GENE/I_LOCATION
regulates O
several O
T-cell B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Molecular O
regulation O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL-3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O
inducible O
T O
cell-restricted O
expression O
requires O
intact O
AP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Elf-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
IL-3 B_GENE
) O
is O
a O
hematopoietic B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem-cell I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentiation I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
is O
expressed O
solely O
in O
activated O
T O
and O
NK O
cells O
. O

Studies O
to O
date O
have O
identified O
elements O
5 O
' O
to O
the O
IL-3 B_GENE
coding I_GENE
sequences I_GENE
that O
regulate O
its O
transcription O
, O
but O
the O
sequences O
that O
confer O
T O
cell-specific O
expression O
remain O
to O
be O
clearly O
defined O
. O

We O
have O
now O
identified O
DNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
are O
required O
for O
T O
cell-restricted O
IL-3 B_GENE
gene I_GENE
transcription O
. O

A O
series O
of O
transient O
transfections O
performed O
with O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL-3-chloramphenicol I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acetyltransferase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CAT I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
plasmids I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
T O
and O
non-T O
cells O
revealed O
that O
a O
plasmid B_GENE/B_LOCATION
containing O
319 O
BP O
of O
5 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
' I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
flanking I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequences I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
active O
exclusively O
in O
T O
cells O
. O

Deletion O
analysis O
revealed O
that O
T O
cell O
specificity O
was O
conferred O
by O
a O
49-bp B_GENE/B_LOCATION
fragment I_GENE/I_LOCATION
( O
bp B_PROTEIN[GENE]/B_MEASURE
-319 I_PROTEIN[GENE]/I_MEASURE
to I_PROTEIN[GENE]/I_MEASURE
-270 I_PROTEIN[GENE]/I_MEASURE
) O
that O
included O
a O
potential B_GENE/B_LOCATION
binding B_GENE/I_LOCATION
site B_GENE/I_LOCATION
for O
AP-1 B_GENE
transcription I_GENE
factors I_GENE
6 O
BP O
upstream O
of O
a O
binding B_GENE/B_LOCATION
site I_GENE/I_LOCATION
for I_GENE/I_LOCATION
Elf-1 I_GENE/I_LOCATION
, O
a O
member O
of O
the O
Ets B_PERSON/B_LOCATION
family B_PERSON/I_LOCATION
of O
transcription B_GENE
factors I_GENE
. O

DNaseI B_GENE
footprint O
and O
electrophoretic O
mobility O
shift O
assay O
analyses O
performed O
with O
MLA-144 O
T O
cell O
nuclear O
extracts O
demonstrated O
that O
this O
49-bp B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O
a O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
includes O
consensus B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AP-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Elf-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition O
, O
extracts O
prepared O
from O
purified O
human O
T O
cells O
contained O
proteins O
that O
bound O
to O
synthetic O
oligonucleotides O
corresponding O
to O
the O
AP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Elf-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
vitro-transcribed O
and O
-translated O
Elf-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bound O
specifically O
to O
the O
Elf-1 B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
Elf-1 O
antisera O
competed O
and O
super O
shifted O
nuclear O
protein O
complexes O
present O
in O
MLA-144 O
nuclear O
extracts O
. O

Moreover O
, O
addition O
of O
anti-Jun O
family O
antiserum O
in O
electrophoretic O
mobility O
shift O
assay O
reactions O
completely O
blocked O
formation O
of O
the O
AP-1-related B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Transient O
transfection O
studies O
in O
MLA-144 O
T O
cells O
revealed O
that O
constructs O
containing O
mutations O
in O
the O
AP-1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
almost O
completely O
abolished O
Cat O
activity O
while O
mutation O
of O
the O
Elf-1 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
the O
NF-IL-3 B_GENE/B_LOCATION
site I_GENE/I_LOCATION
, O
a O
previously O
described O
nuclear B_GENE/B_LOCATION
protein B_GENE/I_LOCATION
binding B_GENE/I_LOCATION
site B_GENE/I_LOCATION
( O
bp. B_GENE/B_DISEASE
-155 I_GENE/I_DISEASE
to I_GENE/I_DISEASE
-148 I_GENE/I_DISEASE
) O
in O
the O
IL-3 B_GENE
promoter I_GENE
, O
reduced O
Cat O
activity O
to O
< O
25 O
% O
of O
the O
activity O
given O
by O
wild-type O
constructs O
. O

We O
conclude O
that O
expression O
of O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IL-3 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
requires O
the O
AP-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Elf-1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O
however O
, O
unlike O
other O
previously O
characterized O
cytokine B_GENE/B_BIO
genes I_GENE/I_BIO
such O
as O
IL-2 B_GENE
, O
the O
AP-1 B_MEASURE/B_GENE
and I_MEASURE/I_GENE
Elf-1 I_MEASURE/I_GENE
factors I_MEASURE/I_GENE
can O
bind O
independently O
in O
the O
IL-3 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
gene I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

( O
abstract B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRUNCATED I_MEASURE
AT O
400 B_LOCATION/B_PERSON
Words I_LOCATION/I_PERSON
) O
. O

combination O
IL-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
IL-4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduces O
glucocorticoid O
receptor-binding O
affinity O
and O
T O
cell O
response O
to O
glucocorticoids O
. O

The O
mechanisms B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contributing O
to O
persistent B_DISEASE_ADJECTIVE[DISEASE]
T I_DISEASE_ADJECTIVE[DISEASE]
cell I_DISEASE_ADJECTIVE[DISEASE]
activation I_DISEASE_ADJECTIVE[DISEASE]
and O
poor B_DISEASE
response I_DISEASE
to O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
inflammatory B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
illnesses B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
such B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
as O
steroid B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
resistant I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
SR B_PROTEIN[GENE]/B_DISEASE
) O
asthma B_DISEASE/B_LOCATION
are O
poorly O
defined O
. O

We O
examined O
the O
possibility O
that O
certain O
cytokines O
, O
specifically O
IL-2 B_GENE
and O
IL-4 B_GENE
, O
could O
affect O
T O
cell O
response O
to O
glucocorticoids O
. O

A O
[ O
3H O
] O
dexamethasone O
radioligand-binding O
assay O
was O
used O
to O
measure O
the O
number O
of O
glucocorticoid B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GR B_LOCATION/B_ORGANIZATION
) O
and O
dissociation O
constant O
( O
Kd O
) O
in O
PBMC O
from O
normal O
donors O
and O
patients O
with O
SR O
asthma O
, O
cultured O
in O
the O
absence O
and O
presence O
of O
these O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

PBMC O
from O
normal O
donors O
incubated O
for O
48 O
h O
in O
the O
presence O
of O
combination O
IL-2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O
IL-4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O
nuclear O
GR O
with O
significantly O
reduced O
binding O
affinity O
( O
GR O
Kd O
= O
36.1 O
+/- O
1.63 O
nm O
, O
mean O
+/- O
SEM O
; O
p O
= O
0.0001 O
) O
as O
compared O
with O
PBMC O
incubated O
with O
medium O
alone O
( O
GR O
Kd O
= O
6.74 O
+/- O
0.46 O
nm O
) O
. O

The O
cytosolic B_MEASURE/B_LOCATION
GR I_MEASURE/I_LOCATION
Kd I_MEASURE/I_LOCATION
remained O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

However O
, O
when O
PBMC O
were O
incubated O
with O
IL-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
or O
IL-4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
, O
no O
change O
in O
GR-binding O
affinity O
was O
observed O
. O

Furthermore O
, O
when O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O
non-T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
individually O
stimulated O
with O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
IL-2 O
+ O
IL-4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
GR-binding B_DISEASE/B_GENE
affinity I_DISEASE/I_GENE
was O
observed O
only O
in O
the O
T B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
population I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
p B_OTHER/B_PROTEIN[GENE]
= O
0.0001 B_MEASURE
) O
. O

The O
IL-2 B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
+ I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
IL-4-induced I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alteration I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
PBMC B_PROTEIN[GENE]/B_LOCATION
GR I_PROTEIN[GENE]/I_LOCATION
Kd I_PROTEIN[GENE]/I_LOCATION
was O
associated O
with O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
GR B_MEASURE/B_DISEASE
number I_MEASURE/I_DISEASE
( O
8348 B_MEASURE
+/- I_MEASURE
964 I_MEASURE
vs I_MEASURE
1710 I_MEASURE
+/- I_MEASURE
228 I_MEASURE
sites/cell I_MEASURE
; O
p O
= O
0.0003 B_MEASURE
) O
. O

More O
importantly O
, O
the O
alteration O
in O
PBMC O
GR-binding O
affinity O
with O
IL-2 B_GENE
+ O
IL-4 B_GENE
was O
associated O
with O
a O
functional O
change O
in O
T O
cell O
response O
to O
methylprednisolone O
MPN O
, O
i.e. O
, O
a O
reduced O
inhibitory O
effect O
of O
MPN O
on O
PMA/ionomycin-induced O
T O
cell O
proliferation O
. O

These O
effects O
of O
IL-2 B_GENE
+ O
IL-4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
PBMC O
GR B_GENE/B_DISEASE
affinity O
and O
response O
to O
MPN O
were O
blocked O
by O
co-incubation O
with O
IFN-gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

freshly O
isolated O
PBMC B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O
four B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
SR B_DISEASE/B_LOCATION
asthma I_DISEASE/I_LOCATION
had O
a O
significantly O
reduced O
GR-binding B_GENE/B_MEASURE
affinity B_GENE/I_MEASURE
( O
Kd B_PROTEIN[GENE]/B_MEASURE
= O
40.0 B_MEASURE
+/- I_MEASURE
2.68 I_MEASURE
nm I_MEASURE
; O
p B_OTHER/B_PROTEIN[GENE]
= O
0.0001 B_MEASURE
) O
when O
compared O
with O
seven B_PERSON/B_MEASURE
normal I_PERSON/I_MEASURE
subjects I_PERSON/I_MEASURE
( O
7.15 B_MEASURE/B_PROTEIN[GENE]
+/- I_MEASURE/I_PROTEIN[GENE]
0.41 I_MEASURE/I_PROTEIN[GENE]
nm I_MEASURE/I_PROTEIN[GENE]
) O
. O

The O
altered O
PBMC O
GR O
binding O
from O
patients O
with O
SR O
asthma O
reversed O
to O
normal O
when O
incubated O
with O
medium O
alone O
, O
but O
was O
sustained O
with O
IL-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
IL-4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

These O
observations O
suggest O
that O
with O
persistent O
inflammation O
certain O
cytokines B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
may O
contribute O
to O
an O
impaired O
response O
to O
glucocorticoids O
. O

Furthermore O
, O
the O
effects O
of O
IL-2 B_GENE
and O
IL-4 B_GENE
were O
blocked O
by O
IFN-gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

characterization O
of O
the O
human B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CD4 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
transcription O
from O
the O
CD4 B_GENE/B_LOCATION
gene I_GENE/I_LOCATION
core I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
is O
tissue-specific O
and O
is O
activated O
by O
Ets B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
analyzed O
the O
5 B_GENE/B_LOCATION
' I_GENE/I_LOCATION
transcription I_GENE/I_LOCATION
control I_GENE/I_LOCATION
sequences I_GENE/I_LOCATION
of O
the O
human B_GENE/B_BIO
CD4 I_GENE/I_BIO
gene I_GENE/I_BIO
. O

We O
located O
the O
transcription B_GENE/B_LOCATION
initiation I_GENE/I_LOCATION
site I_GENE/I_LOCATION
and O
showed O
that O
the O
CD4 B_GENE/B_LOCATION
core I_GENE/I_LOCATION
promoter I_GENE/I_LOCATION
( O
positions B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-40 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+16 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
lacks O
a O
classical O
`` O
TATA O
'' O
or O
initiator B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positioning I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consensus I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
directs O
precise O
and O
efficient O
transcription O
when O
coupled O
to O
the O
ubiquitously O
active O
simian B_GENE/B_LOCATION
virus I_GENE/I_LOCATION
40 I_GENE/I_LOCATION
enhancer I_GENE/I_LOCATION
. O

The O
transcriptional O
activity O
of O
the O
CD4 B_GENE
gene I_GENE
promoter I_GENE
correlated O
with O
CD4 O
expression O
in O
various O
cell O
types O
. O

Interestingly O
, O
the O
CD4 B_GENE
core I_GENE
promoter I_GENE
also O
displayed O
a O
tissue-specific O
transcriptional O
activity O
. O

Within O
this O
fragment O
, O
three O
nucleic O
acid O
sequences O
are O
completely O
conserved O
in O
the O
murine B_GENE/B_BIO
CD4 I_GENE/I_BIO
gene I_GENE/I_BIO
. O

One O
of O
these O
sequences O
contains O
a O
perfect B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ETS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
consensus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sequence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Another O
ETS B_LOCATION/B_PERSON
consensus I_LOCATION/I_PERSON
sequence I_LOCATION/I_PERSON
is O
located O
1060 O
nt O
upstream O
. O

Electrophoretic-mobility-shift O
assays O
showed O
that O
the O
core O
promoter O
ETS O
motif O
binds O
an O
Ets-related B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
specifically O
expressed O
at O
high O
levels O
in O
CD4+ O
cells O
. O

Moreover O
, O
in O
CD4- O
cells O
, O
overexpression O
of O
Ets-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
Ets-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efficiently O
and O
specifically O
activated O
transcription O
from O
the O
CD4 B_GENE
promoter I_GENE
and O
core B_GENE
promoter I_GENE
. O

These O
data O
indicate O
that O
Ets B_GENE
transcription I_GENE
factors I_GENE
play O
a O
central O
role O
in O
controlling O
CD4 O
gene O
expression O
, O
by O
binding O
to O
both O
a O
classical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remote B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
site B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
an O
unusual O
proximal B_GENE/B_LOCATION
activator I_GENE/I_LOCATION
sequence I_GENE/I_LOCATION
. O

glucocorticoid B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
receptor I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
activation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O
inactivation B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
c B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
ultured I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
human I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O

Although O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O
not O
cytolytic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
for O
and O
do O
not O
inhibit O
the O
growth B_ORGANISM_FUNCTION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
IM-9 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
line I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
cultured B_DISEASE
human I_DISEASE
lymphoblasts I_DISEASE
, O
these O
cells B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
have O
a O
high B_DISEASE_ADJECTIVE[DISEASE]
steroid-binding I_DISEASE_ADJECTIVE[DISEASE]
capacity I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
have O
used O
IM-9 O
cells O
in O
order O
to O
examine O
whether O
unoccupied B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
inactivated O
and O
activated O
in O
intact O
cells O
. O

when O
IM-9 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
incubated O
in O
glucose-free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
nitrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
atmosphere I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
both O
their O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
bind O
triamcinolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetonide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
their O
ATP B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decline O
and O
, O
when O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
are O
reintroduced O
, O
ATP B_MEASURE/B_BIO
levels B_MEASURE/I_BIO
and O
receptor B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activity I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
return I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
specific B_MEASURE
glucocorticoid-binding I_MEASURE
activity I_MEASURE
of O
cytosol B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
prepared O
from O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
exposed O
to O
various B_MEASURE/B_LOCATION
degrees B_MEASURE/I_LOCATION
of O
energy B_DISEASE
limitation I_DISEASE
is O
directly O
correlated O
with O
the O
ATP B_MEASURE/B_DISEASE
content I_MEASURE/I_DISEASE
. O

Receptor B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
intact B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
independent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
protein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

cytosol B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
prepared O
from O
inactivated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
can O
not O
be O
activated O
by O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
inactivation O
of O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
occurs O
when O
cytosol O
from O
normal O
IM-9 O
cells O
is O
incubated O
at O
25 O
degrees O
C O
is O
inhibited O
by O
molybdate O
, O
vanadate O
, O
fluoride O
, O
ATP O
, O
and O
several O
other O
nucleotides O
. O

The O
experiments O
with O
intact O
human O
lymphoblasts O
suggest O
that O
assays O
of O
specific O
glucocorticoid-binding O
capacity O
do O
not O
necessarily O
reflect O
the O
cellular O
content O
of O
receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
lymphocytes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

II B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Cell O
cycle-dependent O
changes O
in O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
content O
. O

To O
study O
variations O
in O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O
during O
the O
cell O
cycle O
, O
we O
have O
separated O
mitogen-stimulated O
human O
peripheral O
lymphocytes O
and O
rat O
lymph O
node O
cells O
by O
unit O
gravity O
sedimentation O
and O
measured O
glucocorticoid O
binding O
in O
the O
resultant O
fractions O
. O

By O
morphologic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
criteria I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
thymidine B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
incorporation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
the O
fractions B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
separated O
into O
populations B_LOCATION/B_ORGANIZATION
of O
G0 B_MEASURE/B_PROTEIN[GENE]
and O
G1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
S B_DISEASE
and O
post-S O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
cells B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

A O
2- B_MEASURE/B_LOCATION
to O
3-fold B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
glucocorticoid B_GENE/B_MEASURE
receptor B_GENE/I_MEASURE
sites B_GENE/I_MEASURE
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
, O
for O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
S B_OTHER/B_DISEASE
and O
post-S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
over O
those O
in O
G0 B_PROTEIN[GENE]/B_DISEASE
and O
G1 B_PROTEIN[GENE]
, O
was O
observed O
with O
both O
nonstimulated B_DISEASE_ADJECTIVE[DISEASE]
rat I_DISEASE_ADJECTIVE[DISEASE]
lymph I_DISEASE_ADJECTIVE[DISEASE]
node I_DISEASE_ADJECTIVE[DISEASE]
cell I_DISEASE_ADJECTIVE[DISEASE]
suspensions I_DISEASE_ADJECTIVE[DISEASE]
and O
concanavalin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
A-stimulated O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
observations O
together O
with O
those O
from O
other O
studies O
indicate O
that O
formation O
of O
new O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
near O
the O
S O
phase O
may O
be O
a O
general O
phenomenon O
in O
proliferating O
cells O
. O

We O
propose O
that O
this O
increase O
in O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
during O
the O
cell O
cycle O
may O
explain O
the O
increase O
in O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mitogen-stimulated O
lymphocytes O
. O

The O
leukocyte O
migration O
inhibition O
response O
to O
certain O
breast B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cancer-related B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigens B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MCF-7 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
MuMTV B_GENE/B_SPECIES[BIO]
) O
: O
their O
potential O
as O
discriminants O
. O

Certain B_DISEASE_ADJECTIVE[DISEASE]/B_VIRUS[BIO]
oncogenic B_DISEASE_ADJECTIVE[DISEASE]/I_VIRUS[BIO]
viruses B_DISEASE_ADJECTIVE[DISEASE]/I_VIRUS[BIO]
have O
been O
implicated O
in O
human B_DISEASE
breast I_DISEASE
cancer I_DISEASE
, O
including O
the O
murine B_VIRUS[BIO]/B_DISEASE
mammary I_VIRUS[BIO]/I_DISEASE
tumor I_VIRUS[BIO]/I_DISEASE
virus I_VIRUS[BIO]/I_DISEASE
( O
MuMTV B_LOCATION/B_ORGANIZATION
) O
and O
the O
Mason-Pfizer B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
monkey I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
virus I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MPMV B_VIRUS[BIO]
) O
. O

We O
have O
used O
the O
leukocyte O
migration O
inhibition O
( O
LMI O
) O
response O
to O
assay O
the O
response O
to O
several O
potential O
breast O
cancer-related O
antigens O
, O
including O
MuMTV B_VIRUS[BIO]/B_GENE
, O
MPMV B_GENE/B_BIO
, O
and O
a O
breast O
cancer O
cultured O
cell O
line O
, O
MCF-7 O
, O
in O
96 O
breast O
cancer O
patients O
, O
in O
32 O
women O
with O
benign O
breast O
disease O
, O
and O
in O
67 O
normal O
women O
. O

The O
lowest B_MEASURE/B_LOCATION
tenth B_MEASURE/I_LOCATION
percentile B_MEASURE/I_LOCATION
of O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
LMI B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
) O
responses B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
used O
as O
the O
cutoff B_MEASURE
point I_MEASURE
to O
designate O
responders B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

breast O
cancer O
patients O
showed O
significant O
responses O
to O
MuMTV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
( O
49 O
% O
and O
to O
MCF-7 O
( O
50 O
% O
) O
, O
but O
not O
to O
MPMV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
29 O
% O
) O
. O

In O
a O
paired-antigen O
study O
using O
MuMTV B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
MCF-7 B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
75 O
% O
of O
the O
breast O
cancer O
patients O
responded O
, O
versus O
18 O
% O
of O
the O
normal O
women O
( O
P O
less O
than O
0.0050 O
) O
. O

The O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
this O
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
distinguish O
normal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
'' O
from O
breast B_DISEASE
cancer I_DISEASE
'' O
was O
analyzed O
using O
a O
migration B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
index B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derived O
from O
discriminant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
discriminate O
normal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
'' O
from O
cancer B_DISEASE
'' O
was O
significant B_DISEASE_ADJECTIVE[DISEASE]
( O
P B_MEASURE
less I_MEASURE
than O
0.001 B_MEASURE
) O
and O
showed O
a O
sensitivity B_MEASURE
of O
detecting O
cancer B_DISEASE
'' O
of O
75 B_MEASURE/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
% B_MEASURE/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
overall O
responses O
to O
MuMTV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
and O
MCF-7 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
analyzed O
with O
reference O
to O
certain O
prognostic O
factors O
, O
but O
showed O
no O
relation O
to O
age O
, O
menstrual O
status O
, O
estrogen O
receptor O
status O
, O
or O
stage O
of O
disease O
. O

The O
above O
reactions O
suggest O
that O
a O
large O
proportion O
of O
breast O
cancer O
patients O
exhibit O
presensitization O
to O
antigenfs O
found O
in O
MuMTV B_GENE/B_SPECIES[BIO]
and O
MCF-7 B_DISEASE/B_VIRUS[BIO]
, O
which O
may O
be O
cross-reactive O
with O
antigens O
in O
the O
primary O
cancer O
. O

These O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
appear O
to O
be O
independent B_PERSON/B_LOCATION
of O
major B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prognostic I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
variables I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
refinement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
may O
yield O
one B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O
is O
more O
highly O
discriminating O
for O
breast B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
. O

Chronic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphatic B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leukaemia B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
cellular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vitro B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Glucocorticoid B_GENE
receptor I_GENE
levels O
and O
steroid O
induced O
inhibition O
of O
nucleic O
acid O
precursors O
have O
been O
examined O
in O
lymphocytes O
from O
27 O
patients O
at O
different O
stages O
of O
chronic O
lymphatic O
leukaemia O
. O

No O
correlation O
can O
be O
found O
between O
the O
level O
of O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
stage O
of O
the O
disease O
. O

On O
the O
other B_PERSON/B_LOCATION
hand B_PERSON/I_LOCATION
, O
a O
significant B_MEASURE
difference I_MEASURE
( O
P B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0.02 B_MEASURE
) O
was O
found O
between O
stage B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
stage B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
III/IV I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
patients I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
terms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
[ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uridine I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incorporation I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pyrrolidine O
dithiocarbamate O
inhibits O
NF-kappa B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mobilization O
and O
TNF O
production O
in O
human O
monocytes O
. O

The O
human B_PROTEIN[GENE]/B_LOCATION
TNF I_PROTEIN[GENE]/I_LOCATION
promoter I_PROTEIN[GENE]/I_LOCATION
contains O
four O
potential O
nuclear B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
factor-kappa I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
B I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
NF-kappa I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
B I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
-binding I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sites I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
with O
the O
strongest O
binding O
seen O
for O
the O
-605 O
motif O
. O

Nuclear O
extracts O
from O
unstimulated O
cells O
of O
the O
human O
monocytic O
cell O
line O
, O
Mono O
Mac O
6 O
, O
contain O
one O
specific B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
complex B_GENE/B_DISEASE
II I_GENE/I_DISEASE
) O
, O
consistent O
with O
a O
constitutive B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p50 B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homodimer B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

stimulation O
of O
Mono O
Mac O
6 O
cells O
with O
LPS O
will O
increase O
complex B_LOCATION/B_DISEASE
II B_LOCATION/I_DISEASE
and O
will O
strongly O
induce O
a O
second O
specific O
complex O
( O
complex B_LOCATION/B_PERSON
I I_LOCATION/I_PERSON
) O
, O
which O
represents O
the O
p50/65 B_GENE/B_SEQUENCE[MEASURE]
heterodimer B_GENE/I_SEQUENCE[MEASURE]
. O

Treatment O
of O
Mono O
Mac O
6 O
cells O
with O
pyrrolidine-dithiocarbamate O
( O
PDTC O
) O
at O
300 O
microM O
will O
block O
the O
LPS-induced B_GENE/B_LOCATION
complex I_GENE/I_LOCATION
I I_GENE/I_LOCATION
almost O
completely O
and O
will O
reduce O
complex B_LOCATION/B_DISEASE
II B_LOCATION/I_DISEASE
to O
the O
constitutive O
level O
. O

binding O
activity O
of O
other O
nuclear B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
recognize O
the O
SP-1 O
and O
c/EBP O
motifs O
of O
the O
human B_GENE
TNF I_GENE
promoter I_GENE
is O
not O
affected O
by O
such O
treatment O
. O

Northern O
blot O
analysis O
demonstrates O
that O
PDTC O
treatment O
will O
strongly O
reduce O
LPS-induced B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
TNF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Secreted O
TNF B_DISEASE_ADJECTIVE[DISEASE]
protein I_DISEASE_ADJECTIVE[DISEASE]
as O
detected O
in O
the O
Wehi O
164S/ActD O
bioassay O
and O
in O
a O
sandwich O
immunoassay O
was O
similarly O
reduced O
by O
PDTC O
. O

kinetic O
analyses O
show O
that O
after O
LPS O
stimulation O
, O
NF-kappa B_GENE
B I_GENE
will O
peak O
at O
1 O
h O
, O
TNF O
transcript O
prevalence O
at O
2 O
h O
, O
and O
TNF B_GENE/B_MEASURE
protein B_GENE/I_MEASURE
at O
4 O
h O
. O

PDTC O
did O
not O
shift O
this O
response O
to O
LPS O
to O
a O
later O
time O
, O
but O
suppressed O
NF-kappa O
B O
mobilization O
, O
TNF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
TNF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
over O
the O
entire O
8-h O
observation O
period O
. O

Analysis O
of O
freshly O
isolated O
, O
LPS-stimulated O
blood O
monocytes O
showed O
a O
similar O
blockade O
of O
NF-kappa B_GENE
B I_GENE
. O

Furthermore O
, O
in O
these O
primary O
cells O
, O
induction O
of O
TNF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
determined O
by O
Northern O
blot O
analysis O
and O
by O
quantitative O
polymerase O
chain O
reaction O
, O
was O
prevented O
by O
PDTC O
as O
was O
TNF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
production O
. O

These O
data O
show O
that O
dithiocarbamates O
can O
profoundly O
affect O
cytokine O
expression O
and O
suggest O
that O
NF-kappa B_GENE
B I_GENE
is O
involved O
in O
LPS-induced O
TNF O
gene O
expression O
in O
human O
monocytes O
. O

comparing O
regions O
of O
the O
Epstein-Barr B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ZEBRA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O
function O
as O
transcriptional B_GENE/B_MEASURE
activating I_GENE/I_MEASURE
sequences I_GENE/I_MEASURE
in O
Saccharomyces O
cerevisiae O
and O
in O
B O
cells O
. O

The O
ZEBRA B_GENE
protein I_GENE
activates O
expression O
of O
Epstein-Barr O
virus O
early-lytic-cycle B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
human O
B O
lymphocytes O
. O

Here O
it O
is O
shown O
that O
ZEBRA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
behaves O
as O
a O
sequence-specific B_GENE/B_PERSON
transcriptional I_GENE/I_PERSON
activator I_GENE/I_PERSON
in O
Saccharomyces O
cerevisiae O
. O

Deletional O
mutagenesis O
defined O
three O
regions O
of O
ZEBRA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
participate O
in O
activation O
in O
S. O
cerevisiae O
. O

These O
regions O
are O
designated O
YI B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
amino B_MEASURE
acids I_MEASURE
[ I_MEASURE
aa I_MEASURE
] I_MEASURE
1 I_MEASURE
to I_MEASURE
25 I_MEASURE
) O
, O
YII B_PROTEIN[GENE]/B_LOCATION
( O
aa B_MEASURE
51 I_MEASURE
to I_MEASURE
102 I_MEASURE
) O
, O
and O
YIII B_PROTEIN[GENE]/B_LOCATION
( O
aa B_MEASURE/B_BIO
228 I_MEASURE/I_BIO
to I_MEASURE/I_BIO
245 I_MEASURE/I_BIO
) O
. O

Two O
of O
the O
three O
regions O
of O
the O
native O
ZEBRA B_GENE/B_LOCATION
protein I_GENE/I_LOCATION
act O
together O
to O
mediate O
activation O
when O
assayed O
on O
ZEBRA B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
binding I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
sites I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
when O
fused O
to O
the O
DNA B_GENE/B_LOCATION
binding I_GENE/I_LOCATION
domain I_GENE/I_LOCATION
of O
GAL B_GENE/B_BACTERIUM[BIO]
4 O
and O
assayed O
on O
GAL4 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
regions B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
YII I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
and I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
YIII I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
were O
each O
sufficient O
to O
confer O
activation O
in O
S. O
cerevisiae O
. O

regions O
of O
ZEBRA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
affected O
activation O
in O
S. O
cerevisiae O
were O
also O
required O
in O
human O
B O
lymphocytes O
. O

The O
amino-terminal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ZEBRA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
aa B_PROTEIN[GENE]/B_MEASURE
1 I_PROTEIN[GENE]/I_MEASURE
to I_PROTEIN[GENE]/I_MEASURE
98 I_PROTEIN[GENE]/I_MEASURE
) O
was O
required O
for O
activation O
both O
in O
S. O
cerevisiae O
and O
in O
human O
B O
cells O
; O
deletion O
of O
the O
carboxy-terminal B_LOCATION/B_GENE
18 B_LOCATION/I_GENE
aa B_LOCATION/I_GENE
also O
significantly O
reduced O
activation O
in O
both O
cell O
types O
. O

Thus O
, O
the O
behavior O
of O
ZEBRA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
human O
B O
cells O
and O
S. O
cerevisiae O
suggests O
that O
the O
protein O
contains O
universal B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
activation B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
motifs B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O
interact O
with O
conserved O
components O
of O
the O
transcription O
machinery O
. O

However O
, O
certain O
deletion B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
mutants I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
of O
ZEBRA B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
mutations O
in O
the O
N-terminal B_GENE/B_LOCATION
region I_GENE/I_LOCATION
exhibited O
discordant O
behaviors O
in O
S. O
cerevisiae O
and O
in O
B O
cells O
. O

For O
example O
, O
deletion O
of O
ZEBRA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
aa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
26 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
51 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
impaired O
activation O
to O
a O
great O
extent O
in O
B O
cells O
but O
had O
little O
or O
no O
effect O
in O
S. O
cerevisiae O
. O

The O
discordant O
mutants O
may O
reflect O
interactions O
with O
a O
variable B_MEASURE/B_LOCATION
domain I_MEASURE/I_LOCATION
of O
a O
conserved O
component O
or O
unique O
interactions O
with O
specialized O
components O
of O
the O
basal O
transcription O
apparatus O
in O
different O
cells O
. O

functional O
interaction O
of O
the O
v-Rel B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Rel I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncoproteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O
the O
TATA-binding B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
association O
with O
transcription B_GENE
factor I_GENE
IIB I_GENE
. O

Rel B_PERSON/B_GENE
family I_PERSON/I_GENE
proteins I_PERSON/I_GENE
regulate O
the O
expression O
of O
genes O
linked O
to O
Kappa O
B-binding O
motifs O
. O

Little B_PERSON/B_LOCATION
is O
known O
, O
however O
, O
of O
the O
mechanism B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
which O
they O
enhance O
transcription B_DISEASE/B_GENE
. O

We O
have O
investigated O
the O
ability O
of O
the O
v-Rel B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Rel I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oncoproteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
interact O
with O
components O
of O
the O
basal O
transcription O
machinery O
. O

Here O
we O
report O
that O
both O
the O
acidic O
transcription O
activation O
domain O
mapping O
to O
the O
unique O
C B_LOCATION/B_BIO
terminus I_LOCATION/I_BIO
of O
chicken B_GENE
c-Rel I_GENE
and O
the O
F9 B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
cell-specific I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
activation I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
region I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
common O
to O
both O
v-Rel B_GENE
and O
c-Rel B_GENE
interact O
with O
the O
TATA-binding B_GENE
protein I_GENE
( O
TBP B_GENE/B_LOCATION
) O
and O
transcription B_GENE
factor I_GENE
IIB I_GENE
( O
TFIIB B_GENE/B_DISEASE
) O
in O
vitro O
and O
in O
vivo O
. O

We O
also O
demonstrate O
that O
TPB B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
interaction O
with O
Rel B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leads O
to O
synergistic O
activation O
of O
transcription O
of O
a O
kappa B_GENE
B-linked I_GENE
reporter I_GENE
gene I_GENE
. O

Combined O
with O
the O
observation O
that O
the O
mouse B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
c-Rel I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
human I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
RelA I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
also O
interact O
with O
TBP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
TFIIB B_GENE
in O
vitro O
, O
these O
results O
suggest O
that O
association O
with O
basal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
important O
for O
the O
transcriptional O
activities O
of O
Rel B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

p21ras B_GENE
and O
calcineurin O
synergize O
to O
regulate O
the O
nuclear B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
factor B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
activated O
T O
cells O
. O

In O
T O
lymphocytes O
, O
triggering O
of O
the O
T B_GENE
cell I_GENE
receptor I_GENE
( O
TCR B_LOCATION/B_ORGANIZATION
) O
induces O
several O
signaling O
cascades O
which O
ultimately O
synergize O
to O
induce O
the O
activity O
of O
the O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
activated O
T O
cells O
( O
NFAT O
) O
, O
a O
DNA B_GENE
binding I_GENE
complex I_GENE
critical O
to O
the O
inducibility O
and O
T O
cell O
specificity O
of O
the O
T B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interleukin I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One O
immediate O
consequence O
of O
T O
cell O
activation O
via O
the O
TCR B_GENE
is O
an O
increase O
in O
cytosolic O
calcium O
. O

calcium O
signals O
are O
important O
for O
NFAT O
induction O
, O
and O
recent O
studies O
have O
identified O
calcineurin B_GENE
, O
a O
calcium-calmodulin B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serine-threonine I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphatase I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
a O
prominent O
component O
of O
the O
calcium O
signaling O
pathway O
in O
T O
cells O
. O

A O
second O
important O
molecule O
in O
TCR O
signal O
transduction O
is O
the O
guanine B_GENE
nucleotide I_GENE
binding I_GENE
protein I_GENE
, O
p21ras B_GENE
, O
which O
is O
coupled O
to O
the O
TCR B_GENE
by O
a O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dependent O
mechanism O
. O

The O
experiments O
presented O
here O
show O
that O
expression O
by O
transfection O
of O
mutationally O
activated O
calcineurin B_GENE/B_DISEASE
or O
activated O
p21ras B_GENE
alone O
is O
insufficient O
for O
NFAT O
transactivation O
. O

However O
, O
coexpression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
activated O
calcineurin B_GENE
with O
activated O
p21ras B_GENE
could O
mimic O
TCR B_DISEASE_ADJECTIVE[DISEASE]
signals I_DISEASE_ADJECTIVE[DISEASE]
in O
NFAT B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
induction I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

These O
data O
identify O
calcineurin B_GENE
and O
p21ras B_GENE
as O
cooperative O
partners O
in O
T O
cell O
activation O
. O

expression O
of O
the O
chicken B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
GATA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O
early O
erythroid O
development O
and O
differentiation O
. O

The O
DNA O
motif O
WGATAR O
has O
been O
identified O
within O
transcriptional B_LOCATION/B_GENE
regulatory I_LOCATION/I_GENE
domains I_LOCATION/I_GENE
of O
globin B_GENE
and O
other O
erythroid-specific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
activator B_GENE/B_BIO
proteins I_GENE/I_BIO
that O
bind O
to O
this O
regulatory B_GENE/B_LOCATION
element I_GENE/I_LOCATION
, O
the O
GATA B_GENE/B_BIO
factors I_GENE/I_BIO
, O
belong O
to O
a O
multi-gene B_GENE/B_LOCATION
family I_GENE/I_LOCATION
that O
is O
expressed O
in O
chicken O
erythroid O
cells O
. O

Here O
we O
show O
that O
, O
as O
in O
chickens O
, O
multiple O
members O
of O
the O
GATA B_GENE/B_BIO
factor I_GENE/I_BIO
family I_GENE/I_BIO
are O
expressed O
in O
human O
and O
murine O
erythroid O
cells O
. O

During O
the O
early O
stages O
of O
chicken O
embryogenesis O
( O
well O
before O
blood O
island O
formation O
) O
, O
each O
of O
the O
GATA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
members I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
transcribed O
with O
a O
unique O
temporal O
and O
spatial O
pattern O
. O

In O
the O
primitive O
erythroid O
lineage O
, O
transcription O
of O
the O
embryonic B_GENE/B_MEASURE
epsilon-globin I_GENE/I_MEASURE
gene I_GENE/I_MEASURE
parallels O
GATA-1 O
expression O
while O
the O
switch O
to O
beta-globin O
transcription O
in O
definitive O
erythroid O
cells O
is O
directly O
preceded O
by O
a O
pronounced O
increase O
in O
GATA-3 B_GENE
accumulation O
. O

The O
timing O
and O
pattern O
of O
expression O
of O
these O
different O
mRNAs B_GENE/B_BIO
during O
avian O
erythroid O
development O
and O
differentiation O
suggests O
that O
temporally O
regulated O
changes O
in O
GATA B_GENE/B_BIO
factor I_GENE/I_BIO
expression O
are O
required O
for O
vertebrate O
hematopoiesis O
. O

Molecular O
regulation O
of O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
interleukin I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
2 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O
T-cell O
function O
by O
interleukin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

distinct O
functional O
T-cell O
subsets O
, O
differing O
in O
the O
patterns O
of O
lymphokines B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
, O
regulate O
cell-mediated O
and O
humoral O
immune O
responses O
. O

The O
two O
major O
types O
and O
their O
principal O
products O
, O
interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
4 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
interferon B_MEASURE
gamma I_MEASURE
( O
IL-4 B_GENE
and O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
are O
reciprocally O
negatively O
interactive O
. O

To O
analyze O
the O
molecular O
mechanism O
of O
IL-4-mediated O
suppression O
of O
cell-mediated O
immunity O
we O
studied O
its O
effects O
on O
expression O
of O
interleukin B_GENE
2 I_GENE
( O
IL-2 B_GENE/B_MEASURE
) O
and O
IFN-gamma B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

IL-4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
pretreatment O
of O
Jurkat O
cells O
prior O
to O
stimulation O
resulted O
in O
a O
decrease O
in O
transcription O
of O
the O
IL2 B_GENE
gene I_GENE
. O

IL-4 B_PERSON/B_GENE
suppressed O
IL-2 O
and O
IFN-gamma O
mRNA O
levels O
in O
primary O
human O
T O
cells O
, O
and O
addition O
of O
anti-CD28 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
relieved O
this O
suppression O
. O

Using O
enhancer-reporter B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constructs B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
IL-4 B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O
down-regulated O
the O
NFIL-2B B_GENE
element I_GENE
. O

Electrophoretic O
mobility O
shift O
assays O
using O
a O
DNA O
oligomer O
containing O
the O
NFIL-2B B_GENE
binding I_GENE
site I_GENE
indicated O
that O
IL-4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibited O
the O
NFIL-2B B_GENE
complex I_GENE
and O
that O
the O
NFIL-2B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
distinct O
from O
AP- B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
. O

These O
results O
suggest O
that O
IL-4 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
regulate O
development O
and O
function O
of O
T-cell O
subsets O
involved O
in O
cell-mediated O
immunity O
in O
part O
by O
inhibiting B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
required O
for O
transcription O
of O
the O
IL2 B_GENE
gene I_GENE
. O

Immunochemical O
differences O
between O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
corticoid-sensitive O
and O
-resistant O
malignant O
lymphocytes O
. O

We O
have O
explored O
the O
possibility O
of O
using O
antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
purified O
rat O
liver O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
to O
study O
the O
immunochemical O
properties O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
from O
murine O
and O
human O
malignant O
lymphocytes O
. O

For O
this O
purpose O
, O
purified B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
immune I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
immunoglobulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
G I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
covalently O
linked O
to O
Sepharose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CL-4B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
then O
examined O
the O
ability O
of O
the O
affinity O
gel O
to O
recognize O
cytosolic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
[ I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3H I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
] I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
triamcinolone I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acetonide-receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
the O
corticoid-sensitive O
( O
CS O
) O
and O
-resistant O
strains O
of O
mouse O
lymphoma O
P1798 O
, O
from O
CS O
lymphocytes O
of O
patients O
with O
chronic O
lymphatic O
leukemia O
, O
and O
from O
a O
CS O
clone O
of O
human O
leukemic O
lymphoblasts O
in O
tissue O
culture O
( O
CH6 O
) O
. O

Mouse O
thymus O
was O
used O
as O
a O
source O
of O
glucocorticoid B_GENE
receptor I_GENE
from O
normal O
CS O
lymphocytes O
. O

Whereas O
the O
immunoaffinity O
column O
retained O
70 O
to O
84 O
% O
of O
the O
58- O
to O
62-A O
( O
Stokes O
radius O
) O
[ B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3H B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
triamcinolone B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
acetonide-receptor B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
complexes B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characteristic O
of O
the O
CS O
mouse O
and O
human O
lymphocytes O
, O
it O
failed O
to O
recognize O
the O
27- O
to O
28-A O
( O
Stokes O
radius O
) O
glucocorticoid B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present O
in O
corticoid-resistant O
mouse O
lymphoma O
P1798 O
cells O
. O

Therefore O
, O
under O
appropriate O
experimental O
conditions O
, O
it O
was O
possible O
to O
demonstrate O
cross-reactivity O
between O
the O
antiserum O
against O
rat B_GENE
liver I_GENE
glucocorticoid I_GENE
receptor I_GENE
and O
the O
58- O
to O
62-A O
( O
Stokes O
radius O
) O
glucocorticoid B_PROTEIN[GENE]/B_LOCATION
receptor I_PROTEIN[GENE]/I_LOCATION
from O
species O
as O
diverse O
as O
mouse O
and O
humans O
. O

heterogeneity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
acute B_DISEASE/B_BIO
leukemia I_DISEASE/I_BIO
. O

In O
leukocyte O
population O
freshly O
isolated O
from O
the O
blood O
of O
26 O
patients O
with O
acute O
leukemia O
, O
we O
have O
measured O
several O
parameters O
including O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
nucleoside O
incorporation O
, O
percentage O
of O
cells O
in O
S O
phase O
, O
and O
steroid-induced O
cell O
lysis O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
in O
some O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
short-term B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
steroid O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
determined O
. O

Although O
, O
in O
all O
the O
patients O
studied O
, O
leukocytes O
were O
found O
to O
contain O
glucocorticoid B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
failed O
to O
demonstrate O
any O
correlation O
between O
the O
level O
of O
binding O
sites O
and O
the O
in O
vitro O
or O
in O
vivo O
response O
to O
glucocorticoids O
. O

This O
absence B_DISEASE/B_MEASURE
of O
correlation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
in O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
explained O
by O
the O
marked B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
heterogeneity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
steroid B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
in O
leukocyte B_PERSON/B_DISEASE
subpopulations I_PERSON/I_DISEASE
. O

It O
appears O
, O
however O
, O
that O
the O
degree B_MEASURE
of O
steroid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
vitro B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
the O
extent B_DISEASE/B_MEASURE
of O
spontaneous B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dexamethasone-induced B_DISEASE_ADJECTIVE[DISEASE]
cell I_DISEASE_ADJECTIVE[DISEASE]
death I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
related O
to O
the O
number B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
in O
the O
S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
cell B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Glucocorticoid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
cytosol O
and O
nuclear O
extract O
of O
human O
leukocytes O
. O

cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
cytosol B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
0.4 B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
M I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
KCl I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
extract I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
fraction I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O
human B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
leukocytes I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
studied O
by O
gel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
ion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exchange I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
filtration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
DEAE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellulose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
cytoplasmic B_PROTEIN[GENE]
cortisol I_PROTEIN[GENE]
binding I_PROTEIN[GENE]
protein I_PROTEIN[GENE]
has O
a O
molecular O
weight O
95 O
000 O
and O
the O
soluble B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
nuclear I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
binding I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
protein I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
50 O
000 O
. O

The O
absence B_DISEASE
of O
the O
uptake B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
radioactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cortisol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
by O
isolated B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nuclei I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
apparent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
requirement I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
cytosol B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
for O
glucocorticoid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specific I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
nuclear B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
sites I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
was O
observed O
. O

The O
association B_MEASURE
constant I_MEASURE
characterising O
the O
binding B_GENE/B_MEASURE
of O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
cytosol B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
was O
ka B_LOCATION/B_PROTEIN[GENE]
= O
3.5 B_MEASURE
. O
10 B_MEASURE
( O
9 B_MEASURE
) O
l/mol B_MEASURE/B_BIO
. O

Corticosteroid-induced B_DISEASE_ADJECTIVE[DISEASE]
lymphopenia I_DISEASE_ADJECTIVE[DISEASE]
, O
immunosuppression B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
body B_DISEASE
defense I_DISEASE
. O

The O
apparent O
paradox O
of O
heightened O
adrenal O
corticosteroid O
levels O
associated O
with O
reduction O
in O
the O
competence O
of O
the O
body O
's O
defensive O
apparatus O
to O
cope O
with O
exposure O
to O
new O
microbial B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigens I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
considered O
. O

The O
question B_TIME[MEASURE]/B_PERSON
is O
asked O
how O
this O
lowered O
defensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capability I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
occurs O
in O
the O
face B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
a O
threat B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
body B_PERSON/B_ORGANIZATION
integrity I_PERSON/I_ORGANIZATION
, O
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
Cannon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
's I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
principals I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
the O
wisdom B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
body B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O
'' O
. O

The O
suggestion O
is O
offered O
that O
the O
immunologic O
response O
to O
self-antigens B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
exposed O
by O
disease O
or O
trauma O
may O
be O
suppressed O
by O
corticosteroid O
to O
offset O
the O
likelihood O
of O
autoimmune O
attack O
. O

Protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O
is O
required O
for O
lipopolysaccharide O
induction O
of O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
human O
blood O
monocytes O
. O

bacterial O
LPS O
induce O
production O
of O
cytokines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
such O
as O
IL-1 B_GENE
, O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mononuclear O
phagocytes O
, O
and O
this O
represents O
a O
central O
component O
in O
the O
pathogenesis O
of O
septic O
shock O
syndrome O
. O

However O
, O
the O
mechanisms O
by O
which O
LPS O
activates O
these O
cells O
to O
express O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
are O
not O
completely O
characterized O
. O

The O
present O
study O
addressed O
the O
role O
of O
different O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
kinases B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
LPS O
induction O
of O
cytokines B_DISEASE/B_GENE
. O

It O
is O
shown O
that O
LPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O
a O
12- B_NUMBER[MEASURE]
to O
16-fold B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
IL-1 O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
this O
was O
completely O
or O
more B_MEASURE
than O
80 B_TIME[MEASURE]/B_LOCATION
% I_TIME[MEASURE]/I_LOCATION
blocked O
by O
the O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
herbimycin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
A O
and O
genistein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
the O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
1.7 B_MEASURE
and O
37 B_MEASURE
microM I_MEASURE
, O
respectively O
. O

Protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
inhibition O
by O
staurosporine O
reduced O
LPS O
induction O
of O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
whereas O
it O
had O
no O
effects O
on O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
IL-1 O
beta O
. O

Inhibition O
of O
protein B_GENE
kinase I_GENE
A I_GENE
by O
H89 O
reduced O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O
but O
did O
not O
detectably O
change O
IL-1 O
beta O
or O
TNF-alpha O
mRNA O
levels O
. O

In O
contrast O
, O
LPS O
did O
not O
increase O
leukemia B_GENE
inhibitory I_GENE
factor I_GENE
mRNA I_GENE
, O
which O
was O
constitutively O
expressed O
and O
not O
significantly O
reduced O
by O
these O
inhibitors O
. O

In O
addition O
to O
cytokine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
, O
LPS-induced O
IL-6 O
protein O
synthesis O
and O
IL-6 O
bioactivity O
were O
also O
reduced O
to O
baseline O
levels O
by O
the O
PTK O
inhibitors O
herbimycin O
A O
and O
genistein O
. O

Both O
PTK O
inhibitors O
also O
reduced O
the O
LPS O
activation O
of O
nuclear B_GENE
factor-kappa I_GENE
B I_GENE
( O
NF-kappa B_GENE
B I_GENE
) O
, O
which O
is O
a O
transcription B_GENE/B_MEASURE
factor I_GENE/I_MEASURE
involved O
in O
the O
expression O
of O
cytokine B_GENE/B_DISEASE
genes I_GENE/I_DISEASE
such O
as O
IL-6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
TNF-alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
activation O
of O
NF-kappa B_GENE
B I_GENE
was O
also O
reduced O
by O
H89 O
, O
whereas O
staurosporine O
had O
no O
effect O
on O
this O
response O
. O

In O
summary O
, O
these O
findings O
suggest O
that O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
protein B_GENE
kinase I_GENE
A I_GENE
appear O
to O
have O
selective O
effects O
in O
the O
LPS O
induction O
of O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
whereas O
PTK B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
required O
for O
LPS O
induction O
of O
a O
broad O
spectrum O
of O
cytokines B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
NF-kappa B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O
in O
monocytes O
. O

In O
vivo O
control O
of O
NF-kappa B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O
by O
I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kappa I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
transcription B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
B I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
stored O
in O
the O
cytoplasm O
in O
complexes O
with O
the O
inhibitor B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
kappa B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
B B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
alpha B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

It O
has O
been O
shown O
in O
vitro O
that O
dissociation O
of O
I B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
these O
complexes O
results O
in O
active B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NF-kappa B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
report O
we O
show O
that O
lipopolysaccharide O
( O
LPS O
) O
-induced O
activation O
of O
B O
or O
pre-B O
cells O
results O
in O
loss O
of O
I B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kappa I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O
NF-kappa B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
B I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
complexes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
vivo O
. O

Many O
liberated O
NF-kappa B_GENE
B I_GENE
dimers I_GENE
reached O
the O
nucleus O
, O
where O
increased O
c-rel B_GENE
, O
p65 O
and O
p50 O
were O
detected O
by O
immunoblotting O
and O
by O
DNA O
binding O
assays O
. O

Some O
liberated B_LOCATION/B_ORGANIZATION
dimers I_LOCATION/I_ORGANIZATION
were O
retained O
in O
the O
cytoplasm O
, O
however O
, O
through O
binding O
to O
newly O
synthesized O
I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kappa B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
a O
finding O
which O
strongly O
suggests O
( O
i O
) O
that O
the O
LPS-induced O
signal O
causes O
dissociation O
of O
complexes O
rather O
than O
preventing O
their O
association O
and O
( O
ii O
) O
that O
dissociation O
results O
from O
modification O
of O
I B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
not O
of O
c-rel B_GENE
or O
p65 B_GENE
. O

No O
effect O
of O
LPS O
treatment O
was O
detected O
on O
p105 B_GENE
or O
p100 B_GENE
, O
which O
also O
retain O
rel B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
family I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
members I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
cytoplasm O
. O

Quite O
unexpectedly O
, O
we O
also O
found O
that O
in O
unstimulated O
cells O
there O
is O
a O
constant O
ongoing O
process O
of O
degradation O
and O
replacement O
of O
complexed B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kappa I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

We O
propose O
that O
this O
turnover O
results O
in O
the O
low O
level O
of O
active B_GENE
NF-kappa I_GENE
B I_GENE
presumably O
necessary O
even O
in O
the O
unstimulated O
cell O
, O
and O
that O
the O
high O
rate O
of O
synthesis O
of O
I B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O
the O
ability O
to O
turn O
off O
NF-kappa B_GENE
B I_GENE
activity O
rapidly O
as O
soon O
as O
the O
activating O
signal O
ceases O
. O

identification O
of O
a O
killer B_GENE/B_PERSON
cell-specific I_GENE/I_PERSON
regulatory I_GENE/I_PERSON
element I_GENE/I_PERSON
of O
the O
mouse B_GENE
perforin I_GENE
gene I_GENE
: O
an O
Ets-binding O
site-homologous O
motif O
that O
interacts O
with O
Ets-related B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
gene O
encoding O
the O
cytolytic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
perforin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O
selectively O
expressed O
by O
activated O
killer O
lymphocytes O
. O

To O
understand O
the O
mechanisms O
underlying O
the O
cell-type-specific O
expression O
of O
this O
gene O
, O
we O
have O
characterized O
the O
regulatory O
functions O
and O
the O
DNA-protein O
interactions O
of O
the O
5'-flanking B_GENE/B_MEASURE
region I_GENE/I_MEASURE
of O
the O
mouse B_GENE
perforin I_GENE
gene I_GENE
( O
Pfp B_PROTEIN[GENE]/B_SPECIES[BIO]
) O
. O

A O
region O
extending O
from O
residues B_LOCATION/B_GENE
+62 I_LOCATION/I_GENE
through I_LOCATION/I_GENE
-141 I_LOCATION/I_GENE
, O
which O
possesses O
the O
essential O
promoter O
activity O
, O
and O
regions O
further O
upstream O
, O
which O
are O
able O
to O
either O
enhance O
or O
suppress O
gene O
expression O
, O
were O
identified O
. O

The O
region O
between O
residues B_LOCATION/B_GENE
-411 I_LOCATION/I_GENE
and I_LOCATION/I_GENE
-566 I_LOCATION/I_GENE
was O
chosen O
for O
further O
characterization O
, O
since O
it O
contains O
an O
enhancer-like O
activity O
. O

We O
have O
identified O
a O
32-mer O
sequence O
( O
residues B_PROTEIN[GENE]/B_MEASURE
-491 I_PROTEIN[GENE]/I_MEASURE
to I_PROTEIN[GENE]/I_MEASURE
-522 I_PROTEIN[GENE]/I_MEASURE
) O
which O
appeared O
to O
be O
capable O
of O
enhancing O
gene O
expression O
in O
a O
killer O
cell-specific O
manner O
. O

Within O
this O
segment O
, O
a O
9-mer O
motif O
( O
5'-ACAGGAAGT-3 O
' O
, O
residues B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-505 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-497 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
designated O
NF-P O
motif O
) O
, O
which O
is O
highly O
homologous O
to O
the O
Ets B_GENE/B_TIME[MEASURE]
proto-oncoprotein-binding I_GENE/I_TIME[MEASURE]
site I_GENE/I_TIME[MEASURE]
, O
was O
found O
to O
interact O
with O
two O
proteins O
, O
NF-P1 B_GENE
and O
NF-P2 B_GENE
. O

NF-P2 B_GENE/B_DISEASE
appears O
to O
be O
induced O
by O
reagents O
known O
to O
up-regulate O
the O
perforin O
message O
level O
and O
is O
present O
exclusively O
in O
killer O
cells O
. O

Electrophoretic O
mobility O
shift O
assay O
and O
UV O
cross-linking O
experiments O
revealed O
that O
NF-P1 B_GENE
and O
NF-P2 B_GENE
may O
possess O
common O
DNA-binding B_GENE/B_LOCATION
subunits B_GENE/I_LOCATION
. O

However O
, O
the O
larger O
native O
molecular O
mass O
of O
NF-P1 B_GENE
suggests O
that O
NF-P1 B_GENE/B_PERSON
contains O
an O
additional O
non-DNA-binding B_GENE
subunit I_GENE
( O
s O
) O
. O

In O
view O
of O
the O
homology O
between O
the O
NF-P B_GENE/B_MEASURE
motif I_GENE/I_MEASURE
and O
other O
Ets B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
proto-oncoprotein-binding I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sites I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
it O
is O
postulated O
that O
NF-P1 B_GENE
and O
NF-P2 B_GENE
belong O
to O
the O
Ets B_GENE/B_MEASURE
protein I_GENE/I_MEASURE
family I_GENE/I_MEASURE
. O

Results O
obtained O
from O
the O
binding O
competition O
assay O
, O
nevertheless O
, O
suggest O
that O
NF-P1 B_GENE
and O
NF-P2 B_GENE
are O
related O
to O
but O
distinct O
from O
Ets B_GENE/B_PERSON
proteins I_GENE/I_PERSON
, O
e.g. O
, O
Ets-1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Ets-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
NF-AT/Elf-1 B_GENE
, O
known O
to O
be O
expressed O
in O
T O
cells O
. O

The O
role O
of O
NF-kappa B_GENE
B1 I_GENE
( I_GENE
p50/p105 I_GENE
) I_GENE
gene I_GENE
expression O
in O
activation O
of O
human O
blood O
T-lymphocytes O
via O
CD2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
CD28 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

stimulation O
of O
primary O
human O
T-lymphocytes O
via O
CD2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CD28 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
induces O
a O
long-lasting O
proliferation O
( O
> O
3 O
weeks O
) O
. O

This O
potent O
activation O
does O
not O
require O
accessory O
cells O
, O
such O
as O
monocytes O
, O
but O
depends O
on O
persistent O
interleukin B_GENE
2 I_GENE
( O
IL-2 B_GENE/B_MEASURE
) O
secretion O
and O
receptivity O
, O
which O
is O
associated O
with O
high O
and O
prolonged O
expression O
of O
the O
inducible O
CD25/IL-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-2R I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
chain I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
transcription B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
participates O
in O
the O
regulation O
of O
both O
IL-2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-2R I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
well O
as O
multiple B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
cellular I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
genes I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
involved O
in O
T-cell O
proliferation O
. O

To O
evaluate O
the O
role O
of O
NF-kappa B_GENE
B I_GENE
in O
human O
peripheral O
blood O
T-lymphocytes O
, O
we O
previously O
analyzed O
the O
activation O
of O
NF-kappa B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B-related B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complexes B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
response O
to O
CD2+CD28 O
costimulation O
. O

We O
demonstrated O
a O
long-term O
induction O
of O
p50/p65 B_GENE
heterodimer I_GENE
, O
a O
putative B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p65/c-Rel I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
a O
constitutive O
nuclear O
expression O
of O
KBF1/p50 B_GENE
homodimers I_GENE
. I_GENE
. O

As O
the O
role O
of O
p50 B_GENE
remains O
unclear O
, O
we O
focused O
our O
present O
study O
on O
NF-kappa B_GENE
B1 I_GENE
( O
p50/p105 B_GENE/B_DISEASE
) O
gene O
regulation O
. O

Using O
electrophoretic O
mobility O
shift O
assays O
and O
Western O
and O
Northern O
blot O
analyses O
, O
we O
studied O
NF-kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O
during O
T-cell O
stimulation O
via O
CD2+CD28 B_GENE
. O

We O
observed O
a O
transient B_NUMBER[MEASURE]/B_LOCATION
4- I_NUMBER[MEASURE]/I_LOCATION
to O
5-fold B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
NF-kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
at O
both O
the O
mRNA B_GENE
and O
protein B_GENE
levels I_GENE
, O
lasting O
for O
at O
least O
24 B_MEASURE
h O
. O

p50 O
DNA-binding B_GENE
activity I_GENE
apparently O
stays O
highly O
controlled O
when O
p105 O
expression B_GENE
is O
enhanced O
by O
a O
physiological B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stimulus B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
peripheral B_DISEASE/B_GENE
blood I_DISEASE/I_GENE
T-cells I_DISEASE/I_GENE
. O

partial O
inhibition O
of O
p50 O
and O
p105 O
expression O
by O
NF-kappa B_GENE/B_NUMBER[MEASURE]
B1 I_GENE/I_NUMBER[MEASURE]
antisense O
oligonucleotides O
significantly O
reduced O
T-cell O
proliferation O
and O
CD25/IL-2R B_GENE
alpha I_GENE
cell O
surface O
expression O
. O

( O
abstract B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRUNCATED I_MEASURE
AT O
250 B_LOCATION/B_ENT
Words I_LOCATION/I_ENT
) O
. O

Vitamin B_GENE/B_PERSON
D I_GENE/I_PERSON
receptor I_GENE/I_PERSON
quantitation O
in O
human O
blood O
mononuclear O
cells O
in O
health O
and O
disease O
. O

Vitamin B_PROTEIN[GENE]
D I_PROTEIN[GENE]
receptor I_PROTEIN[GENE]
( O
VDR O
) O
concentration O
was O
quantitated O
in O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
from O
patients O
with O
absorptive O
hypercalciuria O
( O
ah O
) O
and O
patients O
with O
high O
1 O
, O
25 O
( O
OH O
) O
2D3 O
due O
to O
acquired O
or O
transient O
disease O
states O
and O
the O
results O
compared O
to O
those O
in O
normal O
subjects O
. O

VDR B_GENE
concentration I_GENE
in O
resting O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
not O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
represented O
constitutive B_DISEASE_ADJECTIVE[DISEASE]
receptor I_DISEASE_ADJECTIVE[DISEASE]
expression I_DISEASE_ADJECTIVE[DISEASE]
of O
monocytes B_GENE
. O

Following O
activation O
with O
phytohemagglutinin B_BIO/B_GENE
, O
patients O
with O
hypercalcitriolemia O
demonstrated O
significantly O
greater O
VDR O
concentrations O
. O

patients O
with O
ah O
demonstrated O
a O
normal O
value O
for O
the O
group O
, O
but O
6 O
patients O
had O
significantly O
greater O
concentrations O
of O
VDR B_GENE
despite O
normal O
plasma O
1 O
, O
25 O
( O
OH O
) O
2D3 O
in O
four O
of O
the O
patients O
. O

proliferation B_MEASURE/B_GENE
, O
as O
assessed O
from O
[ B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
3H I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
] I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
thymidine I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
incorporation I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
inversely O
correlated O
with O
serum B_MEASURE/B_BIO
1 I_MEASURE/I_BIO
, O
25 B_MEASURE
( O
OH B_LOCATION/B_PROTEIN[GENE]
) O
2D3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
was O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
-0.299 B_MEASURE
, O
p O
= O
0.048 B_MEASURE
) O
. O

taken O
together O
, O
the O
results O
suggest O
that O
PBMC O
provide O
a O
useful O
system O
for O
studying O
VDR B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
status O
in O
transient O
or O
acquired O
states O
of O
hypercalcitriolemia O
. O

Furthermore O
, O
the O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
patients B_PERSON/B_BIO
with O
absorptive B_DISEASE
hypercalciuria I_DISEASE
disclosed O
it O
to O
be O
a O
heterogeneous B_DISEASE/B_GENE
disorder I_DISEASE/I_GENE
, O
characterized O
by O
both O
vitamin B_DISEASE_ADJECTIVE[DISEASE]
D-dependent I_DISEASE_ADJECTIVE[DISEASE]
and O
D-independent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
forms I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
receptor B_DISEASE
up-regulation I_DISEASE
. O

reactive O
oxygen O
intermediates O
activate O
NF-kappa B_GENE
B I_GENE
in O
a O
tyrosine O
kinase-dependent O
mechanism O
and O
in O
combination O
with O
vanadate O
activate O
the O
p56lck B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p59fyn I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
human O
lymphocytes O
. O

We O
have O
previously O
observed O
that O
ionizing O
radiation O
induces O
tyrosine O
phosphorylation O
in O
human O
B-lymphocyte O
precursors O
by O
stimulation O
of O
unidentified O
tyrosine B_ENZYME[GENE]
kinases I_ENZYME[GENE]
and O
this O
phosphorylation O
is O
substantially O
augmented O
by O
vanadate O
. O

Ionizing O
radiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
generates I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reactive I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
oxygen I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intermediates I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
ROI B_DISEASE/B_GENE
) O
. O

Because O
H2O2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O
a O
potent B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ROI I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generator I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
readily O
crosses O
the O
plasma B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
used O
H2O2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
to O
examine O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ROI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
signal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transduction I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
now O
provide O
evidence O
that O
the O
tyrosine O
kinase O
inhibitor O
herbimycin O
A O
and O
the O
free O
radical O
scavenger O
N-acetyl-cysteine O
inhibit O
both O
radiation-induced O
and O
H2O2-induced O
activation O
of O
NF-kappa B_GENE
B I_GENE
, O
indicating O
that O
activation O
triggered O
by O
ROI O
is O
dependent O
on O
tyrosine O
kinase O
activity O
. O

H2O2 O
was O
found O
to O
stimulate O
Ins-1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5-P3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
production O
in O
a O
tyrosine O
kinase-dependent O
manner O
and O
to O
induce O
calcium O
signals O
that O
were O
greatly O
augmented O
by O
vanadate O
. O

The O
synergistic O
induction O
of O
tyrosine O
phosphorylation O
by O
H2O2 O
plus O
vanadate O
included O
physiologically O
relevant O
proteins O
such O
as O
PLC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
treatment O
of O
cells O
with O
H2O2 O
alone O
did O
not O
affect O
the O
activity O
of O
src B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
treatment O
with O
H2O2 O
plus O
vanadate O
led O
to O
activation O
of O
the O
p56lck B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
p59fyn I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
combined O
inhibition O
of O
phosphatases B_GENE
and O
activation O
of O
kinases B_GENE
provides O
a O
potent O
mechanism O
for O
the O
synergistic O
effects O
of O
H2O2 O
plus O
vanadate O
. O

induction O
of O
tyrosine O
phosphorylation O
by O
ROI O
may O
thus O
lead O
to O
many O
of O
the O
pleiotropic O
effects O
of O
ROI O
in O
lymphoid O
cells O
, O
including O
downstream O
activation O
of O
PLC B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gamma I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
NF-kappa B_GENE
B I_GENE
. O

influence O
of O
sex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
albumin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
the O
conversion O
of O
androstenedione O
to O
testosterone O
by O
human O
erythrocytes O
. O

The O
influence O
of O
human B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
serum I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
sex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
globulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
SHBG B_GENE
) O
on O
the O
enzymic O
conversion O
of O
androstenedione O
to O
testosterone O
in O
human O
erythrocytes O
was O
investigated O
in O
vitro O
. O

Total O
plasma O
and O
albumin B_GENE
delayed O
the O
conversion O
rate O
of O
androstenedione O
, O
while O
SHBG B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O
it O
markedly O
. O

The O
effect O
of O
SHBG B_GENE
was O
largely O
abolished O
by O
heating O
to O
60 O
degrees O
C O
for O
1 O
h O
and O
by O
saturating O
its O
binding O
sites O
by O
DHT O
. O

The O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
both O
proteins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
found O
to O
be O
related O
to O
their O
concentration B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
appears O
that O
the O
binding O
sites O
of O
albumin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provide O
a O
mechanism O
for O
retarding O
androstenedione O
uptake O
by O
the O
erythrocytes O
and O
that O
the O
high O
binding O
affinity O
of O
SHBG B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
for O
testosterone O
facilitates O
the O
diffusion O
of O
this O
steroid O
out O
of O
the O
cell O
and O
thus O
, O
displaces O
the O
chemical O
equilibrium O
within O
the O
cell O
. O

glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
lymphocytes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

increased O
glucocorticoid B_GENE
receptor I_GENE
levels O
in O
antigen-stimulated O
lymphocytes O
. O

Recently O
a O
2- O
to O
3-fold O
increase O
in O
the O
number O
of O
glucocorticoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
human O
peripheral O
lymphocytes O
has O
been O
noted O
after O
in O
vitro O
mitogen O
stimulation O
. O

Here O
, O
we O
extend O
these O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
immunization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O

After O
unilateral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
immunization I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
adrenalectomized B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
male I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
50 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
increase I_MEASURE/I_LOCATION
in O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
determined O
by O
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
was O
observed O
in O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
suspensions B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
homolateral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lymph B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
nodes B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
over O
those O
from O
the O
contralateral B_BODY_PART_OR_ORGAN_COMPONENT
nonimmunized I_BODY_PART_OR_ORGAN_COMPONENT
side I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
same B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
animal B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
association B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constant B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
both O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
was O
the O
stereospecificity B_MEASURE
for O
various B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steroids B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
time B_TIME[MEASURE]/B_LOCATION
course B_TIME[MEASURE]/I_LOCATION
of O
cytoplasmic B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
association I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
cytoplasmic-to-nuclear B_DISEASE_ADJECTIVE[DISEASE]
translocation I_DISEASE_ADJECTIVE[DISEASE]
. O

Despite O
a O
50 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
increase I_MEASURE/I_LOCATION
in O
the O
number B_MEASURE
of O
glucocorticoid B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
sites I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
per O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
the O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
the O
homolateral B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
controlateral B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
lymph I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
nodes I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
were O
equally O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
inhibitory B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effects I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
determined O
by O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
incorporation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
radiolabeled B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
precursors I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
protein B_GENE/B_BACTERIUM[BIO]
, O
RNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
and O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
or O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cell I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
survival I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
actions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
rat B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
thymocytes I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
immunologically O
stimulated O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

After O
reviewing O
briefly B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
our O
earlier B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
mechanisms B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
thymus B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
we O
have O
outlined O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
the O
following O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
areas I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
interest I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
in O
our O
laboratories B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
the O
life-cycle B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
'' O
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
complexes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
thymus B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
, O
and O
the O
levels B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O
sensitivity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
immunologically O
stimulated O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Several O
of O
our O
results O
on O
energetics O
and O
kinetics O
of O
hormone O
binding O
to O
glucocorticoid B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rat O
thymus O
cells O
seem O
to O
require O
extension O
of O
the O
simplest O
model O
of O
hormone-receptor O
transformations O
in O
intact O
cells O
. O

ATP-depletion O
experiments O
suggest O
the O
existence O
of O
a O
nonbinding O
form O
of O
the O
receptor O
; O
`` O
chase O
'' O
experiments O
suggest O
reaction O
of O
hormone O
directly O
with O
nuclear-bound O
receptor O
; O
experiments O
on O
depletion O
and O
replenishment O
of O
cytoplasmic B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
using O
cortisol O
and O
dexamethasone O
suggest O
the O
existence O
of O
at O
least O
two O
subpopulations O
of O
nuclear-bound B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hormone-receptor B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complex B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

We O
have O
found O
that O
mitogen O
or O
immunologic O
stimulation O
of O
human O
peripheral O
lymphocytes O
in O
culture O
leads O
within O
24 O
h O
or O
so O
to O
a O
striking O
increase O
in O
the O
number O
of O
glucocorticoid B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O
per O
cell O
. O

We O
believe O
this O
increase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O
be O
due B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
partial B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
synchronization B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
population I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
cell B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cycle I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
which O
receptor B_MEASURE/B_LOCATION
content I_MEASURE/I_LOCATION
is O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

contrary O
to O
the O
widely O
held O
view O
that O
mitogen-stimulated O
cells O
become O
insensitive O
to O
glucocorticoids O
, O
our O
experiments O
show O
that O
with O
respect O
to O
inhibition O
of O
thymidine O
and O
uridine O
incorporation O
and O
glucose O
uptake O
, O
the O
cells O
are O
highly O
sensitive O
to O
dexamethasone O
at O
24 O
, O
48 O
, O
and O
72 O
h O
after O
stimulation O
with O
concanavalin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Nuclear B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I_DISEASE_ADJECTIVE[DISEASE]
binding I_DISEASE_ADJECTIVE[DISEASE]
in O
chronic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lymphatic I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
leukemia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
reliable O
procedure O
is O
described O
for O
isolating O
3H-triamcinolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetonide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3H-TA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
complexes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O
purified O
chronic O
lymphatic O
leukemia O
( O
CLL O
) O
lymphocyte O
nuclei O
, O
based O
on O
the O
use O
of O
carbobenzoxy-L-phenylalanine O
( O
CBZ-L-phe O
) O
to O
prevent O
breakdown O
of O
hormone-receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O
extraction O
of O
nuclei O
with O
0.6M O
KCl O
. O

Using O
this O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
specific B_DISEASE/B_GENE
nuclear I_DISEASE/I_GENE
glucocorticoid I_DISEASE/I_GENE
binding I_DISEASE/I_GENE
was O
demonstrated O
in O
14/14 B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
untreated B_DISEASE/B_LOCATION
CLL I_DISEASE/I_LOCATION
. O

No O
correlation B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
between O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
nuclear-associated B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H-TA I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
peripheral B_DISEASE_ADJECTIVE[DISEASE]
white I_DISEASE_ADJECTIVE[DISEASE]
blood I_DISEASE_ADJECTIVE[DISEASE]
cell I_DISEASE_ADJECTIVE[DISEASE]
count I_DISEASE_ADJECTIVE[DISEASE]
or O
rosetting O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
circulating O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Multiple O
closely-linked O
NFAT/octamer B_GENE/B_LOCATION
and O
HMG B_GENE
I I_GENE
( I_GENE
Y I_GENE
) I_GENE
binding I_GENE
sites I_GENE
are O
part O
of O
the O
interleukin-4 O
promoter O
. O

We O
show O
here O
that O
the O
immediate B_GENE/B_LOCATION
upstream B_GENE/I_LOCATION
region B_GENE/I_LOCATION
( O
from O
position O
-12 O
to O
-270 O
) O
of O
the O
murine B_GENE/B_LOCATION
interleukin I_GENE/I_LOCATION
4 I_GENE/I_LOCATION
( I_GENE/I_LOCATION
Il-4 I_GENE/I_LOCATION
) I_GENE/I_LOCATION
gene I_GENE/I_LOCATION
harbors O
a O
strong O
cell-type O
specific O
transcriptional B_GENE
enhancer I_GENE
. O

In O
T O
lymphoma O
cells O
, O
the O
activity O
of O
the O
Il-4 B_GENE
promoter/enhancer I_GENE
is O
stimulated O
by O
phorbol O
esters O
, O
Ca++ O
ionophores O
and O
agonists O
of O
protein B_GENE
kinase I_GENE
A I_GENE
and O
inhibited O
by O
low O
doses O
of O
the O
immunosuppressant O
cyclosporin O
A O
. O

The O
Il-4 B_GENE
promoter/enhancer I_GENE
is O
transcriptionally O
inactive O
in O
B O
lymphoma O
cells O
and O
HeLa O
cells O
. O

DNase O
I O
footprint O
protection O
experiments O
revealed O
six O
sites O
of O
the O
Il-4 B_GENE
promoter/enhancer I_GENE
to O
be O
bound O
by O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
lymphoid O
and O
myeloid O
cells O
. O

Among O
them O
are O
four O
purine O
boxes O
which O
have O
been O
described O
to O
be O
important O
sequence O
motifs O
of O
the O
Il-2 B_GENE
promoter I_GENE
. O

They O
contain O
the O
motif O
GGAAA O
and O
are O
recognized O
by O
the O
inducible B_GENE/B_ORGANIZATION
and I_GENE/I_ORGANIZATION
cyclosporin I_GENE/I_ORGANIZATION
A-sensitive I_GENE/I_ORGANIZATION
transcription I_GENE/I_ORGANIZATION
factor I_GENE/I_ORGANIZATION
NFAT-1 I_GENE/I_ORGANIZATION
. O

Three O
of O
the O
Il-4 B_GENE/B_LOCATION
NFAT-1 B_GENE/I_LOCATION
sites B_GENE/I_LOCATION
are O
closely O
linked O
to O
weak O
binding O
sites O
of O
Octamer B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Several O
purine O
boxes O
and O
an O
AT-rich B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein-binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
Il-4 O
promoter O
are O
also O
recognized O
by O
the O
high B_GENE/B_LOCATION
mobility I_GENE/I_LOCATION
group I_GENE/I_LOCATION
protein I_GENE/I_LOCATION
HMG I_GENE/I_LOCATION
I I_GENE/I_LOCATION
( I_GENE/I_LOCATION
Y I_GENE/I_LOCATION
) O
. O

Whereas O
the O
binding O
of O
NFAT-1 B_GENE/B_LOCATION
and O
Octamer B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhance O
the O
activity O
of O
the O
Il-4 B_GENE/B_LOCATION
promoter I_GENE/I_LOCATION
, O
the O
binding O
of O
HMG O
I O
( O
Y O
) O
suppresses O
its O
activity O
and O
, O
therefore O
, O
appears O
to O
be O
involved O
in O
the O
suppression O
of O
Il-4 B_GENE/B_DISEASE
transcription O
in O
resting O
T O
lymphocytes O
. O

reversibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
differentiated B_DISEASE_ADJECTIVE[DISEASE]
state I_DISEASE_ADJECTIVE[DISEASE]
in O
somatic B_DISEASE/B_LOCATION
cells I_DISEASE/I_LOCATION
. O

Analysis O
of O
de O
novo O
gene O
activation O
in O
multinucleated O
heterokaryons O
has O
shown O
that O
the O
differentiated O
state O
, O
although O
stable O
, O
is O
not O
irreversible O
, O
and O
can O
be O
reprogrammed O
in O
the O
presence O
of O
appropriate O
combinations O
of O
trans-acting B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulatory I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
properties B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
exploited O
to O
design O
strategies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
identifying O
novel B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulators I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cellular B_DISEASE_ADJECTIVE[DISEASE]
differentiation I_DISEASE_ADJECTIVE[DISEASE]
. O

Phosphatidylcholine O
hydrolysis O
activates O
NF-kappa B_GENE
B I_GENE
and O
increases O
human O
immunodeficiency O
virus O
replication O
in O
human O
monocytes O
and O
T O
lymphocytes O
. O

We O
have O
tested O
whether O
breakdown O
of O
phosphatidylcholine O
( O
PC O
) O
initiated O
by O
exogenous O
addition O
of O
a O
PC-specific B_ENZYME[GENE]/B_DISEASE
phospholipase I_ENZYME[GENE]/I_DISEASE
C I_ENZYME[GENE]/I_DISEASE
( O
PC-PLC B_LOCATION/B_ORGANIZATION
) O
from O
Bacillus O
cereus O
or O
by O
endogenous O
overexpression O
of O
PC-PLC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
induces O
functional O
activation O
of O
NF-kappa B_GENE
B I_GENE
and O
increases O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HIV I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O
. O

PC-PLC-activated O
hydrolysis O
of O
PC O
was O
found O
to O
induce O
bona O
fide O
p50/p65 B_GENE
NF-kappa I_GENE
B I_GENE
binding O
activity O
in O
three O
different O
cell O
lines O
of O
human O
or O
murine O
origin O
. O

No O
significant B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
turnover B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellular I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phospholipids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
detected O
in O
PC-PLC-treated B_DISEASE/B_BIO
cells B_DISEASE/I_BIO
. O

induction O
of O
NF-kappa B_GENE/B_DISEASE
B B_GENE/I_DISEASE
by O
PC-PLC B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
depend O
on O
de O
novo O
synthesis O
of O
proteins O
or O
autocrine O
secretion O
of O
either O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O
interleukin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
human O
monocytic O
and O
lymphoblastoid O
T-cell O
lines O
, O
induction O
of O
NF-kappa B_GENE
B I_GENE
by O
PC-PLC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
resulted O
in O
clear O
induction O
of O
luciferase B_GENE
expression O
vectors O
placed O
under O
the O
control O
of O
synthetic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancers I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
wild O
type O
, O
but O
not O
Kappa O
B-mutated O
, O
HIV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
long I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeat I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

HIV O
replication O
was O
increased O
by O
PC-PLC B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
chronically O
infected O
monocytes O
and O
T O
lymphocytes O
. O

NF-kappa O
B O
activation O
promoted O
by O
addition O
of O
exogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PC-PLC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
correlated O
with O
an O
intense O
production O
of O
diacylglycerol O
. O

However O
, O
addition O
of O
a O
phosphatidylinositol-specific B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PLC B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
B.cereus O
also O
induced O
diacylglycerol O
but O
did O
not O
activate O
kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer-directed I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
vectors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

PC-PLC-induced O
NF-kappa O
B O
activation O
could O
not O
be O
blocked O
by O
a O
specific O
inhibitor O
of O
phorbol B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ester-inducible I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
results O
indicate O
that O
a O
cellular O
transduction O
pathway O
, O
dependent O
on O
specific O
PC O
breakdown O
, O
is O
functional O
in O
T O
lymphocytes O
and O
monocytes O
and O
may O
be O
used O
by O
various O
transmembrane O
receptors O
to O
activate O
HIV O
transcription O
through O
NF-kappa O
B-dependent O
induction O
of O
the O
HIV B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enhancer I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Novel B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
human B_DISEASE/B_GENE
T I_DISEASE/I_GENE
cells I_DISEASE/I_GENE
by O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Glucocorticoids O
inhibit O
signal O
transduction O
through O
IL-2 B_GENE
receptor I_GENE
. O

interaction O
of O
IL-2 B_GENE
with O
its O
high B_GENE
affinity I_GENE
membrane I_GENE
receptor I_GENE
complex I_GENE
( O
IL-2R B_LOCATION/B_ORGANIZATION
) O
present O
on O
activated O
T O
lymphocytes O
induces O
cell O
proliferation O
and O
mediates O
effector O
functions O
. O

Glucocorticoids O
inhibit O
IL-2 B_GENE
production O
by O
inhibiting O
TCR-mediated O
signal O
transduction O
. O

We O
asked O
whether O
they O
also O
inhibit O
the O
action O
of O
IL-2 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
inhibiting O
signal O
transduction O
through O
IL-2R B_GENE
. O

Human O
peripheral O
blood O
T O
cells O
, O
stimulated O
with O
PMA O
for O
48 O
h O
( O
PMA O
blasts O
) O
, O
were O
incubated O
with O
IL-2 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
presence O
of O
incremental O
dosages O
of O
dexamethasone O
( O
Dex O
; O
10 O
( O
-5 O
) O
-10 O
( O
-9 O
) O
M O
) O
. O

Dex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
inhibited O
the O
IL-2-dependent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
proliferation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
PMA B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blasts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
dose-dependent B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fashion B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IC50 B_MEASURE
, O
5 B_MEASURE
x O
10 B_MEASURE
( O
-8 B_MEASURE
) O
M B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

Cell O
surface O
expression O
of O
IL-2R B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta-chains I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
determined O
by O
immunofluorescence O
analysis O
was O
not O
affected O
by O
Dex O
. O

In O
addition O
, O
Scatchard O
plot O
analysis O
of O
125I-labeled B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IL-2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
Dex O
did O
not O
affect O
the O
binding O
of O
IL-2 B_GENE
, O
thus O
suggesting O
that O
inhibition O
is O
due O
to O
a O
postreceptor O
effect O
. O

Inhibition O
of O
T O
cell O
proliferation O
by O
Dex O
was O
associated O
with O
decreased O
IL-2-dependent O
tyrosine O
phosphorylation O
of O
several O
intracellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
decreased O
phosphorylation O
of O
the O
retinoblastoma B_GENE
gene I_GENE
product I_GENE
Rb I_GENE
, O
a O
protein O
essential O
for O
controlling O
the O
progression O
of O
cells O
through O
the O
cell O
cycle O
. O

IL-2-dependent O
IL-2R O
alpha O
expression O
in O
PMA O
blasts O
and O
NF-kB B_GENE
induction O
in O
resting O
human O
T O
cells O
were O
also O
inhibited O
by O
Dex O
. O

These O
results O
demonstrate O
that O
glucocorticoids O
inhibit O
preactivated O
T O
cells O
by O
down-regulating O
signal O
transduction O
through O
IL-2R B_GENE
. O

Chronic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
human I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
immunodeficiency I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
virus I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
type I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
infection I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
stimulates I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
distinct I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
NF-kappa I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
B/rel I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DNA I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
binding I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activities I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
myelomonoblastic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
relationship B_PERSON/B_MEASURE
between O
human B_DISEASE/B_VIRUS[BIO]
immunodeficiency B_DISEASE/I_VIRUS[BIO]
virus B_DISEASE/I_VIRUS[BIO]
type B_DISEASE/I_VIRUS[BIO]
1 B_DISEASE/I_VIRUS[BIO]
( O
HIV-1 B_DISEASE
) O
infection B_DISEASE/B_GENE
and O
the O
induction B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
NF-kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
examined O
in O
a O
myeloid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cell I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
HIV-1 B_DISEASE
infection I_DISEASE
derived O
from O
the O
PLB-985 O
cell B_DISEASE/B_ORGANIZATION
line I_DISEASE/I_ORGANIZATION
. O

Chronic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
PLB-985 O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
led O
to O
increased O
monocyte-specific B_GENE/B_DISEASE
surface B_GENE/I_DISEASE
marker B_GENE/I_DISEASE
expression B_GENE/I_DISEASE
, O
increased O
c-fms B_DISEASE/B_GENE
gene I_DISEASE/I_GENE
transcription I_DISEASE/I_GENE
, O
and O
morphological B_DISEASE_ADJECTIVE[DISEASE]
alterations I_DISEASE_ADJECTIVE[DISEASE]
consistent I_DISEASE_ADJECTIVE[DISEASE]
with O
differentiation B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
along O
the O
monocytic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pathway B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

PLB-IIIB O
cells O
displayed O
a O
constitutive O
NF-kappa O
B-like O
binding O
activity O
that O
was O
distinct O
from O
that O
induced O
by O
tumor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
phorbol O
12-myristate O
13-acetate O
treatment O
of O
the O
parental O
PLB-985 O
cell O
line O
. O

This O
unique O
DNA O
binding O
activity O
consisted O
of O
proteins O
of O
70 B_MEASURE/B_PROTEIN[GENE]
, I_MEASURE/I_PROTEIN[GENE]
90 I_MEASURE/I_PROTEIN[GENE]
, I_MEASURE/I_PROTEIN[GENE]
and I_MEASURE/I_PROTEIN[GENE]
100 I_MEASURE/I_PROTEIN[GENE]
kDa I_MEASURE/I_PROTEIN[GENE]
with O
a O
high O
degree O
of O
binding O
specificity O
for O
the O
NF-kappa B_PROTEIN[GENE]/B_LOCATION
B I_PROTEIN[GENE]/I_LOCATION
site I_PROTEIN[GENE]/I_LOCATION
within O
the O
PRDII B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
domain B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
beta B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
characterize O
the O
nature B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
proteins B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
demonstrate O
that O
binding O
of O
these O
proteins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
also O
induced O
following O
Sendai B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paramyxovirus I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
70-kDa B_PROTEIN[GENE]/B_MEASURE
protein I_PROTEIN[GENE]/I_MEASURE
corresponds O
to O
the O
NF-kappa B_GENE
B I_GENE
RelA I_GENE
( I_GENE
p65 I_GENE
) I_GENE
subunit I_GENE
, O
which O
is O
activated O
in O
response O
to O
an O
acute O
paramyxovirus O
infection O
or O
a O
chronic O
HIV-1 O
infection O
. O

virus O
infection O
does O
not O
appear O
to O
alter O
the O
amount O
of O
RelA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
p65 B_GENE/B_MEASURE
) O
or O
NFKB1 B_GENE
( O
p50 B_MEASURE
) O
but O
rather O
affects O
the O
capacity O
of O
I B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
sequester O
RelA B_GENE
( I_GENE
p65 I_GENE
) I_GENE
, O
therefore O
leading O
to O
constitutive O
levels O
of O
RelA O
DNA O
binding O
activity O
and O
to O
increased O
levels O
of O
NF-kappa O
B-dependent O
gene O
activity O
. O

The O
virally O
induced O
90- B_GENE
to I_GENE
100-kDa I_GENE
proteins I_GENE
have O
a O
distinct O
binding O
specificity O
for O
the O
PRDII B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
domain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
an O
AT-rich B_GENE/B_LOCATION
sequence I_GENE/I_LOCATION
but O
do O
not O
cross-react O
with O
NF-kappa O
B O
subunit-specific O
antisera O
directed O
against O
NFKB1 B_GENE
( O
p105 B_MEASURE/B_GENE
or O
p50 B_MEASURE
) O
, O
NFKB2 B_GENE
( O
p100 B_MEASURE/B_GENE
or O
p52 B_GENE/B_MEASURE
) O
, O
RelA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
p65 B_GENE/B_DISEASE
) O
, O
or O
c-rel B_GENE
. O

DNA O
binding O
of O
the O
90- B_PROTEIN[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100-kDa B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins B_PROTEIN[GENE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
inhibited O
by O
recombinant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
kappa I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha/MAD-3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
was O
resistant O
to O
tryptic O
digestion O
, O
suggesting O
that O
these O
proteins O
may O
not O
be O
NF-kappa B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
related B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Transient O
cotransfection O
experiments O
demonstrated O
that O
RelA O
and O
NFKB1 O
expression O
maximally O
stimulated O
HIV-1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B-dependent I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O
differences O
in O
NF-kappa O
B-like O
binding O
activity O
were O
also O
reflected O
in O
higher O
constitutive O
levels O
of O
NF-kappa O
B-regulated O
gene O
expression O
in O
HIV-1-infected O
myeloid O
cells O
. O

Presence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
estrogen-binding O
sites B_LOCATION/B_BIO
on O
macrophage-like B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synoviocytes B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
CD8+ B_GENE
, O
CD29+ B_GENE/B_DISEASE
, O
CD45RO+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
in O
normal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
rheumatoid B_DISEASE/B_LOCATION
synovium I_DISEASE/I_LOCATION
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
study O
the O
presence B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
estrogen-binding O
sites B_LOCATION/B_BIO
( O
EBS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
in O
the O
synovial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
tissues I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
male B_PERSON
and O
female B_PERSON
patients I_PERSON
with O
rheumatoid B_DISEASE
arthritis I_DISEASE
( O
RA B_LOCATION/B_ORGANIZATION
) O
and O
in O
age- B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
sex-matched B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
healthy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
controls I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Both O
type B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
1 I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
high B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
affinity B_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
binding I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
capacity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O
and O
type B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
2 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
reduced O
affinity B_GENE/B_MEASURE
, O
higher B_DISEASE_ADJECTIVE[DISEASE]
binding I_DISEASE_ADJECTIVE[DISEASE]
capacity I_DISEASE_ADJECTIVE[DISEASE]
) O
EBS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
investigated O
in O
both O
soluble B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
and O
nuclear B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
fractions B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O
homogenized B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synovial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
a O
dextran-coated B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
charcoal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
determine O
what O
type O
of O
synovial O
cell O
was O
positive O
for O
EBS O
, O
cryosections O
of O
synovial O
tissues O
were O
immunostained O
with O
a O
specific O
monoclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti-estrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
anti-ER B_LOCATION/B_ORGANIZATION
MAb I_LOCATION/I_ORGANIZATION
) O
using O
both O
immunofluorescence O
and O
immunoperoxidase O
techniques O
. O

Double O
immunostaining O
with O
the O
anti-ER B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MAb B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
with O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MAb I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
detect O
different O
macrophage B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigens I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Ber-MAC3 B_GENE
, O
MAC387 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
CD68 B_GENE
) O
and O
CD8+ O
T O
cell O
subsets O
( O
CD29+ O
, O
CD45RO+ O
and O
CD29- O
, O
CD45RO- O
) O
was O
performed O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Higher B_PERSON/B_GENE
affinity I_PERSON/I_GENE
EBS I_PERSON/I_GENE
were O
found O
mostly O
in O
nuclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fractions I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
either O
RA B_DISEASE/B_LOCATION
or O
control O
synovial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
tissues I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
( O
28 B_NUMBER[MEASURE]
of O
the O
33 B_MEASURE/B_PERSON
) O
. O

These O
EBS B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
a O
lesser B_MEASURE
extent I_MEASURE
in O
soluble B_LOCATION
cell I_LOCATION
fractions I_LOCATION
( O
11 B_NUMBER[MEASURE]/B_LOCATION
of O
the O
33 B_MEASURE/B_BIO
) O
. O

immunostaining B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O
the O
estrogen B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
receptor-positive I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O
be O
the O
macrophage-like B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synoviocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
CD8+ B_GENE/B_PERSON
, O
CD29+ B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
both O
in O
RA B_DISEASE/B_LOCATION
and O
in O
control B_DISEASE/B_PROTEIN[GENE]
synovial B_DISEASE/I_PROTEIN[GENE]
tissues B_DISEASE/I_PROTEIN[GENE]
. O

Higher B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
content I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
EBS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
more O
intense B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
staining I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
synoviocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
T B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPORT[ENT]
. O

It O
is O
conceivable B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
that O
the O
immunomodulatory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exerted O
by O
estrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
at O
least O
partly O
mediated O
through O
their O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O
EBS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O
are O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
macrophage-like B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synoviocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
functioning O
as O
antigen-processing B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
antigen-presenting O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
, O
and O
on O
antigen-experienced B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
memory B_DISEASE_ADJECTIVE[DISEASE]
) O
CD8+ B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
T I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
lymphocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
( O
CD29+ B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
CD45RO+ B_GENE/B_LOCATION
. O

